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Abstract
Deoxynivalenol (DON) is a mycotoxin primarily produced by Fusarium fungi, occurring predominantly in
cereal grains. Following the request of the European Commission, the CONTAM Panel assessed the risk to
animal and human health related to DON, 3-acetyl-DON (3-Ac-DON), 15-acetyl-DON (15-Ac-DON) and
DON-3-glucoside in food and feed. A total of 27,537, 13,892, 7,270 and 2,266 analytical data for DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside, respectively, in food, feed and unprocessed grains collected
from 2007 to 2014 were used. For human exposure, grains and grain-based products were main sources,
whereas in farm and companion animals, cereal grains, cereal by-products and forage maize contributed
most. DON is rapidly absorbed, distributed, and excreted. Since 3-Ac-DON and 15-Ac-DON are largely
deacetylated and DON-3-glucoside cleaved in the intestines the same toxic effects as DON can be
expected. The TDI of 1 lg/kg bw per day, that was established for DON based on reduced body
weight gain in mice, was therefore used as a group-TDI for the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside. In order to assess acute human health risk, epidemiological data from mycotoxicoses
were assessed and a group-ARfD of 8 lg/kg bw per eating occasion was calculated. Estimates of acute
dietary exposures were below this dose and did not raise a health concern in humans. The estimated
mean chronic dietary exposure was above the group-TDI in infants, toddlers and other children, and at
high exposure also in adolescents and adults, indicating a potential health concern. Based on estimated
mean dietary concentrations in ruminants, poultry, rabbits, dogs and cats, most farmed ﬁsh species and
horses, adverse effects are not expected. At the high dietary concentrations, there is a potential risk for
chronic adverse effects in pigs and ﬁsh and for acute adverse effects in cats and farmed mink.
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of European Food Safety Authority.
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Summary
In a request from the European Commission, the Panel on Contaminants in the Food Chain
(CONTAM Panel) was asked to assess the risk to animal and human health related to the presence of
the mycotoxins deoxynivalenol (DON), metabolites of DON and masked DON in food and feed. Taking
into account the availability of data suitable for the risk assessment of DON and its acetylated and
modiﬁed forms, the CONTAM Panel decided to assess the risk of DON, 3-acetyl-DON (3-Ac-DON),
15-acetyl-DON (15-Ac-DON) and DON-3-glucoside. The CONTAM Panel was asked to consider all
relevant adverse acute and chronic health effects, addressing, in particular, co-occurrence of DON with
its acetylated and modiﬁed forms. Furthermore, to estimate the dietary (chronic and acute) exposure
of the European population addressing, in particular, the consumption patterns of speciﬁc (vulnerable)
groups of the population. The risk for different farm and companion animal species from exposure
from feed should also be assessed.
The structurally related trichothecene-mycotoxins, DON, 3-Ac-DON and 15-Ac-DON, are commonly
found in Europe. They are produced by plant pathogenic fungi of the Fusarium genus growing on the
cereals in the ﬁeld, preferably at temperate climates. DON is one of the most widely studied mycotoxins
worldwide and it co-occurs often with other mycotoxins, particularly with other Fusarium toxins. DON-3-
glucoside is a modiﬁed form of DON (also called masked DON) and is the main plant metabolite of
DON. However, it was noted that other modiﬁed forms of DON have also been reported and more of
them might be discovered in upcoming research. These four forms, DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside, occur predominantly in cereal grains such as wheat, barley, oats, rye and maize.
Trichothecenes are characterised by a tetracyclic sesquiterpenoid 12,13-epoxytrichothec-9-en ring
structure. The epoxide group between C12 and C13 seems to account for many of the typical toxic
effects of trichothecenes. They have been classiﬁed into four groups (A–D) based on their chemical
structures, and type A and type B trichothecenes are predominant in food and feed. DON, 3-Ac-DON
and 15-Ac-DON are type B trichothecenes.
The methods of analysis for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside are well established
and can be applied for cereals, food, feed and biological samples. Accurate quantiﬁcation of DON, its
acetylated forms and DON-3-glucoside is mostly carried out by liquid chromatography coupled with
(multistage) mass spectrometry, presently often with a multianalyte approach. However, this
methodology has not been formally validated through interlaboratory studies and proﬁciency tests
have shown that considerable analytical variability exists in the determination of DON. Direct
approaches (requiring standards) and indirect ones (based on the conversion to DON) have been
reported for the determination of DON-3-glucoside, for which the direct approach is the preferred
method. For DON, performance criteria for methods of analysis and certiﬁed reference materials (both
reference matrices and reference calibrants) are available. Non-certiﬁed calibrants are available for
3-Ac-DON, 15-Ac-DON and DON-3-glucoside. Immunochemical methods for DON provide rapid and
economical alternatives to chromatography, but cross-reactivity and matrix effects have not been fully
considered. Recent progress in biomarker research has allowed the determination of DON and its
metabolites in urine, primarily as DON-glucuronides, by using single or multiple biomarker methods.
However, the commercial sources for the standards of DON-glucuronides are scarce and no (certiﬁed)
reference materials are available for urinary DON biomarkers.
Occurrence data
Within the continuous data collection of EFSA, a total of 21,916, 4,000 and 1,621 analytical results
of DON in food, feed and unprocessed grains of undeﬁned end-use, respectively, fulﬁlled the required
quality criteria. For 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, fewer analytical results, which fulﬁlled
the criteria, were submitted to EFSA. The numbers of results ranged from 430 for 15-Ac-DON in
unprocessed grains of undeﬁned end-use to 11,944 for 3-Ac-DON in food.
For ‘Grains and grain-based products’, which was the food category with the majority of analytical
results, the proportion of left-censored data (results below the limit of detection (LOD) or limit of
quantiﬁcation (LOQ)) was 52% for DON and 59% for DON-3-glucoside, but above 95% for both
acetylated forms. ‘Cereal grains’ was the category with the majority of analytical results for feed and
had only 47% of left-censored data for DON, 80% for 15-Ac-DON, and about 95% for DON-3-glucoside
and 3-Ac-DON. The proportions of left-censored data for unprocessed grains of undeﬁned end-use
ranged from 45% for DON to 96% for the other three forms. The highest mean concentrations of DON
and the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were recorded for the categories
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‘Products for special nutritional use’ and ‘Grains and grain-based products’ for food, ‘Cereal straw’ for
feed and ‘Grains as crops’ for unprocessed grains of undeﬁned end-use.
Because DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside are mostly attached to the outer hull of
the grain, cleaning, sorting, sieving and dehulling of grains lead to marked increases in concentrations
of these toxins in cereal by-products, e.g. bran. During baking and cooking, DON appears to be
relatively stable but the results for 3-Ac-DON and 15-Ac-DON were inconclusive and studies on DON-3-
glucoside showed inconsistent and varying results. Relevant increases of concentrations were observed
during fermentation stages, while relevant reductions occurred during baking. Malting and brewing do
not seem to lead to losses of DON and DON-3-glucoside and no increased concentrations were
observed in by-products of brewing. However, the ratio between DON and DON-3-glucoside
concentrations changed during the process due to a notable increase of the concentrations of DON-3-
glucoside as compared to DON. Studies on the fate of 3-Ac-DON and 15-Ac-DON during malting and
brewing were too limited to draw conclusions. The data on feed processing were limited but since
many of the processes applied to cereal grains for food production are also applied to grains used for
animal feeds, the ﬁndings for food should also apply to feed.
The CONTAM Panel estimated the relative ratios of concentrations of 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside to DON as 10%, 15% and 20%, respectively, and noted that they concurred with
observations in feed and unprocessed grains of undeﬁned end-use, except for ‘Alcoholic beverages’
(‘Beer and beer-like beverage’) where the ratio of DON-3-glucoside to DON was estimated as 80%.
Overall, the concentration ratios varied considerably both for data reported to EFSA and those reported
in the literature.
Human exposure assessment
Based on toxicological considerations (see below), the CONTAM Panel decided to assess the exposure
to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. The mean acute human exposure
across 39 different dietary surveys and all age groups ranged from 0.2 to 2.9 lg/kg body weight (bw)
per day for the minimum lower bound (LB) to the maximum upper bound (UB). The 95th percentile acute
exposure ranged from 0.7 to 6.7 lg/kg bw per day. Infants showed the highest acute dietary exposure.
The mean chronic human exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
across 33 different dietary surveys and all age groups ranged from 0.2 to 2.0 lg/kg bw per day
(minimum LB–maximum UB), and the 95th percentile chronic exposure ranged from 0.5 to 3.7 lg/kg bw
per day (minimum LB–maximum UB). Again infants showed the highest mean chronic dietary exposure.
The highest contributions to the exposure of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside came from grain-based products, especially ‘Bread and rolls’, ‘Fine bakery wares’ and ‘Pasta
(raw)’.
The limited consumption data available for vegetarians did not indicate a signiﬁcant difference in
the dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and 3-DON-glucoside between the
vegetarians and the general population.
The CONTAM Panel noted that the overall human dietary exposure to the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside was mainly driven by DON.
Toxicokinetics and toxicity in rodents and human data
Rat gut intestinal microﬂora metabolised DON to the less toxic metabolite DOM-1 and transformed
acetylated DON to DON ex vivo. Gut microﬂoral transformation of DON or DON-3-glucoside into DOM-1
was less evident in humans than in rats. DON was able to cross the placenta and reach the fetus. The
oral bioavailability of DON has not been quantiﬁed in mice, but plasma, tissue and urine concentrations
indicate that the absorption is high and maximum plasma concentrations are reached rapidly. DON was
rapidly distributed to the tissues, e.g. liver, kidney, spleen and heart in rodents, reaching the maximum
concentrations at about the same time as in plasma with exception for the brain, where the peak of
total concentrations of DON and metabolites was reached later and at a lower concentration than in
other organs. In mice, the distribution pattern of DON was independent of age and the tissue
concentrations decreased rapidly after the peak concentration was reached. The concentrations were
higher in weanling than in young adult mice. In rats, DON was rapidly excreted in faeces and urine.
A signiﬁcant biliary excretion was found in only one study ex vivo. In rat faeces, DON sulfonates were
shown to be major metabolites exceeding the contribution from DON glucuronides. There is evidence
that 3-Ac-DON and 15-Ac-DON were largely deacetylated prior to systemic distribution. DON-3-
glucoside appears to be excreted solely as DON. Limited human data suggested that approximately
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70% of ingested DON is excreted via urine, of which about 80% was in conjugated forms, mainly as
DON-15-glucuronide that was about threefold more efﬁciently formed than DON-3-glucuronide.
After a single oral exposure to DON, feed refusal appeared very quickly in mice. Previous risk
assessments of DON conducted by the Scientiﬁc Committee on Food (SCF) in 1999 and by the Joint
FAO/WHO Expert Committee on Food Additives (JECFA) in 2001 identiﬁed a no-observed-adverse-
effect level (NOAEL) of 0.04 mg DON/kg bw from subacute and subchronic toxicity studies. The
CONTAM Panel reviewed studies that were published since the previous assessments and did not
identify new information that changed this NOAEL of 0.04 mg DON/kg bw. Only one chronic toxicity
study on DON was identiﬁed from which a NOAEL of 0.1 mg/kg bw per day was derived using data on
reduced feed intake and reduced body weight gain in mice. This is in line with previous evaluations
from the SCF and JECFA. No subacute, subchronic and chronic toxicity data on 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside were identiﬁed.
The available data did not show any haemato- or myelotoxicity of DON and differs in that respect
from other trichothecenes. The data on neurotoxicological effects of DON were limited, and the
CONTAM Panel did not identify any dose–response data suitable for hazard characterisation or any link
with the data on the mode of action of DON. For carcinogenicity of DON, no new data were identiﬁed
since the previous assessments in which the only available long-term study did not indicate
carcinogenic properties of DON in mice. For 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, the CONTAM
Panel did not identify data on chronic toxicity, haemato- and myelotoxicity, neurotoxicity and
carcinogenicity.
DON impacts the immune response in vitro and in vivo. Subchronic studies performed in mice and
in farm animals indicate that DON exposure induces an increase in the plasmatic level of
immunoglobulin A (IgA) but it could not be associated with IgA nephropathy. The effects on the
immune response lead to an increased susceptibility to infectious diseases at medium to high doses of
DON (8–10 mg/kg bw). Studies on immune response of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
were scarce.
Oral exposure to DON exhibits both developmental and reproductive toxicity in experimental animals
rats including reduced fertility, embryotoxicity, skeletal abnormalities, effects on body weight and
relative epididymal weight and postnatal mortality. No data were identiﬁed for 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside.
DON is genotoxic in vitro and the data available on the genotoxicity of DON in vivo were
inconclusive. The available evidence suggests that oxidative stress may be involved in the mechanism
of genotoxicity, rather than a direct interaction of DON (adduct formation) with cellular DNA. Similar to
DON, 3-Ac-DON was inactive in a bacterial mutation assay and no data on in vitro genotoxicity tests
with 15-Ac-DON or DON-3-glucoside were identiﬁed. No in vivo genotoxicity studies on 3-Ac-DON,
15-Ac-DON and DON-3-glucoside were identiﬁed.
Human outbreaks from acute exposure to DON have been repeatedly reported in Asia, with
symptoms including nausea, vomiting, diarrhoea, abdominal pain, headaches, dizziness, fever, and in
severe cases, bloody stool. No lethality was reported. However, the evidence of adverse health effects
in humans due to chronic exposure to DON is lacking.
The CONTAM Panel noted that DON urinary biomarkers have been frequently investigated in several
European populations and that these correlate well with dietary DON exposure. The available human
biomarker studies suggested ubiquitous exposure to DON in many populations. The CONTAM
Panel concluded that the exposure estimates, derived from the biomarker data from three European
countries, were of the same order of magnitude as the exposure estimates for the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside derived from the occurrence data reported to the
European Food Safety Authority (EFSA) and the dietary surveys from those countries. However, several
factors were identiﬁed that contributed to the uncertainty of exposure estimates of DON based on
human DON biomarker data.
Concerning the mode of action, DON binds to ribosomes, leading to inhibition of protein synthesis
and subsequently also RNA and DNA synthesis. This binding also induces ribotoxic stress and activates
different mitogen-activated protein kinases (MAPKs). Activation of MAPKs explains several effects of
DON, such as apoptosis or survival of cells, inﬂammatory effect and oxidative stress. Two major
mediators of DON-induced anorexia/emesis have been described: pro-inﬂammatory cytokines and
secretion of satiety hormones, which activate receptors in the abdominal vagus afferent. The data on
the mechanism of action of 3-Ac-DON and 15-Ac-DON were scarce but suggested an activation of MAPK
and an induction of inﬂammatory cytokine and satiety hormones. Because of steric hindrance DON-3-
glucoside cannot bind to the ribosome, and thus, it neither activates MAPKs nor it induces inﬂammation.
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Only few studies compared the toxicity of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in the
same experiment. In mink, DON, 3-Ac-DON and 15-Ac-DON were found to display similar toxicity in
terms of anorectic and inﬂammatory effects, however the emetic capacity of 3-Ac-DON was
substantially lower compared to DON and 15-Ac-DON. In porcine and human intestinal cells, the
cytotoxic potency ranked in the order of 15-Ac-DON > DON > 3-Ac-DON and that was similar for
barrier function, MAPK activation and expression of tight junction, and histological alterations. DON-3-
glucoside was considerably less toxic than DON in both in vitro and in vivo studies.
The available database on effects of combined exposure to DON and other mycotoxins was weak
and insufﬁcient for establishing the nature of combined effects. In addition, no in vivo studies on the
combined effects of 3-Ac-DON, 15-Ac-DON or DON-3-glucoside with other mycotoxins were identiﬁed.
Accounting all toxicokinetic and toxicity information available, the CONTAM Panel noted that
3-Ac-DON and 15-Ac-DON were largely deacetylated to DON prior to systemic distribution, such that
they might induce the same acute and chronic effects as DON. The available data indicate that DON-3-
glucoside can be cleaved to DON by bacteria in the gastrointestinal tract and distributed, metabolised
and excreted similarly to DON. While the mode of action and the toxicity data for 3-Ac-DON and
15-Ac-DON indicated a similar toxicity as that of DON, toxicity data for DON-3-glucoside were limited
and in vivo data on chronic toxicity were missing with the consequence that the CONTAM Panel could
not make a ﬁrm conclusion on the hazard of DON-3-glucoside and could also not compare it with that
of DON and the two acetylated forms. Therefore, the CONTAM Panel applied a conservative approach
assuming that (1) 3-Ac-DON, 15-Ac-DON and DON-3-glucoside are all metabolised to DON and
absorbed at the same extent as DON, (2) the acetylated forms of DON induce the same acute and
chronic adverse health effects as DON and (3) similar acute and chronic adverse health effects of
DON-3-glucoside as DON cannot be excluded. Therefore, the CONTAM Panel decided to characterise
the hazard for the group of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside together, both for
chronic and for acute adverse health effects in humans and farm and companion animals.
The CONTAM Panel identiﬁed vomiting as critical acute effect in humans. Since studies from
experimental- and farm animals could not provide a basis for an acute reference dose (ARfD)
the CONTAM Panel decided to use the human data on vomiting and gastrointestinal effects, collected
in a number of epidemiological studies on the outbreaks of acute mycotoxicosis in Asia, for the human
hazard characterisation. Despite the limitations in the available human data, the CONTAM
Panel decided to use these data to establish a group ARfD for the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside. In addition, the available human biomarker data were exploited as supporting
information.
Based on adverse gastrointestinal effects identiﬁed from the human outbreak data in China and
noting that vomiting occurred within 30 min after an eating occasion, the CONTAM Panel calculated a
NOAEL of 26 lg DON/kg bw for a single eating occasion. By applying a default uncertainty factor of
3.16 for toxicodynamic kinetic differences in the intra-human population variability, a group ARfD of
8 lg/kg bw per eating occasion was determined. The CONTAM Panel concluded that the dose range
calculated from the human biomarker data supported this reference dose.
In the absence of data on chronic effects in humans, the CONTAM Panel identiﬁed reduced body
weight gain in experimental animals as the critical chronic effect for human risk assessment. A clear
dose–response relationship between the exposure to DON and mean body weight was observed both
for female and male mice. The CONTAM Panel combined the data from both sexes to calculate a
BMDL05 of 0.11 mg/kg bw per day for reduced body weight gain, and established a group tolerable
daily intake (TDI) of 1 lg/kg bw per day using the default uncertainty factor of 100 for inter- and
intraspecies variability for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
Risk characterisation for humans
Based on the available occurrence data, the estimates of acute dietary exposure to the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were below the group ARfD of 8 lg/kg bw per
eating occasion for all age groups of humans, and considered not an acute health concern.
The estimates of the UB chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside based on the available occurrence data were above the group TDI of 1 lg/kg bw per
day for the infants, toddlers and other children, and to some extent also for adolescents and adults. At
the LB, estimates only high exposure in toddlers and other children exceeded the group TDI. Regular
exceedance of the group TDI indicates a potential health concern, however, the CONTAM Panel noted
the uncertainty associated with exposure estimates due to a high fraction of left-censored data.
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There are limited data on dietary habits of vegetarians, with data available for only ﬁve European
countries, and with very few subjects in four of them. These limited data did not indicate notable
differences in acute and chronic dietary exposure between the vegetarians and the general population.
Therefore, the conclusions on the general population remain valid also for the subpopulation of
vegetarians.
Farm and companion animal exposure assessment
In contrast to the human exposure assessment, the farm and companion animal exposure was
presented as dietary concentrations because the animal risk assessment was carried out on a
concentration–response basis, except for the farmed mink for which the acute dietary exposure was
presented on a dose-response basis expressed per kg bw. The animal exposure to the sum of DON, 3-
Ac-DON, 15-Ac-DON and DON-3-glucoside was primarily from the consumption of cereal grains, cereal
by-products and forage maize.
For lactating dairy cows and beef cattle, the estimated mean dietary concentrations to the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside ranged from 64.2 to 996 lg/kg diet (lowest LB to
highest UB). The estimated 95th percentile dietary concentrations ranged from 124 to 3,655 lg/kg diet.
For small ruminants, the lowest LB and highest UB mean dietary concentrations were 151 and 414 lg/kg
diet, respectively, and the estimated 95th percentile dietary concentrations 561 and 849 lg/kg diet,
respectively.
For pigs, the estimated lowest LB and highest UB mean dietary concentrations were 437 and
618 lg/kg diet, respectively, and the estimated 95th percentile dietary concentrations 1,284 and
1,302 lg/kg diet, respectively.
For poultry, the lowest LB and highest UB mean dietary concentrations were 794 and 1,494 lg/kg
diet, respectively, and the 95th percentile estimates of dietary concentrations 2,900 and 3,971 lg/kg
diet, respectively. For horses, only mean dietary concentrations could be estimated and they were 155
(LB) and 253 (UB) lg/kg diet.
For farmed ﬁsh (salmonids and carp), the estimated lowest LB and highest UB mean dietary
concentrations were 83.3 and 388 lg/kg diet, respectively, and the 95th percentile estimates of dietary
concentrations 362 and 1,151 lg/kg diet, respectively.
For farmed rabbits, the LB and UB mean dietary concentrations were 196 and 282 lg/kg diet,
respectively, and the estimated 95th percentile dietary concentrations 1,048 and 1,135 lg/kg diet,
respectively.
For farmed mink, the estimated LB and UB mean dietary concentrations were 99.5 and 109 lg/kg
diet, respectively, and the 95th percentile dietary concentrations 407 lg/kg diet (equivalent to
14.7 lg/kg bw per day) and 409 lg/kg diet (equivalent to 14.8 lg/kg bw per day), respectively.
For cats, the estimated LB and UB mean dietary concentrations were 229 and 264 lg/kg diet,
respectively, and the estimated 95th percentile dietary concentrations 968 and 975 lg/kg diet,
respectively. The values for dogs were somewhat lower with the LB and UB mean dietary concentrations
being 174 and 214 lg/kg diet, respectively, and the 95th percentile dietary concentrations being 741 and
753 lg/kg diet, respectively.
The CONTAM Panel noted that the overall dietary concentrations of farm and companion animals to
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were mainly driven by DON.
Toxicokinetics and toxicity in farm and companion animals
Intestinal absorption and metabolism of DON vary largely between different farm animal species
and this may depend on the location of the consecutive intestinal segments, regional pH and activity
of bacteria. Localisation of the gut bacteria prior or after the small intestine affects the bioavailability
of ingested DON and its metabolites.
In cows, DON is extensively transformed to the less toxic de-epoxidised metabolite DOM-1 by the
ruminal ﬂora and only very minor amounts (< 1%) of DON reach systemic circulation. The proportion
of DOM-1 glucuronide in serum is high. The urine seems to be the main route of excretion. No
relevant toxicokinetic data were identiﬁed for 3-Ac-DON, 15-Ac-DON or DON-3-glucoside. While in
healthy ruminants DON is converted into DOM-1 by the rumen ﬂora, the toxicokinetics could be
different in ruminants with acidosis or in young animals such as calves, for which the ruminal system is
not fully functioning. In sheep, DON exhibited a systemic bioavailability and was quickly absorbed.
DON and its metabolites were excreted primarily via the urinary but also via biliary routes. One study
in lambs showed that 3-Ac-DON, administrated intraruminal, was rapidly converted to DON and partly
excreted in the urine. No data were identiﬁed for goats.
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The absorption of DON in pigs was generally high and DON was extensively distributed with a
plasma elimination half-life that varied from 1 to 4 h. DON and its metabolites were excreted primarily
via the urinary but also via biliary routes. 3-Ac-DON was rapidly deacetylated in the upper intestinal
tract and absorbed exclusively as DON. The limited data on DON-3-glucoside indicated that it had two
times lower bioavailability than DON, and it could be concluded that DON-3-glucoside was only
absorbed as DON. An extensive cleavage of DON-3-glucoside is likely to occur, primarily by the
microﬂora in the gastrointestinal tract. No data were identiﬁed for 15-Ac-DON.
For poultry, a low degree of absorption of DON into plasma and a rapid metabolism and clearance
from plasma was observed. The only available study on broiler chickens indicated a nearly complete
hydrolysis of 3-Ac-DON and a partial hydrolysis of 15-Ac-DON to DON. Therefore, the CONTAM
Panel assumed that 3-Ac-DON is absorbed as DON to a larger extent than 15-Ac-DON. The single
available study on broiler chickens indicated that DON-3-glucoside was not hydrolysed to DON and its
oral bioavailability was lower than that of DON.
Limited data on horses indicated a rapid clearance of DON in plasma with a major portion present as
glucuronide. DON may reach the systemic circulation only at low concentrations. DOM-1 was observed
in serum and it correlated with DON exposure. No data were identiﬁed for 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside in horses.
Transfer of DON from feed to food of animal origin was only identiﬁed for dairy cows, pigs and poultry,
and a substantial contribution of the residues of DON in products of animal origin to human exposure was
considered to be unlikely. No information on the transfer of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
was identiﬁed.
Focussing on studies using the highest DON concentrations in feed combined with the longest
periods of time, the CONTAM Panel identiﬁed a NOAEL of 5 mg DON/kg feed for dairy cows because
no adverse effects on body weight, feed intake, milk yield or any other adverse effect were observed
over a period of 13 weeks. In heifers and steers, levels of 10 and 18 mg DON/kg feed, respectively,
did not generate any adverse effects on feed intake, average daily weight gain and feed efﬁciency, and
these levels were identiﬁed as not leading to effects. For sheep, the CONTAM Panel identiﬁed a NOAEL
of 16 mg DON/kg feed for reduced feed intake and reduced body weight gain. In the absence of data
for goats, the lowest NOAEL of 5 mg DON/kg feed of cows was adopted for them. The CONTAM
Panel noted that young animals such as calves with not fully developed rumen and adult animals with
a previous history of ruminal acidosis may have less effective de-epoxidation and, consequently, could
be more susceptible to the toxic effects of DON.
Reduced feed intake and reduced body weight gain were the most relevant chronic adverse effects of
DON in pigs. However, DON may cause several other adverse effects in pigs including lesions in the
oesophageal region of the stomach, in the liver, the lungs and the kidneys and changes in different clinical
chemistry parameters (plasma nutrients and plasma enzyme activities). Several studies described also an
impact of DON on immune responses in pigs but types and the sizes of those responses could not be
associated with relevant adverse immunological effects in pigs. From the available data, the CONTAM
Panel identiﬁed for the acute adverse health effects a lowest-observed-adverse-effect level (LOAEL) of
2.8 mg DON/kg feed for vomiting. For reduced feed intake and reduced weight gain reduction, identiﬁed
as the critical chronic adverse health effects of DON in pigs, wide ranges of NOAEL and LOAEL
values were reported from which an overall NOAEL of 0.7 mg DON/kg feed was identiﬁed by the CONTAM
Panel.
In broiler chicken, levels of 4.6–7 mg DON/kg feed did not generate any adverse effects, but levels
of 10–12 mg DON/kg feed did, including reduced feed intake and reduced body weight gain. Thus, the
CONTAM Panel identiﬁed 5 mg DON/kg feed as a NOAEL for broiler chicken. For laying hens, diets with
DON concentrations up to 18 mg DON/kg feed did not induce any negative impact on body weight
gain, hatchability and egg production in some studies. However, a diet of 10–13 mg DON/kg feed
induced a decrease of feed intake at an early stage of the experiment, and a decrease of relative
weights of spleen and gizzard and egg fertility. In other studies diets containing 5 mg DON/kg feed did
not affect body weight gain, hatchability and egg fertility. Therefore, the CONTAM Panel identiﬁed
5 mg DON/kg feed as a NOAEL for laying hens. For ducks and turkeys, the CONTAM Panel identiﬁed a
NOAEL of 7 mg DON/kg feed because no changes in body weight, weight gain, feed intake or feed
conversion ratios were observed at this concentration.
For horses, the CONTAM Panel conﬁrmed the previous NOAEL of 36 mg DON/kg feed for reduced
feed intake. In rabbits a concentration of 30 mg DON/kg feed was associated with maternal and fetal
body weight reduction, while a concentration of 15 mg DON/kg feed did not induce any adverse
effects in rabbit fetuses. Since a concentration of 4.3 mg DON/kg feed did not induce any effects on
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feed intake, body weight gain and relative organ weights the NOAEL of 4 mg DON/kg feed was
identiﬁed for rabbits.
The limited data on chronic adverse effects in farmed ﬁsh did not allow the identiﬁcation of speciﬁc
NOAELs/LOAELs for each ﬁsh species. In carp, the concentration of 0.95 mg DON/kg feed induced
lipid peroxidation and histopathological changes in the liver and in rainbow trout 0.8 mg DON/kg feed
reduced feed intake, weight gain, growth rate and feed efﬁciency. The lowest NOAEL was 0.6 mg
DON/kg feed observed for carps and the CONTAM Panel decided to use 0.6 mg DON/kg feed as an
overall NOAEL for farmed ﬁsh.
For vomiting as acute effect in farmed mink, BMDL10 values of 0.004, 0.05 and 0.004 mg/kg bw
per day were calculated for DON, 3-Ac-DON and 15-Ac-DON, respectively. From the available subacute
toxicity study on mink, a NOAEL of 1 mg DON/kg feed was identiﬁed for the reduced feed intake and
body weight gain in farmed mink as reference point for chronic adverse effects.
For dogs, one study on acute effects was available. Vomiting was not reported at the concentration
of 6 mg DON/kg feed, which was identiﬁed as the NOAEL for acute effects, while reduced body weight
gain in dogs was observed at this level. Application of the BMD approach resulted in a lowest BMCL10
of 5 mg DON/kg feed for vomiting as reference point of acute effects in dogs. For chronic effects in
dogs, the identiﬁed NOAEL for reduced body weight gain was 4 mg DON/kg feed.
The same study on dogs was also the only available study for acute and chronic adverse effects in
cats. Vomiting was not reported at the concentration of 8 mg DON/kg feed and this was identiﬁed as
the NOAEL for acute effects, while reduced body weight gain in cats was observed at this level.
Application of the BMD approach resulted in a lowest BMCL10 of 1 mg DON/kg feed for vomiting as
reference point of acute effects. For chronic effects in cats, the identiﬁed NOAEL for reduced body
weight gain was 6 mg DON/kg feed.
Risk characterisation for farm and companion animals
For the farm and companion animals, the CONTAM Panel characterised the chronic animal health
risk for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside using the dietary concentration
estimates at the UB mean and UB 95th percentile based on feed composition and the available
occurrence data on feeds and compared them with the identiﬁed NOAELs. For characterising the acute
animal health risk, the calculated UB 95th percentile dietary concentrations (dietary exposure in case
of farmed mink) were used and compared with the respective NOAEL or BMDL/BMCL10 for pigs,
farmed mink, dogs and cats, for whom vomiting was reported.
The dietary concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for
ruminants and horses were clearly below the identiﬁed NOAELs for chronic adverse effects and are
therefore considered unlikely to be a health concern, while for poultry and farmed rabbits the
estimated dietary concentrations indicated that the risk of chronic adverse health effects from the feed
containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is low.
For pigs, the estimated dietary concentrations indicated that the risk of acute adverse health
effects is low, while a possible risk of chronic adverse health effects from feed containing DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside was identiﬁed at the 95th percentile dietary concentrations.
Also for farmed ﬁsh (salmonids and carp), the estimated dietary exposures indicated that possible
risk of chronic adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside was identiﬁed for carp. However, the CONTAM Panel noted that the diet composition of
different ﬁsh species may majorly differ and some ﬁsh species might be more tolerant.
For dogs, the risk of acute and chronic adverse health effects is low. Also for cats and farmed
mink, the estimated dietary concentrations indicated that the risk for chronic adverse health effects is
low, while a possible risk of acute adverse effects from feed containing DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside was identiﬁed for farmed mink and cats.
Recommendations
The CONTAM Panel concluded that although the impact of the uncertainties in the human risk
assessment of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is large, the risk is more
likely to be over- than under-estimated. The impact of the uncertainties in the risk assessment of farm
and companion animals is large. Therefore, the CONTAM Panel recommends interlaboratory validation
and standardisation of liquid chromatography with tandem mass spectrometric (LC–MS/MS)
methodology for the simultaneous quantiﬁcation of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
Certiﬁed reference materials should be made available and proﬁciency tests should be facilitated. The
CONTAM Panel also recommends studies on the co-occurrence of these four forms of DON, where
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each food and feed sample is analysed for all the four forms, and monitoring of the co-occurrence of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and feed to acquire knowledge of possible
trends, e.g. due to climate change or technological processing. With regard to human biomarkers of
exposure, interlaboratory-validation and standardisation of the methods for the analysis of urinary DON
biomarkers are recommended and certiﬁed reference materials should be made available, too. Also,
well-designed quantitative studies on DON urinary excretion in different human sub-population groups
should be encouraged to enable the use of DON biomarkers for human exposure assessments. The
CONTAM Panel further recommends to conduct well-designed studies, which take into account
practical feeding conditions for farm and companion animals to study toxicokinetics and toxicity of the
four forms of DON. In addition, modiﬁed forms of DON, other than those covered in this risk
assessment, which could be potentially relevant concerning their (co-)occurrence and toxicological
properties, should be investigated to further reﬁne the human and animal risk assessment.
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Background as provided by the European Commission
The Scientiﬁc Committee on Food (SCF) adopted a scientiﬁc opinion on deoxynivalenol (DON)1 on 2
December 1999, establishing a tolerable daily intake (TDI) of 1 lg/kg bw.
At the request of the Commission, the European Food Safety Authority (EFSA) adopted a scientiﬁc
opinion on DON as undesirable substance in animal feed2 in 2 June 2004.
Maximum levels for DON were set by Commission Regulation (EC) No 1881/20063.
At that time it was considered not necessary, due to co-occurrence, to consider speciﬁc measures
for the metabolites 3-acetyl deoxynivalenol (3-Ac-DON) and 15-acetyl deoxynivalenol (15-Ac-DON), as
the measures on DON would also protect the human population from an unacceptable exposure from
3-Ac-DON and 15-Ac-DON.
Guidance values have been established for DON in animal feed by Commission Recommendation
2006/576/EC4.
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluated DON at its 72nd
meeting in 2010.
The JECFA decided to convert the provisional maximum tolerable daily intake (PMTDI) for DON to a
group PTMDI of 1 lg/kg bw for DON and its metabolites 3-Ac-DON and 15-Ac-DON as 3-Ac-DON is
converted to DON in vivo and therefore contributes to the total DON-induced toxicity. The Committee
considered the toxicity of the metabolites to be equal to that of DON. The JECFA concluded that there
was insufﬁcient information to include DON-3-glucoside in the group PMTDI.
The JECFA derived a group acute reference dose (ARfD) of 8 lg/kg bw for DON and its metabolites
using the lower limit on the benchmark dose for a 10% response (BMDL10) of 210 lg/kg bw per day
for emesis in pigs. Limited data from human case reports indicated that dietary exposures to DON up
to 50 lg/kg bw per day are not likely to induce emesis.
In view of the recent JECFA evaluation, it is appropriate for EFSA to assess the acute toxicity of
DON in addition to the chronic toxicity and to assess the toxicity of the DON metabolites, in particular
the acetylated derivatives. In recent years, ﬁndings on the presence of masked DON, in particular
DON-3-glucoside has been reported. The toxicity of these masked forms, in particular DON-3-
glucoside, has to be assessed.
Terms of Reference as provided by the European Commission
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the Commission asks EFSA for
a scientiﬁc opinion on the risks to animal and human health related to the presence of deoxynivalenol
(DON), metabolites of DON and masked DON in food and feed.
The scientiﬁc opinion should, inter alia, comprise the:
a) evaluation of the toxicity of DON, metabolites of DON and masked DON for animals and
humans, considering all relevant adverse acute and chronic health effects;
b) assessment of the co-occurrence of DON with metabolites of DON and masked DON in feed
and food;
c) estimation of the dietary exposure (chronic and acute dietary exposure) of the European Union
(EU) population to DON, metabolites of DON and masked DON, including the consumption
patterns of speciﬁc (vulnerable) groups of the population (e.g. high consumers, children,
people following a speciﬁc diet, etc.);
d) estimation of the exposure of the different animal species to DON, metabolites of DON and
masked DON from feed;
e) assessment of the acute and chronic human health risks for the EU population including for
speciﬁc (vulnerable) groups of the population as the consequence of the estimated dietary
exposure;
f) assessment of the animal health risks for the different animal species as the consequence of
the estimated exposure from animal feed.
1 Opinion of the Scientiﬁc Committee on Food on Fusarium-toxins Part 1: Deoxynivalenol (DON), (expressed on 2 December
1999) http://ec.europa.eu/food/fs/sc/scf/out44_en.pdf
2 Opinion of the Scientiﬁc Panel on contaminants in the Food Chain of the European Food Safety Authority (EFSA) on a request
from the Commission related to deoxynivalenol as undesirable substance in animal feed, adopted on 2 June 2004.
3 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in food OJ L
364, 20.12.2006, p. 5.
4 Commission Recommendation 2006/576/EC of 17 August 2006 on the presence of deoxynivalenol, zearalenone, ochratoxin A,
T-2 and HT-2 and fumonisins in products intended for animal feeding. OJ L 229, 23.8.2006, p. 7.
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Assessment
1. Introduction
Deoxynivalenol (DON) belongs to the large group of mycotoxins called trichothecenes, which
represent the main group of Fusarium toxins. DON occurs predominantly in cereal grains such as
wheat, barley, oats, rye and maize. DON is predominantly produced by the plant pathogenic fungi of
the Fusarium genus, mainly by Fusarium graminearum and Fusarium culmorum. These fungi grow on
the cereals in the ﬁeld, preferably at temperate climates as they are commonly found in Europe (Marin
et al., 2013). Crop infection by Fusarium is dependent on the weather and is favoured by high
humidity at the time of ﬂowering (WHO, 2001). Cereal grains intended for food and feed may also
become contaminated during storage. DON is chemically stable and to some extent resistant to
thermal processing (Kabak, 2009). As a result, DON is found in cereal-based foods (Schothorst et al.,
2005; Sirot et al., 2013) and feeds (D€oll and D€anicke, 2011; Streit et al., 2012) ready for consumption.
Ingestion of highly contaminated feed by animals can lead to acute gastrointestinal symptoms such
as vomiting (emesis), feed refusal and bloody diarrhoea. Because of its ability to induce acute vomiting
in pigs (Vesonder et al., 1973), DON has also been assigned the trivial name ‘vomitoxin’. The most
common effects of long-term dietary exposure of animals to DON are weight gain suppression and
anorexia. DON has been involved in a number of incidents of human intoxication in Asia and its acute
effects in humans are similar to those in animals.
DON can co-occur in grains and in cereal-based food and feed together with its acetyl derivatives
3-acetyl deoxynivalenol (3-Ac-DON), 15-acetyl deoxynivalenol (15-Ac-DON) and 3,15-diacetyl-
deoxynivalenol (3,15-Ac-DON). Both DON and its acetylated forms are produced by fungi such as
F. graminearum and F. culmorum as toxic secondary metabolites and are therefore regarded as free or
unmodiﬁed mycotoxins (Berthiller et al., 2013; Varga et al., 2013; Rychlik et al., 2014). Moreover,
different Fusarium strains can produce different patterns of mycotoxins (chemotype). As an example,
3-Ac-DON and 15-Ac-DON chemotypes of F. graminearum produce DON together with 3-Ac-DON, and
DON together with 15-Ac-DON, respectively, and their distribution varies with the geographical location
and years of sampling (Gilbert et al., 2014). However, the acetyl derivatives of DON have been
reported to occur at much lower levels than the parent compound DON (Usleber et al., 1996; Pestka,
2010a; FAO/WHO, 2011) but they also exert toxicity (Pinton and Oswald, 2014). Furthermore, the
CONTAM Panel noted that 3,15-Ac-DON has been reported to occur together with DON, however, at
much lower levels than 3-Ac-DON and 15-Ac-DON (Usleber et al., 1996).
Plants infected by mycotoxin-producing fungi can alter the chemical structure of the mycotoxins
resulting in (at least in part) extractable conjugated and/or non-extractable bound mycotoxins. These
altered mycotoxins were usually not detected when analysing food and feed for the mycotoxins they
originated from, and therefore they have been commonly referred to as ‘masked mycotoxins’ (Gareis
et al., 1990). DON-3-glucoside, the main plant metabolite of DON, is considered to be a masked
mycotoxin and has been detected in cereal grains and cereal-based products (Berthiller et al., 2013;
Varga et al., 2013). This is an example of detoxiﬁcation by glycosylation in the plant. Glycosylation
converts DON into a glucoside that is unable to inhibit protein synthesis of plant ribosomes and is
regarded as non-toxic for plants (Poppenberger et al., 2003). Plant cultivars differ in their ability to
detoxify DON and this depends on genetic and environmental factors (Lemmens et al., 2016; Warth
et al., 2016). However, there is concern that DON-3-glucoside may be converted in the gastrointestinal
tract by humans and animals to DON (FAO/WHO, 2011; Nagl et al., 2012) and thus may contribute to
the overall exposure to DON. It is known that mycotoxins can also be modiﬁed by living organisms
other than plants (e.g. bacteria and mammals), and by further processing of the plants. All the altered
mycotoxins are not covered by the term ‘masked mycotoxins’. Therefore, the CONTAM Panel decided
to use for this opinion the systematic classiﬁcation of the various DON forms as proposed by Rychlik
et al. (2014) (see Table 1) and interpreted the ‘presence of DON, metabolites of DON and masked
DON in food and feed’, as indicated in the TOR, to assess the risks to human and animal health related
to the presence of DON and its acetylated forms (free mycotoxins) and DON-3-glucoside (modiﬁed
mycotoxin) based on currently existing knowledge and data published by July 2016. Overall, the
CONTAM Panel noted that DON is one of the most widely studied mycotoxins worldwide and therefore
more modiﬁed forms of DON might be discovered in upcoming research soon and basic molecular
research (e.g. using techniques of genomics and gene expression) of DON and its various forms are
expected to clarify the biosynthesis pathway of DON and its modiﬁed forms.
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Taking into account the availability of data suitable for the risk assessment of DON and its
acetylated and modiﬁed forms, the CONTAM Panel decided to assess acute and chronic exposure and
the risk of DON, the acetylated forms 3-Ac-DON and 15-Ac-DON, as well as of DON-3-glucoside in this
opinion for food and feed relevant for the European market. This interpretation of the terms of
reference has mutually been agreed with the requestor of the present scientiﬁc opinion. The
uncertainties rising from the lack of information on the other acetylated and modiﬁed forms of DON
are described in the uncertainty chapter.
The Appendix A describes the identiﬁcation and selection of evidence relevant for the present
opinion.
1.1. Previous assessments
In 1993, the International Agency for Research on Cancer (IARC, 1993) evaluated the carcinogenic
effect of Fusarium mycotoxins including DON, and concluded that DON is ‘not classiﬁable as to its
carcinogenicity to humans’ (Group 3).
In 1998, the Nordic Council of Ministers (NCM, 1998) conducted a risk assessment on Fusarium
mycotoxins in cereals and established a temporary tolerable daily intake (t-TDI) of 1 lg/kg bw per day
based on a no-observed-adverse-effect level (NOAEL) of 1 mg/kg feed (0.1 mg/kg bw per day)
derived from the 2-year feeding study in mice of Iverson et al. (1995) and using uncertainty factor of
100. The TDI was declared to be temporary due to the limited long-term study data and the
uncertainty of the mechanisms of action at that time. It was considered to also be protective against
the acute vomiting effect.
In 1999, the Scientiﬁc Committee on Food (SCF, 1999) evaluated DON for the ﬁrst time. As no
carcinogenicity or mutagenicity evidence was identiﬁed, the NOAEL of 0.1 mg/kg bw per day from the
Table 1: Categorisation of various forms of deoxynivalenol (DON) classiﬁed in four hierarchic levels
modiﬁed from Rychlik et al. (2014)
1st level 2nd level 3rd level 4th level Examples of DON forms
Free mycotoxins(a) DON
3-Ac-DON
15-Ac-DON
3,15-Ac-DON
Food and feed matrix-
associated mycotoxins
DON-oligosaccharides
Modiﬁed mycotoxins Biologically
modiﬁed
Conjugated
(phase 2
metabolites)
Conjugated
by plants(b)
DON-3-glucoside
DON-3/15-sulfates(c)
DON-glutathione
Conjugated
by animals
DON-3-glucuronide
DON-15-glucuronide
Differently
modiﬁed(d)
De-epoxy-DON (DOM-1)(e), 3-epi-DON(f)
Chemically
modiﬁed
Thermally
formed
norDON A, B, C, D, F and DON-lactone;
norDON-3-glucoside A B, C, D and
DON- DON-3-glucoside lactone(g)
Non-thermally
formed
DON-sulfonates
norDON A, B, C(h)
(a): Free or unmodiﬁed mycotoxins are formed as toxic secondary metabolites by various fungi.
(b): Mycotoxins conjugated by plants are also known as modiﬁed mycotoxins.
(c): Both DON-sulfates were detected in wheatears after treatment with DON. DON-3-sulfate was the only detected sulfate
conjugate in wheat artiﬁcially infected with Fusarium. Their natural occurrence still needs to be investigated (Warth et al., 2015).
(d): Biologically modiﬁed mycotoxins that are no (plant, animal or fungal) phase 1 nor phase 2 metabolites.
(e): Intestinal metabolite of DON, which is formed by the microbiota of animals and humans.
(f): Bacterial transformation product, produced by the bacterial strainDevosia mutans 17-2-E-8 in aerobic conditions (He et al., 2015).
(g): Various forms of norDON, nor DON-3-glucoside, DON-lactone and DON-3-glucoside lactone have been found as thermal
degradation products of DON and DON-3-glucoside in heat-treated wheat and in the crust of experimental breads
(Kostelanska et al, 2011b; Wu and Wang, 2015).
(h): DON-sulfonates (DONS-1, -2 and -3) have been found in animal feed treated with sulfur reagents such as sodium bisulﬁte or
sodium metabisulﬁte. It has been suggested that the latter two sodium-based compounds could be used for detoxiﬁcation
(Schwartz-Zimmermann et al., 2014).
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2-year feeding study of Iverson et al. (1995) was used as reference point. The uncertainty factor of
100 was used to establish a t-TDI of 1 lg/kg bw per day. The SCF considered this t-TDI to also
protects against the acute vomiting effect and other subchronic or reproductive effects of DON. Later,
the SCF (2002) assessed the group-combined effect of common trichothecenes including T-2 and HT-2
toxins, DON and nivalenol, and concluded that the available data were not sufﬁcient to establish a TDI
for either the combined effects or the relative potencies of the trichothecenes. Based on its
assessment, the SCF decided to turn the t-TDI of 1 lg/kg bw per day for DON to a full TDI.
The National Institute for Public Health and the Environment (RIVM) in the Netherlands also carried
out risk assessments for DON (Pieters et al., 1999). Five toxicological studies (four on mice and one on
swine) were examined for deriving a NOAEL. The 2-year feeding study in mice by Iverson et al. (1995)
was used to derive a provisional TDI. An uncertainty factor of 100 (10 for interspecies and 10 for
interindividual uncertainty) and a more accurate round-up approach than in other assessments
mentioned above were applied and, therefore, the TDI was reported as 1.1 lg/kg bw per day. The
Health Council of the Netherlands also conducted a risk assessment on DON (HCN, 2001). The Council
used the data from the same 2-year feeding study (Iverson et al., 1995) with an uncertainty factor of 210
to establish a TDI of 0.5 lg/kg bw per day. The uncertainty factor comprised the subfactors of 10 for
intra- and 3 for interspecies differences, and a factor of 7 for differences in energy use and differences in
metabolism, possibly affecting body weight changes, between humans and mice. Both TDIs are not
anymore in use in the Netherlands, instead a TDI of 1 lg/kg is used now (Janssen et al., 2015).
At its 56th meeting, the Joint Food and Agriculture Organization of the United Nations/World Health
Organization (FAO/WHO) Expert Committee on Food Additives (JECFA) evaluated the risk of DON
dietary exposure (FAO/WHO, 2001). JECFA considered the same 2-year feeding study in mice (Iverson
et al., 1995) to be appropriate for long-term effect evaluation as did the SCF. A provisional maximum
(PM)TDI of 1 lg/kg bw per day was considered to protect against immunotoxicity, growth reduction
and reproductive effects of DON. However, for acute toxicity, JECFA could not establish a level below
which no effects would be expected to occur in humans.
The Japanese Food Safety Commission (FSCJ) assessed DON in 2010 (FSCJ, 2010). It considered
vomiting, reduced feed intake and reduced body weight gain, and immunotoxicity as the critical effects
for the risk assessment of DON, while at high doses fetal toxicity and teratogenicity could be induced.
The FSCJ considered that given the absence of any evidential genotoxic or carcinogenic effect, a TDI
for DON of 1 lg/kg bw per day could be established based on the same 2-year feeding study in mice
(Iverson et al., 1995).
At its 72nd meeting, JECFA evaluated its previously established PMTDI for DON of 1 lg/kg bw per
day (FAO/WHO, 2011). Taking into account few short-term studies available at that time, the
Committee considered the use of the NOAEL of 0.1 mg/kg bw per day to still be appropriate. JECFA
noted that the acetylated derivatives (3-Ac-DON and 15-Ac-DON) are, in general, not frequently
detected and constitute less than 10% of the DON concentrations. However, they are considered to be
as toxic as DON, and 3-Ac-DON is converted to DON in vivo and therefore contributes to the total
DON-induced toxicity. JECFA converted its previous PMTDI for DON to a group PMTDI of 1 lg/kg bw
per day for DON and its acetylated derivatives (3-Ac-DON and 15-Ac-DON). DON-3-glucoside was not
included in the group PMTDI due to a lack of sufﬁcient data.
For assessing the acute toxicity of DON, JECFA considered that DON-induced systemic emesis was
the critical acute effect. The observations from two studies in pigs with DON exposure through
naturally contaminated feed (Young et al., 1983; Pollmann et al., 1985) were considered appropriate
and were combined for dose–response modelling to establish the acute reference dose (ARfD). Based
on the lowest BMDL10 of 0.21 mg/kg bw per day for emesis in pigs, a group ARfD for DON and its
acetylated derivatives (3-Ac-DON and 15-Ac-DON) of 8 lg/kg bw per day was established. JECFA
considered this to be sufﬁciently protective against human emesis because limited data suggested that
dietary exposures to DON up to 50 lg/kg bw per day are not likely to induce emesis in humans
(FAO/WHO, 2011).
Details on the exposure assessments from the previous assessments are reported in the
Section 6.1.1.
1.2. Chemistry of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
DON, 3-Ac-DON and 15-Ac-DON (see Figure 1) are mycotoxins belonging to the group of
trichothecenes, which are produced by Fusarium species. Trichothecenes are characterised by a
tetracyclic sesquiterpenoid 12,13 epoxytrichothec-9-en ring structure. They have been classiﬁed into
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 20 EFSA Journal 2017;15(9):4718
four groups (A–D) based on to their chemical structures. The epoxide group between C12 and C13
accounts for many of the typical toxic effects of trichothecenes (Betina, 1989).
Epidemiological surveys have demonstrated that the predominant type A and B trichothecenes are
widely distributed in cereals and feeds as natural pollutants, whereas type C (characterised by a
second epoxide at C-7,8 or C-9,10) and type D trichothecenes (containing an ester-linked macrocycle
at C-4,16) occur rarely in food and feed. Type A trichothecenes include T-2 toxin, HT-2 toxin and
4,15-diacetoxyscirpenol, and type B toxins include nivalenol, fusarenon-X, DON, 3-Ac-DON and
15-Ac-DON (Figure 1).
The ﬁrst isolation of DON was reported in 1972 from Japanese Fusarium-damaged barley
(Weidenb€orner, 2001). DON is the trivial name for trichothec-9-en-8-one, 12, 13-epoxy-3,7,15-
trihydroxy-, (3a,7a) (Chemical Abstracts Service (CAS) number 51481-10-8). Its molecular formula is
C15H20O6 and its molecular weight is 296.32 g/mol. DON crystallises as colourless needles and has a
high temperature tolerance (stable at 120°C, moderately stable at 180°C). Ultraviolet (UV) absorption
spectra for DON yield an absorption maximum of 217 nm (Krska et al., 2004). For pure commercially
available crystalline DON, extinction coefﬁcients were 6,727 L/mol per cm (DON standard from Sigma)
and 6,825 L/mol per cm (DON standard from Biopure) (Krska et al., 2004).
3-Ac-DON (trichothec-9-en-8-one, 3-(acetyloxy)-12,13-epoxy-7,15-dihydroxy-,(3a,7a); CAS number
50722-38-8) and 15-Ac-DON (trichothec-9-en-8-one, 15-(acetyloxy)-12,13-epoxy-3,7-dihydroxy-,
(3a,7a); CAS number 88337-96-6) both have the molecular formula of C17H22O7, and a molecular
weight of 338.35 g/mol. Their UV absorption maxima are at 217 and 219 nm, respectively (Krska
et al., 2005).
DON-3-glucoside has been isolated from Zea mays suspension cultures that were treated with DON
(Sewald et al., 1992), in maize and wheat (Berthiller et al., 2005), and in beer (carryover from ﬁeld
barley through malt to beer) (Lancova et al., 2008a). In DON-3-glucoside, DON is bound with the
anomeric carbon of glucose via a glycosidic bond. A UDP-glucosyltransferase from Arabidopsis thaliana
catalyses the transfer of glucose from UDP-glucose to the hydroxyl group at carbon 3 of DON and
15-Ac-DON (Poppenberger et al., 2003).
DON-3-glucoside (trichothec-9-en-8-one, 12,13-epoxy-3-(b-D-glucopyranosyloxy)-7,15-dihydroxy-,
(3a,7a); CAS number 131180-21-7) has the molecular formula C21H30O11 and a molecular weight of
458.46 g/mol.
DON is soluble in water and in some polar solvents (e.g. aqueous methanol, acetonitrile and ethyl
acetate) (EFSA, 2004). The presence of an acetyl moiety in 3-Ac-DON and 15-Ac-DON results in a
decrease in the polarity of the molecule compared with the parent toxin. Conversely, the presence of a
glucoside in DON-3-glucoside leads to an increase in polarity compared with DON (Maresca, 2013).
DON is considered to be a relatively thermostable compound (Kostelanska et al., 2011b). In the
study of Wolf and Bullerman (1998), the effects of heat and pH on the stability of DON were
investigated in an aqueous buffer solution, and only high pH (10.0) and high heat combinations
(170°C, 15 min and 120°C, 30 min) were reported to completely destroy DON.
R1 R2
DON -OH -OH 
3-Ac-DON -OAc -OH 
15-Ac-DON -OH -OAc 
DON-3-glucoside -Ogluc -OH 
Figure 1: Chemical structures of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
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2. Legislation
Worldwide, at least 40 countries have established maximum levels (MLs) or recommendations for
DON in food and animal feed. These countries include the Member States of the EU, the USA and
China (FAO, 2004; LFRA, 2010). MLs for acetylated and modiﬁed forms of DON have not been
reported in any country. In the EU, MLs in food for speciﬁc contaminants shall be established if this is
necessary to protect public health (Article 2 of Council Regulation (EEC) No 315/93 of February 1993
laying down Community procedures for contaminants in food5). MLs are laid down in Regulation (EC)
No 1881/20066, in which legal levels for DON in unprocessed cereals and cereal products for human
consumption have been established (Table 2). MLs for undesirable substances in feed are laid down in
EU Directive 2002/32/EC7. Annex I of this Directive contains MLs of a number of inorganic and organic
contaminants in feed. DON is not regulated under this Directive. DON is regulated, however, within
Recommendation 2006/576/EC8, in which guidance levels are given for DON in certain products
intended for animal feed. The MLs for cereals and cereal products are given in Table 2 and the
guidance levels for products intended for animal feed are given in Table 3.
In Regulation (EC) No 401/20069, as amended by Regulation (EU) No 519/201410, requirements for
methods of sampling and analysis for the ofﬁcial control of the levels of mycotoxins are laid down
(see Section 3 for further details). In Annex I of this Regulation, general provisions for sampling are
stated in part A, speciﬁc provisions for the sampling of cereals and cereal products are given in part B,
and speciﬁc provisions for the sampling of baby foods and processed cereal-baby foods for infants and
young children are stated in part J. Furthermore, in Annex II of this Regulation criteria for sample
preparation and methods of analysis are laid down. Performance criteria for methods of analysis for
DON used in the ofﬁcial control as mentioned in this Regulation are presented in Table 5
(see Section 3).
Within the Codex Alimentarius Commission, supported by FAO and WHO, the Codex Committee on
Food Additives and Contaminants is in the process of drafting MLs for DON in food, which are decisive
in trade conﬂicts. MLs for DON have been proposed for raw cereal grains (wheat, maize and barley);
ﬂour, semolina, meal and ﬂakes derived from wheat, maize or barley; and cereal-based foods for
infants and young children (CAC, 2014).
Table 2: Maximum levels for DON in foodstuffs in EU Regulation (EC) No 1881/2006
Category
number
Foodstuffs(a),(b)
Maximum
levels
(lg/kg)
1 Unprocessed cereals(c),(d) other than durum wheat, oats and maize 1,250
2 Unprocessed durum wheat and oats(c),(d) 1,750
3 Unprocessed maize(c) 1,750
4 Cereals intended for direct human consumption, cereal ﬂour (including maize ﬂour,
maize meal and maize grits) bran as end product marketed for direct human
consumption and germ, with the exception of foodstuffs listed in 7, 8 and 9
750
5 Pasta (dry)(e) 750
6 Bread (including small bakery wares), pastries, biscuits, cereal snacks and
breakfast cereals
500
5 Council Regulation (EEC) No 315/93 of February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–3.
6 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
7 Directive 2002/32/EC of the European Parliament and the Council of 7 May 2002 on undesirable substances in animal feed. OJ
L 140, 30.5.2002, p. 10–21.
8 Commission Recommendation 2006/576/EC of 17 August 2006 on the presence of deoxynivalenol, zearalenone, ochratoxin A,
T-2 and HT-2 and fumonisins in products intended for animal feeding. OJ L 229, 23.8.2006, p. 7–9.
9 Commission Regulation (EC) No 401/2006 of 23 February 2006 laying down the methods of sampling and analysis for the
ofﬁcial control of the levels of mycotoxins in foodstuffs. OJ L 70, 9.3.2006, p. 12–34.
10 Commission Regulation (EU) No 519/2014 of 16 May 2014 amending Regulation (EC) No 401/2006 as regards methods of
sampling of large lots, spices and food supplements, performance criteria for T-2, HT-2 toxin and citrinin and screening
methods of analysis. OJ L 147, 17.5.2014, p. 29–43.
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Category
number
Foodstuffs(a),(b)
Maximum
levels
(lg/kg)
7 Processed cereal-based foods and baby foods for infants and young children(f),(g) 200
8 Milling fractions of maize with particle size > 500 lm falling within CN code 1103
13 or 1103 20 40 and other maize milling products with particle size > 500 lm not
used for direct human consumption falling within CN code 1904 10 10
750
9 Milling fractions of maize with particle size ≤ 500 lm falling within CN code 1102
20 and other maize milling products with particle size ≤ 500 lm not used for direct
human consumption falling within CN code 1904 10 10
1,250
CN, Combined Nomenclature (maize milling fractions are classiﬁed using the particle size in different headings in the Combined
Nomenclature based upon a rate of passage through a sieve with an aperture of 500 lm).
(a): As regards fruits, vegetables and cereals, reference is made to the foodstuffs listed in the relevant category as deﬁned in
Regulation (EC) No 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue
levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC11 as last
amended by Regulation (EC) No 178/200612. This means, inter alia, that buckwheat (Fagopyrum sp.) is included in ‘cereals’
and buckwheat products are included in ‘cereal products’.
(b): Rice is not included in ‘cereals’ and rice products are not included in ‘cereal products’.
(c): The maximum level applies to unprocessed cereals placed on the market for ﬁrst-stage processing. ‘First-stage processing’
shall mean any physical or thermal treatment, other than drying, of or on the grain. Cleaning, sorting and drying procedures
are not considered to be ‘ﬁrst-stage processing’ insofar as no physical action is exerted on the grain kernel itself and the
whole grain remains intact after cleaning and sorting. In integrated production and processing systems, the maximum level
applies to the unprocessed cereals if they are intended for ﬁrst-stage processing.
(d): The maximum level applies to cereals harvested and taken over, as from the 2005/06 marketing year, in accordance with
Commission Regulation (EC) No 824/2000 of 19 April 2000 establishing procedures for the taking over of cereals by intervention
agencies and laying down methods of analysis for determining the quality of cereals,13 as last amended by Commission
Regulation (EC) No 1068/2005 of 6 July 2005 amending Regulation (EC) No 824/2000 establishing procedures for the taking
over of cereals by intervention agencies and laying down methods of analysis for determining the quality of cereals.14
(e): Pasta (dry) means pasta with a water content of approximately 12%.
(f): Foodstuffs listed in this category as deﬁned in Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-
based foods and baby foods for infants and young children.15
(g): The maximum level refers to the dry matter. The dry matter is determined in accordance with Commission Regulation (EC)
No 401/2006 of 23 February 2006 laying down the methods of sampling and analysis for the ofﬁcial control of the levels of
mycotoxins in foodstuffs.16
Table 3: Guidance levels for DON in animal feed in EU Recommendation 2006/576/EC11
Products intended for animal feed(a)
Guidance value in mg/kg
relative to a feedingstuff with
a moisture content of 12%
Cereals and cereal products(b) with the exception of maize by-products 8
Maize by-products 12
Complementary and complete feedingstuffs with the exception of: 5
Complementary and complete feedingstuffs for pigs 0.9
Complementary and complete feedingstuffs for calves (< 4 months),
lambs and kids
2
(a): Particular attention has to be paid to cereals and cereal products fed directly to the animals that their use in a daily ration
should not lead to the animal being exposed to a higher level of these mycotoxins than the corresponding levels of exposure
where only the complete feedingstuffs are used in a daily ration.
(b): The term ‘Cereals and cereal products’ includes not only the feed materials listed under heading 1 ‘Cereal grains, their
products and by-products’ of the non-exclusive list of main feed materials referred to in part B of the Annex to Council
Directive 96/25/EC of 29 April 1996 on the circulation and use of feed materials amending Directives 70/524/EEC, 74/63/
EEC, 82/471/EEC and 93/74/EEC and repealing Directive 77/101/EEC10, but also other feed materials derived from cereals in
particular cereal forages and roughages.
11 OJ L 70, 16.3.2005, p. 1–16.
12 OJ L 29, 2.2.2006, p. 3–25.
13 OJ L 100, 20.4.2000, p. 31–50.
14 OJ L 174, 7.7.2005, p. 65–68.
15 OJ L 339, 6.12.2006, p. 16–35.
16 OJ L 70, 9.3.2006, p. 12–34.
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3. Analysis
The analytical methodology described in this section relates to the determination of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside in food and feed. In addition, there exists analytical
methodology to determine DON, and its acetylated and modiﬁed forms in human and animal tissues
and body ﬂuids such as urine.
3.1. Sampling and storage
Prior to the determination of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, a representative
sample must be provided. There are no speciﬁc requirements or recommendations for DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside that should be followed concerning the sampling and the
storage of the samples intended for the determination of these compounds. Due to the possible
heterogeneous distribution of these toxins in lots (of grains), sampling may contribute to a substantial
extent to the variability in analytical results.
In Commission Regulation (EC) No 519/201413, methods of sampling for the ofﬁcial control of the
levels of mycotoxins are laid down. This Regulation No 519/2014 amended Commission Regulation
(EC) No 401/200617 in which general provisions for sampling are stated in part A, and speciﬁc
provisions for the sampling of cereals and cereal products are given in part B. This sampling procedure
is also of application for the ofﬁcial control of the maximum levels established for Fusarium toxins. The
amendments on sampling concern in particular additional requirements for the sampling of very large
lots or lots stored or transported in a way whereby sampling throughout the lot is not feasible. This
regulation has to be followed when sampling for the determination of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside in cereals. After sampling, the samples are to be stored under appropriate conditions
(dry, preferably frozen) until analysis in order to prevent Fusarium fungi growing further and producing
toxins.
3.2. Determination of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
In the past, most attention was on the determination of DON only, and therefore analytical
methods dedicated to DON are abundant in literature. Later on methods for simultaneous detection
and quantiﬁcation of DON and acetylated and modiﬁed forms were developed and described. In
general, analytical approaches to determine DON do not differ from those applied for other
trichothecenes. They include toxin extraction from samples with an extraction solvent, usually followed
by a clean-up step to eliminate interferences from the sample matrix, and a ﬁnal detection of the
target toxin by suitable methods.
Suitable analytical methodology, summarised also by Ran et al. (2013), relied on high-performance
liquid chromatography (HPLC) with subsequent UV and ﬂuorescence detector (FLD), gas chromatography
with subsequent electron capture detection (GC-ECD) or GC with MS detection (GC–MS). Screening
methods based on techniques such as thin-layer chromatography (TLC) and enzyme-linked
immunosorbent assay (ELISA) have also been published. More recent trends in mycotoxin analysis have
led to the development of HPLC coupled with MS with minimal extract clean-up, with the possibility for
multitoxin analysis applicable to a wide variety of matrices.
All analytical methods for DON are potentially also suitable for the acetylated and modiﬁed DON
forms (Berthiller et al., 2013). However, the structural differences of 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside compared with DON induce changes in the physicochemical properties, such as
solubility and polarity (see Section 1.2) that require different conditions for analysis.
The main challenge for both acetylated forms was the separation of the 3-Ac-DON and the 15-Ac-
DON isomers in the analytical methods (Iba~nez-Vea et al., 2011; Kostelanska et al., 2011a). As the two
acetylated DONs are isomers and the only difference in structure is the position of the acetyl group,
chromatographic retention times and most tandem mass spectrometry (MS/MS) product ions are
similar for the two compounds (Yoshinari et al., 2013). Some authors therefore take both 3-Ac-DON
and 15-Ac-DONs together for quantiﬁcation (Kostelanska et al., 2011a). Other authors focus on only
one of the two acetylated derivatives (Rasmussen et al., 2012). Monbaliu et al. (2009); De Boevre
et al. (2012); Yoshinari et al. (2012, 2013) and Versilovskis et al. (2012) successfully separated 3-Ac-
DON and 15-Ac-DON in their optimised HPLC method. However, Habler and Rychlik (2016) could
17 Regulation (EC) No 401/2006 of the European Parliament and the Council of 23 February 2006 laying down the methods of
sampling and analysis for the ofﬁcial control of the levels of mycotoxins in foodstuffs. OJ L 70, 9.3.2006, p. 1234.
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quantify 3-Ac-DON and 15-Ac-DON without chromatographic separation, especially by the difference in
the intensities of the product ions.
Generally, two different approaches are reported in the literature for the determination of DON-3-
glucoside. The ﬁrst one is the analytical technique, which directly detects the modiﬁed form as it is
(direct methods). This approach is usually based on MS analysis and requires calibrants. The second
approach is the conversion into DON by enzymatic and/or chemical treatment before the analysis
(indirect methods). In such a way, the sum of DON and DON-3-glucoside was simultaneously detected
in the sample (Berthiller et al., 2013). The indirect approach works with the common chromatographic
or immunochemical techniques and it does not require any calibrant. Its main drawback is the lack of
efﬁcacy of the cleavage reaction and therefore, direct methods remain the method of choice for the
determination of DON-3-glucoside (Malachova et al., 2015) (see Section 3.2.1).
3.2.1. Analyte isolation
As DON is a polar mycotoxin, it can easily be extracted from food and feed by shaking or blending
with pure water or mixtures of water with other polar solvents such as acetonitrile or methanol. The
most important procedures for clean-up of extracts and concentration of DON are liquid–liquid
extraction, solid-phase extraction (SPE), immunoafﬁnity columns (IAC), and multifunctional columns
(Ran et al., 2013). However, as DON-3-glucoside is more polar than DON, SPE techniques might not
be suitable for this modiﬁed mycotoxin (De Boevre et al., 2012; Berthiller et al., 2013). As more
sensitive HPLC–MS equipments have become available, it has been possible to replace clean-up by
diluting the sample extract (Sulyok et al., 2006) or by evaporating and redissolving the sample extract
(Monbaliu et al., 2009; Kostelanska et al., 2011a).
For the isolation of DON together with 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, extraction
solvents containing acetonitrile and water in different ratios, eventually acidiﬁed with acetic acid and/or
formic acid are the most often used (Sulyok et al., 2006; Iba~nez-Vea et al., 2011; Kostelanska et al.,
2011a; De Boevre et al., 2012; De Angelis et al., 2013; Juan et al., 2013). In addition, modiﬁed
QuEChERS (quick, easy, cheap, effective, rugged and safe) sample preparation procedures, based on
the partitioning between water or methanol and acetonitrile by the addition of salt mixtures, was
proposed in combination with MS (Zachariasova et al., 2010; Desmarchelier and Seefelder, 2011; Cirlini
et al., 2012; Pereira et al., 2015). Dall’Asta et al. (2013) used a higher amount of acetonitrile and a
lower amount of salts. Acceptable recoveries were also obtained for DON-3-glucoside.
For indirect methods, the use of glucosidases is in general not effective to hydrolyse DON-3-glucoside
(Sewald et al., 1992). However, a promising glucosidase from Biﬁdobacterium able to hydrolyse DON-3-
glucoside in cereal matrices was recently identiﬁed (Michlmayr et al., 2015). Enzyme treatment with
amylolytic, proteolytic or cell wall-degrading enzymes had an effect on the quantity of DON released
from its modiﬁed forms in barley (Zhou et al., 2007). An acid hydrolysis procedure based on hot
trichloroacetic acid was applied to samples containing 3-Ac-DON and 15-Ac-DON (Liu et al., 2005). The
procedure did not hydrolyse all of the Ac-DON known to be present. Tran and Smith (2011) determined
optimal conditions for hydrolysis of conjugated DON in maize and wheat with triﬂuoromethanesulfonic
acid. However, after a critical evaluation, Malachova et al. (2015) strongly discourage the use of indirect
methods based on acidic or alkaline hydrolysis as none of the hydrolytic conditions were found to be
suitable for achieving reliable decomposition of modiﬁed forms of DON to DON.
3.2.2. Chromatographic methods
Chromatographic methods have been developed for the identiﬁcation and quantiﬁcation of several
trichothecenes including DON, 3-Ac-DON and 15-Ac-DON and DON-3-glucoside in various matrices
including food and feed as well as samples of human and animal origin.
TLC was the ﬁrst chromatographic method to be applied for DON determination, and an ofﬁcial
method of the Association of Analytical Communities (AOAC) exists for determination of DON in wheat by
ﬂuoro-densitometric quantiﬁcation at levels ≥ 300 lg/kg (Eppley et al., 1986). TLC is a fast and low-cost
method, but it is laborious and its application is now mainly limited to developing countries (Berthiller
et al., 2013). In the past, GC methods were routinely used for the determination of DON, 3-Ac-DON and
15-Ac-DON (Krska et al., 2001), and an ofﬁcial AOAC method exists for determination of DON in wheat by
GC with ECD for quantiﬁcation at levels ≥ 350 lg/kg (Ware et al., 1986). However, the major limitation is
the necessity of a time-consuming derivatisation of the polar analytes prior to determination. Methods
using ECD (Ware et al., 1986; Black et al., 1987; Hallier et al., 2011; Simsek et al., 2012) or MS detection
(Black et al., 1987; Krska et al., 2001; Edwards, 2009a; Iba~nez-Vea et al., 2011; Pereira et al., 2015)
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have been described. Limits of quantiﬁcation (LOQs) can differ substantially depending on the analytical
scheme used (see Table 4 for typical examples). HPLC-analysis can be performed with ﬂuorescence
(FLD), UV, or diode-array (DAD), or MS detection. For FLD, a pre- or post-column derivatisation is
required, which makes this type of analysis time-consuming. UV detection is often limited by a lack of
speciﬁcity due to the use of low wavelengths (see Section 1.2). Nevertheless, European Committee for
Standardisation (CEN) methods exist for DON in animal feed (EN15791:200918) and for DON in cereals,
cereal products and cereal-based food for infants and young children (EN15891:201019), with HPLC-UV.
Examples of HPLC methods together with LOQs are reported in Table 4.
High- and ultra-high-performance liquid chromatography (HPLC/U-HPLC) coupled with various MS
detectors has become the most frequently used hyphenated technique in mycotoxin determination and
especially for the simultaneous determination of multiple mycotoxins, including DON and its acetylated
and modiﬁed forms. Unlike GC–MS, there is no need for derivatisation. The majority of HPLC–MS-
based methods for the quantiﬁcation of DON and other B-trichothecenes is based on MS/MS in
combination with selected reaction monitoring (SRM) (Gottschalk et al., 2009; Sulyok et al., 2010; Juan
et al., 2012). Ionisation methods used are atmospheric pressure chemical ionisation (APCI) and
electrospray ionisation (ESI) in positive as well as negative ionisation modes. ESI seems to be more
robust than APCI and is thus more frequently employed for analysis of mycotoxins including DON
(Monbaliu et al., 2009; Santini et al., 2009; Desmarchelier et al., 2010; Han et al., 2010; Desmarchelier
and Seefelder, 2011; De Boevre et al., 2012; Juan et al., 2012; De Angelis et al., 2013). Quantiﬁcation
by means of method matrix-matched calibration curves (calibration curves constructed with spiked
blank matrix) is usually considered as a good option to compensate for both losses during extraction
and matrix effects generated during the ionisation of the analytes (Desmarchelier and Seefelder,
2011). Matrix effects, however can be further minimised by adding isotope-labelled internal standards
(Ran et al., 2013). Moreover, multi-mycotoxin LC–MS methods using of either isotope-labelled internal
standards or matrix-matched calibration curves depending on the availability of the internal standards
for the analytes have also been described (Habler and Rychlik, 2016). LOQs can differ substantially
depending on the analytical scheme used, (see Table 4 for typical examples).
3.2.3. Immunochemical methods
Immunochemical methods, based on antigen–antibody reactions, provide rapid and economical
alternatives to chromatographic methods and represent one of the most practical options for farmers
and industries for a fast and easy control of DON in raw materials and processed food and feed (De
Saeger and Van Egmond, 2012; Zachariasova et al., 2014a). Different formats of immunochemical
methods for DON detection have been described in literature and/or are commercially available,
including ELISA (Ji et al., 2011; Hiraoka et al., 2013), lateral ﬂow test strips (Kolosova et al., 2008;
Huang et al., 2012; Albert et al., 2013; Lattanzio et al., 2016), ﬂow-through tests (Ediage et al.,
2012a), ﬂuorescence polarisation immunoassay (Maragos and Plattner, 2002; Lippolis et al., 2006),
immunosensors (Romanazzo et al., 2010; Dorokhin et al., 2011; Maragos, 2011; Zhilei et al., 2011)
and IAC (the latter for clean-up) (Brenn-Struckhofova et al., 2009). However, the ELISA tests still
dominate the routine screening practice (Zachariasova et al., 2014a). Recently, a trend towards multi-
mycotoxin detection has been observed for immunochemical methods (Peters et al., 2011; Ediage
et al., 2012a; He et al., 2012; Lattanzio et al., 2012; Song et al., 2014).
Different antibodies against DON are (commercially) available and described in the literature
(Usleber et al., 1991; Maragos and McCormick, 2000; Maragos et al., 2006; Lee et al., 2013; Sanders
et al., 2014). Antibodies against DON can cross-react with acetylated and/or modiﬁed forms of DON.
Cross-reactivity of DON antibodies with 3-Ac-DON and/or 15-Ac-DON has been frequently reported
with levels ranging between 51–770% and 0–65%, respectively (Tangni et al., 2010; Sanders et al.,
2014; Zachariasova et al., 2014a). However, very speciﬁc 3-Ac-DON antibodies have also been
described (Sanders et al., 2014). No antibodies have speciﬁcally targeted and been selected against
DON-3-glucoside. In an overview of antibodies and (commercial) ELISA and IAC for DON, with special
focus on DON-3-glucoside, Berthiller et al. (2013) showed that cross-reactivity with DON-3-glucoside
18 Animal feeding stuff – Determination of Deoxynivalenol in animal feed - HPLC method with UV detection and immunoafﬁnity column
clean-up. Available online: http://standards.cen.eu/dyn/www/f?p=204:110:0::::FSP_PROJECT,FSP_ORG_ID:28286,6308&cs=
1C28E32D46DBFB607F7C58DFA1FA66526
19 Foodstuffs – Determination of deoxynivalenol in cereals, cereal products and cereal based foods for infants and young children
- HPLC method with immunoafﬁnity column cleanup and UV detection. Available online: http://standards.cen.eu/dyn/www/f?
p=204:110:0::::FSP_PROJECT,FSP_ORG_ID:27749,6256&cs=1C5E441A544C20E01B7841833F77E0B7B
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can signiﬁcantly20 vary from 0% to 157% depending on the antibodies used. Due to these cross-
reactivities to different DON derivatives, discrepancies between the results for DON obtained from
ELISA and LC–MS/MS demonstrate a possible risk for biased results when using immunochemical
methods. Not only the DON derivatives, but also the unidentiﬁed matrix components are responsible
for concentration overestimation of the target DON analyte (Kostelanska et al., 2009; Dzuman et al.,
2014; Zachariasova et al., 2014a). Cross-reactivity values have been reported for most of the
commercially available products, but several studies in literature reveal that values declared by kit
producers are often fairly different from those determined within the in-house validation (Zachariasova
et al., 2014a). A guideline on how to characterise antibodies used in immunochemical methods for
mycotoxins analysis has been provided by Fremy and Usleber (2003). Typical examples of
immunochemical methods together with LOQs are in Table 4.
3.2.4. Other approaches
One of the emerging techniques is direct analysis in real time (DART). In this technique,
(chromatographic) separation and clean-up are omitted. Vaclavik et al. (2010) demonstrated the use
of DART coupled to high-resolution MS (HRMS) to quantify DON and 3-Ac-DON in QuEChERS-based
extracts prepared from cereals.
A very recent trend is the use of HRMS for untargeted metabolic proﬁling and metabolomics.
Besides the known mycotoxins and metabolites, novel metabolites, biotransformation products and/or
modiﬁed fungal metabolites can be identiﬁed. The stable isotope labelling-assisted untargeted
metabolic proﬁling method developed by Kluger et al. (2013) revealed novel conjugates of DON in
wheat. One of the products was annotated as DON-glutathione conjugate. Zachariasova et al. (2012)
revealed by using HRMS that also oligoglycosylated DON forms were present in cereal-based products.
HRMS was also used to study thermal degradation products of DON in roasted wheat samples and
baked bread (Kostelanska et al., 2011b). De Dominicis et al. (2015) developed an U-HPLC-HRMS
method for simultaneous quantitative determination of pesticides, antibiotics and mycotoxins in
different food products (milk, wheat ﬂour and mini-cakes).
20 In this opinion, if not indicated in the text explicitly the term ‘signiﬁcant(ly)’ always indicates the presence of statistical
signiﬁcance at the level of 0.05.
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Table 4: Typical examples of the method characteristics and limits of quantiﬁcation (LOQ) of analytical methods used for the determination of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and feed
Analytical
technique
Method characteristics
LOQ (lg/kg)
References
DON
3-Ac-
DON
15-Ac-
DON
DON-3-
glucoside
TLC Screening (qualitative–semiquantitative) 300(a) n.a. n.a. n.a. Eppley et al. (1986)
ELISA Screening (semiquantitative–quantitative) 25–300 n.a. n.a. n.a. Maragos and McCormick (2000), Hiraoka et al. (2013),
Dzuman et al. (2014)
GC-ECD Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
5–350(a)
16–28(b)
16–23(b) 18–23(b) n.a. Ware et al. (1986), Labuda et al. (2005), Valle-Algarra
et al. (2005), Yue et al. (2010)
GC–MS(/MS) Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
1–120 1–57 8–25 n.a. Edwards (2009a,b,c), Cunha and Fernandez (2010),
Iba~nez-Vea et al. (2011), Tran et al. (2012), Rodrıguez-
Carrasco et al. (2014b), Pereira et al., (2015)
HPLC-UV or
HPLC-FLD
Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
5–380 60(c) 56(c) n.a. Kl€otzel et al. (2005), Klinglmayr et al. (2010), Soleimany
et al. (2011), Heidtmann-Bemvenuti et al. (2012), Yang
et al. (2013)
LC–MS(/MS) Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
1–260 2–46 2–250 2–30 Desmarchelier et al. (2010), Desmarchelier and
Seefelder (2011), Eckard et al. (2011), Kostelanska
et al. (2011a), De Boevre et al. (2012), Juan et al.
(2012), Lim et al. (2012), Soleimany et al. (2012),
Yoshinari et al. (2012), Habler and Rychlik (2016)
n.a.: not applicable; LOQ: limit of quantiﬁcation; TLC: thin-layer chromatography; GC: gas chromatography; ECD: electron capture detection; MS: mass spectrometry; HPLC: high-performance
liquid chromatography; UV: ultraviolet; FLD: ﬂuorescence detection; n.a.: not applicable.
(a): Association of Analytical Communities (AOAC) ofﬁcial method.
(b): Only reported as limit of detection (LOD).
(c): LOQs based on one reference only (Yang et al., 2013).
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While matrix interferences in extracts can have a signiﬁcant effect on response in MS detectors,
electroactive interferents are relatively rare, and thus electrochemical measurements have been
applied for DON (Hsueh et al., 1999; Ricci et al., 2009).
The use of sensors using molecularly imprinted polymers (MIP) as synthetic receptors for DON
(as an alternative for natural antibodies) was applied by Choi et al. (2011). The sensor was selective
for DON, 3-Ac-DON and 15-Ac-DON in standard solutions.
In addition to the chemical and immunochemical methods for DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside, there exist non-invasive screening methods based on the spectroscopic
characteristics of the analytes or on the acoustic characteristics of DON-contaminated grain kernels.
(Kos et al., 2004; Juodeikiene et al., 2008, 2014; Liu et al., 2009; Fox and Manley, 2013). Another
alternative screening method that can detect DON contamination of cereal grains with high sample
throughput is the electronic nose (Campagnoli et al., 2011; Lippolis et al., 2014).
3.3. Analytical quality assurance: performance criteria, reference
materials and proﬁciency testing for analysis of food
In Annex II of the Regulation (EU) No 401/2006 of 23 February 2006,12 as amended by the
Regulation (EU) No 519/2014 of 16 May 201413 criteria for methods of analysis of various mycotoxins
are laid down. Performance criteria for conﬁrmatory methods of analysis of DON used in the ofﬁcial
control as mentioned in this Regulation are presented in Table 5. For in-house validated methods, as
an alternative, a ‘ﬁtness-for-purpose’ approach may be used to assess their suitability for ofﬁcial
control. In this approach, certain criteria for the measurement uncertainty must be fulﬁlled. These
requirements are not toxin speciﬁc. In Regulation (EU) No 519/201413, speciﬁc requirements for
semiquantitative screening methods are also laid down. These speciﬁc requirements apply to methods
of which the result of the measurement is a numerical value, for example a (relative) response from a
dip-stick reader or a signal from LC–MS, and for which normal statistics apply. While numerical
performance criteria in terms of precision and recovery speciﬁc for DON are given for the conﬁrmatory
methods (Table 5), the requirements in Regulation (EU) No 519/201412 for semiquantitative screening
methods are limited to instructions and procedures for both single laboratory and interlaboratory
validation. These are general requirements and they are not speciﬁcally given for DON. In the case of
bio-analytical methods that give a combined response for a certain mycotoxin group applicability must
be demonstrated and limitations of the test must be mentioned in the scope of the method. Undesired
cross-reactivity (e.g. DON-3-glucoside, 3-Ac-DON or 15-Ac-DON for immuno-based methods for DON)
is not considered to increase the false-negative rate of the target mycotoxins, but may increase the
false suspect rate. This unwanted increasing will be diminished by conﬁrmatory analysis for
unambiguous identiﬁcation and quantiﬁcation of the mycotoxins.
The quality of analytical results regarding accuracy, precision and comparability is essentially linked
to the use of reference materials and certiﬁed reference materials (CRMs). Several test materials
(various ground grains with DON) and standards for DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside, including 13C-labelled (internal) standards for DON and 3-Ac-DON, are offered by
commercial suppliers. In addition, de-epoxy-DON (DOM-1) is frequently used as an internal standard
and is commercially available. Moreover, CRMs for DON in maize and wheat ﬂour and reference
calibrant solutions certiﬁed for DON content are available from the Joint Research Center-Institute for
Reference Materials and Measurements (JRC-IRMM).21 Proﬁciency tests for the determination of DON
in breakfast cereals, biscuits, wheat ﬂour and animal feed are regularly organised by FAPAS®22 and by
the JRC-IRMM (Stroka et al, 2009; Kunsagi et al., 2012; Kujawski et al., 2014). The studies organised
by the JRC-IRMM showed that the major methodologies used (LC–MS and HPLC-optical detection) and
Table 5: Performance criteria for conﬁrmatory methods of analysis for DON
Concentration (lg/kg) RSDr (%) RSDR (%) Recovery (%)
> 100 to ≤ 500 ≤ 20 ≤ 40 60–110
> 500 ≤ 20 ≤ 40 70–120
RSDr: relative standard deviation under repeatability conditions; RSDR: relative standard deviation under reproducibility conditions.
21 https://ec.europa.eu/jrc/en/institutes/irmm
22 http://fapas.com/
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the minor methodologies used (ELISA and GC) led to comparable results. A proﬁciency test for multi-
mycotoxin determination, including DON, in maize by using HPLC–MS/MS methodology was conducted
within the EC’s FP-6 project Monitoring and Quality Assurance in the Food Supply Chain (MoniQA)23
(De Girolamo et al., 2013; Solfrizzo et al., 2013a). This study revealed a considerable analytical
variability in the determination of DON with LC–MS(/MS) methodology. A robust and reliable method
for simultaneous determination of 11 mycotoxins (including DON) in maize could not be identiﬁed from
the results of this proﬁciency test.
3.4. Analytical methods for urinary DON biomarker
Several analytical methods have been developed for the determination of urinary DON and its
metabolites in the past decade (see also Section 7.5.2). DON, DON-3-glucuronide and the predominant
DON-15-glucuronide are the common forms of DON in human urine. In this opinion, the sum of these
three forms refers to total DON (tDON). Although urinary DOM-1 and its conjugates were reported in
some studies, the levels varied in different populations and across species (see Section 7.1). Except for
the recent studies of Huybrechts et al. (2015) and Heyndrickx et al. (2015) which reported high levels
of DOM-1-glucuronide in human urine, low levels of urinary DOM-1 were reported in the other studies.
These results do not yet warrant to consider DOM-1 as a biomarker of exposure of DON (Turner et al.,
2010b, 2011a).
During the early stage of biomarker development in animal experiments, it was reported that DON
can be detected using HPLC-UV method in urine samples from rats (Meky et al., 2003) and from pig
(Thieu and Pettersson, 2009).
A single biomarker method developed for tDON analysis by Turner et al. (2008a) has been applied
in most of the single biomarker studies reviewed in this opinion. For LODs/LOQs of the single
biomarker methods, see Table 52. DON-glucuronide can be detected following digestion with
b-glucuronidase (Turner et al., 2008b). However, DON-3-glucuronide and DON-15-glucuronide cannot
be separated by this approach, and therefore simply DON-glucuronide or tDON was reported in the
study. An adjustment of urinary pH and b-glucuronidase digestion gave the optimal recovery and
repeatability for the urinary DON biomarker method (Turner et al., 2008a). The samples were puriﬁed
with IAC and analysed by HPLC–MS using an internal standard (13C-DON). The method was validated
using the UK Adult National Diet and Nutrition Survey (ANDNS) data and individual 24-h urine samples
(see Turner et al., 2008a, 2010a).
Fast advances in LC–MS technology have allowed multiple mycotoxins to be analysed
simultaneously. This technique was applied to multiple mycotoxin biomarker development and several
methods have been reported recently. For LODs/LOQs of the multi-biomarker methods see Table 53.
Solfrizzo et al. (2011) developed a multi-biomarker method using UPLC–MS/MS for detection of DON,
DOM-1 and six other mycotoxins and their metabolites following a combined IAC and SPE puriﬁcation.
b-Glucuronidase/sulfatase were added to deconjugate DON prior to extraction. Wallin et al. (2015)
analysed urinary DON and DOM-1 concentrations using the multiple urinary biomarker LC–MS/MS
method following 6-in-1 IAC column puriﬁcation. Using a ‘dilute and shoot’ approach, Warth et al.
(2011) reported an analytical method to directly quantify DON-3-glucuronide. They further developed a
‘dilute-and-shoot’ LC-ESI-MS/MS method for the quantitative determination of 15 mycotoxins in human
urine including DON and each DON-glucuronide (Warth et al., 2012a). Also, Gerding et al. (2015) used
a ‘dilute-and-shoot’ LC–MS/MS method for DON and DON-glucuronides but were not able to separately
identify DON-3-glucuronide and DON-15-glucuronide by this method.
Ediage et al. (2012b) reported a multi-biomarker method for 18 mycotoxins and their metabolites
using an LC–MS/MS method. Solvent extraction and SPE clean-up were used for sample preparation,
and DON-3-glucuronide was directly measured. A LC–MS/MS method for 32 mycotoxins including DON,
DOM-1, 3-Ac-DON, 15-Ac-DON and several metabolites such as 3-Ac-DON-15-glucuronide, 15-Ac-DON-
3-glucuronide, DON-3-glucuronide, DON-15-glucuronide and DOM-glucuronide was reported by
Huybrechts et al. (2015).
Commercial sources for DON-glucuronide standards are scarce. The standards described in
literature were in-house produced methods e.g. by using rat and human liver microsomes followed by
isolation and puriﬁcation (Versilovskis et al., 2012; Uhlig et al., 2013) or by chemical synthesis
(Fruhmann et al., 2012). CRMs are not available for urinary DON biomarkers.
23 https://www.moniqa.eu/
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The performance of analytical methods for DON biomarkers have also been compared in an
interlaboratory study. Three laboratories compared their LC–MS mycotoxin biomarker methods: (1) the
single biomarker method, (2) the eight mycotoxins biomarker method following b-glucuronidase
digestion and IAC and SPE clean-up, and (3) the ‘dilute and shoot’ multi-biomarker method. At ﬁrst, a
pre-interlaboratory validation revealed that there was satisfactory agreement between laboratories for
DON analysis (Solfrizzo et al., 2013b). Then, the comparison of the three methods was further
expanded to a human study in South Africa (Shephard et al., 2013) where urine samples from 53
female subjects were collected and distributed to the three laboratories. Creatinine concentrations
were measured and urinary DON concentrations both with and without creatinine adjustment were
calculated. The single biomarker method reported tDON in all samples (mean concentration
20.4  49.4 ng/mL). The eight mycotoxins biomarker method detected DON in 87% of the samples
(mean concentration 11.3  27.1 ng/mL). The ‘dilute and shoot’ method detected DON, DON-3-
glucuronide and DON-15-glucuronide in 13%, 26% and 55% of the samples, respectively with
maximum concentrations of DON, DON-3-glucuronide and DON-15-glucuronide of 21 ng/mL, < LOQ
and 109 ng/mL in urine, respectively. The third method was not as sensitive as the two other methods
(no urinary tDON results from this method). Overall, the DON biomarker results of the different
laboratories were well correlated, suggesting the compatibility between single DON biomarker and the
multi-mycotoxin biomarker approach. However, discrepancy in urinary DON concentrations among
methods and the large difference in the detection sensitivity between laboratories were noted.
In contrary to methods above, Rodrıguez-Carrasco et al. (2014b) developed a novel GC–MS/MS
method for detection of 15 mycotoxins and metabolites following a salting-out liquid–liquid extraction
without enzyme digestion. A GC–MS method has also been used for tDON analysis using 13C-DON as
internal standard and SPE clean-up (Cunha and Fernandes, 2012).
3.5. Conclusions
It is important to notice that prior to the determination of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside, a representative food and feed sample must be provided.
In the past, most attention has been paid to the determination of DON only, and therefore
analytical methods dedicated to DON are abundantly present in the literature. Later on methods for
simultaneous detection and quantiﬁcation of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were
developed. The LOQs differ substantially depending on the analytical scheme, matrix and technology
used. However, LOQs are in the same range (lg/kg) for DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside. LC–MS(/MS) is currently the most frequently used method for simultaneous analysis of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside. LC–MS(/MS) methods have not been formally validated
through interlaboratory studies, however proﬁciency tests have shown that considerable analytical
variability exists in the determination of DON with LC–MS(/MS) methodology.
Two different approaches are reported for the determination of DON-3-glucoside. The ﬁrst is the
use of an analytical technique able to directly detect the modiﬁed form as it is (direct methods). This
approach is usually based on LC–MS analysis and requires standard calibrants. The second approach is
the conversion into DON by enzymatic and/or chemical treatment before the analysis (indirect
methods). Because of the lack of efﬁcacy of the cleavage reaction, direct methods are the method of
choice.
Immunochemical methods for DON, based on antigen-antibody reactions, provide rapid and
economical alternatives to chromatography, but considerable attention should be paid to the cross-
reactivities and matrix effects, which are inherent to this type of analysis.
Performance criteria for methods of analysis (screening and conﬁrmatory) for DON used in the
ofﬁcial control of food and feed are laid down in the regulation of the European Commission
(see Section 3.3). Furthermore, (certiﬁed) reference materials and proﬁciency tests are part of the
necessary quality control systems used in analytical laboratories. These are available for DON, but
CRMs and proﬁciency tests are not (yet) available for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
New trends in high-resolution MS for untargeted metabolic proﬁling and metabolomics will unravel
and identify novel metabolites, biotransformation products and/or modiﬁed DON forms.
Research on DON biomarkers in the past decade has made great progress. Urinary DON and its
metabolites can be detected in single or in multiple biomarker approaches. The single biomarker
approach was of appropriate sensitivity and precision, and showed a strong correlation between tDON
in urine and dietary intake. The multi-biomarker methods detected not only DON and metabolites of
DON, but also many other mycotoxins. Most of the reported analytical methods for DON biomarker
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 31 EFSA Journal 2017;15(9):4718
analysis in urine were sensitive enough to differentiate exposure levels. However, commercial sources
for DON glucuronide standards are scarce and no certiﬁed reference materials are available for urinary
DON biomarkers.
4. Occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
food and feed
4.1. Occurrence data reported in the literature
A large amount of published results on the occurrence of DON for the EFSA FoodEx food categories
‘grains intended for human consumption’ and ‘grain based food products’ has also been reported in
the scientiﬁc literature. However, papers with information about 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside were rare and only small data sets reported analytical results as numerical values on the
co-occurrence separately for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside (see Section 4.2). The
occurrence data of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for the food category ‘Food for
infants and young children’ were particularly scarce. Therefore,the CONTAM Panel decided not to
review all available literature on the occurrence of DON, but to review only the more recently
published data on DON from 2004 onwards also including data on the occurrence of 3-Ac-DON and
15-Ac-DON and of DON-3-glucoside alone or together with DON for the two FoodEx categories
mentioned above. Only data relating to the European market were considered. However, for the
category of ‘baby food and infant food’ a full review is provided on all available data in the published
literature for DON, 3-Ac-DON and 15-Ac-DON and of DON-3-glucoside. It was noted that some articles
provided only limited information, which sometimes made their interpretation difﬁcult. Since the
literature occurrence data on food and feed were not systematically checked for possible duplicate
occurrence in the data reported in Section 4.2, a partial overlap with the data reported in Section 4.2
cannot be excluded.
4.1.1. Occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in grains
and grain-based products (excluding food for infants and young children)
intended for human consumption
Details on published data on the occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
in grains and grain products intended for human consumption (except food for infants and young
children) are summarised in Table B.1 (Appendix B).
4.1.1.1. Grains intended for human consumption
Nine studies reported the occurrence of DON in combination with 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside in grains intended for human consumption. The results are extensively presented in
Table B.1 (Appendix B), and summarised data are given in Table 6 below. Several papers provided
diverse and sometimes only limited information making comparisons of reports difﬁcult. Since
maximum concentrations were reported in most of the studies, these are speciﬁcally presented in
Table 6. It appeared that maximum concentrations of DON, DON-3-glucoside, 3-Ac-DON and 15-Ac-
DON varied widely between studies, which may partly reﬂect different fungal varieties, and differences
in climatic and agricultural conditions during the growing seasons in the various regions, where the
grains were grown. The studies also showed that the highest concentrations were found for DON,
while maximum concentrations for DON-3-glucoside, 3-Ac-DON and 15-Ac-DON were (much) lower.
4.1.1.2. Grain-based food products
Twelve published studies described the occurrence of DON in combination with 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside in grain-based food products. The results are extensively presented in
Table B.1 (Appendix B), and summarised data are given in Table 7 below. Maximum concentrations are
speciﬁcally presented in Table 7 for reasons mentioned in Section 4.1.1.1 varied widely between
studies, but the maximum concentration were (much) lower than found for grains intended for human
consumption (see Section 4.1.1.1). Interestingly, in the category malt and beer maximum
concentrations for DON-3-glucoside were found at the same level as maximum concentrations for
DON. This might be explained by the formation and release of DON-3-glucoside during germination
and brewing.
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4.1.2. Occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food
for infants and young children
In Table B.2 (Appendix B), published data on the occurrence of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside in baby food and infant food are summarised. The data have been published in ﬁve
different papers and they represent four countries from southern, western and central Europe.
Altogether, 179 samples were investigated. In all ﬁve studies analyses were performed for DON; in one
study, 3-Ac-DON and DON-3-glucoside were also looked for; and in another study, analyses were
performed for 3-Ac-DON and 15-Ac-DON in addition to DON. DON was found in four studies with
occurrence percentages ranging from 36% to 76% and in levels up to 286 lg/kg (in baby food from
Spain). The levels of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were below the LOD in all samples
investigated. Results recently reported by Pereira et al. (2015) for 12 samples of baby food,
investigated for DON, 3-Ac-DON and 15-Ac-DON, were not included in Table B.2 (Appendix B) because
of insufﬁcient information on the methodology used.
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Table 6: Summary of published study results on occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in grains intended for human
consumption
Country
Type of
samples
Number of
samples
Maximum
(lg/kg) DON
Maximum
(lg/kg) DON-3-
glucoside
Maximum
(lg/kg) 3-
Ac-DON
Maximum
(lg/kg) 15-
Ac-DON
Observations and remarks Reference
Austria,
Germany,
Slovakia
Wheat, maize 77 4,130 1,070 n.r. n.r. Berthiller et al. (2009)
Belgium Grains 168 2,029 390 120 97 Data reported as means of
positive samples, instead of
maximum values. (All barley)
Vanheule et al. (2014)
Denmark Grains 49 2,638 342 136 n.r. Maximum value for DON:
winter wheat
Maximum value for DON-3-
glucoside: oats
Maximum value 3-Ac-DON:
winter wheat
Rasmussen et al. (2012)
Italy Durum wheat 150 3,715 842 203 244 Dall’Asta et al. (2013)
Italy Durum wheat 47 1,230 n.r. 33 105 Alkadri et al. (2014)
Finland Barley, oats,
wheat
95 23,800 6,600 2,720 n.r. All oats
Values reported as unusually
high as compared to previous
years
Nathanail et al. (2015)
Austria, UK Grains 16 237 n.d. n.d. n.r. Vendl et al. (2010)
France,
Germany,
Poland,
Romania, UK
Grains 18 2,864 237 n.r. n.r. Desmarchelier and
Seefelder (2011)
Poland Mixtures of oat,
wheat, barley
18 21.2 n.r. 2.8 4.3 Data reported as means Ostrowska-Kołodziejczak
et al. (2016)
n.r.: not reported; n.d.: not detected.
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Table 7: Summary of published study results on occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in grain-based food products
Country
Type of
samples
Number of
samples
Maximum
(lg/kg)
DON
Maximum
(lg/kg) DON-
3-glucoside
Maximum
(lg/kg)
3-Ac-DON
Maximum
(lg/kg)
15-Ac-DON
Observations and remarks Reference
Austria, UK Cereal-based
foods
62 254
248
n.d. n.d. n.r. Maximum DON values given for
Austria (bran ﬂakes) and UK
(crackers), respectively
Vendl et al. (2010)
Belgium Cereal-based
foods
174 718 425 431 194 Maximum values for DON, 3-Ac-DON
and 15-Ac-DON: corn ﬂakes
Maximum value for DON-3-glucoside:
ﬁbre-enriched bread
De Boevre et al. (2012)
Belgium Bread and
breakfast
cereals
45 316 n.d. n.d. n.d. Data reported as means of positive
samples instead of maximum values;
mean value for DON: bread
Vanheule et al. (2014)
Poland Malt syrup 1 n.d. n.d. n.r. n.r. Desmarchelier and
Seefelder (2011)
Italy Grain-based
cereals
182 83 n.r. 5 n.r. Maximum values in wheat-based
cereals
Rodrıguez-Carrasco et al.
(2014b)
Czech Republic Cereal-based
products
116 594 94 n.r n.r. Maximum value DON: ﬂour
Maximum value DON-3-glucoside:
snacks
Malachova et al. (2011)
Czech Republic malt, beer,
commercially
baked goods
36 139
62
431
186
82
33
n.r. n.r. Maximum values given for malt, beer
and baked goods respectively
Zachariasova et al.
(2012)
Germany Beer 9 28 63 n.r. n.r. Habler et al. (2016)
Germany Barley malt
from 2012,
2013, 2014
30 10,300 19,000 436 287 Maximum values were all from 2012 Habler and Rychlik
(2016)
Produced in 38
countries,
purchased in
Central Europe
Beer 374 89 81 n.d. n.r. Varga et al. (2013)
Austria Beer 60 30 32 n.d. n.r. Malachova et al. (2012)
25 European
countries
Beer 106 19 n.r. n.d. n.d. Bertuzzi et al. (2011)
n.r.: not reported; n.d.: not detected.
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4.1.3. Occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in feed
EFSA reviewed the occurrence of DON in feeds in 2004 (EFSA, 2004), and therefore the CONTAM
Panel has only reviewed papers reporting the occurrence of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside published from 2004 onwards. In common with many other reviews, EFSA (2004)
concluded that the occurrence of DON is predominantly associated with cereals and cereal by-
products. A number of other surveys of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in feeds,
particularly on DON, have been undertaken since 2004 but have come to similar conclusions. In this
section, more emphasis is given to those studies which reported occurrence of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside in other feed materials than cereal grains because the occurrence
of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in cereal grains was well covered by the EFSA
occurrence database. The selected studies are brieﬂy summarised below, with details given in
Table B.3 (Appendix B).
Compound (complete) feedingstuffs are important for livestock, particularly in intensive production
for pigs and poultry. In a survey of 277 commercially manufactured feeds for fattening pigs in
Portugal, DON was detected in only 47 samples, with levels ranging from 100 to 864 lg/kg. Only four
samples had DON concentrations above 500 lg/kg and none above 900 lg/kg (Almeida et al., 2011).
De Boevre et al. (2012) reported the results of a survey of 67 compound feeds for poultry, pigs,
horses and cattle sampled in Belgium in 2010 and 2011. In summary, DON was found in all feed
samples analysed. The feed type with the highest mean concentration of DON (318 lg/kg) was for
piglets, while the highest individual level of DON (1,250 lg/kg) was found in one sample of compound
feed for fattening pigs. The mean across all groups were less than 400 lg/kg. DON-3-glucoside, 3-Ac-
DON and 15-Ac-DON were also found in all samples with the exception of compound feeds for cattle
and young stock, where DON-3-glucoside was not detected. The highest concentrations of DON-3-
glucoside, 3-Ac-DON and 15-Ac-DON were 121, 47 and 50 lg/kg, respectively. Across all samples,
levels of DON-3-glucoside, 3-Ac-DON and 15-Ac-DON were approximately 18, 19 and 18% of the
concentration of DON, but variation between samples was lower for 15-Ac-DON than for the other two
forms.
These authors also reported data for 19 feed materials commonly used in the manufacture of
compound feeds for livestock. They consisted predominantly of cereals, cereal by-products and oilseed
meals. DON levels were generally low (< 500 lg/kg) but were 1,533 and 1,381 lg/kg in two samples
of maize gluten feed and wheat, respectively. DON-3-glucoside, 3-Ac-DON and 15-Ac-DON were also
reported for these feed materials. The highest concentrations of DON-3-glucoside was reported for a
sample of maize gluten feed (542 lg/kg), but was not detected in 5 of the feeds analysed and < LOD
in a further 5 samples. For 3-Ac-DON, the highest concentration (271 lg/kg) was observed in a
sample of maize grain but was not detected or below the level of detection in 13 of the 19 samples
analysed. The same sample of maize grain had the highest level of 15-Ac-DON (194 lg/kg) but
otherwise levels were below 100 lg/kg. It was not detected or below the level of detection in 10 of
the 19 samples (De Boevre et al., 2012).
Driehuis et al. (2008a) reported the results of a survey of feedstuffs for dairy cows (comprising
silages, feed commodities and compound feeds) from 24 dairy farms in the Netherlands sampled
during 2005. The incidence of DON ranged from 38% to 54%, and was particularly high in compound
feed and silage samples, where the average concentrations were 433 and 550 lg/kg, respectively.
DON was detected in only ﬁve samples of other feed classes: two corn gluten samples, one barley
grain sample and two grass hay samples. It was not detected in any of the ensiled by-product
samples.
Mitak et al (2011)24 reviewed levels of DON in various farm animal feeds and feed mixtures sampled
in Croatia during 2009 and 2010. A total of 94 samples were examined for DON (64 in 2009, 30 in
2010). In 2009 DON was detected in 25% of samples with a mean concentration (in contaminated
samples) of 22.07 lg/kg. In contrast, 96% of samples in 2010 were contaminated with DON, with a
mean concentration 1,432 lg/kg. For feed mixtures, concentrations greater than 900 lg/kg were
detected in seven samples of pig feed (range 1,008–4,055 lg/kg). The levels were elevated also in the
complete feeds for poultry (maximum 3,695 lg/kg) and cattle (maximum 384 lg/kg).
Samples of wheat and maize were obtained from four EU countries and analysed for DON, 3-Ac-
DON and 15-Ac-DON (Monbaliu et al., 2010). In the 50 samples analysed (wheat n = 8, maize n = 42),
DON, 3-Ac-DON and 15-Ac-DON were found in 40, 34 and 31 samples, respectively. In only half of the
24 Original paper in Croatian, text based on the translation to English.
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samples were all three mycotoxins detected, while only DON and 3-Ac-DON co-occurred in six
samples, and only DON and 15-Ac-DON in four samples. Mean DON concentrations were
approximately 40 and 10 times higher than those of 3-Ac-DON and 15-Ac-DON, respectively. The mean
concentrations of DON, 3-Ac-DON and 15-Ac-DON in wheat were 2,657, 33.3 and 38.2 lg/kg,
respectively, while for the maize grains they were 891, 36.5 and 134 lg/kg, respectively.
Zachariasova et al., (2014b) analysed a total of 343 different of feed materials (forages, cereals,
cereal by-products oilseed meals and compound feeds) originating from the Czech Republic
(256 samples) and the UK (87 samples) over a 4-year period (2008–2012) for DON, DON-3-glucoside,
and for the sum of 3-Ac-DON and 15-Ac-DON. Details are given in Table B.4, Appendix B. The highest
concentration of DON was found in dried distiller’s grains with solubles (5,981 lg/kg), a fermented
feedingstuff. For DON-3-glucoside, the highest reported value (773 lg/kg) was in malt sprouts, while
28 samples had a mean concentration of DON-3-glucoside 229 lg/kg. The maximum of the sum of
3-Ac-DON and 15-Ac-DON (458 lg/kg) was similar to that of DON (494 lg/kg). Apart from this
feedingstuff, the mean concentration of DON-3-glucoside was less than 22% of that of the mean
concentration of DON for those feeds for which both were reported. With the exception of maize dried
distiller’s grains with solubles, the concentrations of DON-3-glucoside were higher than those of the
sum 3-Ac-DON and 15-Ac-DON.
Both grain maize and silage maize are important animal feed sources. While the grain is used widely as
a feed for non-ruminant livestock, the whole plant is used as silage (Dorn et al., 2011). In a 2-year (2006
and 2007) maize hybrid study from one site in Switzerland, DON was found in all of the maize kernels
analysed in both 2006 (range 0.21–8.58 mg/kg, mean 2.30 mg/kg) and 2007 (range 0.02–2.19 mg/kg,
mean: 0.97 mg/kg) (Dorn et al., 2011). In the 2 years of the study, 63% and 50% of the samples were
above the recommended limit of 0.9 mg/kg in complete feeds for pigs. Mycotoxin concentrations in crop
residues were also reported to be very high and ranged from 2.6 to 15.3 mg/kg.
In another Swiss study of Eckard et al. (2011), DON was detected in 19 out of 20 samples of maize
silage sampled from farmers’ ﬁelds. Levels were between 780 and 2,990 lg/kg. The mean
concentrations of DON and the sum of 3-Ac-DON and 15-Ac-DON in maize silages were 1,356 and
218 lg/kg, respectively. However, while DON was present in all 19 samples analysed, the sum of 3-Ac-
DON and 15-Ac-DON was only detected in two samples (at concentrations of 135 and 300 lg/kg). In a
further two samples the concentrations of the sum 3-Ac-DON and 15-Ac-DON were below the LOQ
(46 lg/kg).
A survey of forage crops (140 maize, 120 grass and 30 wheat silages) produced in the Netherlands
between 2002 and 2004 was reported by Driehuis et al. (2008b). Although the DON concentrations were
all below 8,000 lg/kg,11 it was detected above the LOQ (250 lg/kg) in 72% of maize and 10% of wheat
silages. Average DON concentrations were 854 and 621 lg/kg, respectively, and maximum
concentrations were 3,142 and 1,165 lg/kg, respectively. A maximum concentration of 3,142 lg/kg of
DON was detected in a maize silage sample from 2004. In this study, forages were also analysed for
acetylated DON. No 3-Ac-DON was detected in maize silage samples from any of the sampling years.
Analysis for 15-Ac-DON was only undertaken on the 2004 samples, but in that year it was detected in
three maize silage samples (5% of the samples analysed) in concentrations of 729, 962 and 1,013 lg/kg.
DON was also detected in three (10%) whole-crop wheat silage samples.
Although grass has been reported to be contaminated with DON, levels are generally low. In a
study from the Czech Republic, mean levels of DON in ﬁve grass species and sampled between June
and December in 2008 and 2009 of 37.6 and 46.3 lg/kg DM, respectively. Differences between
species and years were not signiﬁcant (Skladanka et al., 2011).
Cortinovis et al. (2012) undertook a survey in northern Italy of cereal grains intended speciﬁcally as
feeds for horses. The barley grains were most frequently contaminated (73% positive samples, median
concentration 650 lg/kg) although the highest median concentrations were in the maize and rice bran
feeds (37% and 30% positive samples, 810 and 850 lg/kg, respectively). In another survey, Liesener
et al. (2010) analysed 62 samples of commercial horse feed preparations (complementary feeds)
containing cereal mixtures (‘muesli’ or mash, n = 39; pelleted feeds, n = 12), and plain horse feed
grains (maize, n = 5; oats, n = 4; barley, n = 2) purchased from 21 different producers/distributors
from the German market. DON was detected in all samples, ranging from 16 to 4,900 lg/kg (mean
and standard deviation) 410  660 lg/kg; LOD 10 lg/kg).
In 29 samples of dry dog food sampled in Vienna, 24 (83%) were positive for the presence of
DON, with a mean concentration of 409 lg/kg (B€ohm et al., 2010). The highest value detected was
1,390 lg/kg.
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DON may also be present in other feedingstuffs as a result of inappropriate storage and handling
during processing. Rafai et al. (2000) reported DON in soybean (60–720 lg/kg) and sunﬂower seeds
(150 lg/kg) intended for animal feed. Mankeviciene et al. (2011) examined 22 representative samples
of oil seeds produced in Lithuania during 2007–2009 (8 winter rapeseed, 8 spring rapeseed, 6 linseed
and 7 rapeseed cake). DON was detected in all types of feed, although levels and percentage
contamination varied between years and feed type. The maximum reported concentration in oilseeds
was 278 and 271 lg/kg in oilseed rape and linseed, respectively. Of particular interest is that DON was
detected in all of the samples of rapeseed cake (n = 7; mean concentration 387 lg/kg). Since
rapeseed cake is used as a protein source in livestock diets, this represents a potential source of
exposure. Palm kernel cake is also used as a feed for livestock, and recently Yibadatihan et al. (2014)
reported levels of DON of between 49 and 108 lg/kg in 19 of 25 samples of Malaysian palm kernel
cake (LOD 10 lg/kg, LOQ 33 lg/kg).
4.1.4. Co-occurrence of DON with 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
food and feed
While the CONTAM Panel identiﬁed several studies on the co-occurrence of DON with 3-Ac-DON,
15-Ac-DON and DON-3-glucoside in food there were only few of them on feed. Co-occurrence proﬁles
may differ due to different Fusarium chemotypes occurring in various parts of the world as well as
different plant cultivars with different detoxiﬁcation abilities. The CONTAM Panel selected only studies
(from 2004 till the end of July 2016) relevant for the European market where the ratios of 3-Ac-DON
and/or 15-Ac-DON and/or DON-3-glucoside to DON were reported or could be calculated. See also the
co-occurrence reported for the current occurrence data reported to EFSA in Section 4.3.3.
4.1.4.1. Co-occurrence in food
A number of published studies investigated co-occurrence of DON, 3-Ac-DON and 15-Ac-DON and
DON-3-glucoside in the food categories ‘grains intended for human consumption’, ‘grain-based food
products’ and ‘malt and beer’. The analytical methods used were MS based (see Section 3). The CONTAM
Panel used the results from these studies (including some from Personal communication, Dall’Asta, 2016)
to calculate ratios of DON-3-glucoside, 3-Ac-DON and 15-Ac-DON to DON. Unfortunately, data reported
in the literature were often incomplete and highly inconsistent, which hampered calculation of ratios
based on reported mean values. Only a limited number of studies reported means (usually of samples
being positive) for DON and 3-Ac-DON and/or 15-Ac-DON and/or DON-3-glucoside that allowed the
CONTAM Panel to calculate at least ratios of those means. More often only maximum values were
reported. For these reasons, the CONTAM Panel summarised the published information on co-occurrence
as ratios of means and/or ratios of maxima. A number of studies on ‘grains intended for human
consumption’, ‘grain based food products’ and ‘malt and beer’ could be summarised for the calculation of
ratios of DON-3-glucoside to DON (Tables 8–10). Much less data were available for the calculation of
ratios of the two acetylated forms to DON, and therefore no tables were made for these.
For the category ‘grains intended for human consumption’, the concentration ratios of DON-3-
glucoside to DON roughly varied from 0.12 to 0.26 (overall mean: 0.23; overall median: 0.21) for the
reported means and from 0.06 to 1.10 (overall mean: 0.26; overall median: 0.19) for the reported
maxima (Table 8). Studies investigating the co-occurrence of 3-Ac-DON and/or 15-Ac-DON with DON
did often not detect the acetylated forms at concentrations above the LOQ and when those
concentrations were above the respective LOQ they were usually much lower than the concentrations
of DON. The scarce available data showed that the 3-Ac-DON to DON concentration ratios roughly
varied from 0.03 to 0.22 for the reported means and from 0.01 to 0.11 for the reported maxima. The
15-Ac-DON to DON concentration ratios roughly varied from 0.05 to 0.34 for the reported means and
from 0.07 to 0.09 for the reported maxima.
The DON-3-glucoside to DON ratios in ‘grain-based food products’ (except for beer) ranged from
0.07 to 0.13 (overall mean: 0.10; overall median: 0.10) for the reported mean concentrations and
from 0.07 to 3.08 (overall mean: 0.43; overall median: 0.12) for the reported maximum
concentrations, respectively (Table 9). The reported maximum concentrations for DON and DON-3-
glucoside in grain-based food products were lower than in ‘grains intended for human consumption’.
The CONTAM Panel noted that co-occurrence for the acetylated forms of DON were reported in two
studies only (De Boevre et al., 2012; Rodrıguez-Carrasco et al., 2014b) and the ratios of 3-Ac-DON to
DON and 15-Ac-DON to DON could only be calculated from the reported maxima, ranging from 0.06 to
1.27 and from 0.12 to 0.35, respectively.
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For the category ‘malt and beers’, the concentration ratios of DON-3-glucoside to DON differed due
to the malting process (see Section 4.3.1.4) and were (often much) higher than in grains. Co-
occurrence of 3-Ac-DON and 15-Ac-DON with DON was only occasionally looked for but no
concentrations above the respective LOQ/LOD were identiﬁed. The calculated ratios of DON-3-
glucoside to DON in ‘malt and beer’ ranged from 0.34 to 1.61 (overall mean: 0.93; overall median:
0.67) for the means and from 0.26 to 1.84 (overall mean: 1.07; overall median: 1.00) for the maxima
(Table 10).
Janssen et al. (2015) used published data (collected up to 2013, and including some non-EU
studies) on co-occurring levels of DON-3-glucoside and DON to estimate the DON-3-glucoside to DON
ratio for several food product categories. This resulted in a DON-3-glucoside to DON ratio of 0.2 (90%
conﬁdence interval (CI), 0.04–0.9) in grains and grain-milling products, 0.3 (90% CI, 0.03–2.8) in
grain-based products and 0.8 (90% CI, 0.4–1.8) in beer. These ratios are in line with those given for
the DON-3-glucoside to DON ratios in Tables 8–10.
In summary, the scarce data from the available literature revealed that the 3-Ac-DON to DON
concentration ratios varied roughly from 0.03 to 0.22 for the reported mean concentrations and from
0.01 to 0.11 for the reported maximum concentrations, while for the ratios of 15-Ac-DON to DON
were roughly 0.05–0.34 based on mean concentrations and 0.07–0.09 based on maximum
concentrations. The overall mean ratio of DON-3-glucoside to DON calculated from the ratios of mean
concentrations of the samples on ‘Grains intended for food consumption’ from the available literature
was 23%. The overall mean ratio of DON-3-glucoside to DON calculated from the ratios of maximum
concentrations of the samples was similar. The ratios of DON-3-glucoside to DON calculated for
‘Grain-based food products’ were more variable than those for ‘Grains for food consumption’ but were
not in disagreement with each other. For category ‘malt and beer’ the concentration ratios of
DON-3-glucoside to DON differed due to the malting process and were (often much) higher than in
grains. Co-occurrence of 3-Ac-DON and 15-Ac-DON with DON was only occasionally looked for in malt
and beer. The ratios of DON-3-glucoside to DON in ‘malt and beer’ ranged from 0.34 to 1.61 based on
the mean concentrations and were similar at the maximum concentrations.
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Table 8: Summary of maximum, mean and ratio values for DON and DON-3-glucoside based on published studies on occurrence in grains intended for
food consumption from a total of 763 samples
Country
Type of
samples
Number of
samples
Maximum
DON
(lg/kg)
Maximum
DON-3-
glucoside
(lg/kg)
Mean
DON
(lg/kg)
Mean DON-
3-glucoside
(lg/kg)
Ratio DON-3-
glucoside/DON
based on
maximum
Ratio DON-3-
glucoside/DON
based on mean
Reference
Austria +
Germany +
Slovakia
Wheat
Maize
23
54
4,130
3,680
1,070
763
1,500
753
393
141
0.26
0.21
0.26
0.19
Berthiller et al. (2009)
Belgium Wheat
Barley
Triticale
93
65
10
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
1,053
2,029
1,145
250
390
169



0.24
0.19
0.15
Vanheule et al. (2014)
Denmark Spring barley
Rye
Oat
Triticale
Winter wheat
15
12
11
5
6
< 60
< 50
2,216
737
2,638
< LOD
< LOD
287
109
342
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.


0.13
0.15
0.13



Rasmussen et al. (2012)
Italy Durum wheat 150 3,715 842 n.r. n.r. 0.23  Dall’Asta et al. (2013)
Wheat (2014)
Wheat (2015)
53
162
2,283
1,703
841
648
1,351
936
558
281
0.37
0.38
0.41
0.30
Dall’Asta et al. (2016),
personal
communication(a)
Finland Barley
Oats
Wheat
34
31
30
1,180
23,800
5,510
1,300
6,600
922
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
1.10
0.28
0.17



Nathanail et al. (2015)
France
Germany
Maize
Wheat
Durum
5
3
1
2,864
181
603
237
11
74
n.r.
n.r.
603
n.r.
n.r.
74
0.08
0.06
0.12


0.12
Desmarchelier and
Seefelder (2011)
Overall mean 0.26 0.23
Overall median 0.19 0.21
n.r.: not reported; < LOD: not detected; : could not be calculated by the CONTAM Panel.
(a): Due to scarcity of data also some data obtained via personal communication were included.
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Table 9: Summary of maximum, mean and ratio values for DON and DON-3-glucoside based on published studies on occurrence in grain-based food
products (except beer) from a total of 360 samples
Country Type of samples
Number of
samples
Maximum
DON
(lg/kg)
Maximum
DON-3-
glucoside
(lg/kg)
Mean
DON
(lg/kg)
Mean DON-3-
glucoside
(lg/kg)
Ratio DON-3-
glucoside/DON
based on
maximum
Ratio DON-3-
glucoside/DON
based on mean
Reference(a)
Belgium Fibre-enriched bread
Bran-enriched bread
Corn ﬂakes
Popcorn
Oatmeal
52
36
61
12
13
138
127
718
442
91
425
103
63
96
97
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
3.08
0.81
0.09
0.21
1.07





De Boevre et al. (2012)
Belgium Bread
Breakfast cereals
25
20
n.r.
n.r.
n.r.
n.r.
316
n.r.
n.r.
n.r.




Vanheule et al. (2014)
Czech
Republic
White ﬂour products
Mixed ﬂour products
Breakfast cereals
Snacks
Flours
17
36
7
34
22
350
431
347
320
594
30
41
66
94
72
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
0.09
0.10
0.19
0.29
0.12





Malachova et al. (2011)
Czech
Republic
Wheat, wheat-rye,
multi cereal and
sunﬂower baguettes
BIO wheat ﬂakes
14
1
431
347
33
46
252
347
25
46
0.08
0.13
0.10
0.13
Zachariasova et al. (2012)
Germany
Poland
Romania
UK
Durum semolina
Barley ﬂour
Oat ﬂour
Wheat ﬂour
Malt syrup
Wheat ﬂour
Wheat ﬂour
1
1
1
2
1
1
3
177
5.5
6.3
n.r.
< LOD
45
1,478
12
< LOQ
n.r.
2.6
< LOD
4.8
99
177
5.5
6.3
n.r.
< LOD
45
n.r.
12
< LOQ
n.r.
n.r.
< LOD
4.8
n.r.
0.07




0.11
0.07
0.07




0.11

Desmarchellier et al. (2011)
Overall mean 0.43 0.10
Overall median 0.12 0.10
n.r.: not reported; < LOD: not detected; < LOQ: not quantiﬁed; : could not be calculated by the CONTAM Panel.
(a): Vendl et al. (2010) analysed DON and DON-3-glucoside in a number of different grain products from Austria and the UK. They reported quantiﬁed maximum DON concentrations only for a few
products and < LOD for DON-3-glucoside for all analysed products. Therefore the ratios could not be calculated and are not reported in Table.
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Table 10: Summary of maximum, mean and ratio values for DON and DON-3-glucoside based on published studies on occurrence in malt and beers
from a total of 459 samples
Type of
samples
Number of
samples
Maximum
DON (lg/kg)
Maximum
DON-3-
glucoside
(lg/kg)
Mean
DON
(lg/kg)
Mean DON-
3-glucoside
(lg/kg)
Ratio DON-3-
glucoside/DON
based on
maximum
Ratio DON-3-
glucoside/DON
based on mean
Reference(a)
Austria Pale beer
Wheat beer
Dark beer
Bock beer
Non-alcoholic
beer
Shandy beer
10
10
10
10
10
10
30
27
11
22
3.7
6.4
19
15
16
32
3.1
5.5
13
14
11
13
3.7
6.4
8.3
8.6
9.6
16
2.3
3.5
0.63
0.61
1.45
1.45
0.84
0.86
0.64
0.61
0.87
1.23
0.62
0.55
Malachova et al. (2012)
Czech Republic Malt
Beer
6
15
139
62
186
82
68
21
105
34
1.34
1.32
1.54
1.61
Zachariasova et al. (2012)
Germany Barley malt
2012
2013
2014
10
10
10
10,300
406
60
19,000
441
86
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
1.84
1.09
1.43



Habler and Rychlik (2016)
Germany Beer 9 28 63 13 23 2.25 1.77 Habler et al. (2016)
Produced in 38
countries,
purchased in
Central Europe
Pale beer
Wheat beer
Dark beer
Bock beer
Non-alcoholic
beer
Shandy beer
217
46
47
20
19
25
89
50
45
27
26
13
81
28
26
33
6.6
7.9
12
18
22
14
8.7
6.9
9.3
12
11
15
3.0
3.8
0.91
0.56
0.57
1.22
0.26
0.61
0.78
0.67
0.50
1.07
0.34
0.55
Varga et al. (2013)
Overall mean 1.07 0.93
Overall median 1.00 0.67
n.r.: not reported; < LOD: not detected; : could not be calculated by the CONTAM Panel.
(a): Vendl et al. (2010) analysed DON and DON-3-glucoside in beer including wheat beer from Austria and the UK. They reported DON and DON-3-glucoside concentrations < LOD for the analysed
beer samples. Therefore the ratios could not be calculated and are not reported in Table.
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4.1.4.2. Co-occurrence in feed
A number of published studies have examined the co-occurrence of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside in feeds, predominantly in grains, intended for animal feed. Monbaliu et al.
(2010) reported concentrations of DON, 3-Ac-DON and 15-Ac-DON in samples of wheat and maize
from four EU countries (see Section 4.1.3 and Appendix B, Table B.3). Mean DON concentrations were
approximately 40 and 10 times higher than those of 3-Ac-DON and 15-Ac-DON, respectively. The ratios
of the mean concentrations (of positive samples) of 3-Ac-DON and 15-Ac-DON to DON were 0.013 and
0.014, respectively. However, the authors reported that the relationships were poorly correlated (for
3-Ac-DON and DON was r2 = 0.31; for 15-Ac-DON and DON was r2 = 0.18).
In a survey of maize silages produced in Switzerland, the ratio of the mean concentrations of the
sum of 3-Ac-DON and 15-Ac-DON to DON (for positive samples) was 0.10 (Section 4.1.3 and
Appendix B, Table B.3) (Eckard et al., 2011).
De Boevre et al. (2012) reported levels of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
compound feeds for poultry, pigs, horses and cattle sampled in Belgium in 2010 and 2011 (see details
in Section 4.1.3 and Appendix B). The DON-3-glucoside to DON ratio, based on the mean
concentrations, ranged from 0.15 to 1.04, with the highest value for fattening pig feed. The ratio of
3-Ac-DON to DON calculated from the means ranged from 0.06 to 0.49, while for 15-Ac-DON to DON
the range was 0.13 to 0.25. In the same study, 19 samples of raw feed materials were analysed for
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. Only in samples of maize gluten feed (n = 1) and
maize grain (n = 3) were all four forms (DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside) found.
The DON-3-glucoside to DON ratio, based on the mean concentrations, ranged from 0.04 (a sample of
maize grain) to 1.39 (soy bean), while the ratios of the mean concentrations of 3-Ac-DON to DON and
15-Ac-DON to DON ranged from 0.12 to 0.37 and 0.19 to 0.26, respectively.
Zachariasova et al., (2014b) analysed different feed materials originating from the Czech Republic
and the UK for DON, DON-3-glucoside, and the sum of 3-Ac-DON and 15-Ac-DON. In those feeds
where both DON and DON-3-glucoside were measured, the data showed that the concentration ratios
for DON-3-glucoside to DON varied from 0.05 to 1.49 based on the reported mean concentrations, and
from 0.04 to 4.56 for the reported maximum concentrations respectively. The high DON-3-glucoside to
DON concentration ratio was due to high levels of DON-3-glucoside in malt sprouts.
Berthiller (2016, Personal communication) analysed co-occurrence for DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside in various feed materials, including compound feed (animal species not
speciﬁed), barley, wheat, maize silage, hay and straw in nearly 700 samples from 20 European
countries and three bordering countries (Russia, Ukraine and Turkey) from the year 2015 harvest. In
the vast majority of these samples, 3-Ac-DON and 15-Ac-DON were not detected. From the
concentrations of the positive samples, the CONTAM Panel calculated the mean of the ratios of 3-Ac-
DON to DON of 0.02 for compound feed (n = 45, mainly from Poland and Italy), 0.01 for maize
(n = 16, from Austria, Germany, the Netherlands, Poland and the UK) and 0.05 for oats (n = 3, from
Finland). The mean of the ratios of 15-Ac-DON to DON was 0.03 for 45 compound feed samples from
eight European countries (mostly from Italy, Poland, Austria and Croatia) and 0.27 for 35 maize
samples mainly from Germany. The calculated means of the ratios of DON-3-glucoside to DON were
0.09 for compound feed (n = 236, across 18 countries), 0.24 for barley (n = 51, mainly from Austria),
0.09 for wheat (n = 8, mainly from Austria), 0.19 for oats (n = 6 from Finland, Sweden and Germany).
For an example, for other types of feeds than cereals and/or cereal-based feeds (compound feed;
consisting ~ 50% of cereals), a ratio of means of DON-3-glucoside to DON of 0.08 for eight straw
samples from Germany and the UK was calculated.
Overall, for the limited number of feed material samples reported in the literature, the means of the
ratios calculated from the mean concentrations for 3-Ac-DON to DON ranged from 0.01 to 0.49, for
15-Ac-DON to DON from 0.01 to 0.25 and for DON-3-glucoside to DON from 0.09 to 1.49. A large
variation of the ratios was observed across the different feed materials.
4.1.5. Co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside with
other Fusarium mycotoxins
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside are found to co-occur in grains and food products
with various other Fusarium mycotoxins, including culmorin, quisetin, fumonisins, fusaproliferin, fusaric
acid, fusarenon-X, moniliformin, beauvericin, enniatins, monocerin, nivalenol, T-2 and HT-2 toxins and
zearalenone and their derivatives (Malachova et al., 2011; De Boevre et al., 2012; Serrano et al., 2012;
Juan et al., 2013; Lindblad et al., 2013; Streit et al., 2013). In the study of Streit et al. (2013),
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83 samples of feed and feed raw materials were analysed by a multi-mycotoxin LC–MS/MS method and
the authors concluded that a co-contamination of mycotoxins is the rule. They indicated that mixtures
of Fusarium toxins are detected most frequently and noted the fact that as Fusarium species are plant
pathogens of high importance worldwide, especially in cereal production, this co-occurrence is not
surprising. The CONTAM Panel also investigated the co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside in food and feed with other Fusarium mycotoxins in the occurrence data reported to
EFSA (see Section 4.2.7).
4.1.6. Conclusions on occurrence data reported in the literature
Published studies, which investigated the concentrations of DON and at least one of 3-Ac-DON, 15-Ac-
DON and/or DON-3-glucoside in grains intended for human consumption, showed frequent occurrence of
DON. Concentrations up to 23,800 lg/kg were reported for DON. Lower levels were reported for DON-3-
glucoside (maximum reported level 6,600 lg/kg) and even lower concentrations were also observed for
3-Ac-DON and 15-Ac-DON with maximum reported concentrations of 2,720 lg/kg and 244 lg/kg,
respectively.
While published data of DON, 3-Ac-DON and 15-Ac-DON and DON-3-glucoside in grain-based food
products are rather scarce, the general pattern of occurrence was comparable with that in grains
intended for human consumption, while the concentrations found were generally lower. This is
different though for the category of beer, where only DON and DON-3-glucoside were found, at
relatively low concentrations, but with DON-3-glucoside often present at higher concentrations than
DON. The scarce studies investigating food for infants and young children focused mainly at DON,
which was found in almost half of the samples at relatively low levels. 3-Ac-DON and 15-Ac-DON and
DON-3-glucoside were not found in these food products.
In general, studies on feeds have focussed mainly on DON, with relatively fewer data on 3-Ac-DON
and 15-Ac-DON and DON-3-glucoside. In feed grains, the maximum reported levels were 9,528, 339
and 1,047 lg/kg for DON, 3-Ac-DON and 15-Ac-DON, respectively.
In food and feed grains, and grain based food products and feed materials DON concentrations are
on average 4–5 times higher than concentrations of DON-3-glucoside, and at an order of magnitude
higher than concentrations of 3-Ac-DON and 15-Ac-DON. However, the variation in reported ratios of
3-Ac-DON, 15-Ac-DON and DON-3-glucoside to DON is substantial. In beer the average levels for DON
and DON-3-glucoside are at the same order of magnitude, while 3-Ac-DON and 15-Ac-DON have not
been detected in beer.
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside have been reported to co-occur with various
other Fusarium mycotoxins.
4.2. Current occurrence data in food, feed and unprocessed grains of
undeﬁned end-use reported to EFSA
Following an European Commission mandate to EFSA, a call for annual collection of chemical
contaminant occurrence data in food and feed, including DON, the acetylated derivatives 3-Ac-DON
and 15-Ac-DON, and DON-3-glucoside, was issued by the former EFSA Dietary and Chemical
Monitoring Unit (now DATA Unit)25 in December 2010 with a closing date of 1 October of each year.
European national authorities and similar bodies, research institutions, academia, food business
operators and other stakeholders were invited to submit analytical data on DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside in food and feed. The data submission to EFSA followed the requirements
of the EFSA Guidance on Standard Sample Description for Food and Feed (EFSA, 2010a).
In addition to the data collected from the Member States within the call for data, the CONTAM
Panel also explored the literature and reviewed the studies on occurrence data on acetylated forms
and DON-3-glucoside in food and feed in order to include additional data in the occurrence data sets
submitted to EFSA. As an outcome of this exercise, ﬁve European research groups were contacted.
The occurrence data on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food, feed and unprocessed
grains of undeﬁned end-use were obtained from two contacted research groups from institutes in
Belgium and Italy.
A total of 89,157 analytical results for DON (n = 49,833), 3-Ac-DON (n = 18,708), 15-Ac-DON
(n = 18,286) and DON-3-glucoside (n = 2,330) from 28 European countries (Figure 2) were available
for the assessment. The major contributor of DON data was Germany, which reported 34% of the
25 From 1 January 2014 onwards, Evidence Management Unit (DATA).
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DON data, followed by the Netherlands and Hungary. The major contributor of DON acetylated forms
and DON-3-glucoside data was the Netherlands, reporting 37%, 38% and 42% of 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside analytical results, respectively. Other important contributors to results for
DON acetylated forms results were Germany, Austria and the UK. DON-3-glucoside data were
submitted by the Netherlands, Belgium, Italy, the UK and the Czech Republic. The origin of the
samples was not always the European country reporting the data, i.e. the data set also contained
samples originating from North and South America, Africa, Asia and Australia.
The left-censored data (analytical data below the LOD/LOQ) were treated by the substitution
method as recommended in the ‘Principles and Methods for the Risk Assessment of Chemicals in Food’
(WHO, 2009). The same method is indicated in the EFSA scientiﬁc report ‘Management of left-
censored data in dietary exposure assessment of chemical substances’ (EFSA, 2010b) as an option in
the treatment of left-censored data. The guidance suggests that the lower bound (LB) and upper
bound (UB) approach should be used for chemicals likely to be present in the food (e.g. naturally
occurring contaminants, nutrients and mycotoxins). At the LB, results below the LOQ or LOD were
replaced by zero; at the UB, the results below the LOD were replaced by the LOD and those below the
LOQ were replaced by the value reported as LOQ. Additionally, a middle bound (MB) approach was
also used by assigning a value of LOD/2 or LOQ/2 to the left-censored data. The use of different cut-
off values on the reported LOQs was also evaluated in order to reduce the uncertainty associated to
the exposure estimations.
The 95th percentile estimates obtained on dietary surveys/age classes with less than 60
observations and food categories with 5 or less samples may not be statistically robust (EFSA, 2011b).
Those estimates were not included in the analysis.
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Results were reported for food, feed and unprocessed grains of undeﬁned end use. AT, Austria; BE, Belgium; BG, Bulgaria; CY, Cyprus; CZ, the Czech Republic; DE, Germany; DK,
Denmark; EE, Estonia; ES, Spain; FI, Finland; FR, France; GR, Greece; HU, Hungary; IE, Ireland; IT, Italy; LT, Lithuania; LU, Luxembourg; LV, Latvia; MT, Malta; NL, the Netherlands;
NO, Norway; PO, Poland; PT, Portugal; RO, Romania; SE, Sweden; SI, Slovenia; SK, Slovakia; UK, the United Kingdom.
Figure 2: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside collected from the European countries
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The data covered food and feed, but also unprocessed grains of undeﬁned end-use. After deletion
of duplicates (n = 200), separate data sets were extracted and analysed for food, feed and
unprocessed grains of undeﬁned end-use based on product category information. The distribution of
data between food, feed and unprocessed grains of undeﬁned end-use is detailed in Table 11. The
data were reported on samples collected between years 2007 and 2014 (Figure 3).
The data providers were asked to codify all food descriptors in accordance with the EFSA FoodEx 1
classiﬁcation system (EFSA, 2011a). FoodEx 1 is a provisional food classiﬁcation system that was
developed by the EFSA DATA Unit in 2009 with the objective of simplifying the linkage between
occurrence and food consumption data when assessing exposure to hazardous substances. It contains
20 main food categories (FoodEx level 1), which are further divided into subgroups having 140 items
at the FoodEx level 2, 1,260 items at the FoodEx level 3 and reaching about 1,800 end-points (food
names or generic food names) at the FoodEx level 4. It is based on a hierarchical coding for an easier
cross-checking and it is structured in a child-parent relationship, where each element (‘child’) depends
on upper element (‘parent’).
4.2.1. Cleaning and validation of the occurrence data
To ensure the quality of the occurrence data, several cleaning and validation steps were applied
prior to statistical analysis. Only data sampled since the beginning of 2007 were considered in the
further assessment. A group of data was excluded because of duplicate submission, or due to
incomplete or insufﬁcient level of description (lack of information on analytical method, LOD/LOQ), or
due to uncertainties in the unit of expression of the results. If the data providers could not exclude an
Table 11: Number of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
food, feed and unprocessed grains of undeﬁned end-use as submitted to EFSA
Toxin Food Feed
Unprocessed grains of
undeﬁned end-use
Total
DON 39,997 6,980 2,676 49,653
3-Ac-DON 15,525 1,649 1,514 18,688
15-Ac-DON 15,629 1,210 1,447 18,286
DON-3-glucoside 860 932 538 2,330
Total 72,011 10,771 6,175 88,957
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Figure 3: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside over
the sampling years
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error in reporting results, the corresponding data or data sets were not further taken into account in
the analysis.
Analytical data obtained by ELISA were not included in further analysis because cross-reactivity of
antibodies employed in ELISA-based methods for DON may lead to biased results (see Sections 4.2.3.3
and 4.2.4.3). Components structurally related to DON, such as the acetyl-forms of DON, DON-3-
glucoside and other co-occurring trichothecenes (e.g. nivalenol), thus may cause overestimation of the
DON concentration. TLC methods have only been interlaboratory validated to determine DON at levels
≥ 300 lg/kg matrix (see Table 4 in Section 3.2.3) which is above the cut-off values as discussed in
Sections 4.2.3.1, 4.2.4.1 and 4.2.5.1. Therefore analytical data obtained by TLC were not included in
further analysis. In addition, analytical results generated with other methodologies not having a
sufﬁciently low LOQ were excluded from further analyses (see Sections 4.2.3.1, 4.2.4.1 and 4.2.5.1 for
further details).
In summary, the cleaning process led to the exclusion of 19,692 results of DON data, 4,074 results
of 3-Ac-DON data, 4,203 results of 15-Ac-DON and 799 results of DON-3-glucoside because of:
• 5.1% sampling before 2007,
• 0.2% duplicate submission,
• 2.1% inconsistent and/or incomplete description, uncertainties in the unit of expression,
• 24% unreliable analytical method or information on analytical method missing.
4.2.2. Calculation of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
The CONTAM Panel decided to consider concentrations for the sum of the concentrations of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside in its risk assessment. The reasons for this are explained
in the beginning of Section 7.8 and details of the calculation are described in Section 4.2.8. In the
following Sections 4.2.3–4.2.5, the statistical descriptors of the occurrence data are ﬁrst calculated
separately for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside and then for the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside for food, feed and unprocessed grains of undeﬁned end-use,
respectively. In addition, the concentrations for DON alone were considered in this opinion (see
Appendix F for DON).
It should be noted, that not all samples of the data set were analysed for all four DON forms (DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside) (see Sections 4.2.3.4.5 and 4.2.7). Therefore, the
concentrations for the non-analysed forms of DON (DON or 3-Ac-DON or 15-Ac-DON or DON-3-
glucoside) in these samples were estimated using available knowledge from the published scientiﬁc
literature and the information obtained from the occurrence data submitted to EFSA (see
Section 4.2.8).
4.2.3. Data on food
4.2.3.1. Data collection in food
A total of 72,011 results (39,997 analytical results on DON, 15,525 analytical results on 3-Ac-DON,
15,629 analytical results on 15-Ac-DON and 860 analytical results on DON-3-glucoside) on food were
obtained from 27 reporting countries and were related to samples collected between 2007 and 2014
(Figures 4 and 5). The major contributing country was Germany (42% of DON data, 37% of 3-Ac-DON,
38% of 15-Ac-DON), followed by the Netherlands. The major contributor of the DON-3-glucoside data
was Italy reporting 47% of the data. The original analytical results were reported in mg/kg (14%), lg/L
(0.04%) or in lg/kg (86%). All measurements were converted to lg/kg. Results were reported on
whole weight (99.8%) or on dry matter (0.2% of samples). For consistency in the assessment, the
latter were converted to values expressed on a whole-weight basis.
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It was noted that the detection capabilities of the methods used for the determination of DON, 3-
Ac-DON, 15-Ac-DON and DON-3-glucoside were not always sufﬁcient, having high LODs and LOQs
(LOQs up to 750 lg/kg) and thus resulting in a large number of left-censored data (results below LOD
or LOQ). Those data would bias the outcome of the assessment and, therefore, only results obtained
by methods with LOQs ≤ 50 lg/kg on ‘Food for infants and small children’ and with LOQs ≤ 100 lg/kg
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AT, Austria; BE, Belgium; BG, Bulgaria; CY, Cyprus; CZ, the Czech Republic; DE, Germany; DK, Denmark; EE,
Estonia; ES, Spain; FI, Finland; FR, France; GR, Greece; HU, Hungary; IE, Ireland; IT, Italy; LT, Lithuania; LU,
Luxembourg; LV, Latvia; MT, Malta; NL, the Netherlands; NO, Norway; PO, Poland; RO, Romania; SE, Sweden; SI,
Slovenia; SK, Slovakia; UK, the United Kingdom.
Figure 4: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
food collected from the European countries
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Figure 5: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
food over the sampling years
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 49 EFSA Journal 2017;15(9):4718
for other food categories were included in the assessment. By this approach, 1,985 results of DON
data, 9 results of 3-Ac-DON data and 5,516 results of 15-Ac-DON were not included in the food data
set to be used for occurrence analysis and dietary exposure assessment.
After applying the exclusion criteria described in (Section 4.2.3.) and applying the LOQ cut-off, the
ﬁnal food data set (n = 41,027) included observations on DON (n = 21,916), 3-Ac-DON (n = 11,944),
15-Ac-DON (n = 6,370) and DON-3-glucoside (n = 797).
4.2.3.2. Distribution of samples across food groups
The distribution of analytical results across different food groups for DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside classiﬁed in accordance with the EFSA FoodEx 1 classiﬁcation system (see
Section 4.2) is illustrated in Figure 6.
As described above (Section 4.2), food samples were classiﬁed in accordance with the FoodEx 1
classiﬁcation system. In total, 16 out of 20 food categories were covered at FoodEx level 1 with the
vast majority of data on ‘Grains and grain-based products’, followed by ‘Legumes, nuts and oilseeds’.
Only six food categories had data available for all four toxins (DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside). At FoodEx level 2, ‘Grain milling products’ and ‘Grains for human consumption’ dominated
the product coverage of all four toxins (DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside). A more
detailed distribution and statistical description of concentrations are reported in Tables 12–16
(Section 4.2.3.4.) up to the third level of the FoodEx.
4.2.3.3. Analytical methods used for food
The information on analytical methods and/or on LOQ levels was not available for 19% of food
analytical results. In addition, the measurements obtained by ELISA and TLC methods were not
considered reliable. According to the criteria described in Section 4.2.3, those data did not fulﬁl the
Figure 6: Distribution of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside analytical results across
food groups
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quality criteria and were not included in the further analyses. With this approach, 26% of the analytical
data on food were excluded.
For DON in food, 42% of the data were obtained by LC–MS-based methods (LC–MS/MS 33%,
LC–MS quadrupole 9%), 34% by HPLC-based methods (HPLC-UV 15%, HPLC with standard detection
methods (not speciﬁed) 11%, HPLC-FLD 8%) and 24% by GC-based methods (GC–MS 9%, GC with
standard detection methods (not speciﬁed) 7.5%, GC-ECD 7%, GC-HRMS 0.5%). The data set on food
contained overall 63% of left-censored data (results below LOD/LOQ) for DON. The LOQs varied with
the method used, the food matrix and the laboratory. A range of LOQs was observed with the lowest
median LOQ of 15 lg/kg for the food category ‘Milk and dairy products’ and the highest median LOQ
of 59 lg/kg for the food category ‘Composite food’.
Regarding the acetylated forms, data on 3-Ac-DON in food were obtained by LC–MS-based
methods (66%) and GC-based methods (34%). Analytical data on 15-Ac-DON in food were measured
only by LC–MS-based methods. The data sets comprised 98% and 97% of left-censored data for 3-Ac-
DON and 15-Ac-DON, respectively. A range of LOQs was observed with the lowest median LOQ of
7 lg/kg for the food category ‘Alcoholic beverages’ obtained for 15-Ac-DON and the highest median
LOQ of 100 lg/kg observed for 3-Ac-DON in nine food categories.
Analytical data on DON-3-glucoside in food were obtained by LC–MS-based methods (49%), HPLC-
based methods (18%) and GC-based methods (33%). The left-censored data accounted for 57% of
the results. LOQs were observed at a median LOQ of 20 lg/kg for ﬁve food categories and at a
median LOQ of 26 lg/kg observed for the food category ‘Grains and grain-based products’.
The distribution of LOQs for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside across food
categories is illustrated in Figure 7. A detailed presentation of the proportion of left-censored data
across food categories is given in Tables 12–16 (Section 4.2.3.4).
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(a) DON
(c) 15-Ac-DON
(b) 3-Ac-DON 
(d) DON-3-glucoside
(Box-plot: whiskers at minimum and maximum, box at 25th percentile and 75th percentile with line at 50th percentile). When the median is equal to the lower or upper quartile, the
median and the quartile overlap and in the graph a bold single line is displayed. This may occur especially when the number of left-censored data is high. Moreover, when the
maximum (minimum) value is equal to the upper (lower) quartile, whiskers overlap with the box and a bold line is displayed.
Figure 7: Distribution of the LOQs for (a) DON, (b) 3-Ac-DON, (c) 15-Ac-DON and (d) DON-3-glucoside across food groups
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4.2.3.4. Occurrence data in food
4.2.3.4.1. Currently reported occurrence data on DON in food
Occurrence data on DON were reported in 16 FoodEx level 1 food categories. An overview of the
number of data points available for evaluation, the proportion of left-censored data as a percentage,
mean and 95th percentile (P95) concentration values is presented in Table 12. The majority of the data
received for DON were on ‘Grains and grain-based products’ (n = 15,943), with 52% of left-censored
data followed by ‘Legumes, nuts and oilseeds’ (n = 1,990) with 99.6% of left-censored data. Taking into
account this limitation, ‘Products for special nutritional use’ was the food category that recorded
the highest values of DON in comparison with all other food categories (LB mean = 127 lg/kg; UB
mean = 146 lg/kg) followed by ‘Grains and grain-based products’ (LB mean = 84.5 lg/kg; UB
mean = 107 lg/kg). For the food groups ‘Wine’, ‘Animal and vegetable fats and oils’, ‘Follow-on formulae,
powder’, ‘Berries and small fruits’, ‘Fruit and fruit products’, ‘Pome fruit’, ‘Fruit and vegetable juices’, ‘Other
seeds’, ‘Tree nuts’ and ‘Vegetable products’, DON was not detected or quantiﬁed. The predominant food
category at the FoodEx level 1 ‘Grains and grain-based products’, covered seven food groups at the
FoodEx level 2: ‘Grains for human consumption’, ‘Grain milling products’, ‘Bread and rolls’, ‘Breakfast
cereals’, ‘Fine bakery wares’, ‘Pasta (raw)’ and ‘Grains and grain-based products, unspeciﬁed’. Within this
category, the highest mean concentrations were measured in ‘Grains for human consumption’, with 55%
of left-censored data and the LB mean at 122 lg/kg and UB mean at 144 lg/kg.
The statistical description of results reported on DON in accordance with FoodEx level 3 food
categories is summarised in Tables 12 and 13.
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Table 12: Statistical description of the concentrations of DON across the food categories (FoodEx Level 1(bold) and Level 2 (regular typeface))
Food groups(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Alcoholic beverages 1,123 90 2.21 15.9 29.7 13.2 25.0 50.0
Beer and beer-like beverage 742 85 3.42 11.3 19.3 21.0 25.0 50.0
Wine 381 100 0 25.0 50.0 0 25.0 50.0
Animal and vegetable fats and oils 72 100 0.00 20.1 40.1 0 25.0 50.0
Composite food (including frozen products) 68 85 19.1 32.7 46.3 108 108 108
Cereal-based dishes 6 83.3 18.0 38.0 58.0   
Composite food, unspeciﬁed 6 83.3 55.2 66.4 77.7   
Meat-based meals 1 100 0 25.0 50.0   
Potato based dishes 4 25.0 118.6 121.1 123.6   
Ready to eat soups 43 91 7.42 21.7 36.1   
Rice-based meals 7 100 0 12.5 25.0   
Vegetable-based meals 1 0.0 65.0 65.0 65.0   
Food for infants and small children 849 85 8.33 21.8 35.4 57.0 57.0 57.0
Cereal-based food for infants and young children 735 83 9.32 23.2 37.1 58.3 58.3 58.3
Follow-on formulae, powder 13 100 0 13.0 26.0   
Food for infants and small children, unspeciﬁed 40 98 3.61 12.4 21.3   
Fruit juice and herbal tea for infants and young children 1 100 0 25.0 50.0   
Infant formulae, powder 3 100 0 11.7 23.3   
Ready-to-eat meal for infants and young children 48 96 0.72 13.7 26.6   
Yoghurt, cheese and milk-based dessert for infants and
young children
9 100 0 12.8 25.6   
Fruit and fruit products 1,019 99 1.81 26.2 50.5 0 25.0 50.0
Berries and small fruits 25 100 0 23.2 46.4   
Dried fruits 463 99.8 0.23 25.1 49.9 0 25.0 50.0
Fruit and fruit products, unspeciﬁed 37 100 0 25.0 50.0   
Miscellaneous fruits 287 99.7 0.30 24.9 49.5 0 25.0 50.0
Pome fruits 13 100 0 23.8 47.7   
Stone fruits 194 96 8.70 31.4 54.1 0 25.0 50.0
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Food groups(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Fruit and vegetable juices 91 100 0 25.0 50.0 0 25.0 50.0
Concentrated fruit juice 7 100 0 25.0 50.0   
Fruit juice 73 100 0 25 50   
Fruit nectar 11 100 0 25 50   
Grains and grain-based products 15,943 52 84.5 95.5 107 357 357 357
Grains for human consumption 3,491 55 122 133 144 560 560 560
Grain milling products 4,609 50 86.8 98.0 109 369 369 369
Bread and rolls 2,837 44 66.3 75.8 85.6 262 262 262
Breakfast cereals 2,169 64 56.0 68.5 81.1 246 246 246
Fine bakery wares 975 53 62.4 72.0 81.6 241 241 241
Pasta (Raw) 1,803 51 81.6 93.7 104 342 342 342
Grains and grain-based products, unspeciﬁed 59 73 68.6 84.6 101   
Herbs, spices and condiments 96 91 9.90 27.4 44.9 57.0 57.0 70.0
Baking ingredients 1 100 0 12.5 25.0   
Condiment 51 96.1 3.10 27.1 51.1   
Flavourings or essences 2 100 0 10.0 20.0   
Herb and spice mixtures 7 85.7 57.1 71.4 85.7   
Herbs 5 100 0 10.0 20.0   
Herbs, spices and condiments 4 100 0 10.0 20.0   
Seasoning or extracts 4 25.0 49.0 51.5 54.0   
Spices 22 86 9.10 19.1 29.1   
Legumes, nuts and oilseeds 1,990 99.6 0.70 24.9 49.2 0 25.0 50.0
Legumes, beans, dried 365 99 2.53 25.8 49.0 0 25.0 50.0
Oilseeds 390 99 1.00 23.9 46.8 0 25.0 50.0
Other seeds 34 100 0 25.0 50.0   
Tree nuts 1,201 100 0 25.0 50.0 0 25.0 50.0
Milk and dairy products 4 75 12.5 17.5 22.5   
Non-alcoholic beverages 1 100 0 25.0 50.0   
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Food groups(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Products for special nutritional use 39 56 127 137 146   
Dietary supplements 9 44.4 302.8 313.9 325.0   
Dietetic food for diabetics 3 33.3 108.1 119.8 131.5   
Food for weight reduction 1 100 0 10.0 20.0   
Medical food 23 65 33.5 40.2 46.8   
Products for special nutritional use, unspeciﬁed 3 100 0 29.2 58.3   
Snacks, desserts, and other foods 265 49 81.5 92.8 104 360 360 360
Ices and desserts 1 100 0 10.0 20.0   
Snack food 262 48 82.4 93.6 105 360 360 360
Other foods 2 100 0 18.8 37.5 2 100.0 0.0
Starchy roots and tubers 6 100 0 17.5 35.0   
Sugar and confectionery 23 91 9.70 27.7 45.7   
Chocolate (Cocoa) products 8 100 0 24.1 48.1   
Confectionery (non-chocolate) 6 66.7 37.0 48.3 59.5   
Dessert sauces 2 100 0 25.0 50.0   
Sugar and confectionary 4 100 0 10.0 20.0   
Sugars 3 100 0 21.7 43.3   
Vegetables and vegetable products (including fungi) 327 98 2.10 25.5 48.9 0 25.0 50.0
Cocoa beans and cocoa products 276 99 0.41 25.2 50.0 0 25.0 50.0
Coffee imitates (Solid) 8 100 0 9.1 18.1   
Fruiting vegetables 29 86 20.6 39.4 58.2   
Legume vegetables 1 100 0 35.0 70.0   
Vegetables and vegetable products (including fungi) 2 100 0 18.8 37.5   
Vegetable products, unspeciﬁed 11 100 0 18.8 19.1   
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle Bound; UB: upper bound.
(a): FoodEx Level 1 categories in bold and Food Level 2 categories in regular typeface.
(b): The 95th percentiles obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and are therefore not reported in the table and replaced
by a dash.
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 56 EFSA Journal 2017;15(9):4718
Table 13: Statistical description of the concentrations of DON in the grain and grain based products across FoodEx level 3
Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Grains and grain-based products 15,943 52 84.5 95.5 107 357 357 357
Grains for human consumption 3,491 55 122 133 144 560 560 560
Barley grain 357 62 143 152 162 708 708 708
Buckwheat grain 63 92 38.0 48.3 58.5 263 263 263
Corn grain 226 41 41.8 50.9 60.0 320 320 320
Grains for human consumption, unspeciﬁed 28 71 140 146 152   
Millet grain 42 76 129 137 144   
Oats, grain 228 42 2.90 20.4 37.9 13.8 34.3 62.0
Other grains 41 59 53.4 68.6 84.0   
Rice 140 94 39.2 49.7 60.1 118 118 118
Rye grain 543 67 181 190 200 751 751 751
Spelt grain 200 62 66.2 79.4 92.7 268 268 268
Wheat grain 1,623 47 6.40 21.5 36.5 50.0 50.0 70.0
Bread and rolls 2,837 44 66.3 75.8 85.6 261 262 262
Bread and rolls, unspeciﬁed 728 44 79.7 88.9 98.3 308 308 308
Bread products 88 40 136 145 155 488 488 488
Mixed wheat and rye bread and rolls 483 45 65.5 75.3 85.1 249 249 249
Multigrain bread and rolls 217 29 68.7 75.4 83.1 298 298 298
Other bread 114 52 51.3 62.0 72.6 184 184 184
Rye bread and rolls 97 59 52.8 62.1 71.4 231 231 231
Unleavened bread, crisp bread and rusk 424 57 31.9 43.5 55.3 136 136 136
Wheat bread and rolls 686 37 68.7 77.9 87.2 252 252 252
Breakfast cereals 2,169 64 56.0 68.5 81.1 246 246 246
Breakfast cereals, unspeciﬁed 278 55 73.6 81.5 89.7 270 270 270
Cereal bars 31 77 19.1 36.0 53.0   
Cereal ﬂakes 940 60 75.0 86.7 98.3 335 335 335
Grits 28 86 99.0 117 136   
Mixed breakfast cereals 37 24 80.5 85.6 90.7   
Muesli 685 72 25.7 40.8 55.8 132 132 132
Popped cereals 126 73 41.6 57.4 73.2 201 201 201
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Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Grain milling products 4,609 50 86.8 98.0 109 369 369 369
Buckwheat milling products 60 88 12.5 32.9 53.3 133 133 140
Corn milling products 884 56 99.2 113 126 460 460 460
Grain milling products, unspeciﬁed 209 57 69.1 81.3 93.6 317 317 317
Oat milling products 225 47 58.5 65.4 72.7 220 220 220
Other milling products 76 65 68.4 80.3 92.3 370 370 370
Rice milling products 61 98 1.21 24.8 48.3 0.00 25.0 50
Rye milling products 639 56 53.4 65.6 78.1 240 240 240
Spelt milling products 254 56 46.0 56.7 67.7 227 227 227
Wheat milling products 2,201 42 105 116 126 410 410 410
Grains and grain-based products, unspeciﬁed 59 73 68.6 84.6 100   
Pasta (Raw) 1,803 51 81.6 8.80 104 342 342 342
Noodle, wheat ﬂour, with eggs 67 48 61.0 69.2 77.4 338 338 338
Noodle, wheat ﬂour, without eggs 84 6 220 222 223 730 730 730
Noodle, rice 2 100 0 8.8 17.5   
Pasta (Raw), unspeciﬁed 473 69 53.8 69.6 85.5 260 260 260
Pasta, spelt ﬂour 13 46 123 129 135   
Pasta, spelt wholemeal 16 63 17.8 29.0 40.2   
Pasta, wheat ﬂour, ﬁlled 16 44 65.4 74.2 82.9   
Pasta, wheat ﬂour, with eggs 487 40 92.6 102 111 324 324 324
Pasta, wheat ﬂour, without eggs 448 47 87.0 95.3 104 377 377 377
Pasta, wheat wholemeal, with eggs 94 73 40.3 59.3 78.2 316 316 316
Pasta, wheat wholemeal, without eggs 103 59 80.5 92.8 105 388 388 388
Fine bakery wares 975 53 62.4 72.0 81.6 241 241 241
Biscuits (cookies) 626 50 61.5 69.9 78.3 241 241 241
Fine bakery wares, unspeciﬁed 187 60 61.2 74.1 87.0 230 230 230
Pastries and cakes 162 60 67.1 77.7 88.3 288 288 288
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle Bound; UB: upper bound.
(a): FoodEx Level 1 categories in bold, Food Level 2 categories in bold ﬁrst indent, FoodEx level 3 in regular typeface.
(b): The 95th percentiles obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and are therefore not reported in the table and replaced
by a dash.
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4.2.3.4.2. Currently reported occurrence data on 3-Ac-DON in food
Occurrence data on 3-Ac-DON covered 13 food categories. An overview of the number of data
points available for evaluation, proportion of left-censored data as a percentage, mean and 95th
percentile (P95) concentration values is presented in Table 14. The majority of the data received for
3-Ac-DON were on ‘Grains and grain-based products’ (n = 7,044), with 97% of left-censored data,
followed by ‘Legumes, nuts an oilseeds’ (n = 1,982) with 99.9% of left-censored data. All remaining
food categories comprised only left-censored data. The mean concentrations in ‘Grains and grain-
based products’ were observed at a level of 1.30 lg/kg for the LB and at a level of 40.9 lg/kg for the
UB. The highest mean concentrations according FoodEx level 2 were measured in ‘Breakfast cereals’
(LB mean = 4.71 lg/kg; UB mean = 42.0 lg/kg).
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Table 14: Statistical description of the concentrations of 3-Ac-DON across the FoodEx food categories (FoodEx Level 1(bold) and Level 2 (regular
typeface))
Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Alcoholic beverages 835 100 0 30.6 61.2 0 50.0 100
Beer and beer-like beverage 454 100 0 14.3 28.7 0 50.0 100
Wine 381 100 0 50.0 100 0 50.0 100
Animal and vegetable fats and oils 71 100 0 38.3 76.6 0 50.0 100
Vegetable fat 53 100 0 50.0 100   
Vegetable oil 18 100 0 3.9 7.8   
Composite food (including frozen products) 11 100 0 14.3 28.6   
Cereal-based dishes 2 100 0 7.5 15.0   
Meat-based meals 1 100 0 50.0 100   
Rice-based meals 7 100 0 12.5 25.0   
Vegetable-based meals 1 100 0 5.0 10.0   
Food for infants and small children 346 100 0 13.5 27.1 0 25.0 50.0
Cereal-based food for infants and young children 288 100 0 14.4 28.7 0 25.0 50.0
Follow-on formulae, powder 12 100 0 12.5 25.0   
Food for infants and small children 18 100 0 7.1 14.2   
Infant formulae, powder 2 100 0 5.0 10.0   
Ready-to-eat meal for infants and young children 24 100 0 10.4 20.8   
Yoghurt, cheese and milk-based dessert for infants and
young children
2 100 0 5.0 10.0   
Fruit and fruit products 1,017 100 0 48.9 97.8 0 50.0 100
Berries and small fruits 25 100 0 45.2 90.4   
Dried fruits 461 100 0 49.8 99.7 0 50.0 100
Fruit and fruit products 37 100 0 50.0 100.0   
Miscellaneous fruits 287 100 0 49.2 98.3 0 50.0 100
Pome fruits 13 100 0 46.9 93.8   
Stone fruits 194 100 0 46.7 93.4 0 50.0 100
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Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Fruit and vegetable juices 91 100 0 50.0 100 0 50.0 100
Concentrated fruit juice 7 100 0 50.0 100   
Fruit juice 73 100 0 50.0 100 0 50.0 100
Fruit nectar 11 100 0 50.0 100   
Grains and grain-based products 7,044 97 1.3 21.1 40.9 0 50.0 100
Grains for human consumption 1,434 98 0.4 16.6 32.7 0 50.0 100
Grain milling products 2,173 99 0.3 26.5 52.6 0 50.0 100
Bread and rolls 875 95 2.1 13.4 24.8 0 25.0 50.0
Breakfast cereals 1,196 92 4.7 23.3 42.0 31.2 50.0 100
Fine bakery wares 379 99 0.2 11.4 22.6 0 25.0 50.0
Pasta (Raw) 942 100 0 22.6 45.1 0 50.0 100
Grains and grain-based products, unspeciﬁed 45 100 0 47.1 94.3   
Herbs, spices and condiments 89 100 0 32.3 64.6 0 50.0 100
Baking ingredients 1 100 0 12.5 25.0   
Condiment 48 100 0 49.1 98.1   
Flavourings or essences 2 100 0 10.0 20.0   
Herb and spice mixtures 5 100 0 18.0 36.0   
Herbs 5 100 0 10.0 20.0   
Herbs, spices and condiments 3 100 0 10.0 20.0   
Seasoning or extracts 4 100 0 6.3 12.5   
Spices 21 100 0 13.8 27.6   
Legumes, nuts and oilseeds 1,982 100 0.1 48.4 96.7 0 50.0 100
Legumes, beans, dried 361 100 0 46.0 92.1 0 50.0 100
Oilseeds 387 100 0.4 45.5 90.6 0 50.0 100
Other seeds 34 100 0 50.0 100   
Tree nuts 1,200 100 0 50.0 100 0 50.0 100
Milk and dairy products 2 100 0 5.0 10.0   
Non-alcoholic beverages 1 100 0 50.0 100   
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Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Products for special nutritional use 12 100 0 14.4 28.8   
Dietary supplements 1 100 0 50.0 100   
Food for weight reduction 1 100 0 10.0 20.0   
Medical food 4 100 0 12.5 25.0   
Medical food (are specially formulated and intended for the
dietary management of a disease that has distinctive
nutritional needs that cannot be met by normal diet alone;
intended to be used under medical supervision)
5 100 0 10.0 20.0   
Products for special nutritional use 1 100 0 12.5 25.0   
Snacks, desserts and other foods 118 100 0 17.7 35.3 0 50.0 100
Ices and desserts 1 100 0 10.0 20.0   
Other foods (foods which cannot be included in any other
group)
1 100 0 12.5 25.0   
Snack food 116 100 0 17.8 35.6 0 50.0 100
Starchy roots and tubers 6 100 0 30.0 60.0   
Sugar and confectionery 14 100 0 32.9 65.7   
Chocolate (Cocoa) products 6 100 0 50.0 100   
Confectionery (non-chocolate) 2 100 0 10.0 20.0   
Dessert sauces 2 100 0 50.0 100   
Sugar and confectionary 4 100 0 10.0 20.0   
Vegetables and vegetable products (including fungi) 305 100 0 47.2 94.4 0 50.0 100
Cocoa beans and cocoa products 276 100 0 50.0 100 0 50.0 100
Coffee imitates (Solid) 8 100 0 8.9 17.7   
Fruiting vegetables 8 100 0 45.0 90.0   
Vegetable products 11 100 0 9.5 19.1   
Vegetables and vegetable products (including fungi) 2 100 0 31.3 62.5   
N: number of samples; % LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): Food Level 1 categories in bold and Food Level 2 categories in regular typeface.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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4.2.3.4.3. Currently reported occurrence data on 15-Ac-DON in food
Occurrence data on 15-Ac-DON covered 11 food categories. An overview of the number of data points
available for evaluation, proportion of left-censored as a percentage, mean and 95th percentile (P95)
concentration values is presented in Table 15. The majority of the data received for 15-Ac-DON were on
‘Grains and grain-based products’ (n = 5,392), with 96% of left-censored data, followed by ‘Alcoholic
beverages’ (n = 336) with 99% of left-censored data. Only a limited number of food categories
comprised detected/quantiﬁed results of 15-Ac-DON. The highest mean concentrations in food groups
were observed in ‘Products for special nutritional use’ (LB mean = 5.23 lg/kg; UB mean = 29.3 lg/kg),
‘Snacks, desserts, and other foods’ (LB mean = 3.01 lg/kg; UB mean = 21.2 lg/kg) and ‘Grains and
grain-based products’ (LB mean = 2.20 lg/kg; UB mean = 25.7 lg/kg). Within the food category
‘Products for special nutritional use’, 15-Ac-DON was quantiﬁed only in ‘Medical food’.
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Table 15: Statistical description of the concentrations of 15-Ac-DON across the FoodEx food categories (FoodEx Level 1(bold) and Level 2 (regular
typeface))
Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Alcoholic beverages 336 99 0.1 5.5 10.9 0 50.0 100
Animal and vegetable fats and
oils
18 100 0 6.9 13.9   
Composite food (including
frozen products)
10 100 0 10.8 21.5   
Cereal-based dishes 2 100 0 7.5 15.0   
Rice-based meals 7 100 0 12.5 25.0   
Vegetable-based meals 1 100 0 5.0 10.0   
Food for infants and small
children
334 100 0 14.5 29.1 0 25.0 50.0
Cereal-based food for infants and
young children
288 100 0 15.1 30.1 0 25.0 50.0
Follow-on formulae, powder 12 100 0 12.5 25.0   
Food for infants and small children 18 100 0 7.1 14.2   
Infant formulae, powder 2 100 0 5.0 10.0   
Ready-to-eat meal for infants and
young children
12 100 0 18.3 36.7   
Yoghurt, cheese and milk-based
dessert for infants and young
children
2 100 0 5.0 10.0   
Fruit and fruit products 28 100 0 10.0 20.0   
Berries and small fruits 3 100 0 10.0 20.0   
Dried fruits 2 100 0 10.0 20.0   
Miscellaneous fruits 6 100 0 10.0 20.0   
Pome fruits 1 100 0 10.0 20.0   
Stone fruits 16 100 0 10.0 20.0   
Grains and grain-based
products
5,392 96 2.2 13.9 25.7 0 25.0 50.0
Grains for human consumption 1,151 97 1.5 10.1 18.8 0 25.0 50.0
www.efsa.europa.eu/efsajournal 64 EFSA Journal 2017;15(9):4718
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Grain milling products 1,314 95 3.8 14.8 25.9 0 25.0 50.0
Grains and grain-based products 3 100 0.0 7.9 15.8   
Bread and rolls 855 95 1.2 13.1 25.3 6.0 25.0 50.0
Breakfast cereals 989 94 3.9 18.4 32.9 4.7 25.0 50.0
Fine bakery wares 374 99 0.6 12.2 23.8 0 25.0 50.0
Pasta (Raw) 706 100 0.0 14.2 28.4 0 25.0 50.0
Herbs, spices and condiments 37 97 0.4 17.5 34.6   
Baking ingredients 1 100 0.0 12.5 25.0   
Condiment 1 0 16.0 16.0 16.0   
Flavourings or essences 2 100 0 10.0 20.0   
Herb and spice mixtures 4 100 0 17.5 35.0   
Herbs 5 100 0 25.0 50.0   
Herbs, spices and condiments 3 100 0 15.0 30.0   
Seasoning or extracts 4 100 0 6.3 12.5   
Spices 17 100 0 19.7 39.4   
Legumes, nuts and oilseeds 79 100 0 8.6 17.1 0 10.0 20.0
Legumes, beans, dried 34 100 0 7.9 15.8   
Oilseeds 45 100 0 9.1 18.1   
Milk and milk product imitates 2 100 0 5.0 10.0   
Products for special nutritional
use
11 91 5.2 17.2 29.3   
Food for weight reduction 1 100 0 10.0 20.0   
Medical food 4 100 0 12.5 25.0   
Medical food (are specially
formulated and intended for the
dietary management of a disease
that has distinctive nutritional needs
that cannot be met by normal
diet alone; intended to be used
under medical supervision)
5 80 11.4 23.4 35.4   
Products for special nutritional use 1 100 0 12.5 25.0   
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Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Snacks, desserts and other
foods
93 90 3.0 12.1 21.2 23.0 25.0 50.0
Ices and desserts 1 100 0 25.0 50.0   
Other foods (foods which cannot be
included in any other group)
1 100 0 12.5 25.0   
Snack food 91 90 3.1 12.0 20.9 23.0 25.0 50.0
Starchy roots and tubers 3 100 0 10.0 20.0   
Sugar and confectionary 6 100 0 10.0 20.0   
Confectionery (non-chocolate) 2 100 0 10.0 20.0   
Sugar and confectionary 4 100 0 10.0 20.0   
Vegetables and vegetable
products (including fungi)
21 100 0 10.0 20.0   
Coffee imitates (Solid) 8 100 0 9.2 18.4   
Fruiting vegetables 1 100 0 10.0 20.0   
Vegetable products 11 100 0 9.5 19.1   
Vegetables and vegetable products
(including fungi)
1 100 0 12.5 25.0   
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MD: middle Bound; UB: upper bound.
(a): Food Level 1 categories in bold and Food Level 2 categories in regular typeface.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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4.2.3.4.4. Currently reported occurrence data on DON-3-glucoside in food
Occurrence data on DON-3-glucoside were reported for four food categories. An overview of the
number of data points available for evaluation, proportion of left-censored data as a percentage, mean
and 95th percentile (P95) concentration values is presented in Table 16. The data received for DON-3-
glucoside were predominantly on ‘Grains and grain-based products’ (n = 706) with 59% of left-censored
data and only a limited number of results were reported for other food categories. ‘Grains and grain-
based products’ was also the food category with the highest mean concentrations of DON-3-glucoside
(LB mean = 93.4 lg/kg; UB mean = 109 lg/kg). According to the FoodEx level 2 classiﬁcation, the
highest DON-3-glucoside concentrations were measured in ‘Grains for human consumption’ (LB
mean = 159 lg/kg; UB mean = 170 lg/kg), followed by ‘Grain milling products’ (LB mean = 32.2 lg/kg;
UB mean = 44.4 lg/kg).
Apart from grain-based products food categories, DON-3-glucoside was quantiﬁed in ‘Beer and
beer-like beverage’ (LB mean = 15.2 lg/kg; UB mean = 25.6 lg/kg) and ‘Cereal-based food for infants
and young children (LB mean = 14.9 lg/kg; UB mean = 49.9 lg/kg).
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Table 16: Statistical description of the concentrations of DON-3-glucoside across the FoodEx food categories (FoodEx Level 1 (bold) and Level 2 (regular
typeface))
Food group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Alcoholic beverages 30 50 15.2 20.3 25.6   
Beer and beer-like beverage 30 50 15.2 20.3 25.6   
Animal and vegetable fats and oils 1 100 0.0 10.0 20.0   
Food for infants and small children 30 90 6.01 19.0 32.0   
Cereal-based food for infants and young children 12 75 14.9 32.4 49.9   
Ready-to-eat meal for infants and young children 18 100 0.00 10.0 20.0   
Grains and grain-based products 706 59 93.4 101 109 481 481 481
Grains for human consumption 382 52.1 159 165 170 570 570 570
Grain milling products 22 32 32.2 38.0 44.4   
Fine bakery wares 3 100 0.0 15.0 30.0   
Bread and rolls 131 64 19.7 28.5 38.2 101 101 101
Breakfast cereals 168 72 10.8 21.8 33.3 63.8 63.8 63.8
Herbs, spices and condiments 29 100 0.00 10.0 20.0   
Herb and spice mixtures 2 100 0 10.0 20.0   
Herbs 5 100 0 10.0 20.0   
Herbs, spices and condiments 4 100 0 10.0 20.0   
Spices 18 100 0 10.0 20.0   
Snacks, desserts, and other foods 1 100 0 10.0 20.0   
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): Food Level 1 categories in bold and Food Level 2 categories in regular typeface.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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4.2.3.4.5. Currently reported occurrence data on the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in food
To assess the exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, the
CONTAM Panel reviewed the occurrence data for the sum of concentrations of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside in food with the number of samples available for evaluation and statistical
descriptors of the results (mean and 95th percentile for LB, MB and UB results) as shown in Table 17.
See Sections 4.2.2 and 4.2.8 for the calculation of the sum of concentrations of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside. It should be noted that the occurrence data on the sum of
concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside refer to the number of samples
instead of the number of the analytical results. (The exposure assessment of DON alone is presented
in Appendix F).
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Table 17: Statistical description of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food across the FoodEx food categories (FoodEx
Level 1 (bold) and Level 2 (regular typeface))
Food group(a) N
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Alcoholic beverages(a) 1,123 4.51 55.8 107 27.1 98.8 198
Animal and vegetable fats and oils 72 0 66.6 133 0 83.8 168
Composite food (including frozen products) 68 27.4 50.6 73.8 157 157 168
Food for infants and small children 849 11.8 40.9 70.2 80.5 84.1 160
Fruit and fruit products 1,019 2.53 84.4 166 0 83.8 168
Fruit and vegetable juices 91 0 83.7 168 0 83.8 168
Grains and grain-based products 15,943 117 144 173 493 506 519
Grains for human consumption(a) 3,491 171 195 220 787 793 797
Grain milling products 4,609 119 150 181 513 523 539
Bread and rolls 2,837 91.2 112 133 356 361 371
Breakfast cereals 2,169 77.3 112 146 338 357 370
Fine bakery wares 975 83.5 106 128 334 334 343
Pasta (Raw) 1,803 110 143 175 469 477 489
Grains and grain-based products, unspeciﬁed 59 96.3 154 212   
Herbs, spices and condiments 96 13.4 75.6 138 82.7 94.1 168
Legumes, nuts and oilseeds 1,990 0.99 82.1 163 0 83.8 168
Milk and dairy products 3 18.2 29.7 41.4   
Non-alcoholic beverages (excepting milk based beverages) 1 0 83.7 168   
Products for special nutritional use 39 177 198 219   
Snacks, desserts, and other foods 265 113 140 167 518.4 522 522
Starchy roots and tubers 6 0 57.86 116   
Sugar and confectionery 23 14.0 61.3 109   
Vegetables and vegetable products (including fungi) 327 3.08 79.3 156 0 83.8 168
N: number of samples; LB: lower bound; MB: middle Bound; UB: upper bound.
(a): Food Level 1 categories in bold and Food Level 2 categories in regular typeface. Left-censored data not reported because the table reports the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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4.2.4. Data on feed
4.2.4.1. Data collection in feed
The data set on feed comprised 10,771 analytical results, including 6,980 results for DON, 1,649 for
3-Ac-DON, 1,210 for 15-Ac-DON and 932 analytical results for DON-3-glucoside. A total of 10,771
analytical results were submitted. Data on feed were reported by 18 European countries (Figure 8). The
major contributing countries were the Netherlands (19% of the DON data, 50% of the 3-Ac-DON data,
68% of the 15-Ac-DON data and 86% of the DON-3-glucoside data) and Hungary (35% of the DON
data). The distribution of the occurrence data over the sampling years is presented in Figure 9. EFSA
called data for feed samples between 2004 and 2014 but no data were reported to EFSA before 2007.
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BE, Belgium; BG, Bulgaria; CZ, the Czech Republic; DE, Germany; EE, Estonia; ES, Spain; FI, Finland; FR, France;
HU, Hungary; LT, Lithuania; LU, Luxembourg; NL, the Netherlands; NO, Norway; PT, Portugal; RO, Romania; SI,
Slovenia; SK, Slovakia; UK, the United Kingdom.
Figure 8: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
feed across the European countries
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Feeds were classiﬁed based on the catalogue of feed materials speciﬁed in the Commission Regulation
(EU) No 575/2011 of 16 June 2011 creating the Catalogue of feed materials.26 Where information was
available, compound feedingstuffs were classiﬁed in groups based on the species/production categories
for which the feed is intended.
‘Compound feed’ was the feed category with the highest number of results reported for DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside, which accounted for 58%, 37%, 37% and 40%, respectively.
In addition, the feed categories ‘Cereal grains’, ‘Forages and roughage, and products derived thereof’
and ‘Oilseeds, oil fruits, and products derived thereof’ were well represented. Only a limited number of
occurrence data were submitted for other feed categories. A distribution of the samples in feed groups
is shown in Figure 10. Results were reported on whole weight (48% samples) or on 88% dry matter
(52% of samples). For consistency in the assessment, the latter were converted to values expressed
on a whole-weight basis.
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Figure 9: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
feed over the sampling years
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Figure 10: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
the feed categories
26 Commission Regulation (EU) No 575/2011 of 16 June 2011 on the Catalogue of feed materials, OJ L 195, 17.6.2011, p. 25–65.
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In order to include only the results obtained by analytical methods with sufﬁcient sensitivity, LOQ
cut-off value ≤ 250 lg/kg was applied. As a result of this approach, 622 results of the DON data, 736
results of the 3-Ac-DON data, 720 results of the 15-Ac-DON data and one result of the DON-3-
glucoside data were not included in the feed data set to be used for occurrence analysis and dietary
exposure assessment. After applying the exclusion criteria described in Section 4.2. and applying the
LOQ cut-off, the ﬁnal feed data set included observations on DON (n = 4,000), 3-Ac-DON (n = 894),
15-Ac-DON (n = 470) and DON-3-glucoside (n = 931).
4.2.3.2. Distribution of samples across feed categories
The distribution of analytical results across different feed groups for DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside classiﬁed based on the catalogue of feed materials (see Section 4.2.4.1) is
illustrated in Figure 11.
‘Compound feed’ was the feed category with the major number of results reported for DON and
DON-3-glucoside, which accounted for 52% and 37%, respectively. For acetylated forms (3-Ac-DON
and 15-Ac-DON) ‘Cereal grains, their products and by-products’ was the feed category comprising the
major number of results. For DON and DON-3-glucoside, ‘Forages and roughage, and products derived
thereof’ and ‘Oilseeds, oil fruits, and products derived thereof’ were also well represented. A more
detailed distribution and statistical description of concentrations is reported in Tables 18–21
(Section 4.2.4.4).
4.2.4.3. Analytical methods used for feed
Only occurrence data with information on the analytical method and on LOD/LOQ levels fulﬁlled the
inclusion criteria for the present analysis. The measurements obtained by ELISA and TLC methods
were not considered reliable. By this approach, about 28% of feed data were excluded.
For DON in feed, 82% of the data were obtained by LC–MS-based methods (LC–MS/MS 44%,
LC–MS quadrupole 38%), 11% by HPLC-based methods (HPLC-UV 7%, HPLC with standard detection
methods (not speciﬁed) 1%, HPLC-FLD 3%), 4% by GC-based methods (GC–MS 3%, GC with standard
detection methods (not speciﬁed) 0.8%, GC-HRMS 0.2%), and 3% by other methods. The data set
was characterised by a proportion of 43% of left-censored data (results below the LOD/LOQ). The
LOQs varied with the method used, the food matrix and the laboratory. A range of LOQs was observed
with the lowest median LOQ of 40 lg/kg for the feed categories ‘Compound feed’ and ‘Land animal
products and products derived thereof’, while the highest median LOQ of 200 lg/kg was observed for
several feed categories, including legume seeds, oilseeds, oil fruits, other plants, algae, other seeds
and fruits, tubers and roots.
Regarding acetylated forms, 97% of 3-Ac-DON data and 94% of 15-Ac-DON data in feed were
obtained by LC–MS-based methods (96% of 3-Ac-DON data and 93.6% of 15-Ac-DON data by LC–MS/MS)
and only a small number of results were measured by GC-based methods (4% of 3-Ac-DON data and
6.4% of 15-Ac-DON data). The data sets comprised 92% and 65% of left-censored data for 3-Ac-DON
and 15-Ac-DON, respectively. The median LOQ of 50 lg/kg was observed in all feed categories for
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Figure 11: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
the feed categories
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3-Ac-DON. A range of LOQs was observed for 15-Ac-DON with the lowest median LOQ of 10 lg/kg for
‘Cereal grains, their products and by-products’ and the highest median LOQ of 200 lg/kg for ‘Forages and
roughage’ and ‘Oilseeds and oil fruits’.
Analytical data on DON-3-glucoside in feed were obtained by LC–MS-based methods (89%), HPLC-
based methods (7%) and GC-based methods (4%). The left-censored data accounted for 91% of the
results. The median LOQ was at a level of 250 lg/kg for all feed categories.
A detailed presentation of the proportion of left-censored data across feed categories is given in
Tables 18–21 (Section 4.2.4.4).
4.2.4.4. Currently reported occurrence data on feed by feed group
Results below the LOD or LOQ accounted for 43%, 92%, 65% and 91% of the results for DON, 3-
Ac-DON, 15-Ac-DON and DON-3-glucoside, respectively. Apart from ‘Compound feed’, ‘Cereal grains,
their products and by-products’, ‘Forages and roughage, and products derived thereof’ and ‘Oilseeds,
oil fruits, and products derived thereof’, only a limited number of data were available for other feed
groups, e.g. ﬁsh, legume seeds, peas, sweet lupins, products from the bakery and pasta industry,
citrus pulp and sugar beet. Therefore, the occurrence data are presented in Tables 18–21 for the
aggregated feed groups. For cereal grains, the data for individual grains speciﬁed for feed (e.g. wheat,
barley etc.) have been combined with those for those unprocessed grains of undeﬁned end-use.
For DON, the highest mean concentration levels were measured in ‘Forages and roughage, and
products derived thereof’ (LB mean = 485 lg/kg, UB mean = 536 lg/kg). Similar DON levels were found
also in ‘Cereal grains, their products and by-products’, ‘Compound feed’ and ‘Miscellaneous’. Within
the forages and roughages, the ‘Cereal straw’ had the highest concentrations for DON (LB
mean = 1,074 lg/kg, UB mean = 1,128 lg/kg). Within the cereals, the highest values were measured in
‘Maize’ (LB mean = 641 lg/kg, UB mean = 689 lg/kg). ‘Compound feed’ covered by complementary
and complete feed was mostly represented by complete feed for breeding pigs, growing/fattening pigs
and piglets. The highest DON levels were measured in complementary feed for fattening chickens,
fattening sheep and fattening rabbits and unspeciﬁed complete and complementary feed (Appendix C).
In ‘Oilseeds, oil fruits, and products derived thereof’ covered mostly by toasted soya beans and sunﬂower
seeds, mean concentrations ranged from 7.00 to 153 lg/kg in LB and UB scenarios, respectively.
Similar to DON, also for 3-Ac-DON and 15-Ac-DON, the highest occurrence levels were observed in
‘Forages and roughage, and products derived thereof’ with mean LB and UB concentrations of 53.2 and
95.9 lg/kg for 3-Ac-DON, and 1,054 and 1,116 lg/kg for 15-Ac-DON. Within the ‘Compound feed’
category, excluding the categories with all samples non-detected, the highest 3-Ac-DON and 15-Ac-DON
concentration levels were in complete feed for poultry and piglets and in unspeciﬁed complete feed
(Appendix C). In ‘Cereal grains, their products and by-products’ covered mostly by barley, maize, oats
and wheat, mean concentrations were 2.20–34.9 lg/kg (LB–UB) for 3-Ac-DON and 41.4–64.2 lg/kg
(LB–UB) for 15-Ac-DON with the highest concentration levels observed in ‘Maize’.
The data set on DON-3-glucoside in feed was characterised by a high proportion of left-censored
data, which inﬂuenced the mean concentrations at UB level. Taking into account this uncertainty, the
highest DON-3-glucoside levels were reported in ‘Forages and roughage, and products derived thereof’
(LB mean = 60.8 lg/kg, UB mean = 228 lg/kg. In ‘Cereal grains, their products and by-products’
covered mostly by barley, maize, oats and wheat, the mean concentrations ranged between the LB of
29.6 and the UB of 235 lg/kg. Limited data on other feed categories do not allow conclusions to be
drawn in relation to DON-3-glucoside concentrations.
To assess the exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, the
CONTAM Panel reviewed the occurrence data for the sum of concentrations of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside in feed with the number of samples available for evaluation and statistical
descriptors of the results (mean and 95th percentile for LB, MB and UB results) as shown in Table 22.
See Sections 4.2.2 and 4.2.8 for the calculation of the sum of concentrations of DON, 3-Ac-DON, 15-
Ac-DON and DON-3-glucoside. It should be noted that the occurrence data on the sum of
concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside refer to the number of samples
instead of the number of the analytical results. (The exposure assessment of DON alone is presented
in Appendix F).
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Table 18: Statistical description of the concentrations of DON across the feed categories (all results expressed in lg/kg whole-weight) (Feed Material
Catalogue Level 1 (bold) categories and Level 2 categories (regular typeface))
Feed group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Cereal grains, their products and by-products 1,288 47 427 454 480 1,815 1,815 1,815
Barley 209 58 148 187 227 591 591 591
Maize 394 44 641 667 689 2,470 2 470 2,470
Oats 127 43 516 530 546 2,203 2 203 2,203
Wheat 465 42 401 423 442 1,589 1 589 1,589
Compound feed 1,996 32 401 416 431 1,580 1 580 1,570
Compound feed, unspeciﬁed 66 94 16.0 40.0 63.9 69.0 69.0 115
Complementary feed (incomplete diet) 215 36 254 277 291 1,065 1,210 1,065
Complete feed 1,715 30 433 448 462 1,680 1,680 1,680
Fish, other aquatic animals and products derived thereof 1 0 182 182 182   
Forages and roughage and products derived thereof 412 47 485 510 536 1,810 1,810 1,810
Cereal straw 125 44 1,074 1,101 1,128 3,372 3,372 3,372
Grass, ﬁeld dried, [Hay] 101 78 16.0 60.0 105 50.0 69.0 138
Maize silage 129 15 410 417 423 1,340 1,340 1,340
Land animal products and products derived thereof 5 80 10.0 17.0 24.0   
Legume seeds and products derived thereof 5 80 10.0 74.4 137   
Minerals and products derived thereof 2 100 0.00 58.1 116   
Miscellaneous 11 18 441 445 449   
Oil seeds, oil fruits and products derived thereof 250 94 7.00 80.0 153 50.0 100 200
Sunﬂower seed 67 100 0 43.2 87.0 0  250
Toasted soya (beans) 146 95 6.10 95.3 181 0  200
Other plants, algae and products derived thereof 4 100 0.0 96.0 192   
Other seeds and fruits, and products derived thereof 2 100 0.0 96.0 192   
Tubers, roots and products derived thereof 11 73 98.0 164 229   
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The occurrence data at Feed Catalogue Level 2 are reported only for feed categories with more than 60 analytical results.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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Table 19: Statistical description of the concentrations of 3-Ac-DON across the feed categories (all results expressed in lg/kg whole-weight). (Feed
Material Catalogue Level 1 categories (bold) and Level 2 categories (regular typeface))
Feed group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Cereal grains, their products and by-products 402 95 2.20 19.0 34.9 3.30 39.0 78.4
Barley 52 98 0.41 13.2 25.9 0 39.0 78.8
Maize 100 93 4.60 24.1 44.0 22.5 50.1 74.6
Oats 71 87 5.92 11.1 16.5 34.0 34.1 49.9
Rice, broken 3 100 0 24.4 47.8   
Rye 1 100 0 39.0 78.4   
Triticale 2 100 0 25.1 49.7   
Wheat 169 100 0 20.3 39.1 0 25.1 49.7
Cereal grains, unspeciﬁed 4 100 0 24.1 47.9   
Compound feed 357 87 7.41 25.0 43.3 52.6 53.0 100
Compound feed, unspeciﬁed 64 100 0 25.4 49.0 0 25.1 50.2
Complementary feed (incomplete diet) 38 97 2.00 16.2 30.1   
Complete feed 255 82 10.0 27.3 43.5 69.3 69.3 100
Forages and roughage, and products derived thereof 71 94 53.2 75.0 95.9 385 385 385
Cereal straw 47 91 80.4 103 126   
Grass, ﬁeld, dried 6 100 0 19.1 37.9   
Maize silage 18 100 0 19.1 37.5   
Legume seeds and products derived thereof 1 100 0 24.1 47.9   
Peas 1 100 0 24.1 47.9   
Miscellaneous 1 100 0 17.0 34.1   
Products from the bakery and pasta industry 1 100 0 17.0 34.1   
Oil seeds, oil fruits, and products derived thereof 59 100 0 27.1 55.7   
Rape seed 1 100 0 25.2 49.8   
Sunﬂower seed 48 100 0 25.2 50.5   
Toasted soya (beans) 13 100 0 34.0 75.3   
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The occurrence data at Feed Catalogue Level 2 are reported only for feed categories with more than 60 analytical results
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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Table 20: Statistical description of the concentrations of 15-Ac-DON across the feed categories (all results expressed in lg/kg whole-weight). (Feed
Material Catalogue Level 1 (bold) and Level 2 (regular typeface))
Feed group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Cereal grains, their products and by-products 236 80 41.4 53.0 64.2 280 280 280
Barley 47 94 1.70 19.1 35.9   
Maize 62 53 120 132 144 641 641 641
Oats 67 81 31.3 35.1 37.8 185 185 185
Rice, broken 3 67 48.3 84.2 120   
Rye 1 100 0 98.1 196   
Wheat 46 100 0 13.1 26.2   
Compound feed 191 47 22.7 36.0 50.0 105 105 200
Complementary feed (incomplete diet) 27 67 23.1 37.1 51.5   
Complete feed 164 44 22.6 36.2 49.6 85.6 100 200
Forages and roughage, and products derived thereof 36 58 1,054 1,085 1,116   
Cereal straw 16 13 2,353 2,366 2,378   
Grass, ﬁeld dried 1 100 0 69.2 138   
Maize silage 19 95 15.8 60.1 105   
Oil seeds, oil fruits, and products derived thereof 7 100 0.00 100 200   
Sunﬂower seed 1 100 0 100 199   
Toasted soya (beans) 6 100 0 100 200   
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The occurrence data at Feed Catalogue Level 2 are reported only for feed categories with more than 60 analytical results.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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Table 21: Statistical description of the concentrations of DON-3-glucoside across the feed categories (all results expressed in lg/kg whole-weight). (Feed
Material Catalogue Level 1 (bold) and Level 2 (regular typeface))
Feed group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Cereal grains, their products and by-products 222 94 29.6 133 235 251 251 257
Barley 41 98 9.85 130 250   
Maize 75 99 3.34 118 232 0 116 232
Oats 41 76 137 171 205   
Rice, broken 4 100 0 128 257   
Rye 8 100 0 122 245   
Spelt 4 100 0 122 245   
Triticale 4 100 0 124 248   
Wheat 43 98 6.51 128 249   
Cereal grains, unspeciﬁed 2 100 0 120 239   
Compound feed 374 84 16.6 107 198 89.9 126 253
Complementary feed (incomplete diet) 49 82 37.1 109 180   
Complete feed 325 84 13.7 107 200 77.6 125 250
Forages and roughage, and products derived thereof 220 96 60.8 144 228 0.0 121 241
Cereal straw 81 88 165 271 376 665 665 645
Forage meal 2 100 0 64.1 127   
Grass, ﬁeld dried 55 100 0 86.1 172   
Lucerne 1 100 0 120 239   
Maize silage 80 100 0 59.0 117 0 59.0 117
Pea straw 1 100 0 120 239   
Legume seeds and products derived thereof 1 100 0 122 245   
Sweet lupins 1 100 0 122 245   
Oil seeds, oil fruits, and products derived thereof 110 100 0 125 249 0 125 250
Linseed 1 100 0 120 239   
Palm kernel expeller 5 100 0 120 239   
Rape seed 2 100 0 125 249   
Sunﬂower seed 3 100 0 125 249   
Toasted soya (beans) 99 100 0 125 250 0 125 250
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Feed group(a) N %LC
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Other plants, algae and products derived thereof 2 100 0 120 240   
Other plants, algae and products derived thereof, unspeciﬁed 2 100 0 120 239   
Other seeds and fruits, and products derived thereof 1 100 0 120 240   
Citrus pulp 1 100 0 120 239   
Tubers, roots, and products derived thereof 1 100 0.00 122 245   
Sugar beet 1 100 0.00 122 245   
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The occurrence data at Feed Catalogue Level 2 are reported only for feed categories with more than 60 analytical results.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and is therefore not reported in the table and replaced by a dash.
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Table 22: Statistical description of the sum of the concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside across the feed categories
(all results expressed in lg/kg whole-weight). (Feed Material Catalogue Level 1 (bold) and Level 2 (regular typeface))
Feed group(a) N
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Cereal grains, their products and by-products 1,288 610 654 698 2,465 2,465 2,465
Barley 209 212 274 337 857 857 867
Maize and corn 394 936 975 1,015 3,582 3,582 3,582
Oats 127 695 719 747 2,644 2,654 2,664
Wheat 465 570 607 644 2,304 2,304 2,304
Compound feed 1,996 580 605 631 2,291 2,291 2,291
Compound feed, unspeciﬁed 66 22 78 134 93 119 167
Complementary feed (incomplete diet) 215 374 401 428 1,755 1,755 1,755
Complete feed 1,715 628 649 670 2,436 2,436 2,436
Fish, other aquatic animals and products derived thereof(c) 1 264 264 264   
Forages and roughage, and products derived thereof 412 750 792 835 2,689 2,691 2,715
Cereals straw 125 1,717 1,765 1,813 5,541 5,541 5,541
Grass, ﬁeld dried, [Hay] 101 23 89 155 73 100 200
Maize silage 129 588 606 624 1,943 1,943 1,943
Land animal products and products derived thereof 5 15 25 35   
Legume seeds and products derived thereof 5 15 111 207   
Minerals and products derived thereof 2 0 84 168   
Miscellaneous 11 639 646 653   
Oil seeds, oil fruits, and products derived thereof 250 9 123 237 73 181 363
Sunﬂower seed 67 0 80 161 0 181 363
Toasted soya (beans) 146 9 143 277 0 260 319
Other plants, algae and products derived thereof 4 0 139 278   
Other seeds and fruits, and products derived thereof 2 0 139 278   
Tubers, roots, and products derived thereof 11 142 237 333   
N: number of samples; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The occurrence data at Feed Catalogue Level 2 are reported only for feed categories with more than 60 analytical results. Left-censored data not reported because the table reports the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA, 2011b) and therefore not reported in the table.
(c): Fish used as feed.
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4.2.5. Data on unprocessed grains of undeﬁned end-use
4.2.5.1. Data collection on unprocessed grains of undeﬁned end-use
In addition to food and feed, 6,175 analytical results were reported for unprocessed grains of undeﬁned
end-use (hereinafter referred to unprocessed grains). As the samples analysed cannot be considered to be
either food or feed, and the processing might inﬂuence the concentration of the toxin in the end product,
these occurrence data are described separately. The data set on unprocessed grains comprised 2,676
analytical results for DON of which 85.5% were analysed by LC–MS-based methods (LC–MS/MS 74%, LC–
MS 11.5%), 8.5% by HPLC methods (HPLC-UV 4%, HPLC standard detection methods (not speciﬁed) 2%,
HPLC-FD 2.56%), and 6% by GC-methods (GC–MS 5.4%, GC-ECD 0.3%, GC-HRMS 0.06%). For the other
forms of DON, the main method applied was LC–MS/MS; 1,514 analytical results for 3-Ac-DON (LC–MS/MS
70%, LC–MS 21%, GC–MS 8.7%, GC-ECD 0.3%), 1,447 analytical results for 15-Ac-DON (LC–MS/MS 96%,
GC–MS 3.3%, GC-ECD 0.7%) and 538 analytical results for DON-3-glucoside (LC–MS/MS 100%).
The distribution of unprocessed grains samples across the European countries and over the
sampling years is presented in Figures 12 and 13, respectively. The majority of data were reported by
the Netherlands, followed by the UK and Belgium. The sampling period covered the years 2007–2014.
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BE, Belgium; BG, Bulgaria; CY, Cyprus; CZ, the Czech Republic; DE, Germany; DK, Denmark; FI, Finland; FR,
France; HU, Hungary; IE, Ireland; LT, Lithuania; NL, the Netherlands; RO, Romania; SI, Slovenia; SK, Slovakia;
UK, the United Kingdom.
Figure 12: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
unprocessed grains of undeﬁned end-use across the European countries
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Figure 13: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
unprocessed grains of undeﬁned end-use over the sampling years
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Unprocessed grains of undeﬁned end-use were classiﬁed in accordance with the EFSA FoodEx 1
classiﬁcation system as described in Section 4.2.3. The majority of data were on unprocessed wheat
grains, barley grain and rice (crop). Other types of grains were less represented. A distribution of the
samples in unprocessed grains of undeﬁned end-use is shown in Figure 14.
Similar to feed, from the total number of data submitted (n = 6,175), only data obtained by
methods with LOQ ≤ 250 lg/kg were considered in the evaluation. As a result, 17 results of DON data
and 557 results of 15-Ac-DON were not included in the unprocessed grains data set to be used for
occurrence analysis and dietary exposure assessment. After applying the exclusion criteria described
before (Section 4.2.3) and applying the LOQ cut-off, the ﬁnal cleaned data set of unprocessed grains
of undeﬁned end-use included observations on DON (n = 1,621), 3-Ac-DON (n = 1,054), 15-Ac-DON
(n = 430) and DON-3-glucoside (n = 538).
The information on analytical methods and/or on LOQ levels was not available for 27% of the
analytical results of unprocessed grains of undeﬁned end-use. In addition, the measurements obtained
by ELISA and TLC methods were not considered reliable. According to the criteria described in
Section 4.2.3 those data did not fulﬁl the quality criteria and were not included in the further analyses.
With this approach, 40% of the analytical data on unprocessed grains of undeﬁned end-use were
excluded. The data set was characterised by 67% of left-censored data (results below LOD/LOQ). The
LOQs ranged between 3 and 200 lg/kg with a mean of 32.5 lg/kg.
4.2.5.2. Currently reported occurrence data on unprocessed grains of undeﬁned end-use
The category ‘Unprocessed grains’ comprised grains of undeﬁned end-use, deﬁned also as ‘Grains as
crops’. As the end-use of the grains at harvest is not established and because normally grains for human
and animal consumption undergo several processing steps before being used, it was considered
appropriate to report their concentrations separately. Results below the LOD or LOQ accounted for 56%,
91%, 68 and 66% of the results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, respectively.
The highest mean DON concentrations were reported in unspeciﬁed grains (‘Grains as crops’ and
‘Other grains’) for which the origin was unknown. ‘Wheat grain’ and ‘Barley grain’ were also categories
mostly contaminated with DON with mean LB-UB concentrations of 432–447 lg/kg in wheat grains
and 475–493 lg/kg in barley grains (Table 23).
High concentrations of 3-Ac-DON were reported in ‘Grains as crops (unspeciﬁed)’ (LB
mean = 94.6 lg/kg; UB mean = 101 lg/kg) followed by ‘Barley grain’ (LB mean = 9.12 lg/kg; UB
mean = 59.3 lg/kg) (Table 24). It should be noted that 3-Ac-DON data of unprocessed grains
comprised a high proportion of left-censored data. For 15-Ac-DON, the highest mean concentrations
were in ‘Grains as crops (unspeciﬁed)’ (LB mean = 107 lg/kg; UB mean = 110 lg/kg), followed by
‘Corn grain’ (LB mean = 53.8 lg/kg; UB mean = 54.1 lg/kg) (Table 25).
Regarding concentrations of the DON-3-glucoside in unprocessed grains, high concentrations were
reported in ‘Barley grains’ (LB mean = 218 lg/kg; UB mean = 225 lg/kg) followed by ‘Wheat grain
crop’ (LB mean = 67.0 lg/kg; UB mean = 75.2 lg/kg) (Table 26).
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Figure 14: Distribution of analytical results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
unprocessed grains across grain groups
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The frequency of contamination and the concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside were higher in ‘unprocessed grains’ than in ‘Grains for human consumption’, with the
exception of DON-3-glucoside concentrations in wheat grains (Tables 12 and 23–27). However, the
high proportion of left-censored data and different LOQ cut-off values applied to foods and
unprocessed grains should be taken into consideration when interpreting this observation. With regard
to the feed cereal grains, a comparison was possible for barley grains, oats and wheat grains only.
Concentrations were higher in unprocessed grains for barley and wheat grains, while they were lower
for oats than in the feed cereal grains (Tables 18–21 and 23–26).
Table 23: Statistical description of the concentrations of DON at the FoodEx Level 3 across the
unprocessed grains of undeﬁned-use (all results expressed in lg/kg whole-weight)
Type of unprocessed
grain
N %LC
Concentration range (lg/kg)
Mean 95th percentile(a)
LB MB UB LB MB UB
Barley grain 332 45 475 484 493 2,934 2,934 2,934
Buckwheat grain 20 100 0 18.3 36.5 – – –
Corn grain 64 41 205 224 243 560 560 660
Millet grain 7 86 77 136 195 – – –
Oats grain 97 49 130 138 147 670 670 670
Rice 280 100 0 25.0 50.0 0 25 50.0
Rye grain 130 68 37.1 48.5 59.8 200 200 228
Spelt grain 2 50 100 108 115 – – –
Wheat grain 411 36 432 439 447 1,663 1,663 1,663
Other grains 24 17 566 568 570 – – –
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA,
2011b) and is therefore not reported in the table and replaced by a dash.
Table 24: Statistical description of the concentrations of 3-Ac-DON at the FoodEx Level 3 across the
unprocessed grains of undeﬁned-use (all results expressed in lg/kg whole weight)
Type of unprocessed
grain
N %LC
Concentration range (lg/kg)
Mean 95th percentile(a)
LB MB UB LB MB UB
Barley grain 220 91 9.19 34.2 59.3 55.0 58.0 100
Buckwheat grain 8 100 0 50.0 100 – – –
Corn grain 15 100 0 5.00 10.0 – – –
Grains as crops 115 46 94.5 97.7 101 357 357 357
Millet grain 3 100 0.00 50.0 100 – – –
Oats grain 17 89 2.60 44.1 85.6 – – –
Rice 279 100 0 50.0 100 0 50.0 100
Rye grain 58 98 0.23 21.0 41.8 – – –
Wheat grain 187 96 1.00 5.4 9.74 0 10.0 10.0
Other grains 22 100 0 5.00 10.0 – – –
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA,
2011b) and therefore not reported in the table and replaced by a dash.
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 83 EFSA Journal 2017;15(9):4718
To assess the exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, the
CONTAM Panel reviewed the occurrence data for the sum of concentrations of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside in unprocessed grains of undeﬁned-use with the number of samples
available for evaluation and statistical descriptors of the results (mean and 95th percentile for LB, MB
and UB results) as shown in Table 27. See Sections 4.2.2 and 4.2.8 for the calculation of the sum of
concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. It should be noted that the
occurrence data on the sum of concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
refer to the number of samples instead of the number of the analytical results.
Table 25: Statistical description of the concentrations of 15-Ac-DON at the FoodEx Level 3 across
the unprocessed grains of undeﬁned-use (all results expressed in lg/kg whole-weight)
Type of unprocessed
grain
N %LC
Concentration range (lg/kg)
Mean 95th percentile(a)
LB MB UB LB MB UB
Barley grain 91 80 22.5 27.3 32.1 147 147 147
Corn grain 15 7 53.8 53.8 54.1 – – –
Grains as crops 115 27 107 109 110 367 367 367
Wheat grain 187 91 6.50 11.1 15.8 60.0 60.0 60.0
Other grains 22 91 15.1 20.6 26.1 – – –
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA,
2011b) and is therefore not reported in the table and replaced by a dash.
Table 26: Statistical description of the concentrations of DON-3-glucoside at the FoodEx Level 3 across
the unprocessed grains of undeﬁned-use (all results expressed in lg/kg whole-weight)
Type of unprocessed
grain
N %LC
Concentration range (lg/kg)
Mean 95th percentile(a)
LB MB UB LB MB UB
Barley grain 91 44 218 222 225 928 928 928
Grains as crops 115 64 29.5 34.7 39.8 116 116 116
Rye grain 33 100 0 5.00 10.0 – – –
Wheat grain 277 69 67.0 71.1 75.2 347 347 347
Other grains 22 73 46.2 52.0 57.8 – – –
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; MB: middle bound; UB: upper bound.
(a): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust
(EFSA, 2011b) and is therefore not reported in the table and replaced by a dash.
Table 27: Statistical description of the sum of the concentrations of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside across the unprocessed grains of undeﬁned-use
Type of unprocessed
grain(a)
N
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Barley grain 332 594 625 655 3,528 3,539 3,550
Buckwheat grain 20 0 43 86 – – –
Corn grain 64 294 323 352 812 812 957
Grains as crops 116 1,256 1,262 1,269 5,863 5,863 5,863
Millet grain 7 112 217 323 – – –
Oats, grain 97 187 207 226 972 972 972
Rice 280 0 84 167 0 84 168
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4.2.6. Comparison of the occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in foods, feeds and unprocessed grains of undeﬁned end-use
from organic and conventional farming
Due to the limited information on the farming methods of the production on food, feed and
unprocessed grains of undeﬁned-use in the occurrence data submitted to EFSA, the CONTAM
Panel also reviewed the literature.
In a review article of Olsen (2008), occurrence of DON in organic and conventional foods were
compared, based on 10 published European studies. Most of the studies focused on grains and milling
products, in a few studies bread and beer were investigated. In four studies conventionally produced
grains yielded lower levels of DON than organically produced grains. In the other six studies (which
included bread and beer), no statistically signiﬁcant differences were found.
In the Norwegian review of the NVK (2014) on the comparison of organic and conventional food
and food production, 27 studies were included, comparing DON content in organically and
conventionally produced cereals. Some studies compared DON content in more than one cereal
species. In the majority of the studies, no signiﬁcant differences in DON content in cereals from the
two cultivation systems were found. Eleven studies reported lower DON content in organic compared
to conventional cereals and four studies reported the opposite.
In some of the studies reviewed by the NVK (2014), not only cereals but also grain products
resulting from organically and conventionally grown cereals were investigated for DON (Twazur _ek
et al., 2013; Vidal et al., 2013; Błajet-Kosicka et al., 2014). In addition, a few studies were published
in which solely grain products derived from organically and conventionally grown cereals were
investigated for DON (Cirillo et al., 2003; Schollenberger et al., 2005; Anselme et al., 2006). The
studies reviewed in NVK (2014) revealed a tendency towards more frequent occurrence and higher
concentrations of DON in conventionally produced food products as compared to organically produced
food products but the observed tendency was rather weak and only in some cases statistically
signiﬁcant. This pattern conﬁrmed the ﬁndings of Olsen (2008) that DON levels in organically produced
grains (and products thereof) were either similar or slightly lower than in conventionally produced
grains (and products thereof). In the study of Anselme et al. (2006), which focused speciﬁcally on
organically and conventionally produced beers sold on the Belgian market, no statistically signiﬁcant
differences were found for DON levels or occurrences. An earlier report of the NVK (2013) about risk
assessment of mycotoxins in cereal grains in Norway hypothesised that lower mycotoxin content
recorded in organically grown cereals compared with conventionally grown cereals could be due to
more widespread use at organic farms of cultivation practices known to reduce the risk of mycotoxin
contamination in cereals.
Published studies on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in foods from organic farming
were hardly found. Only in the studies of Twazur _ek et al., 2013, and of Błajet-Kosicka et al. (2014)
occurrence of 3-Ac-DON was compared between organic and conventional oats/oats products and rye
products respectively. 3-Ac-DON was more frequently detected in conventional oats/oats products, but
comparative levels were not reported. 3-Ac-DON was not detected in both types of rye products.
The various literature studies in which occurrence and concentrations of DON in organic and
conventionally produced grains and foods were compared, showed a slight tendency of more frequent
occurrence and higher concentrations of DON in conventional products as compared to organic
products. However, this tendency was only signiﬁcant in a limited number of studies. No relevant
Type of unprocessed
grain(a)
N
Concentration range (lg/kg)
Mean 95th percentile(b)
LB MB UB LB MB UB
Rye grain 130 52 77 103 270 275 331
Spelt grain 2 145 156 167 – – –
Wheat grain 411 546 561 576 2,057 2,068 2,079
Other grains 23 723 735 748 – – –
N: number of samples; LB: lower bound; MB: middle bound; UB: upper bound.
(a): Left-censored data not reported because the table reports the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
(b): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust
(EFSA, 2011b) and therefore not reported in the table and replaced by a dash.
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conclusions can be drawn about differences in occurrence and concentrations of 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside, due to lack of data.
In the food occurrence data submitted to EFSA, a number of results (n = 8,912) with a clear
speciﬁcation of the method of production was available. A comparison of the DON occurrence in food
from organic and conventional farming was possible for ‘Food for infants and small children’, ‘Grains
and grain-based products’, ‘Products for special nutritional use’ and ‘Snacks, desserts, and other foods’
(Table 28).
Regarding the feed data, the comparison of the occurrence from organic and conventional farming
was possible only for DON concentrations of the ‘Cereal grains, their products and by-products’ feed
category (Table 29). For unspeciﬁed grains, the comparison of DON concentrations was possible for
barley, oats, rye and wheat grains (Table 30). Overall, the EFSA data showed that the concentrations
of DON in food and feed grains tended to be higher in conventionally cultivated cereal grains than in
grains from the organic farming, but no ﬁrm conclusions could be made due to the heterogenicity in
cultivation years, countries of origin, applied analytical methods and high percentage of left-censored
data in the available data sets.
Table 28: DON concentrations (lg/kg) in food groups coming from organic farming (a) and
conventional farming (b) (2007–2013)
Food group level 1 N %LC
Concentrations (lg/kg)
Mean 95th percentile(a)
Lower bound
Food for infants and small children (a) 93 66 9.47 58.0
Food for infants and small children (b) 58 91 5.38 –
Grains and grain-based products (a) 1,399 59 41.7 180
Grains and grain-based products (b) 2,392 56 92.6 400
Products for special nutritional use (a) 11 64 40.4 –
Products for special nutritional use (b) 7 29 389 –
Snacks, desserts, and other foods (a) 12 25 75.5 –
Snacks, desserts, and other foods (b) 37 70 39.4 –
Middle bound
Food for infants and small children (a) 93 66 19.8 58.0
Food for infants and small children (b) 58 91 26.9 –
Grains and grain-based products (a) 1,399 59 53.9 200
Grains and grain-based products (b) 2,392 56 107 400
Products for special nutritional use (a) 11 64 47.1 –
Products for special nutritional use (b) 7 29 400 –
Snacks, desserts, and other foods (a) 12 25 81.8 –
Snacks, desserts, and other foods (b) 37 70 62.8 –
Upper bound
Food for infants and small children (a) 93 66 29.7 58.0
Food for infants and small children(b) 58 91 46.9 –
Grains and grain-based products (a) 1,399 59 64.3 200
Grains and grain-based products (b) 2,392 56 122 400
Products for special nutritional use (a) 11 64 53.8 –
Products for special nutritional use (b) 7 29 411 –
Snacks, desserts, and other foods (a) 12 25 88.0 –
Snacks, desserts, and other foods (b) 37 70 86.2 –
N: number of samples; %LC: percentage of left-censored data.
(a): The 95th percentile obtained on occurrence data with fewer than 60 analytical results may not be statistically robust (EFSA,
2011b) and therefore not reported in the table and replaced by a dash.
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Table 29: DON concentrations (lg/kg) in feed category ‘Cereal grains, their products and
by-products’ coming from organic farming (a) and conventional farming (b)
N %LC
Concentrations (lg/kg)
Mean 75th percentile(a)
Lower bound
Cereal grains, their products and by-products (a) 8 75 239 255
Cereal grains, their products and by-products (b) 156 26 324 305
Middle bound
Cereal grains, their products and by-products (a) 8 75 246 268
Cereal grains, their products and by-products (b) 156 26 328 293
Upper bound
Cereal grains, their products and by-products (a) 8 75 253 280
Cereal grains, their products and by-products (b) 156 26 333 293
N: number of samples; %LC: percentage of left-censored data.
(a): The 75th percentile concentration was calculated because the number of samples was below 11.
Table 30: DON concentrations (lg/kg) in unprocessed grains of undeﬁned end-use coming from
organic farming (a) and conventional farming (b)
N %LC
Concentrations (lg/kg)
Mean 75th percentile(a)
Lower bound
Barley grain (a) 11 73 44.6 150
Barley grain (b) 93 74 57.3 50.0
Oats, grains (a) 32 38 62.2 98.5
Oats, grains (b) 41 49 233 110
Rye grain (a) 9 100 0.00 0.00
Rye grain (b) 52 83 44.4 0.00
Wheat grain crop (a) 14 50 354 450
Wheat grain crop (b) 192 59 79.5 79.4
Middle bound
Barley grain (a) 11 73 65.0 150
Barley grain (b) 93 68 76.4 50.0
Oats, grains (a) 32 38 68.1 98.5
Oats, grains (b) 41 49 243 110
Rye grain (a) 9 100 27.8 25.0
Rye grain (b) 52 83 56.6 26.0
Wheat grain crop (a) 14 50 383 450
Wheat grain crop (b) 192 59 87.8 92.2
Upper bound
Barley grain (a) 11 73 85.5 150
Barley grain (b) 93 68 95.4 60.0
Oats, grains (a) 32 38 74.0 99.5
Oats, grains (b) 41 49 253 110
Rye grain (a) 9 100 55.6 50.0
Rye grain (b) 52 83 68.8 50.0
Wheat grain crop (a) 14 50 411 450
Wheat grain crop (b) 192 59 96.1 100
N: number of samples; %LC: percentage of left-censored data; LB: lower bound; UB: upper bound.
(a): The 75th percentile concentration was calculated because the number of samples was below 11.
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In summary, based on limited available information the data from the literature on comparative
occurrence of DON in organically and conventionally produced cereal grains (used for food and feed)
and grain products generally conﬁrmed the pattern as derived from the data on occurrence of DON in
food, feed and unprocessed grains of undeﬁned end-use submitted to EFSA. DON concentrations were
either generally at the same level or marginally lower in organically produced grains (and food and
feed products) as compared to conventionally produced grains (and food and feed products).
4.2.7. Currently reported co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside in food, feed and unprocessed grains of undeﬁned end-use
The occurrence data submitted to EFSA, where analytical results on DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside in all possible combinations (singletons, pairs, triplets or quadruplets) were
reported for the same samples, were extracted from the EFSA database. While all samples complying
with the criteria established in Sections 4.2.3–4.2.5 were used to calculate the exposure to the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, only those samples for which the analysis resulted
in numerical values at the respective LOQs or above were selected to calculate the ratios of 3-Ac-DON,
15-Ac-DON and DON-3-glucoside to DON. The number of samples available for each of the three
paired combinations and the mean, median and minimum-maximum values of the ratios were
calculated. These current co-occurrence results were generally consistent with the co-occurrence data
reported in the literature in Section 4.1.4.
From the current occurrence data in food (Section 4.2.3), the CONTAM Panel selected the data of
‘Grains and grain-based products’ at FoodEx level 1 (and those subtypes at FoodEx level 2 for which
ratios were available) and ‘Alcoholic beverages’ (subdivided into FoodEx levels 2 of ‘Beer and beer-like
beverages’) to evaluate the co-occurrence (Table 31). There were a total of 142, 168 and 83 samples
with quantiﬁed ratios of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside to DON, respectively, for the
group of ‘Grains and grain-based products’. The CONTAM Panel noted that these ratios represented
only a very small proportion of the entire database of occurrence in food (see Tables 12–17). The
mean ratios were 1.6 for 3-Ac-DON to DON, 0.7 for 15-Ac-DON to DON and 1.9 for DON-3-glucoside
to DON for the food group of ‘Grains and grain-based products’. For ‘Alcoholic beverages’ the number
of quantiﬁed ratios was too small to draw any conclusions (Table 31).
The CONTAM Panel noted that the ratios in ‘Grain and grain-based products’ for 3-Ac-DON, 15-Ac-
DON, and DON-3-glucoside to DON (i.e. 3.0, 1.2 and 2.1, respectively) were higher for one MS
compared to other countries where the ratios were 0.2, 0.4 and 0.8, respectively. It was also noted
that acetylated DON concentrations reported in the published literature were typically < 10% of those
reported for DON (FAO/WHO, 2011). For DON-3-glucoside, concentrations have been reported to be
5–46% of those reported for DON (Berthiller et al., 2009; Desmarchelier and Seefelder, 2011). The
deviating results of these food samples led the CONTAM Panel to request further investigations by the
analytical laboratory of the MS who submitted the samples and by another MS laboratory.27 Both
laboratories had provided large amounts of occurrence data on DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside to EFSA for this opinion. Therefore, the CONTAM Panel initiated a comparative ad hoc
study for which 20 samples (10 from each laboratory) were selected by the two laboratories in 2014
and cross-evaluated by the two laboratories. It was concluded that the method performance of the
two laboratories was similar and gave comparable results for DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside for this set of samples. However, since no samples of ‘Grain and grain-based products’ were
available where DON concentrations were lower than the other DON forms (i.e. ratio > 1) this ad hoc
study could not conﬁrm the higher concentrations of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
compared to DON reported by the one MS shown in Table 31.
For feed, there were 44, 69 and 50 samples with quantiﬁed ratios of 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside to DON, respectively, all for complete feed, the largest category of samples of feed.
As for food, the CONTAM Panel noted that these ratios represented only a very small proportion of the
entire database of occurrence in feed. The mean ratios were 0.3 for 3-Ac-DON to DON, 0.3 for 15-Ac-
DON to DON and 0.4 DON-3-glucoside to DON.
For grains of undeﬁned end-use in grain and grain-based products, there were 94, 125 and 175
samples with quantiﬁed information for the ratios of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside to
27 The analyses were performed in 2015. A full report of the comparative study was submitted to EFSA and it is available on
request.
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DON, respectively, again only a small proportion of the entire database. The mean ratios were 0.2 for
3-Ac-DON to DON, 0.3 for 15-Ac-DON to DON and 0.4 for DON-3-glucoside to DON.
A comparison of the three ratios of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside to DON as derived
from the EFSA database with those found in the literature was difﬁcult to make since the ratios derived
from data in the EFSA database were means of the ratios, while it was not possible to derive these
from the literature data (see Section 4.1) in a reliable way due to the inconsistent way of reporting in
the literature (see also Section 4.1.4).
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Table 31: Concentration ratios of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside to DON in different food categories among the occurrence data providers
(FoodEx Level 1(bold) and Level 2 (regular typeface))
Food category
Ratio of 3-Ac-DON to DON Ratio of 15-Ac-DON to DON Ratio of DON-3-glucoside to DON
N Mean Median SD Min Max N Mean Median SD Min Max N Mean Median SD Min Max
All countries
Grains and grain-based
products
142 1.6 0.3 4.7 0.0 53 168 0.7 0.4 1.6 0.0 16 83 1.9 1.2 2.0 0.0 13
Bread and rolls 33 2.5 2.6 2.7 0.1 15 37 1.6 0.9 3.1 0.0 16 40 2.5 1.5 2.4 0.1 13
Breakfast cereals 75 1.8 0.3 6.2 0.1 53 46 0.7 0.7 0.7 0.0 4.3 35 1.4 0.9 1.6 0.0 6.0
Fine bakery wares 3 0.3 0.3 0.3 0.0 0.7 4 0.3 0.3 0.1 0.2 0.4 0 – – – – –
Grain milling products 14 0.3 0.1 0.6 0.0 1.6 56 0.3 0.2 0.2 0.0 1.1 8 1.1 1.1 0.8 0.1 2.4
Grains for human
consumption
17 0.1 0.1 0.1 0.0 0.3 25 0.3 0.1 0.4 0.0 1.8 0 – – – – –
Alcoholic beverages 0 – – – – – 2 0.4 0.4 0.2 0.3 0.5 4 1.7 1.5 0.7 1.1 2.6
Beer and beer-like beverage 0 – – – – – 2 0.4 0.4 0.2 0.3 0.5 4 1.7 1.5 0.7 1.1 2.5
All countries (excluding one MS)
Grains and grain-based
products
73 0.2 0.1 0.5 0.0 3.4 96 0.4 0.3 0.3 0.0 1.8 11 0.8 0.9 0.5 0.2 1.6
Bread and rolls – – – – – – 1 0.0 0.0 – 0.0 0.0 1 1.5 1.5 – 1.5 1.5
Breakfast cereals 41 0.4 0.2 0.6 0.1 3.4 14 0.7 0.8 0.3 0.3 1.2 6 0.5 0.4 0.3 0.2 1.0
Fine bakery wares 3 0.3 0.3 0.4 0.0 0.7 4 0.3 0.3 0.1 0.2 0.4 – – – – – –
Grain milling products 12 0.1 0.0 0.1 0.0 0.3 52 0.3 0.2 0.3 0.0 1.1 4 1.1 1.1 0.5 0.4 1.6
Grains for human
consumption
17 0.1 0.1 0.1 0.0 0.3 25 0.3 0.1 0.4 0.0 1.8 – – – – – –
Alcoholic beverages – – – – – – 2 0.4 0.4 0.2 0.3 0.5 4 1.7 1.5 0.7 1.1 2.6
Beer and beer-like beverages – – – – – – 2 0.4 0.4 0.2 0.3 0.5 4 1.7 1.5 0.7 1.1 2.6
Excluded MS
Grains and grain-based
products
69 3.0 1.5 6.5 0.1 53 72 1.2 0.8 2.4 0.0 16 72 2.1 1.3 2.1 0.1 13
Bread and rolls 33 2.5 2.6 2.7 0.1 15 36 1.7 0.9 3.2 0.1 16 39 2.5 1.6 2.4 0.1 13
Breakfast cereals 34 3.5 1.2 8.9 0.1 53 32 0.7 0.7 0.8 0.0 4.3 29 1.6 0.9 1.7 0.1 6.0
Grain milling products 2 1.6 1.6 0.1 1.5 1.7 4 0.3 0.3 0.2 0.1 0.5 4 1.2 1.2 1.2 0.1 2.4
N: number of samples; SD: standard deviation; Min: minimum; Max: maximum; Dash means that there are no data to calculate the ratio.
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4.2.8. Estimating the occurrence of the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside in food, feed and unprocessed grains of undeﬁned
end-use
This section provides details on the calculation of the concentrations of the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside for the reasons described in Section 4.2.2. The results of the
calculation are presented in the Sections 4.2.3.4.5, 4.2.4.4 and 4.2.5.2 for food, feed and unprocessed
grains of undeﬁned end-use, respectively.
Noting that the co-occurrence data on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in the
same sample was scarce, because all four forms of DON were simultaneously analysed for a very small
number of samples, the CONTAM Panel explored whether the non-analysed values could be estimated
by %-ratios calculated from the available ratios of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside to DON
as described in Section 4.2.7 for samples for the food groups ‘Grains and grain-based products’ and
‘Alcoholic beverages’ for which analysis results with a numerical values were reported. The data from
these food groups were considered the most relevant due to the high number of overall reported
results and the sufﬁcient number of quantiﬁed results. Noting that the pairs of samples with such
quantiﬁed co-occurrence results were only a small proportion of the entire occurrence database, the
CONTAM Panel decided to supplement these ratios by ratios calculated from the available literature
data for food and feed (see Section 4.1.4). Excluding the data of the one MS (see Section 4.2.7 and
Table 31), the ratios for 3-Ac-DON and 15-Ac-DON to DON for ‘Grains and grain-based products’ were
approximately 0.1 and 0.3 respectively. Accounting furthermore for the ratios reported in the literature
(see Section 4.1), the CONTAM Panel concluded that a %-ratio of 10% for 3-Ac-DON to DON was well
supported by literature data. In contrast, a %-ratio of 30% for 15-Ac-DON to DON was not at all
supported by the ratios reported in the literature, which were ranging from 0.05 to 0.3. Therefore, a
%-ratio of 15% for 15-Ac-DON to DON appeared to be a plausible estimate.
For the estimation of a %-ratio for DON-3-glucoside to DON, the CONTAM Panel decided to use
only literature data because the amount of samples with quantiﬁed co-occurrence results available to
calculate the ratio of DON-3-glucoside to DON was much smaller in the EFSA database than in the
available literature (see Section 4.1). From the ratios of DON-3-glucoside to DON calculated based on
available literature data on ‘Grains intended for food consumption’ (see Section 4.1.4.1 and Table 8)
and ‘Grains and grain-based food products’ (see Section 4.1.4.1 and Table 9), the CONTAM
Panel concluded that a %-ratio of 20% for DON-3-glucoside to DON would be plausible. The literature
data for malt and beer suggested a %-ratio of 80% for DON-3-glucoside to DON as plausible for
‘Alcoholic beverages’ (‘Beer and beer-like beverage’) (see Section 4.1.4.1 and Table 10). This was
supported by the information on the effects of the malting process on the concentrations of DON and
DON-3-glucoside (see Section 4.3.1.4) and therefore an 80% ratio of DON-3-glucoside to DON
appeared justiﬁed. The CONTAM Panel also noted that the %-ratio of 80% for DON-3-glucoside to
DON should be used for the by-products from ‘Alcoholic beverages’ (‘Beer and beer-like beverage’)
used as animal feed.
Although the data on the concentration ratios on cereal grains for feed were scarce in both the
available literature and the EFSA database (see Sections 4.1.4 and 4.2.7), the available calculated
concentration ratios for cereal grains for feed were not inconsistent with those calculated for food.
Therefore the CONTAM Panel assumed that using the %-ratios derived for food would also be plausible
for feed and unprocessed grains of undeﬁned end-use.
The CONTAM Panel also explored whether the non-analysed concentrations of 3-Ac-DON and/or
15-Ac-DON and/or DON-3-glucoside in the food sample could be estimated by the mean concentration
of the respective DON-form of the same food category. Such an approach would then also apply for
the non-analysed concentrations of feed or the concentrations of unprocessed grains of undeﬁned
end-use. Regarding the mean human exposures to the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside (across the European dietary surveys and age groups at the LB, MB and UB) the
same ranges of exposure were obtained as when using the %-ratio approach described above.
However, the ranges of the 95th percentile dietary exposures differed. Particularly, the maximum 95th
percentile dietary exposure was substantially higher when the non-analysed DON-form concentrations
were replaced by the mean concentration of the respective DON-form of the respective food category.
This difference was also observed for calculated exposures of farm and companion animals. Regardless
of the uncertainties of the approach, the CONTAM Panel concluded that the use of the %-ratios to
replace the non-analysed DON-forms is currently the most appropriate way to estimate the exposures
to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for both humans and farm and
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companion animals. A more accurate exposure estimation may be possible in future when more
analytical data on the co-occurrence of the four DON-forms are available.
The CONTAM Panel noted that the estimation of the respective %-ratios and the calculation of the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and feed using the percentages of
10, 15 and 20% of DON, respectively, (with the exception of the 80% used for DON-3-glucoside for
‘Alcoholic beverages’ and the by-products from the production of ‘Alcoholic beverages’ used as feed
materials) has to be considered as the outcome of an expert judgement of the CONTAM Panel on the
basis of available information on the co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in food and feed.
4.2.9. Currently reported co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside with other Fusarium mycotoxins in food, feed and
unprocessed grains of undeﬁned end-use
In order to assess the co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside with other
Fusarium toxins, the occurrence data submitted to EFSA (see Section 4.2) which reported all four DON
forms and at least one of the other Fusarium toxins in the same sample were extracted from the EFSA
database. Co-occurrence of DON, 3-Ac-DON, 15-Ac-DON or DON-3-glucoside with zearalenone,
a/b-zearalenols, nivalenol, sum of T-2 and HT-2 toxins or fumonisins (mainly B1) were calculated
considering 266,686 samples both with quantiﬁed and detected results reported for food, feed and
unprocessed grains of undeﬁned end-use. The highest co-occurrence with the other Fusarium toxins was
observed for DON (58% of the samples) with one of the other Fusarium toxins. The highest
co-occurrence was for DON and nivalenol (63% of the samples) and the second highest for fumonisins
(56% of the samples). Co-occurrence of approximately 50% was observed for DON with zearalenone and
for DON with the sum of T-2 and HT-2 toxins, whereas 20% of the samples for DON and a/b-zearalenols
co-occurred at approximately 20% only. The CONTAM Panel noted that these percentages are only rough
estimates of the co-occurrences affected with a high level of uncertainty since the numbers of samples
tested for the different Fusarium toxins varied widely and only a limited number of toxins was tested per
sample. Therefore these percentages should be compared with caution.
The limited number of data does not allow any detailed analysis of the co-occurrence of 3-Ac-DON
and/or 15-Ac-DON and/or DON-3-glucoside with other Fusarium toxins. However, it seems that DON
either alone or together with DON-3-glucoside co-occur regularly with other Fusarium toxins in cereal-
based food products, in particular with zearalenone. The submitted co-occurrence data conﬁrm the
co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside with other Fusarium mycotoxins in
food found in the literature (see Section 4.1.5).
4.3. Food and feed processing
4.3.1. Food processing
The extent to which cereals are processed depends on the cereal type and the ﬁnal feed/food
product. In general it is known that processing reduces Fusarium toxin concentrations in products for
human consumption but may increase levels in food or feed by-products. This is because mechanical
cleaning of cereals (dehulling) may lead to by-products (for the feed industry) in which Fusarium
toxins concentrate signiﬁcantly. This may result in (much) higher concentrations of Fusarium toxins in
these materials than in the cereals before cleaning. The effects of processing of cereals and cereal
products, in ways common to the food and feed industry, on the concentrations of DON, 3-Ac-DON,
15-Ac-DON and 3-DON-glucoside in food and feed have been investigated in various studies. The focus
of most of these investigations was on DON, often in combination with other Fusarium toxins. In some
studies, in particular those on the effects of malting and baking processes, the fate of DON and DON-
3-glucoside was also studied. Only few studies were published where the effects of processing on the
concentrations of acetyl-forms of DON were (also) investigated.
4.3.1.1. Cleaning and sorting
In general, sorting of cereals by removing extensively damaged or infected kernels such as those
with visible mould growth or shrivelled kernels, has the effects of lowering the concentrations of
mycotoxins in subsequently produced products (Abbas et al., 1985; Ryu et al., 2008; Scudamore and
Patel, 2009). Fusarium-contaminated grains can be recognised using a range of optic, laser, gravity-
based or acoustic analysis methods, and segregated from healthy grains to remove them before they
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are incorporated into food. The reduction of DON levels by cleaning can be signiﬁcant in those grains
that are heavily contaminated initially, and reductions in DON concentrations up to 74% after sorting
of grossly contaminated samples have been reported (Hazel and Patel, 2004).
Delwiche (2005) conducted an experiment on high speed optical sorting of Fusarium-damaged
wheat. Wheat contaminated with DON at a range of 0.6–20 mg/kg was segregated into fractions that
contained 0.2–12 mg/kg (accepts) and 3.4–58 mg/kg (rejects) after single sorting. Reductions of 38
and 21% of DON were observed in the cleaning stage of wheat, containing between 1,400 and 1,900
lg/kg, when using industrial (several separators, sieves and aspirator devices) and traditional cleaning
methods (a simple screen device and an integrated aspirator), respectively (Lesnik et al., 2008). In a
similar study, DON levels of four wheat samples with initial concentrations ranging from approximately
100 to 3,000 lg/kg were reduced by cleaned by sieving, scouring and polishing to roughly 50%
(Lancova et al., 2008b).
Matumba et al. (2015) investigated the effectiveness of hand sorting, ﬂotation/washing and
dehulling on moulded maize that contained DON, 3-Ac-DON and 15-Ac-DON at levels of 54 lg/kg of
DON and 29 lg/kg of the sum of 3-Ac-DON and 15-Ac-DON. Hand sorting was most efﬁcient and led
to a reduction of the toxins of approximately 96%. Dehulling reduced the levels of the toxins by
50–60% and ﬂotation by 30–60%.
4.3.1.2. Rolling and milling
Milling has the effect of reduction and redistribution of DON. Ryu et al. (2008) described the effect
of dry milling as causing a redistribution of DON into separate milling fractions, and causing higher
concentrations of DON in particular fractions such as the bran and shorts. During dry milling, DON
concentrates in the fractions containing the outer parts of the grain rather than in those fractions
containing the inner parts of the grain (Abbas et al., 1985; Lesnik et al., 2008). Thus, the highest
levels of DON are observed in the germ, screenings, dust and bran while the ﬂour and grits contain
lower levels than those found in the grain before dry milling (Hazel and Patel, 2004). Wet milling
results in dissolving and redistribution of DON in by-products and steep water (Ryu et al., 2008).
Cheli et al. (2013) reviewed 15 studies published in the period 2004–2011 on the repartitioning of
DON (and other Fusarium toxins) during wheat milling. Various types of mills were used. Similar trends
were reported. The concentrations of DON in semolina and ﬂour ranged from 25–89% as compared to
the initial concentrations, while concentrations of DON in bran ranged from 81–340% in comparison
with the initial levels. Five studies on the effect of milling on the content of DON of grains (including
wheat, maize and barley) published after the review of Cheli et al. (2013), showed similar amounts of
reduction in semolina and ﬂour, and an increase of DON concentrations in bran (Brera et al., 2013;
Burger et al., 2013; Gimenez et al., 2013; Zheng et al., 2014; Tibola et al., 2015).
The effects of three types of milling processes (industrial roller-grinding, grain hammer crashing
and traditional millstone grinding) on the DON levels in wheat (1,400–1,900 lg/kg) were compared in
two studies on the distribution of DON in the milling products (Lesnik et al., 2008; Khatibi et al.,
2014a). Lesnik et al. (2008).Roller grinding resulted in a 71% reduction in the concentrations of DON
from the grain to the ﬂour, while hammer crashing and millstone milling resulted in minor reductions of
0.5% and 9.5%, respectively. Khatibi et al. (2014a) compared roller milling and precision milling (with
blades) for their ability to reduce DON levels in the endosperm-enriched tissue in barley. Roller milling
removed a much smaller percentage of DON than precision milling, resulting in 13% and 77%
reductions in the concentrations of DON from the grain to the ﬂour, respectively.
In the study of Kostelanska et al. (2011b), the fractionation of DON and DON-3-glucoside in milling
fractions of wheat was rather similar. White ﬂours contained approximately 60–70% of the
concentrations of DON and DON-3-glucoside in unprocessed wheat grains, while in bran these
concentrations were 160–170% as compared to initial concentrations. Schwake-Anduschus et al.
(2015) investigated the distribution patterns of DON, DON-3-glucoside, 3-Ac-DON and 15-Ac-DON in
ten milling fractions of naturally contaminated wheat. DON and DON-3-glucoside were found in similar
amounts in all fractions. In bran, the levels were only slightly higher than in the endosperm. In
contrast, 3- and 15-Ac-DON were dominantly present in the bran fractions. The authors explained the
observed differences in distribution between DON/DON-3-glucoside and the acetylated forms by the
polarity of the components: 3-Ac-DON and 15-Ac-DON are less polar, which would reduce their
mobility in the aqueous environment of the plant.
Zhang and Wang (2014), detected a reduction of DON and DON-3-glucoside concentrations in
wheat ﬂour by 79–90% and by 23–39%, respectively. Concentrations of DON and DON-3-glucoside in
bran were 1.2–2.2 times and 2.9–4.4 times higher respectively than initial concentrations, and they
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were slightly lower in shorts as compared to bran. The total amount of DON in all fractions decreased
by 30–40% compared to the whole wheat, whereas the amount of DON-3-glucoside increased by 50–
100%. The authors indicated that the temperature becomes increasingly high as milling time continues
and they hypothesised that modiﬁcation of the DON structure by interaction with wheat components
may occur leading to a reduction of DON and an increase of DON-3-glucoside after milling.
4.3.1.3. Cooking and baking
There have been quite a number of studies to determine the effect of various forms of thermal
processing (cooking, pasta preparation and baking) on the fate of DON. In several studies also the
stability of DON-3-glucoside was investigated. The studies were often carried out with mutually
different experimental designs and conditions, which made comparisons sometimes difﬁcult.
A few studies focussed on the fate of DON (and DON-3-glucoside) during the preparation of
noodles and spaghetti. In the study of Nowicki et al. (1988) wheat naturally contaminated with DON
at 12.5 mg/kg was processed to Japanese-style and Chinese-style noodles. The amount of DON
retained in cooked Japanese and Chinese noodles averaged 52% and 42%, respectively, of the
amount of DON in the ﬂour. In the same study, wheat naturally contaminated with DON at 9.6 mg/kg
was processed to spaghetti. Retention of DON in cooked spaghetti averaged 43–53% of the amount
present before cooking. Overcooking resulted in a slight further decrease. Visconti et al. (2004)
investigated the reduction of DON during spaghetti cooking starting from durum wheat, naturally
contaminated with DON at levels ranging from 0.3 to 13.1 mg/kg and observed stronger reductions.
As compared to the uncleaned wheat, the percentage levels of DON were 33% in spaghetti and 20%
in cooked spaghetti.
In the study of Zhang and Wang (2015), the fate of DON and DON-3-glucoside was studied during
the preparation of Chinese-style noodles from wheat ﬂour samples naturally contaminated with DON
and DON-3-glucoside at ﬁve different levels, ranging from 0.94–5.89 and 0.11–0.77 lg/kg,
respectively. The study revealed a 52% reduction in DON between wheat ﬂour and cooked noodles
(not reported whether wet or dry weight), which conﬁrmed the ﬁndings of Nowicki et al. (1988). For
DON-3-glucoside, a stronger decrease of 79% after noodle making was observed. DON and DON-3-
glucoside were detected in cooking water, but DON-3-glucoside at very minor and non- quantiﬁable
levels. Moazami et al. (2014) studied the effect of three food additives (L-ascorbic acid, L-cysteine and
sodium bisulﬁte) on DON reduction in fried instant noodle strands. The noodles were prepared from
wheat ﬂour fortiﬁed with DON at 1 lg/g. The authors observed reductions of DON up to 67%.
Vidal et al. (2014) reviewed a dozen of studies on the effect of bakery processing on DON
contamination in wheat products (bread, cakes, biscuits). Initial DON levels in wheat ﬂours ranged
from 40–1,824 lg/kg. Loaf sizes, fermentation and prooﬁng conditions, use of additives in the dough
mixture and baking conditions (time, temperature) varied in these studies. Some of the studies
reported a signiﬁcant increase in DON levels during dough fermentation (up to 99% increase,
hypothesised as possibly due to the enzymatic release of native DON from conjugated forms occurring
in the raw material). In contrast, other studies showed a reduction of 62% in fermented dough,
hypothesised to be due to transformation of DON during dough fermentation into a substance that
could not be determined by conventional analysis. Regarding baking, most studies reported that DON
concentrations were reduced to a variable extend (up to 79% reduction), with the degree of reduction
affected by baking time, temperature, and loaf size. The published studies indicate that DON is largely
stable and (partly) survives the bread making process. Reduced levels found in ﬁnished products could
also be attributed to a dilution of the levels of DON due to the incorporation of ingredients such as fat,
sugar and water, rather than to a thermal degradation (Scudamore et al., 2009).
Several recent studies (Kostelanska et al., 2011b; Suman et al., 2012; Zachariasova et al., 2012; de
Angelis et al., 2013; Vidal et al., 2014, 2015; Zhang and Wang, 2014; Wu and Wang, 2015; Generotti
et al., 2015) on the effect of baking and steaming on DON content included investigations on the fate
of DON-3-glucoside and (incidentally) on 3-Ac-DON and 15-Ac-DON.
Kostelanska et al. (2011b) studied the effects of baking technologies on levels of DON and DON-3-
glucoside as part of a larger study, where also the effects of milling of wheat were investigated (see
Section 4.3.1.2) Concentrations of DON and DON-3-glucoside in kneaded dough ranged from 43–758
lg/kg for DON and from 7–105 lg/kg for DON-3-glucoside. No substantial changes of DON and DON-
3-glucoside occurred during the dough preparation process, i.e. kneading, fermentation and prooﬁng.
However, when bakery improvers enzymes mixtures were employed as a dough ingredient, a distinct
increase of DON-3-glucoside concentrations up to 145% as compared to initial concentrations in white
ﬂour occurred in proofed dough. This was assumed to be due to the release of DON-3-glucoside from
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bonded forms to starch-based matrix, rather than to glucosidation of DON, since for DON no
signiﬁcant changes in concentrations were noted. Some decrease of both DON and DON-3-glucoside
compared to proofed dough (decrease of 13% and 10%, respectively) took place during baking.
Thermal degradation products of DON and DON-3-glucoside were detected in roasted wheat and in
baked bread samples, mostly located in the crust.
Zachariasova et al. (2012) compared the fate of DON-3-glucoside with the fate of DON during the
preparation of bread, starting from wheat ﬂour contaminated with DON and DON-3-glucoside at 729
and 160 lg/kg, respectively. The DON level in the ﬁnal bread decreased during the fermentation and
baking to approximately 86% of the initial concentration in the wheat ﬂour. The DON-3-glucoside/DON
ratio slightly increased during prooﬁng which was assumed to be due to the enzymatic activity after
the application of a bakery improver. However, the ﬁnal DON-3-glucoside level in the bread was only
approximately 50% of the initial concentration in the wheat ﬂour.
The multitude of contradictory information on the fate of DON during baking prompted De Angelis
et al. (2013) to investigate the fate of DON and DON-3-glucoside upon baking. Three batches of whole
wheat ﬂour were used, naturally contaminated with DON at 1,824, 954 and 816 lg/kg. DON-3-
glucoside concentrations were at 23% of the DON concentrations. The baking process yielded DON
concentrations, approximately 18% higher in bread than in the original ﬂour. Parallel with the increase
of DON content during baking, a corresponding decrease of DON-3-glucoside was recorded in the
same samples analysed, making a possible release of DON from the conjugated form likely during
baking. This could have been due to yeast activity during fermentation.
Vidal et al. (2014) studied the fate of DON and DON-3-glucoside during the bread making process,
starting from 3 wheat ﬂours, contaminated with DON at 2,090, 1,459 and 1,012 lg/kg levels, while
DON-3-glucoside was at the same level in the ﬂours (45 lg/kg). Loaf breads were made. The
concentrations of DON decreased in fermented dough by 22–37% as compared to the concentrations
in wheat ﬂour. Subsequently reductions in DON concentrations from proofed dough to bread were
observed for baking times of 75 min and over, but the levels of reduction varied (highly signiﬁcant at
high DON concentrations and non-signiﬁcant at low DON concentration). However, the data provided
did not allow quantitative estimates. For DON-3-glucoside a 25% decrease was observed from ﬂour to
fermented dough and, in contrast to DON, a subsequent substantial increase from fermented dough to
ﬁnal bread was found, leading to an overall DON-3-glucoside concentration increase of 224% during
baking, as compared to the concentration in the fermented dough. Its increase could not be linked to
baking temperature/time levels and it was hypothesised that glycosidation of DON in the initial stages
of baking occurred, before enzyme inactivation.
Vidal et al. (2015) focused on the thermal stability and kinetics of degradation of DON and DON-3-
glucoside, and in addition on the fate of 3-Ac-DON during baking of wheat bakery products. Two
wheat ﬂours were used with DON concentrations of 1,042 and 550 lg/kg, while in both ﬂours the
DON-3-glucoside concentration was 45 lg/kg. DON concentrations reduced during the baking process,
depending on the baking temperature and time. Reduction at 40 min baking time varied from 29% at
140°C to 81% at 200°C. In contrast, DON-3-glucoside increased signiﬁcantly during the initial baking
phase from 30% after 5 min at 160°C, up to 642% after 10 min at 180°C, while a strong reduction to
< LOD (1.6 lg/kg) was observed at the higher temperature/time conditions. The concentration of
3-Ac-DON (8.5 lg/kg in the unbaked cake) tended to decrease during baking with increasing
temperature and baking time, but the low initial concentration, close to the LOQ (4.5 lg/kg), and
contradictory results in some of the analysed samples, made it difﬁcult to draw ﬁrm conclusions.
The fate of DON and DON-3-glucoside during Chinese steamed bread processing was investigated by
Zhang and Wang (2014). Five sets of whole wheat samples were used, naturally contaminated with DON
and DON-3-glucoside at levels ranging from 4,680 to 3,672 lg/kg for DON and 170 to 1,040 lg/kg for
DON-3-glucoside, with a constant ratio between DON and DON-3-glucoside. The production of steamed
bread involved mixing with yeast, dough preparation, fermenting, and steaming for 20 min at 100°C. Up
to the stage of fermentation, DON concentrations hardly changed, but they doubled in the steamed
bread. In contrast DON-3-glucoside concentrations in mixed and fermented dough and in steamed bread
were rather similar, but almost 50% lower than in the ﬂour. Bases on the study, dough-making seemed to
decrease the amount of DON-3-glucoside, while steaming increased the amount of DON.
Wu and Wang (2015) investigated levels and conversion proﬁles of DON, 3-Ac-DON and 15-Ac-DON
during bread-making. Five Fusarium toxin-free ﬂours were spiked with DON at levels from 100 to
500 lg/kg. Another set of ﬁve Fusarium toxin-free ﬂours were spiked with 3-Ac-DON and 15-Ac-DON at
levels from 100 to 1,500 lg/kg. Bread loaves were baked at 225°C for 20 min. No signiﬁcant changes of
DON levels were observed during dough preparation stages. During bread baking, a modest reduction of
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DON levels was observed, ranging from 4 to 14%. Decreases of 20–40% for 3-Ac-DON and of 28–60%
for 15-Ac-DON were found during the fermentation stage. Further losses of 3-Ac-DON and 15-Ac-DON
were observed after the prooﬁng process, but the 3-Ac-DON and 15-Ac-DON levels gained a signiﬁcant
increase after baking. Parallel with the 3-Ac-DON and 15-Ac-DON concentration decreases a
corresponding increase of DON was noted, which pointed at a conversion taking place from 3-Ac-DON
and 15-Ac-DON to DON. The mechanism of this conversion remained unclear to the authors.
Suman et al. (2012) studied the fate of DON and DON-3-glucoside throughout the industrial (pilot-
scale) production of wholegrain crackers, starting with wheat bran naturally contaminated with DON
and DON-3-glucoside at 3,436 and 45 lg/kg, respectively. The process involved dough preparation
followed by kneading, fermentation and baking. The authors applied an experimental multifactorial
design, allowing to study the inﬂuence of fermentation time, fermentation temperature, baking time,
baking temperature and sodium bicarbonate on the ﬁnal levels of DON and DON-3-glucoside in the
wholegrain crackers. For DON hardly any effect during fermentation and a limited reduction during
baking were noted, especially at higher baking temperatures (255 and 270°C) where reductions
ranged from 3% to 46%. It was not possible to identify inﬂuences of the technological process
parameters on the DON-3-glucoside levels, because of the relatively low DON-3-glucoside values and
the associated uncertainties in analytical measurements.
A comprehensive study (Generotti et al., 2015) on the effects of industrial processing focused on
the fate of DON and DON-3-glucoside along the chain of industrial production of rusks, characterised
by three steps: fermentation, baking and toasting. Three batches of bran naturally contaminated with
DON at 600, 1,050 and 1,500 lg/kg were used for the study, which showed how concentrations of
DON and DON-3-glucoside are inﬂuenced by modifying ingredients and operative conditions. Ten
factors were taken into account: DON concentration of the starting bran, dextrose, yeast and enzyme
amounts, fermentation time and temperature, baking time and temperature and toasting time and
temperature. It appeared that the evolution of DON is mostly affected by the baking and roasting
stages, with decreases in DON levels from 8% to 19%, and from 19% to 65%, respectively. The co-
occurrence of DON-3-glucoside in the batches of bran at 32 lg/kg allowed to observe an increase in
the concentration of DON-3-glucoside up to 48% after the fermentation step, followed by a reduction
during baking and toasting.
4.3.1.4. Malting process
Lancova et al. (2008a) investigated the fate of DON, the sum of 3-Ac-DON and 15-Ac-DON and
DON-3-glucoside from ﬁeld barley through malt to beer. Two batches of barley, naturally and artiﬁcially
infected with Fusarium species were used for processing experiments. The naturally infected batch
contained DON, the sum of 3-Ac-DON and 15-Ac-DON and DON-3-glucoside at low levels of 12, < 5
and < 10 lg/kg dry weight, respectively, while the artiﬁcially infected batch contained these toxins at
levels of 234, 14 and 140 lg/kg dry weight, respectively. In addition, two batches of malt grist were
prepared, naturally and artiﬁcially infected with DON, the sum of 3-Ac-DON and 15-Ac-DON and DON-
3-glucoside at 316, 67, 133 lg/kg, and 1,712, 349 and 933 lg/kg, respectively. During the steeping of
barley grains, the toxins were not detectable in the naturally infected series, while in the artiﬁcially
infected series levels reduced to < 10% of the original amounts in the samples of barley, except for
DON-3-glucoside, which remained at the initial level. During subsequent stages in the beer brewing
process, substantially increases of DON and DON-3-glucoside occurred in both series of experiments.
In particular, the presence and formation of high levels of DON-3-glucoside were documented, leading
to DON-3-glucoside levels in ﬁnal beers to exceed those of DON. In sweet wort the relative DON-3-
glucoside content was ten times higher as compared with that in malt grist taken for the processing
experiment. The authors explained the concentration changes observed by de novo growth of
Fusarium under certain malting conditions and enzymatic activity during the mashing of malt grists,
thus releasing DON-3-glucoside from insoluble forms. For 3-Ac-DON and 15-Ac-DON, the transfer to
ﬁnal beers was found to be slightly above 100%.
Kostelanska et al. (2011b) studied the concentration changes of DON and DON-3-glucoside in the
brewing process of four beer brands: light, dark tap and two lagers, produced from ground malt
mixtures differing in composition and toxin content. In a ﬁrst monitoring period mixture malts were
used, contaminated with DON and DON-3-glucoside at average levels of 31.5 and 55.7 lg/kg
respectively. A relative increase of DON plus DON-3-glucoside content occurred during brewing. In the
ﬁnal beer, the increase of DON and of DON-3-glucoside was in the range 195–365 and 275–460%,
respectively, depending on the beer brand. These increases conﬁrmed the ﬁndings of Lancova et al.
(2008a). In a second monitoring period where new malts were used contaminated with DON and
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DON-3-glucoside at average levels of 15.7 lg/kg and 15.6 lg/kg, respectively, these concentration
changes ranged from 49% to 248% and 139% to 416%, respectively. No relationship between the
contamination level of the malt and the trend of the concentration change could be observed, and
both an increase and a decrease of DON was found during brewing. Without any exception, DON-3-
glucoside levels increased during brewing.
Zachariasova et al. (2012) used barley, artiﬁcially infected with Fusarium spp., for the production of
malt and beer and studied the fate of DON and DON-3-glucoside during that process. The barley
contained DON at 2,467 lg/kg and DON-3-glucoside at 939 lg/kg and the levels in the ﬁnal malt were
11,638 lg/kg for DON and 20,912 lg/kg for DON-3-glucoside. The increase of DON was explained by
Fusarium fungus growth and de novo production of DON. An even much stronger increase of DON-3-
glucoside during the malting process was observed, leading to concentrations of DON-3-glucoside
much higher than DON in ﬁnal malt. thought to result from the glycosidation of DON by glucose during
the starch hydrolysis and from the enzyme-catalysed release from the binding with polysaccharides in
the cells. During the subsequent brewing process beers were produced containing DON at 2,760 lg/L
and DON-3-glucoside at 3,883 lg/L, resulting in a DON-3-glucoside/DON ratio of approximately 1.4
which is in line with results obtained from surveys of beer (see Section 4.1.1.2)
4.3.2. Feed processing
4.3.2.1. Cereal grains
Cereal grains intended for use as animal feed are usually subject to some of the processes used for
processing grains for human consumption (cleaning, sorting, drying, rolling/grinding and/or extrusion)
before being fed to livestock, and therefore many of the effects reported above for food
(Section 4.3.1) apply equally to cereal grains for animal feed. In addition, by-products of processing
grains for human consumption are widely used as feeds for livestock.
The initial cleaning of cereal grains is usually a physical process involving the use of screens, to
remove smaller particles. Tittlemeier et al. (2015) reported that for Canadian wheat, DON was found
in at levels of up to 2.9 mg/kg in the material removed by cleaning.28 The levels of DON in the
uncleaned samples were 0.5–4.4 mg/kg.
For long-term storage, a maximum moisture content of approximately 12% is generally
recommended. In order to achieve this, air temperatures of up to 125–130°C may be used, resulting in
grain temperatures of up to 45°C. DON is relatively stable when exposed to heat, even at temperatures
of 120°C (Hazel and Patel, 2004) or more (Wolf-Hall et al., 1999; Lancova et al., 2008b) and therefore
drying is unlikely to affect DON concentrations in grains dried in this way.
Prior to feeding, grains may be further processed by rolling, milling, extruding or ﬂaking. These
processes involve the application of pressure (e.g. rolling, extruding) and/or heat (e.g. cooking,
ﬂaking), but DON appears to be stable under these conditions (Scudamore, 2008).
Where whole cereal grains are fed, the application of an alkali has been used as a means of
reducing levels of DON present. Abramson et al. (2005) demonstrated that the application of an alkali
(1 M Na2CO3) in combination with heat (80°C) resulted in signiﬁcant reductions in DON, from 18.4 to
4.7 mg/kg after 1 day, and to 0.4 mg/kg after 8 days with the addition of 10% v/w alkali. When 20%
v/w alkali was used, DON declined to 1.4 mg/kg after 1 day and near zero levels after 8 days. The
effect of alkali therefore appears to be dependent on both the duration of the heat application and the
concentration of the alkali used.
4.3.2.2. Cereal by-products
The by-products of grain processing for human consumption are widely used in livestock diets. The
European Commission Catalogue of Feed Materials29 lists over 80 cereal by-products used as animal
feeds. These include by-products from the major cereals (wheat, barley, oats and maize) used in the
manufacture of foods for human consumption, as well as in the production of alcohol.
In common with other mycotoxins, DON is found predominantly on the outer layer of the grain. Dry
milling generally results in a redistribution of DON into separate milling fractions, and an increase of
DON in particular fractions such as the bran and grits. Scudamore and Patel (2009) showed that
28 In Northern America this is known as dockage, and includes husk, rootlets, unthreshed wheat heads or spikelets, chaff, dust,
loose hulls, and fragments of stem or rachis.
29 Commission Regulation (EU) No 68/2013 of 16 January 2013 on the Catalogue of Feed Materials.
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concentrations of DON in maize by-products could be three to four times higher than in the original
grain, with variability attributed to both the source of the grains and the milling process used.
By-products of the brewing industry are widely used as feeds for livestock, but reports of the
transfer of mycotoxins to animal by-products are somewhat contradictory. A number of studies have
demonstrated that mycotoxins are transmitted from contaminated grains to beer (Scott, 1995;
Papadopoulou-Bouraoui et al., 2004). For DON, the transfer from malt grist to ﬁnished beer was
reported to be between 80% and 93% (Schwarz et al., 1995), and Lancova et al. (2008a) concluded
that a relatively high proportion of the DON in contaminated grains is transferred to the beer but not
to the by-products of brewing. In contrast, the carry-over of DON, 3-Ac-DON, 15-Ac-DON and 3-DON-
glucoside to co-products of bioethanol production has been reported. Distillers dried grains with
solubles (DDGS) are a co-product of bioethanol production and a valuable feed material for farm
animals. Schaafsma et al. (2009) and Zhang and Caupert (2012) reported increases of between 3.0
and 3.5 times in the concentration of DON in DDGS relative to starting material from bioethanol plants
in the USA. In another survey from the USA, Khatibi et al. (2014b) reported DON concentrations in
DDGS following bioethanol fermentation that were about 1.6 to 8.2 times higher than in the starting
grain, depending on the barley line/cultivar used in the mash. Recently, a number of trichothecene
3-O-acetyltransferases have been evaluated for their ability to modify DON, and small-scale barley
ethanol fermentations using two of these enzymes demonstrated their potential to reduce DON in
DDGS (Khatibi et al., 2011b). Pinotti et al. (2016) concluded that contamination, by DON and 3-Ac-
DON, 15-Ac-DON and 3-DON-glucoside, of by-products of the malting and brewing process for animal
feeding was inﬂuenced by a number of factors, including the initial levels of the mycotoxins in the
barley and the brewing process technology.
4.3.2.3. Compound feeds
Compound feeds consist of mixtures of feed materials and additives formulated to meet the speciﬁc
nutritional requirements of the livestock to which they are fed. They may be complete feeds that
provide all of the daily requirements of nutrients, or complementary feeds that provide part of the
ration (e.g. protein and energy). For ruminants and horses, compound feeds usually represent part of
the ration and are supplemented with forages, while for pigs, poultry, rabbits, ﬁsh, cats and dogs they
are usually the sole feed. It is estimated that 155 million tonnes of compound feed were manufactured
in the EU-27 in 2013 (FEFAC, 2014).
One of the ﬁnal stages in the compound feed manufacturing process is the production of feed
pellets, which results in an increase in temperature. The extent of the temperature rise will depend on
a number of factors, including the types of ingredients used in the formulation, the amount of
moisture added and the equipment used, but pellets generally leave the die at temperatures ranging
between 60 and 95°C (Thomas et al., 1997). Like most trichothecenes, DON is stable at these
temperatures (Schwake-Anduschus et al., 2010).
4.3.2.4. Forage cereals/silage
Forages, including maize, sorghum and other cereals, may be preserved by ensiling for use when
fresh feeds are unavailable. The presence of DON in forages has been regularly observed in both fresh
and ensiled form (Driehuis et al., 2008b; Rodrigues et al., 2012; Storm et al, 2014), although there is
evidence that the physical, chemical, or microbiological changes associated with ensiling may reduce
levels of DON in silage relative to those in the fresh herbage (Mansﬁeld et al., 2005). Although it is
generally accepted that contamination with DON is the result of infection with Fusarium pre-harvest,
contamination has been reported to occur post-harvest in poorly preserved silages (Rasmussen et al.,
2010).
4.3.3. Conclusions
Drying after harvest does not affect levels of DON in the grains. Application of alkali to whole grains
for feed reduces the DON content signiﬁcantly. During mechanical cleaning, sorting and milling of grains
DON, like other Fusarium toxins, is unevenly redistributed between the grain fractions (bran, endosperm
and germ), and is mostly attached to the outer hull of the grains and therefore the toxin occurs at much
higher concentrations in the bran than in other parts of the grain. As a result, the dehulling process may
result in by-products used in the food or feed industries in which levels of DON are signiﬁcantly higher
than in the original grain. The scarce studies that also involved DON-3-glucoside and 3-Ac-DON and
15-Ac-DON showed that concentrations of these DON forms were also reduced in the dehulled products,
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but at varying degrees. The corresponding increase of their concentrations in shorts (consisting of bran,
germ and ﬂour) and bran was often more substantial than that of DON.
During cooking and baking DON appears to be a relatively stable compound, for which often some
degradation was reported, with more reduction at higher processing temperatures and longer times.
Studies on the fate of DON-3-glucoside during cooking and baking showed rather inconsistent and
varying results, ranging from no substantial changes to signiﬁcant increase of concentrations during
fermentation stages, mostly followed by reductions during baking steps. The incidental studies that
also focussed on 3-Ac-DON and 15-Ac-DON led to contradictory results.
Malting and brewing do not seem to lead to losses of DON/DON-3-glucoside or increased
concentrations in by-products of brewing used in the feed industry. However, the ratio between
concentrations of these compounds in beer changes signiﬁcantly, leading to (often) higher concentrations
in beer of DON-3-glucoside than those of DON. Studies on the fate of the 3-Ac-DON and 15-Ac-DON
during beer preparation are limited, but point at a transfer to ﬁnal beer of approximately 100%. DON
concentrates in distillers’ dried grains with solubles at levels up to eight times higher than in the starting
grain.
Overall, CONTAM Panel noted that processing has been reported to reduce DON concentrations in
cereals at a range of 10–80% depending on the method of processing.
Some of the processes applied to cereal grains for food production (particularly drying, cleaning,
sorting, rolling and milling) are also applied to grains used for animal feeds, and therefore the effects
on concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside reported for food also apply to
feed. Published studies conﬁrm that milling can minimise concentrations of these toxins in grains, but
concentrate them into fractions commonly used as animal feed.
Overall, the literature data on the effects of processing of food and feed are not always consistent,
but lead to the conclusion that both increases and decreases of concentrations of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside in the processed food and feed products occur, depending on the
type and intensity of the form of processing.
5. Food and feed consumption
5.1. Food consumption
Since 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive
Database) has been populated with national data from national information on food consumption at a
detailed level. Competent authorities in the European countries provide EFSA with food consumption
data at the level of the individual consumer from the most recent national dietary survey in their country
(cf. Guidance of EFSA ‘Use of the EFSA Comprehensive European Food Consumption Database in
Exposure Assessment’ (EFSA, 2011a)). New consumption surveys added in 2015 in the Comprehensive
Database30 were also taken into account in this assessment.31
Food consumption data included in the Comprehensive Database were collected through different
methodologies, and thus direct country-to-country comparisons should be interpreted with caution.
Depending on the food category and the level of detail used in the exposure calculations, uncertainties
can be introduced because of possible subjects’ underreporting and/or misreporting of the consumption
amounts. Nevertheless, the food consumption data gathered at EFSA in the Comprehensive Database
are the most complete and detailed data currently available in Europe.
Competent authorities in the European countries provided EFSA with data from the most recent
national dietary survey in their country at the level of consumption by the individual consumer. This
included food consumption data concerning infants (6 surveys from 6 countries), toddlers (11 surveys
from 10 countries), children (20 surveys from 17 countries), adolescents (20 surveys from 17
countries), adults (24 surveys from 22 countries), elderly (16 surveys from 15 countries) and very
elderly (14 surveys from 14 countries) for a total of 41 different dietary surveys carried out in 23
different countries covering more than 78,400 individuals. Surveys on children were mainly obtained
through the Article 36 project ‘Individual food consumption data and exposure assessment studies for
children’ (acronym EXPOCHI) (Huybrechts et al., 2011). Two additional surveys provided information
on speciﬁc population groups of ‘Pregnant women’ (≥ 15 years to ≤ 45 years old) and ‘Lactating
women’ (≥ 28 years to ≤ 39 years old) from two countries.
30 Available online: http://www.efsa.europa.eu/en/press/news/150428.htm
31 Available online: http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm
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As suggested by EFSA (EFSA, 2011b), dietary surveys with only 1 day per subject were not
considered for the calculation of chronic dietary exposure, as they are not adequate to assess
repeated exposure. Similarly, subjects who participated for only 1 day in the dietary studies although
the protocol prescribed more reporting days per individual, were excluded. Thus, for chronic exposure
assessment, food consumption data were available from 35 different dietary surveys carried out in 19
different European countries (Table D.1, Appendix D). In addition to the studies used for chronic
exposure, six dietary surveys with only 1 day per subject from six different countries were used for the
acute exposure assessment.
Within the dietary studies, subjects were classiﬁed in different age classes as deﬁned below:
1) Infants: < 12 months old
2) Toddlers: ≥ 12 months to < 36 months old
3) Other children: ≥ 36 months to < 10 years old
4) Adolescents: ≥ 10 years to < 18 years old
5) Adults: ≥ 18 years to < 65 years old
6) Elderly: ≥ 65 years to < 75 years old
7) Very elderly: ≥ 75 years old
Two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’ (≥ 15
years to ≤ 45 years old) and ‘Lactating women’ (≥ 28 years to ≤ 39 years old).
Consumption records were coded in accordance with the FoodEx classiﬁcation system (see
Section 4.2.3), which has been developed by the DATA Unit in 2009 (EFSA, 2011a). Further details on
how the Comprehensive Database is used were published in the Guidance of EFSA (EFSA, 2011b).
5.2. Feed consumption
As reported above, DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside occur predominantly in
cereal grains and their by-products following processing. These are widely used as feed for livestock;
in the EU more than 91 million tonnes was used in the manufacture of compound feeds in 2012,
accounting for 60% of all feed materials used,32 almost all of which (> 95%) are grown or processed
in the EU.
In addition to incorporation in compound feeds, cereal grains and by-products are frequently fed in
on-farm mixes or as single ingredients, particularly to supplement forages for ruminant livestock.
Therefore, the total amount of cereal grains and cereal by-products used as feed for livestock will be
considerably greater than that reported for compound feed production. However, there are no industry
data on the partition of these cereal grains between livestock species (cattle, pigs, poultry, etc.).
Mycotoxin-producing Fusarium species may also be present in infect forage crops used as livestock
feed. Although not widely reported to be present on fresh grass, the presence of DON in maize and
cereal silages has been regularly observed (Driehuis et al., 2008b; Rodrigues et al., 2012; Storm et al.,
2014).
There is considerable variation in both the feeds used and the feeding systems adopted for farm
livestock, companion animals and ﬁsh throughout Europe. This variation is largely due to the
availability of feeds and market demands for speciﬁc animal products, the quality of the feeds available
and nutritional needs of the animals concerned.
Estimating the exposure to DON and to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside (Section 6.2) requires estimates of feed intake, and in this opinion two approaches have
been adopted. For many livestock, part or all of the daily ration is commonly is provided in the form of
manufactured compound feeds, and where data on levels of DON and its acetylated and modiﬁed
forms in species speciﬁc compound feeds are available these have been used to estimate exposure.
Because the compound feeds are what the animals receive, this must be the preferred method of
calculating exposure. However, for some livestock categories information on levels in compound feeds
has not been given, or insufﬁcient data have been provided to allow reliable estimates of exposure to
be made. Since data on individual feed materials have been presented (Appendix C), estimates of
exposure have also therefore been made using example diets. It should be stressed that these do not
represent ‘average’ diets, nor are the feeding systems ‘typical’ for all of Europe. Instead, they are used
to estimate levels of exposure to DON and to its acetylated and modiﬁed forms that might be
indicative. They are based on published guidelines on nutrition and feeding (AFRC, 1993; Carabano
32 Source: FEFAC 2012 statistics. Available online: www.fefac.eu
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and Piquer, 1998; NRC, 2007a,b; Leeson and Summers, 2008; EFSA FEEAP Panel, 2012; OECD, 2009;
McDonald et al., 2011), data on EU manufacture of compound feeds (FEFAC, 2012)32 and expert
knowledge of production systems in Europe. For companion animals (cats and dogs), information on
typical diet formulations have been provided by The European Pet Food Industry.33 Details of feed
consumption of farm and companion animals and the rations used are given in Appendix E.
5.2.1. Ruminants
For most ruminants, forages (either fresh or conserved) are the main ingredient in their diet, and in
some cases may represent the total diet.
5.2.1.1. Dairy cows
For this scientiﬁc opinion, exposure is estimated for a 650-kg dairy cow, with a milk yield of 40 kg
per day (considered as a high milk yield), for which the main forages are either grass or grass silage,
maize silage or hay. Assumptions on the amounts of forages and non-forage feed, and the proportions
of cereal grains, their products and their by-products in the diet, are given in Appendix E, Tables E.1
and E.3.
5.2.1.2. Beef cattle
In this opinion, exposures are estimated for fattening beef cattle in which the forage is supplemented
with species speciﬁc compound feed. Two scenarios are considered; in the ﬁrst the compound feed is fed
with grazed grass or grass silage, which are assumed to make no contribution to exposure. In the second
scenario, grass hay is assumed to be the forage. Three other feeding systems are also considered, in
which the forages are either maize silage or cereal straw, and ‘cereal-beef’ (intensively reared beef cattle
on cereal-based diet) with, in each case, appropriate supplementation. For exposure estimates, live
weights of 300 or 400 kg, and feed intakes of between 6.6 and 10 kg dry matter per day have been
assumed, depending on the feeding regime (see details in Appendix E, Tables E.1 and E.3).
5.2.1.3. Sheep and goats
The CONTAM Panel has used a daily dry matter intake of 2.8 kg for an 80-kg lactating sheep
feeding twin lambs to estimate the exposures (Appendix E, Table E.1). Details on the composition of
the diets used in estimating the exposure for lactating sheep are given in Appendix E, Table E.4.
The dry matter intakes of goats reared for meat and fed ad libitum can be as high as 3.8% of body
weight (Devendra and Burns, 1983). The CONTAM Panel has used daily dry matter intakes of 3.3 kg
for a 60-kg goat for milking (4 kg milk/day) and 1.5 kg for a 40-kg goat for fattening to estimate the
exposures (Appendix E, Table E.4). Details on the composition of the diets used in estimating the
exposure for goats are given in Appendix E, Table E.4.
5.2.2. Pigs
Exposure estimates have been made for piglets (20 kg bw), fattening pigs (100 kg bw) and
lactating sows (200 kg bw) using feed intakes proposed by EFSA (2009). The proportions of cereal
grains, their products and by-products used in estimating the exposure for pigs are given in
Appendix E, Table E.2.
5.2.3. Poultry
The CONTAM Panel applied the live weights and feed intakes reported for different poultry (broilers,
laying hens and turkeys) by EFSA (2009) and for ducks by Leeson and Summers (2008) for the
exposure estimations. The proportions of cereal grains, their products and by-products used in
estimating the exposure for poultry are given in Appendix E, Table E.2.
5.2.4. Horses
The CONTAM Panel estimated the exposure for a 450-kg horse, with a daily intake of 9 kg dry
matter/day, of which half is in the form of grass hay and where cereal grains, their products and
by-products represent 82% of the non-forage component of the daily ration (Appendix E, Table E.1
and Section E.2.1).
33 FEDIAF, Personal communication by email, May 2016
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5.2.5. Rabbits
For the exposure estimates, the CONTAM Panel assumed a live weight of 2 kg, and a feed intake of
75 g/kg bw per day. The proportions of cereal grains, their products and by-products used in
estimating the exposure are given in Appendix E, Section E.2.3.
5.2.6. Farmed ﬁsh (salmonids and carp)
Berntssen et al. (2010) provided details of the composition of a diet for growing salmonids, and the
CONTAM Panel used this feed formulation to estimate the exposures, for salmon (2 kg) with a feed
intake of 0.04 kg dry matter/day (EFSA FEEDAP Panel, 2012) (Appendix E, Tables E.2 and E.5).
For carp, the CONTAM Panel have used the ingredients of commercial compound feeds for carp
reported by Schultz et al. (2012) to estimate the exposures for ﬁsh of 1 kg live weight and a feed
intake of 0.022 kg dry matter/day (Appendix E, Tables E.2 and E.5).
5.2.7. Farmed mink
For estimating exposure, the CONTAM Panel have assumed a live weight of 2.07 kg for a male mink
at pelting, and with a feed intake of 227 g/day (75 g dry matter) (NRC, 1982). The proportions of
cereal grains, their products and by-products used in estimating the exposure are given in Appendix E,
Section E.2.5.
5.2.8. Dogs and cats
The amounts of food consumed by dogs and cats are inﬂuenced by many factors, including breed,
size, level of activity and their reproductive state. For estimating the exposure, the CONTAM
Panel applied a live weight of 4 kg and a feed intake of 60 g per day of standard-quality pet food for
cats (Appendix E, Section E.1.4). For dogs, a live weight of 25 kg and a feed intake of 360 g per day
of standard-quality pet food were assumed (Appendix E, Table E.5).
6. Exposure assessment of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in humans and animals
6.1. Human exposure assessment
6.1.1. Human exposure assessments reported in the literature
A large number of human exposure assessments have been conducted for DON, with only one
study including acetylated DON and metabolites. Below are summarised the evaluations of those
conducted by international or national bodies, especially for the European countries (see Table 32).
In the exposure assessment of the Nordic Council (NCM, 1998) mean concentrations of DON in
grains and the consumption data from the food balance sheets and from individual quantitative
questionnaires were used. The mean DON exposure for adults in Finland, Denmark, Iceland, Norway
and Sweden ranged from 0.14 to 0.57 lg/kg bw per day, and the 95th percentile exposure from 0.28
to 1.14 lg/kg bw per day. The biggest contribution came from wheat, followed by oats.
The SCOOP task 3.2.10 assessed exposure to several Fusarium mycotoxins in 11 EU Member
States. Of the 11,022 samples, 57% had detectable DON concentrations (Schothorst and van Egmond,
2004). The average DON exposure ranged from 0.08 to 1.51 lg/kg bw per day across all countries
with France having the highest and Sweden the lowest exposure. Wheat ﬂour and bread were the
major source of DON exposure.
JECFA (2001) evaluated the dietary exposure to DON using the average concentrations (mostly
using pooled data and excluding processed food) and the average food consumption data from the
ﬁve regional diets in the Global Environment Monitoring System – Food Contamination Monitoring and
Assessment Programme (GEMS/Food) (WHO, 1998). DON exposure was estimated to range from 0.77
to 2.4 lg/kg bw per day. Wheat contributed the largest proportion of DON exposure in Europe (79%).
In 1998–1999, high DON concentrations in the cereals were reported in a national exposure
assessment of the Netherlands (Pieters et al., 2001) using consumption data of 2 consecutive days
were from the National Food Consumption Survey. The median exposure level to DON was 0.3 lg/kg
bw per day in 6,247 individuals. Young children had the highest exposure. Other dietary exposure
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assessments of DON in young Dutch children showed a similar level of exposure (Pieters et al., 2004;
Boon et al., 2009).
The ﬁrst French total diet study measuring various contaminants including DON in ‘ready to eat’
food was conducted in 2000 by the French National Institute for Agricultural Research (INRA) and
AFSSA (now ANSES). The mean DON exposure was 0.28 and 0.45 lg/kg bw per day in adults and
children, respectively. Depending on the different types of vegetarians, DON average exposure ranged
between 0.32 and 0.41 lg/kg bw per day in this subpopulation. Cereal products, particularly bread/
rusk contributed over 90% of DON exposure (Leblanc et al., 2005; AFSSA, 2009). The second French
Total Diet Study (ANSES, 2011) assessed exposure to DON, 3-Ac-DON and 15-Ac-DON based on the
French Individual and National study of Food Consumption (INCA2) during 2006–2007. The average
exposure to the sum of DON, 3-Ac-DON and 15-Ac-DON ranged from 0.37 to 0.62 (UB) lg/kg bw per
day. The DON exposure of the latter study was higher than that of the ﬁrst one. Acetylated DON
constituted less than 10% of DON.
JECFA (FAO/WHO, 2011) estimated the exposure to DON using their diet cluster system from the
GEMS/Food and occurrence data reported in the literature or provided by the member states of FAO.
DON occurrence data were obtained for barley, maize, wheat, rice, rye and oats. The dietary exposure
to DON varied from 0.2 to 14.5 lg/kg bw per day across the different regions. For Europe the average
exposure was 1.4 lg/kg bw per day. The acetylated forms of DON were not included in the dietary
exposure estimates due to limited data and also because the levels of the acetylated forms of DON
were typically less than 10% of those reported for DON. Wheat was the major contributor (56–100%)
to DON exposure in the majority of the regions (FAO/WHO, 2011). Acute DON exposure was assessed
using the highest mean occurrence data and the 97.5th percentile consumption data for the sum of
DON, 3-Ac-DON and 15-Ac-DON using the GEMS/Food database. For the acute exposure calculation,
bread was taken as the representative food type due to the frequent daily consumption (typically 9 g/kg
bw per day). Based on the concentration of 1 mg DON/kg, the estimated acute dietary exposure was 9
lg/kg bw per day (FAO/WHO, 2011).
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Table 32: Previous dietary exposure assessments of DON in different countries and regions
Country Population group Dietary exposure (lg/kg bw per day) Reference
Europe Adult 1.4(a)
0.22, 1.02 (means for different populations)
0.22, 1.11 (mean, minimum LB, maximum UB)
FAO/WHO (2001)
EFSA (2013)
EFSA (2014)
All regions 0.2–14.5 (means for different regions) FAO/WHO (2011)
Finland Adult 0.36, 0.72(b)
0.14, 0.28(b)
0.57, 1.14(b)
0.49, 0.98(b)
0.40, 0.80(b)
NCM (1998)
(Based on food balance sheets
consumption data)
Denmark Adult
Iceland Adult
Norway Adult
Sweden Adult
France
Germany
Netherland
Norway
Portugal
Sweden
United Kingdom
Austria
Belgium
Denmark
Finland
Adult
Child
Adult
Infant 4 months
Adult
Child 1–6 years
Adult (male)
Adult (female)
Infant 6 months
Adult
Adult
Adult (female)
Adult (male)
4–6 years
< 1 year
Infant
Adult
13–18 years old
Adult
Adult
0.46, 0.89(c)
0.73, 1.51(c)
0.27, 0.38(c)
0.51, 0.60(c)
0.34(c)
0.76(c)
0.34, 0.61(c)
0.30, 0.53(c)
0.29, 0.44(c)
0.36, 1.00(c)
0.08, 0.13(c)
0.14(c)
0.18(c)
0.50(c)
0.48(c)
0.37(c)
0.29, 0.66(c)
0.25, 1.26(c)
0.17, 0.21(c)
0.14, 0.25(c)
SCOOP (2003)
Finland EVIRA data
MTT data
0.04, 0.10(b)
0.08, 0.18(b)
Rautala et al. (2008)
France Adult 15+ years
Child 3–14 years
Vegetarian
0.28, 0.57(b)
0.45, 0.93(b)
0.32, 0.96(b)
Leblanc et al. (2005)
Adult
Child
0.38, 0.72(b)
0.56, 1.03(b)
ANSES (2011)
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Country Population group Dietary exposure (lg/kg bw per day) Reference
The Netherlands Child 1year old
Child
Child 1 year old
0.66(a)
0.29(a)
0.30, 0.50(b)
Schothorst et al. (2005)
Bakker et al. (2009)
Boon et al. (2009)
Norway Child 1–2 years old
Adult
0.89, 1.80(d)
0.27, 0.55(d)
NVK (2013)
New Zealand Not reported 0.01(a) Cressey and Thomson (2006)
Japan Total (year 2005)
Child < 1 year old (year 2003)
Child 1–6 years old (year 2003)
0.01–0.02
0.17(a)
0.36(a)
FSCJ (2010)
bw, body weight; LB: lower bound; UB: upper bound.
(a): Overall mean.
(b): Average consumer and high consumer (consumption at 95th percentile).
(c): Mean 1 and mean 2 in the SCOOP study: mean food consumption and mean 1 (count for all values, middle bound (MB)) or 2 (count for only positive values, UB) occurrence data. Where only
one is shown, mean 1 is used.
(d): Based on occurrence data of earlier and later years. For details see NVK (2013).
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6.1.2. Current mean and 95th percentile dietary exposure to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside
The CONTAM Panel considered it appropriate to estimate both acute and chronic exposure to the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside and to DON alone (see Appendix F,
Table F.2) for all age groups (Section 5.1). The sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside was estimated by summing up the individual concentrations of all four forms, DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside (see Sections 4.2.2 and 4.2.8).
The food categories, which were represented by a very low number of samples (≤ 5 samples) or for
which all the data were left-censored, were not considered suitable, and were not used in exposure
calculation.
6.1.2.1. Current mean and 95th percentile acute dietary exposure
The acute dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside and
the exposure to DON (Appendix F, Table F.2) was calculated on a per day basis, since individual meals
are recorded for only a few countries in the consumption database. The preferred option is, therefore,
to use individual consuming days. Consuming days offer a conservative estimate of the exposure, since
it will sum the contribution of all meals during the same day.
Acute exposure was assessed for each reporting day by multiplying the total consumption amount
for each food category by an occurrence level randomly drawn among individual results available for
that food category. Respective intakes of the foods consumed that day were summed and ﬁnally
divided by the individual’s body weight. This process was iterated 100 times for each consuming day
reported by each participant.
The mean and 95th percentile of acute exposure (LB, MB and UB estimates) to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside obtained for different age groups are shown in Table 33.
The distribution of the mean and 95th percentile of acute exposure to DON alone obtained for
different age groups is shown in Appendix F, Table F.2.
Table 33: Summary statistics of probabilistic acute dietary exposure assessment to the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside (at the lower, middle and upper
bound) across European dietary surveys (lg/kg bw per day) by age group
Age group(a)
Mean dietary exposure
(lg/kg bw per day)
95th percentile dietary exposure
(lg/kg bw per day)
n Minimum Maximum Minimum Maximum
Lower bound
Infants(b) 6 0.3 (0.1–0.5) 0.5 (0.4–0.9) 1.7 (1.6–1.8) 2.2 (1.9–2.7)
Toddlers 11 0.6 (0.3–1.1) 1.0 (0.9–1.1) 1.8 (1.6–2.0) 3.2 (2.1–4.5)
Other children 20 0.5 (0.5–0.6) 1.0 (0.9–1.1) 1.5 (1.4–1.6) 3.0 (2.7–3.4)
Adolescents 20 0.3 (0.3–0.4) 0.7 (0.6–0.7) 0.8 (0.7–0.9) 2.2 (2.2–2.2)
Adults 24 0.2 (0.2–0.3) 0.4 (0.3–0.5) 0.8 (0.7–1.0) 1.5 (1.3–1.7)
Elderly 16 0.2 (0.2–0.3) 0.4 (0.3–0.5) 0.7 (0.6–0.7) 1.4 (1.1–1.7)
Very elderly 14 0.3 (0.2–0.5) 0.4 (0.3–0.6) 0.7 (0.5–1.0) 1.5 (1.1–2.2)
Middle bound
Infants(b) 6 0.6 (0.6–0.7) 1.7 (1.6–2.1) 1.8 (1.7–1.9) 4.1 (4.1–4.2)
Toddlers 11 1.0 (0.8–1.5) 1.6 (1.5–1.7) 2.5 (2.3–2.7) 4.1 (3.1–5.6)
Other children 20 0.9 (0.8–1.0) 1.5 (1.4–1.5) 2.0 (1.9–2.1) 3.6 (3.4–3.9)
Adolescents 20 0.4 (0.4–0.4) 0.9 (0.8–1.0) 1.0 (1.0–1.1) 2.3 (2.0–2.7)
Adults 24 0.4 (0.3–0.5) 0.7 (0.6–0.7) 1.1 (1.0–1.2) 2.0 (1.9–2.2)
Elderly 16 0.4 (0.4–0.5) 0.6 (0.5–0.7) 1.0 (0.9–1.2) 1.7 (1.4–2.1)
Very elderly 14 0.4 (0.4–0.5) 0.6 (0.6–0.8) 0.9 (0.9–0.9) 1.8 (1.4–2.5)
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Infants (< 12 months)
Six dietary surveys were available for this age group, one of which had less than 60 survey
participants and therefore could not be included in calculation of the 95th percentile exposure. The
mean acute dietary exposure was between 0.3 and 2.9 lg/kg bw per day (minimum LB and maximum
UB) and the 95th percentile dietary exposure ranged from 1.7 to 6.7 lg/kg bw per day (minimum LB
to maximum UB). Infants had the highest estimates of acute dietary exposure to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside. This can be explained by the higher intake of food per kg
bw in younger age groups.
Toddlers (≥ 12 months to < 36 months old)
There were 11 surveys available reporting food consumption for toddlers. The mean acute dietary
exposure ranged from 0.6 to 2.2 lg/kg bw per day (minimum LB to maximum UB), and the 95th
percentile dietary exposure ranged from 1.8 to 5.4 lg/kg bw per day (minimum LB to maximum UB).
Other children (≥ 36 months to < 10 years old)
There were 20 surveys available reporting food consumption for other children. The mean acute
dietary exposure ranged from 0.5 to 2.0 lg/kg bw per day (minimum LB to maximum UB), and the 95th
percentile dietary exposure ranged from 1.5 to 4.5 lg/kg bw per day (minimum LB to maximum UB).
Adolescents (≥ 10 years to < 18 years old)
There were 20 surveys available reporting food consumption for adolescents. The mean acute dietary
exposure ranged from 0.3 to 1.2 lg/kg bw per day (minimum LB to maximum UB), and the 95th
percentile dietary exposure ranged from 0.8 to 2.9 lg/kg bw per day (minimum LB to maximum UB).
Adults (≥ 18 years to < 65 years)
There were 24 surveys available reporting food consumption for adults including pregnant and
lactating women. In the adult population, the mean acute dietary exposure to the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside varied from the minimum LB of 0.2 lg/kg bw per day to the
maximum UB of 1.0 lg/kg bw per day. The 95th percentile dietary exposure estimate varied from 0.8
to 2.8 lg/kg bw per day (minimum LB to maximum UB).
Elderly and very elderly (≥ 65 years old)
There were 16 surveys available reporting food consumption for elderly and 14 surveys available
reporting food consumption for very elderly participants. The dietary exposure to the sum of DON, 3-
Ac-DON, 15-Ac-DON and DON-3-glucoside varied for the mean between 0.2 and 1.0 lg/kg bw per day
(minimum LB to maximum UB) with a 95th percentile ranged between 0.7 and 2.2 lg/kg bw per day
(minimum LB to maximum UB).
Table 34 shows the estimates of average % of acute exposure to the sum of DON, 3-Ac-DON, 15-
Ac-DON and DON-3-glucoside through the daily consumption per age class and individual foods/food
Age group(a)
Mean dietary exposure
(lg/kg bw per day)
95th percentile dietary exposure
(lg/kg bw per day)
n Minimum Maximum Minimum Maximum
Upper bound
Infants(b) 6 1.0 (0.9–1.0) 2.9 (2.8–3.2) 2.7 (2.6–2.8) 6.7 (6.2–7.1)
Toddlers 11 1.5 (1.2–1.9) 2.2 (2.0–2.6) 3.5 (3.3–3.6) 5.4 (4.5–6.5)
Other children 20 1.2 (1.1–1.3) 2.0 (1.9–2.0) 2.6 (2.5–2.7) 4.5 (4.2–4.9)
Adolescents 20 0.6 (0.6–0.6) 1.2 (1.1–1.3) 1.3 (1.3–1.4) 2.9 (2.7–3.2)
Adults 24 0.5 (0.5–0.5) 1.0 (1.0–1.0) 1.5 (1.4–1.6) 2.8 (2.8–2.8)
Elderly 16 0.5 (0.5–0.6) 0.8 (0.8–0.9) 1.3 (1.1–1.6) 2.2 (1.9–2.6)
Very elderly 14 0.5 (0.5–0.6) 0.9 (0.8–1.0) 1.3 (1.2–1.4) 2.2 (1.7–2.9)
bw: body weight; n: number of surveys.
The corresponding 95% conﬁdence intervals are presented in the brackets. Estimates are rounded to one decimal place.
(a): Section 5.1 describes the age range within each age class.
(b): One the dietary surveys had less than 60 survey participants and therefore could not be included in calculation of the 95th
percentile exposure.
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groups across European dietary surveys. The values presented are minimum and maximum values
across the different surveys and corresponding 95% conﬁdence intervals. The highest contributions
came from grain-based products across all age groups ranging between 65% (in infants) and 94% (in
very elderly). Other relevant contributions came from food for infants and small children (maximum
64% in that age group), from fruit and fruit products (maximum 26% and 20% in infants and
toddlers, respectively) and from composite foods (maximum 24% in adults).
Given the high number of occurrence data reported for DON alone and the high percentage of left-
censored data for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, the CONTAM Panel calculated that the
% of the contribution34 of the acute exposure that could be attributed to DON alone (Appendix F).
The acute exposure from DON alone was between 50% and 90% of the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside across different age groups, and the CONTAM Panel concluded that
the overall dietary exposure was driven by DON.
34 The %-contribution of DON alone to the exposure of the sum of DON and its modiﬁed forms was calculated as (exposure to
DON alone divided by exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside) 9 100, for the different age
groups.
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Table 34: Estimates of average % contribution (95% conﬁdence intervals) to acute exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside across age class and European dietary surveys at FoodEx level 1
Food group
Infants
(n = 6)
Toddlers
(n = 11)
Other children
(n = 20)
Adolescents
(n = 20)
Adults
(n = 22)
Elderly
(n = 16)
Very elderly
(n = 14)
Min Max Min Max Min Max Min Max Min Max Min Max Min Max
Alcoholic
beverages
– – – – – – – 3 (2–4) 2 (2–2) 12 (12–13) 1 (0–1) 13 (12–14) – 7 (5–9)
Composite food
(including
frozen
products)
4 (3–4) – 11 (10–12) – 20 (19–21) – 18 (17–19) – 24 (23–25) – 14 (12–16) – 16 (14–20)
Food for infants
and small
children
22 (22–22) 64 (63–65) – 18 (16–20) – 5 (5–5) – – – – – – – –
Fruit and fruit
products
8 (6–10) 26 (25–26) 10 (9–11) 20 (20–20) 6 (6–6) 15 (14–15) 4 (4–4) 12 (11–13) 4 (4–5) 18 (18–19) 4 (4–5) 15 (14–16) 3 (2–3) 16 (15–17)
Grains and
grain-based
products
15 (11–20) 65 (64–66) 56 (54–57) 78 (76–80) 65 (63–66) 84 (83–86) 60 (58–63) 88 (85–92) 54 (51–57) 89 (87–90) 61 (56–66) 92 (87–98) 67 (58–77) 94 (88–100)
Snacks,
desserts, and
other foods
– 1 (1–1) – 4 (3–4) – 5 (4–6) 1 (1–1) 7 (6–7) – 3 (3–4) – 2 (1–2) – 1 (1–1)
Vegetables and
vegetable
products
(including fungi)
– 5 (5–5) – 6 (5–8) – 5 (5–6) – 3 (3–4) – 2 (2–2) – 1 (1–1) – 1 (1–1)
n: number of surveys; Min: minimum; Max: maximum.
Food category < 5% in all age groups are not reported are represented by a dash.
(a): Section 5.1 describes the age range within each age class.
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6.1.2.2. Current mean and 95th percentile chronic dietary exposure
For assessing the chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside and DON alone, food consumption and body weight data at the individual level were
accessed in the Comprehensive Database. Occurrence data and consumption data were linked at the
lowest FoodEx code possible.
Exposure estimates were calculated per dietary survey and age class for each of the 35 different
dietary surveys carried out in 19 different European countries (see Section 5.1). However, it should be
noted that not all countries provided consumption information for all age groups of interest or in some
cases the same country provided more than one consumption survey.
The mean and the 95th percentile chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside and to DON alone were calculated separately for each dietary survey using
consumption data recorded at the individual level. Individual food consumption data were combined
with the mean occurrence values in order to provide mean and the 95th percentile exposure
estimates. Exposure estimates were calculated for both LB and UB scenarios. Exposure estimates of
DON alone are presented in Appendix F and not further discussed below.
The percentage of left-censored data, mostly for 3-Ac-DON and 15-Ac-DON, in the food occurrence
data set accounted for more than 90% of the data and may result in a large difference between the
dietary exposure estimates in the LB and UB scenarios.
6.1.2.2.1. Current mean and 95th percentile chronic dietary exposure to the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside
The chronic mean and the 95th percentile dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside for all age groups across dietary surveys are summarised in Table 35. Mean
and 95th percentile dietary exposure estimates calculated for each of the dietary survey are presented
in Appendix F, Table F.3. In accordance with the speciﬁcations of the EFSA Guidance on the use of the
Comprehensive database (EFSA, 2011b), the 95th percentile estimates for dietary surveys/age classes
with less than 60 observations may not be statistically robust and therefore they were not considered
in the exposure assessment.
Given the high number of occurrence data reported for DON alone and the high percentage of left-
censored data for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, the CONTAM Panel calculated that the
% of the contribution38 of the chronic exposure to DON alone (Appendix F) to the chronic exposure of
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was between 60% and 85% across
different age groups and concluded that the overall dietary exposure was driven by DON.
Table 35: Summary statistics of the chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside (lg/kg bw per day) by age group
Age group
Lower Bound Middle Bound Upper Bound
n
Min Median Max Min Median Max Min Median Max
Mean dietary exposure in total population (lg/kg bw per day)
Infants 6 0.2 0.4 0.5 0.5 0.7 1.3 0.6 1.0 2.0
Toddlers 10 0.6 0.9 1.1 0.9 1.2 1.4 1.1 1.6 1.7
Other children 18 0.6 0.8 1.1 0.7 1.0 1.3 0.9 1.2 1.6
Adolescents 17 0.3 0.4 0.6 0.4 0.6 0.8 0.4 0.7 0.9
Adults 17 0.3 0.3 0.4 0.3 0.4 0.5 0.4 0.5 0.7
Elderly 14 0.2 0.3 0.4 0.3 0.4 0.5 0.4 0.5 0.6
Very elderly 12 0.3 0.3 0.4 0.3 0.4 0.5 0.4 0.5 0.6
95th percentile dietary exposure in total population (lg/kg bw per day)
Infants(a) 5 0.7 1.2 1.5 1.0 1.7 2.6 1.4 2.2 3.7
Toddlers(a) 7 1.1 1.5 1.7 1.4 2.0 2.1 1.8 2.6 2.7
Other children 18 0.9 1.3 1.9 1.1 1.6 2.3 1.4 2.0 2.7
Adolescents 17 0.5 0.9 1.2 0.6 1.0 1.5 0.7 1.3 1.8
Adults 17 0.5 0.6 0.8 0.7 0.8 1.0 0.8 1.0 1.4
Elderly 14 0.5 0.6 0.8 0.6 0.7 1.0 0.7 0.9 1.1
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Infants (< 12 months)
Six dietary surveys were available for this age group, one of which had less than 60 survey
participants and therefore could not be included in calculation of the 95th percentile exposure. The
mean chronic dietary exposure was between 0.2 and 2.0 lg/kg bw per day (minimum LB and
maximum UB) and the 95th percentile dietary exposure ranged from 0.7 to 3.7 lg/kg bw per day
(minimum LB to maximum UB). Infants had the highest estimates of chronic dietary exposure to the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. This can be explained by the higher intake
of food per kg bw in younger age groups.
Toddlers (≥ 12 months to < 36 months old)
There were 10 surveys available reporting food consumption for toddlers covering a total of 4,103
survey participants. The mean chronic dietary exposure ranged from 0.6 to 1.7 lg/kg bw per day
(minimum LB to maximum UB), and the 95th percentile dietary exposure ranged from 1.1 to 2.7 lg/kg
bw per day (minimum LB to maximum UB).
Other children (≥ 36 months to < 10 years old)
There were 18 surveys available reporting food consumption for other children covering a total of
9,534 survey participants. The mean chronic dietary exposure ranged from 0.6 to 1.6 lg/kg bw per
day (minimum LB to maximum UB), and the 95th percentile dietary exposure ranged from 0.9 to 2.7
lg/kg bw per day (minimum LB to maximum UB).
Adolescents (≥ 10 years to < 18 years old)
There were 17 surveys available reporting food consumption for adolescents covering a total of
8,946 survey participants. The mean chronic dietary exposure ranged from 0.3 to 0.9 lg/kg bw per
day (minimum LB to maximum UB), and the 95th percentile dietary exposure ranged from 0.5 to 1.8
lg/kg bw per day (minimum LB to maximum UB).
Adults (≥ 18 years to < 65 years)
There were 17 surveys available reporting food consumption for adults including pregnant and
lactating women covering a total of 33,392 survey participants. In the adult population, the mean
chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside varied from
the minimum LB of 0.3 lg/kg bw per day to the maximum UB of 0.7 lg/kg bw per day. The 95th
percentile dietary exposure estimate varied from 0.5 to 1.4 lg/kg bw per day (minimum LB to
maximum UB).
Elderly and very elderly (≥ 65 years old)
There were 14 surveys available reporting food consumption for elderly covering a total of 5,186
survey participants and 12 surveys available reporting food consumption for very elderly covering a
total of 2,406 survey participants. The dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside varied for the mean between 0.2 and 0.6 lg/kg bw per day (minimum LB to
maximum UB) with a 95th percentile range between 0.5 and 1.1 lg/kg bw per day (minimum LB to
maximum UB).
6.1.2.2.2. Contributions of different food groups to DON and the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside chronic dietary exposure
The contribution of individual food groups to chronic dietary exposure to the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside and to DON alone (see Appendix F, Section F.5) varied
between the dietary surveys. This is explained by the speciﬁc food consumption patterns in the
Age group
Lower Bound Middle Bound Upper Bound
n
Min Median Max Min Median Max Min Median Max
Very elderly(a) 9 0.5 0.5 0.7 0.6 0.7 0.9 0.8 0.8 1.0
bw: body weight; n: number of surveys; Min: minimum; Max: maximum.
Estimates are rounded to one decimal place.
(a): One dietary survey for infants, and three dietary surveys for toddlers and very elderly had less than 60 survey participants
and therefore could not be included in calculation of the 95th percentile exposure.
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individual European countries and even in the different regions of one country. In two dietary surveys,
grain-based products (e.g. bread, ﬁne bakery products) were disaggregated to ingredients (ﬂour) and
therefore these studies did not qualify for calculation of the contribution of food groups to the
exposure. The contribution to chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside and to DON alone (see Appendix F, Section F.5) for the individual food groups was
assessed separately for each survey and age group. The results are reported as a number of surveys
for the following contribution ranges: 0–5, 6–10, 11–25, 26–50 and higher than 50%. A summary of
the median values calculated from the average contribution of each food group across the dietary
surveys and the range of the lowest and highest average contribution is shown in Tables 36 and 37.
Grains and grain-based foods made the largest contribution to the dietary exposure to the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in all age groups. For DON alone, see Appendix F,
Section F.5. The most important contributors within this food category were ‘Bread and rolls’, followed
by ‘Fine bakery wares’ and ‘Pasta (raw)’ (only in one country with high consumption of pasta
reported). It can be assumed that a high contribution of ‘Bread and rolls’ is more likely driven by high
consumption of this food category. Other important contributors were ‘Grain milling products’,
‘Breakfast cereals’ and for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside also ‘Beer and
beer-like beverage’ (only in countries with higher consumption of beer reported).
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Table 36: Number of surveys split according to their percentage contribution to chronic dietary exposure of the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside (LB) concentrations for toddlers, other children and adolescents
Food category
Toddlers(a) Other children(a) Adolescents
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=
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0
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1
0
%
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0
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2
5
%
6
5
–
5
0
%
[
5
0
%
Barley grain 4 8 6
Beer and beer-like beverage 4 12 15
Bread and rolls 1 1 4 4 1 12 5 1 11 5
Breakfast cereals 4 1 4 1 7 8 3 10 7
Buckwheat grain 4 5 2
Cereal-based dishes 4 2 11 1 1 10 2 1
Cereal-based food for infants and young children 7 1 11 6
Cocoa beans and cocoa products 10 16 17
Cocoa beverage 3 7 8
Composite food (including frozen products) 2 7 5
Condiment 9 18 17
Corn grain 2 5 5
Dietary supplements 6 8 6
Dried fruits 8 16 16
Fine bakery wares 2 7 1 2 9 7 2 13 2
Food for infants and small children 1
Grain milling products 5 1 3 1 9 3 4
Grains and grain-based products, unspeciﬁed 1
Grains for human consumption 1 3 3
Medical food 2 3 2
Millet grain 3 3 5
Miscellaneous fruits 10 18 17
Oats, grain 3 3 2
Other grains 2 2 4
Pasta (raw) 3 2 4 1 4 4 9 1 3 3 10 1
Peanut (Arachis hypogea) 7 18 17
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Food category
Toddlers(a) Other children(a) Adolescents
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Pumpkin seeds (Cucurbita pepo var. oleifera) 2 6 6
Ready to eat soups 8 1 14 1 14 1
Ready-to-eat meal for infants and young children 7 9 2
Rice 10 18 17
Rye grain 1 2
Snack food 7 3 13 5 10 7
Soya beans (Glycine max) 2 5 8
Spelt grain 1 1 1
Stone fruits 9 18 17
Sweet corn (Zea mays var. saccharata) 7 16 16
Wheat grain 4 9 8
(a): FI/1 survey excluded from calculation of the contribution of ‘Grains and grain-based products’.
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Table 37: Number of surveys split according to their percentage contribution to chronic dietary exposure of the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside (LB) concentrations for adults, elderly and very elderly
Food category
Adults(a) Elderly(a) Very elderly
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Barley grain 9 4 3
Beer and beer-like beverage 12 5 12 2 11 1
Bread and rolls 11 6 5 9 3 9
Breakfast cereals 12 3 2 8 2 2 2 5 4 2 1
Buckwheat grain 3 3 2
Cereal-based dishes 11 3 9 8
Cereal-based food for infants and young children 5 1 2
Cocoa beans and cocoa products 16 14 11
Cocoa beverage 10 7 5
Composite food (including frozen products) 6 1 1
Condiment 17 14 12
Corn grain 4 3 2 1
Dietary supplements 6 5 1 4
Dried fruits 17 14 11
Fine bakery wares 3 13 1 2 2 8 2 1 3 5 3
Grain milling products 7 5 5 10 4 7 2 2
Grains and grain-based products, unspeciﬁed 2 2 1
Grains for human consumption 6 1 2
Medical food 2 4 4
Millet grain 7 4 2
Miscellaneous fruits 17 14 12
Oats, grain 5 5 2
Other grains 7 3 1
Pasta (Raw) 5 4 7 1 8 4 1 1 6 4 1 1
Peanut (Arachis hypogea) 17 12 9
Pumpkin seeds (Cucurbita pepo var. oleifera) 12 9 6
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Food category
Adults(a) Elderly(a) Very elderly
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Ready to eat soups 15 1 12 1 10 1
Ready-to-eat meal for infants and young children 3 14 1
Rice 17 1 12
Rye grain 3 14 1
Snack food 16 1 5 9
Soya beans (Glycine maximum) 11 2 3
Spelt grain 1 14 1
Stone fruits 17 12 12
Sweet corn (Zea mays var. saccharata) 16 6 10
Wheat grain 13 4 6
(a): FI/1 survey excluded from calculation of the contribution of ‘Grains and grain-based products’.
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6.1.2.3. Current acute and chronic dietary exposure the sum of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside for speciﬁc groups
Dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for vegetarian
diets include more cereal and cereal-based products and therefore it was considered that the exposure
to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in this consumer group could be
higher. The Comprehensive Database contains only limited data on food consumption of vegetarians.
Dietary exposure was calculated and compared to the exposure of all subjects included in the
respective dietary study. Generally, for acute exposure, higher mean and 95th percentile exposures
were not observed compared to the general population, with the exception of toddlers, other children
and adults who appeared to have marginally higher exposures (Table 38). Similarly, for chronic
exposure higher mean and 95th percentile exposures were not generally observed in vegetarians
compared to the total population within the same dietary survey (Table 39). Thus, the limited data on
vegetarians do not indicate a substantial difference in the dietary exposure to the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside between the vegetarians and the general population. This
ﬁnding was supported by the estimated exposure based on the database in the EFSA biomarker study
(Brera et al., 2015) (see also Section 7.5.2).
Table 38: Summary statistics of probabilistic acute dietary exposure assessment to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside (at the lower, middle and upper bound)
(lg/kg bw per day) by age group in vegetarians. The corresponding 95% conﬁdence
intervals are presented in the brackets. Estimates are rounded to one decimal place
Age group(a)
Mean dietary exposure
(lg/kg bw per day)
95th percentile dietary exposure
(lg/kg bw per day)(b)
n Minimum Maximum Minimum Maximum
Lower bound
Infants 1 0.5 (0.2–0.8) – –
Toddlers 3 0.6 (0.2–1.1) 1.2 (0.2–2.9) – –
Other children 2 0.4 (0.0–1.1) 1.2 (0.8–1.6) – –
Adolescents 4 0.3 (0.2–0.4) 0.6 (0.3–1.0) – –
Adults 10 0.2 (0.1–0.4) 0.7 (0.3–1.3) 1.6 (1.0–2.4) 2.7 (2.2–3.7)
Elderly 7 0.1 (0.0–0.3) 0.6 (0.3–0.9) – –
Very elderly 4 0.3 (0.1–0.6) 0.4 (0.0–1.0) – –
Middle bound
Infants 1 1.1 (0.8–1.5) – –
Toddlers 3 1.3 (0.9–2.1) 2.4 (1.5–4.5) – –
Other children 2 0.5 (0.2–1.1) 1.8 (1.5–2.4) – –
Adolescents 4 0.5 (0.4–0.7) 0.9 (0.7–1.2) – –
Adults 10 0.3 (0.2–0.6) 0.9 (0.5–1.5) 2.0 (1.3–2.8) 3.0 (2.5–3.6)
Elderly 7 0.2 (0.1–0.4) 0.8 (0.5–1.3) – –
Very elderly 4 0.5 (0.3–0.9) 0.7 (0.5–1.4) – –
Upper bound
Infants 1 1.6 (1.4–2.1) – –
Toddlers 3 2.0 (1.5–3.1) 3.9 (2.7–6.1) – –
Other children 2 0.6 (0.3–1.2) 2.4 (2.0–2.7) – –
Adolescents 4 0.7 (0.6–0.8) 1.1 (0.9–1.4) – –
Adults 10 0.4 (0.3–0.6) 1.2 (1.1–1.3) 2.4 (1.8–3.4) 3.4 (2.8–4.1)
Elderly 7 0.2 (0.1–0.4) 1.2 (0.8–1.7) – –
Very elderly 4 0.6 (0.5–0.9) 1.1 (0.8–1.8) – –
bw: body weight; n: number of surveys; Min: minimum, Max: maximum.
(a): Section 5.1 describes the age range within each age class.
(b): Not calculated for the other age groups because estimates were only available from one dietary survey.
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6.1.2.4. Conclusions
Acute dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside across 23
European countries in different age groups, using LB and UB concentrations, ranged from 0.2 lg/kg
bw per day in adults and elderly to 2.9 lg/kg bw per day in infants (the range represents minimum LB
to the maximum UB from the different countries). The 95th percentile ranged from 0.7 lg/kg bw per
day in the elderly and very elderly to 6.7 lg/kg bw per day in infants (the range represents minimum
LB to the maximum UB from the different countries).
Infants had the highest estimates of chronic dietary exposure to the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside (the mean exposure 0.2–2.0 lg/kg bw per day and the 95th
percentile 0.7–3.7 lg/kg bw per day). This can be explained by the higher intake of food per kg bw in
younger age groups. Similar or for some age groups slightly lower exposure estimates were reported
in the previous exposure assessment from earlier years (see Section 6.1.1), but this was probably due
to important differences in the assessment methodologies (e.g. data obtained by methods with
different LODs/LOQs, different treatment of left-censored data, use of aggregated consumption data).
The highest contributions to the exposure of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside were from grain-based products across all age groups. Other relevant contributions were
found in food for infants and small children, fruit and fruit products in infants and toddlers, and
composite foods in adults.
The CONTAM Panel noted that the overall dietary exposure was mainly driven by DON.
The limited consumption data on vegetarians do not indicate a major difference in the acute and
chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and 3-DON-glucoside between
vegetarians and the general population.
6.2. Potential non-dietary sources of exposure
Grain dust samples have been reported to contain DON, sometimes even more often than the
kernels. Inhalation and occupational exposure to DON has been reviewed by IARC (Pitt et al., 2013).
Several studies have reported a high prevalence of DON in grain dust samples in the elevator and
surfaces of workplace (Nordby et al., 2004; Krysinska-Traczyk et al., 2007; Mayer et al., 2007). DON
levels in raw wheat materials were correlated with levels in corresponding dust samples (Sanders
et al., 2013; Sanders et al., 2014). Straumfors et al. (2015) reported higher levels of DON, 3-Ac-DON
and DON-3-glucoside in grain elevator samples than in compound feed mills. A mean inhalation
exposure of 20 ng/m3 of fungal metabolites was estimated. A study in French farmers showed that
maize acreage of the farmer is a key determinant of DON exposure biomarker level, indicating the
occupational exposure route of DON (see Section 7.1.3) (Turner et al., 2010b).
In summary, current evidence from grain dust in grain elevators suggest the possibility of
occupational inhalational exposure to DON, 3-Ac-DON, 15-Ac-DON and metabolites. However,
Table 39: Summary statistics of the chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside (lg/kg bw per day) by age group in vegetarians. Estimates
are rounded to one decimal place
Age group
Lower bound Middle bound Upper bound
n Min Median Max Min Median Max Min Median Max
Mean dietary exposure in vegetarians (lg/kg bw per day)
Infants 1 0.3 0.4 0.5 0.6 0.7 1.4 0.7 1.0 2.1
Toddlers 3 0.6 0.8 1.1 0.9 1.2 1.4 1.1 1.6 1.7
Other children 2 0.6 0.7 1.1 0.7 1.0 1.3 0.9 1.2 1.6
Adolescents 4 0.3 0.4 0.6 0.4 0.6 0.8 0.4 0.7 0.9
Adults 8 0.3 0.3 0.4 0.3 0.4 0.5 0.4 0.5 0.7
Elderly 7 0.2 0.4 0.5 0.3 0.4 0.5 0.4 0.5 0.6
Very elderly 3 0.3 0.3 0.4 0.3 0.4 0.5 0.5 0.6 0.7
95th percentile dietary exposure in vegetarians (lg/kg bw per day)(a)
Adults 8 0.4 0.6 0.8 0.5 0.7 0.8 0.5 0.7 0.8
n: number of surveys; bw: body weight; Min: minimum, Max: maximum.
(a): Not calculated for the other age groups because estimates were only available from one dietary survey.
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quantitative comparison of oral and inhalation exposure is not possible due to limited data. This route
is not relevant for general population.
6.3. Animal exposure assessment
For all species, the LB and UB of the mean (chronic) and 95th percentile dietary concentrations and
exposures have been estimated.35 According to EFSA (2011b), caution is needed when calculating the
95th percentile exposure where data on less than 60 samples are available, since the results may not
be statistically robust. Therefore estimates of 95th percentile exposure were only made where data on
> 60 samples were available. Where the number of samples reported was ≤ 9, the data provided were
not used to estimate dietary concentration and exposure.
For many farm animals in Europe, feeds are supplied in the form of commercially produced blends
or compound feeds, and for some of the livestock categories considered in this opinion data on the
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside contents of species-speciﬁc compound feeds were
provided by the European countries (see Section 4.2.2 and Appendix C, Table C.2). Where these data
were provided in sufﬁcient numbers, the mean and 95th percentile dietary concentrations and
exposures have been calculated using the concentrations reported.
For those farm animal categories for which insufﬁcient data were provided (i.e. for less than 10
samples), the CONTAM Panel identiﬁed example diets and feed inclusion rates (see Appendix E for
details), and used concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
individual feed materials (Appendix C, Table C.2) to estimate the mean and 95th percentile exposure.
Again, where concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were derived from
< 60 samples, these have not been used to estimate dietary concentration and exposure.
As previously reported (Section 5), a wide range of feeds and feeding systems are used for
livestock in Europe. It must be stressed that the feed intakes or diet compositions used in estimating
dietary concentrations and exposures in this scientiﬁc opinion are not ‘average’ diets, nor are they an
attempt to describe ‘worst case’ scenarios. Rather, they are intended to provide an indication of likely
dietary concentration and exposure to DON alone (Appendix F, Section F.4) and to the sum of DON, 3-
Ac-DON, 15-Ac-DON and DON-3-glucoside across a range of feeding systems in Europe. In some
situations, dietary concentration and exposure may be higher than described in this opinion.
The CONTAM Panel also estimated the animal dietary concentrations and exposures to DON alone
(see Appendix F, Section F.4). The %-contribution of DON alone (mean and 95th percentile
concentrations/exposures) to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside at both
the LB and UB levels and for farm and companion animals (across all species) was calculated. The
mean value for this contribution was 68% (SD = 7.4%) for all the animal species, both for dietary
concentrations/exposures based on species-speciﬁc compound feeds and on the individual feed
materials and their relative proportions in diets.
For ruminants and horses, forages are a major component of the diet, and in much of Europe fresh or
conserved grass (conserved as silage or hay) is the main or sole feed. As shown in Tables 18–21, no data
on levels of DON, 3-Ac-DON, 15-Ac-DON or DON-3-glucoside were available for fresh grass or grass silage.
Furthermore, other authors (Driehuis et al., 2008a; Rodrigues et al., 2012) have reported that they are
not normally present in these feeds. Therefore it has been assumed that where fresh grass and/or grass
silage are the sole forages, that they make no contribution to dietary concentration and exposure. In other
feeding systems, grass hay is the main or sole forage, and therefore data for these Fusarium toxins in
grass hay have been used to estimate dietary concentration and exposure for this feeding regime.
The dietary concentrations and exposures of farm and companion animals to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside are presented below
6.3.1. Estimates of animal exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside
6.3.1.1. Ruminants and horses
Mean (chronic) and 95th percentile dietary concentration and exposure estimates for high yielding
dairy cows, fattening beef cattle and horses to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside were derived from data on species-speciﬁc compound feed and are presented in Table 40.
35 Dietary concentrations and exposures assume a 12% moisture content in the feed (i.e. they are expressed on an 88% DM
basis).
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As described above, there is a wide range of feeding systems fed different forages but there were
insufﬁcient data on compound feeds used in these systems to permit this approach. Therefore,
example rations and concentrations in individual feed materials (see Appendix E, Table E.5) were used
to estimate dietary concentration and exposure. The livestock categories chosen were dairy cows
(maize silage-based rations), fattening beef cattle (diets where the major ingredient was maize silage,
cereals or straw) and sheep, goats and horses (fed grass hay-based diets). Estimates of dietary
concentrations and exposures for these are given in Table 41.
The dietary concentrations and exposures by ruminants reported in Table 41 are generally higher
than those estimated for high yielding dairy cows derived from data for compound feeds (Table 40). In
the latter it was assumed that the forages contributed little (hay-based diet) or no (grass or grass
silage-based diet) to dietary concentration and exposure, since levels of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside are not reported in grass and are markedly lower in grass hay than in cereals,
maize silage and cereal straw (Tables 18–21).
Table 41: Estimated mean and 95th percentile dietary concentration and exposure at the LB and UB
to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside by ruminants derived
from concentrations in individual feed materials and their relative proportions in diets
Dietary concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean
95th
percentile
Mean
95th
percentile
Mean
95th
percentile
Lactating dairy cows:
maize silage-based diet
LB 703 2,562 19,188 69,950 29.5 107
UB 783 2,574 21,370 70,276 32.9 108
Fattening beef cattle:
intensive cereal-based diet
LB 290 1,756 2,902 17,561 7.26 43.9
UB 391 1,816 3,908 18,164 9.77 45.4
Table 40: Estimated mean and 95th percentile dietary concentration and exposure at the LB and
UB to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for dairy cows,
fattening beef cattle and horses derived from concentrations in species-speciﬁc
compound feeds
Dietary concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Dairy cow high
yielding(a)
LB 86.6 522 1,793 10,805 2.76 16.6
UB 113 522 2,337 10,805 3.60 16.6
Dairy cow high
yielding(b)
LB 95.6 571 1,979 11,829 3.04 18.2
UB 218 658 4,510 13,629 6.94 21.0
Fattening beef
cattle(a)
LB 64.2 124 617 1,186 1.54 2.97
UB 80.8 124 776 1,186 1.94 2.97
Fattening beef
cattle(b)
LB 77.0 194 739 1,859 1.85 4.65
UB 230 317 2,203 3,041 5.51 7.60
Horses(a) LB 155 (c) 1,397 (c) 3.11 (c)
UB 166 (c) 1,493 (c) 3.32 (c)
Horses(b) LB 163 (c) 1,465 (c) 3.26 (c)
UB 253 (c) 2,280 (c) 5.07 (c)
bw: body weight, LB: lower bound; UB: upper bound.
(a): Fresh grass and/or grass silage-based diets (i.e. assumes no exposure from forages).
(b): Grass hay-based diets.
(c): Insufﬁcient number of samples reported (i.e. < 60) to calculate 95th percentile concentration.
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6.3.1.2. Pigs and poultry
Estimates of mean and 95th percentile dietary concentration and exposure by pigs and poultry to
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were derived from data for species-
speciﬁc compound feeds, and are given in Table 42.
6.3.1.3. Farmed ﬁsh (salmonids and carp), farmed rabbits and farmed mink
In the absence of reliable data on concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside in species-speciﬁc compound feeds, estimates of dietary concentration and exposure
were made by using example rations and concentrations in individual feed materials (see Appendix E,
Table E.5) for details of rations used and are reported in Table 43.
Table 42: Estimates of mean and 95th percentile dietary concentration and exposure at the LB and
UB to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for pigs and poultry
(fattening chickens, laying hens, fattening turkeys and fattening ducks) derived from
concentrations in species-speciﬁc compound feeds
Dietary concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw per
day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Pig starter LB 242 975 242 975 12.1 48.8
UB 410 1,088 410 1,088 20.5 54.4
Pig ﬁnisher LB 437 1,284 1,312 3,851 13.1 38.5
UB 515 1,284 1,546 3,851 15.5 38.5
Lactating sow LB 515 1,302 3,088 7,810 15.4 39.1
UB 618 1,302 3,709 7,810 18.5 39.1
Fattening chickens LB 1,016 3,295 121.9 395 61.0 198
UB 1,033 3,295 124.0 395 62.0 198
Laying hens LB 794 3,378 95.2 405 47.6 203
UB 814 3,378 97.6 405 48.8 203
Fattening turkeys LB 1,480 3,971 592 1,588 49.3 132
UB 1,494 3,971 598 1,588 49.8 132
Fattening ducks LB 1,029 2,900 144 406 48.0 135
UB 1,043 2,900 146 406 48.7 135
bw: body weight; LB: lower bound; UB: upper bound.
Dietary concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean
95th
percentile
Mean
95th
percentile
Mean
95th
percentile
Fattening beef cattle:
maize silage-based diet
LB 506 1,669 3,341 11,017 11.1 36.7
UB 581 1,714 3,833 11,312 12.8 37.7
Fattening beef cattle:
cereal straw-based diet
LB 878 3,608 7,022 28,866 23.4 96.2
UB 996 3,655 7,966 29,239 26.5 97.5
Lactating sheep(a) LB 151 749 421 2,098 5.27 35.0
UB 285 849 797 2,376 9.96 39.6
Lactating goats(a) LB 298 561 1,013 1,906 16.9 31.8
UB 414 613 1,407 2,084 23.4 34.7
Fattening goats(a) LB 168 653 252 979 6.31 24.5
UB 305 747 457 1,120 11.4 28.0
bw: body weight; LB: lower bound; UB: upper bound.
(a): Note that these concentrations/exposures assume that grass hay is the sole forge. Where fresh grass or grass silage are the
main or sole forage concentration/exposure are likely to be lower.
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6.3.1.4. Companion animals (dogs and cats)
Few data on concentrations of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in proprietary
feeds for dogs and cats were available, and therefore dietary concentration and exposure were
estimated using example rations (see Appendix E, Table E.5 for details) and concentrations of the sum
of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in individual feed materials. The dietary
concentrations and exposures are reported in Table 44.
6.3.2. Conclusions
In the absence of data on levels of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in fresh
grass or grass silage, data for grass hay have been used in estimating the contribution from forages
for lactating dairy cows and beef cattle. As discussed above, this approach may have overestimated
dietary concentration and exposure. The estimated dietary concentration and exposure estimates were
generally highest for beef and dairy cattle fed diets in which the forages were maize silage or cereal
straw, or for fattening beef cattle on cereal grain-based diets.
Cereal grains are widely used in the diets of pigs and poultry, and in commercially manufactured
compound feeds they may represent 60% or more of the total ingredients. However, levels of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside are markedly lower in compound feeds for pigs than they are for
poultry, and this is reﬂected in lower estimates of dietary concentration and exposure for these species.
While estimates of dietary concentration and exposure of the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside for fattening chickens (broilers) were possible using data for compound feeds,
there was insufﬁcient information on compound feeds for laying hens, and therefore the alternative
approach of estimating dietary concentration and exposure, i.e. using example rations and
concentrations of these toxins in individual feed materials was used.
Table 44: Estimated mean and 95th percentile dietary concentration and exposure at the LB and
UB to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside by companion
animals (dogs and cats) derived from concentrations in individual feed materials and
their relative proportions in diets
Dietary concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Dogs LB 174 741 10.5 44.5 2.62 11.1
UB 214 753 12.8 45.2 3.21 11.3
Cats LB 229 968 82.3 348 3.29 13.9
UB 264 975 95.1 351 3.80 14.0
bw: body weight; LB: lower bound; UB: upper bound.
Table 43: Estimated mean and 95th percentile dietary concentration and exposure at the LB and
UB to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for farmed rabbits,
farmed ﬁsh and farmed mink derived from concentrations in individual feed materials and
their relative proportions in diets
Dietary concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw per
day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Salmonids LB 83.3 362 3.33 14.5 1.67 7.25
UB 123 380 4.93 15.2 2.47 7.60
Carp LB 254 1,084 5.60 23.8 5.60 5.60
UB 388 1,152 8.53 25.3 8.53 8.53
Farmed rabbits LB 196 1,048 29.5 157 14.7 78.6
UB 282 1,135 42.2 170 21.1 85.1
Farmed mink LB 99.5 407 7.46 30.52 3.61 14.7
UB 109 409 8.16 30.65 3.94 14.8
bw: body weight; LB: lower bound; UB: upper bound.
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7. Hazard identiﬁcation and characterisation
This scientiﬁc opinion on the risks for human and animal health related to the presence of DON, its
acetylated and modiﬁed forms in food and feed updates the previous risk assessments of the SCF for
DON in food (SCF, 1999) and of the EFSA for DON as undesirable substance in animal feed (EFSA,
2004). While the SCF opinion on DON established a TDI of 1 lg/kg bw per day for humans chronically
exposed to DON in food, the EFSA opinion addressed the toxicity of DON and its impact on animal
health and also its transfer into animal products. Since these two previous risk assessments on DON
reviewed the available data on DON at these times, the current opinion, and in particular this section
on the identiﬁcation and characterisation of the hazard of DON will focus on the description and
analysis of the more recent data available since 1999 and 2004 for humans and animals, respectively,
except for studies considered of importance for the current risk assessment and which need to be
reported in detail even if they have already been discussed in previous opinions. Regarding hazards
from the 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and feed, which were not assessed by
the SCF (1999) or EFSA (2004), all available data will be assessed in the next sections of this chapter.
If not otherwise stated quantitative results reported as number  number are (arithmetic) means
plus/minus the standard deviation (SD).
7.1. Toxicokinetics
The toxicokinetics of DON have been reviewed by JECFA (FAO/WHO, 2001, 2011), Pestka and
Smolinski (2005), Pestka (2007, 2010a,b), Sobrova et al. (2010), Maresca (2013) and Wu et al.
(2014a). While Section 7.1.1 considers primarily ex vivo studies, Section 7.2.1 reports the more
recently published in vivo studies.
7.1.1. In vitro studies in experimental animals
7.1.1.1. DON
The role of gut organisms in the metabolism of DON has been studied in vitro using incubations of
DON with faeces or gut content from different animal species. The faecal microbiota from several
species, including rats, poultry and pigs have been shown to be able to transform DON to DOM-1
(Swanson et al., 1988; Worrel et al., 1989; He et al., 1992; FAO/WHO 2001, 2011). No phase-I
metabolism was found in incubations with rat liver microsomes (Co^te et al., 1997).
In a perfused rat liver from a male Wistar rat, 3 mg DON was added to recirculating perfusion
system and samples of bile, perfusate and liver homogenates collected during the 90 min of infusion
were analysed for DON with and without the addition of b-glucuronidase. A total of 40.4% of the
added DON was glucuronide-conjugated. Of the administered DON, 20.4% was found as glucuronide
conjugate in the perfusate, 19.2% in the bile and 0.8% in the liver homogenate. Only 1.3% of the
total DON was recovered as free DON (1.1% in the perfusate and 0.2% in the bile). The DON
glucuronide conjugates in the bile were cleaved when incubated with intestinal content under
anaerobic conditions (Gareis et al., 1987). However, the total recovery of the administered dose was
below 50%, which according to the authors indicated that unknown metabolites may have been
formed or that the remaining fraction may be bound in the liver.
After incubations with liver microsomes from rat, carp, pigs and cows DON was glucuronidated
(Maul et al., 2012, 2014; Uhlig et al., 2013). DON-3-glucuronide was the dominant glucuronide in
microsomal incubations, accompanied by smaller amounts of DON-15-glucuronide. In addition, small
amounts of a third glucuronide, tentatively assigned as DON-7-glucuronide, was present in incubations
with carp and rat liver microsomes (Maul et al., 2012) (see also Section 7.1.4.1), while nuclear
magnetic resonance studies of a glucuronide formed in incubations with rat microsomes revealed that
this was DON-8-glucuronide (Uhlig et al., 2013).
7.1.1.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.1.1.3. DON-3-glucoside
No data were identiﬁed.
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7.1.2. In vivo studies in rodents
7.1.2.1. Absorption
7.1.2.1.1. DON
Mice
The toxicokinetics of DON were compared between weanling female mice (3–4 weeks old) and
young adult female mice (8–10 weeks old, n ≥ 8/group) given a single oral dose of 5 mg/kg bw and
killed after 15, 30, 60 and 120 min. The DON concentrations were measured by ELISA in plasma,
spleen, kidney, liver and lung. Maximum plasma concentrations were measured 15–30 min after
administration. The maximum concentrations were approximately 1.0 lg/mL in young adults and twice
that in weanling mice, indicating that the absorption is higher in very young animals (Pestka and
Amuzie, 2008).
A 4-week feeding study in male mice given 2–20 mg DON/kg diet demonstrated a dose-dependent
increase in plasma concentrations of DON equivalents ranging from 20 ng/mL to 90 ng/mL
approximately as measured by Pestka et al. (2008).
Rats
Male Sprague–Dawley rats were given a single oral dose of 5.0 mg radiolabelled DON/kg bw, and
plasma samples were collected at 8, 24 and 72 h after dosing. The maximum measured plasma
radioactivity occurred after 8 h, at which time approximately 9% was bound to plasma protein. The
maximum concentration was 291 ng/mL and decreased to approximately 14% of that level in 24 h
post-dosing. A total of 37% of the administered radioactivity was excreted in the urine and DON-
glucuronides were the major urinary metabolites (Meky et al., 2003). The CONTAM Panel noted that in
this study, as well as in many other studies, the authors did not identify the forms of DON-
glucuronides.
Wistar rats (n = 3 males and 3 females/group) were given a single oral dose of 0.5 or 2.5 mg
radiolabelled DON/kg bw (Wan et al., 2014). The urinary recovery during a collection period of 96 h in
female rats was 57.1  1.2% for the 0.5 mg/kg bw group and 42.3  3.1% in the group given 2.5
mg/kg bw For males, the urinary recovery rates for DON were 27.3  0.7% in the low dose and 24.0
 2.3% in the high–dose group. According to the authors, this indicated that the bioavailability may be
higher in female than in male rats.
Male Sprague–Dawley rats (n = 6) were given a single oral dose of 2.0 mg DON/kg bw by gavage
on days 1, 8 and 15. Urine and faeces were collected after 48 h and samples were analysed for DON,
DON-3-glucuronide and DOM-1. In addition, an enzymatic deconjugation was performed to check for
other potential DOM-1 glucuronides. Only 17% of the administered DON was recovered as DON and
its metabolites in the urine, indicating a limited oral bioavailability. However, the total recovery was low
(28% in total for urine and faeces after 48 h) and unknown metabolites may have been formed (Nagl
et al., 2012). Later, the samples from this experiment were reanalysed with a new analytical method
(described in the study by Wan et al. (2014) (see above) which could detect additional metabolites
(Schwartz-Zimmermann et al., 2014). When these additional metabolites (see also Section 7.1.2.3.1)
were included, the total recovery of DON increased to 75% of the administered dose. Most of the
administered DON was recovered in faeces and only a small portion (11%) in urine.
7.1.2.1.2. 3-Ac-DON and 15-Ac-DON
Rats
The only report identiﬁed for rats is a limited study using two Wistar rats (weight 330 and 368 g)
which indicated that the acetylated forms are transformed to DON prior to absorption. Each rat was
given a single oral dose of a mixture of 25 lg of both 3-Ac-DON and 15-Ac-DON and sacriﬁced 55 min
after exposure. Different tissues in each rat were analysed for 3-Ac-DON and 15-Ac-DON, DON, DON-
3-glucuronide, 3-Ac-DON-glucuronide and 15-Ac-DON-glucuronide (Versilovskis et al., 2012). Absolute
amounts of DON (302 ng) and DON-3-glucuronide (1,240 ng) were measured in the liver of one rat,
while DON (386 ng), DON-3-glucuronide (586 ng) and 15-Ac-DON-3-glucuronide (89 ng) were
measured in the bladder of the other rat, indicating that DON and/or the acetylated forms of DON had
been absorbed, but the bioavailability could not be quantiﬁed.
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7.1.2.1.3. DON-3-glucoside
Nagl et al. (2012) (see also Section 7.1.2.1.1 for the part of the study on DON) compared the
absorption of DON-3-glucoside with that of DON in male Sprague–Dawley rats given a single oral
equimolar dose of 3.1 mg DON-3-glucoside/kg bw (equimolar 2.0 mg DON/kg bw) using the same
protocol. DON-3-glucoside was found in urine, but the urinary recovery was low and only 6.9  2.2 nmol
was recovered in the urine 24 h after exposure, while 26  4.9 nmol was recovered as DON, 24  5.0
nmol as DON-glucuronides and 15  7.3 nmol as DOM-1. However, including all analysed metabolites,
only 4% of the administered DON-3 glucoside was recovered in the urine compared to 17% of the DON
in rats given a similar dose of DON. The recovery of administered DON-3-glucoside from faeces was
17%. The authors concluded that the bioavailability of DON-3-glucoside was lower than that of DON.
When these samples were reanalysed by Schwartz-Zimmermann et al. (2014) (see Section 7.1.2.1.1),
only traces of the sulfonate conjugates were found in the urine, and even when the additional
metabolites were included, only 5% of the administered DON-3-glucoside was recovered as metabolites
in urine, supporting the assumption that the oral bioavailability of DON-3-glucoside is low. With the new
metabolites included, the recovery from faeces increased to 63% of the administered DON-3-glucoside.
7.1.2.2. Distribution
7.1.2.2.1. DON
Mice
Male B6C3F1 mice 10–12 weeks of age (n = 3/group) were given a single oral dose of 5 or 25 mg
radiolabelled DON/kg bw Maximum DON concentrations measured as radioactivity, were found 30 min
after administration in spleen, Peyer’s patches, kidney, liver and large intestine and plasma and after 1
h in the small intestine. The highest concentrations were found in the liver (radiolabelled compounds
equivalent to 4.9 and 18.4 pmol/mg wet weight in the 5 and 25 mg/kg dose groups), kidney
(equivalent to 5.6 and 19.8 pmol/mg wet weight, respectively) and plasma (equivalent of 4.4 and 22.3
pmol/mg wet weight, respectively). The concentrations decreased rapidly after 1 h following a two
compartment kinetics in all tissues and at both doses (Azcona-Olivera et al., 1995).
Male B6C3F1 mice (n = 3 per group and 8 weeks old) were given a single oral dose of 25 mg DON/kg
bw, and tissue and plasma samples were taken at several time points from 5 min to 24 h after
administration. All samples were analysed by an ELISA kit, which according to the producer binds to
DON and 3-Ac-DON and no other trichothecenes. The recovery of this ELISA in spiked liver samples was
90% or more. The cross reactivity in this ELISA to potential DON metabolites was not reported and the
results are reported as DON equivalents per mL plasma or per g tissue. The highest plasma
concentrations (12.1 and 11.5 lg DON/mL plasma) were observed at the two-ﬁrst sampling times, 5 and
15 min after exposure. The plasma concentrations decreased rapidly thereafter, following two
compartment kinetics with a distribution half-life (t1/2a) of 20.4 min and a clearance half-life (t1/2b) of
11.8 h. DON was rapidly distributed to all tissues, reaching a maximum tissue concentration 5–15 min
after exposure. The concentration decreased rapidly thereafter. A similar pattern, with the highest
concentrations observed 5–15 min after the oral administration of DON, followed by a rapid decrease,
was observed in liver, kidney, spleen and heart. The maximum DON concentrations were 19.6 lg/g in
liver, 9.0 lg/g in kidney, 7.9 lg/g in the spleen, and 6.8 lg/g in the heart. The half-lives in tissues were
in the same range as for plasma (t1/2a = 22–41 min, t1/2b = 9–21 h). Compared to the other examined
tissues, DON entered to the brain slower and peaked at lower concentrations, 0.7–1.0 lg/g, lasting from
5 min to 2 h (Pestka et al., 2008).
Using the same analytical method, Pestka and Amuzie (2008) (see Section 7.1.2.1.1) measured
DON concentrations in plasma, spleen, kidney, liver and lung of weaning and young adult female mice
for up to 2 h after treatment and observed the same kinetics of DON in all ﬁve organs. The highest
tissue concentrations were found in kidney where approximately 2 lg DON/g after 15 min was
measured in adults. The maximum concentrations in the other investigated tissues were approximately
half of that. The tissue concentrations were approximately twice as high in weanling mice compared to
the young adults. The tissue concentrations decreased rapidly and were reduced by 78% and 81%
within 2 h in weanling and young adults, respectively.
In female mice, the tissue distribution was compared between oral or nasal exposure following a
single dose of 5 mg DON/kg bw (Amuzie et al., 2008). Independent of exposure route, the
concentrations in plasma, spleen, liver, lung and kidney were maximal after 15–30 min and they
declined thereafter by 75–90% in 120 min. The maximum plasma concentrations were approximately
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1 lg/mL after oral and approximately 3 lg/mL after nasal exposure. The peak DON concentrations in
spleen, liver, lung and kidney were 0.77, 1.10, 0.95 and 1.76 lg/g tissue after oral exposure, and 1.87,
2.37, 2.20 and 3.37 lg/g after nasal exposure, respectively.
The tissue concentrations, measured as DON-equivalents by an ELISA kit, was higher in aged mice
(22 months) than in adult mice (3 months) 12 h after an i.p. injection of 1 mg DON/kg bw The
ﬁndings indicated an age-difference in distribution and elimination (Clark et al., 2015). When the mice
were given either 2.5 or 10 mg DON/kg diet for 2 weeks, a non-signiﬁcant tendency towards lower
tissue concentrations in the aged mice compared to adult mice was observed. However, since the mice
were fed ad libitum, the reduced tissue concentrations might also result from a tendency towards
reduced feed consumption in the elderly rather than reﬂecting an age-dependent kinetic.
Rats
No detectable radioactivity was retained in any tissue in rats 96 h after a single oral dose of 10 mg
radiolabelled DON/kg bw (Lake et al., 1987).
Female and male Wistar rats (n = 15/gender) were given one daily dose of radioactively labelled DON
at either 0.5 or 2.5 mg DON/kg bw per day for 5 days and sacriﬁced at 6, 24, 48, 72 and 96 h after last
dosing (Wan et al., 2014) (see also Section 7.1.2.1.1). Total DON (DON and metabolites measured as
radioactively labelled substance) was rapidly distributed to all examined tissues, i.e. plasma, muscle,
adipose tissue, gastrointestinal tract, bile, liver, kidney, heart, brain, lung, skin, spleen, brain, testes,
ovary and adrenals. The highest concentrations were found at the ﬁrst sampling, 6 h after the last dosing,
in the large intestine (5,226 lg DON/kg), followed by stomach (1,795.9 lg DON/kg), small intestine
(1,473.7 lg DON/kg), liver (776.6 lg DON/kg), kidney (418.7 lg DON/kg), lung (254 lg DON/kg), spleen
235.4 lg DON/kg), heart (211.3 lg DON/kg), testes (218.4 lg DON/kg), skin (194.0 lg DON/kg), kidney
(172.9 lg DON/kg), ovary (171.1 lg DON/kg), plasma (160.4 lg DON/kg), muscle (132.0 lg DON/kg),
brain (100.0 lg DON/kg) and adipose tissue (50.1 lg DON/kg). The concentrations thereafter decreased
steadily at the following sampling times of 24, 48, 72 and 96 h after the last treatment.
7.1.2.2.2. 3-Ac-DON and 15-Ac-DON
Rats
In the study by Versilovskis et al. (2012) (see details in Section 7.1.2.1.2) on two rats, 3-Ac-DON
and 15-Ac-DON could not be detected in the liver, but 3-Ac-DON-7-glucuronide, 3-Ac-DON-15-
glucuronide and 15-Ac-DON-3-glucuronide were detected at levels below the LOQ. In addition, DON
(386 ng), DON-3-glucuronide (5,041 ng) and 15-Ac-DON-3-glucuronide (89 ng) were found in the
bladder of the other rat. These ﬁndings indicate that these acetylated forms are mainly transformed to
DON prior to absorption.
7.1.2.2.3. DON-3-glucoside
Rats
Two male Wistar rats (each of 275 g) were given each a single oral dose of a mixture of 25 lg
unlabelled DON-3-glucoside, unlabelled zearalenone-glucoside, 13C-DON and 13C-zearalenone
(Versilovskis et al., 2012). The animals were sacriﬁced 55 min after exposure. The DON-3-glucoside was
recovered mainly in the gastrointestinal tract but 2% of the DON-3-glucoside was recovered as DON in
the stomach. No metabolite of DON-3-glucoside was found in spleen and lungs and only traces in the
kidneys (< 0.1% of the administered dose). The total recovery of DON-3-glucoside was below 60%.
7.1.2.3. Metabolism
7.1.2.3.1. DON
Mice
Since the available studies of the toxicokinetics in mice have used ELISA methods or focussed only
on radioactivity in the case of radiolabelled DON, no information on the potential metabolites of DON is
available in mice.
Rats
De-epoxidation and glucuronide conjugation have been considered to be the main metabolic
transformations of DON in rats. However, recent studies have shown that sulfonate conjugation is
another important metabolic pathway (Schwartz-Zimmermann et al., 2014; Wan et al., 2014).
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The de-epoxy metabolite DOM-1 was identiﬁed as a metabolite in rat urine already in 1983
(Yoshizawa et al., 1983). DOM-1 was also found in faeces and urine of rats after a single oral dose of
10 mg DON/kg bw (Worrell et al., 1989). The DOM-1 was not found in rats treated with antibiotics
prior to administration of DON. Furthermore, incubations of DON with gut content resulted in the
formation of DOM-1, while no such transformation was found in incubations with liver homogenate.
The authors concluded that the appearance of DOM-1 in urine and faeces of rats was a result of gut
bacterial metabolism.
Male Wistar rats (n = 8) were given feed containing an extract of F. graminearum with a ﬁnal DON
concentration of 33.9 mg/kg feed for 4 days, with a mean DON intake of 3.57 mg/kg bw per day. The
urine contained 1.9–4.9 lg/mL DON and 1.6–5.9 lg/mL DOM-1. In addition, two unidentiﬁed DON-
glucuronide metabolites and one unidentiﬁed DOM-1 glucuronide were present but not quantiﬁed
(Lattanzio et al., 2011).
Wan et al. (2014) gave rats a single dose of either 0.5 or 2.5 mg radioactively labelled DON/kg bw
(see Section 7.1.2.1.1) and found the highest concentrations of DON in urine and faeces, followed by
an unidentiﬁed metabolite and DOM-1. In addition, DON-3-sulfonate and DOM-3-sulfonate were
detected only in faeces (< 10% of the total radioactivity) while DON-3-glucuronide was only detected
in the urine (2% of the total radioactivity). DON-3-sulfonate and DOM-1-sulfonate were only detected
in the faeces 24 h after the administration.
In the male Sprague–Dawley rats given a single oral dose of 2.0 mg DON/kg bw (Nagl et al., 2012)
(described in Section 7.1.2.1.1), most of DON was recovered from faeces in the forms of DON and
DOM-1, but the total recovery was low (28%), indicating that other metabolites may be formed. The
reanalysis by Schwartz-Zimmermann et al. (2014) (see Section 7.1.2.1.1) identiﬁed three different
sulfonate conjugates of DON and two forms of DOM-1 sulfonate conjugates. Only traces of sulfonate
conjugates were present in urine (< 1% of the administered dose), while 48% of the administered
DON was recovered as sulfonate conjugated forms of DON and DOM-1 in the faeces within 48 h.
The presence of DOM-1-glucuronide was reported in the male Sprague–Dawley rats of the study of
Meky et al. (2003) (see Section 7.1.2.2.1) given 5 mg radioactively labelled DON/kg bw by gavage. In
this study, a main peak containing approximately 80% of the total urinary radioactivity and a minor
peak coeluting with DON-labelled standard containing approximately 8% were found in rat urine.
Incubation with sulfatase did not alter this pattern, but incubation with glucuronidase decreased the
main peak to approximately 30% of the total radioactivity while the second peak increased to
approximately 43% of the radioactivity. In addition, a minor peak containing 9% of the radioactivity
appeared after the deconjugation. The authors indicated that this peak would correspond to DOM-1,
but this was not veriﬁed in the study. They concluded that DON-glucuronide was the main metabolite
in rat urine followed by DON and that a third metabolite, assumed to be DOM-1-glucuronide, was
present. DON glucuronides were determined by enzymatic deconjugation but the different
glucuronides in the urine were not speciﬁed.
7.1.2.3.2. 3-Ac-DON and 15-Ac-DON
Rats
In the two Wistar rats receiving a mixture of 25 lg of both 3-Ac-DON and 15-Ac-DON by gavage
(Versilovskis et al., 2012) (see Section 7.1.2.1.2), both 3-Ac-DON and 15-Ac-DON, DON and their
glucuronides were detected in the content of the gastrointestinal tract. DON was the most prevalent
form in the stomach, indicating that a hydrolysation of the acetylated forms releasing DON occurs in
the stomach. 3-Ac-DON disappeared slower than 15-Ac-DON. No de-epoxide was detected, possibly
due to the short exposure time. 3-Ac-DON was not detected in liver or bladder, but a low level of
15-Ac-DON-3-glucuronide (89 ng compared to 386 ng DON and 504 ng DON-3-glucuronide) was found
in the bladder.
7.1.2.3.3. DON-3-glucoside
Rats
In the other two male Wistar rats given a single oral dose of a mixture of 25 lg of DON-3-glucoside
(Versilovskis et al., 2012) (see Section 7.1.2.2.3), the DON-3-glucoside was recovered mainly in the
gastrointestinal tract as DON-3-glucoside (42–56% of the administered dose), but 2% of the DON-3-
glucoside was recovered as DON in the stomach. The total recovery of DON-3- glucoside was below
60%.
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Urine and faeces were collected for 48 h after each single oral dosing and were analysed for DON,
DON-3-glucuronide and DOM-1 in the male Sprague–Dawley rats in the study of Nagl et al. (2012)
(see Section 7.1.2.1.3). In addition, an enzymatic deconjugation was performed to check for other
potential DOM-1 glucuronides. Most of the recovered DON-3-glucoside metabolites were from faeces in
the forms of DON (17%) and DOM-1, but the total recovery was low 20.9  6.6% indicating that
other metabolites might have been formed. The reanalysis by Schwartz-Zimmermann et al. (2014)
(see Section 7.1.2.1.3) showed the presence of three different sulfonate conjugates of DON (DONS
1–3) and two forms of DOM-1 sulfonate conjugates. Only traces of sulfonate conjugates were present
in urine (< 1% of the administered dose), while 47% of the administered DON-3-glucoside was
recovered as sulfonate conjugated forms of DON, DOM and DON-3-glucoside.
7.1.2.4. Excretion
7.1.2.4.1. DON
Mice
The plasma elimination rate in mice given one single oral dose follows two-compartment kinetics
with t1/2a of 0.29–0.5 h and a t1/2b of 7.6–11.8 h (Azcona-Olivera et al., 1995; Amuzie et al., 2008;
Pestka et al., 2008). A slower secondary elimination rate was observed in mice given a high dose (25
mg DON/kg bw) compared to a lower dose (5 mg DON/kg bw) (Azcona-Olivera et al., 1995). This was
considered to be due to a minor second plasma peak concentration occurring after 4–8 h in the
high-dose group.
Rats
Following a single oral dose of 10 mg radioactively labelled DON/kg bw, 25 and 64% of the
compound was recovered in urine and faeces within 96 h, with no apparent radioactivity retained in
the tissues (Lake et al., 1987).
DON was rapidly excreted from Wistar rats in the study of Wan et al. (2014) described above
(Section 7.1.2.1.1) in which 73–77% of the radioactive dose was recovered in urine and faeces within
48 h. By 96 h, the total urinary and faecal recovery were accumulated to 83–88%. The urinary
excretion of the radioactivity was 40% in the low dose and 33% in the high dose. There was a
signiﬁcant difference in the urinary excretion rate between gender, when the females excreted with
57% and 42% and the males only 27% and 24% at the low and high dose, respectively.
In the male Sprague–Dawley rats given a single oral dose of 2.0 mg DON/kg bw in the study of
Nagl et al. (2012) (see Section 7.1.2.1.1), 15% of the applied dose was recovered in the urine and
13% in the faeces with a total recovery of only 28%. When sulfonate conjugates were included in the
analytical method in the re-analysis of Schwartz-Zimmermann et al. (2014) (see Section 7.1.2.1.1) the
total recovery of DON related metabolites was 64% in the faeces and 11% in the urine. The ﬁndings
indicate that a large proportion is excreted as faecal metabolites.
7.1.2.4.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.1.2.4.3. DON-3-glucoside
Only 17% of the administered DON-3-glucoside was recovered in faeces within 48 h in male in the
Sprague–Dawley rats, while only 4% was recovered from urine (Nagl et al., 2012) (see
Section 7.1.2.1.3). The total recovery was only 21%. The re-analysis of these samples when the
additional sulfonate conjugates were detected (see Section 7.1.2.1.3) showed a total recovery of
metabolites of DON-3-glucoside from faeces of 44% during the ﬁrst 24 h and another 19% between
24 and 48 h after dosing. Only small amounts of sulfonate conjugates (0.8%) were recovered from the
urine and the total recovery from urine was 4.5%. The total recovery of DON increased from 21% to
68% in the second 24-h period, indicating that DON-3-glucoside and its metabolites are mainly
excreted in the faeces.
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7.1.3. Conclusions on in vitro and in vivo studies on toxicokinetics in experimental
animals
In rats, the gut intestinal microﬂora metabolised DON to DOM-1 and transformed acetylated DON
to DON, while no data were identiﬁed on acid hydrolysis, which may contribute to the deacetylation
prior to absorption.
In mice, the oral bioavailability of DON has not been quantiﬁed. DON was rapidly absorbed after
oral exposure and maximum plasma concentrations were reached in 15–30 min. Following absorption,
DON was rapidly distributed to liver, kidney, spleen and heart but the total concentrations of DON and
metabolites (not speciﬁed in the study) peak later and at lower concentrations in the brain than in
other organs. The absorption was apparently higher in female rats than in male rats given the same
doses. The distribution pattern was independent of age, but tissue concentrations were higher in
weanling than in young adult mice given the same single oral dose. DON was glucuronidated at
several sites of the molecule and the glucuronidation proﬁle was species-dependent.
In rats, DON sulfonates were shown to be major metabolites in faeces in addition to the DON
glucuronides. The tissue concentrations of DON in mice and rats decreased rapidly after the peak
concentrations (t1/2a in the range of 20–40 min in mice) and the decrease in the tissue concentrations
followed the decrease in the plasma concentrations. In rats, DON was rapidly (48 h) excreted in faeces
and urine with no apparent accumulation in any tissue. A signiﬁcant biliary excretion was found in one
ex vivo rat liver study, but there are no in vivo data from the bile of experimental animals.
The oral bioavailability of 3-Ac-DON and 15-Ac-DON has not been quantiﬁed and a study with only
two rats indicates that 3-Ac-DON and 15-Ac-DON were largely deacetylated prior to systemic
distribution, which is in line with ex vivo experiments.
The available studies from rats indicated that the bioavailability of DON-3-glucoside was lower than
that for DON, but it has not been quantiﬁed.
7.1.4. Human studies
7.1.4.1. In vitro studies
The bioaccessibility of DON from cooked pasta was determined in an in vitro model of the human
gastrointestinal digestion (Raiola et al., 2012). Bioaccessibility has been deﬁned as the fraction of a
compound that is released from its matrix in the gastrointestinal tract and thus becomes available for
intestinal absorption (Benito and Miller, 1998). The mean gastric bioaccessibility was 23% and the
mean duodenal bioaccessibility was 12% (Raiola et al., 2012).
DON is glucuronidated at several sites of the molecule. Experiments showed that two main
metabolites DON-15-glucuronide and DON-3-glucuronide are formed in the human liver microsomal
fraction. These metabolites are also the two major conjugates found in human urine. In addition, small
amounts of a third glucuronide, tentatively assigned as DON-7-glucuronide by the authors, was
present in incubations with human liver microsomes (Maul et al., 2012, 2014) (see below and
Section 7.5.2). The microsomal glucuronidation using human liver microsomes was slower than the
glucuronidation using liver microsomes from other species.
The role of gut organisms in the metabolism of DON has been studied in vitro using incubations of
DON with faeces or gut content from humans. Gut microﬂoral transformation of DON is less evident in
humans than in rats. Gut microﬂora transformation of DON was not found in incubations with faeces
collected from 10 humans (Eriksen and Pettersson, 2003) and only traces of its de-epoxylated
metabolite DOM-1 were detected in incubations with faeces from nine individuals for 24 h (Dall’Erta
et al., 2013). Gratz et al. (2013) found that DON was transformed to DOM-1 in incubations with faecal
samples from one out of ﬁve individuals.
Both an in vitro study with cell lines representing the human placenta (BeWO cells, b30 clone) and
two ex vivo studies indicate that DON is able to cross the human placenta and reach the fetus (Nielsen
et al., 2011; Mose et al., 2012).
The absorption of DON, 3-Ac-DON and 15-Ac-DON were compared in vitro using a Caco-2 cell line
model (Kadota et al., 2013). All three toxins were transported across the monolayer. The apparent
absorption of 15-Ac-DON was signiﬁcantly higher than that of DON and 3-Ac-DON. The total recovery
of the toxins was 81–108%. Less than 1% of sum of the two acetylated forms of DON was
deacetylated to DON. This indicates that the acetylated forms of DON were absorbed across the
Caco-2 cell monolayer without deacetylation.
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In the cell medium from HepG2 cells incubated with either 3-Ac-DON or 15-Ac-DON for 24, 48 or
72 h, products from acetylated DON conjugated with glutathione, sulfuric acid and the amino group
from the cysteine conjugates were reported by Juan-Garcia et al. (2015). No DON or DON related
metabolites were reported from any of the toxins. The CONTAM Panel noted that there were no
standards for the determination of the conjugates and lack of details given on the analytical methods
in this study.
After 24 h incubations of 3-Ac-DON with human faeces, DON was the only metabolite detected and no
3-Ac-DON was found (Eriksen and Pettersson, 2003). There were no studies identiﬁed on 15-Ac-DON.
DON-3-glucoside added to infant formulae was not hydrolysed in any detectable amount in an
in vitro digestion model with addition of enzymes and pH adjustments to simulate the human digestion
(De Nijs et al., 2012). Furthermore, DON-3-glucoside was not metabolised nor transported from the
apical to the basolateral side in a Caco-2 cell monolayer, while DON was transported across the cell
monolayer in this study. Based on these ﬁndings, the authors concluded that the bioavailability of
DON-3-glucoside may be low compared to DON.
The fate of DON-3-glucoside during digestion has been investigated in several in vitro assays using
different models. When the stability of both DON and DON-3-glucoside in naturally contaminated
bread was tested in a gastroduodenal in vitro digestion model, an increase in DON-3-glucoside
concentration was reported together with a decrease in DON concentration. The authors suggested
that a conversion of DON to DON-3-glucoside is likely to occur during digestion (De Angelis et al.,
2014). Berthiller et al. (2011) reported that DON-3-glucoside is resistant to both 0.2 M hydrochloric
acid and artiﬁcial stomach and gut juice, suggesting that DON-3-glucoside will not be hydrolysed under
the conditions of low gastric pH. DON-3-glucoside was also found to be resistant towards human
cytosolic glucosidase. The fungal enzymes cellulase and cellobiase were able to cleave 11 and 60% of
the DON-3-glucosidase after 3 h incubations. Furthermore, DON-3-glucoside was incubated with
different bacterial strains isolated from guts to test for potential bacterial hydrolysis in the gut. Even
though the hydrolysis was low or negligible in most incubations, a signiﬁcant proportion of the DON-3-
glucoside was hydrolysed after incubations with some strains, reaching a maximum of 39% after 4 h
and 66% after 8 h. The study demonstrated that there was strain-speciﬁc ability of gut microﬂoral to
cleave DON-3-glucoside and produce free DON and that this ability may differ between individual,
depending on the composition of the gut microﬂora.
In incubations with human faeces, 25–38% of DON-3-glucoside was transformed into DON after 4
h of incubations and 100% in incubations with faeces from four out of ﬁve individuals after 6 h (Gratz
et al., 2013). Even traces of DOM-1 have been reported from incubations of DON-3-glucoside with
human faeces (Dall’Erta et al., 2013; Gratz et al., 2013).
7.1.4.2. In vivo studies
Turner et al. (2010a) estimated the human urinary excretion of DON in 35 UK adults. Based on the
individual concentrations of urinary DON and DON-glucuronides and the total dietary exposure to DON,
the geometric mean (95% conﬁdence interval) excretion was calculated to 72% (59–85%). The
excretion percentage was not correlated with age, sex, body weight and DON intake (for more details
see Section 7.6).
A metabolic study (Warth et al., 2013) was conducted in one human volunteer who consumed a
diet naturally contaminated with 138 lg DON, 20 lg 3-Ac-DON and 7 lg DON-3-glucoside for 4 days.
Urinary DON and conjugated DON were measured in urine samples collected over a period of 8 days
including 2 days before and 2 days after the 4 exposure days. The daily excretion of total DON was on
average 68% (range 60–73%) during the 4 exposure days. The excretion of DON on the 2 days
before and the 2 days after the exposure (a mycotoxin reduced diet was taken during this period) was
almost always below the LOD. DON-3-glucoside and 3-Ac-DON were not detected in the urine
samples. DON-15-glucuronide was the main conjugation product, constituting 73% of total
DON-glucuronides (range 69–76%), while DON-3-glucuronide constituted only 27% (range 24–31%).
DON-glucuronides constituted 76% (range 72–80%) of the total DON. The ratios of DON-15-
glucuronide, DON-3-glucuronide and DON-glucuronides to DON were fairly stable over the 8 days. A
third DON-glucuronide was identiﬁed as either DON-7-glucuronide or DON-8-glucuronide. Research on
human metabolites is ongoing and other metabolites of DON may be identiﬁed.
7.1.4.3. Conclusions on in vitro and in vivo studies on toxicokinetics in humans
Limited available data suggests that DON, 3-Ac-DON, 15-Ac-DON and DON-glucoside may be
absorbed across intestine monolayer at different efﬁciency. Gut microﬂoral transformation of DON or
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DON-3-glucoside into DOM-1 was less evident in humans than in rats. Individual differences in the gut
transformation may depend on the composition of the gut microﬂora. DON was able to cross the
placenta and reach the fetus. Limited human data suggested that approximately 70% of ingested DON
would be excreted via urine, of which about 80% were in conjugated forms with DON-15-glucuronide
as the main conjugation product, about threefold more than DON-3-glucuronide.
7.1.5. Farm and companion animals
The toxicokinetics of DON in ruminants, pigs and poultry were reviewed in the previous 2004 EFSA
opinion (EFSA, 2004). Since then kinetics and metabolism of DON, 3-Ac-DON and 15-Ac-DON in farm
animals were reviewed by D€anicke and Brezina (2013), Maresca (2013) and speciﬁcally in poultry by
Guerre (2015). Data on toxicokinetics of DON were available for ruminants, pigs, poultry and horses.
No information was identiﬁed for other farm and companions animal species. Information on
toxicokinetics of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was identiﬁed for pigs and poultry only.
7.1.5.1. Ruminants
7.1.5.1.1. DON
As indicated in the EFSA (2004) opinion, DON is metabolised by the ruminal ﬂora to the de-epoxy
metabolite DOM-1. Swanson et al. (1987a) showed that DON incubated in vitro for 48 h with rumen
microorganisms obtained from a ﬁstulated dairy cow was completely metabolised after 48 h. When a
single oral dose of 920 mg DON was administered to two lactating cows of similar weight (1.9 mg
DON/kg bw), less than 1% of DON was systemically absorbed. Serum DON concentrations reached
90–200 ng/mL, of which 24–46% was a b-glucuronide with serum half-life of approximately 4 h
(Prelusky et al., 1984b). When dairy cows were fed 66 mg DON/kg feed, about 20% of DON was
recovered in urine and faeces as unconjugated metabolites, primarily DOM-1. Enzymatic (b-
glucuronidase) treatment of the urine released more DOM-1 than DON (Co^te et al., 1986). Low
concentrations of DOM-1 in plasma and urine from lactating Holstein cows were conﬁrmed by MS
(Yoshizawa et al., 1986).
D€anicke et al. (2005a) examined the metabolism of DON by feeding contaminated wheat to six
dairy cows (ﬁve being non-lactating). Each of two experiments included a control period in which the
uncontaminated control wheat was fed and a period in which the control wheat was replaced by
Fusarium toxin-contaminated wheat containing 8.05 mg DON/kg and 0.26 mg zearalenone/kg, and
7.15 mg DON/kg and 0.1 mg zearalenone/kg. The two concentrations of DON corresponded to dietary
concentrations of 3.1 and 3.5 mg DON/kg feed (88% dry matter basis), respectively. While the
concentrations of DON and its metabolites in the duodenal digesta were either not detectable or
marginal during the control periods, distinct concentrations were measured during the feeding with
contaminated wheat. DON was nearly completely metabolised to DOM-1.
Seeling et al. (2006) performed an experiment involving 14 ‘German Friesian’ cows fed a diet
containing 60% of complementary feedstuffs and 40% of maize and grass silage (50/50). The only
cereal component of the complementary feedstuffs was either 55% of low contaminated wheat
(during the control period) or 55% of high contaminated wheat (during the exposure period), the rest
was soybean meal, sugar beet pulp, soy oil and minerals. The high contaminated wheat contained
8.21 mg of DON, 0.05 mg of 3-Ac-DON, 0.12 mg of 15-Ac-DON, 0.09 mg zearalenone and 0.05 mg
nivalenol per kg dry matter, while the low contaminated wheat contained 0.25 mg of DON, 0.01 mg of
3-Ac-DON, 0.01 mg of 15-Ac-DON, 0.05 mg of zearalenone and 0.04 mg of nivalenol per kg dry
matter. Each cow was subject for two periods of 4 weeks to the low (control) contaminated diet
containing 0.3 mg DON/kg and then to the high contaminated diet containing 3.4 mg DON/kg
complete ration, respectively. In serum, no DON but only DOM-1 was detected, 100% as glucuronide.
Excretion of DON and DOM-1 occurred through both urinary and faecal routes, with the urinal route
being the most important one. The authors concluded that DON was almost completely
biotransformed to DOM-1 directly passed to the liver. DON and DOM-1 residues were only detected in
the milk from cows fed the high contaminated diet (see also Section 7.1.5.5).
The metabolism of DON was examined by Keese et al. (2008a) in lactating German Holstein cows
in an experiment divided in two periods. During the ﬁrst period of 11 weeks, cows (n = 13) were fed
an isoenergetic total mixed ration with 50% complementary feedstuffs containing 5.3 mg DON/kg dry
matter and 0.12 mg zearalenone/kg dry matter (called Myco group) and were compared with control
cows (n = 14) fed an isoenergetic total mixed ration containing 0.6 mg DON/kg dry matter and 0.05
mg zearalenone/kg dry matter. In the second period (18 weeks), the same 27 cows plus ﬁve additional
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cows were divided into four groups (n = 8): Control-30 (30% complementary feedstuffs), Myco-30
(30% complementary feedstuffs containing 4.4 mg DON/kg dry matter), Control-60 (60%
complementary feedstuffs) and Myco-60 (60% complementary feedstuffs containing 4.6 mg DON/kg
dry matter). DON and DOM-1 in serum and bile were determined by HPLC-UV (LODs approximately 2
ng/mL in serum and 4 ng/mL and bile for both DON and DOM-1). The bile were taken from each cow
by percutaneous ultrasound-guided cholecystocentesis. During both periods, unmetabolised DON was
not detected or was close to the LODs in the body ﬂuids. During the ﬁrst period, the concentrations of
DOM-1 in serum and bile ranged between 22 and 123 ng/mL and between < LOD and 391 ng/mL in
the Myco group, respectively. In the second period, cows in Myco-30 group had signiﬁcantly higher
DOM-1 concentrations in serum and bile (< LOD–69 ng/mL and 6–114 ng/mL, respectively) compared
to cows in Myco-60 group (4–52 and 4–93 ng/mL, respectively). The authors noted that beside the
different complementary feedstuff proportion also the proportion of maize- and grass silage differed
between the two groups and that the release and bioavailability of DON coming from the maize silage
might be different from the kinetics of the contaminated triticale. Transfer into milk investigated in this
study is described in Section 7.1.5.5.
In another study of the same group (Winkler et al., 2014), 30 lactating German Holstein cows were
divided into three groups (n = 10). The animals received for 13 weeks either a control diet (CON) with
50% grass silage and 50% of the complementary feedstuffs with low mycotoxin-contaminated maize
(approximately 0.07 mg DON/kg and 0.02 mg zearalenone/kg on dry matter basis), a low
contaminated diet (FUS-50) with 50% grass silage, 25% low mycotoxin-contaminated maize (CON)
and 25% highly contaminated maize grain (approximately 2.62 mg DON/kg, 0.33 mg DON-3-
glucoside/kg, 0.25 mg 15-Ac-DON/kg and 0.33 mg zearalenone/kg dry matter) or a high contaminated
diet (FUS-100) with 50% grass silage and 50% highly contaminated maize grain (approximately 5.24
mg DON/kg, 0.66 mg DON-3-glucoside/kg, 0.50 mg 15-Ac-DON/kg and 0.66 mg zearalenone/kg dry
matter). Zearalenone, DON and DOM-1 were detected in all plasma samples and the authors recorded
in the FUS-50 and FUS-100 groups a marked increase for all three toxins within the ﬁrst week. DON
concentrations ranged from 0.27 to 0.88 ng/mL in CON, from 0.41 to 1.69 ng/mL in FUS-50 and from
0.83 to 5.06 ng/mL in FUS-100. In contrast, DOM-1 was detected at much higher concentrations than
DON: 1.2–5.9 ng/mL in CON, 3.7–22.4 ng/mL in FUS-50, and 4.6–61.7 ng/mL in FUS-100, respectively.
The calculated mean proportion of DOM-1 in the sum of DON and DOM-1 was about 93%. Plasma
levels of DOM-1 were signiﬁcantly correlated with DON exposure.
In two follow-up studies of that experiment, DON and DOM-1 were analysed in serum, follicular
ﬂuid and urine. In the ﬁrst study, the ratio between plasma and follicular ﬂuid concentrations of DON
ranged between 0.5 and 2.2 for DON and between 0.6 and 1.1 for DOM-1. DON and DOM-1
concentrations signiﬁcantly correlated both in plasma and in follicular ﬂuid (Winkler et al., 2015a). In
the second study, DON and DOM-1 were detected in all urine samples with the concentration of
DOM-1 being 17.5-fold higher than the concentration of DON in the two Fusarium contaminated
groups (Winkler et al., 2015b). DON was almost completely metabolised to DOM-1 (83–98%)
independently of the level of DON exposure. Moreover, conjugated toxins were the major urinary
metabolites. Despite a high variation between the different urine samples, a signiﬁcant difference
existed between the Fusarium contaminated groups and the control group, for both DON and DOM-1
and there was also a correlation between DON exposure levels and urinary-DON and DOM-1
concentrations, respectively. The authors concluded that increased urine-DON concentrations may
indicate DON exposure through the diet and thus the studied mycotoxins and their detected
metabolites could be used as biomarkers of exposure.
The kinetic of DON and DOM-1 was studied in a total of eight non-pregnant and non-lactating
cows, aged 5 years (two cows), 4 years (three cows) and 3 years (three cows), by D€anicke et al.
(2016). During a 6 week pre-experimental period, their diet changed from a pure straw ration to a
total mixed ration containing 60% complementary feedingstuffs, 24% corn silage and 16% grass
silage containing 0.19, 0.58 and 0.06 mg DON/kg dry matter and 0.02, 0.05 and 0.02 mg
zearalenone/kg dry matter. The composition of the total mixed ration was then kept constant from
week 7 to week 16 at 0.274 mg DON/kg bw per day. Blood samples were collected at four weekly
intervals and in blood DON was exclusively available as DOM-1 following the time course of DON
exposure over the 16 weeks. The authors concluded that rumen microbes nearly completely
metabolised DON to DOM-1 irrespective of dietary DON concentration and diet composition.
As reviewed by EFSA (2004), in four rumen-ﬁstulated male sheep (60–70 kg) systemic
bioavailability of DON amounted to 7.5% after oral administration of a single dose of 5 mg DON/kg bw
(Prelusky et al., 1985). In this study, DON was quickly adsorbed (tmax=4–5.3 h) and efﬁciently
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glucuronidated (75%). Elimination half-live of the glucuronide was considerably longer than that of the
parent toxin (t1/2b = 100–125 min and 6.1–7.1 h, respectively). DOM-1 was detected in plasma only as
minor portion of < 0.3% of the orally administered DON. The urinary excretion rates of the major
metabolites reached maximum levels 6–9 h after the treatment, and declined then exponentially with
t1/2 values of 3.2, 4.0, and 5.0 h for DON, conjugated DON, and conjugated DOM-1, respectively. In
agreement with the low bioavailability, urinary (7.0%) and biliary (0.11%) recovery was generally low.
In the urine, 2.1% of the administered dose was detected as DON, 3.6% as DON-glucuronide, 0.06%
as DOM-1 and 1.2% as DOM-1-glucuronide.
Metabolism and elimination of DON in sheep have further been investigated by intravenous
administration of 14C-radiolabelled-DON (4.0 mg/kg bw) to two 1-year-old lactating ewes (70–80 kg)
(Prelusky et al., 1987). The plasma clearance of radioactivity was rapid and followed a triphasic decay
with a rapid distribution phase (t1/2a = 16.2 min), slower elimination phase (t1/2b = 66.5 min) and the
formation and elimination (t1/2b = 188.0 min) of the predominant conjugate in plasma, the DON-
glucuronide, accounting for 13% of the measured radioactivity. The recovered radioactivity after
urinary (91%) and biliary (6%) excretion accounted for 54% as DON-glucuronide, 13% as DOM-1-
glucuronide, 11% as unmetabolised DON, 6% as unmetabolised DOM-1, DON-sulfate conjugate for
3% and unidentiﬁed radioactive components for 10%.
The distribution of DON in cerebral spinal ﬂuid has been investigated following i.v. administration of
1 mg DON to four 1-year-old wethers (60–70 kg). DON was detected rapidly in the cerebral spinal
ﬂuid, peak levels occurring at 5–10 min after injection (Prelusky et al., 1990).
No data were identiﬁed for goats.
7.1.5.1.2. 3-Ac-DON and 15-Ac-DON
Seeling et al. (2006) and Winkler et al. (2014) (see above) exposed cows also to 3-Ac-DON and/or
15-Ac-DON but did not report any results on toxicokinetics for the two acetylated forms. Radioactively
labelled 3-Ac-DON (5 mg/kg bw) was administered intraruminally to two female lambs (Brewer et al.,
1996). The authors reported the 3-Ac-DON was rapidly hydrolysed to DON. Rumen ﬂuid collected only
5 min after administration indicated the presence of 3-Ac-DON and DON in the ratio of 1:1. An
apparent half- life of 46 min was calculated by the authors for DON in the rumen. The maximum
radioactivity of the serum was observed 300–400 min after dosing. Twenty-three per cent of the
radioactivity was excreted in the urine.
No data were identiﬁed for goats.
7.1.5.1.3. DON-3-glucoside
Winkler et al. (2014) (see above) exposed cows also to DON-3-glucoside but did not report any
results on its toxicokinetics. No data were identiﬁed for sheep and goats.
7.1.5.2. Pigs
7.1.5.2.1. DON
Kinetic parameters in pigs measured in experiments administrating single doses of DON were
summarised by EFSA (2004). In the sections below, the ﬁndings of EFSA (2004) are summarised and
relevant studies published since then are described in detail.
DON is rapidly absorbed in the proximal parts of the digestive tract of pigs. After intragastric dosing of
radiolabelled DON (600 lg/kg bw), the absorption half-time was less than 30 min, and DON showed a
high bioavailability ranging from 48% to 65% (Prelusky et al., 1988). After feeding pigs with a diet
containing naturally DON-contaminated wheat (4.2 mg DON/kg feed), the maximum serum DON
concentration was found after 4.1 h (D€anicke et al., 2004a). Avantaggiato et al. (2004) developed an
in vitro model using preparations of gastric, biliary and pancreatic secretions to simulate physiological
conditions of the gastrointestinal tract in pigs. The rate of intestinal absorption of DON (2.8  0.3 mg/kg
wheat) was measured by pumping dialysis liquid through hollow ﬁbre membranes (method previously
described by Minekus et al., 1995). They postulated an absorption rate of 51% for DON from that model.
D€anicke and Brezina (2013) summarised 12 independent published balance experiments with a
total of 122 pigs and estimated the systemic absorption of DON as 0.044–0.6 mg/kg bw An average
systemic DON absorption of 49% in fattening pigs was postulated.
In an ex vivo-experiment after slaughtering, Halawa et al. (2013) compared the intestines of
animals exposed to 141 lg DON/kg bw for at least 1 week with controls (n = 8 per group) under
restricted feeding, and observed a higher jejunal mucosal uptake of DON in the exposed group. They
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also identiﬁed a statistically signiﬁcant interaction between the change of dietary concentration of DON
in feed and the change of rate of absorption.
The inﬂuence of wheat grain, straw and chaff on the bioavailability was studied in pigs exposed to
DON (53 lg/kg bw) but no matrix-dependency was observed (Rohweder et al., 2013). Neither the
invasion (0.76, 0.77 and 0.48 h), nor the elimination half-life (3.74, 3.96 and 4.75 h) differed
signiﬁcantly. A DON-mediated effect on the liver clearance capability (Goyarts and D€anicke, 2006) and
on tight junction proteins (Pinton et al., 2010; Diesing et al., 2011) might have contributed to the
ﬁnding that chronic feeding of a DON-contaminated diet (68.5  4.9 lg/kg bw, n = 5) for 5–8 weeks
resulted in a signiﬁcantly higher bioavailability when compared to an acute oral single bolus of 77.3 
2.4 lg/kg bw (Goyarts and D€anicke, 2006).
Earlier investigations of the distribution to organs in pigs have been performed following a single
i.v. injection 1 mg DON/kg bw ((Prelusky and Trenholm, 1991) revealing high initial concentrations in
plasma, kidney and liver (1–2 mg/kg organ weight). Measurable concentrations were, however,
detected also in the abdominal fat, back fat, lung, adrenals, spleen, testis, heart, brain, muscle tissue,
intestines and pancreas (0.02–0.5 mg/kg organ weight), indicating a large volume of distribution
(EFSA, 2004).
Since then several studies, reviewed by D€anicke and Brezina (2013) have been performed to
characterise the distribution of DON. The highest transfer rate of the sum of DON and DOM-1 into
edible tissues of pigs was found for kidneys (3.4%) by D€anicke et al. (2010). Other maximum transfer
rates were lower by the factor of 5, 7, 11 and 33 for liver, muscle, spleen and back fat, respectively
(D€anicke and Brezina, 2013) (see also Section 7.1.5.5).
In contrast to ruminants, only a minor metabolisation of DON takes place in pigs. However, DON can
be de-epoxidated by the gastrointestinal microﬂora (Eriksen et al., 2002). In an experiment of D€anicke
et al. (2004a), 11 castrated male pigs (88.1  3.9 kg bw), adapted to a diet containing 52 lg DON/kg bw
for 7 days, de-epoxidation occurred particular in the distal segments of the porcine digestive tract.
In earlier in vitro studies (Co^te et al., 1987), no metabolic conversion of DON by hepatic microsomes
(1 lmol/mL) was observed. More recently, it has been recognised that DON undergoes extensive
conjugation with glucuronic acid in pigs. The DON-3-glucuronide was identiﬁed as predominant phase-II-
metabolite in vitro after incubation of a 3.75 lM solution of DON with liver microsomes from six animal
species including pigs (Maul et al., 2012). The formation of DON-15-glucuronide by porcine liver
microsomes has also been shown, while DON-7-glucuronide could not be detected after incubation with
DON concentrations of 0.4–50 lM (Maul et al., 2014) (see also Section 7.1.1).
In gilts, after administration of up to 163.5 lg/kg bw (n = 9 per group) for 5 weeks, 36–56% of the
total DON content in urine was present as glucuronide, while the proportion of glucuronides
(glucuronide forms not stated) in serum was 19–45% (D€anicke et al., 2005b), which was similar to the
ﬁndings in fattening pigs (average of 35%) (D€anicke et al., 2013). Only a small proportion of DOM-1
was detected in urine (1.2–7.9% of DON detected as DOM-1) and in blood (average of 7% of DON
detected as DOM-1) in barrows (n = 12, mean live weight 40.1 kg) after oral administration of 104 lg
DON/kg bw for 7 days in a balance experiment (D€anicke et al., 2014). These small amounts point to a
substantial absorption of DON in pigs in the upper digestive tract preventing microbial de-epoxidation.
The plasma elimination half-life varied between 1.2 and 3.9 h in pigs (Coppock et al., 1985;
Prelusky and Trenholm, 1991; Eriksen et al., 2003). When radiolabelled DON (600 lg/kg bw) was
given by gavage, plasma clearance was found to be 7.14 h (Prelusky et al., 1988). D€anicke et al.
(2012) demonstrated that the apparent volume of distribution and the plasma clearance differed
signiﬁcantly between exposure via simultaneous i.v. administration of DON (100 lg/kg per h) and
lipopolysaccharides (LPS) (7.5 lg/kg per h) and administration of DON alone (2.14 vs 1.45 L/kg and
11.9 vs 5.87 mL/kg per minute). Interactions between DON and LPS have been revealed in several
other studies from the group of D€anicke and collaborators.
D€anicke and Brezina (2013) concluded from their review (see above) the existence of a linear
relationship between oral DON exposure and urinary excretion of the metabolites of DON (not further
speciﬁed) which was 90–95% of total excretion. Only weak relationships were found between DON
exposure and the amount of DON or DOM-1 excreted with faeces. The authors estimated in this
review a recovery of only 40% and concluded that the low recovery was probably due to post-
absorptive rather than intestinal effects. That post-absorptive effects might suggest that a steady-state
was not reached and that post-renal matrix effects of urine might have occurred Therefore, DON
might have further been converted to non-detectable compounds or it was included in poorly
extractable complexes.
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7.1.5.2.2. 3-Ac-DON and 15-Ac-DON
In pigs, 3-Ac-DON is rapidly deacetylated in the upper intestinal tract and absorbed exclusively as
DON, as the acetylated form could not be detected in plasma, urine and faeces after oral
administration of 98 lg/kg bw The absorption half-time for 3-Ac-DON was estimated to be 1.26 h
(Eriksen et al., 2003). There is no similar information available for 15-Ac-DON.
7.1.5.2.3. DON-3-glucoside
The metabolism of DON-3-glucoside has been evaluated by the consecutive oral administration of
water (control), DON-3-glucoside (116 lg/kg bw) and the equimolar amount of DON (75 lg/kg bw) to
four piglets per group on day 1, 5 and 9 of the experiment, respectively, followed by an i.v.
administration of 15.5 lg DON-3-glucoside/kg bw on day 13 (Nagl et al., 2014). As the urinary
excretion of metabolites for DON-3-glucoside was about two times less compared to DON (40.3  8.5
and 84.8  9.7%, respectively), a lower bioavailability of the conjugated form was concluded in this
study. However, only small amounts of DON metabolites were recovered in faeces (1.8  1.6% as
DOM-1). The majority of orally administered DON-3-glucoside was excreted via urine as DON, DON-15-
glucuronide, DOM-1 and DON-3-glucuronide. While urinary DON-3-glucoside accounted for only 2.6 
1.4% after oral, but for 99.9  8.9% after i.v. administration of DON-3-glucoside, it seems that a
nearly complete cleavage of the modiﬁed mycotoxin occurred, primarily in the intestinal tract before
systemic absorption.
In a cross-over trial with i.v. and oral administration of 55.7 lg DON-3-glucoside/kg bw and 36 lg
DON/kg bw, respectively, the contribution of DON-3-glucoside to DON exposure in pigs (n = 6, 26.3 
1.8 kg bw) was studied (Broekaert et al., 2016). The bioavailability, hydrolysis and toxicokinetics of
DON-3-glucoside were calculated after quantiﬁcation of the systemic and portal plasma concentrations
of DON, DON-3-glucoside and DOM-1. The complete presystemic hydrolysis of the absorbed fraction of
DON-3-glucoside was indicated by the exclusive detection of DON in plasma after oral administration
of DON-3-glucoside. After i.v. administration of DON-3-glucoside, no hydrolysis to DON was observed,
indicating the absence of systemic hydrolysis. After oral administration the absorbed fraction of DON-3-
glucoside, recovered as DON, was approximately 5 times lower (16.1  5.4%) than that of DON
(81.3  17.4%.). The authors concluded that hydrolysis occurs at the site of the gastrointestinal tract
(microbiota or gastrointestinal tissues). The observed lag time for DON absorption after oral
administration of DON-3-glucoside to pigs (83.6 min) further supports this hypothesis, as the higher
pH-values in the distal parts of the small intestine may lead to a more abundant growth of microbiota
and therefore a higher probability of DON-3-glucoside hydrolysis. Furthermore, the analysis of phase II
metabolites in this study revealed that biotransformation of DON and DON-3-glucoside in pigs mainly
consists of glucuronidation (ratio of DON-glucuronides/DON equal to 4.98 after oral administration).
7.1.5.3. Poultry
In the previous assessment of EFSA (2004), only two studies, one on laying hens and one on
ducks, described the toxicokinetics in poultry.
7.1.5.3.1. DON
In studies performed in chicken a low degree of absorption into plasma and tissues (1%) as well as
rapid clearance (Prelusky et al., 1986) was observed. Intestinal microﬂora can convert DON to DOM-1
in poultry (Lun et al., 1986, 1988; He et al., 1992).
No DON or DOM-1 residues could be detected in plasma and bile of broilers in an experiment
where the DON concentrations reached approximately 1.5 mg/kg diet (D€anicke et al., 2007a).
Yunus et al. (2010) evaluated the transfer of DON to DOM-1 in the plasma of chicken. Naturally
contaminated oats with 9.5 mg DON/kg were fed to four broilers (35 days of age) at a dose of 20 g
per bird. The sum of DON and DOM-1 appearing in the plasma at 1 and 2 h of post-feeding in the
birds was estimated to be 0.044 and 0.036% of the total DON fed, respectively. The authors
concluded that the absorption rate of DON is very low in broilers and that there is also a rapid
transformation, and clearance from plasma. However, individual variability in the capacity of birds to
de-epoxidise DON was reported.
In a study by Awad et al. (2011), a total of 45 one-day-old broiler chickens (Ross 308 males) were
randomly allotted to three dietary treatments (15 birds/treatment) and were fed (1) a control diet with
0.088 mg DON/kg, 0.005 mg 3-Ac-DON/kg and 0.014 mg zearalenone/kg feed, (2) a diet
contaminated with 0.872 mg DON/kg, 0.018 mg 3-Ac-DON/kg and 0.110 mg zearalenone kg feed, and
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(3) a diet contaminated with 5.017 mg DON/kg, 0.114 mg 3-Ac-DON/kg and 0.352 mg zearalenone/kg
feed for 5 weeks. DON and DOM-1 were measured in serum, bile, liver, faeces and digesta from
consecutive segments of the digestive tract (gizzard, caecum, and rectum). DON and DOM-1
concentrations in serum, bile and liver were lower than the LOD of 7.0 ng DON/g for the used LC–MS/MS
method. No DOM-1 was recovered in the large intestine and in faeces DON was recovered to 18–22% in
cecum and to about 10–12 and 6% in gizzard and faeces, respectively, not inﬂuenced by the amount of
DON-concentration ingested. The authors noted that de-epoxidation occurred in these birds in the
proximal small intestine, where the majority of DON is absorbed, but hardly in the distal segments of
the digestive tract. The results showed that the majority of the ingested DON quickly disappears through
the gastrointestinal tract.
Yunus et al. (2012b) explored the intestinal absorptive functionality and DON metabolism in broilers.
DON was produced by inoculating rice with F. graminearum. Ross broilers at 7 days of age were fed
either a control diet (0.265 mg DON/kg, 0.009 mg 3-Ac-DON/kg and 0.013 mg zearalenone/kg), a low
DON diet (1.68 mg DON/kg, 0.198 mg 3-Ac-DON and 0.145 mg zearalenone/kg), or a high DON diet
(12.209 mg DON/kg, 1.446 mg 3-Ac-DON/kg and 1.094 mg zearalenone/kg). After 5 weeks of exposure
the birds were intubated into the crops with a solution of Fusarium mycotoxin concentrate containing
DON, 3-Ac-DON and zearalenone at concentrations of 616.5, 67.2 and 20.55 lg/mL, respectively.
Higher amounts of DON and DOM-1 were found 5 h of post-intubation in the gut of birds raised on the
low and high DON diets than in that of birds fed the control diet. The plasma level of DON in the
birds at 1 h of post-intubation linearly decreased with increasing dietary exposure during the previous
period.
Two experiments of Osselaere et al. (2012, 2013a,b) showed a rapid clearance of DON in plasma.
In a ﬁrst experiment of Osselaere et al. (2012), three groups (n = 8 per group) of 1 day old chickens
were treated for 3 weeks after 10 days of acclimatisation. Group 1 (Control) was fed
non-contaminated feed, group 2 artiﬁcially contaminated feed (2.44 mg DON, 0.09 mg nivalenol, 0.57
mg 3-Ac-DON, 2.05 mg 15-Ac-DON and below 0.05 mg (LOD) fumonisins B 1–3 per kg feed, and
group 3 naturally contaminated maize (7.54 mg DON, below 0.07 mg (LOD) nivalenol, 1.48 mg 3-Ac-
DON, below 0.005 mg (LOD) 15-Ac-DON and 0.70 mg fumonisin B1, 0.20 mg fumonisin B2, 0.21 mg
fumonisin B3 per kg feed). No signiﬁcant differences of effects on zootechnical parameters (feed
intake, body weight gain, ﬁnal live body weight) were observed between the three groups. No DOM-1
was detected in the three groups and DON was above the LOD (1.25 lg/mL) only in the plasma of the
birds in group 3. Plasma concentrations of DON were higher after week 1 than after week 3 and no
DON was detected after week 3 in group 3, but it was above the LOD in bile. DOM-1 was detected in
groups 2 and 3 with concentrations lower in group 2 than in group 3. No residues of DON or DOM-1
were detected in liver and kidneys in any of the three groups (see also Section 7.1.6.1).
A second experiment of Osselaere et al. (2013a,b) on eight broiler chickens was performed
following a two way design where four animals received a single dose i.v. and four animals orally a
bolus of 0.75 mg DON/kg bw Blood was collected at several time points. Plasma levels of DON and
DOM-1 were quantiﬁed using LC–MS/MS (LOQs 1.0–2.5 ng/mL). After oral administration no plasma
concentrations of DOM-1 were detected above the LOQ. Moreover, from 2 h after administration on
DON was below the LOQ. The maximum DON concentration in plasma was reached after
approximately 35 min (about 26 ng/mL). The plasma concentration after i.v. administration was much
higher than that after oral administration. Oral bioavailability of DON was determined to be 19.3  7.42%.
Elimination half times after oral and i.v. were 38.2  11.2 and 27.9  6.9 min, respectively.
Tritium-labelled DON, 3b-3H-DON (1.1 mCi/g) in ethanol was orally administered to broilers at the
dose of 2.5 mg DON/kg bw for 5 days and analysed by radio-HPLC-TOF-MS (Wan et al., 2014). DON
was widely distributed and quickly eliminated in all tested tissues tested. Its concentration was the
highest in the gastrointestinal tract and substantially lower in the kidney, liver, heart, lung, spleen and
brain. Amongst the three metabolites identiﬁed (10-DON-sulfonate, 10-DOM-1- sulfonate and DON-3-
sulfate), DON-3-sulfate was most prominent one.
Toxicokinetics of DON, 3-Ac-DON and 15-Ac-DON were investigated separately in a pilot study on
three male broiler chickens of 20 days of age (Broekaert et al., 2014) and an experimental study of
Broekaert et al. (2015) involving 18 broilers of 3 weeks of age by gavage in a two-way-cross-over
design with a washout period lasting 4 days. In the pilot study, the three toxins were administered
puriﬁed at three doses equivalent to 5 mg DON/kg feed, respectively. The absorbed fractions of DON,
3-Ac-DON or 15-Ac-DON were 10.6, 18.2 and 42.2%, respectively. No DOM-1 was detected in any of
the plasma samples (LOD 0.51 ng/mL) taken. In a follow up study using the design of Broekaert et al.
(2014), this group investigated the metabolism of DON (Devreese et al., (2015). In plasma, the major
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metabolite of DON was DON-3-sulfate, with high ratios of DON-3-sulfate to DON ratios ranging
between 243–453 and 1,365–29,624 after i.v. and gavage, respectively. Only trace amounts of other
metabolites such as DON- and DOM-1-glucuronides, 10-DON-sulfonate, DOM-1- and 10-DOM-1-
sulfonate were detected. The authors concluded a low absolute oral bioavailability of DON, a rapid
absorption and elimination of DON, and an extensive biotransformation of DON to DON-3-sulfate.
Broekaert et al. (2016) studied the toxicokinetics of DON and DON-3-glucoside in 6 broiler chickens
(Ross 308) treated with either DON or DON-3-glucoside by i.v. bolus injection or gavage in a two-way-
cross-over design with a washout period lasting 3 days. The administered doses of pure toxins in
solution were equivalent to a feed of 5 mg DON/kg feed. After i.v. and after gavage administrations of
DON-3-glucoside, no hydrolysis to DON was observed. The oral bioavailability of DON-3-glucoside was
low (3.79  2.68%). No DOM-1 was detected in the plasma samples. The mean elimination half life
for DON-3-glucoside in broilers was 34.0  6.2 min. Analysis of phase II metabolites revealed that
biotransformation of DON and DON-3-glucoside in chickens mainly consisted of conjugation with
sulfate compared to glucuronidation.
Schwartz-Zimmerman (2015) analysed by LC–MS/MS excreta samples from different feeding trials
with chickens, pullets and roosters. Control groups were fed with basal poultry feed naturally
contaminated with 0.2 mg/kg DON. Five-week old chickens (Ross 508) of the DON group received basal
poultry feed enriched with DON from culture material to a concentration of 1.7 mg DON/kg during 1 day.
Excreta were collected every 3 h on the same day and one sample collected the next morning. Twelve-
week old pullets (Lohmann LSL) were exposed to 4.4 mg DON/kg feed during 2 weeks. The feed also
contained traces of 3-Ac-DON (0.13 mg/kg) and 15-Ac-DON (0.03 mg/kg). Excreta were collected every
morning and afternoon for 1 week. Adult roosters received diet containing 11 mg DON/kg during 9 days
and excreta were collected as for pullets. The authors indicated that DON-3-sulfate was the major
metabolite of DON found in excreta in all these poultry species.
In the only study mentioned in EFSA (2004) of Prelusky et al. (1986) on laying hens, a single oral
dose of radiolabelled DON (2.2 mg per animal) was given. DON was found to be poorly absorbed
(< 1% of the administrated dose). Elimination of the radiolabelled DON into excreta occurred rapidly
and recovered radioactivity accounted for 98.5% of the dose after 72 h. In the experiment performed
by Ebrahem et al. (2014a) 23-week-old laying hens (n = 80) were fed low contaminated wheat with
0.054 mg DON and 0.069 15-Ac-DON/kg feed and wheat with 0.04 mg DON/kg feed (control). Highly
contaminated wheat (previously inoculated with an F. culmorum strain) contained 13.5 mg DON, 4.7
mg aurofusarin, 0.76 mg DON-3-glucoside and 0.23 mg 3-Ac-DON/kg and was used to prepare the
diet containing 9.9 mg DON/kg feed. In the 70th week of the life, all hens were slaughtered and
samples of blood and bile were collected and analysed by LC–MS/MS for DON and DOM-1. DON was
detected only in hens given the toxic diet in plasma and bile with levels ranging between 0.2 and 0.6
ng/mL and 1.8 and 4.1 ng/mL, respectively. No DOM-1 was detected.
As also mentioned in the EFSA (2004), diets with increasing proportions of Fusarium-toxin-
contaminated wheat were fed to 54 one year old Pekin ducks for 49 days. Dietary DON concentration
was 7 mg/kg. Concentrations of DON and DOM-1 in plasma and bile were lower than the LODs of 6 and
16 ng/mL, respectively, when using HPLC (D€anicke et al., 2004b). No data were identiﬁed since then.
Gauvreau (1991) administered DON solutions orally and i.v. at 5 and 1 mg/kg bw, respectively, to
24 one-day old turkeys at the end of their growing period of 8 weeks (weighing about 3 kg). Orally
given DON was poorly absorbed from the gastrointestinal tract (0.96% of the ingested DON) and the
majority was eliminated within 3 h in the excreta. A rapid plasma clearance (t1/2 = 44 min) occurred
after i.v. injection. In an experiment of D€anicke et al. (2007b), 4 groups of 48 male turkeys were fed
with increasing proportions of naturally DON contaminated wheat at approximately 0.1, 2.0, 4.6 and
5.4 mg DON/kg feed from day 21 to day 56 of age. DON and DOM-1 concentrations in plasma were
lower than the LOQ of 2 ng/mL and the DON concentration in bile reached up to 13–23 ng/mL,
whereas DOM-1 concentrations were lower than 4 ng/mL. Devreese et al. (2014) conducted an
experiment on 120 one-day-old male turkey poults for 12 weeks including starter, grower, developer
and ﬁnisher phases. Birds were randomly distributed into two groups of three pens each either fed a
control diet containing 0.06–0.39 mg DON, below 0.05 (LOD)–0.10 mg 15-Ac-DON and below 0.03 mg
of other mycotoxins per kg feed or a naturally contaminated diet containing 4.0–6.5 mg DON,
0.45–0.55 mg 15-Ac-DON, 0.25–1.2 mg FB1+FB2 and 0.37–0.67 mg zearalenone, per kg feed. No
DON or DOM-1 was detected in any plasma samples of the birds fed the control diet but both were
detected in all analysed samples of birds fed the contaminated diet. Plasma concentrations of 1.14 ng
DON/mL and 2.45 ng DOM-1/mL were measured during the starter phase, and increased to a
maximum of 3.21 ng DON/mL and 9.51 ng DOM-1/mL at the end of the grower phase. The authors
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attributed the increased DON absorption to intestinal damage, as demonstrated with the morphometry
indices (see Section 7.3.3.1).
Devreese et al. (2015) administered DON to six turkey poults of 7 weeks of age (body weight around
1.27 kg) at 0.75 mg/kg bw per o.s. and i.v. in a two-way-cross-over design. DON was absorbed rapidly
(tmax = 0.57 h) but incompletely as the oral availability was only 20.9%. DON was also rapidly eliminated
both after oral (t1/2 elimination = 0.86 h) and i.v. (t1/2 elimination = 0.62 h) administration. Semiquantitative
analysis using HRMS (see Broekaert et al., 2014), revealed that the major metabolite of DON in plasma
was DON-3-sulfate, with DON-3-sulfate/DON ratios between 1.3–12.6 and 32.4–140.8 after i.v. and oral
administration, respectively. Glucuronidation of DON to DON-3-glucuronide was a minor pathway. Only
trace amounts of other metabolites were found including 10-DON-sulfonate, DOM-1 and 10-DOM-1-
sulfonate. The authors concluded a low absolute oral bioavailability, a rapid absorption and elimination,
and an extensive biotransformation to DON-3-sulfate.
Schwartz-Zimmerman (2015) analysed by LC–MS/MS excreta samples from feeding trial with
turkeys. Control group was fed with basal poultry feed naturally contaminated with 0.3 mg DON/kg.
Eleven-week old turkeys of the DON group received basal poultry feed enriched with DON from culture
material to a concentration of 1.5 mg/kg during 1 day. Excreta were collected every 3 h on the same
day and one sample collected the next morning. The authors indicated that DON-3-sulfate was the
major metabolite of DON found in turkey excreta.
7.1.5.3.2. 3-Ac-DON and 15-Ac-DON
Broekaert et al. (2014, 2015) reported toxicokinetic data on 3-Ac-DON and 15-Ac-DON in broiler
chickens (see details above). The absorbed fraction after gavage administration of 3-Ac-DON and 15-
Ac-DON was 18.2 and 42.2%, respectively. The absorbed fraction of 3-Ac-DON was completely
hydrolysed presystemically to DON and 75.4% of the absorbed fraction of 15-Ac-DON to DON. No
DOM-1 was detected in any of the plasma samples (LOD 0.51 ng/mL).
7.1.5.3.3. DON-3-glucoside
Broekaert et al. (2016) reported toxicokinetic data on DON-3-glucoside and DON in broiler chickens
(see details above). The results indicated that DON-3-glucoside was not hydrolysed to DON. The oral
bioavailability of DON-3-glucoside was low (mean  SD: 3.79  2.68%) and comparable to that of
DON. The absence of DOM-1 in all analysed samples of plasma was observed. The mean t1/2 elimination
for DON-3-glucoside in broilers was 34.0  6.2 min. Analysis of phase II metabolites revealed that
biotransformation of DON-3-glucoside in chickens mainly consisted of conjugation with sulfate
compared to glucuronidation.
7.1.5.4. Horses
7.1.5.4.1. DON
No information on toxicokinetics of DON, its acetylated forms or DON-3-glucoside in horses was
reported in the previous EFSA (2004) opinion. Two studies on horses have been published since then.
Setyabudi et al. (2012) investigated the concentrations of DON and DOM-1 in plasma samples of ﬁve
Haﬂinger mares fed oats contaminated with DON (12 mg DON/kg), total exposure being 36 mg of
DON per day during 10 days. The concentrations of DON and DOM-1 were determined using HPLC-
IAC-UV. In the plasma samples (without treatment with b-glucuronidase) collected 24 h after feeding
on day 10, concentrations of DON and DOM-1 ranged from below LOD (4 ng/mL) to just below LOQ
(13 ng/mL). In plasma, the majority of DON was present as glucuronides of DON and DOM-1
representing 53–79% of the sum of DON and detected metabolites. Schulz et al. (2015) fed for 21
days 12 geldings with wheat based feed naturally contaminated with DON (14.6  6.5 mg DON/kg dry
matter). The feed intake was adjusted to 4 kg wheat per day and 1.7 kg silage/100 kg bw per day.
Three groups of 4 horses were fed either a control diet with 0% contaminated wheat or two wheat
mixtures: one with 53  2% of DON-contaminated wheat (7.7 mg DON/kg feed) and one with 78  4%
of DON-contaminated wheat (11.4 mg DON/kg feed). Blood samples were collected on day 0 and 21
before and 3 h after the wheat intake. Serum DON concentrations increased with higher DON
exposure. After the ﬁrst day of wheat intake, the metabolite DOM-1 was not detected in serum until
day 21 of DON exposure. DOM-1 was only detected in serum on day 21 after feeding the two DON
diets. DOM-1 concentrations in serum correlated with DON exposures.
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7.1.5.4.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.1.5.4.3. DON-3-glucoside
No data were identiﬁed.
7.1.5.5. Conclusions on toxicokinetics in farm and companion animals
The CONTAM Panel concluded that overall intestinal absorption and metabolism of DON varies
largely between different farm animal species and this may depend on the location of the consecutive
intestinal segments, regional pH and activity of bacteria. One may distinguish polygastric animals (e.g.
ruminants) and birds (e.g. poultry) from monogastric animals (e.g. pigs) when considering the location
of high bacterial content which is both before and after the small intestine in the ﬁrst and only after
the small intestine, in particular in colon, in the second case, see e.g. review of Maresca (2013).
Localisation of the gut bacteria affects the bioavailability of ingested DON and its metabolites.
In cows, DON is almost completely metabolised by the ruminal ﬂora to DOM-1 and only minor
amounts of DON reach systemic circulation (< 1%). The proportion of DOM-1 glucuronide conjugate in
serum is high. The urine seems to be the main route of excretion, whereas faecal and biliary excretion
routes seem to be less important. Relevant toxicokinetic data were not identiﬁed for 3-Ac-DON and/or
15-Ac-DON and/or DON-3-glucoside for cows. When orally administered to sheep, DON has systemic
bioavailability of 7.5% and is quickly absorbed. Following absorption, DON is efﬁciently glucuronidated;
de-epoxidation seems to play a minor role (< 0.3% DOM-1 in plasma). Excretion of DON and
metabolites occurred through both urinary and biliary routes, with urinary excretion being most
important. One study on lambs showed that radioactively labelled 3-Ac-DON administrated
intraruminally was rapidly converted to DON. Twenty-three per cent of the radioactivity was excreted
in the urine. No data were identiﬁed on the toxicokinetics of the 15-Ac-DON or DON-3-glucoside for
sheep. For goats no data were identiﬁed. The CONTAM Panel noted that toxicokinetics could be
different in ruminants with acidosis or young animals such as calves for which the ruminal system is
not fully functioning.
The absorption of DON in pigs is generally high (48–65%) and may depend on the level of
exposure. DON shows an extensive organ distribution and also a rapid renal excretion, partly
conjugated to glucuronic acid. The plasma elimination half-life was found to vary between 1.2 and 3.9
h. Excretion of DON and metabolites occurred through both urinary and biliary routes, with urinary
excretion being the most important route in pigs. No data were identiﬁed for 15-Ac-DON but 3-Ac-DON
was rapidly deacetylated in the upper intestinal tract and absorbed exclusively as DON. Limited data
on DON-3-glucoside indicated that its bioavailability was two times lower than that of DON, and it can
be concluded that DON-3-glucoside was only absorbed as DON. Cleavage of DON-3-glucoside may
occur extensively and primarily by the microﬂora in the gastrointestinal tract.
For poultry, a low degree of absorption of DON into plasma up to 10% was observed as well as a
rapid metabolism and clearance from plasma. The only available study on broiler chickens indicated a
nearly complete hydrolysis of 3-Ac-DON to DON and a partial (74%) hydrolysis of 15-Ac-DON to DON.
Therefore the CONTAM Panel assumed that 3-Ac-DON is absorbed as DON to a larger extent than
15-Ac-DON. Only one available study in chickens indicated that DON-3-glucoside was not hydrolysed to
DON in vivo. Furthermore, the absolute oral bioavailability of DON-3-glucoside was low (3.8%) and
comparable to that of DON. The results of all identiﬁed studies in poultry species indicated the absence
of DOM-1 in plasma. Analysis of phase II metabolites revealed that biotransformation of DON and
DON-3-glucoside in chickens mainly consisted of conjugation with sulfate compared to glucuronidation.
In broiler chickens and turkey poults the major metabolite of DON in plasma was DON-3-sulfate.
Glucuronidation of DON to DON-3-glucuronide is a minor pathway. Only trace amounts of other
metabolites were found including 10-DON-sulfonate, DOM-1 and 10-DOM-1-sulfonate. DON-3-sulfate
was also identiﬁed as the major metabolite of orally administrated DON in excreta of several poultry
species.
In horses, rapid clearance of DON in plasma was observed and it is assumed that only low
concentrations (approximately 10 ng/mL) could reach the systemic circulation. One study indicated the
presence of DOM-1 in serum, which was correlated with the amount of DON intake. Consequently,
microbial de-epoxidation of DON could also take place in the horse gut. Another study in horses
indicated that 76–79% of the absorbed DON is present in plasma as its glucuronide form. No data
were identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in horses.
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For dogs and cats, no information on toxicokinetics was identiﬁed in the literature for DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside.
7.1.6. Transfer in farm animals
7.1.6.1. DON
The transfer of DON into edible products from livestock was reviewed by EFSA (2004), and
subsequently by Pestka and Smolinski (2005), Pestka (2007, 2010a,b), Fink-Gremmels (2008), V€olkel
et al. (2011), D€anicke and Brezina (2013) and Flores-Flores (2015).
For ruminants, a study was performed by Prelusky et al. (1984b) in which a single oral dose of
920 mg DON was administered to two lactating cows of similar weight (1.9 mg/kg bw DON). Both free
DON and DON b-glucuronide were detected in milk at low concentrations (< 4 ng/mL), with an LOD of
1 ng/mL (see Section 7.1.5.1). After the administration of up to 12 mg DON/kg of complementary feed
for 10 weeks, neither DON nor DOM-1 were found in cow milk above the LOD of 1 ng/mL (Charmley
et al., 1993). In the study of Seeling et al. (2006) on lactating cows, the transfer from a daily oral
DON exposure of 16.6–75.6 mg DON to milk was low in the range of 0.01–0.02%, while for DOM-1 it
varied between 0.04% and 0.24%. Keese et al. (2008a) performed a long-term study to investigate
the metabolism of DON and its transfer into milk (for details see Section 7.1.5.1). DON and DOM-1 in
freeze-dried milk were determined by HPLC-UV with a LOD of 4 lg/kg in freeze-dried milk
(corresponding to 0.5 lg/kg milk with 12.5% dry matter). No unmetabolised DON was detected in
milk. Concentrations of DOM-1 in milk of cows fed a contaminated diet with 5.3 mg DON/kg feed
ranged between 0.6 and 2.2 lg DOM-1/kg milk. Milk samples of control cows did not contain
measurable amounts of DOM-1 (< 0.5 lg/kg). The total transfer ranged between 0.02 and 0.1% and
tended to be linearly correlated with the milk yield.
Winkler et al. (2015c) studied the transfer rate of zearalenone, DON and their metabolites into milk
(see details in Section 7.1.5.1.1). For milk analysis, an LC–MS/MS method was used for the
simultaneous determination of zearalenone, DON and their metabolites. The mycotoxin concentrations
in milk of cows fed the control diet were signiﬁcantly lower compared with cows fed the contaminated
diet. DOM-1 showed the highest concentration (5.03 ng/mL milk). In addition, DON concentrations up
to 2.5 ng/mL were detected in the milk samples. The calculated transfer ranged between 0% and
0.17% for DON and were independent of the DON exposure.
Prelusky et al. (1987) performed two experimental studies on ewes. When 16.5–18.9 mg DON/kg
bw was orally administered, levels up to 0.017 and 0.205 lg/L of DON and DOM-1 were observed in
milk, respectively. In another study, when 4 mg DON/kg bw was administered intravenously, the
highest concentrations in milk were 0.061 lg DON/L and 1.220 lg DOM-1/L, respectively.
In pigs, fed DON both ad libitum or with restrictive diets up to 6.68 mg/kg over a period of 12
weeks, mean transfer rates of the sum of DON and DOM-1 were 1.5% for kidneys, 0.5% for liver,
0.23% for serum, 0.16% for muscle and 0.02% for back fat. The time period between the end of
feeding and slaughter had no consistent effect on concentrations of the sum of DON and DOM-1 in the
analysed specimen (Goyarts et al., 2007). In the review of D€anicke and Brezina (2013), a maximum
transfer rates of DON for muscle and back fat were 0.43 and 0.12%, respectively.
For broilers, no DON or DOM-1 residues were detected (LOD 4 lg/kg) in liver and breast meat of
broilers in an experiment where the DON concentration reached approximately 1.5 mg/kg diet
(D€anicke et al., 2007a). In an experiment performed by CODA-CERVA (2011–2012), 80 broilers were
fed with a control starter diet during 12 days and then divided in two groups of 40 animals. One group
used as control was fed with the slightly contaminated feed as control containing 0.16 mg DON/kg,
0.002 mg 3-Ac-DON/kg feed and other Fusarium toxins. The other group was fed with a highly
contaminated feed containing 1.71 mg DON/kg, 0.04 mg 3-Ac-DON/kg, 0.09 mg 15-Ac-DON/kg feed
and other Fusarium toxins. The exposure period of 14 days was followed by a depletion period of 14
days during which animals received again the control feed. No DON, 3-Ac-DON, 15-Ac-DON and their
metabolites were detected in the meat, liver and skin of any group. In the experiment of Osselaere
et al. (2012) (see Section 7.1.5.3.1) in three groups of 8 broiler chickens none of the residues were
detected in liver and kidneys in any groups.
In three experiments performed by Prelusky et al. (1986, 1987, 1989), laying hens were fed
contaminated diet with spiked radiolabelled 14C-DON. In a ﬁrst experiment, radiolabelled DON given at
a single dose of 2.2 mg/bird. Maximum tissue levels were measured at 3 h in liver, kidney, heart,
spleen and gizzard, while for muscle and fat the maximum radioactivity was measured after 6 h.
Clearance of radioactivity from tissues had an average half-life of 16.83  8.2 h (Prelusky et al., 1986,
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1987). In a second experiment, birds were fed daily over a period of 12 days with a diet spiked with
DON (2.2 mg DON/bird and per day during 6 days, followed by 2.2 mg 14C-DON/bird per day for 6
days). Measured radioactivity levels in eggs increased with each subsequent egg laid up until the end
of the exposure. The maximum accounted level was equivalent to 4.2 lg of DON or metabolites/60 g
egg, corresponding to 0.19% of the daily dose. Residues declined quickly once the birds were fed
non-contaminated diet (Prelusky et al, 1987). In a third experiment, birds were fed with a diet spiked
at 0.55 mg 14C-DON/bird per day during a 65-day period followed by a 21-day period during which
birds were fed by a non-contaminated diet. At day 8 of exposure the maximum level was 1.7 lg of
DON or metabolites-equivalents/60 g egg corresponding to 0.31% of the daily 0.550 mg DON
exposure of hen. The yolk, albumen and membrane contributed to 70, 29 and 1% of measured
radioactivity, respectively. At the 30th day, levels declined to 25% from the measured maximum level
and remained constant until the end of the contamination period and became quickly negligible when
birds were fed non-contaminated diet (Prelusky et al., 1989).
Neither DON nor DOM-1 were detected in yolk or albumen (concentrations < LODs of 2.5 and 1 lg/kg,
respectively) at a dietary DON concentration of 11.9 mg/kg feed (Valenta and D€anicke, 2005). After
feeding laying hens diets with DON concentrations between 5 and 10 mg/kg, trace amounts of DON in
the range of 0.13 and 0.79 lg/kg whole egg were detected. These trace concentrations corresponded to
estimated transfer between 0.003% and 0.007% (Sypecka et al., 2004).
In the study performed by CODA-CERVA (2011–2012) (see above), 36 laying hens (30–55 weeks
old), were selected on zootechnical performance during 4 weeks and then divided in two groups of 18
animals. The ﬁrst group was fed with the low contaminated feed as control containing 0.46 mg
DON/kg, 0.02 mg 3-Ac-DON/kg and 0.1 mg 15-Ac-DON/kg feed. The second group was fed with the
highly contaminated feed containing 2.23 mg DON/kg, 0.07 mg 3-Ac-DON and 0.23 mg 15-Ac-DON/kg
feed. This exposure period of 14 days was followed by a depletion period of 14 days during which
animals received again the control feed. No DON or its acetylated forms were detected in eggs (see
also Section 7.3.3.1).
In the experiment of Ebrahem et al. (2014a) (see details in Section 7.1.5.3.1) in the 60th week of
the hen’s life, 10 eggs from each group were collected and analysed by LC–MS/MS for DON and
DOM-1. DON levels in egg yolk and albumen ranged between 0–0.46 lg/kg and 0–0.35 lg/kg,
respectively, corresponding to transfer rates of DON into eggs from 0% to 0.0016%. No differences in
DON levels or transfer were observed between the two tested breeds.
Male turkeys were fed from day 21 to day 56 of age with increasing proportions of Fusarium
toxin-contaminated wheat containing up to approximately 5.4 mg DON/kg diet. Concentrations of DON
and DOM-1 in liver and breast meat were lower than the LODs of 4 lg/kg (D€anicke et al., 2007b).
No information on transfer of DON in animal species other than dairy cows, pigs and poultry was
identiﬁed.
7.1.6.2. 3-Ac-DON and 15-Ac-DON
In the CODA-CERVA (2011/2012) study, neither 3-Ac-DON nor 15-Ac-DON were detected in the
liver, muscles and skin of the broilers nor in the eggs (see details above) of laying hens. In the
experiment of Osselaere et al. (2012) on chickens no residues of 3-Ac-DON or 15-Ac-DON were
detected in liver. No data on other animals than chicken were identiﬁed regarding transfer of 3-Ac-DON
or 15-Ac-DON.
7.1.6.3. DON-3-glucoside
No data were identiﬁed.
7.1.6.4. Conclusions on transfer
The available data on DON in dairy cows, pigs and poultry show that its transfer from feed to food
products of animal origin is very low. The CONTAM Panel concluded that residues of DON in products
of animal origin are unlikely to contribute substantially to human exposure. No information on transfer
of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was identiﬁed for dairy cows, pigs or poultry. For other
farm animal species, no information on transfer of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
was identiﬁed.
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7.2. Toxicity in experimental animals
Since the assessment of the SCF (1999), the toxicity of DON has been reviewed by JECFA (2001,
2011), Pestka and Smolinski (2005), Pestka (2007, 2010a,b) and Sobrova et al. (2010). Toxicity data
available for 3-Ac-DON and 15-Ac-DON have been reviewed by JECFA (2011). The SCF (1999)
characterised acute/subacute toxicity of DON as vomiting, feed refusal, weight loss and diarrhoea. At
that time, reduced feed intake, reduced body weight gain and changes of some haematological
parameters were identiﬁed as subchronic effects of DON and its chronic toxicity was described on the
basis of the data reported by Iverson et al. (1995). Since then more studies on the acute, subacute,
subchronic and chronic toxicity in experimental animals have been published, a few of them also
describe the toxicity of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. For this opinion, the most
relevant ones were identiﬁed and considered for the hazard characterisation of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside (see also Table 45 for the studies).
7.2.1. Acute toxicity in rodents
This section describes studies on acute effects of an oral exposure to DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside in rodents. Acute effects in farm and companion animals are reported under the
respective subsections in Section 7.3.8.
7.2.1.1. DON
After oral administration, the LD50 values for DON have been calculated as 78 and 46 mg/kg bw in
B6C3F1 and DDY mice, respectively (Yoshizawa et al., 1983).
After the SCF (1999) assessment on DON, two studies were published on mice. In one study, a single
oral administration of 6.25, 12.5 and 25 mg DON/kg bw to adult mice (DBA/llac J) revealed that DON
profoundly affected and altered the night-time food intake and meal microstructure measured from 3 to
168 h after treatment (Girardet et al., 2011a,b). Flannery et al. (2011) reported that within 2 h of
exposure to 2.5 and 5 mg DON/kg bw by oral gavage, food consumption was reduced by 68 and 77%,
respectively, while doses of 0.5 and 1.0 mg DON/kg bw had no effect in female B6C3F1 mice.
7.2.1.2. 3-Ac-DON and 15-Ac-DON
Schiefer et al. (1985) studied acute toxicity of 3-Ac-DON after a single intragastrical administration
at doses of 0, 5, 10, 20 or 40 mg/kg bw in male mice ([Crl:CDl (ICR) BR) (n = 175) fasting 16 h
before and 6 h after dosing and sacriﬁcing batches of n = 5 after 2, 4, 6, 12, 24, 48 and 96 h. After 12
h, the animals started to show behavioural signs (e.g. restricted moving). Histopathological
examination showed duodenal crypt injury (reduced mitosis and necrosis) and necrosis in spleen and
thymus post severe at the highest dose of 40 mg 3-Ac-DON/kg bw where all animals died until 96 h.
Since the intensity of lesions in the 40 mg/bw group corresponded to lesions known to be caused
by 4 mg/kg of T-2 toxin, the authors concluded that 3-Ac-DON was considerably less toxic than T-2
toxin, but caused acute effects in the dividing cells of the body in a manner characteristic of
trichothecenes. The CONTAM Panel noted that no LD50 value for 3-Ac-DON could be calculated from
this study.
Doses of 1 and 2.5 mg/kg bw of 3-Ac-DON and 15-Ac-DON, respectively, caused in female B6C3F1
mice feed refusal within 2 h after exposure, but afterwards a compensatory increase in food intake
was observed over the next 14 h (Wu et al., 2014a).
7.2.1.3. DON-3-glucoside
DON-3-glucoside was tested in a nocturnal mouse food consumption model. Oral administration of
DON-3-glucoside, at doses of 2.5–10 mg/kg bw induced feed refusal that lasted up to 16 and 6 h,
respectively. Exposure to 2.5 mg DON-3-glucoside/kg bw stimulated plasma elevations of the gut
satiety peptides cholecystokinin and to a lesser extent, peptide YY3-36 that corresponded to reduced
feed consumption (Wu et al., 2014d).
7.2.1.4. Conclusions on acute toxicity in rodents
The CONTAM Panel noted that after a single DON exposure feed refusal appeared very quickly in
mice. After oral administration, the lowest LD50 values for DON was 46 mg/kg bw in mice. It was also
noted that as rodents do not vomit. However, decreased feed intake was identiﬁed as relevant
endpoint for acute effects in mice.
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 142 EFSA Journal 2017;15(9):4718
7.2.2. Subacute toxicity
After the SCF (1999) assessments, the following studies below were identiﬁed by the CONTAM Panel.
7.2.2.1. DON
7.2.2.1.1. Mice
Groups of 10 male and 10 female BALB/c mice were fed diets with 0, 0.25, 0.5, 1.0 and 2.0 mg
DON/kg feed (equivalent to 0, 0.047, 0.094, 0.188 and 0.376 mg/kg bw per day in males and 0,
0.056, 0.112, 0.225 and 0.450 mg/kg bw per day in female) for 14 and 28 days (Wu et al., 2009). All
200 mice grew normally with no gross signs of illness. There was no signiﬁcant difference in initial and
ﬁnal body weight and also in feed intake in the four dose groups compared with controls, except that
the mean feed intake was signiﬁcantly lower in female mice fed 2 mg DON/kg for 28 days (3.13  0.05 g
per day) compared with control females (3.34  0.05 g per day). Using ﬂow cytometry with staining for
leukocyte surface markers, the percentage of CD19+ leukocytes (B cells) in peripheral blood was
decreased in both sexes of BALB/c mice after 14 days of exposure to 1.0 or 2.0 mg DON/kg, whereas
exposure to DON over 28 days did not reduce B cells at any dose compared to the control diet. The
percentage of mononuclear cells in peripheral blood was decreased in female mice fed 1.0 and 2.0 mg
DON/kg after 14 days compared to mice under the control diet. The percentage of CD11b(+)
leukocytes (monocytes) in peripheral blood and total CD11b(+) splenic leukocytes was decreased in
female mice fed 1.0 and 2.0 mg DON/kg only after 28 days compared with control mice. Form these
data, the CONTAM Panel concluded that the female BALB/c mice were more sensitive to DON than the
males and that BALB/c mice adapted to DON exposure because peripheral blood cellular effects of
DON at 14 days disappeared by 28 days with the exception of monocyte changes in females. The
CONTAM Panel considered the haematological disturbances as relevant effects to identify a NOAEL
from this study (see Section 7.2.6 and Table 45).
The CONTAM Panel noted that Kobayashi-Hattori et al. (2011) and Clark et al. (2015) also reported
subacute toxicity of DON in mice but limitations in the design of the studies did not allow to identify
NOAELs and they were not considered further for hazard characterisation.
7.2.2.1.2. Rats
Subacute toxicity in male and female Sprague–Dawley rats (n = 25 rats per dose group and sex)
exposed to 0. 0.25, 0.5 or 1 mg DON/kg bw per day approximately for 9 weeks was reported by
Arnold et al. (1986) from a substudy of a project which also studied reproductive toxicity (Khera et al.,
1984) (see Section 7.2.7.1.1). Body weight gain correlated with reduced feed intake and was
signiﬁcantly reduced in all treated female rats from the lowest dose group of 0.25 mg/kg bw per day
and in male rats at the highest dose group of 1.0 mg DON/kg bw compared with controls. No
haematological disturbances and histopathological lesions were attributed to DON (see Section 7.2.6),
but signiﬁcant decreases in thymidine labelling occurred in the spleens and jejunums of the male rats,
markedly at the highest dose of 1 mg DON/kg bw. No NOAEL could be identiﬁed since adverse effects
were observed at the lowest dose in this study.
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Table 45: The selected subacute, subchronic and chronic studies on adverse effects in rodents orally exposed to DON
Study
duration
Animal
species
Exposure Adverse effects observed
No effect dose
(mg/kg bw per day)
Reference
Subacute 14
and 28 days
Mouse 0, 0.25, 0.5, 1.0, 2.0 mg/kg diet (equivalent to 0.047,
0.094, 0.188, 0.376 mg/kg bw per day (males) and
0.056, 0.112, 0.225, 0.450 mg/kg bw per day (females)
for 14 and 28 days(a)
Haematological disturbances
(14 days)
0.094 (male) Wu et al. (2009)
Decreased feed intake Not identiﬁed
< 0.047
Subacute
9 weeks
Rat 0, 0.25, 0.5, 1 mg/kg bw per day(a) for 9 weeks Decreased DNA synthesis in
spleen and thymus
Decreased feed intake
Decreased body weight gain
Not identiﬁed
< 0.25
Arnold et al. (1986)
Subacute
28 days
Rat 0, 0.5, 1, 2.5, 5 mg/kg bw per day(a) Modiﬁcation of male
reproductive parameters
Decreased feed intake
1 Sprando et al. (2005)
Subchronic
90 days
Rat 20 mg/kg diet, equivalent 1.62 mg/kg bw per day(b) for
90 days
Decrease in feed conversion
efﬁciency
Not identiﬁed
< 1.62
Morissey et al. (1985)
Subchronic
80 days
Rat 0, 0.06, 0.25 mg/kg bw per day for 80 days Decreased body weight 0.06 Li et al. (2011)(e)
Articular lesions Not identiﬁed
< 0.06
Subchronic
26 weeks
Mouse 0, 0.09, 0.53, 1.57 mg/kg bw per day(a) for 26 weeks Decreased body weight 0.09(d) Bondy et al. (2016)
Chronic 2
years
Mouse 0, 0.098, 0.506, 1.126 mg/kg bw per day (males) and 0,
0.115, 0.661, 1.520 mg/kg bw per day (females)(c) for 2
years
Decreased feed intake
Decreased body weight
0.1 Iverson et al. (1995)
NOAEL: no-observed-adverse-effect; LOAEL: lowest-observed-adverse-effect; bw: body weight; n.a.: not applicable
(a): Dose calculated by the authors
(b): Dose calculated by the CONTAM Panel according to EFSA guidance documents (EFSA Scientiﬁc Committee FEEDAP Panel, 2012).
(c): Dose calculated by the CONTAM Panel by using the values reported in the study.
(d): Bench mark dose (BMD)-interval of 0.11–0.90 mg DON/kg bw per day was calculated by the CONTAM Panel (see Section 7.8.3).
(e): Original paper in Chinese, text based on the translation to English.
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Sprando et al. (2005) studied the effect of DON on male reproductive function (see also
Section 7.2.7). Male Sprague–Dawley rats were divided into a control group and four treatment groups
(0.5, 1.0, 2.5 and 5.0 mg DON/kg bw per day) exposed to DON daily for 28 days via gastric
intubation. Four animals were removed from the 5.0 mg/kg dose group prior to tissue collection
because of treatment related effects resulting from DON exposure. These animals were emaciated and
presented with an ocular and/or nasal discharge, rapid respiration, diarrhoea and/or oedema in the
front and rear legs. Both body weight gain and the ﬁnal body weight of animals in the 5.0 mg/kg dose
group and feed consumption in animals in the 2.5 mg/kg and 5.0 mg/kg dose groups were
signiﬁcantly reduced compared to controls. The body weight gain for the animals receiving 5.0 mg/kg
bw DON was decreased during the entire dosing period. The left testis and left epididymis from each
of the experimental and control animals were removed and weighed prior to perfusion ﬁxation. The
other testis and epididymis, the prostate and seminal vesicles were weighed after tissue ﬁxation.
Heart, spleen, liver, kidneys, adrenal and brain were collected and weighed, after perfusion ﬁxation.
Statistically signiﬁcant reduced heart and kidney weights (expressed per gram of brain weight) for
experimental animals were reported. A decrease in heart weight/gram of brain weight occurred in the
5.0 mg/kg dose group while effects on paired kidney weight per gram of brain weight occurred in the
2.5 mg/kg bw and 5.0 mg/kg bw Statistically signiﬁcant differences in organ weights were not
observed when expressed per gram of body weight. The animals were examined in detail for
reproductive effects, in particular on epididymal and seminal vesicle weights (expressed per gram of
body weight and brain weight), prostate weight (expressed per gram of body weight and brain
weight), germ cell degeneration, sperm retention, abnormal nuclear morphology, spermatid numbers,
cauda epididymal sperm numbers expressed per gram cauda epididymis), sperm tail abnormalities,
sperm swimming speed (see Section 7.2.7.1.1), including effects on serum follicle-stimulating hormone
(FSH) and luteinising hormone (LH). Overall, the CONTAM Panel identiﬁed a NOAEL of 1 mg DON/kg
bw per day at which no reduced feed intake was observed (see also Section 7.2.7.1.1).
7.2.2.1.3. Pigs, dogs and mink
Several studies have been conducted in pigs, dogs and mink to evaluate the subacute effects of
dietary levels of DON-contaminated feed on performance and pathology. These studies were not
further used for human hazard characterisation but were used for hazard characterisation of farm and
companion animals and are therefore reported in Section 7.3.
7.2.2.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.2.3. DON-3-glucoside
No data were identiﬁed.
7.2.2.4. Conclusions on subacute toxicity in rodents
Subacute toxicity of DON was characterised also as vomiting, feed refusal, weight loss and
diarrhoea. No data on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were identiﬁed.
7.2.3. Subchronic toxicity in rodents
7.2.3.1. DON
As reported by the SCF (1999), subchronic oral toxicity studies in mice, rats and pigs showed
several effects i.e. reduced feed intake, reduced weight gain, and changed levels in some blood, with
NOAELs ranging from 0.04 to 0.06 mg/kg bw per day from the available data.
7.2.3.1.1. Rats
The SCF (1999) did not consider the 90-day study of Morissey et al. (1985). Puriﬁed DON
incorporated into the diet at a level of 20 mg/kg (equivalent to 1.62 mg/kg bw per day as calculated
by the CONTAM Panel using the data reported by the authors) was provided to male Sprague–Dawley
rats ad libitum for 90 days (10 animals each in control and treated groups). Few clinical signs of
toxicity were observed. Rats in the DON treatment group were less efﬁcient in converting feed into
body mass, but there was no feed refusal. Terminal body weight was reduced in the DON-treatment
group. A few appreciable effects in haematological parameters and differential white blood-cell counts
were observed (Section 7.2.6). In the DON treatment group there were slightly fewer red and white
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cells, less haemoglobin and more segmented neutrophils than in the control group. None of these
changes was statistically signiﬁcant. Slight but not statistically signiﬁcant differences in serum enzyme
activities and substrates were also reported. No adverse effects were observed in the liver
detoxiﬁcation system, the liver/body weight ratio or the activity of glutathione S-transferase. The data
from this study indicated that DON decreased feed conversion efﬁciency in rats at the level of 1.62
mg/kg bw per day. The CONTAM Panel noted that this was a 90-day study but because only one single
dose was used it was not considered further for hazard characterisation.
In another study, two groups of healthy male SPF-grade Wistar rats (24 young rats of 20 days of
age) and adults (24 animals) were divided into a young rat control group, young rat low dose group,
young rat high-dose group, and normal adult rat control group, adult rat low dosage group and adult
rat high-dosage group (Li et al., 201136). Each group contained eight animals. Animals in all
experimental groups were exposed during 80 days to DON via gavage every day with the low dosage
groups given 0.06 mg/kg bw per day, the high dosage groups given 0.25 mg/kg bw per day and the
control groups were given an equivalent volume of saline. Following DON exposure, no abnormalities
were observed in the control groups, but animals in the highest dose groups showed a slight decrease
in body weight and manifested increased sensitivity and irritability in response to external stimuli. In
both young and adult rats, the number of lesions increased and lesions on articular cartilage, but also
bone development adversely affected primarily in the form of developmental abnormalities and growth
stagnation (cessation) in the trabecular bone were more severe as the dose of DON increased. The
CONTAM Panel noted that no NOAEL could be identiﬁed.
In 2016, Bondy et al. (2016) performed a study on p53+/+ and p53+/ male mice exposed to DON
(10 animals per group) via diet during 26 weeks at doses of 0, 1, 5 and 10 mg/kg diet equal to 0,
0.09, 0.53 and 1.57 mg/kg bw per day as calculated by the authors. No toxicologically signiﬁcant
modiﬁcations of haematological and biochemical parameters were observed. A statistically signiﬁcant
decrease of body weight compared with controls was observed at the middle and highest doses (0.53
and 1.57 mg/kg bw per day, respectively) for the p53(+/+) and at the highest dose only for p53(+/)
mice, but not at the lowest dose, indicating a NOAEL for reduced body weight of 0.09 mg/kg diet.
Food consumption was signiﬁcantly lower than controls only at the highest dose and only up to week 2
and weeks 2–3 for the two genotypes, respectively, but higher than the controls later on at weeks
6–12 and 5–22, respectively. Therefore the authors calculated no single dose per concentration group
but a range of possible doses for each group based on these varying intake. No tumours were
observed after the DON treatment (see also Section 7.2.10).
7.2.3.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.3.3. DON-3-glucoside
No data were identiﬁed.
7.2.3.4. Conclusions on subchronic toxicity in rodents
For DON, no NOAEL could be identiﬁed from the new studies available after the assessment of the
SCF in 1999 where NOAELs of 0.04–0.06 mg/kg bw were indentiﬁed. However, the lowest calculated
LOAEL was 0.06 mg DON/kg bw per day for decreased body weight in rats. No data on 3-Ac-DON, 15-
Ac-DON and DON-3-glucoside were identiﬁed.
7.2.4. Chronic toxicity in rodents
7.2.4.1. DON
Only one chronic/carcinogenicity toxicity study was identiﬁed in the literature (see also Table 46). The
design of this study of Iverson et al. (1995) was very similar to the OECD Guidelines 452 (2009).37 Male
and female B6C3F1 mice in groups of 50 (2 mice per cage, male and females separated) were given diets
containing DON mixed with 4% corn oil at a concentrations of 0, 1, 5 and 10 mg/kg diet, equal to 0,
0.115, 0.661 and 1.520 mg/kg bw per day in males and 0, 0.098, 0.506 and 1.126 mg/kg bw per day in
females for 2 years. Exposure was calculated by the CONTAM Panel using the available information on
36 Original paper in Chinese, text based on the translation to English.
37 OECD Guidelines for the Testing of Chemicals, section 4. Test No. 452 (2009): Chronic Toxicity Studies. Available from: http://
www.oecd-ilibrary.org/environment/test-no-452-chronic-toxicity-studies_9789264071209-en
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average body weight and average feed consumption reported by the authors. The purity of DON was
> 95%, and it contained no 3-Ac-DON, 15-Ac-DON or 7-deoxy-DON. It was conﬁrmed that control diet
contained less than 0.1 mg DON/kg diet. Consumption and body weight was based on 2-weekly
weighing. The 2-year survival rates were similar in males (68–84%) and females (72–84%) with deaths
starting after about 1 year in males and after about 1.5 years in females.
There was no signiﬁcant difference in food consumption between the control and the female
treated mice. Male mice at the top two doses consumed signiﬁcantly less than those on the control
diet. Body weight curves differed between males and females. While males reached a saturation by
around 1 year and then the curves declined, females continue to gain weight up to about 1.5 years.
Lower weight gains were associated with increasing amounts of DON in the diet, and both males and
females in the top two doses showed a signiﬁcant decrease in body weight compared to the control
animals. In females there was a decreasing linear dose-related trend in the absolute liver and kidney
weights, but this was not apparent after adjustment for body weight differences.
In male mice, there was a decreasing linear dose-related trend in absolute and adjusted liver
weights, the differences being signiﬁcant for animals receiving the 5 and 10 mg DON/kg diet Adjusted
spleen weights also had a decreasing dose-related trend and testes weights an increasing dose-related
trend, with a statistical difference in weights at the DON dose of 10 mg/kg diet. There was a linear
increasing dose-related trend in serum IgA and IgG levels in female mice but not in males, and a
statistically signiﬁcant increase in IgA concentrations in female mice treated with 10 mg DON/kg in the
diet. Sporadic changes were noted in haematological and clinical chemical end-points, but the authors
considered that these changes were not biologically signiﬁcant.
From this study, the CONTAM Panel calculated a NOAEL of 0.1 mg/kg bw per day for reduced feed
intake and reduced body weight.
7.2.4.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.4.3. DON-3-glucoside
No data were identiﬁed.
7.2.4.4. Conclusions on chronic toxicity in rodents
Only one chronic toxicity study on DON was identiﬁed in the literature. From this study, the
CONTAM Panel identiﬁed a NOAEL of 0.1 mg/kg bw per day for reduced feed intake and reduced body
weight. No data on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were identiﬁed.
7.2.5. Immunotoxicity
Both the SCF (1999) and JECFA (2011) have recognised the effect of DON on immune response. The
SCF (1999) noted that ‘studies with experimental animals demonstrated effects on the immune system,
notably effects on immunoglobulin A (IgA). There are indications for a suppression of humoral and
cellular immunity, resulting in an increased susceptibility for infectious diseases (NOAEL of 0.25 mg/kg
bw per day and a lowest-effect level of 0.22 mg/kg bw per day in studies with male Swiss-Webster and
male Balb/C mice, respectively)’. More recently, JECFA (2011) noted that ‘results from studies on
immunotoxicity in mice and pigs showed that low doses of DON increase IgA levels in the blood. There
were insufﬁcient data with which to establish a threshold for IgA nephropathy. Most mechanistic studies
on immunological end-points in mice and pigs were unsuitable for deriving a NOAEL’.
The ﬁrst section below focuses on studies performed in vivo (ingestion of contaminated diet) on
experimental animals and assessing immune functions. In vitro experiments performed on human
immune cells are also described since they may be relevant for hazard characterisation. Due to the
large database on in vivo and in vitro studies on immunotoxicity of DON, the CONTAM Panel decided
to base the description of the immunotoxicity of DON mainly on review papers (Rotter et al., 1996;
Pestka, 2003, 2010b; Pestka et al., 2004; Antonissen et al 2014; Wu et al., 2014c; Payros et al.,
2016). The evidence database was far smaller for the 3-Ac-DON, 15-Ac-DON and DON-3-glucoside and
for these compounds the CONTAM Panel reviewed all the identiﬁed studies.
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7.2.5.1. In vivo studies on rodents
7.2.5.1.1. DON
As reported by the SCF (1999), studies with experimental animals demonstrated effects on the
immune system notably effects on IgA. In mice, DON induces a dramatic increase in the level of serum
IgA up to 10–15-fold, as well as a marked elevation of serum IgA-immune complex and polymeric IgA
(as reviewed by Pestka, 2003). A concomitant increase in immunoglobulin E (IgE) and decrease in IgG
and IgM levels has also been observed in some experiments (as reviewed by Pestka et al., 2004). In
rodents, the threshold for this effect is 2 mg DON/kg diet, with maximal effects occurring in the 10–25
mg DON/kg range (Rotter et al., 1996). A study on growing pigs fed with a semisynthetic diet
contaminated with 0, 300, 600, and 1,200 lg pure DON/kg diet indicated a statistically signiﬁcant
increase of IgA levels in the serum in animals receiving levels 600 lg/kg feed (Drochner et al., 2004).
An increased IgA level has also been observed in duodenal washing from BALB/c mice orally
administered with 0.5 or 2 mg DON/kg bw for 14 days (Islam et al., 2013 ). What is notable is that in
this experiment as well as in the 2-year study of Iverson et al. (1995) the increased serum IgA level
was seen only in females exposed to the highest dose of DON (1,600 lg/kg bw).
The capacity of DON to expand IgA-secreting cells in mice is mediated by increased cytokine
production, especially IL-6, by macrophages and T cells (as reviewed in Pestka et al., 2004).
In mice, oral exposure to DON also induces at the protein and the mRNA levels a diverse array of
pro-inﬂammatory cytokines and chemokines that can be expressed in spleen, liver, kidney and lung
(as reviewed by Pestka, 2010b). The inﬂammatory response was observed in male B6C3F1 mice after a
single oral exposure of 5 and 25 mg/kg bw DON as early as 2 h after exposure, showing the induction
of mRNAs that encode for proinﬂammatory cytokines (IL-1beta, IL-6, and TNF-alpha), T helper 1
cytokines (interferon-gamma IL-2 and IL-12p40) and T helper 2 cytokines (IL-4 and IL-10). Lower doses
had no marked effect. IL-12p40 mRNA was also induced, but not IL-12p35 mRNA. The effects were
more pronounced in the spleen than in the Peyer patches. No effect was observed at 1 mg DON/kg bw
The same protocol was used to investigate the effect of repeated doses (2, 4 or 7 consecutive days).
Upon exposure to 2 and 5 mg/kg bw DON, the relative abundance of IL-1beta, IL-6, TNF-alpha, IL-12
p35, IL-12p40, IL-2 and IL-10 mRNAs increased with dose frequency, whereas IFN-gamma and IL-4
mRNAs were unaffected. From this study the NOAEL for DON reported by the authors was 0.5 mg/kg
bw per day (review of Pestka and Smolinski, 2005). The CONTAM Panel considered this to be a NOEL
instead of a NOAEL as stated by authors. This DON-induced ‘cytokine storm’ likely contributes to the
shock-like effects observed in acute high-dose toxicity. It might also contribute to impaired appetite and
weight gain observed during chronic DON exposure by directly acting on the central nervous system or
indirectly by interfering with the growth hormone axis (see Section 7.7). Lipopolysaccharide and other
toll-like receptor agonists potentiate DON toxicity in mice (Pestka, 2010b), suggesting that if collateral
damage to gut integrity occurs during DON exposure, resultant bacterial translocation would greatly
magnify trichothecene toxicity.
In one study, where DON was administrated at very low doses (1, 2.5 or 25 lg/kg bw per day for
10 or 30 days) in C57BL/6 mice a low grade inﬂammatory response was observed (Tardivel et al.,
2015). Plasma IL-1b levels increased by 1.59 fold after 10 days administration of 25 lg DON/kg bw
per day but remained unaffected by a 2.5 lg DON/kg bw per day treatment. This lowest dose
increased plasma IL-1b when administered during 30 days (2.1 fold). At the mRNA level, a 10 days
DON administration at 25 lg/kg bw per day resulted in a TNFa and IL-1b upregulation in the liver
(2.9-fold increase). Transcript quantiﬁcation showed that DON administered at 2.5 lg/kg bw per day
during 10 days did not modify TNFa and IL-1b gene expression. Interestingly, when the intoxication
period was extended to 30 days, an upregulation of TNF-a and IL-1b mRNAs expression was detected
in the liver at this dose. Contrary to the liver, TNF-a and IL-1b mRNA expressions remained unchanged
in the spleen. Noticeably, IL-6 mRNA remained undetectable with qPCR. DON exposure at 1 lg/kg bw
per day during 30 days had no effect on systemic IL-1b concentration and did not induce any
signiﬁcant gene expression modulation. The CONTAM Panel noted an increase at the protein and
mRNA levels of inﬂammatory cytokines but no pathological or other adverse effects in these animals.
Therefore the CONTAM Panel did not consider this study further for hazard characterisation.
DON also modulates immune cell numbers and functions. Islam et al. (2013) observed that DON had
different effects on T and B cells, in female BALB/c mice orally administered DON at a dose of 0.5 or
2 mg/kg bw for 14 days. DON treatment increased the population of CD8+ and Foxp3+ regulatory T cells
in the spleen and CD4+ T cells in the mesenteric lymph node, and decreased the population of CD19+
and CD11c+ immune cells in the spleen and mesenteric lymph nodes, and of F4/80+ cells in the spleen.
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The above mentioned effects on the immune response may lead to adverse effects, such as
increased susceptibility to infectious diseases, observed at medium to high doses of DON (8 to 10 mg/kg
bw) as described in detail below.
In mice, DON in drinking water (0.2 mg DON/L (equivalent to 8 mg/kg bw)) reduced the resistance
to oral infection with Salmonella enteritidis by promoting translocation of Salmonella to mesenteric
lymph node (MLN), liver and spleen (Hara-Kudo et al., 1996). Reduction in survival time to death in
mice infected i.v. with Listeria monocytogenes was observed by Tryphonas et al. (1986) and Li et al.
(2005) observed after a single gavage of 10 mg DON/kg bw inability to clear a reovirus from the
intestine, and increased fecal shedding of the virus indicating suppressed host immune response to
viral infection. Exposure to DON increased the intestinal viral load, which could increase inﬂammation
and discomfort to the host during the infection process, decreased the cell-mediated viral clearance by
suppressing the gene expression of IFN-c in Peyer’s patches and enhanced Th2 cytokine expression
prior to and after reovirus infection, which potentiates the IgA and IgG responses to reovirus.
7.2.5.1.2. 3-Ac-DON and 15-Ac-DON
Very few studies have investigated the in vivo effect of 3-Ac-DON and 15-Ac-DON on the immune
response. Kasali et al. (1985) incorporated 2.5, 5, 10 or 20 mg 3-Ac-DON/kg feed (corresponding to
0.36, 0.72, 1.44 and 2.88 mg 3-Ac-DON/kg bw per day, calculated by the CONTAM Panel using default
values of EFSA Scientiﬁc Committee (2012) into a semisynthetic diet and fed male mice for up to 48
days. The humoral immune response assessed using the Jerne plaque assay was not signiﬁcantly
affected after seven or 14 days, but at 21 days, a dose-dependent enhanced response was observed.
The effect of 3-Ac-DON was also studied on mitogen-induced lymphocyte proliferation and antibody
production in male CD-1 mice exposed for 35 days to diets contaminated at 2.5, 5 or 10 mg/kg feed.
Mitogen-induced lymphocyte proliferation and T-cell-independent antibody responses to dinitrophenyl-
ﬁcoll or Escherichia coli were not altered by dietary exposure to 3-Ac-DON. By contrast, the T-cell-
dependent antibody response to sheep red blood cells was increased by dietary exposure to 3-Ac-DON
(Tomar et al., 1987).
Acute oral exposure to 3-Ac-DON and 15-Ac-DON (gavage with 2.5 mg toxin/kg bw) induced a
transient upregulation of TNF-a, IL-1b, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expression in the spleen
of mice (Wu et al., 2014a).
7.2.5.1.3. DON-3-glucoside
Only the above mentioned study of Wu et al. (2014d) investigated the effect of DON-3-glucoside
on the immune response of mice. Mice orally gavaged with 2.5 mg/kg bw DON-3-glucoside failed
eliciting cytokine or chemokine mRNA responses in the spleen.
7.2.5.2. In vitro studies on human cells
7.2.5.2.1. DON
In vitro studies indicated that DON (100–400 ng/mL) inhibits proliferation of B- and T-cell subsets
stimulated by different mitogens (Forsell and Pestka, 1985; Meky et al., 2001). At concentration
ranging from 150 to 1,500 ng/mL, DON was also described to inhibit the activation of different
immune cells. It altered lymphocyte activation, as measured by the expression of CD71 (Johannisson
et al., 1999) and macrophage activation as measured by the expression of CD54, CD14, CD119 and
HLA-DP/DQ/DR (Wache et al., 2009a). It also inhibited the maturation of dendritic cells as measured
by the expressions of CD86, HLA-DR and CCR7, the capacity for endocytosis, and the secretion of
interleukins (IL-10 and IL-12) (Hymery et al., 2006).
DON was also described to up-regulate cytokine production. In Jurkat T cells and in primary human
lymphocytes prestimulated with mitogens, DON (62.5–500 ng/mL) up-regulated the production of IL-2,
IFN-gamma, IL-4, IL-6 and IL-8 (Meky et al., 2001; Pestka et al., 2005; Severino et al., 2006). In
human macrophage cell lines (U937 and HL60), DON (500–1,000 ng/mL) upregulated the production
of TNF-a, IL-6, IL-8, and the macrophage inﬂammatory proteins MIP-1a and MIP-1b (Sugita-Konishi
and Pestka, 2001; Nagashima et al., 2012).
7.2.5.2.2. 3-Ac-DON and 15-Ac-DON
Tomar et al. (1986) investigated the effects of 3-Ac-DON on the in vitro mitogen responses and the
antibody producing ability of human peripheral blood lymphocytes. 3-Ac-DON inhibited the proliferative
response to pokeweed mitogen and concanavalin A at a lower concentration (100 ng/mL) as compared
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to phytohemagglutinin (200 ng/mL). The antibody producing ability was inhibited by 3-Ac-DON
concentrations of greater than 200 ng/mL. Concentrations of 3-Ac-DON greater than 300 ng/mL
produced severe suppression of plaque forming cell response in vitro and reduced the total yield of
lymphocytes without altering cell viability (Tomar et al., 1986).
The previously mentioned studies (Sugita-Konishi and Pestka, 2001; Pestka et al., 2005) also
compared the effect of DON and acetylated forms of DON on the human U937 macrophage and Jurkat
T-cell lines. 3-Ac-DON and 15-Ac-DON were also capable of upregulating or suppressing TNF-alpha,
IL-6, and IL-8 production in U937 macrophages at concentrations similar to that of DON. Similarly
15-Ac-DON at 62.5–500 ng/mL and 3-Ac-DON at 625–5,000 ng/mL also upregulated IL-8 production
in Jurkat T-cell line. In contrast, no effect on IL-2 synthesis was seen at concentrations of 62.5–500
ng/mL 3-Ac-DON and 15-Ac-DON (Pestka et al., 2005).
7.2.5.2.3. DON-3-glucoside
No data were identiﬁed.
7.2.5.3. Conclusions on immunotoxicity
DON has an impact on the immune response. Subchronic studies performed in mice and in farm
animals indicate that the ingestion of this toxin induces an increase in the plasmatic level of IgA. The
DON-induced elevated IgA level was not associated with IgA nephropathy in humans and rodents. In
studies with high doses, DON induced inﬂammation in mice. An increase in TNF-a and IL-1-b was
observed at doses as low as 2.5 lg DON/kg bw per day but this was seen in the absence of an
observed adverse effect.
In the one available 2-year study the increase of IgA was observed in female mice at the highest
dose only, and inﬂammatory responses were not investigated. The effects on the immune response
(doses 8–10 mg/kg bw) lead to an increased susceptibility to infectious diseases.
The data concerning the effect of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside on the immune
response were scarce and none of them investigated effects on IgA levels. As far as the inﬂammatory
response is concerned, one study observed a lower expression of genes encoding for inﬂammatory
cytokines when compared to DON. The effect of DON-3-glucoside on the immune response was
reported in only one study and no induction of inﬂammatory cytokine was observed.
The CONTAM Panel noted that no suitable dose–response data were identiﬁed on immunological
adverse effects, including increase susceptibility to infection in humans or animals, relevant for risk
assessment.
7.2.6. Haematotoxicity and myelotoxicity
Haematotoxicity and myelotoxicity of DON, 3-Ac-DON, 15-Ac-DON and/or DON-3-glucoside were
not explicitly considered in the previous risk assessment of the SCF (1999). However, the CONTAM
Panel noted that haematological effects have been reported in several in vivo and in vitro studies since
then and therefore these are summarised below together with the few older reports.
7.2.6.1. In vivo studies
7.2.6.1.1. DON
Groups of 10 female and 10 male BALB/c mice were fed 0, 0.25, 0.5, 1.0 and 2.0 mg DON/kg feed
for 14 and 28 days (Wu et al., 2009). Haematological disturbances appeared after 14 days of exposure
at the two highest doses in both sexes, but decreased in male mice after 28 days (see details in
Section 7.2.2). From this study, the CONTAM Panel identiﬁed the NOAEL of 0.094 mg DON/kg bw per
day for haematological disturbances in mice (see also Table 45).
The CONTAM Panel noted that a study of Arnold et al. (1986) on male and female Sprague–Dawley
rats (see details in Section 7.2.2) reported that in the haematological assessment no dose-related
haematological disturbances were observed. In addition, the CONTAM Panel noted a more recent
study of Chatopadhyay et al. (2011) on haematological effects in mice but did not consider them
further in this opinion due to imprecisely reported data. Filimon et al. (2012) observed haematological
effects in male Sprague–Dawley rats after the administration of DON with feed. Since the unit of the
DON administrated to the animals was not reported precisely enough also this study was not
considered for hazard characterisation in this opinion.
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Morissey et al. (1985) conducted a single dose study (1.62 mg DON/kg bw per day ad libitum) on
male Sprague–Dawley rats for 90 days in which some haematological disturbances are described (see
details in Section 7.2.3 and Table 45).
In the 2-year study by Iverson et al. (1995), described in detail in Section 7.2.4.1, the mean RBC
and eosinophil values were signiﬁcantly higher in males at the highest dose (0.130 mg DON/kg bw per
day) than in controls, and there was some evidence for a linear increasing dose-related trend.
7.2.6.1.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.6.1.3. DON-3-glucoside
No data were identiﬁed.
7.2.6.2. In vitro studies
7.2.6.2.1. DON
Several in vitro studies have been published over the years. DON has been tested on human and
rat haematopoietic progenitors and circulating blood cells and the effect has been compared to those
of T-2 toxin, HT-2 toxin and DAS on the same cells (Rizzo et al., 1992; Lautraite et al., 1997; Rio et al.,
1997; Froquet et al., 2001). No severe myelotoxicity or cytotoxicity of DON on circulating blood was
detected. A review of Parent-Massin (2004) on in vitro studies concluded that DON appeared to be the
least haematotoxic and myelotoxic toxin of the trichothecenes and the CONTAM Panel adopted this
conclusion for the available in vitro studies.
7.2.6.2.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.6.2.3. DON-3-glucoside
No data were identiﬁed.
7.2.6.3. Conclusions on haematotoxicity and myelotoxicity
The CONTAM Panel noted that no neutropenia, agranulocytosis or aplastic anaemia have been
described in in vivo studies conﬁrming the low toxicity of DON described in vitro studies. The CONTAM
Panel noted that haematotoxicity and myelotoxicity DON is less compared with that from the other
trichothecenes, such as T-2 toxin, HT-2 toxin and nivalenol, which are known to induce haematological
effects. No data on haematotoxicity or myelotoxicity of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
were identiﬁed.
7.2.7. Developmental and reproductive toxicity
7.2.7.1. DON
The conclusion of the SCF (1999) on the reproductive toxicity and teratogenicity of DON was that
‘Oral studies in mice, rats and rabbits did not show teratogenic effects. Embryotoxic effects were
observed in mice and rabbits at maternally toxic doses, i.e. 1 mg/kg bw Increase in postnatal mortality
was observed in mice with a NOAEL = 0.375 mg/kg bw (Khera et al., 1984). Absence and fusions of
ribs were also noted in mice at the maternally toxic doses; the NOAEL was 0.5 mg/kg bw (Khera et al.,
1982). In one study with rats a slight decrease in fertility was observed at 2 mg/kg bw, the only dose
tested, whereas in another rat study doses up to 1 mg/kg bw did not show any effect (Khera et al.,
1982, 1984, 1986; Eriksen and Alexander, 1998; Baars et al., 1999)’.38
‘Two studies exposing swine to DON in the diet during gestation are reported. Gilts fed diets
containing 0.1-4.8 mg DON/kg feed did not exhibit overt maternal toxicity or decreased feed
consumption, but 1-2 mg/kg feed (0.03-0.07 mg DON/kg bw per day) caused reduced weight gain. No
effect in number of offspring or survival or any deformities was observed. No effect of DON on
reproduction was observed in doses lower than those leading to reduced weight gain (1-2 mg/kg feed)
(Bergsj€o et al., 1992, 1993a,b; Eriksen and Alexander, 1998; Baars et al., 1999)’.38
38 In this opinion the reference of ‘Eriksen and Alexander, 1998’ is cited as NCM, 1998.
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The JECFA assessment of DON (FAO/WHO, 2001) considered the studies of Khera et al. (1982,
1984, 1986), Friend et al. (1983, 1986a,b), Morrissey (1984), Morrissey and Vesonder (1985), Tutel’ian
et al. (1991), Bergsj€o et al. (1993a,b) and Sprando et al. (1999). The conclusion was that
‘deoxynivalenol was teratogenic but not maternally toxic when given to pregnant mice at 5 mg/kg bw
per day by gavage over a short critical period (days 8–11) of gestation, but not when given at
2.5 mg/kg bw per day. When deoxynivalenol was administered in the feed, the NOAEL for maternal
toxicity and fetotoxicity was 0.38 mg/kg bw per day’.
Key studies considered by these assessments and the more recent studies of Sprando et al. (2005),
Collins et al. (2006) and Hou et al. (2014) are described below. See also Table 46.
7.2.7.1.1. Reproductive toxicity
In the study of Khera et al. (1984), weanling male and female F0 mice were fed diets containing
DON at concentrations that resulted in doses of 0 or 2 mg/kg bw per day (experiment 1) or 0, 0.38,
0.75 or 1.5 mg/kg bw per day (experiment 2). After 30 days the mice were allowed to mate. The F1a
progeny of 10 dams from the control group and that from the 1.5 mg/kg bw group were cross-
fostered at birth. The F0 mice were then rebred to produce F1b litters and the fetuses examined for
malformations. The result of the DON treatment was a reduction in the following parameters: feed and
water intakes and body weights of male and female F0 mice, numbers of live pups and postnatal
survivors, postnatal body weight of F1a progeny, number of live fetuses, and mean weight of F1b
fetuses. Statistically signiﬁcant effects on the lowering of the number of postnatal survivors were seen
at doses of 0.75 mg/kg bw per day and above. The fertility of male and female F0 mice was not
adversely affected and the F1b generation had no major malformations. Cross-fostering of the
offspring of control dams and those at 1.5 mg DON/kg bw per day adversely affected postnatal
survival and body weight showing that these were affected by prenatal exposure as well as by
combined pre- and postnatal exposure. On the basis of postnatal survival, the CONTAM
Panel concluded that the NOAEL from this experiment is 0.38 mg DON/kg bw per day.
When groups of 15 male and 15 female Sprague–Dawley rats were fed diets in the study of Khera
et al. (1984) that resulted in doses of 0, 0.25, 0.5 and 1 mg DON/kg bw per day for 6 weeks before
and throughout pregnancy, fertility was not impaired. The fetal viscera were normal, although some
dilation of the renal pelvis and urinary bladder, of unknown biological signiﬁcance, was noted at all
dose levels. The CONTAM Panel considered that the NOAEL for this experiment was 1 mg DON/kg bw
per day.
The CONTAM Panel noted that Morrissey and Vesonder (1985) reported an adverse effect of DON
on the fertility, pregnancy and postnatal development of Sprague–Dawley rats (puriﬁed DON at a
concentration of 20 mg/kg (approximately 2 mg/kg bw)). Treatment was for 60 days (males) or 15
days (females) before breeding, and female rats then continued on the same diet. The CONTAM
Panel also noted that Sprando et al. (1999) reported an adverse effect of DON in a study of testicular
morphology and testicular and epididymal sperm counts in three strains of mice (diet containing 10 mg
DON/kg feed, equivalent to 2 mg DON/kg bw per day, for 90 days). However, as these studies were
single dose studies they were not considered further for hazard characterisation.
Sprando et al. (2005) characterised the effect of DON on selected male reproductive endpoints in
the Sprague–Dawley rat (for details see Section 7.2.2.1). Groups were exposed daily to DON for 28
days via gastric intubation at doses of 0.5, 1.0, 2.5 and 5.0 mg/kg bw There were signiﬁcantly
reduced epididymal (right and left) and seminal vesicle weights (expressed per gram of bw and brain
weight) in animals treated with 2.5 and 5 mg/kg bw. Sperm swimming speed was increased only in
the 2.5 mg/kg bw dose group. In the 2.5 mg/kg and 5.0 mg/kg bw dose groups there was an increase
in germ cell degeneration, sperm retention and abnormal nuclear morphology. As treatment-related
effects were not seen in the 1.0 mg/kg bw group, the CONTAM Panel concluded that a NOAEL of 1
mg/kg bw per day can be identiﬁed.
Hou et al. (2014) investigated the effects of a diet co-contaminated with DON, zearalenone and
aﬂatoxin on oocyte quality in ICR mice. Since the extent of the contribution of DON to the effect was
unknown, the CONTAM Panel did not consider this study further hazard characterisation.
7.2.7.1.2 Developmental toxicity
Groups of 15–19 pregnant Swiss-Webster mice were administered DON by oesophageal intubation
daily on gestation days 8–11 (Khera et al., 1982). Two experiments were carried out, one at high
doses (0, 5.0, 10.0 and 15.0 mg/kg bw per day) and one at lower doses (0, 0.5, 1.0 and 2.5 mg/kg
bw per day). On the 19th day of pregnancy, animals were sacriﬁced and examined. There was a
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progressive decrease in body weight gain in the dams at doses of 5.0 mg/kg bw and higher. At the
10.0 and 15.0 mg/kg bw doses, the incidence of resorptions was 100%. At the 5.0 mg/kg bw dose,
the incidence of resorptions was 80% and there was a reduced number of live fetuses per dam and
reduced fetal weight. The resorptions at the dose of 2.5 mg/kg bw were lower (9%) but still
statistically signiﬁcant. At the dose of 5 mg/kg bw there were some external and visceral anomalies
including exencephaly, syndactyly and hypoplastic cerebellum. Lower levels of external and visceral
anomalies were also observed in the 1.0 and 2.5 mg/kg bw dose groups. A number of skeletal
malformations were present in the 1.0, 2.5 and 5.0 mg/kg bw dose groups and these increased
with dose. They included lumbar vertebrae with fused arches or partly absent centra, absent or fused
ribs, missing, fused or scrambled sternebrae. There were no treatment-related pathological changes in
fetal tissues at any dose of DON. The CONTAM Panel concluded that the NOAEL in this study was
0.5 mg/kg bw per day.
In order to study the teratogenic potential of DON, feed containing DON was fed ad libitum to
groups of female Fischer 344 rats during the entire course of pregnancy (Morrissey, 1984). The
concentrations of DON were 0, 0.5, 2.0 and 5.0 mg/kg, equivalent to 0, 0.06, 0.24 and 0.6 mg/kg bw
per day. No signs of toxicity or statistically signiﬁcant differences in feed consumption were observed
in the treated animals. After removal of the uterus and pups the carcass weights of dams receiving the
2.0 and 5.0 mg/kg concentrations were signiﬁcantly lower than those of the control animals. No
signiﬁcant differences were observed between the groups on markers of the outcome of pregnancy
and fetal development, such as the number of pregnant animals per group, the number of male and
female pups per pregnant animal, male and female pup weights, the number of litters with early
resorption, the percentage of pre-implantation or post-implantation losses and the number of corpora
lutea. No statistically signiﬁcant effect of DON treatment on visceral morphology or skeletal
development was found, although some malformations and aberrations were observed. Neither dams
nor pups showed any signiﬁcant histopathological changes. The CONTAM Panel concluded that the
NOAEL for developmental toxicity from this study was 0.6 mg/kg bw per day.
A teratology study of DON was carried out in adult female New Zealand white rabbits by Khera et al.
(1986). On days 0–30 of gestation, the animals (groups of 13–15) were fed diets containing DON at
concentrations of 0, 7.5, 15, 30, 60, 120 or 240 mg/kg, equivalent to 0, 0.3, 0.6, 1.0, 1.6, 1.8 and 2.0
mg/kg bw per day. A pair-fed group was also included. Maternal body weight and feed consumption
were signiﬁcantly below control levels in groups receiving 1.0, 1.6, 1.8 and 2.0 mg/kg bw per day of
DON in their diet. Resorptions were increased to 100% at doses of 1.8 and 2.0 mg DON/kg diet and
fetal weight was decreased at doses of 1.0 and 1.6 mg/kg bw and the pair-fed group. No teratogenic
effects were observed in the treated animals. As the lower dose of 0.6 mg/kg bw per day was not
maternotoxic or fetotoxic, this dose was considered by the CONTAM Panel as the NOAEL for this study.
Tutel’Yan et al. (1991)39 studied female Wistar rats for fertility and their offspring for developmental
toxicity of DON (purity not reported). The CONTAM Panel decided not to consider this study further
because of substantial limitations in design and analysis (feed consumption not reported, small number
of dams selected, litter effects and intralitter correlation not considered and the numbers of fetuses
and dams not reported for the various endpoints tested).
Collins et al. (2006) studied the effect of DON on fetal development in pregnant Charles River
Sprague–Dawley rats, who were gavaged daily on gestation days 6–19, in groups of 24, with doses of
DON of 0, 0.5, 1.0, 2.5 and 5.0 mg/kg bw. Reproductive and developmental parameters were measured
at caesarean section on gestation day 20. A dose-related increase in salivation was observed in the
number of females with excessive salivation, which was statistically signiﬁcant at doses of 2.5 and 5
mg/kg bw. Feed consumption, body weight gain and gravid uterine weight were signiﬁcantly reduced in
the group dosed with 5 mg/kg bw. Much smaller effects on these parameters were seen at 2.5 mg/kg
bw and no effects were observed at doses below this. Liver-to-body weight ratios increased dose
dependently in all treated groups, and the increases were signiﬁcant at doses of 1, 2.5 and 5 mg/kg bw
DON delayed fetal development. At 2.5 and 5 mg/kg bw, fetal body weight and crown-rump length
were signiﬁcantly reduced and the incidence of runts was increased (reaching signiﬁcance at 5 mg/kg
bw). DON at 5 mg/kg bw per day signiﬁcantly increased the average number of fetuses per litter with at
least one, at least two or at least three sternebral variations. In addition, the average number of fetuses
with at least one sternebral variation was signiﬁcantly increased at 2.5 mg/kg bw. At 5 mg/kg bw, there
were signiﬁcant decreases in skeletal ossiﬁcation in centra, dorsal arches, metacarpals, and metatarsals
which may be related to maternal toxicity. A decrease was also seen in the average number of ossiﬁed
39 Original paper in Russian, text based on the translation to English.
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vertebrae per fetus at 2.5 and 5 mg/kg bw per day which the authors suggested may be related to
maternal toxicity. The authors proposed that, based on anomalous sternebrae development, DON could
be considered a teratogen at 5 mg/kg bw per day, and the CONTAM Panel concluded that the NOAEL
for this effect was 1 mg/kg bw per day. No adverse developmental effects were observed at 0.5 or 1
mg/kg bw per day, and the CONTAM Panel concluded that a NOAEL for fetal toxicity of 1 mg/kg bw and
a NOAEL for maternal toxicity of 0.5 mg/kg bw could be identiﬁed from this study.
In conclusion, the most critical effect, already noted by the SCF (1999), was the increase in
postnatal mortality in mice treated orally with DON, with a NOAEL of 0.38 mg/kg bw per day. The new
studies since that report, do not add further to this conclusion.
7.2.7.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed for developmental or reproductive toxicity.
7.2.7.3. DON-3-glucoside
No data were identiﬁed for developmental or reproductive toxicity.
7.2.7.4. Conclusions
DON exhibits both developmental and reproductive toxicological effects. Based on studies of rats
treated orally with DON, the CONTAM Panel concluded that the NOAEL was 1.0 mg/kg bw per day for
reproductive endpoints, 1.0 mg/kg bw per day for fetal toxicity and 0.5 mg/kg bw per day for
maternal toxicity. Therefore, the CONTAM Panel agreed with the SCF (1999) that the most critical
effect is the increase in postnatal mortality in pups from mice treated orally with DON, with a NOAEL
of 0.38 mg/kg bw per day. No data were identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
Table 46: Developmental and reproductive toxicity studies on DON in experimental animals
Species
n per
group
Dose
(mg/kg bw
per day)
Route Effect
NOAEL
(mg/kg
bw per day)
Reference
Reproductive toxicology
Mouse, Swiss
Webster,
weanling
7–20 0, 0.38, 0.75,
1.5, 2.0
Diet Postnatal
survival
0.38 Khera et al.
(1984)
Rat, Sprague–
Dawley, male/
female
15/15 0, 0.25, 0.5, 1.0 Diet Embryotoxicity/
maternal toxicity
1.0 Khera et al.
(1984)
Rat, Sprague–
Dawley, male/
female
10 m,
25 f
2.0 Diet Reduced fertility 2.0 (LOAEL) Morrissey and
Vesonder
(1985)
Mouse,
B6C3F1 IL-
6KO and WT
3–6 2.0 Diet Body weight,
epididymal
weight
2.0 (LOAEL) Sprando et al.
(1999)
Rat, Sprague–
Dawley, male
15–16 0, 0.5, 1.0, 2.5,
5.0
Gavage, 28 days Reproductive
endpoints
1.0 Sprando et al.
(2005)
Developmental toxicity
Mouse, Swiss
Webster,
pregnant
15–19 0, 0.5, 1.0, 2.5,
5.0, 10.0, 15.0
Gavage,
gestation days
8–11
Skeletal
abnormalities
0.5 Khera et al.
(1982)
Rat, Fischer,
female
22–23 0, 0.06,0.24, 0.6 Diet No teratogenic/
reproductive
effects
0.6 Morrissey et al.
(1984)
Rabbit, New
Zealand,
female
13–15 0, 0.3, 0.6, 1.0,
1.6, 1.8, 2.0
Diet Maternal and
fetal weight
0.6 Khera et al.
(1986)
Rat, Sprague–
Dawley,
pregnant
24 0.5, 1.0, 2.5, 5.0 Gavage,
gestation day
6–19
Fetal toxicity
Maternal toxicity
1.0
0.5
Collins et al.
(2006)
n: number; bw: body weight; LOAEL: lowest-observed-adverse-effect level; m: male; f: female.
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7.2.8. Neurotoxicity
No neurotoxic effects suitable for hazard characterisation were identiﬁed by the SCF (1999, 2002)
or JECFA (FAO/WHO, 2001). The conclusion of JECFA (FAO/WHO, 2001) was that decreased food
consumption and emesis observed after administration of DON may be linked to increased central
serotoninergic activity.
7.2.8.1. DON
Al-Hazmi and Waggas (2013) investigated the neurophysiological and behavioural effects of orally
administered DON in mice but because of some inconsistencies in the reported doses and results, the
CONTAM Panel did not consider this study further. Several other studies with rats, cockerels and pigs
have demonstrated alterations in biogenic amine levels after treatment with DON, but no
neurotoxicological effects were reported (Fitzpatrick et al., 1988a,b; Prelusky et al., 1992; Prelusky,
1993). In a study with adult male Long Evans rats, Ossenkopp et al. (1994) demonstrated that when
DON was administered (i.p. 0.125 mg/kg bw) after treatment of the rats with a saccharin solution, a
taste aversion to the latter developed, and that this was mediated by the area postrema.
7.2.8.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.8.3. DON-3-glucoside
No data were identiﬁed.
7.2.8.4. Conclusions
The data on neurotoxicological effects of DON were limited. The CONTAM Panel noted that no
dose–response data suitable for hazard characterisation were available. No data on neurological effects
were identiﬁed for 3-Ac-DON, 15-Ac-DON or DON-3-glucoside. Based on the available studies, a link
between the neurotoxicity and mode of action could not be identiﬁed by the CONTAM Panel.
7.2.9. Genotoxicity
The assessment of the genotoxicity of DON by the SCF in 1999 and 2002 concluded that DON did
not show mutagenic activity in bacteria and mammalian cells, or cause unscheduled DNA synthesis
(UDS) in rat primary hepatocytes. DON enhanced cell transformation in mouse embryo cells in vitro,
and induced clastogenic effects and inhibited gap-junctional intercellular communication in Chinese
hamster V79 cells. It was noted that DON inhibited protein synthesis in Chinese hamster ovary cells
in vitro in the same dose range as that inducing clastogenic effects (as cited in SCF 1999, 2002). FAO/
WHO (2001) concluded that DON was not mutagenic in bacteria, but suggested that DON is genotoxic
as chromosomal aberrations were observed both in vitro and in vivo. However, the overall signiﬁcance
of the results observed in the only study conducted in vivo was considered to be equivocal as most of
the chromosome aberration studies consisted of gaps.
Studies whose results formed the basis of the JECFA (FAO/WHO, 2001) and SCF (1999)
assessments are summarised below together with the more recent studies identiﬁed since then of Li
and Guo (2001), Hsia et al. (2004), Lin and Sun (2004), Bony et al. (2006), Frankic et al. (2006,
2008), Zhang et al. (2009), Bensassi et al (2009), Awad et al. (2012b, 2014), Takakura et al. (2014),
Yang et al. (2014) and Abdel-Wahhab et al. (2015).
The in vitro and in vivo studies identiﬁed by the CONTAM Panel are described below and results
also shown in Table 47. Additionally, in vitro and in vivo genotoxicity studies of DON have been carried
out by Le Hegarat et al. (2014). These were conducted according to the EFSA Scientiﬁc opinion on
genotoxicity testing strategies applicable to food and feed safety assessment (EFSA Scientiﬁc
Committee, 2011) in the context of a grant agreement between EFSA and the authors. The results are
not published in a peer-reviewed journal but as an EFSA external report.
7.2.9.1. In vitro studies
7.2.9.1.1. DON
Wehner et al. (1978) showed that DON was inactive in the Salmonella Typhimurium bacterial
mutation assay (Ames test) using strains TA98, TA100, TA1535 and TA1537 (0.4–400 lg DON/plate)
with and without metabolic activation with an induced rat liver S9 fraction. DON was also subsequently
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tested by Knasm€uller et al. (1997) using S. Typhimurium strains TA98 and TA100 (0.7–500 lg
DON/plate) and in the SOS-chromotests with E. coli strain PQ37 (5–500 lg DON per assay) with and
without S9, and it did not induce mutations. Negative results were observed by Takakura et al. (2014)
in the Ames test performed on S. Typhimurium strains TA98, TA100 and TA102 (0.03–500 lg
DON/plate), both with and without Aroclor 1,254-induced rat liver S9.
DON gave negative results in differential DNA repair assays with E. coli K-12 strains (343/753,
uvrB/recA and 343/765, uvr+/rec+) at concentrations ranging from 0.7 to 500 lg/mL (Knasm€uller
et al., 1997).
Rogers and Heroux-Metcalf (1983) reported that DON, at concentrations up to 3 lg/mL, had no
mutagenic activity to V79 cells at the hypoxanthine-guanine phosphoribosyl transferase (HGPRT) locus,
with or without hepatocyte-mediated activation. The number of 6-thioguanine-resistant mutants at
marginally cytotoxic levels of 6 and 8 lg/mL was not signiﬁcantly increased.
Knasm€uller et al. (1997) observed a dose–response relationship for the effect of DON (0.001–10.0
lg/mL) on chromosome aberrations (CAs) in primary cultures of rat hepatocytes. The CA numbers
increased at the lower dose levels studied and the maximal effect on CAs (which was statistically
signiﬁcant) was seen at 1 lg/mL at which the CA rate was approximately sixfold over the background
level. CAs declined at the highest concentration evaluated which was 10.0 lg/mL, probably due to
inhibition of cell division. The mitotic index decreased at a concentration of 10 lg DON/mL, and DON
showed a pronounced cytotoxic effect at a concentration of 100 lg/mL. Micronuclei were also studied
in the same cells by Knasm€uller et al. (1997). A signiﬁcant increase was seen at a DON concentration
of 0.01 lg/mL. However, this positive result was not considered to be biologically relevant as no clear
dose–response relationship was seen and micronuclei levels declined at DON concentrations above
0.1 lg/mL.
Hsia et al. (2004) reported the induction of CAs in Chinese hamster V79 cells by HPLC-puriﬁed
fractions with the retention time of DON (concentration 300 ng/mL) derived from extracts of wheat
ﬂour, barley and corn from Linxian, China. This conﬁrmed earlier results with HPLC-puriﬁed fractions
which had the retention time of DON from a corn extract from Linxian (Hsia et al., 1988). The
CONTAM Panel could not use the results from either of these studies for risk assessment as the
number of samples was insufﬁcient, and also the purity of DON in the HPLC fractions was not clear.
Pure DON was also reported to produce CAs in V79 cells at concentrations up to 1 lg/mL although
details of the experiment were not completely reported (Hsia et al., 1988).
Takakura et al. (2014) carried out the micronucleus test in accordance with the Organisation for
Economic Co-operation and Development (OECD) Guideline 487 (with some modiﬁcations) in two
human cell lines, the lymphoblastoid TK6 and the hepatoma HepaRG cells. At concentrations below
12.5 lM DON failed to induce micronuclei formation in TK6 cells after 3 h of treatment with or without
human and rat liver S9. Positive results were seen at 25 lΜ (-S9) and at 12.5 and 25 lΜ (+ human
S9). However, DON was more than 60% cytotoxic at a concentration of 25 lM. After 24 h of
treatment, DON signiﬁcantly increased micronuclei formation at 1.6 and 3.2 lM compared to the
negative control. However, these concentrations of DON produced more than 60% cytotoxicity, a
higher level of cytotoxicity than that recommended by OECD Guideline 487. DON did not induce
micronuclei formation in metabolically competent HepaRG cells.
The induction of oxidative stress and genotoxicity by DON was studied in human peripheral
lymphocytes by Yang et al. (2014). Cell viability was tested and DNA damage was determined using the
Comet assay. Other assays were for sister chromatid exchange (SCE), micronucleus (MN) formation,
ROS generation, lipid peroxidation, levels of GSH and the amounts of 8-OHdG in DNA. Human
lymphocytes were from both male and female volunteers. DON reduced the viability of lymphocytes of
both sexes, treated at concentrations of 0, 6.25, 12.5, 25, 50, 100, 250 and 500 ng/mL DON for 6, 12
and 24 h, in a concentration- and time-dependent manner. With concentrations 0, 6.25, 12.5, 25 and
50 ng/mL DON for 6, 12 and 24 h, DNA damage (tail length, tail DNA percentage and tail moment), MN
and SCE were signiﬁcantly increased, compared with controls at all DON concentrations and times of
treatment. The effects increased with higher concentrations and times of incubation. Similar responses
were seen for increases of lipid peroxidation, ROS generation and 8-OHdG in DNA. GSH levels were
reduced and GSSG levels were increased. In addition, DON was shown to enhance mRNA or protein
expressions of DNA repair genes HOGG1, XRCC1 and haem oxygenase 1 at 6 h, the effect then
decreased with time. Damage to the cell membrane was also observed, which increased with dose of
DON and time of incubation. The CONTAM Panel considered that the genotoxicity might be related to
oxidative stress.
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In the study of Li and Guo (2001),36 hepatocytes from male SD rats were incubated with DON
(0.01 to 1 lg/mL) for 2 h and the cells were analysed using single cell gel electrophoresis (Comet
assay). DNA damage, assessed from the Comet tail, was observed at all the studied concentrations of
DON and increased with DON concentration.
Lin and Sun (2004)44 incubated Vero cells with DON (1, 5 and 10 lmol for 4 and 16 h, respectively
and analysed the cells using the Comet assay. With increase of dose and time, the damage in the cells
increased. A short-term incubation time (4 h) mainly caused the increase of the number of DNA
fragments, while a long-term incubation (16 h) mainly caused the smaller size of DNA fragments. Cells
that had been treated with 10 lmol DON were re-incubated for 15, 30, 60 and 120 min to test the
DNA repair. Cells began to repair after removing DON and being re-incubated. If the cells were
incubated with DON for 4 h, it took less time to start repair (< 15 min) than if the cells were incubated
with DON for 16 h. Repair was complete after 120 mins.
The DNA damaging potential of DON was assessed in the concentration range 0.01–0.5 lM in
undifferentiated and differentiated Caco-2 cells using the alkaline Comet assay (Bony et al., 2006).
Dividing cells were found to be more sensitive to DON than differentiated cells and the lowest 10%
inhibitory concentration (IC10) (0.5 lM) obtained for dividing cells exposed for 72 h was used as the
highest working concentration in the genotoxicity study. Results were assessed after 24 or 72 h of
exposure. Both differentiated and dividing cells responded with a concentration-dependent relationship
to DON in terms of DNA damage in the 0.01–0.5 lM range.
Bensassi et al. (2009) investigated the pathway of DON-induced apoptosis in human colon
carcinoma cells (HT-29) (Section 7.7.1.3). Cells treated with DON underwent a p53 and caspase-
dependent apoptosis. DNA damage was measured by the alkaline Comet assay, and increased in a
time-dependent manner in HT-29 cells after treatment with DON (10 lM) for 2, 4, 8, 12, 16 and 24 h.
No signiﬁcant generation of ROS was observed in the cells and the authors concluded that the DNA
damage was not a consequence of oxidative injury.
The aim of the study of Zhang et al. (2009) was to assess the role of oxidative stress in DON-
induced DNA damage, using human hepatoma HepG2 cells. Exposure of the cells to DON caused a
signiﬁcant increase of DNA migration in the comet assay at concentrations of 3.75–30 lM, which
suggests that DON caused DNA strand breaks. It was found that DNA migration was dramatically
decreased after pretreatment with the antioxidant hydroxytyrosol (HT). A signiﬁcant increase in the
level of ROS, assessed using 2,7-dichloroﬂuorescein diacetate (DCFH-DA) assay, was observed in
HepG2 cells at a concentration of DON of 60 lM. Conﬁrmation of the involvement of lipid peroxidation
in the DNA damage was obtained by immunoperoxidase staining for 8-hydroxydeoxyguanosine
(8-OHdG) and by measuring levels of thiobarbituric acid-reactive substances (TBARS). Signiﬁcant
increases in these markers were observed at DON concentrations of 60 lM and 15 lM, respectively.
The authors concluded that these results indicate that the DNA damage induced by DON in HepG2
cells is probably related to the oxidative stress. Liu et al. (2016, see supplementary information)
conﬁrmed the DNA damaging effects of DON at a concentration of 3 lg/mL, and of the protecting
effect of HT, using the same methodology as Zhang et al. (2009).
In the investigation of Takakura et al. (2014), the Comet assay was performed on TK6 and HepaRG
cells treated with DON for 24 h (DON concentrations of 0–1.5 lM and 0–35 lM, respectively). No DNA
damage was induced by DON, whereas positive controls, methyl methanesulfonate (MMS) and
cyclophosphamide (CPA), clearly induced DNA migration in these cells. DON was cytotoxic to both cell
lines, although proliferative TK6 cells were more sensitive than quiescent HepaRG cells.
Using the Comet assay, Le Hegarat et al. (2014) investigated the extent of DNA damage induced
by DON in TK6 cells. The assay was carried out with or without the presence of formamidopyrimidine
DNA glycosylase (fpg). Fpg recognises 7,8-dihydro-8-oxoguanine (8-oxoguanine), 2,6-diamino-4-
hydroxy-5-formamidopyrimidine (Fapy-Gua), 4,6-diamino-5-formamido-pyrimidine (Fapy-Ade) and to a
smaller extent 7,8-dihydro-8-oxoadenine (8-oxoadenine) as well as apurinic/apyrimidinic sites. The
authors reported that no signiﬁcant increase of DNA migration in TK6 cells was induced by DON,
1.56–25 lg/mL after 3 h or 0.25–1.5 lg/mL after 24 h incubation with or without fpg. TK6 cells were
also pretreated with buthionine sulfoximine (BSO) to deplete glutathione 1 day before treatment with
DON. The Comet assay carried out after 24 h exposure was reported not to show any increase in DNA
migration with or without fpg. The antioxidant NAC was reported not have any signiﬁcant effect on the
Comet assay responses after DON treatment in TK6 cells. The CONTAM Panel considered that the
study was inconclusive, because of lack of some toxicity data, variations in tail DNA intensity in control
samples, and the observed effects of BSO and NAC on the oxidation status of the cells.
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Overall, based on the available evidence, the CONTAM Panel considered that DON is not mutagenic
in bacteria, and is negative in one study of mutagenicity in mammalian cells. In studies on
chromosomal effects and DNA damage in mammalian cells, several positive results have been
observed. DON is cytotoxic at high doses in some of these tests and increases in oxidative stress have
also been observed. The CONTAM Panel considered that DON is genotoxic in vitro, and that the effects
may be related to oxidative stress.
7.2.9.1.2. 3-Ac-DON and 15-Ac-DON
Wehner et al. (1978) showed that 3-Ac-DON was inactive in the S. Typhimurium bacterial mutation
assay (Ames test) using strains TA98, TA100, TA1535 and TA1537 (0.4–400 lg 3-Ac-DON/plate), with
and without metabolic activation, with an induced rat liver S9 fraction. Hsia et al. (1988) showed that
3-Ac-DON induced chromosome aberrations in Chinese hamster V79 cells with a maximum effect at a
concentration of 1 lg/mL. The CONTAM Panel did not use the data from this study for risk assessment
as the publication provided only limited experimental details, no information on cytotoxicity and no
statistical assessment of results. No data were identiﬁed for 15-Ac-DON.
7.2.9.1.3. DON-3-glucoside
No data were identiﬁed.
7.2.9.2. In vivo studies
7.2.9.2.1. DON
In vivo studies on the effect of DON on CAs have been carried out by Bilgrami et al. (1993)
who studied mice treated with 3 mg DON/kg bw two times per week by gavage for 8 weeks, or
0.4  0.05 mg DON/kg in diet, equivalent to 0.08 mg/kg bw per day. The total frequency of abnormal
chromosomes in bone marrow cells in the gavage study was 10.0  1.7% in the DON-treated animals,
which was signiﬁcantly higher than the control group (3.3  1.0%). The total frequency of abnormal
chromosomes after dietary administration of DON was 6.3  1.4%, a non-signiﬁcant increase compared
with the control group. The CONTAM Panel noted that gaps, precocious chromatid separation and gross
aberrations were included in the total number of aberrations, and considered that the study was
inconclusive.
In a limited study by Singh et al. (2015), six female Balb/c albino mice received DON orally at a
dose of 1,000 mg/kg bw. The frequency of micronucleated polychromatic erythrocytes in bone marrow
cells and DNA damage in primary cultures of hepatocytes were studied. The CONTAM Panel could not
interpret the results in view of the high dose of DON administered.
Groups of ﬁve Swiss male mice were administered DON by gavage in sterile saline solution at doses
of 4, 8 and 16 mg/kg bw (Le Hegarat et al., 2014). A control group was treated with saline and a
positive control group with methyl methanesulfonate (80 mg/kg bw). The gavage schedule was at 0,
24 and 45 h with a volume of 10 mL/kg, and animals were sacriﬁced 3 h after the ﬁnal administration.
The Comet assay of blood, liver, duodenum, kidney, spleen, colon, and bone marrow with and without
fpg, and the determination of MN in bone marrow (according to the OECD guideline 474) and the
colon, were carried out on the animals. The authors reported that DON did not signiﬁcantly increase
DNA damage measured by the Comet assay in any organ studied, with or without fpg. The CONTAM
Panel considered that this study was inconclusive because of inconsistencies in the control value of %
tail DNA.
No induction of MN was observed in bone marrow cells or in the colon of mice treated with DON.
In the colon MN assay, at the lowest dose of 4 mg/kg bw, there was an increase in mitotic cell ﬁgures;
at the dose of 8 mg/kg bw, there was a decrease in mitotic ﬁgures; and, at the dose of 16 mg/kg bw,
there was an absence of mitotic ﬁgures and a large increase in apoptosis.
In a follow-up in vivo study by Le Hegarat et al. (2014) (see above), groups of ﬁve male Swiss
mice were treated with DON. The Comet assay with and without hOGG1 was carried out in blood
collected 3 h after the ﬁnal treatment with DON, and the same set of animals was used for the Pig-a
assay using blood collected 28 and 45 days after the ﬁnal treatment with DON. All the animals in the
highest dose group died 2 days after the last gavage, and so a repeat study was carried out with
doses of 2, 4 and 8 mg/kg bw using the Pig-a assay and the Comet assay with and without fpg. The
authors reported that DON at doses of 4, 8 and 16 mg/kg bw did not increase DNA fragmentation in
the presence or in the absence of hOGG1. The CONTAM Panel noted that the reason for a decrease in
breaks that was observed at doses of 4 and 8 mg DON/kg bw was not determined. In the subsequent
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experiment at doses of 2, 4 and 8 mg/kg bw, no decrease in DNA migration was reported in blood
cells in the absence of fpg. In the presence of fpg, a signiﬁcant increase in DNA migration was
reported, but only at the dose of 2 mg DON/kg bw. The CONTAM Panel considered that these studies
of Le Hegarat et al. (2014) using the Comet assay were inconclusive because of inconsistencies in
values of % tail DNA in controls and in the effects of DON.
In the Pig-a assay of Le Hegarat et al. (2014) in mice, the frequency of mutant phenotype
reticulocytes and erythrocytes was measured to examine the genotoxic effect of DON. The only
statistically signiﬁcant increase in mutant phenotype erythrocytes was observed 28 days following the
ﬁnal dose of 2 mg/kg bw per day. No other increases of mutant frequency were seen for any of the
tested doses at the two post-exposure time points. The CONTAM Panel concluded that this substudy
was inconclusive because of the choice of collection times used.
The conclusion by the authors of these studies (Le Hegarat et al. (2014)), which were conducted
according to the EFSA Scientiﬁc Opinion on genotoxicity testing strategies applicable to food and feed
safety assessment (EFSA Scientiﬁc Committee, 2011), is that DON showed no genotoxic effect in mice
using the multiple organ Comet assay, the MN test in bone marrow and the colon, and the Pig-a assay.
However, the CONTAM Panel considered that the results from the Comet assay and the Pig-a assay
were inconclusive.
The study of Abdel Wahhab et al. (2015) investigated if activated carbon (AC) or Egyptian
montmorillonite (EM) was able to protect against the toxic effects of DON in male Sprague–Dawley
rats. Treatment with DON (oral, 5 mg/kg bw in corn oil for 3 weeks) caused a signiﬁcant increase in
the frequency of micronucleated polychromatic erythrocytes (Mn-PCEs). Addition of AC or EM to this
diet caused a signiﬁcant reduction in the frequency of Mn-PCEs. DON also showed a cytotoxic effect as
it signiﬁcantly reduced the ratio of polychromatic erythrocytes to normochromatic erythrocytes. An
increase in DNA fragmentation was observed in the livers of DON-treated rats together with an
increase in lipid peroxidation and a decrease in hepatic glutathione, indicating oxidative stress. The
CONTAM Panel considered that the study was inconclusive as only one dose was tested, and this was
cytotoxic.
Four assays that are not part of the normal standard screening procedures for genotoxicity have
been carried out on DNA damage in pigs and chickens.
Chickens (n = 10 per group) were exposed to DON in feed (fortiﬁed to 10 mg/kg) with or without the
addition of dietary nucleotides (2 g nucleotides/kg feed) (Frankic et al., 2006). The objective was to study
if dietary nucleotides protected against this damage. After 17 days of treatment, the Comet assay was
used to measure DNA damage in spleen leukocytes. DON was found to signiﬁcantly induce DNA damage
(percentage of DNA in tail of comet), and the addition of nucleotides decreased this non-signiﬁcantly.
However, DON did not induce a change in DNA damage as assessed by the tail moment.
Pigs (11.7 kg starting weight, n = 9) were fed a diet containing 4 mg DON/kg for a period of
2 weeks. The body mass and the daily live weight gain was signiﬁcantly reduced compared to that of
a control group (n = 12). Using the Comet assay, DON treatment was found to cause a 28% increase
in lymphocyte DNA damage, as measured from the proportion of DNA in the tail of the Comet. Vitamin
E supplementation of the diet (100 mg/kg) non-signiﬁcantly reduced the percentage of DNA in the tail.
Markers of oxidative stress were not affected by the treatment but levels of total antioxidant status
were lowered by treatment with DON with or without vitamin E (Frankic et al., 2008).
The effect of DON on lymphocyte DNA fragmentation in broilers fed low-protein diets and the
potential of a commercial food additive, that is intended to protect animal health by deactivating
mycotoxins found in contaminated feed, was evaluated by Awad et al. (2012b). Thiobarbituric acid
reactive substances (TBARS) in the liver were measured as an indicator of lipid peroxidation. Broiler
chicks in four groups of eight animals were fed with (1) a non-contaminated diet, (2) a non-
contaminated diet supplemented with the feed additive (0.25%), (3) a diet contaminated with DON at
10 mg/kg diet, and (4) a diet contaminated with DON (10 mg/kg diet) supplemented with the feed
additive (0.25%). Chicks were fed the normal starter diets from day 1 to day 13 and a low protein
grower diet from day 14 to day 35. The degree of lymphocyte damage was determined using the
Comet assay. The concentration of TBARS in the liver did not differ between the DON-treated group
and the control group, with or without the food additive. The proportion of DNA in the tail of the
comet was statistically increased by DON exposure, and the feed additive reduced this increase, with
the level reverting to approximately control levels.
In a subsequent paper, Awad et al. (2014) used a similar experimental design using groups of 10
broiler chicks. Birds were fed a starter feed from 1 to 13 days and grower feed from 14 to 35 days.
TBARS level was measured in plasma, heart, kidney, duodenum and jejunum. TBARS levels in plasma,
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heart, kidney, duodenum did not show signiﬁcant changes due to DON exposure, but the level in
jejunal tissue increased (p < 0.001). The commercial microbial feed additive described in Schatzmayr
et al. (2006) had no effect on reducing the TBARS level in jejunal tissue. After 5 weeks, DON
increased the % of DNA damage in lymphocytes (p < 0.001), and addition of the feed additive
prevented this rise, giving a DNA damage level similar to that of controls. The authors concluded that
DNA damage induced by DON is probably caused through oxidative stress.
Overall, based on the available evidence, the CONTAM Panel considered that the data on the
genotoxicity of DON in vivo are inconclusive.
7.2.9.2.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.9.2.3. DON-3-glucoside
No data were identiﬁed.
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Table 47: Genotoxicity studies on DON and 3-Ac-DON in vitro and in vivo
Test system Cells/animals Concentration/treatment Results Comment Reference
In vitro
Bacterial reverse
mutation assay
(Ames test)
S. Typhimurium TA98, TA100,
TA1535, TA1537
0.4–400 lg of DON or 3-Ac-DON/plate
(S9)
Negative Wehner et al. (1978)
0.4–400 lg of DON or 3-Ac-DON/plate
(+S9)
Negative
Bacterial reverse
mutation assay
(Ames test)
S. Typhimurium TA98, TA100 0.7–500 lg/plate (S9) Negative Knasm€uller et al. (1997)
0.7–500 lg/plate (+S9) Negative
Bacterial reverse
mutation assay
(Ames test)
S. Typhimurium TA98, TA100,
TA102
0.03–500 lg of DON/plate (S9) Negative Takakura et al. (2014)
0.03–500 lg/plate (+S9) Negative
SOS chromotest E. coli PQ37 5–500 lg/assay (S9) Negative Knasm€uller et al. (1997)
5–500 lg/assay (+S9) Negative
DNA repair assay E. coli K12 (343/753, uvrB/
recA and 343/765, uvr+/rec+)
0.7–500 lg/mL (S9) Negative Knasm€uller et al. (1997)
0.7–500 lg/mL (+S9) Negative
Mammalian cell
forward mutation
assay
Chinese hamster V79 cells/
HGPRT with or without
hepatocyte-mediated
activation
1–3 lg/mL Negative Rogers and Heroux-Metcalf
et al. (1983)
In vitro CAs Rat hepatocytes 0.001–10.0 lg/mL Positive at 1 and 10
lg/mL
Mitotic index decreased at
10 lg/mL. Pronounced
cytotoxicity at 100 lg/mL
Knasm€uller et al. (1997)
In vitro CAs Chinese hamster V79 cells HPLC-puriﬁed fractions with the
retention time of DON from extracts of
corn (concentration 0.1–1.0 lg/mL)
Increased CAs Purity of DON in the HPLC
fraction not clear
Insufﬁcient number of
samples. Inadequate data
for risk assessment
Hsia et al. (1988)
Pure DON and 3-Ac-DON (up to
10 lg/mL)
Increased CAs Insufﬁcient details given of
results
In vitro CAs Chinese hamster V79 cells HPLC-puriﬁed fractions with the
retention time of DON from extracts of
wheat ﬂour (30 ng/mL), barley (200
ng/mL) and corn (300 ng/mL
Increased CAs Purity of DON in the HPLC
fraction not clear
Insufﬁcient number of
samples
Inadequate data for risk
assessment
Hsia et al. (2004)
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Test system Cells/animals Concentration/treatment Results Comment Reference
Micronucleus
assay
Rat hepatocytes 0.001–10.0 lg/mL Positive at 0.01 lg/mL,
but not at higher
concentrations
Positive result not considered
biologically relevant as no
dose response
Mitotic index decreased at
10 lg/mL. Pronounced
cytotoxicity at 100 lg/mL
Knasm€uller et al. (1997)
Micronucleus
assay
Lymphoblastoid TK6 cells 1.6–25.0 lM, 3 h (+) or () rat or
human S9
() S9: positive at
25.0 lM (> 60%
cytotoxicity)
(+) rat S9: negative
(+) human S9: positive
at 12.5 lM and 25 lM
(> 60% cytotoxicity)
Induction of micronuclei only
at cytotoxic doses
Takakura et al. (2014)
0.4–3.2 lM, 18 or 24 h Positive at 1.6 lM and
3.2 lM (both >60%
cytotoxicity)
Hepatoma HepaRG cells 1.6–50.0 lM, 3 h Negative
5.0–35.0 lM, 24 h Negative
Micronucleus
assay
Human peripheral
lymphocytes
6.25, 12.5, 25, 50 ng/mL for 6, 12 or
24 h
Positive Dose-dependent increase in
MN
DON induced oxidative
stress and decreased cell
viability
Yang et al. (2014)
Sister chromatid
exchange
Human peripheral
lymphocytes
6.25, 12.5, 25, 50 ng/mL for 6, 12 or
24 h
Positive DON induced oxidative
stress and decreased cell
viability
Yang et al. (2014)
DNA strand
breaks (Comet
assay)
Human peripheral
lymphocytes
6.25, 12.5, 25, 50 ng/mL for 6, 12 or
24 h
Positive DON induced oxidative
stress and decreased cell
viability
Yang et al. (2014)
DNA strand
breaks (Comet
assay)
Rat hepatocytes 0.01–1 lg/mL for 2 h Positive Li and Guo (2001)
DNA strand
breaks (Comet
assay)
Vero cells 1, 5 and 10 lM for 4 and 16 h(a) Positive Lin and Sun (2004)
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Test system Cells/animals Concentration/treatment Results Comment Reference
DNA strand
breaks (Comet
assay)
undifferentiated and
differentiated Caco-2 cells
0.01–0.5 lM, 24–72 h Positive Bony et al. (2006)
DNA strand
breaks (Comet
assay)
Human colon carcinoma cells
(HT-29)
10 lM, 2, 4, 8, 12 and 24 h Positive Bensassi et al, (2009)
DNA strand
breaks (Comet
assay)
human hepatoma HepG2 cells 3.75–30 lM Positive After pretreatment with an
antioxidant, the DNA
migration dramatically
decreased. Authors
considered that the DNA
damage is probably related
to oxidative stress
Zhang et al. (2009)
DNA strand
breaks (Comet
assay)
Lymphoblastoid TK6
hepatoma HepaRG cells
0.25–1.5 lM, 24 h Negative Cytotoxicity > 50% at
1.5 lM
Takakura et al. (2014)
5–35 lM, 24 h Negative Cytotoxicity > 50% at 30 lM
and 35 lM
DNA strand
breaks (Comet
assay)
TK6 cells 1.56–25 lg/mL for 3 h 0.25–1.5 lg/mL
for 24 h
Incubation with or without fpg
Inconclusive Lack of some toxicity data.
Variations in tail DNA
intensity in control samples
Effects of BSO and NAC on
the oxidation status of the
cells not interpretable
Le Hegarat et al. (2014)
In vivo
Pig-a mutation
assay
male Swiss mice, peripheral
blood cells
2, 4, and 8 mg/kg bw per day, 3 days Inconclusive Inappropriate choice of
collection times.
Le Hegarat et al. (2014)
Micronucleus
assay
six female Balb/c albino mice Oral, 1,000 mg/kg bw Increased micronuclei
(study not used by the
CONTAM Panel)
Micronuclei were increased
but the CONTAM Panel could
not interpret the results in
view of the high dose of
DON administered
Singh et al. (2015)
Micronucleus
assay
Swiss male mice, bone
marrow, colon
4, 8 and 16 mg/kg bw per day for 3
days. Gavage at 0, 24 and 45 h
Negative In the colon, there was an
increase in mitotic cell
ﬁgures with 4 mg DON/kg
bw per day, and of apoptotic
cells with 16 mg DON/kg bw
per day
Le Hegarat et al. (2014)
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Test system Cells/animals Concentration/treatment Results Comment Reference
Micronucleus
assay
Male Sprague–Dawley rats,
bone marrow
5 mg/kg bw orally, 3 weeks, with or
without supplementation with
activated carbon (AC) or Egyptian
montmorillonite (EM)
Inconclusive Toxicity shown by reduced
ratio of PCEs to NCEs.
Oxidative stress observed.
Single dose study
Supplementation with AC or
EM reduced the DNA
damage caused by DON.
Abdel-Wahhab et al.
(2015)
Chromosome
aberrations
Male and female Albino mice,
bone marrow cells
3 mg DON/kg bw two times per week
orally for 8 weeks
Increased total
number of aberrations,
but inconclusive
The CONTAM Panel noted
that gaps, precocious
chromatid separation and
gross aberrations were
included in the total number
of aberrations, and therefore
considered that the study
was inconclusive
Bilgrami et al. (1993)
0.4  0.05 mg DON/kg in diet,
equivalent to 0.08 mg/kg bw per day
Negative
DNA strand
breaks (Comet
assay)
Male broiler chickens, spleen
leukocytes
Feed containing 10 mg/kg DON for 17
days with or without the addition of
dietary nucleotides (2 g nucleotides/kg
feed)
Positive (without
supplementation with
nucleotides)
Chickens not normally used
in standard genotoxicity
screening procedures
Frankic et al. (2006)
DNA strand
breaks (Comet
assay)
Male pigs, lymphocytes Feed containing 4 mg DON/kg for 2
weeks with or without
supplementation with vitamin E
Positive (without
supplementation with
vitamin E)
Pigs not normally used in
standard genotoxicity
screening procedures
Frankic et al. (2008)
DNA strand
breaks (Comet
assay)
Broiler chicks, lymphocytes Feed containing 10 mg DON/kg for 21
days with or without a supplement of
feed additive
Positive Chickens not normally used
in standard genotoxicity
screening procedures. A
microbial feed additive
reduced the DNA damage
caused by DON
Awad et al. (2012a,b)
DNA strand
breaks (Comet
assay)
Broiler chicks, lymphocytes Feed containing 10 mg DON/kg for 21
days with or without a supplement of
feed additive
Positive Chickens not normally used
in standard genotoxicity
screening procedures. A
microbial feed additive
reduced the DNA damage
caused by DON
Awad et al. (2014)
DNA strand
breaks (Comet
assay)
Swiss male mice, blood, bone
marrow, liver, kidney, spleen,
duodenum, colon.
4, 8 and 16 mg/kg bw per day, 3
days. Gavage at 0, 24 and 45 h
With or without fpg.
Inconclusive Inconsistencies in values of
% tail DNA in controls
Le Hegarat et al. (2014)
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Test system Cells/animals Concentration/treatment Results Comment Reference
DNA strand
breaks (Comet
assay)
Swiss male mice, blood cells 4, 8 and 16 mg/kg bw per day for 3
days with or without hOGG1
Inconclusive Inconsistencies in values of
% tail DNA in controls and in
the effects of DON
Reason for the decrease in
breaks that was observed at
doses of 4 and 8 mg DON/
kg bw was not determined
16 mg/kg bw caused death
of all animals
Le Hegarat et al. (2014)
2, 4 and 8 mg/kg bw per day for 3
days with or without fpg
Inconclusive Inconsistencies in values of
% tail DNA
2 mg/kg bw with fpg was
positive, but was not
considered biologically
signiﬁcant, as there was no
dose response
bw: body weight.
(a): The unit lmol was used in the paper but the CONTAM Panel assumed that the unit was lM and not the one as stated in the paper.
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7.2.9.3. Conclusions
DON has not shown mutagenicity in bacteria or in mammalian cells in vitro. Studies of the ability of
DON to induce chromosome damage or DNA damage in cells in vitro have yielded conﬂicting results,
but several positive results have been reported. The CONTAM Panel noted that there is evidence for
oxidative stress in some of these experiments. The CONTAM Panel considers that DON is genotoxic
in vitro, and that the effects may be related to oxidative stress. 3-Ac-DON was inactive in a bacterial
mutation assay. In one study it induced chromosome aberrations in cells in vitro, but this study could
not be used for risk assessment because of lack of published information. The CONTAM Panel did not
identify genotoxicity data for 15-Ac-DON or DON-3-glucoside.
Based on the available evidence, the CONTAM Panel considered that the data on the genotoxicity of
DON in vivo are inconclusive with the majority of positive results obtained from assays in pigs and
chickens that are unusual in standard genotoxicity screening procedures. Overall, the evidence
suggests that oxidative stress induced DNA damage, rather than a direct interaction of DON with DNA,
underlies the genotoxic effects of DON.
No in vivo genotoxicity studies on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were identiﬁed by
the CONTAM Panel.
7.2.10. Carcinogenicity
7.2.10.1. DON
The IARC classiﬁed DON as being in Group 3, ‘not classiﬁable as to its carcinogenicity to humans’
(IARC, 1993). In the SCF assessment in 1999, it was stated that ‘only one long-term feeding study is
available. No increase in tumour frequency or other sign of carcinogenic effect were found in this
study (Iverson et al., 1995). There are no indications for carcinogenic and/or mutagenic properties of
DON’ (SCF, 1999). The JECFA assessment in 2001 concluded that ‘a study of carcinogenicity in mice
showed fewer tumours of the liver in treated male mice than in controls. The Committee concluded
that the lower incidence was due to the reduced body weight of the treated animals. No signiﬁcant
difference in tumour incidence was seen in female mice’ (FAO/WHO, 2011).
In a long-term carcinogenicity study performed by Iverson et al. (1995) (for details of the study
design see Section 7.2.4), the majority of lesions observed were of a benign hyperplastic nature. In
male mice dose-related changes were observed for hepatic nodular hyperplasia, hepatic adenoma,
hepatocellular carcinoma, soft tissue ﬁbrosarcoma and large islets in the pancreas, with the only
signiﬁcant lesion after adjustment using the Bonferroni procedure being nodular hyperplasia. However,
in the liver and pancreas, the correlation with dose was negative, i.e. there was a decrease in
preneoplastic and neoplastic lesions with increasing DON doses. The negative trend for the liver might
have resulted from the known positive correlation between body weight and the appearance of
spontaneous hepatic neoplasms in this strain of mouse. The only positive trend reported was for
ﬁbrosarcomas where three were observed in the high-dose group. Female mice produced no
statistically signiﬁcant differences.
In a subsequent subchronic study, the effects of DON were studied in p53 heterozygous (p53+/)
and p53 homozygous (p53+/+) male mice (Bondy et al., 2016) (see also Section 7.2.4). Groups of
animals (n = 10) received a diet containing 0, 1, 5 or 10 mg DON/kg diet for 26 weeks. There was no
evidence of carcinogenicity in either the (p53+/) or the (p53+/+) mice, consistent with the results of
the 2-year feeding study in B6C3F1 mice (Iverson et al., 1995).
Huang et al. (2004)36 studied a potential modulation of the carcinogenicity of sterigmatocystin by
DON using an incomplete two-factorial design with six groups of 30 NIH mice (n = 15 males and 15
females). This included a control group, a group exposed to DON only (1.5 g/kg), two groups exposed
to sterigmatocystin only (3 and 30 g/kg) and two groups exposed to sterigmatocystin and DON
combined at these doses using intragastrical administration three times per week for a total of 24
weeks. Deterioration of the general condition of the animals in all groups treated with DON and/or
sterigmatocystin was reported, and a total of 49 out of 180 animals died after 10 days of treatment
(doses not speciﬁed). The incidence of glandular stomach mucosal dysplasia and tumours in the lung,
speciﬁed as adenocarcinoma, was reported for subsets of animals (varying between n = 8–16 per
group) of the study. Although this study has been repeatedly cited for evidence of possible
carcinogenicity of DON, the CONTAM Panel identiﬁed several ﬂaws of the design, conduct and
reporting of the results (incomplete factorial design, large intercurrent mortality, no information on the
distribution of the animals to the dose groups and the sacriﬁce times and the treatment of the
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 166 EFSA Journal 2017;15(9):4718
controls). The CONTAM Panel concluded that the data do neither support carcinogenicity nor a
synergistic effect of DON when added to sterigmatocystin, and cannot be used for hazard
characterisation.
The CONTAM Panel also noted the studies of Lambert et al. (1995) and Mishra et al. (2014b; 2016)
on topical application of DON to skin of rodents but did not consider these studies further for the risk
assessment of DON in food.
7.2.10.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.2.10.3. DON-3-glucoside
No data were identiﬁed.
7.2.10.4. Conclusions
In summary, as was the case for the SCF (1999) assessment, there is only one long-term feeding
study available for consideration of the carcinogenicity of DON, and this showed no indications of
carcinogenic properties of DON in mice. The CONTAM Panel did not identify carcinogenicity data for
3-Ac-DON, 15-Ac-DON or DON-3-glucoside.
7.3. Adverse effects in farm and companion animals
The previous EFSA (2004) opinion reported the available data at that time on the potential adverse
effects from diets in pigs, cattle, sheep, poultry, horses, dogs and cats for DON only. Since then new
studies on the toxicity of DON have been published including additional farm animals and also
including 3-Ac-DON, 15-Ac-DON or DON-3-glucoside. Since 2004 a number of studies reported
speciﬁcally the co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and/or DON-3-glucoside which is likely
due to analytical progress made by using optimised chromatographic methods. However, most studies
report almost exclusively data on animals exposed to naturally contaminated feed which may contain
also other mycotoxins.
In this section, the CONTAM Panel decided to use the mycotoxin concentration in feed/diet (mg
DON/kg feed) to express the NOAEL and LOAEL instead of a dose (mg/kg bw per day) because when
decreases in feed intake and vomiting were the reported adverse effects it was considered
inappropriate to express exposure on the body weight basis. In particular, the CONTAM Panel noted
that the use of dose caused misleading NOAEL/LOAELs for pigs because it has been observed that the
ﬁrst adverse effect seen in pigs when fed DON-contaminated feed at the low concentrations was
reduced feed intake, resulting in reductions in the body weight and body weight gain during the
feeding period when pigs consumed less feed. However, over time the hunger in pigs increased and
they turned to eat normal rations of the available DON contaminated feed resulting in a recovery and
an increase in body weight and body weight gain after some delay. As this observation on adaptation
has also been seen in poultry and farmed ﬁsh, it may also be relevant for other species than pigs,
poultry and farmed ﬁsh, the CONTAM Panel decided to use the concentration to express NOAELs/
LOAELs for all animals considered below with the exception of farmed mink when vomiting was
observed as acute effect in this species (see Section 7.3.8). The CONTAM Panel further remarked that
the primary effect of DON in farm and companion animals was a reduced feed intake, resulting in
reduced body weight gain or reduced body weight depending on the energy balance of the animal.
Therefore, as adult animals have reached a stable weight or have a very slow weight gain, ‘reduced
body weight gain’ and ‘reduced body weight’ measure virtually the same effect of DON but of different
severity. The CONTAM Panel also noted that vomiting due to DON exposure has only occasionally been
observed in farm and companion animals while reduction in feed intake has been regularly reported.
Vomiting has typically been reported at higher concentrations of DON than those associated with
reduced feed consumption.
7.3.1. Ruminants
A number of studies have reviewed the health effects of DON in cattle (DiConstanzo and Murphy,
1994; Yiannikouris and Jouany, 2002; Pestka, 2007, 2010b; Fink-Gremmels, 2008; Whitlow et al.,
2010). As described in the toxicokinetic section (see Section 7.1.5.1), DON is converted into the less
toxic de-epoxidised metabolite DOM-1 by the ruminal ﬂora. Therefore from the studies available in the
literature, only those performed using the largest number of animals and the highest DON
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concentrations in feed combined with the longest periods of time were selected for this opinion.
However, young ruminants, in which the rumen is not fully developed, could be less active in
de-epoxidation and might therefore be more sensitive than adult ruminants when exposed to DON. For
small ruminants (sheep and goats) the database on adverse effects of DON, 3-Ac-DON, 15-Ac-DON
and/or DON-3-glucoside was very limited or lacking.
7.3.1.1. Cattle
7.3.1.1.1. DON
In the study of Nelson et al. (1984) reported by Wagner (2002), heifers and steers were fed diets
containing 0.2, 2.3 and 10 mg DON/kg feed for 126 days. The low-DON diet was corn based, while
the medium and the high-DON diets contained wheat contaminated with 13.7 mg DON/kg
incorporated in the ration at 5.17% and 65%, respectively. Results reported for the low-, medium- and
high-DON diets were similar regarding feed intake, average daily weight gain and feed efﬁciency.
During a 166-day experiment conducted by DiConstanzo and Murphy (1994), 180 crossbred steers
were fed diets containing 0, 6, 12 or 18 mg DON/kg diet dry matter. Data were analysed separately for
the initial 28 days and the remaining 138 day ﬁnishing period. Feeding diets containing as much as 18
mg DON/kg did not affect feed intake, average daily weight gain, feed efﬁciency or carcass
characteristics. The CONTAM Panel identiﬁed from the above studies that feeding heifers a diet at 10
mg DON/kg feed and feeding steers a diet at 18 mg DON/kg feed did not affect feed intake, average
daily weight gain and feed efﬁciency, and identiﬁed these values as NOAELs for heifers and steers for
reduced feed intake and reduced body weight gain.
A slight temporary decrease in the consumption of complementary feedstuff by dairy cows was
recorded when the concentration of DON was increased from 1.5 to 6.4 mg/kg complementary feeding
stuffs (Trenholm et al., 1985). No effect was seen on weight gain or hay consumption. The
complementary feedstuff consumption returned to the previous levels when the cows were again fed
the complementary feeding stuffs after 6–10 weeks containing 1.5 mg DON/kg. However, DON fed to
dairy cows at 66 mg/kg for 5 days (Co^te et al., 1986) did not cause performance reduction or signs of
illness. No decrease in feed intake and milk production was shown after the administration of 0, 6.0
and 12 mg DON/kg of complementary feedstuff over 10 weeks to lactating cows (Charmley et al.,
1993). However, cows given DON at 6.0 mg/kg of complementary feeding stuffs dry matter had the
lowest milk fat content and fat output. Later studies by Ingalls (1996) showed that dairy cattle may
tolerate diets containing up to 8.5 mg DON/kg for 21 days without major health effects. During two
experiments performed by D€anicke et al. (2005a), the pH-value and the concentration of volatile fatty
acids in the rumen ﬂuid were not signiﬁcantly inﬂuenced by feeding with contaminated wheat at
dietary DON concentrations of 3.1 and 3.5 mg/kg (88% dry matter basis) to dry cows (see details in
Section 7.1.5.1). In contrast, the postprandial ammonia concentration was consistently higher when
the mycotoxin-contaminated wheat was fed. This might be the result of the higher protein intake due
to the higher crude protein concentration of the contaminated wheat and/or due to a decreased
capacity of rumen microbes to utilise the released ammonium for microbial protein synthesis (D€anicke
et al., 2005a).
No adverse effects were observed in feed consumption, body weight, body condition score, milk
production, milk composition or milk somatic cell count of Holstein cows exposed to 3.6 mg DON/kg
feed (Smith et al., 2006). While the total serum protein and globulin concentrations were increased
and albumin–globulin ratio decreased, there was no elevation in other markers of inﬂammation. A
similar observation was reported by Kinoshita et al. (2015) who concluded that a long-term exposure
to DON cannot be associated with an inﬂammation in cows. Therefore, the CONTAM Panel did not
consider these observations as adverse effects. The CONTAM Panel noted in the study of Mendoza
et al. (2014)40 on Holstein cows that there was a difference in feed composition between the control
and contaminated diets which may have biased the effect of DON observed as lower fat content in
milk from treated cows. Therefore, the CONTAM Panel did not consider this study further. Marczuk
et al. (2012) reported DON and zearalenone mycotoxicosis in a herd of dairy cows but because the
mycotoxin concentrations were not reported, the CONTAM Panel did not consider this study further.
The CONTAM Panel noted a study of D€anicke et al. (2016) on whether the change of composition of
the diet containing DON could challenge the immune system in cows but did not consider this study
further because no effects in the immune system were reported.
40 Original paper in Spanish, text based on the translation to English.
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In the study of Winkler et al. (2014) on 30 lactating German Holstein cows were divided into three
groups (see details in Section 7.1.5.1.1). No clinical signs of acute or chronic DON intoxication were
observed. Thus, DON and zearalenone concentrations of the diets up to 5 and 0.5 mg/kg feed
respectively did not exert negative effects on performance parameters such as body weight, dry
matter intake and milk yield and composition. The CONTAM Panel noted that both control and toxic
diet compositions were similar and based on maize as ingredient. The CONTAM Panel noted that a
relationship between DON exposure and clinical signs of cows with regard to performance parameters
could not be identiﬁed due to the absence of adverse effects in this study. Moreover, no effects of
mycotoxin contaminated feed were observed on milk production and milk composition in this study.
The CONTAM Panel noted that the Winkler et al. (2014) study provided the highest concentration of
5.24 mg DON/kg feed which did not generate any adverse effects during the longest time of
experiment and considered this study as pivotal to establish a NOAEL for dairy cows.
7.3.1.1.2. 3-Ac-DON and 15-Ac-DON
In the experiments performed on dairy cows by Seeling et al. (2006) and Winkler et al. (2014) (see
Section 7.1.5.1.1 above) on 3-Ac-DON and 15-Ac-DON, no speciﬁc data were reported on adverse
effects associated to the acetylated forms of DON.
7.3.1.1.3. DON-3-glucoside
Winkler et al. (2014) (see Section 7.1.5.1.1 above) did not report any speciﬁc data on adverse
effects associated to DON-3-glucoside.
7.3.1.2. Sheep and goats
The only available studies on sheep were previously reported by EFSA (2004). No data on goats
were identiﬁed.
7.3.1.2.1. DON
Harvey et al. (1986) fed eight lambs (mean body weight = 17.90 kg), wheat contaminated with
15.6 mg DON/kg for 28 days. No differences were observed in feed consumption, body weight gain,
feed efﬁciency or other parameters tested between the lambs fed with DON-contaminated diet and the
control animals. D€anicke and team (D€anicke et al., 2002; D€anicke, 2002) concluded that the sheep
rumen fermentation was not impaired (pH, concentration of short chain fatty acids and ammonia) by a
diet with 4.6 mg DON and 0.34 mg zearalenone per kg feed although a decreasing trend in the
digestibility of slowly degradable straw was observed. In the absence of any other data, the CONTAM
Panel decided to use 15.6 mg DON/kg feed as a NOAEL for sheep.
7.3.1.2.2. 3-Ac-DON and 15-Ac-DON
The CONTAM Panel noted the study of Brewer et al. (1996) on two lambs exposed via intraruminal
dosing to radioactively labelled 3-Ac-DON at a high dose of 5 mg/kg bw, but did not consider the
study further for hazard characterisation due to the use of that high dose. No data were identiﬁed for
15-Ac-DON.
7.3.1.2.3. DON-3-glucoside
No data were identiﬁed.
7.3.1.3. Conclusions on adverse effects in ruminants
Data that can be used for hazard characterisation were available for dairy cows, heifers, steers and
sheep but not for goats. For cows, from the available studies in the literature, the CONTAM
Panel selected the studies performed using the highest DON concentrations in feed combined with the
longest periods of time for hazard characterisation. The concentration of 5.24 mg DON/kg feed did not
generate adverse effects on body weight, feed intake, milk yield and composition or any other adverse
effect in dairy cows over 13 weeks, and therefore, the CONTAM Panel considered this concentration as
a NOAEL for dairy cows. The levels of 10 and 18 mg DON/kg feed did not generate any adverse
effects on feed intake, average daily weight gain and feed efﬁciency in heifers and steers, respectively.
Therefore, the CONTAM Panel considered a NOAEL of 10 mg DON/kg feed for heifers and 18 mg
DON/kg feed for steers. For sheep, the CONTAM Panel identiﬁed the NOAEL of 15.6 mg DON/kg feed
for reduced feed intake and body weight gain. Acute effects could not be identiﬁed for ruminants from
the available literature.
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In healthy ruminants, DON is converted into the less toxic de-epoxidised metabolite DOM-1 by the
rumen ﬂora. Dairy cows, cattle and young animals have not been compared directly in the same
experiment. However, young animals such as calves with not fully developed rumen and adult animals
with a previous history of ruminal acidosis may have less effective de-epoxidation and, consequently,
could be more susceptible to the toxic effects of DON.
Due to the limited or lack of data on adverse effects in ruminants caused by 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside, no speciﬁc NOAELs/LOAELs could be identiﬁed for these forms.
7.3.2. Pigs
Amongst livestock pigs show the highest susceptibility to DON among the animals evaluated
(Pestka, 2007). At high doses, DON leads to complete feed refusal, vomiting and haematological
disorders. Long-term exposure results in reduced feed consumption and growth reduction (Rotter
et al., 1996; D€oll and D€anicke, 2011).
Due to the high number of studies available in the literature for adverse effects on pigs since the
recent assessment of EFSA (2004), the CONTAM Panel decided to consider the recent publications
since then only when a causal relationship between exposure to DON and/or its acetylated and
modiﬁed forms was stated or was plausible to conclude from the reported data. Studies which
reported substantial co-contamination with other mycotoxins such as fusaric acid, whose effects are
sometimes attributed to the effects of DON, or zearalenone which may contribute to adverse effects
(e.g. the reproductive disorders) of DON were not included in this section neither studies of low quality
due do limitations in design and reporting or studies which aimed at not primarily to investigate
adverse effects of DON (e.g. aiming at mycotoxin degradation or adsorption to feed supplements). An
overview of the studies included by the CONTAM Panel in this opinion is presented in Table 48.
7.3.2.1. DON
The feeding studies on the effects of DON in pigs were summarised in EFSA (2004) and are brieﬂy
described below (see also Table 48). Among these studies, the adverse effects of either crystalline
DON or naturally or artiﬁcially Fusarium infected cereals containing DON were distinguished. Naturally
infected feed had a stronger effect on the feed intake and weight gain than pure DON, and this lead
to the assumption that the presence of other toxins and compounds (e.g. bacterial polysaccharides) in
feed affects the toxicity of DON and other trichothecenes (EFSA, 2004). In many studies, particularly
those conducted with puriﬁed DON, no effect was found at 0.6–0.9 mg DON/kg feed. Feeding trials,
where naturally or artiﬁcially infected material had been mixed into the diet, showed decreased feed
intake and body weight gain in pigs at concentrations as low as 0.35 mg DON/kg feed (Trenholm
et al., 1983).
In one of the subtrials of Young et al. (1983) with piglets (n = 20) concentrations from 9.0 mg
DON/kg in naturally contaminated feed caused a large depression in performance, and there were
indications that at least one pig fed 19.7, 33.5 or 43.4 mg DON/kg feed vomited on the ﬁrst day of the
trial. In another subtrial, 24 piglets were fed 1.3–11.9 mg DON/kg diet for 21 days resulting in
reduction of body weight gain, feed consumption and feed conversion but no vomiting was observed.
From this study, the CONTAM Panel identiﬁed the LOAEL of 1.3 mg DON/kg feed for the reduced feed
intake, and the NOAEL of 11.9 mg DON/kg feed and the LOAEL of 19.7 mg DON/kg feed for vomiting.
Feed contaminated with 2.0 mg DON/kg diet fed to piglets (n = 8, average body weight = 7.7 kg)
for 3 weeks resulted in reduced feed intake (Pollmann et al., 1985). Another subtrial in the same study
(n = 4, average body weight = 8.3 kg) showed a reduced feed intake at 1.4 mg/kg diet for 2 weeks,
but not at higher concentrations. A third subtrial was conducted for 6 weeks with grower-ﬁnishing pigs
with an average body weight of 60.8 kg. Evidence of vomiting was reported from the third subtrial (6
weeks old grower-ﬁnishing pigs with average body weight of 60.8 kg) at a concentration of 2.8 mg/kg
diet, but not at higher concentrations, and reduced feed intake occurred at 2.2 mg/kg feed.
Based on the available studies (see also Table 48), the CONTAM Panel concluded that vomiting was
the critical acute effect in pigs, and that the concentration of 2.8 mg/kg feed was considered a LOAEL
for vomiting. The CONTAM Panel noted that this value was lower than the NOAEL of 11.9 mg/kg feed
observed in another study (Young et al., 1983) in another breed of pigs, but still higher than the lowest
NOAEL identiﬁed as 0.7 mg/kg feed observed by Forsyth et al. (1977). A NOAEL of 0.7 mg/kg feed was
reported by Bergsj€o et al. (1993b) for reduced feed intake.
The CONTAM Panel noted that several studies, summarised by EFSA (2004) and a number of more
recent studies (see Table 48), investigated the impact of DON on immune responses in pigs.
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However, no suitable parameter for the risk assessment of DON (nor its acetylated and modiﬁed
forms) could be identiﬁed among the various immune responses reported in these studies, nor could
the observed size of the change of investigated immune responses be associated with relevant adverse
immunological effects. Therefore, the CONTAM Panel concluded that no suitable concentration–
response data on adverse immunological effects were available for the hazard characterisation of pigs.
In the previous assessment of EFSA (2004), various studies reported changes in different clinical
chemistry parameters (plasma nutrients and plasma enzyme activities), while in other studies no
changes were observed. Reported alterations were often considered as the consequence of the
reduced feed intake and not a direct effect of DON since no changes in these parameters were
observed when compared to pair-fed controls (Lun et al., 1985). Lusky et al. (1998) reported changes
in kidney tubular epithelium in pigs after 90 days of DON exposure but no such changes were found in
the control pigs.
EFSA (2004) also summarised the studies of the effects of DON on pig reproduction and noted
that signiﬁcant trends towards a lower fetal weight and length in fetuses of sows fed DON
contaminated feed during pregnancy were reported by Friend et al. (1986a,b) and Chavez (1984),
while Friend et al. (1986a) did not ﬁnd effects of DON on litter size, weight or size at birth, or weight
gain during lactation or survival rate of piglets when gilts were fed naturally DON contaminated feed.
Later, Alm et al. (2006) reported that a combination of 6.1 mg/kg feed of DON and 0.235 mg/kg feed
of zearalenone fed for a period of 35 days resulted in a reduced oocyte quality (reduced proportion
having immature chromatin and reaching metaphase II in culture) in gilts. When Stanek et al. (2012)
evaluated the combined effect of orally administered DON contaminated diet and LPS on hepatic
histopathology and blood clinical parameters in barrows, no impact of DON alone on liver morphology
and function was observed. The CONTAM Panel concluded that these ﬁndings on reproductive and
developmental effects were not convincing to be used for the hazard characterisation of DON in pigs.
Genotoxic effects of DON in pigs are reported in Section 7.2.9 and the CONTAM Panel noted due
to the short life time of pig these effects were not relevant for the chronic adverse effects in pigs.
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Table 48: Selected studies on adverse effects in pigs
Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Studies reported in EFSA (2004)
Yorkshire
(6 weeks)
6 0–9 Pure toxin 7 days Reduced feed intake and body weight gain 4 n.a. Prelusky
(1997)
Yorkshire
(6 weeks)
7 0–3 ad libitum
and pair fed
controls
Contaminated
corn
28 days First 7 days: Reduced feed intake and body weight
gain
0.75 n.a. Rotter et al.
(1994)
Days 8–28: Reduced feed intake and body weight
gain, decreased thyroid weight (not compared to
pair-fed)
Linearly decreased skin temperature and thyroid
weight, improved feed efﬁciency, increased serum T4,
albumin and decreased serum a-globulin compared to
ad libitum control, but not to pair-fed. Reduced anti-
body response to SRBC after 1 and 2 weeks, but not
after 3 weeks
1.5 n.a.
Landrace X Piet
(no age or bw
reported)
9 0.3–1.2 Pure toxin 8 weeks No effect on body weight gain. Tendency towards
reduced IGF-1 and IgA
n.a. 1.2 G€otz-Schr€om
et al. (1998)
Yorkshire
(7–8 weeks)
8 0, 4.0 ad libitum
and pair fed
controls
Contaminated
corn
42 days Reduced feed intake (20%) and body weight gain
(13%), corrugated stomach compared to controls,
temporary decreased serum protein after 2 and 3
weeks, and temporary reduced b-globulin weeks 2–4.
4.0 n.a. Rotter et al.
(1995)
Landrace
(~ 25 kg)
8 0.1–4.5 Contaminated
oat
8, 14 weeks Transient reduced feed consumption and body weight
gain (8 weeks)
2.3 1.14 Bergsj€o et al.
(1992)
Reduced feed consumption (14 weeks) 4.5 2.3
Landrace
(~ 21 kg)
17–20 0.05–3.50 Contaminated
oat
~ 3 months
(2–100 kg)
Decreased feed consumption 1.68 0.7 Bergsj€o et al.
(1993b)Transient reduction in PCV, decreased serum calcium
and phosphorus, increased relative liver weight
3.5 1.68
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Yorkshire
(4–5 weeks)
3 0, 5.9–15.1 Pure 2 weeks Reduced feed intake, reduced bw gain, particularly on
the ﬁrst 3 days (partially recovered at concentrations
< 12 mg/kg)
5.9 n.a. Trenholm
et al. (1994)
4 0, 3.49–19.1 Contaminated
wheat
2 weeks Reduced feed intake, reduced body weight gain,
particularly on the ﬁrst 3 days
3.4 n.a.
4–5 0–8.7 Contaminated
wheat
7 weeks Reduced feed intake and body weight gain, increased
relative liver weight, and increased relative stomach
weight
3.9 n.a.
Landrace
(12–13 weeks)
6 0, 2.5 Contaminated
corn
5 weeks Reduced feed intake and body weight gain. Signiﬁcant
changes in stomach mucosa.
2.5 n.a. Friend et al.
(1992)
Yorkshire
(12–15 weeks)
5 0, 6 Pure toxin 21 days Reduced feed intake, body weight gain and slightly
reduced feed efﬁciency. Lesions in stomach
6 n.a. Rotter et al.
(1992)
Yorkshire
(9–10 weeks)
3 0–5.2 Contaminated
maize and pure
DON
7 weeks Reduced feed intake and body weight gain, increased
relative stomach and urinary bladder weights.
Stomach lesions
5.2 n.a. Foster et al.
(1986)
Breed not
reported
(16–18 kg)
15–16 0–5.26 Contaminated
wheat
90–110 days
(~ 17–90 kg)
Reduced feed intake and increased age at slaughter
weight
5.26 2.89 Friend et al.
(1986a)
No signiﬁcant increase in weight of kidney, liver and
uterus. No effect on feed efﬁciency
n.a. 5.26
Yorkshire
(~ 25 kg)
18 3.7, 4.2 Contaminated
wheat or
inoculated
maize
7 weeks Decreased feed consumption and body weight gain 3.7 n.a. Friend et al.
(1986b)
Breed not
reported
(7–9 kg)
3–4 0.14–875 Contaminated
corn
4–21 days
(4 trials)
Vomiting 19.7 11.9 Young et al.
(1983)Reduced feed intake and body weight gain 1.3 n.a.
Increased serum protein, albumin, cholesterol,
decreased serum P, glucose and alkaline phosphatase
1.3 n.a.
Breed not
reported (cross-
breed 5 weeks)
8–10 0.7–5.8 Contaminated
corn
4 week Reduced feed intake and body weight gain (male
more than female, reversed in females when given
control feed), reddening of mucosa in stomach and
small intestines and oedema in the mesenteric lymph
nodes
3.1 n.a. Co^te et al.
(1985)
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Breed not
reported
(8–9 kg)
10 10.5 ad libitum
and pair fed
controls
Contaminated
corn
21 days Reduced feed consumption and body weight gain,
reduced feed efﬁciency (p < 0.07) compared to
ad libitum control. Decreased serum haematocrit,
haemoglobin, glucose, P compared to ad libitum
control
10.5 n.a Lun et al.
(1985)
No reduced feed consumption and body weight gain,
reduced feed efﬁciency (p < 0.07) compared to pair-
fed control.
Higher haemoglobin and no other signiﬁcant change
compared to pair-fed control
n.a. 10.5
Breed not
reported
(~ 9 kg)
8 0–2.8 Contaminated
wheat
2 or 3 weeks Reduced feed intake and body weight gain (no
difference in body weight gain when fed a clean diet
after 4 weeks exposure)
2.0 0.9 Pollmann
et al. (1985)
Breed not
reported
(~ 61 kg)
4 0–4.2 42 days Reduced feed intake and body weight gain. No effect
on organ weight
2.2 0.9
Vomiting 2.8 2.2
Breed not
reported
(45 kg)
4 0, 6.3 Pure toxin 4 days Reduced feed intake 6.3 n.a Forsyth et al.
(1977)(b)4 12.5 Contaminated
corn
Feed refusal 12.5 n.a
Breed not
reported
(20 kg)
4 0–40 Pure toxin 4 days Dose-dependent reduction in feed intake 3.6 n.a
3 0–16 Contaminated
corn
3 days Reduced feed intake and reduced body weight gain.
(Pigs receiving 3.6 mg DON/kg naturally contaminated
corn had a lower feed intake and average daily body
weight gain than all pigs receiving pure toxin)
3.6 n.a.
Breed not
reported
(~ 9 kg)
3 0.025–0.2
mg/kg bw
Pure toxin Single dose, i.p Vomiting 0.05
mg/kg bw
0.025
mg/kg bw
3 0–0.4 mg/kg bw Pure toxin Single dose,
oral (gavage)
Vomiting 0.1 mg/kg
bw
0.075
mg/kg bw
Breed not
reported
(~ 24 kg)
12 0–14.1 Contaminated
wheat
14 days Vomiting 12.7 8.3 Williams et al.
(1988)Reduced feed intake and growth rate 8.3 5.0
54 0–11.0 Contaminated
wheat
14 weeks Vomiting 4.4 1.6
Reduced feed intake 4.4 1.6
Reduced growth rate 6.6 4.4
Reduced feed to body weight gain ratio 9.1 6.6
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Landrace
(~ 25 kg)
8 0.6, 1.8, 4.7 Contaminated
oats
100 days
(25–100 kg)
Reduced feed intake, feed conversion and reduced
antibody response toward tetanus toxoid (only after 9
weeks, not after 3 and 6)
1.8 n.a. Overnes et al.
(1997)
Inconclusive lymphocyte response towards PHA
mitogen.Interstitial hepatitis in liver (p ~ 0.05)
n.a. n.a.
Landrace
(≥ 22 kg)
15 0.03, 6.0 Contaminated
wheat
12 weeks Reduced feed consumption and body weight gain
(not in the enhanced diet)
6.0 n.a. Chavez and
Rheaume
(1986)
Breed not
reported
(80–90 kg)
11 8 Contaminated
wheat
11 days Reduced feed consumption compared to previous 5
days. Slowly increasing from day 6Degeneration of
hepatocytes, degenerative changes in renal tubular
epithelium and eosinophilic inﬁltration in lymphatic
organs
8 n.a. Marpegan
et al. (1988)
Yorkshire
(~ 39 kg)
6 0.05, 0.75 Contaminated
wheat
21 days Reduced feed intake and reduced body weight gain in
the ﬁrst 3 days. No difference later, but the loss was
never recovered
0.75 n.a. Friend et al.
(1982)
Yorkshire
(~ 75 kg)
6 0.05–0.75 21 days Concentration-dependent reduction in feed intake and
body weight gain in the ﬁrst 3 days, which were not
recovered. Discolouration of oesophageal region of the
stomach
0.38 n.a.
Yorkshire
(~ 43 kg)
4 0.05–0.75 7 weeks Reduced feed intake and reduced feed to body weight
gain ratio
(only
trend)
n.a.
Yorkshire
(~ 21 kg)
4 0.05–0.75 4 weeks Reduced weight gain, signiﬁcant trend for body weight
gain and feed intake
(only
trend)
n.a.
Yorkshire(age
and weight not
speciﬁed)
6 0–0.7 Contaminated
wheat
21 days Reduced feed intake and average body weight gain 0.35 n.a. Trenholm
et al. (1983)
Yorkshire
(~ 30 kg)
10 0.20, 5.08 Contaminated
wheat
5 weeks Reduced feed intake and reduced body weight gain 5.08 n.a. Friend et al.
(1984)
Yorkshire
(9 weeks)
6 0–3.0 Contaminated
corn and pure
toxin
32 days Reduced feed intake and body weight gain (whole
period for naturally contaminated feed, only 2 days for
pure toxin). Signiﬁcant decrease in serum c-globulin
content and trend towards a decrease in total globulin
content. No signiﬁcant pathological changes in
stomach region, but trend towards more mucosal
folding and thickening of oesophageal region tissue
with increasing DON.
3.0 1.0 Prelusky et al.
(1994)
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Breed not
reported (60 kg)
6 0, 1.0 Pure toxin 90 days No effect on feed intake or body weight gain or other
parameters measured.
n.a. 1.0 Lusky et al.
(1998)
Breed not
reported
(70–83 days)
6 0–1.4 Contaminated
wheat
100–125 days No effect on feed intake, body weight gain or other
parameters measured
n.a. 1.4 Richter
(1989)
Breed not
reported(~ 30
kg)
12–18 0.2–2.8 30–100 kg No effect on feed consumption, body weight gain or
other parameters measured
n.a. 2.8
Yorkshire (~ 90
kg) (≥ 178 days,
during
pregnancy)
12 0.1–3.5 Contaminated
wheat
50–54 days Reduced maternal body weight and feed intake 3.5 n.a. Friend et al.
(1986a,
1986b)
Signiﬁcant trend towards reduced fetal weights and
fetal lengths
3.5 n.a.
Four-strain male
and female
hybrids (~ 30 kg)
12 2.4–3.1 Contaminated
wheat
98 days
(~ 30–110 kg)
Reduced feed intake and reduced body weight gain,
no effects on clinical chemistry
2.4 n.a. D€anicke et al.
(2004c)
Four-strain male
and female
hybrids
(14 days)
(~ 28–36 kg)
16 2.6, 4.1 Contaminated
wheat
14 days
(~ 28–36 kg)
Pigs fed the highest DON-concentrations showed
reduced feed intake to approximately 50% of the
control group within 2 days after the beginning of the
experiment. Some individual pigs completely refused
feed
2.6 n.a. D€anicke et al.
(2004e)
Four-strain male
and female
hybrids
(70 days,
~ 56–103 kg)
18 0.2, 0.7, 1.2, 2.5,
3.7
Contaminated
wheat
70 days
(~ 56–103 kg)
No signiﬁcant effects on performance with a tendency
of a concentration-independent decrease in
performance due to DON-presence in the diets
No effects on clinical chemistry, linearly related
increase of DON-concentration in serum, and no
effects on nutrient digestibility
n.a. 3.7 D€anicke et al.
(2004d)
Four-strain
female hybrids
(~ 12.5 kg)
20 0.2–3.9 Contaminated
corn
35 days
(12.5–32.5 kg)
Reduced feed intake and reduced body weight gain.
Reduced total serum protein at 3.9 mg/kg
Serum activity of GLDH signiﬁcantly decreased at and
above 0.8 mg/kg
No or no consistent effects on organ weights of the
digestive tract or related organs and immune globulin
concentration in the serum. Linearly related increase
of DON-concentration in the serum
3.9 n.a. D€oll et al.
(2003)
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Four-strain
female hybrids
(~ 10 kg)
20 2.3 Contaminated
corn
35 days
(10.5–27.5 kg)
Reduced feed intake, reduced body weight gain and
feed to body weight gain ratio.
Increased relative weight of stomach and heart.
Decreased serum albumin concentration and activity
of GLDH.
2.3 n.a. D€oll et al.
(2004)
12 3.2 35 days
(9.7–21.4 kg)
Reduced feed intake and body weight gain 3.2 n.a.
Yorkshire
(10 kg)
35 4.6 Contaminated
corn and wheat
21 days Reduced feed intake and body weight gain.
Decreased relative liver and kidney weights.
Signiﬁcantly decreased concentrations of
neurotransmitters in pons and hypothalamus.
Signiﬁcantly increased serum concentrations of
immune globulins A and M
4.6 n.a. Swamy et al.
(2002)
Yorkshire
(9.3 kg)
30 3.9 and 5.8 (with
pair fedcontrol)
Contaminated
corn and wheat
21 days Concentration-dependent reduced feed intake and
body weight gain.
Decreased albumin-globulin ratio, total serum protein
and globulin concentrations (as compared to pair fed
pigs).
No effects on organ weights, serum immune
globulines, percentages of peripheral blood
lymphocyte subsets and primary response to sheep
red blood cells
3.9 n.a. Swamy et al.
(2003)
Studies identiﬁed after EFSA (2004)
Male and female
hybrids
(11.2 kg)
12 0, 0.28, 0.56,
0.84
Contaminated
wheat
28 days No effect on 34 haematological, biochemical and
immune variables
n.a. 0.84 Accensi et al.
(2006)
Dutch Landrace
(7.9 kg)
10 0, 0.9 Pure toxin 10 days Reduced body weight gain 0.9 n.a. Alizadeh et.al.
(2015)Histomorphological alterations in the duodenum and
jejunum
0.9 n.a.
Affected mRNA expression of different tight junction
proteins, of inﬂammatory markers (IL-1 beta, IL-10,
haem oxygenase).
0.9 n.a.
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Deutsches
Edelschwein 9
Pietrain (8 kg)
13,15 0, 3.0 Contaminated
wheat
8 weeks Reduced feed intake (19%) and reduced body
weight gain (14%)
3.0 n.a. B€ohm and
Razzazi
(2003)
Male hybrids
(10.2 kg)
6 0, 2.8 Fungal culture 35 days Histopathological lesions in the liver, the lungs and the
kidney. Morphological and histological changes in the
jejunum. Reduced number of immune cells and an
upregulation of the expression levels of several
cytokines
2.8 n.a. Bracarense
et al. (2012)
Male hybrids
(23 kg)
5–8 5.7 Contaminated
wheat
4 weeks Reduced protein synthesis in kidneys, spleen and
ileum
5.7 n.a. D€anicke et al.
(2006)
83 lg/kg bw Acute oral 83 lg/kg
bw
n.a.
Crossbred
piglets (5 weeks)
10 0, 0.5, 1.5 n.r. 15 days Increase of serum concentrations of urea and
c-glutamyl transferase
0.5 n.a. Dinischiotu
et al. (2007)
Male hybrids
(23 kg)
5–7 5.7 Contaminated
wheat
4 weeks No alterations in the number of positive stained cells
for IgA+, CD3+, CD4+ and CD8+ from cryosections of
spleen and jejunum
n.a. 5.7 D€oll et al.
(2006)
83 lg/kg bw Acute oral n.a. 83 lg/kg
bw
Female hybrids
(9.8 kg)
34 0–1.2 Pure toxin 8 weeks No difference in body weight gain (restricted feeding) n.a. 1.2 Drochner
et al. (2004)Depression of glucose levels 1.2 n.a.
Cortisol and IGF-1 levels were not signiﬁcantly
affected
n.a. 1.2
Increase of IgA concentration in serum 0.6
Female hybrids
(9.8 kg)
9 0–1.2 Pure toxin 8 weeks No difference in body weight gain (restricted feeding) n.a. 1.2 Drochner
et al. (2006)Blood concentrations of aspartate aminotransferase
were elevated
1.2
No systematic effect on other enzymes (alanine
aminotransferase, c-glutamyl transferase, glutamate
dehydrogenase and sorbit dehydrogenase)
n.a. 1.2
Increasing urea level and declining glucose
concentrations
1.20 n.a.
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Pietrain male
(35 days)
10 0.12, 1.5 Contaminated
wheat
28 days No difference in body weight gain n.a. 1.5 Gerez et al.
(2015)Liver lesions 1.5 n.a.
Decrease in villi height (jejunum) 1.5 n.a.
Reduction in crypt depth 1.5 n.a.
Intestinal lesions 1.5 n.a.
Number of Goblet cells decreased 1.5 n.a.
Epithelial cell proliferation decreased 1.5 n.a.
Spleen and lymph nodes lesions increased 1.5 n.a.
German
Landrace x
Pietrain (26 kg)
48 0, 6.51 Contaminated
wheat
11 weeks
(26–100 kg)
Reduced feed intake (15%), reduced body weight gain
(13%)
6.51 n.a. Goyarts et al.
(2005)
No effect on feed to body weight gain ratio n.a. 6.51
No effect on body weight gain (restrictive feeding) n.a. 6.51
Increase of metabolisable energy, nitrogen retention,
digestibility of organic matter, crude protein and crude
ﬁbre diet consuming time (restrictive feeding)
increased
6.51 n.a.
Serum IgA concentration increased 6.51 n.a.
German
Landrace 9
Pietrain (40 kg)
7–10 0, 5.7 Contaminated
wheat
4–6 weeks No differences in plasma concentrations of total
protein, albumin, ﬁbrinogen and serum enzymes
n.a. 5.7 Goyarts et al.
(2006)
5.7 Acute oral Decreased fractional synthesis rate of albumin and
lymphocytes
5.7 n.a.
German
Landrace gilts
(180 kg)
3 4.42 Contaminated
triticale
Days 63–70 of
gestation
No macroscopic lesions in any organ (sows and
piglets)
n.a. 4.42 Goyarts et al.
(2010)
No histopathological alterations of sows liver and
spleen
n.a. 4.42
No effect on proliferation rate of peripheral blood
mononuclear cells
n.a. 4.42
No adverse effects on health, fertility, maintenance of
pregnancy, and performance of sows and their fetuses
n.a. 4.42
Crossbred
piglets
(7.7 kg)
5 0, 2.0 Crude toxin
extract
38 days Reduced body weight gain 2.0 n.a. Changyun
et al. (2014)
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Landrace 9
Yorkshire
(28 days)
8 0, 3.5 Contaminated
wheat
42 days IgG antibody response to OVA increased 3.5 n.a. Lessard et al.
(2015)Downregulation of claudin, occludin, and vimentin
genes
3.5 n.a.
Upregulation of expression of IL-8, CXCL10, interferon-
c and major antioxidant glutathione peroxidase 2
(GPX-2) genes
3.5 n.a.
Downregulation of GPX-3, GPX-4 and superoxide
dismutase-3 genes
3.5 n.a.
Reduced body weight gain 3.5 n.a.
Crossbred pigs
(22.9 kg)
6, 18 0.2, 5 Contaminated
distiller grain
120 days No differences in macroscopic or microscopic lesions,
bone ash and density
n.a. 5.0 Madson et al.
(2012)
Growing pigs 5 0–2.85 n.r. 35 days Decreased claudin-4 expression 2.85 n.a. Pinton et al.
(2009)
Crossbred
piglets (8.9 kg)
25 0–4.52 Contaminated
maize
29 days Reduced body weight gain 4.52 n.a. Rempe et al.
(2013)No effect on visceral organ weights n.a. 4.52
No effect on histopathological organ specimens n.a. 4.52
No effect on total leukocytes, differential blood count
and stimulation index of peripheral blood mononuclear
cells
n.a. 4.52
Crossbred
piglets
(28 days)
6 0, 2.5, 3.5 Contaminated
wheat
42 days Inhibition of vaccination efﬁciency of PRRSV live
attenuated vaccine by impairing viral replication
2.5 n.a. Savard et al.
(2015)
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Breed of pig
(body weight
or age)
n
Concentration
(mg/kg feed)
Toxin source
Exposure
time(a)
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Crossbred
(16.3 kg)
6 0, 3, 6, 12 Contaminated
maize
21 days Increased daily body weight gain 12 6 Wu et al.
(2015)Increased relative liver weight 12 6
Elevated blood urea nitrogen, alkaline phosphatase,
alanine aminotransferase and aspartate amino
transferase
3 n.a.
Decreased serum concentrations of L-valine, glycine,
L-serine and L-glutamine, serum total superoxide
dismutase, glutathione peroxidase
3 n.a.
Decreased microvilli height, increased lymphocyte cell
number
3 n.a.
Elevated mRNA expression levels of excitatory amino
acid transporter-3, sodium-glucose transporter-1,
dipeptide transporter-1, cationic amino acid
transporter-1 and y+L-type amino acid transporter-1
3 n.a.
n: number of animals per group; bw: body weight, n.r.: not reported; ~: approximately; n.a.: not applicable because not identiﬁed by the authors of the study or by the CONTAM Panel; SRBC:
sheep red blood cells; IGF: Insulin-like growth factors; PCV: Packed cell volume; PHA: Phytohaemagglutinin; GLDH: Glutamate dehydrogenase; PRRSV: porcine reproductive and respiratory
syndrome virus.
The ﬁrst part of the table (until the reference of Swamy et al. 2003) has been modiﬁed from EFSA (2004). Note that the units are expressed as mg/kg feed unless otherwise stated.
(a): The exposure time is indicated as time period and/or as body weight reached at the of the time period.
(b): Not reported by FAO/WHO (2001, 2010).
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Time-dependent effects of feed contaminated with low doses of DON and zearalenone were
reported in female piglets (initial mean weight = 8.9 kg, n = 4 per group) (Rempe et al., 2013). A
signiﬁcant weight gain reduction after the 5th (last) week of the experiment was observed at the
highest dose group only (4.52 mg DON/kg feed, 0.29 mg zearalenone/kg feed) Histopathological
examination of the organs did not reveal any toxin-related lesions, and the haematological and clinical-
chemical parameters showed only minor effects. However, in the EFSA (2004) assessment it was noted
that the consumption of DON-contaminated feed was associated with epithelial lesions in the
oesophageal region of the stomach when pigs had been given naturally infected feed containing from
about 3–6 mg DON/kg feed. More recently, Grenier et al. (2011) studied the effects of 2.8 mg/kg feed
of DON in piglets (5-week old male, initial body weight of 10.2  1.9 kg, n = 6 per group) and observed
induced histopathological lesions in the liver, lungs and kidneys after 35 days, including morphological
and histological changes in the jejunum. Furthermore, Gerez et al. (2015) reported liver and intestinal
lesions even after 28 days of feeding of 1.5 mg DON/kg feed to 35 days old piglets (n = 5).
Based on the available evidence (see Table 48), the CONTAM Panel concluded that the reduced
feed intake and reduced body weight gain were the critical chronic adverse effects of DON in pigs. The
CONTAM Panel conﬁrmed what had been noted earlier by EFSA (2004), that although reduced feed
intake at the lowest DON concentrations tested was often temporary and the pigs adapted to these
concentrations, the reduction in body weight gain observed during the ﬁrst period was not fully
compensated by the time when the pigs reached slaughter weight. The CONTAM Panel noted that in
several studies the LOAELs for reduced feed intake and reduced body weight gain were lower than the
NOAELs in the other studies; e.g. LOAEL of 0.35 mg DON/kg feed from Trenholm et al. (1983)
compared to the NOAEL of 2.8 mg DON/kg feed from Richter et al. (1989). Therefore, a wide range of
NOAELs for reduced feed intake and reduced body weight gain (0.7–5.0 mg DON/kg feed) was
observed overlapping with even a wider range of LOAELs (0.35–13 mg DON/kg feed).
7.3.2.2. 3-Ac-DON and 15-Ac-DON
The only identiﬁed study on acetylated forms of DON was on intestinal toxicity of DON, 3-Ac-DON
and 15-Ac-DON ex vivo and in vivo (Pinton et al., 2012). In the 4-week feeding trial, weaned piglets (n
= 6 per group) were fed a diet either containing 2.29 mg DON/kg feed only or a mixture of DON and
15-Ac-DON 1.24 and 0.935 mg/kg feed, respectively (3-Ac-DON at 100 times lower concentrations).
The in vivo experiment showed more histological lesions in the group exposed to 15-Ac-DON
compared to the animals of the DON and the 3-Ac-DON group indicating an enhanced intestinal
toxicity of 15-Ac-DON compared to DON. This effect was correlated with the abilities of DON, 3-Ac-
DON and 15-Ac-DON to lead to an increased phosphorylation of MAPK, which conﬁrmed the
observations from the ex vivo experiment (see Section 7.7.2). However, as only one concentration was
tested no speciﬁc NOAEL/LOAEL for 3-Ac-DON or 15-Ac-DON could be identiﬁed.
7.3.2.3. DON-3-glucoside
The only study available on the toxicity of DON-3-glucoside was the ex vivo study of Pierron et al.
(2016b) on the glucosylation of DON (see Section 7.7) and thus no NOAEL/LOAEL could be identiﬁed
for DON-3-glucoside in pigs.
7.3.2.4. Conclusions on pigs
Reduced feed intake and reduced body weight gain were the most often reported chronic adverse
effects of DON in pigs. However, DON may cause several other adverse effects in pigs including lesions
in the oesophageal region of the stomach, in the liver, the lungs and the kidneys and changes in
different clinical chemistry parameters (plasma nutrients and plasma enzyme activities). Several studies
described an impact of DON on immune responses in pigs but the type and the size of those
responses could hardly be associated with relevant adverse immunological effects and thus no dose-
concentration/response data were identiﬁed to assess adverse immunological effects. While the acute
NOAEL for vomiting varied between 0.7 and 12 mg DON/kg feed a lowest LOAEL of 2.8 mg DON/kg
feed was identiﬁed for vomiting from the available data. Reduced feed intake and weight gain
reduction were identiﬁed as the critical chronic adverse effects of DON in pigs and wide ranges of
NOAEL and LOAEL values were identiﬁed by the CONTAM Panel. The overall NOAEL for reduced feed
intake and weight gain was 0.7 mg DON/kg feed and the overall LOAEL 0.35 mg DON/kg feed. The
CONTAM Panel noted that the LOAELs in some studies on pigs were lower than the NOAELs in other
studies and depending on the observation period NOAELs were equal to the LOAELs in some studies,
which was likely due to adaptation of the pigs to the DON exposure. However, reiterating EFSA (2004),
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the CONTAM Panel noted that the reduction in body weight gain observed during the ﬁrst period was
not fully compensated by the time when the pigs reached slaughter weight. Due to the limited or lack
of data on adverse effects in pigs caused by 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, no speciﬁc
NOAELs/LOAELs could be identiﬁed for these forms.
7.3.3. Poultry
Health effects of DON on poultry have recently been reviewed by Awad et al. (2008), Awad et al.
(2012a, 2013). Several experimental studies using feed naturally contaminated by Fusarium
mycotoxins including acetylated forms of DON were identiﬁed, while no studies were found using feed
containing modiﬁed forms of DON.
Due to the high number of studies available for adverse effects on poultry, the CONTAM
Panel decided not to consider the publications in which the effects could not directly be linked solely to
DON because of the substantial co-contamination with other mycotoxins such as fusaric acid,
zearalenone, fumonisins, enniatins and beauvericin or the details on methods of analysis, presence/
absence of other mycotoxins and concentrations in feeds were not reported. The overview of the
studies on broiler chickens included by the CONTAM Panel in this opinion is presented in Table 49.
7.3.3.1. DON
The CONTAM Panel noted that the studies summarised by EFSA (2004) and more recent studies of
Chowdhury et al. (2005), Girgis et al. (2008), Levkut et al. (2009), Ghareeb et al. (2012, 2016) and
Yunus et al. (2012a) investigated the impact of DON to immune response or immunocompetence in
poultry besides zootechnical parameters such as feed intake and body weight gain (see also Table 49
on broiler chickens). However, no suitable parameter for the risk assessment of DON (nor its
acetylated and modiﬁed forms) in poultry could be identiﬁed among the various immune responses
reported in these studies or the observed size of the change of investigated immune responses could
not be associated with relevant adverse immunological effects. The CONTAM Panel concluded that no
suitable concentration–response data on adverse immunological effects were available for the hazard
characterisation of poultry. Chowdhury (2005) studied effects of DON on haematology in poultry but
no haematotoxicity was observed.
Acute mycotoxicosis in broiler chickens associated to DON was characterised by extensive
ecchymotic haemorrhaging throughout the carcass, widespread deposition of urates, disturbance of
the nervous system, and irritation of the upper gastrointestinal tract. An approximate oral LD50 dose of
140 mg/kg bw was reported by the authors (Huff et al., 1981).
The previous EFSA (2004) opinion reported data on the potential adverse effects of DON in
chickens. Reduced feed intake and body weight gain were only found when concentrations reached
16–20 mg DON/kg feed (Kubena et al., 1987a, 1988, 1989; Kubena and Harvey, 1988; Harvey et al.,
1991). Kubena et al. (1985) describe, however, a decrease in the relative and absolute liver weight
and an increase on the relative and absolute gizzard weight in chickens fed 9 or 18 mg DON/kg feed
for days 1–35 of age.
D€anicke et al. (2003) used ﬁve groups of 64 male broilers from day 1 to day 35 of age to evaluate
the effects of different dietary proportions of wheat (0, 16.5, 33, 49.5 and 66%) naturally
contaminated with 21.2 mg of DON and 0.4 mg of zearalenone per kg of wheat (0, 3.5, 7, 10.5 and 14
mg DON/kg diet). The feed intake and body weight gain decreased linearly in broilers given DON at
concentrations of 10.5 and 14 mg/kg feed. The authors concluded that feeding of diets containing
approximately 10 mg DON/kg or more affected the performance of broilers negatively. Based on these
data, the CONTAM Panel considered the concentrations of 10 and 7 mg DON/kg feed as LOAEL and
NOAEL for chickens, respectively.
Several experiments on broilers chicks were performed by Awad et al. (2004, 2006, 2012b, 2014)
and Ghareeb et al. (2012, 2014) using diets supplemented by 10 mg DON/kg feed The ﬁrst
experiment was on broilers chicks (one-day-old) fed for 42 days (Awad et al., 2004, 2006). The control
group (n = 91) was fed starter and grower diets based on wheat, soybean meal, maize, rapeseed oil,
and a premix with vitamins, minerals, amino acids, salt, and dicalcium phosphate. The DON-group
(n = 95) was fed the starter and grower diets supplemented with 10 mg DON/kg feed. The DON-diet
impaired intestinal transfer and uptake of nutrients such as glucose, but it did not impair growth
performance such as body weight gain and feed conversion. The absolute or relative organ (liver,
gizzard, duodenum, pancreas, heart and spleen) weights were not altered signiﬁcantly in broilers fed
the diet containing DON and no pathological lesions were found in the gut. However, a decrease of the
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weight and alteration of the morphology of the small intestine were observed: slight villus atrophy and
irregular crypts especially in the duodenum and jejunum (shorter and thinner villi) such that the
authors concluded that, diets with DON concentrations below the levels that induce a negative impact
on performance could alter small intestinal morphology in broilers. In the two follow-up studies, Awad
et al. (2012b, 2014) investigated the genotoxic effects of DON in broiler chickens (see Section 7.2.9)
but the CONTAM Panel noted that these effects are not relevant for the health of broiler chickens due
to their short life time. Using the design of Awad et. al. (2004, 2006), but with 10 animals per group,
Ghareeb et al. (2014) observed an elevation of plasmatic corticosterone and increased the heterophil-
lymphocyte ratio (stress index) at 10 mg DON/kg diet. Body weight and body weight gain were
reduced during the starter phase and during the grower phase, respectively. Based on these studies
above the CONTAM Panel identiﬁed the concentration of 10 mg/kg feed as LOAEL for broiler chickens.
In the review of Ghareeb et al. (2015) on the impact of DON contaminated diet on intestine
integrity in chickens, a level around 5 mg DON/kg feed generated shorter villi and a decrease of villi
surface area without any decrease of villus height and crypt depth and consequently without any
impact on feed intake and body weight. However, at a level of 10–12 mg DON/kg feed the alteration
of intestine morphology results in reduced body weight gain and a LOAEL of 10 mg DON/kg feed was
identiﬁed.
Unlike the above studies using the artiﬁcially contaminated diets, Awad et al. (2011) fed broiler
chickens with a diet naturally contaminated with DON, 3-Ac-DON and zearalenone (see details in
Section 7.1.5.3.1). None of the zootechnical parameters (body weight, body weight gain, feed intake
and feed conversion) responded to increased DON levels in the diet and the absolute and relative
weights of organs (liver, heart, proventriculus, gizzard, small intestine, spleen, pancreas, colon, cecum,
bursa of Fabricius and thymus) remained unaltered; also the intestine density (weight/length ratio).
However, in the jejunum, the villi were shorter and the villus surface area decreased in DON fed birds
compared to controls; however villus width, crypt depth, and villus height/crypt depth ratio in the
jejunal mucosa showed no changes. Therefore, the CONTAM Panel indentiﬁed the 5 mg DON/kg in
feed as a NOAEL.
Yunus et al. (2012b) investigated the effects of DON in male broilers, and in particular body weight
gain and intestinal morphology (see details in Section 7.1.5.3.1). DON was negatively (linear and
signiﬁcant over the ﬁrst 3 weeks only) correlated with body weight gain. No difference in body weight
gain was observed after the third week between treated and control birds. A negative correlation was
also observed for the relative density (weight/length) of the small intestine, itself correlated with a
decrease in villus height. The transport function of the epithelium per unit area was reduced at higher
concentrations of DON when investigating the short circuit current of the jejunal epithelium. DON was
positively (linear over the ﬁrst 4 weeks only) correlated with the length of the jejunum. The authors
concluded that consumption of contaminated grains resulted in adverse effects on intestinal
morphology during early growth phases. Since no differences in body weight between control and
DON exposed birds was observed at the end of the experiment, the authors considered these chickens
may adapt to a chronic DON exposure by morphological and functional modiﬁcations.
Osselaere et al. (2012) fed Ross chickens with control, artiﬁcially and naturally DON-contaminated
feed (see details in Section 7.1.5.3.1). No statistically signiﬁcant effects on zootechnical parameters
(feed intake, body weight gain and ﬁnal live body weight) were observed between the two groups 2
and 3 and controls and the authors interpreted that as development of a tolerance to DON either due
to aging or due to an adaptation via metabolic and hormonal compensatory mechanisms. In the
follow-up study (see Section 7.1.5.3.1), Osselaere et al. (2013a) treated of eight 3-week old Ross
broiler chickens in a two-way cross-over design: four animals received an oral bolus and four animals
received intravenously DON single doses at 0.750 mg/kg bw. After a wash-out period was applied, the
animals that previously received an oral bolus, received at that time an intravenous dose and vice
versa. Since no clinical signs of intoxication were observed the authors interpreted this outcome also
as tolerance of poultry to DON given the observed high plasma clearance.
Kautzman et al. (2015) fed Ross 308 male broiler chickens (n = 15 per group) for 35 days with
naturally contaminated feed at the levels of 0.5–1.5, 0.7–3.7, 1.0–6.9 and 1.2–8.3 mg DON/kg feed.
No signiﬁcant difference in body weight, feed intake and feed conversion ratio was observed between
the groups. Since this study did not include a control group, it was not considered for hazard
characterisation by the CONTAM Panel.
One-day-old broiler chickens (Ross 308, both sexes) were divided into two groups, each consisting
of eight pens of seven birds each, and were fed for 2 weeks either a control diet (0.2 mg DON/kg
feed) or a DON-contaminated diet (4.6 mg DON/kg feed), which was a mixture of the control feed
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with toxic culture medium (Antonissen et al., 2015). No signiﬁcant differences were observed in body
weight and feed conversion ratio between the control group and chicken fed a DON-contaminated
diet. The expression of the gene coding for MUC2 was signiﬁcantly down-regulated in the duodenum
of broilers fed DON-contaminated diet (see also Section 7.2.9). However, this genotoxic effect was not
considered relevant for broiler chickens by the CONTAM Panel. From this study, the CONTAM
Panel identiﬁed 4.6 mg DON/kg in feed as a NOAEL for body weight gain and feed conversion ratio.
In a cross-over trial of Broekaert et al. (2016), 5 mg DON/kg feed was administered orally to
broiler chickens (see details in Section 7.1.5.3.3). No adverse effects were observed in broiler chickens
but since this was a single dose study it was not considered for hazard characterisation.
Conclusions on broiler chickens exposed to DON. From the above experiments in broiler
chickens (see also Table 49), the CONTAM Panel selected the studies performed using the highest DON
concentrations in feed combined with the longest periods of time to determined a NOAEL for chicken.
Referring in particularly to the data of D€anicke et al. (2003), Awad et al. (2011) and Antonissen et al.
(2015), the CONTAM Panel concluded that the range of 4.6–7.0 mg DON/kg feed did not generate
adverse effects on feed intake, body weight gain and ﬁnal live body weight. Based on the available
data, particularly from D€anicke et al. (2003), Yunus et al. (2012b), Awad et al. (2012b, 2014) and
Ghareeb et al. (2014), the CONTAM Panel noted that concentrations of 10–12 mg DON/kg feed did not
only induce modiﬁcations in intestine morphology but also generated a reduction of body weight gain.
Therefore, the concentration ranges of 4.6–7 and 10–12 mg DON/kg feed were identiﬁed by the
CONTAM Panel as the ranges for NOAELs and LOAELs, respectively, for chickens.
Potential adverse effects of DON in laying hens, were reported in the previous EFSA (2004)
assessment. Diets containing DON up to 83 mg/kg feed did not have a signiﬁcant effect on the egg
production. Hatchability was not affected by levels of up to 18 mg DON/kg feed (Hamilton et al., 1985;
Lun et al., 1986; Kubena et al., 1987b; Bergsj€o et al., 1993a). However, a small increase in the
incidence of minor malformations, considered as delayed fetal maturation (delayed ossiﬁcation, un-
withdrawn yolk sac) were observed in chick fetuses from hens given a feed containing 2.5 or 3.1 mg
DON/kg, but not in the group given 4.9 mg DON/kg feed (Bergsj€o et al., 1993a). No abnormalities
were recorded in hens given 0–4.9 mg DON/kg feed (Hamilton et al., 1985).
A 16-week experiment tested 25 Lohmann Brown laying hybrids hens (18-week-old) using two
types of diets: a contaminated diet containing 17.63 mg DON, 5.5 mg 15-Ac-DON, 1.60 nivalenol, 1.58
mg zearalenone and 0.09 mg 3-Ac-DON per kg and an uncontaminated diet as control containing 0.21
mg DON and 0.04 mg zearalenone per kg (other mycotoxins were not analysed). Feeding of the
contaminated diet depressed feed intake by approximately 5% (D€anicke et al., 2002).
Forty-two 26-week old broiler breeder hens were fed a control (0.2 mg DON/kg) and a
contaminated (13 mg DON/kg) diet (lower levels were reported for 15-Ac-DON and zearalenone)
(Smith et al., 2007). Similarly, nine roosters (Ross 308) were fed a control (0.9 mg DON/kg) and a
contaminated (7.8 mg DON/kg) diet. Rooster semen volume and sperm concentration, viability, motility
and relative weights of testes were not signiﬁcantly affected by DON. When inseminating the hens
three times during the week before egg collection with 50 lL of fresh pooled semen from these
roosters, no effects of DON were observed for feed intake, feed efﬁciency (feed consumed/egg
produced), body weight and for liver, spleen and kidney relative weights. There was also no effect on
egg weight, yolk weight, albumen height and eggshell deformity and body weight or viability of newly
hatched chicks. However, egg shell thickness was reduced after 4 weeks and in early (1–7 day)
embryonic mortality was increased. In conclusion, DON concentration at 13 mg DON/kg feed in the
diet of Ross breeder hens had a negative impact on fertility.
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Table 49: Adverse effects of broiler chickens exposed to DON in feed
Animals (age) n
Concentration
(mg/kg feed)
Toxin source
Exposure
time
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Studies reported in EFSA (2004)
Ross (day 1) 45 1.8–5.4 Contaminated
maize
37 days Increased heart weight n.a. 3.6 Leitgeb et al.
(1999)
Broiler chicks
(day 1)
36 16 Contaminated
wheat
21 days No effect on feed intake, body weight gain or other
parameters measured
n.a. 16 Harvey et al.
(1997)
White Leghorn
(day 1)
100 0, 18 Contaminated
wheat
12 weeks Reduced body weight after 4 and 8 weeks, but not
12 weeks, increased relative gizzard weight, decreased
haemoglobin at 4 weeks, but not after 8 and
12 weeks
18 n.a. Kubena and
Harvey
(1988)
White Plymouth
Rock x White
Cornish (day 1)
240 0.1–3.4 Contaminated
oats
35 days No effect on feed intake, body weight gain or meat
quality
n.a. 3.4 Bergsj€o and
Kaldhusdal
(1994)
Hubbard x
Hubbard (day 1)
0, 16 0, 16 Contaminated
wheat
3 weeks Reduced body weight gain, increased feed:body
weight gain ratio, relative gizzard weight and relative
bursa weight
16 n.a. Kubena et al.
(1989)
Hubbard
xHubbard)
(day 1)
60 0, 16ad libitum Contaminated
wheat
3 weeks Reduced body weight gain, increased feed:body
weight gain ratio, increased relative gizzard weight,
increased red blood cell count and serum phosphorus,
decreased mean corpuscular haemoglobin and glucose
16 n.a. Kubena et al.
(1988)
White Leghorn
(day 1)
51 0, 9, 18 Contaminated
wheat
35 days Reduced liver weight, increased gizzard weight,
temporary decreased plasma triglycerides, glucose,
increased creatinine, increased plasma haemoglobin
and temporary red blood cells
9 n.a. Kubena et al.
(1985)
White Leghorn
(day 1 to egg
production)
30 0, 18ad libitum Contaminated
wheat
48 weeks Small signiﬁcant increase in shell weight, shell
thickness, decrease in serum uric acid, glucose,
triglycerides and cholesterol and increase in serum
c-glutamyltransferase and alkaline phosphatase
18 n.a. Kubena et al.
(1987a)
White Leghorn
(day 7)
50 0–0.7 Contaminated
wheat
14 days No signiﬁcant effect on feed intake, body weight gain
or other parameters measured (control feed
composition differed from the contaminated diet)
n.a. 0.7 Hamilton
et al. (1985)
White Leghorn
(day 7)
50 3.1–4.1 Contaminated
wheat
28 days Increased feed intake, body weight gain and feed:gain
ratio or no apparent lesions in oral activity or other
parameters measured (control feed composition
different from the contaminated diet)
n.a. 4.1
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Animals (age) n
Concentration
(mg/kg feed)
Toxin source
Exposure
time
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
White Leghorn
(day 1)
60, 0, 18 Contaminated
wheat
18 and 9
weeks
Reduced immune response to vaccine reduced
mitogen-induced lymphoblastogenesis
18 n.a. Harvey et al.
(1991)
Hubbard 9
Hubbard and
white Leghorn
(day 1)
10 0, 50 Pure toxin 9 weeks Reduced response to mitogens in female broiler
chickens, no effect in male broiler chickens or in
leghorn chickens of either gender
50 n.a.
White mountain
9 Hubbard
(6 days)
24 0–210 Contaminated
maize
5 days Increased feed conversion, reversible concentration-
dependent increase in oral and gizzard epithelial
lesions
49.4 n.a. Moran et al.
(1982),
Reduced feed intake n.a. 116.1
Shaver (day 1) 18 9 2 < 0.2–1.87 Contaminated
wheat
28 days No effect on feed intake, body weight gain, liver or
kidney
n.a. 1.89 Hulan and
Proudfoot
(1982)
Hubbard 9
Hubbard (day 1)
60 0, 16 Contaminated
wheat
3 weeks Reduced body weight, increased feed efﬁciency,
increased relative gizzard weight, anaemia, decreased
lactate dehydrogenase and serum triglycerides
16 n.a. Huff et al.
(1986)
White Leghorn
9 Single Comb
(26 weeks)
10 0, 83 Contaminated
wheat
27 days Small erosions in the gizzard, no other pathological
changes
83 n.a. Lun et al.
(1986)
Different types 3 0–0.70 Contaminated
wheat
86 or 135 days Increased liver triglycerides and total liver lipid at 0.35
mg/kg, not at 0.70 mg/kg
n.a. Farnworth
et al. (1983)
Studies identiﬁed after EFSA (2004)
Lohmann
(1 day)
64 0, 3.5, 7, 10.5, 14 Contaminated
wheat
3–5 weeks Decreased spleen weight, reduced body weight gain,
decreased Newcastle Disease Virus vaccine response
10.5 7 D€anicke et al.
(2003)
Ross (1 day) 95 0, 10 Toxin added to
feed
6 weeks No effects on feed intake or body weight gain or other
zootechnical parameters, alteration of intestinal
morphology
10 n.a. Awad et al.
(2004, 2006)
Ross (1 day) 8 0, 10 Toxin added to
feed
5 weeks Reduced feed intake, reduced body weight gain during
the ﬁrst 2 weeks, reduced total lymphocyte count,
decreased Infectious Bronchitis Virus vaccine response
10 n.a. Ghareeb
et al. (2012,
2014)
Ross (1 day) 15 0.9, 5 Contaminated
wheat
7 weeks Reduced feed intake, reduced body weight, body
weight gain during the ﬁrst 2 weeks but not later,
relative weight of organs not altered, in the jejunum
the villi were shorter but the villi width not modiﬁed
n.a. 5 Awad et al.
(2011)
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Animals (age) n
Concentration
(mg/kg feed)
Toxin source
Exposure
time
Effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Ross (7 day) 25 0.3, 1.7, 12 Contaminated
culture medium
added to feed
5 weeks Reduced feed intake, reduced of body weight gain
and alteration of intestinal morphology during the ﬁrst
3 weeks, no zootechnical effects at the end of the
experiment
12 n.a. Yunus et al.
(2012a,b)
Ross (3 weeks) 8 2.4, 7.5 Toxin added to
feed
3 weeks No effects on feed intake or body weight gain or other
zootechnical parameters at the end of the experiment
n.a. 7.5 Osselaere
et al. (2012,
2013a)
Ross (1 day) 56 0.2–4.6 Contaminated
culture medium
added to feed
2 weeks No effects on feed conversion ratio and body weight
gain
n.a. 4.6 Antonissen
et al. (2015)
n: number of animals per group; n.a.: not applicable because not identiﬁed by the authors of the study or by the CONTAM Panel.
The ﬁrst part of the table (until the reference of Farnworth et al. 1983) has been modiﬁed from EFSA (2004). Note that the units are expressed as mg/kg feed.
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Ebrahem et al., (2014b) examined diets with three increasing levels of DON in 216 laying hens
(23-week-old, Lohmann Brown and Lohmann Selected Leghorn) and 24 adult roosters for the
reproductive performance and the health of the newly hatched chicks. Very low contaminated wheat
with 0.054 mg DON and 0.069 15-Ac-DON/kg was used as ingredient to prepare the control diet which
contained 0.04 mg DON/kg feed. Highly contaminated wheat (inoculated by a F. culmorum strain) with
13.5 mg DON, 4.7 mg aurofusarin, 0.76 mg DON-3-glucoside and 0.23 mg 3-Ac-DON was used as
ingredient to prepare the other two DON-containing diets which contained around 5 and 10 mg DON/
kg feed. Hatchability was signiﬁcantly more affected by the presence of DON in Lohmann brown than
the Lohmann selected Leghorn chicks. An interaction between the concentration of DON in the diet
and the breed was observed for fertility. At 10 mg DON/kg diet the fertility was lower for the eggs
from Lohmann brown hens compared with Lohmann Selected Leghorn hens. Compared with controls,
chicks hatching from exposed eggs had signiﬁcantly decreased spleen relative weights, and gizzard
relative weight was signiﬁcantly decreased only in Lohmann Brown chicks at 10 mg DON/kg. No
haematological disturbances were observed and no organ histopathology was identiﬁed. DON showed
no effects on the fertility of the roosters (the percentage of fertile eggs of all laid eggs). However, from
the observation at 10 mg DON/kg diet on fertility and hatchability of eggs for the Lohmann Brown
strain, the authors concluded that the breed of the hens might modulate the effect of DON on
reproductive performance of laying and they considered 5 mg DON/kg feed as no-effect level for
reproductive performance of hens.
Conclusions on laying hens exposed to DON. From the studies on laying hens described
above, the CONTAM Panel identiﬁed the range of LOAELs of 10–13 mg DON/kg feed for inducing a
decrease of feed intake, spleen and gizzard relative weights, egg fertility and hatchability. Since diets
of 4.9 and 5 mg DON/kg did not generate any abnormality in zootechnical parameters such as feed
intake, hatchability and egg fertility, 5 mg DON/kg feed was considered as overall NOAEL for laying
hens.
In Pekin ducks, as reported in the EFSA (2004) opinion, no signiﬁcant differences in feed intake,
body weight gain, and feed to gain ratio was observed at DON concentrations up to 7 mg/kg feed,
although during the ﬁrst week of exposure a slight depression in body weight gain was observed,
which was, however, fully compensated later. Gross macroscopical inspection of the upper digestive
tract did not reveal any signs of irritation, inﬂammation or other pathological changes. The relative
organ weight of the bursa of Fabricius decreased dose dependently. Activities of glutamate-
dehydrogenase and c-glutamyltransferase in serum were not or inconsistently affected by DON
exposure (D€anicke et al., 2004). No later data than that reported in the 2004 EFSA opinion were
identiﬁed in the recent literature. Yoshizawa and Morooka (1974) (not included in the EFSA, 2004)
reported for the 10-day old duckling the minimum emetic dose subcutaneously administered of 10 mg
DON/kg bw. Based on these studies above on ducks, the CONTAM Panel identiﬁed concentration of 7
mg DON/kg feed from the study of D€anicke et al. (2004) generating no zootechnical parameters
change as the NOAEL for ducks in this study.
Grimes et al. (2010) performed a trial on 168 male turkey poults placed into 24 pens (7 birds/pen;
6 pens/treatment) and reared to 3 weeks (21 days) involving four diets with naturally contaminated
corn: (1) clean maize as control, and diets containing (2) 0.1 mg aﬂatoxin B1, (3) 1.7 mg DON and (4)
0.05 mg aﬂatoxin B1 + 0.9 mg DON per kg feed. Poults fed DON contaminated diets (3 and 4) showed
reduced feed intake and reduced body weight gain and had the lowest feed consumption among the
four groups. The relative spleen weight of DON fed birds was also reduced. Relative weights of heart,
gizzard, bursa of Fabricius and the colours of breast muscle and gizzard were not affected. There were
no differences in antibody productions between the four groups. Based on data from the group (3), a
diet only contaminated with DON at 1.7 mg/kg feed generated changes in zootechnical parameters
(feed intake, body weight gain, feed to gain ratio and organ weight). However, this study was
conducted for a short period of time (3 weeks).
Devreese et al. (2014) conducted an experiment on 120 one-day-old male turkey poults fed a
control diet containing 0.06–0.39 mg DON, below 0.05 (LOD)–0.10 mg 15-Ac-DON, and below 0.03
mg of others mycotoxins per kg feed, and a naturally contaminated diet containing 4.0–6.5 mg DON,
0.45–0.55 mg 15-Ac-DON, 0.026–0.120 mg fumonisins B1+B2 and 0.37–0.67 zearalenone, per kg feed
(see details in Section 7.1.5.3). Except for the starter phase, no signiﬁcant differences in performance
parameters (body weight, body weight gain, feed intake or feed conversion ratios) were observed. The
feeding of contaminated diets reduced duodenal villus height and apparent villus surface area. An
adaptation to DON exposure was observed by the authors after the starter stage of the trial (see also
Section 7.1.5.3.1). The CONTAM Panel noted that Devreese et al. (2014) reported effects in this study
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for the longest period of time and considered these results as the most relevant for the hazard
characterisation of DON in farmed turkeys. Since the concentration of 6.5 mg/kg feed generated no
major changes in zootechnical parameters (body weight, body weight gain, feed intake or feed
conversion ratios), this value was identiﬁed as overall NOAEL for turkeys.
7.3.3.2. 3-Ac-DON and 15-Ac-DON
Although a number of the studies on chickens, ducks, turkeys or laying hens described above
dealt with diets that contained 3-Ac-DON/kg and/or 15-Ac-DON/kg feed, the described effects could
not be causally related to 3-Ac-DON and/or 15-Ac-DON and such a speciﬁc hazard characterisation of
3-Ac-DON/kg and/or 15-Ac-DON/kg feed could not be performed.
7.3.3.3. DON-3-glucoside
The only identiﬁed study on DON-3-glucoside performed cross-over animal trials with oral
administration of 5 mg DON-3-glucoside/kg feed to broiler chickens (Broekaert et al., 2016) (see
details in Section 7.1.5.3.3). No adverse effects were observed. However, as only one concentration
was tested no NOAEL/LOAEL for DON-3-glucoside was identiﬁed.
7.3.3.4. Conclusions on poultry
For broiler chickens, the level of 4.6–7 mg DON/kg feed did not generate any adverse effects. The
level of 10–12 mg DON/kg feed did not only cause some modiﬁcations in intestine but also generated
some feed intake and body weight gain changes. The CONTAM Panel identiﬁed 4.6–7 mg DON/kg feed
as the range of NOAELs and of 10–12 mg DON/kg feed as the range of LOAELs for chickens. For laying
hens diets with DON concentrations up to 18 mg DON/kg, feed did not induce any negative impact on
as body weight gain, hatchability and egg production. However, a diet of 10–13 mg DON/kg feed
induced a decrease of feed intake at an early stage of the experiment, a decrease of spleen and gizzard
relative weights and a decrease of egg fertility. The diets of 4.9 and 5 mg DON/kg did not generate any
abnormality in body weight gain, hatchability and egg fertility. Therefore the CONTAM Panel identiﬁed
10–13 mg DON/kg feed as the range of LOAELs and 5 mg DON/kg feed as NOAEL for laying hens. For
ducks, the CONTAM Panel identiﬁed the concentration of 7 mg DON/kg feed and for turkeys the
concentration of 6.5 mg/kg feed generating no changes in body weight, weight gain, feed intake or
feed conversion ratios as the NOAELs for these animals. Due to the limited or no data on adverse
effects caused by 3-Ac-DON, 15-Ac-DON and/or DON-3-glucoside, no speciﬁc NOAELs/LOAELs could be
identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for poultry.
7.3.4. Horses
Only few studies on the toxicity of DON were identiﬁed in horses and are described in this section.
7.3.4.1. DON
The previous EFSA (2004) opinion reviewed two studies on the effects of DON in horses of Johnson
et al. (1997). Barley contaminated with 36–44 mg/kg DON was fed to ﬁve healthy horses for 40 days.
Blood for clinical investigations was sampled every 10th day. Haematocrit values decreased slightly in a
linear fashion, but changes in the peripheral white blood cell counts, polymorphonuclear leukocytes
and lymphocyte counts were not detected. No changes in serum creatinine, sodium, potassium,
chloride, total calcium, and inorganic phosphate were detected. Serum enzyme activities of
c-glutamyltransferase (GGT), aspartate aminotransferase (AST) and creatine kinase decreased slightly
in a linear fashion during the experimental period. Total serum protein, serum albumin and globulin, as
well as serum IgG and IgA, also decreased but changes were not-signiﬁcant and all values were within
the normal range. The horses showed no reduced feed intake or any other signs of adverse effects at
the concentrations of 36–44 mg/kg feed. The CONTAM Panel identiﬁed 36 mg/kg feed as the overall
NOAELs from this study.
New data that have been reported since the EFSA (2004) opinion have been published and are
described next. Among those were four studies that were not consider further by the CONTAM Panel,
namely the two studies of Raymond et al. (2003, 2005) since co-contamination of the diet with high
levels of fusaric acid could have introduced bias in the observed effects of DON, the study of Caloni and
Cortinovis (2010) reporting a weight loss and elevated hepatic enzymes in riding horses connected with
straw contaminated without quantifying the DON concentrations and the study of Urosevic et al. (2011)
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investigating mycotoxicosis associated to the occurrence of DON in oats where relationship of DON
levels in diets and feed intake by animals were imprecise.
Khol-Parisini et al. (2012) observed no adverse effects on general health in a cross-over design the
impact of DON on cellular and humoral immune effects in horses fed for 14 days naturally
contaminated 2 kg oat diets with low (0.49 mg DON/kg diet) and high (20.2 mg DON/kg diet) levels,
allowing for a 3-week wash-out. Serum haptoglobin concentration was signiﬁcantly elevated at the
high dose, but only minor effects were noted for differential blood counts and serum biochemistry, and
no effects were seen for lymphocytes and their proliferation (concanavalin A, phytohaemagglutinin and
pokeweed mitogen). The authors concluded that the concentration of 20.2 mg DON/kg feed appeared
to have no major impact on the measured immune response of horses and the CONTAM
Panel identiﬁed this concentration as the NOAEL for horses.
Schulz et al. (2015) fed 12 geldings with control, low DON intake (7.7 mg DON/kg) and high DON
intake (11.4 mg DON/kg) diets for 21 days (see details in Section 7.1.5.4.1). None of the horses
demonstrated any adverse effects on health status. Although the reported data on body weights were
limited they seemed to remain unchanged throughout the experiment. No changes in haematological
and serum parameters or serum globulins were observed. From this study the concentration of 11.4
mg DON/kg feed was considered as the NOAEL by the CONTAM Panel.
7.3.4.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.3.4.3. DON-3-glucoside
No data were identiﬁed.
7.3.4.4. Conclusions on horses
Overall, the CONTAM Panel identiﬁed only three studies suitable for the characterisation of hazard
of horses, among them the study over 40 days identiﬁed previously by EFSA (2004) from which
NOAELs of 36–44 mg DON/kg feed for reduced feed intake were derived. Two recent studies allowed
the identiﬁcation of NOAELs of 20.2 and 11.4 mg DON/kg feed based on short-term studies of only 2
and 3 weeks, respectively. Accounting for the longer period of observation time without generating
adverse effects, the CONTAM Panel concluded that the NOAELs of 36–44 mg DON/kg feed were still
valid for horses and decided to use 36 mg DON/kg feed as currently most reliable value for the NOAEL
of horses. No endpoints for acute effects in horses were identiﬁed. Due to the lack of data on adverse
effects caused by 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, no speciﬁc NOAELs/LOAELs could be
identiﬁed.
7.3.5. Farmed rabbits
7.3.5.1. DON
The previous EFSA (2004) opinion noted that the available data on the potential adverse effects of
DON on rabbits were limited. Khera et al. (1986) carried out a teratology study in which maternal and
fetal body weights were decreased at the level of 30 mg/kg feed or higher (see details in
Section 7.2.7). That level was considered by the CONTAM Panel as the LOAEL and the next lower dose
of 15 mg/kg feed which was not maternotoxic or fetotoxic was considered as the NOAEL for farmed
rabbits.
Since then two studies on rabbits exposed to DON were identiﬁed. Hewitt et al. (2015) investigated
the effects of feeding diets containing grains naturally contaminated with mycotoxins to fryer rabbits.
During 21 days, thirty 5-week old male New Zealand white rabbits (0.4–0.9 kg at the beginning) were
fed a control diet that contained DON, aﬂatoxin B1 and ochratoxin A at a concentration of 0.25,
0.0024 and 0.0011 mg/kg feed, respectively, and a contaminated diet that contained DON, 15-Ac-
DON, aﬂatoxin B1 and ochratoxin A at a concentration of 4.3, 0.12, 0.0026 and 0.0009 mg/kg feed,
respectively. Concentrations of the other mycotoxins were below their LODs (0.05 mg/kg feed for
3-Ac-DON 0.12 mg/kg feed for nivalenol, 0.04–0.07 mg/kg feed for T-2 toxin, HT-2 toxin,
diacetoxyscirpenol and neosolaniol, and 0.25 mg/kg feed for zearalenone). Body weight gain and
water intake were greater in rabbits fed the contaminated diet compared with control. However, the
authors suggested that the increase in body weight gain of rabbits fed the contaminated diet was
caused by increased water consumption. There was no effect on haematological parameters and
relative organ weights, but decreased inﬁltration of eosinophilic granulocytes in different regions of the
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intestine was observed. However, the CONTAM Panel did not use this histopathologic observation as an
endpoint for hazard characterisation due to the co-occurrence of several mycotoxins or possible other
causes such as infections. Consequently, the concentration of 4.3 mg DON/kg feed was considered by
the CONTAM Panel as the NOAEL of this study.
Kachlek et al. (2015) investigated the impact of DON contaminated diet on caecal microbiota and
fermentation of growing rabbits. Two groups of 12 Pannon White rabbits were reared for 6 weeks from
35 (after weaning) until 77 days of age and were fed either a control diet or a diet containing 10.1 mg
DON/kg feed prepared from a mixture of the control feed with homogenised fungal cultures of a DON
producing Fusarium strain. DON increased the number of aerobic bacteria in the caecum of rabbits
which is an undesirable situation due to the anaerobic conditions (in physiological state) of caecum.
The authors concluded that DON affected adversely the number of aerobic bacteria in caecum. The
concentration of 10.1 mg DON/kg feed was considered by the CONTAM Panel as the LOAEL from this
study.
7.3.5.2. 3-Ac-DON and 15-Ac-DON
The CONTAM Panel identiﬁed only the study of Hewitt et al. (2012) reporting a diet with 15-Ac-
DON/kg feed with a concentration of 0.12 mg/kg feed (see details above) which was more than 30
times lower than the DON content. The CONTAM Panel noted that effects caused speciﬁcally by 15-Ac-
DON cannot be identiﬁed in this study. Therefore, and since no data on adverse effects in rabbits
caused by 3-Ac-DON were identiﬁed, the hazard of acetylated forms of DON could not be assessed.
7.3.5.3. DON-3-glucoside
No data were identiﬁed.
7.3.5.4. Conclusions on farmed rabbits
Limited or no data were available on the adverse effects of DON, and acetylated and modiﬁed
forms of DON in rabbits. Maternal and fetal body weights were decreased from the concentration of 30
mg DON/kg feed in one study on teratology but not at the lower concentration of 15 mg DON/kg feed.
From a study in which no adverse effects on body weight gain, average feed intake, relative organ
weights and haematological parameters were observed, a NOAEL of 4.3 mg DON/kg feed was
identiﬁed. In another study, a concentration of 10.1 mg DON/kg feed adversely affected the
composition of caecal microbiota, and consequently a LOAEL of 10.1 mg DON/kg feed was identiﬁed.
No speciﬁc endpoints for acute effects in rabbits have been identiﬁed. Due to the limited or no data on
adverse effects caused by 3-Ac-DON, 15-Ac-DON and/or DON-3-glucoside, no speciﬁc NOAELs/LOAELs
could be identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for rabbits.
7.3.6. Farmed ﬁsh
Among a reasonable number of publications on DON in ﬁsh, the CONTAM Panel decided not to
consider those studies. where substantial co-contamination with other mycotoxins (e.g. with
zearalenone) and the cause of the adverse effects could not be attributed to DON.
7.3.6.1. DON
Three different levels of puriﬁed DON (0.35, 0.62 and 0.95 mg DON/kg feed) were added to a
non-cereal-based ﬁsh feed and given to carp (12–16 cm length, 4 tanks per diet, with 6 ﬁsh each) for
4 weeks, at which 2 tanks per diet were sampled while the remaining 2 tanks per diet were given
uncontaminated feed for 2 weeks (Pietsch et al., 2014a). DON did not affect growth and mass of ﬁsh
during the 6-week long experiment. Only marginal DON concentrations were found in muscle (the
highest concentration was 1.4 lg/kg found in the low-dose group, and in all other groups) and DON
was not found in plasma samples. Blood parameters were not inﬂuenced although the erythrocytes in
ﬁsh given feed containing 0.35 mg DON/kg were smaller than in ﬁsh from the other groups.
Superoxide dismutase and catalase activities were increased in ﬁsh fed the low-dose feed.
In a second study of this group of authors, carp were given a feed containing virtually the same
concentrations (0.352, 0.619 or 0. 953 mg pure DON/kg feed for 6 weeks (Pietsch et al., 2014b). DON
increased lipid peroxidation in liver, head kidney and spleen in carp given 0.95 mg pure DON/kg feed
but not at 0.35 or 0.62 mg DON/kg feed. These effects were mostly reversed after 2 weeks of feeding
with uncontaminated feed. Histopathological examinations revealed increased liver damage in DON-
treated ﬁsh at all doses, which persisted after the 2-week recovery phase. More fat was found in the
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whole-body homogenates of ﬁsh from the highest dose group than in controls. Furthermore, increased
lactate dehydrogenase (LDH) activity in the kidneys and decreased LDH in muscle was observed.
According to the authors, the results indicated that DON affects metabolism. A NOAEL of 0.62 and a
LOAEL of 0.95 mg/kg feed for lipid peroxidation and histopathological damages in the liver were
identiﬁed in this study by the CONTAM Panel.
The CONTAM Panel also noted a study of He et al. (2010) on reduced body weight gain in carp
after exposure to DON in feed, but since the study design was not clear it was not considered further
for the risk assessment.
Feed based on the inclusion of contaminated maize containing DON concentrations of 0, 3.3, 5.5,
7.7 or 8.8 mg DON/kg feed (based on ELISA analysis) were used in a study with channel catﬁsh for
a total of 7 weeks in a 10 week-experiment. Twenty catﬁsh (starting weight from 5.9 g/ﬁsh) in each of
40 aquaria, giving eight aquaria per treatment, were used in the experiment. Seven weeks of feeding
did not affect growth, feed intake or feed conversion ratio. After 7 weeks, the ﬁsh were challenged
with Edwardsiella ictaluri a gram-negative bacteria (ﬁnal concentration of 1.04 9 106 colony-forming
units (CFU)/mL water for 30 min. DON apparently had a protective effect, as the cumulative 21-day
post-challenge mortality of the ﬁsh was signiﬁcantly lower in ﬁsh receiving at least 5.0 mg DON/kg
feed (no more than 5% post-challenge mortality) than the control and ﬁsh at 2.5 mg DON/kg feed (61
and 50% post-challenge mortality, respectively) (Manning et al., 2014). From this study, the CONTAM
Panel identiﬁed a NOAEL of 8.8 mg DON/kg feed for channel catﬁsh based on unaltered feed intake,
growth and feed conversion ratio. A level of 5.5 mg DON/kg feed apparently increased the resistance
towards infection in this study.
Rainbow trouts (starting weight from 24 g/ﬁsh) were fed diets containing 0.3 (control), 0.8, 1.4,
2.0 or 2.6 mg DON/kg feed (12 ﬁsh/tank and three tanks/diet). The contaminated diets were prepared
by mixing naturally DON contaminated maize into the control feed (composition of both feeds were
comparable) (Hooft et al., 2013). Statistically signiﬁcant decreasing trends in feed intake, body weight
gain, growth rate, feed and efﬁciency, retained nitrogen, recovered energy, energy retention efﬁciency
and nitrogen retention were observed. In addition, there was a pair-fed control given the lowest feed
consumption. Fish fed with the diet of highest DON concentration had a signiﬁcantly higher growth
rate, feed efﬁciency and whole-body crude protein concentration than the other groups. According to
the authors, the results indicated that, rainbow trout are sensitive to DON from naturally contaminated
grains and that the effects of DON on rainbow trout are not simply related to a reduction of feed
intake, but rather are due to metabolic effects. Based on the authors’ statistical trend analysis (no
pairwise comparisons between does groups and the controls performed) The CONTAM Panel identiﬁed
the lowest dose of 0.8 mg DON/kg feed as a LOAEL for in feed intake, body weight gain, growth rate,
feed and efﬁciency, retained nitrogen, recovered energy, energy retention efﬁciency and nitrogen
retention.
Matejova et al. (2014) fed 40 one-year-old rainbow trout a commercial feed subdivided into a
control (0.23 mg DON/kg feed) and one experimental group with the addition of 1.96 mg DON/kg
feed for 23 days with two tanks per group and 10 ﬁsh in each tank. There were no differences
between the groups in body lengths, body weight, liver weight, Fulton’s condition factor or
hepatosomatic index. Histopathological examinations revealed severe hyaline droplet degeneration in
the tubular epithelial cells of the caudal kidneys in 9 out of 10 ﬁsh given the DON-amended feed and
none for the control ﬁsh. No histopathological changes were found in the gills, skin, liver, cranial
kidney and spleen. However, the mean cell haemoglobin was signiﬁcantly decreased and a signiﬁcant
decrease in plasma concentrations of glucose, cholesterol and ammonia were recorded in exposed ﬁsh
compared to the controls at the end of the experiment. No NOAEL or LOAEL could be identiﬁed from
this study as only one dose was used, but the CONTAM Panel noted that 1.96 mg DON/kg feed caused
alterations in the tubular epithelial cells of the caudal kidney and in clinical chemistry compared to ﬁsh
given 0.23 mg DON/kg feed.
Diets containing < 0.1 (control), 3.1 or 6.4 mg DON/kg feed were fed to rainbow trout for 7 weeks
(30 ﬁsh/tank, three tanks/treatment) (Ryerse et al., 2014). In addition, there was one pair-fed control
to the high-dose group. The ﬁsh were experimentally infected (i.p.) with the gram-negative bacterium
Flavobacterium psychrophilum after 4 weeks of exposure. A dose-dependent signiﬁcant reduction in
feed intake was observed during the ﬁrst 4 weeks, but was not after the infection. After infection, the
mortality of rainbow trout fed 6.4 mg DON/kg feed was signiﬁcantly reduced (p < 0.05) in comparison
with trout fed the control diet. However, a reduced mortality after bacterial infection was also observed
in pair-fed control ﬁsh, indicating that the effect may be related more to the reduced feed intake than
to DON in the feed (mortality: in control 35.0  5.0%, in high-dose group 13.3  2.8% and in the
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pair-fed control 13.3  3.6%). In a second feeding experiment, trouts (35 ﬁsh/tank, three tanks/
group) were fed either a control diet, a diet containing 3.3 mg DON/kg feed naturally contaminated
with DON or 3.8 mg pure DON/kg feed for up to 35 days and a pair-fed control. Both feed intake and
body weight gain were signiﬁcantly reduced in both DON-exposed groups compared with the control,
while there was no effect on the feed efﬁciency. Fish given 3.8 mg pure DON/kg feed also had
signiﬁcantly lower feed consumption and body weight gain than ﬁsh given 3.3 mg DON/kg feed
naturally contaminated with DON. From these studies on rainbow trout a LOAEL of 3.1 mg/kg feed
was identiﬁed by the CONTAM Panel for reduced feed intake and body weight gain.
Feeding rainbow trouts 2 mg DON/kg feed for 23 or 32 days signiﬁcantly induced markers of
oxidative stress such as glutathione peroxidase in kidney, glutathione reductase in gill and kidney,
catalase in kidney and liver and glutathione S-transferase in gill and liver compared to controls
(Sisperova et al., 2015). No other concentrations were used.
No studies on the adverse effects of DON in salmon were identiﬁed by the CONTAM Panel.
In zebraﬁsh (Danio rerio) used as a model for farmed ﬁsh (13 ﬁsh/tank, four to ﬁve tanks/group),
pure DON (0.1, 0.5, 1.5, 2.0 or 3.0 mg DON/kg feed) did not affect the performance when given in
the feed for 45 days starting from 30 days after hatching (Sanden et al., 2012).The liver CYP1A mRNA
levels were signiﬁcantly higher in ﬁsh fed 2 mg DON/kg feed than in the other groups. Gene
transcripts of CuZn SOD and cyclin G1 in the liver increased with increasing content of dietary DON. In
the follow up (up to 8 months), no difference in the levels of 5-methylcytosine in embryos was found
between the groups. The fecundity of ﬁsh recorded between three and 8 months in controls and ﬁsh
fed 0.5, 1.5 and 3.0 mg/kg feed was 22% higher in the 1.5 mg DON/kg group compared with the
control group, while the fecundity in ﬁsh fed 3.0 mg DON/kg feed was statistically signiﬁcantly lower
than both the control and the group given 1.5 mg/kg feed. A feed concentration of 0.5 mg DON/kg
feed did not have any observed effect and was identiﬁed as the NOAEL of this study by the CONTAM
Panel.
7.3.6.2. 3-Ac-DON and 15-Ac-DON
No data were identiﬁed.
7.3.6.3. DON-3-glucoside
No data were identiﬁed.
7.3.6.4. Conclusions on farmed ﬁsh
The available data on the toxicity of DON to farmed ﬁsh were limited. For farmed ﬁsh, no speciﬁc
endpoints for acute effects in any ﬁsh species were identiﬁed. The CONTAM Panel also noted that the
hazard characterisation of DON was overall more difﬁcult than for other farm animals because of the
designs and analysis methods chosen by the authors and a large variation in experimental protocols
and endpoints measured. Reduced feed intake and/or body weight gain was reported from trout given
0.8 mg DON/kg feed, while no reduction in feed intake was found in carp given up to 0.95 mg
DON/kg feed. Channel catﬁsh may be rather tolerant towards this effect of DON as no effect on feed
intake was found in catﬁsh given as much as 8.8 mg DON/kg feed. DON was shown to reduce the
reproduction in zebraﬁsh at 1.5 mg DON/kg feed (a NOAEL of 0.5 mg DON/kg feed) and to cause lipid
peroxidation and histopathological damages in the liver of carp at 0.95 mg DON/kg feed with a NOAEL
of 0.62 mg DON/kg feed. No studies on the adverse effects of DON in salmon were identiﬁed by the
CONTAM Panel. There were no studies on these parameters from other species. Based on the available
data, the CONTAM Panel decided to use the NOAELs of 0.6–0.8 DON/kg feed from carp and rainbow
trout for farmed ﬁsh species. However, the CONTAM Panel noted that the diet composition of different
ﬁsh species may differ to a major extent between the ﬁsh species and that some ﬁsh species might be
more tolerant for the effects of DON than the others. Due to the lack of data on adverse effects
caused by 3-Ac-DON, 15-Ac-DON and/or DON-3-glucoside, no speciﬁc NOAELs/LOAELs could be
identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for farmed ﬁsh species.
7.3.7. Farmed mink
The CONTAM Panel noted that the majority of studies on farmed mink had been designed, in
particular by one group of authors, for the risk assessment of DON and its acetylated and modiﬁed
forms using pure/puriﬁed toxin not as concentration in feed but as bolus dose administered by gavage
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and expressed in mg/kg bw. Therefore, the CONTAM Panel assessed the acute hazard of DON and its
acetylated and modiﬁed forms using the dose and not the concentration in this section.
7.3.7.1. DON
Gibson et al. (1993) studied in a ﬁrst of two experiments the adverse effect of DON on 32 adult
female pastel mink (Neovison, formerly Mustela vison) randomly allocated into four groups treated for
28 days. A basal diet was given the controls and 0.28, 0.62 and 1.18 mg DON/kg feed added as DON-
contaminated ground wheat to the basal diet (equivalent to 36, 93 and 195 lg DON/kg bw per day,
respectively, calculated by the CONTAM Panel from the data reported by the authors). The DON-
contaminated diets had no statistically signiﬁcant adverse effect on feed intake or body weight in the
adult female mink over the 4 weeks. Average feed consumption was lower at the highest dose during
the ﬁrst week since one mink consistently ate very little, whereas the others reduced consumption for
no more than 3 days. A second experiment showed that the animals having the choice preferred to
eat non-contaminated feed except one animal which preferred contaminated diet. The study did not
consider vomiting and no apparent illness was noted. The CONTAM Panel identiﬁed 1.18 mg DON/kg
feed, the highest concentration tested, as a NOAEL for reduced feed intake and body weight for
farmed mink as chronic adverse effects.
Standard dark 1- to 2-year-old female mink (Neovison, formerly Mustela Vison) (6 animals per
group), bred and housed at an experimental fur farm, were administered orally via gavage 0.01, 0.05,
0.25 and 0.5 mg DON/kg bw or saline (Wu et al., 2013a) gives as bolus. The mink had been fasted for
24 h prior to dosing (water available ad libitum) and provided 50 g of feed 30 min before exposure to
DON on the day of experiment.41 Animals were then monitored for emesis (characterised in the
publications of this group of authors as either vomiting or retching42) for 3 h during which the
incidence of emesis, latency to emesis, emesis duration and number of emetic events were recorded
(0/6 animals with emesis in the control and the lowest dose group, 5/6, 6/6 and 6/6 animals with
emesis in the next higher dose groups, respectively). Latency to emesis refers to the time from dosing
of DON to the ﬁrst emetic event, whereas emesis duration is the time from the ﬁrst occurrence of
emesis to the end of the last emesis. Plasma DON level returned to basal level 2 h after the exposure.
According to the authors, the NOAEL was 0.01 mg/kg bw and the LOAEL 0.05 mg/kg bw for emesis.
The effective dose resulting in emetic events in 50% of the animals for oral exposure to DON was
estimated to be 0.030 mg/kg bw by the authors. Using the Wu et al. (2013a) data, Male et al. (2016)
reported a BMD10 value of 0.024 mg/kg bw for DON. The CONTAM Panel performed a BMD analysis
following the EFSA guidance (EFSA Scientiﬁc Committee, 2017) and calculated a BMD10 value of 0.013
mg/kg bw and a BMDL10 value of 0.004 mg/kg bw for DON (see Appendix G).
7.3.7.2. 3-Ac-DON and 15-Ac-DON
In the same oral exposure study in female minks by Wu et al. (2013a,b), 3-Ac-DON (0, 0.05, 0.25,
0.5 and 1 mg/kg bw) and 15-Ac-DON (0.1, 0.25, 0.5 and 1 mg/kg bw) were tested using the same
experimental design as for DON. Emesis was reported in 0/6 animals in the control and in 0/6, 1/6,
5/6 and 6/6 in the dose groups, respectively, for 3-Ac-DON and in 0/6 animals in the control and in
0/6, 5/6, 6/6 and 6/6 in the dose groups for 15-Ac-DON, respectively. According to the authors the
NOAEL for the 3-Ac-DON was 0.05 mg/kg bw, the LOAEL 0.25 mg/kg bw, and the effective dose for
emetic events in 50% of the animals 0.29 mg/kg bw. For 15-Ac-DON, the NOAEL was 0.01 mg/kg bw,
the LOAEL 0.1 mg/kg bw and the effective dose for emetic events in 50% of the animals 0.04 mg/kg
bw. Using the Wu et al. (2013a) data, Male et al. (2016), reported BMD10 values of 0.198 and
0.040 mg/kg bw for 3-Ac-DON and 15-Ac-DON, respectively. The BMD analysis of the CONTAM
Panel following the EFSA guidance (EFSA Scientiﬁc Committee, 2017), resulted in the BMD10 values
of 0.14 and 0.007 mg/kg bw and BMDL10 values of 0.05 and 0.004 mg/kg bw for 3-Ac-DON and
15-Ac-DON, respectively (Appendix G).
7.3.7.3. DON-3-glucoside
In another study on mink, Wu et al. (2014d) tested DON-3-glucoside for emesis at the doses of
0, 0.05, 0.25, 0.5, 1 and 2 mg/kg bw (2 animals/group) and observed emesis in only one of the two
41 EFSA contacted the authors of Wu et al. (2013a) for further clariﬁcations of the study and received the reply by email on
31.8.2015.
42 Vomiting is deﬁned as rhythmic abdominal contraction with oral expulsion of either solid or liquid material, whereas retching
refers to responses that mimicked vomiting but without any material being expelled.
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animals at the highest dose. The small number of animals per dose did not allow the CONTAM Panel to
conclude on a NOAEL/LOAEL/BMDL10 of DON-3-glucoside in mink.
7.3.7.4. Conclusions on farmed mink
For vomiting as acute effect in farmed dark mink, NOAELs of 10, 5 and 10 lg/kg bw per day were
identiﬁed for DON, 3-Ac-DON and 15-Ac-DON, respectively. BMDL10 values of 0.004, 0.05 and 0.004
mg/kg bw were calculated for DON, 3-Ac-DON and 15-Ac-DON, respectively. Due to insufﬁcient data
on DON-3-glucoside, no NOAEL, LOAEL or BMDL10 was calculated for acute effects. From the available
subacute toxicity study on pastel mink (Gibson et al., 1993), a NOAEL of 1.18 mg DON/kg feed was
identiﬁed for the reduced feed intake and body weight in farmed mink as chronic effects. Due to the
lack of data on chronic adverse effects 3-Ac-DON and 15-Ac-DON and DON-3-glucoside no speciﬁc
NOAELs/LOAELs could be identiﬁed for chronic toxicity of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
7.3.8. Dogs and cats
7.3.8.1. DON
The previous EFSA opinion (2004) reported two studies on cats and dogs conducted by Hughes
et al. (1999). Reviews have also been published by Pestka (2007) and Boermans and Leung (2007).
In the subacute study by Hughes et al. (1999) on dogs, wheat naturally contaminated with 37 mg
DON/kg was used to prepare diets containing 0, 1, 2, 4, 6, 8 or 10 mg DON/kg feed. The
contaminated wheat was examined for co-contamination with other mycotoxin. It was found to
contain 1 mg of 15-Ac-DON/kg feed but none of the following mycotoxins (LODs in brackets expressed
mg/kg feed): T-2 toxin (0.1 mg/kg feed), HT-2 toxin (0.1 mg/kg feed), diacetoxyscirpenol (0.3 mg/kg
feed), neosolaniol (0.5 mg/kg feed), fusarenon-X (0.5 mg/kg feed), 3-Ac-DON (0.1 mg/kg feed),
nivalenol (0.5 mg/kg feed), zearalenone (0.2 mg/kg feed) and zearalenol (0.3 mg/kg feed). Forty-nine
mature (1 to 7 years of age) Brittany and Beagle dogs (not distinguished in the analysis) weighing
from 15 to 20 kg were involved in an experimental period of 14 days. Dogs were weighed at the start
of the study and on day 7 and 14. Dogs assigned diets with DON levels of 0, 1, 2 or 4 mg/kg feed
consumed 84 to 100% of the food offered during the 14-day test period and no vomiting was
observed. There was no apparent inﬂuence of these levels of DON on body weight gain or food intake.
The 14 dogs fed diet with DON level of 6 mg/kg feed did not vomit, but food intake was depressed
and they lost weight during the study. The CONTAM Panel considered the concentration of 4 mg
DON/kg feed and of 6 mg/kg feed as the NOAEL and LOAEL for chronic effects, respectively. The two
dogs housed in one pen and fed diet with a DON level of 8 mg/kg feed consumed a total of 544 g on
day 1. Both dogs vomited within 2 h after being fed. Overall, vomiting was observed in ﬁve of seven
pens assigned to diet with DON level of 10 mg/kg feed. However, CONTAM Panel noted that the
authors observed a high variability in emetic patterns among individual dogs, with some being highly
susceptible and others being very resistant. The CONTAM Panel also noted that dogs are known to
vomit easily as a defence mechanism. The CONTAM Panel identiﬁed the concentrations of 6 mg
DON/kg feed as the NOAEL and 8 mg/kg feed as the LOAEL for vomiting.
Leung et al. (2007) investigated the effects of feeding cereal-based diets that were naturally
contaminated with DON, 3-Ac-DON, 15-Ac-DON and fusaric acid (highest concentration) together with
several other Fusarium toxins and aﬂatoxins to mature female Beagle dogs for 14 days. The CONTAM
Panel concluded that as it is uncertain whether the adverse effects were caused by DON only in this
study and did not consider it further for hazard characterisation.
Only one study on cats was identiﬁed (Hughes et al., 1999). In this subacute study, 20 mature
(1 to 9 years of age) American Shorthair cats (from 2 to 4 kg) were fed the same diets of 0, 1, 2, 4
and 6 mg DON/kg feed as used for dogs (see above) during the same period of 14 days. Vomiting was
observed in four of the seven cages only at the highest level of 10 mg/kg feed. Therefore, the
CONTAM Panel identiﬁed for vomiting a NOAEL of 8 mg/kg feed and a LOAEL of 10 mg/kg feed. Since
average daily feed intake was reduced at 8 mg DON/kg feed, the CONTAM Panel identiﬁed a NOAEL of
6 mg DON/kg feed and the LOAEL of 8 mg DON/kg feed for reduced feed intake.
7.3.8.2. 3-Ac-DON and 15-Ac-DON
The study on dogs of Leung et al. (2007) included 3-Ac-DON and 15-Ac-DON in the treatment
diet. However, for the same reasons as given in Section 7.3.8.1, the CONTAM Panel did not consider
this study further. No other data on adverse effects in dogs or in cats were identiﬁed.
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7.3.8.3. DON-3-glucoside
No data were identiﬁed.
7.3.8.4. Conclusions on dogs and cats
From the available data on vomiting, the concentrations of 6 and 8 mg DON/kg feed in dogs and
cats, respectively, were considered by the CONTAM Panel as the NOAELs for acute effects in dogs and
cats, respectively, and the levels of 8 and 10 mg DON/kg feed as the LOAELs for acute effects in dogs
and cats, respectively. With regard to the reduced body weight,43 the CONTAM Panel identiﬁed the
NOAELs of 4 and 6 mg DON/kg feed for dogs and cats, respectively, and the LOAELs of 6 and 8 mg
DON/kg feed for dogs and cats, respectively. Due to the limited or lack of data on acute and chronic
adverse effects in cats and dogs caused by 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, no speciﬁc
NOAELs/LOAELs could be identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
7.3.9. Overall conclusions on adverse effects in farm and companion animals
Despite the use of naturally contaminated feed containing both DON and its acetylated and
modiﬁed forms in some of the studies, mainly data on the effects of DON only are available. For most
of the animal species the limited or lack of data on adverse effects caused by 3-Ac-DON, 15-Ac-DON
and/or DON-3-glucoside, did not allow the identiﬁcation of the speciﬁc NOAELs/LOAELs for 3-Ac-DON,
15-Ac-DON and DON-3-glucoside.
For cows not subject to rumen acidosis, the concentration of 5.2 mg DON/kg feed did not
generate any adverse effects on body weight, dry matter intake and milk yield and milk composition,
and therefore the CONTAM Panel considered this level as a NOAEL for cows. For heifers and steers,
the levels of 10 and 18 mg DON/kg feed, respectively, did not generate any adverse effects in feed
intake, average daily weight gain and feed efﬁciency, and they were identiﬁed as NOAELs by the
CONTAM Panel. For sheep, the CONTAM Panel identiﬁed the NOAEL of 15.6 mg DON/kg feed for
reduced feed intake and body weight gain, while for goats no data were identiﬁed.
In healthy ruminants, DON is converted into the less toxic de-epoxidised metabolite DOM-1 by the
rumen ﬂora. Dairy cows, cattle and young animals have not been compared directly in the same
experiment. However, young animals such as calves with not fully developed rumen and adult animals
with a previous history of ruminal acidosis may have less effective de-epoxidation and, consequently,
could be more susceptible to the toxic effects of DON.
In pigs, DON may cause several adverse effects including lesions in the oesophageal region of the
stomach, in the liver, the lungs and the kidneys and changes in different clinical chemistry parameters
(plasma nutrients and plasma enzyme activities). The immune modulating properties of DON have also
been conﬁrmed in pigs by several feeding studies. The acute effect of vomiting was observed primarily
at higher DON concentrations, but may also occur occasionally at lower concentrations. While the
acute NOAEL for vomiting varied between 0.7 and 12 mg DON/kg feed, a lowest LOAEL of 2.8 mg
DON/kg feed was identiﬁed for vomiting. Reduced feed intake and body weight gain reduction are the
critical effects of DON in pigs, and a wide range of NOAELs/LOAELs were identiﬁed by the CONTAM
Panel. The CONTAM Panel noted that the overall identiﬁed NOAEL of 0.7 mg DON/kg feed for reduced
feed intake and body weight gain in pigs was higher than the overall LOAEL of 0.35 mg DON/kg feed
for these chronic adverse effects.
For broiler chickens, the concentration range of 4.6–7.0 mg DON/kg feed did not generate any
adverse effects on feed intake and body weight gain. The level of 10–12 mg DON/kg feed generated
some feed intake and body weight gain reductions and also caused some modiﬁcations in intestines,
and was identiﬁed by the CONTAM Panel to be the range of LOAELs for broiler chickens. For the
laying hens, the CONTAM Panel identiﬁed the NOAEL of 5.0 mg DON/kg feed and LOAELs of range of
10–13 mg DON/kg feed for reduced feed intake and decreased egg fertility. For ducks, the CONTAM
Panel identiﬁed the concentration of 7.0 mg DON/kg feed and for turkeys, the concentration of 6.5
mg DON/kg feed generating no changes in body weight, body weight gain, feed intake or feed
conversion ratios. Thus, these DON concentrations in feed were identiﬁed as the NOAELs for these
poultry species. Only one recent study allowed to identify the NOAEL of 5.0 mg DON-3-glucoside/kg
feed for broiler chickens.
For horses, only data from three studies were available. No reduced feed intake or any other signs
of adverse effects were observed in horses at the concentrations of 36–44 mg DON/kg feed. Although
43 The term body weight is used for adult dogs and cats as they do not gain weight.
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the studies involved a limited number of animals, the CONTAM Panel considered that the concentration
of 36 mg DON/kg feed can be used as the NOAELs for horses.
Data from three studies were used for farmed rabbits. From one study, the concentration of 30
mg DON/kg feed was associated with maternal and fetal body weight reduction, but a concentration of
15 mg DON/kg feed did not appear to be maternotoxic and did not induce any adverse effects in
fetuses. From another study, a concentration of 4.3 mg DON/kg feed induced no effects on body
weight gain, average feed intake, relative organ weights and haematological parameters. In another
study, a diet level of 10.1 mg DON/kg feed adversely affected the composition of caecal microbiota.
Therefore, the CONTAM Panel considered that the concentrations of 4.3 and 10.1 mg DON/kg feed can
be used as the NOAEL and LOAEL, respectively, for farmed rabbits.
Limited data on farmed ﬁsh derived from variable experimental designs and feed concentrations
were available. The data were not sufﬁcient to identify speciﬁc NOAELs/LOAELs for each ﬁsh species.
In addition, the diet composition of different ﬁsh species may differ markedly between the ﬁsh species,
and some ﬁsh species might be more tolerant to the adverse effects of DON than others. Based on the
studies with carp, in which 0.95 mg DON/kg feed induced lipid peroxidation and histopathological
changes in the liver, and with rainbow trout in which 0.8 mg DON/kg feed reduced feed intake, body
weight gain, growth rate and feed efﬁciency, the CONTAM Panel considered that 0.6 mg DON/kg feed
can be used as a NOAEL for farmed ﬁsh.
For farmed mink, NOAELs for vomiting of 10, 5 and 10 lg/kg bw and BMDL10 values of 4, 50 and
4 lg/kg bw were obtained for DON, 3-Ac-DON and 15-Ac-DON, respectively, (see Section 7.8.4 for
dose–response modelling). No sufﬁcient data on acute adverse effects were available for DON-3-
glucoside but the limited data available indicated a lower toxic potency compared with DON. For
adverse effects in a subchronic study, a NOAEL of 1.18 mg DON/kg feed was identiﬁed for the reduced
feed intake and body weight.
From the available data on vomiting in dogs and cats, the concentrations of 6 and 8 mg DON/kg
feed were considered by the CONTAM Panel as the NOAELs for dogs and cats, respectively, and the
levels of 8 and 10 mg DON/kg feed as the LOAELs for vomiting in dogs and cats, respectively. With
regard to the reduced body weight, the CONTAM Panel identiﬁed the NOAELs of 4 and 6 mg DON/kg
feed for dogs and cats, respectively, and the LOAELs of 6 and 8 mg DON/kg feed for dogs and cats,
respectively.
Due to the lack of data on chronic adverse effects for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside,
no speciﬁc NOAELs/LOAELs could be identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in the
farm and companion animals.
7.4. Combined effects of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
with other mycotoxins
Co-exposure to more than one mycotoxin in animals and humans through food and feed has been
reported (Grenier and Oswald, 2011; Streit et al., 2012). In vitro and in vivo experiments were
performed to analyse the effect of DON when present with other mycotoxins. This chapter reports only
studies in which the experiment design was set to study combined effects and in which the
conclusions were drawn on the combined effects (Table 50). Other studies reporting effects due to
mixtures of mycotoxins in the feed fed to the animals in the experiments were not considered but it
was noted that a few of these studies on adverse effects in farm animals suggested that fusaric acid
induced similar effects as DON (Leung et al., 2007; Girish and Smith, 2008; Marczuk et al., 2012) (see
Section 7.3).
7.4.1. In vivo experiments
Several in vivo experiments have been performed to analyse the effect of DON when present with
other mycotoxins. Only experiments comparing the toxicological effects due to the exposure to a
mycotoxin combination with the effects due to an exposure to single mycotoxins have been
considered. Most of these experiments were performed on farm animals and few of them used
laboratory animals. Grenier and Oswald (2011) have previously reviewed the combined effects of DON
with other mycotoxins. Table 50 summarises the data obtained from in vivo experiment and the
conclusion drawn by the authors. The CONTAM Panel noted that because of the lack of dose–response
data, it is difﬁcult to perform a reﬁned statistical analysis and to draw deﬁnitive conclusion.
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7.4.2. In vitro experiments
Combined effect of DON and others mycotoxins has also been studied in vitro in many different
studies (Thompson and Wannemacher 1986; Thuvander et al., 1999; Kouadio et al., 2007; Malekinejad
et al., 2007; Luongo et al., 2008; Ruiz et al., 2011; Ficheux et al., 2012; Wan et al., 2013). Combined
effects of DON, 3-Ac-DON and 15-Ac-DON have only been studied in vitro on intestinal epithelial cells
from human and porcine origins (Alassane-Kpembi et al., 2013, 2015). When human Caco-2 cells were
exposed to low concentrations (cytotoxic effect was between 10 and 30–40% at the concentrations
from 0.15 to 0.55 lM), the binary and ternary mycotoxin mixture of DON, 3-Ac-DON and 15-Ac-DON
demonstrated a synergistic cytotoxic effect. At higher concentrations with cytotoxic effect of around
50%, the combinations had an additive or nearly additive effect. Conversely antagonism was observed
at 70% cytotoxicity and above. The in vitro synergy between DON and its acetyl derivatives was
quantiﬁed using the reduction indices and ranged from 2 to 5 (Alassane-Kpembi et al., 2013). In vitro
studies allowed to investigate the dose–response and to use more sophisticated analysis of the
combined effects. They indicated that combined effects of DON and other trichothecenes vary with
the concentrations chosen, and that at low concentration the in vitro studies showed a synergy for the
combined cytotoxic effect of mycotoxins. This type of interaction need to be conﬁrmed in in vivo
experiments.
7.4.3. Conclusions
The available database describing possible effects of combined exposure to DON and other
mycotoxins was weak and not sufﬁcient for establishing the nature of combined effects. No studies on
the combined effects of 3-Ac-DON, 15-Ac-DON or DON-3-glucoside with other mycotoxins were
identiﬁed.
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Table 50: Possible combined effects between DON and other mycotoxins in vivo
Tested mycotoxin/DON
Species (exposure period)
Concentrations
(tested
mycotoxin/DON)
(mg/kg feed)
Additive or synergistic combined effects Antagonistic combined effect Reference
Aﬂatoxin/DON
Pig (28 days)
3.0/3.0 - cytokines
- total proteins
- cholesterol, glucose
- white blood cells
- body weight gain
- gamma-glutamyltransferase, aspartate
aminotransferase
- blood urea nitrogen
- calcium, magnesium
- albumin
- alkaline phosphatase
- potassium, phosphorus
- red blood cell, haemoglobin, prothrombin time
Harvey et al.
(1989)
Aﬂatoxin/DON
Chicken (21 days)
2.5/16 - body weight gain
- haemoglobin
- aspartate aminotransferase
- liver/gizzard/proventriculus weight
- alanine aminotransferase
- spleen/kidney weight
- total serum protein, albumin, uric acid, cholesterol,
triglyceride
- calcium
- glucose
- lactate dehydrogenase
- liver lipid
- red blood cell
- phosphorus
Huff et al. (1986)
Aﬂatoxin/DON
Mouse (14 days)
2.5/5 - total serum protein
- liver weight
- liver apoptotic gene expression
- alanine aminotransferase
- aspartate aminotransferase
- serum albumin
- liver total antioxidant capacity
- liver malondialdehyde
Sun et al. (2014)
Sterigmatocystin/DON
Mouse (24 weeks)
0.3/1.5 - adenocarcinoma of the lungs - stomach dysplasia Huang et al.
(2004)(b)
Sterigmatocystin/DON
Mouse (24 weeks)
3/1.5 No parameter tested - adenocarcinoma of the lungs
- stomach dysplasia
Huang et al.
(2004)(b)
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Tested mycotoxin/DON
Species (exposure period)
Concentrations
(tested
mycotoxin/DON)
(mg/kg feed)
Additive or synergistic combined effects Antagonistic combined effect Reference
Ochratoxin A/DON
Chicken (21 days)
2.0/16 - gizzard weight
- red Blood cells
- body weight gain
- liver, kidney, proventriculus weight,
- glucose, total serum proteins, albumin
- blood urea nitrogen
- uric acid
- creatinine
- triglycerides
- cholesterol
- inorganic phosphorus
Kubena et al.
(1988)
Fumonisins/DON
Pig (28 days)
50/4.0 - feed intake
- lung weight
- body weight gain
- aspartate aminotransferase, CHL, alanine
aminotransferase
- lymphocytes stimulation
- creatinine
- albumin
- cholesterol
- gamma-glutamyltransferase
- liver weight
Harvey et al.
(1996)
Fumonisins/DON
Chicken (21 days)
300/15 - gizzard relative weight
- blood urea nitrogen
- gamma-glutamyltransferase
- feed intake
- mortality
- proventriculus weight
- cholesterol
- aspartate aminotransferase
- lactate dehydrogenase
- feed intake
- body weight gain
- liver/kidney/heart/bursa of Fabricius weight
- total serum proteins
Kubena et al.
(1997)
Fumonisins/DON
Pig (35 days)
6.0/3.0 - severity, extent of liver and lung lesions
- speciﬁc antibody, IgG
- cytokines expression
- cytokines (IL-10, TNF-a)
- goblet cells
- intestinal eosinophils
- neutrophils
- severity, extent of kidney lesions
- speciﬁc lymphocytes stimulation
- creatinine, albumin
- speciﬁc antibody, immunoglobulin A
- severity, extent of intestinal lesions
- cytokines (interferon gamma, interleukin-1beta,
interleukin-6)
Grenier et al.
(2011), Bracarense
et al. (2012)
Zearalenone/DON
Mouse (56 days)
10/5.0 - no parameter tested - body weight- liver weight- immunoglobulin A- red
blood cell
Forsell et al.
(1986)
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Tested mycotoxin/DON
Species (exposure period)
Concentrations
(tested
mycotoxin/DON)
(mg/kg feed)
Additive or synergistic combined effects Antagonistic combined effect Reference
Zearalenone/DON
Mouse (14–21 days)
10/25 - bacteria in spleen - delayed-type hypersensitivity reaction Pestka et al.
(1987)
Zearalenone/DON
Mouse (14 days)
5/5 - serum albumin- liver total antioxidant
capacity- total serum protein- liver apoptotic
gene expression
- liver weight- alanine aminotransferase- aspartate
aminotransferase- liver malondialdehyde
Sun et al. (2014)
T-2 toxin/DON
Pig (35 days)
0.4/2.5 No parameter tested - body weight, feed intake Friend et al.
(1992)0.8/2.5 No parameter tested - body weight, feed intake
1.6/2.5 No parameter tested - body weight, feed intake
3.2/2.5 - body weight, feed intake - no parameter tested
T-2 toxin/DON
Chicken (21 days)
4.0/16 - body weight- cholesterol - gizzard/bursa of Fabricius relative weight- total
serum protein, albumin- lactate dehydrogenase-
oral lesions
Kubena et al.
(1989)
Nivalenol/DON
Mouse (28 days)(a)
0.071/0.071 - total serum proteins- PROD- uric acid - immunoglobulin A- CDNB- total CO2- EROD Gouze et al.
(2005)0.355/0.071 - total serum proteins- immunoglobulin A-
CDNB- uric acid
- total CO2- DCNB- EROD, PROD- feed intake
0.071/0.355 - total CO2- total proteins- phosphorus- uric
acid
- immunoglobulin A- CDNB- EROD, PROD
0.355/0.355 - total serum proteins- phosphorus-
immunoglobulin A- DCNB
- total CO2- uric acid- CDNB- EROD, PROD- feed
intake
(a): Administration twice a week for 4 weeks (Gouze et al., 2005); (b): Original paper in Chinese, text based on the translation to English.
No parameter tested: In a given study there was no parameter tested that demonstrated synergistic, additive or antagonistic combined effect: CHL: cholinesterase; IL-10: interleukin-10; TNF-a:
tumour necrosis factor-a; PROD: pentoxyresoruﬁn-O-depenthylase; CDNB: 1-chloro-2,4-dinitrobenzene; EROD: ethoxyresoruﬁn-O-dealkylase.
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7.5. Human data
7.5.1. Observations in humans
While a number of reports on acute intoxications of DON were identiﬁed in the scientiﬁc literature,
human data related to chronic exposure to DON were lacking. Most human studies on intoxications of
DON have previously been reviewed by the SCF (1999) and JECFA (FAO/WHO, 2001, 2011) and are
summarised below.
Acute outbreaks due to ingestion of DON contaminated food has occurred repeatedly in China and
India, as reviewed by IARC (1993), JECFA (FAO/WHO, 2001, 2011) and Pestka and Smolinski (2005).
Typically, an acute DON associated toxicosis showed symptoms such as nausea, vomiting, diarrhoea,
abdominal pain, headaches, dizziness, fever, and in severe cases, bloody stool. The onset of the
symptoms was typically within 30 min after ingestion. There have been no human deaths directly
attributed to DON toxicosis. However, in most of the reported cases, speciﬁc effects could not be
conclusively attributed to DON because exposure was likely from a mixture of trichothecenes in mouldy
grains.
Already in the early 1890s, a disease known as ‘taumelgetreide’ was reported in Siberia with
symptoms including vomiting, headache and vertigo. This disease was later suspected to be related to
ingestion of trichothecenes (as reviewed by Pestka and Smolinski, 2005).
In India, a severe outbreak of gastrointestinal disease following ingestion of bread made of rain-
damaged mouldy wheat occurred in 1989, when 50,000 people in the Kashmir Valley were reported to
be ill, with primary symptoms of abdominal pain, a feeling of fullness in the stomach, irritation of the
throat and diarrhoea (Bhat et al., 1989) (see Table 51). From wheat and (reﬁned) wheat ﬂour samples
collected from the affected area, DON was the most frequently detected trichothecenes. It was found
in half of the 24 wheat and wheat ﬂour samples, with levels up to 8 mg/kg wheat ﬂour. Ac-DON at
levels between 0.6 and 2.4 mg/kg were found in 16% of the 24 wheat and wheat ﬂour samples (the
type of acetyl form was not reported). From this study, a NOAEL of 0.44 mg/kg bw was calculated by
the SCF (1999) using an average consumption of 67 g wheat products and a body weight of 52 kg.
Luo (1994) reported 32 outbreaks in China between 1961 and 1981 where 5,998 cases were
associated with the consumption of scabby wheat/barley and mouldy corn. However, DON and other
mycotoxins were not analysed due to a lack of facilities. Subsequently, in 21 outbreaks occurring
between 1984 and 1991, DON levels in wheat and corn samples (range of 0.34–92.8 mg/kg as
reported by the authors) were associated with food poisoning. In 1984, there were 362 out of 383
people (95%) intoxicated in the Hebei province of China were and later in 1985 after unseasonal
rainfall, the prevalence of scabby wheat in Gansu province was associated with a total of 1,357 cases
of food poisoning out of a population of 1,594 people. The typical symptoms were similar as those
described above and started usually within 30 min after consumption of food based on scabby wheat.
The occurrence was not age or sex dependent, but was associated with consumption of food items
prepared from scabby wheat. The largest outbreak in China was in Anhui and Jangsu provinces in
1991, affecting 130,141 and 6,560 people, respectively. These outbreaks are also summarised in
Table 51.
Table 51: The outbreaks of DON intoxications in humans in China and India – modiﬁed from Luo
(1994)
Year Region
Number of
outbreaks
Number of
poisoning
cases
Number of
vomiting
cases
DON
(mg/kg)
Number of
samples
Reference
1961–
1981
Yangzi river,
China
32 5,998 n.r. n.r. n.r. Information from local
regional government
1984 Hebei, China 1 362 232 n.r. n.r. Luo and Li (1985)
1985 Gansu, China 1 1357 n.r. n.r. n.r. Tang and Su (1988)
1985 Henan, China 1 101 n.r. 2–40 14 Luo et al. (1987)
1988 Guangxi,
China
1 40 34 1.5–2.2 3 Liu et al. (1989)
1988 Hebei, China 1 270 59 20–50 3 Zhao et al. (1989)
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The CONTAM Panel noted that amongst these outbreaks the most detailed report of DON acute
intoxication outbreak was that of Luo et al. (1987) from 1985 in Puyang, Henan province in China. A
total of 246 people from four villages were studied, 217 of them consumed scabby wheat ﬂour, and
101 food poisoning cases were identiﬁed. Matching information on patients with food DON
concentrations, data were available from three of the four villages affected (see Table 52). Food
poisoning prevalence was 100 and 24% in Haitong (Wumiao) and Zian, respectively, but no case was
reported from Qingzu. The most common symptoms in the 44 cases from Haitong (Wumiao) were
nausea (89%), fatigue (52%) and vomiting (46%). Dizziness and headache were less frequent. The
symptoms usually started within 10–30 min after eating contaminated food and most people recovered
in about 2 h time. No deaths were reported in all the 101 persons. DON was detected in the scabby
wheat samples using TLC method, which was the state-of-art method at that time. Levels of DON
were found to be the highest in samples from Haitong (Wumiao), and lowest in those from Qingzu,
corresponding well with the order of the intoxication percentage. The data from the three villages are
detailed in Table 52.
Between 1998 and 1999, scabby wheat was also highly prevalent in Puyang and DON was reported
to be the predominant toxin, with levels up to 14.0 mg/kg (mean 2.9 mg/kg) in 30 out of 31 wheat
samples collected from this area. 15-Ac-DON was detected in 15 out of the 31 samples with a mean
concentration of 0.4 mg/kg. In the neighbouring Zhumadian region, which did not have a history of
scabby cereal intoxication outbreaks, DON was detected in 25 out of 28 wheat samples at a lower
concentration (mean 0.2 mg/kg) than that of Puyang region (Li et al., 2002).
Body weight reduction has not been reported in any human populations in relation to long-term
exposure to DON. However, three studies reported the association between chronic exposure to DON
and the occurrence of human cancers including oesophageal cancer, liver cancer and stomach cancer.
Gao and Yoshizawa, (1997) collected 54 maize and 40 wheat samples from Chinese counties of
Linxian, an area known to have a high oesophageal cancer incidence, and Shangqui, an area known to
have a low oesophageal cancer incidence. The concentrations of DON and 15-Ac-DON were higher in
samples from Linxian than from Shangqui. This ﬁnding was supported by another study analysing the
Year Region
Number of
outbreaks
Number of
poisoning
cases
Number of
vomiting
cases
DON
(mg/kg)
Number of
samples
Reference
1988 Shanxi, China 1 142 n.r. n.r. n.r. Information from local
regional government
1989 Guanxi, China 1 10 n.r. n.r. n.r. Information from local
regional government
1989 Sichuan,
China
1 17 n.r. n.r. n.r. Information from local
regional government
1989 Shanxi, China 1 701 n.r. n.r. n.r. Information from local
regional government
1991 Anhui, China 8 130 141 2–50 10 Huang (1992); Yang
et al. (1992)
1991 Jiangsu, China 4 6,560 n.r. n.r. n.r. Yuan et al. (1992)
1987 Kashmir, India 1 50,000 n.r. Up to 8.4 24 Bhat et al. (1989)
n.r.: not reported.
Table 52: An outbreak of DON toxicosis from consumption of scabby wheat in China -modiﬁed from
Luo et al. (1987)
Town
Number of wheat
samples tested
DON concentration in scabby
wheat (mg/kg)
Number of
wheat food
consumers
Prevalence
of food
poisoning (%)
% of
vomiting
cases
Haitong
(Wumiao)
12 2.0, 10.0, 16.0, 16.0, 20.0, 20.0,
26.7, 26.7, 26.7, 30.0, 30.0, 40.0
44 100 46
Zian 2 16.0, 27.6 37 24 n.r.
Qingzu 5 1.0, 4.0, 6.0, 6.0, 8.0 73 0 0
n.r.: not reported by the author.
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urinary DON biomarker in 11 Chinese adults in Linxian (mean 37 ng/mL) and four in Gejiu (mean 12
ng/mL), an area of low levels of oesophageal cancer (Meky et al., 2003). Turner et al. (2012)
investigated the exposure to DON in 110 women (aged 39–72 years) from Golestan in Iran, an area
with a high risk of oesophageal cancer. Using a single urinary biomarker method described in Turner
et al. (2008a), the presence of urinary DON was detected in 72% of the women, with the maximum of
6 ng/mL. Overall, the CONTAM Panel noted that this type of studies were of the ecological nature
(IARC, 1993; FAO/WHO, 2001) and did not allow a valid conclusion on the relationship between DON
exposure and oesophageal cancer.
A few recent studies utilising a biomarker method reported the association between human DON
exposure and other human health outcomes such as child growth (Ediage et al., 2013) and HIV status
(Abia et al., 2013) (see Section 7.5.2). However, the CONTAM Panel considered that these studies
were of limited value in interpreting the human health risk owing to either the small sample size and
immaturity of biomarker development.
Human exposure to DON-3-glucoside was not reported in any of the identiﬁed studies.
In conclusion, the CONTAM Panel noted that several outbreaks of acute mycotoxicosis, through the
consumption of mouldy food in larger populations in Asia with DON concentrations up to 8 mg/kg
wheat (ﬂour) in India and varying between non-detect/non-reported up to 50 mg/kg scabby wheat.
For the acetylated forms of DON concentrations up to 2.4 mg/kg wheat ﬂour were recorded in India,
whereas in China the data on acetylated DON forms were scarce and only a mean level of 0.4 mg/kg
wheat was reported for 15-Ac-DON. Although chronic exposure to DON is common worldwide, data
related to adverse health effects due to chronic exposure are lacking.
7.5.2. Biomarkers of exposure
DON, DON-3-glucuronide and the predominant DON-15-glucuronide are the common forms of DON
in human urine, while DOM-1 appears to be low in human urine and unsuitable as a biomarker.
Numerous recent studies have suggested that tDON (total DON) urinary biomarker measured by
LC–MS methods is well correlated with dietary DON exposure and allows an integrated exposure
assessment for DON and possibly also its acetylated and modiﬁed forms present in many foods. The
DON urinary biomarker methods (see Section 3.4) have been applied in several exposure studies in
many countries suggesting that DON exposure was ubiquitous in many populations. These studies are
summarised in Table 53 for the single biomarker methods and in Table 54 for multiple biomarker
methods and some of them described below in more detail. It should be noted that the DON urinary
biomarker can be expressed either as ng/mL or as ng/mg. In the latter case it has been adjusted for
variations caused by ﬂuctuations in the urinary ﬂow rate.44
Turner et al. (2008a) used a detailed 7-day weighted food diary data to calculate the total cereal
consumption in the UK. The 1,724 women were ranked according to their total cereal consumption as
low, medium and high cereal consumers. Urinary tDON was measured in 100 women from each of the
three consumption groups and detected in 99% of the urine samples. The urinary tDON had a strong
positive correlation with total cereal consumption (p < 0.0005). The correlation analysis suggests that
wholemeal made up the largest portion to urinary tDON per unit of consumption, while white bread
contributed most to urinary tDON because of its high consumption. The data also showed that urinary
tDON was better explained by the cereal consumption in the most recent 2 days than the average
cereal intake in the previous 7 days (Turner et al., 2009).
44 Urine creatinine daily excretion (mg) is generally considered stable for a healthy individual. Urine ﬂow rate variation inter- and
intra-individually can inﬂuence urinary creatinine and urinary DON concentration in a similar manner. Hence urinary creatinine
concentration is used for adjusting urine ﬂow rate in DON biomarker studies. However, creatinine excretion can be inﬂuenced
by age, diet and health condition. Urinary creatinine mean concentration is typically higher in adults than in children, hence
there is controversy when adults and children biomarker levels are compared using creatinine adjusted values.
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Table 53: Summary of literature reports of urinary DON/DON-glucuronides/DOM-1 biomarker data using the single biomarker method (DON expressed
as ng DON/mL urine or ng DON/mg creatinine) (ordered by publishing year)
Population
Number of
subjects (F/M)
Age
(year)
Positive samples
(%)
Total DON
Mean (range) 
standard deviation
(ng/mL)
Total DON
Mean (range) 
standard deviation
(ng/mg)
Analytical method
(LOD/LOQ, ng/mL)
Reference
UK 202 (128/74) 3–> 65 DON: 93 31.4, median: 19.3 DON (0.12/0.25) Brera et al. (2015)
DOM-1: 0 DOM-1 (0.25/0.5)
Italy 203 (122/81) DON: 76 9.12, median: 6.54 DON (0.25/0.5)
DOM-1: 1.5 DOM-1 (0.25/0.5)
Norway 230 (138/92) DON: 97 8.29, median: 6.12 DON (0.005/0.015)
DOM-1: 12 DOM-1 (0.09/0.27)
UK 15 (7/8) 22–50 DON: 100 (Year 1) 7.1  8.0 DON (n.r./0.1) Gratz et al. (2014)
DON: 100 (Year 2) 13.5  12.0
Sweden 326 (n.r.) 18–80 DON: 90 Median: 2.9 (< LOD–65.8) DON (0.25/0.5) Wallin et al. (2013)
UK 5 (3/2) n.r. DON: 100 3.62 (0.38–10.05) DON (0.1/n.r.) Gratz et al. (2013)
UK 85 (85/0) 16–44 DON: 100 10.3 (0.5–116.7)(a) DON (0.25/0.5) Hepworth et al.
(2012)DOM-1: 0 DOM-1 (LOQ = 0.06)
UK(b) 34 (16/18) Adults DON: 100 17.8 (5–78.2), median: 3.8 DON (0.25/0.5) Turner et al. (2011a)
DOM-1: 0.3 0.65 (one sample) DOM-1 (LOQ = 0.06)
UK 35 (18/18) 21–59 DON: 94 11.6 (< LOD–78.2) 10.1 (< LOD–70.7)(a) DON (0.5/n.r.) Turner et al. (2010a)
France 76 (0/76) 23–74 DON: 99 Median: 6.8 (0.5–28.8) DON (0.5/n.r.) Turner et al. (2010b)
DOM-1: 34 0.2 (0.2–2.8) (positive samples) DOM-1(LOD = 0.05)
UK 300 (158/142) 19–64 DON: 99 7.2 (6.2–8.2)(a) (L)
9.2 (8.1–10.5)(a) (M)
10.9 (9.5–12.4)(a) (H)
DON (0.1/0.6) Turner et al. (2008a)
UK 25 (16/9) 21–59 DON: 100 10.7 (2.4–67.8)(a) 7.2 (4.9–10.5)(a) DON (n.r./0.6) Turner et al. (2008b)
n.r.: not reported; F: female; M: male; LOD: limit of detection; LOQ: limit of quantiﬁcation; L: low dietary exposure; M: medium dietary exposure; H: high dietary exposure.
All urine samples were treated with enzymatic hydrolysis followed by IAC extraction prior to determination by HPLC-MS.
(a): geometric mean (95% CI); (b): all are selected positive samples from another study.
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Table 54: Summary of literature reports of urinary DON/DON-glucuronides/DOM-1 biomarker data using multiple biomarker method (concentration
expressed as ng DON/mL urine or ng DON/mg creatinine) (ordered by publishing year)
Population
Number of
subjects (F/M)
Age
(year)
Positive samples (%)
Total DON Mean
(range)  standard
deviation (ng/mL)
Total DON Mean
(range)  standard
deviation (ng/mg)
Analytical method
(LOD/LOQ, ng/mL)
Reference
Germany 50 (n.r.) Adults DON: 16 11.2  13.0 (median 7.5) 11.7 (SD not reported) DON: 4/4DON-G: 4/4 Gerding et al.
(2015)DON-G: 54
Sweden 252 (n.r.) Adults Total DON: 63 4.40  19.6 7.02  24.4 See Solfrizzo et al.
(2014)
Wallin et al.
(2015)DOM-1: 8 0.12  0.55 1.56  1.26
Spain(a) One male person 26 one 24-h urine sample DON: 18.8  3.5 DON: 0.1/0.23-Ac-
DON: 0.2/0.5DOM-1:
0.2/0.5
Rodrıguez-Carrasco
et al. (2015)
Belgium 239 (133/106) 19–65 DON: 37 3.9 (0.5–129.8) 0.2(c) for all forms Heyndrickx et al.
(2015)DON-15-G: 100 53.8 (1.1–460.8)
DON-3-G: 77 7.5 (0.5–126.2)
DOM-1-G: 22 16.9 (0.6–172.0)
155 (88/67) 3–12 DON: 70 5.2 (0.5–32.5)
DON-15-G: 100 58.4 (4.3–343.0)
DON-3-G: 91 10.6 (0.7–43.0)
DOM-1-G: 17 91.7 (1.1–526.1)
Italy
(Southern)
52 (26/26) 3–85 Total DON: 96 11.9  10.1 Total DON: n.r./1.5 Solfrizzo et al.
(2014)DOM-1: n.r. n.r. DOM-1: n.r./9.9
Spain(a) 16 (n.r.) Children DON: 56 27.8 (< LOQ–84.5) DON: 0.12/0.25DOM-
1: 0.25/0.50
Rodrıguez-Carrasco
et al. (2014a)DOM-1: 6 1.3 (in one sample)
16 (6/10) Young
adults
DON: 75 32.9 (< LOQ–69.1)
DOM-1: 6 4.2 (in one sample)
22 (10/12) Adults DON: 73 14.8 (< LOQ–56.9)
DOM-1: 0 0
Spain(a) 10 (n.r.) 8–11 DON: 30 7.4 (< LOD–21.1) DON: 0.12/0.25 Rodrıguez-Carrasco
et al. (2014b)DOM-1: 10 1.3 DOM-1: 0.25/0.50
Belgium 32 (16/16) n.r. DON: 72 0.4 (< LOD–3.0) DON: 0.2/0.5 Huybrechts et al.
(2015)DON-15-G: 100 82.6 (3.0–420.0) DON-15-G: 0.2/0.5
DON-3-G: 91 10.7 (< LOD–55.0) DON-3-G: 0.2/0.5
DOM-1: 0 DOM-1: 0.1/0.3
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Population
Number of
subjects (F/M)
Age
(year)
Positive samples (%)
Total DON Mean
(range)  standard
deviation (ng/mL)
Total DON Mean
(range)  standard
deviation (ng/mg)
Analytical method
(LOD/LOQ, ng/mL)
Reference
Croatia 40 (40/0) 26–33 DON: 76 18.3 (< LOD–275.0) Free DON: 4/13 Sarkanj et al.
(2013)DON-15-G: 98 120.4 (< LOD–1,237.7) DON-15-G: 3/11
DON-3-G: 83 28.8 (< LOD–298.1) DON-3-G: 6/20
Belgium 40 (n.r.) n.r. DON: 13 < LOD–68.3 DON: 2.85/5.7 Ediage et al.
(2012b)DON-3-G: 0 DON-3-G: 2.25/4.5
DOM-1: 0 DOM-1: 0.65/1.3
Austrian 27 (n.r.) 20–63 DON: 0 13.7 DON: 4/13 Warth et al.
(2012b)DON-15-G: 63 (< LOD–43.0) DON-15-G: 3/11
DON-3-G: 4 13 (in one sample) DON-3-G: 6/20
Total DON: 59 20.4 (< LOD–63)  2.4 Total DON: 4/13
Portugal 13 (8/5) 20–50 DON: 15 1.8, 8.8 (in two samples) DON: 0.08/0.25 Cunha and
Fernandes (2012)15-Ac-DON: 0.60/2.0
3-Ac-DON: 0.30/1.0
DOM-1: 0 DOM-1: 0.15/0.50
Total DON: 69 16.3 (< LOD–26.2)
Italy 10 (5/5) 26–87 DON: 50 1.98 (< LOD–14.0)  1.4 DON: 0.8/1.6 Solfrizzo et al.
(2011)Total DON: 70 3.67 (< LOD–14.2)  1.6 Total DON: 0.8/1.6
Italy 2 (1/1) 30–45 DON: 100 3.0, 8.0 DON: 2.0/6.0 Lattanzio et al.
(2011)DOM-1: 0 DOM-1: 1.0/3.0
Spain 27 (10/17) 21–77 DON: 33 < LOD–35 DON: 10/35 Rubert et al.
(2011)
n.r.: not reported; F: female; M: male; LOD: limit of detection; LOQ: limit of quantiﬁcation; DON-3-G: DON-3-glucuronide; DON-15-G: DON-15-glucuronide; DOM-1-G: DOM-1-glucuronide
All studies were conducted using LC–MS/MS method unless otherwise speciﬁed.
(a): using GC–MS detection method;
(b): geometric mean (95% CI);
(c): limit of detection.
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In the intervention study by Turner et al. (2010a), morning urine was collected from 35 UK adult
volunteers in 5 consecutive days over 2 consecutive weeks. After a normal diet in week 1, a partially
or fully restricted diet on low wheat content food was used in week 2. Urinary tDON levels in the two
intervention groups were 54 and 3% of control diet group. The reduction in urinary tDON was
consistent with the reduction in the total cereal consumption. Average DON daily exposure was
estimated based on average DON concentration and consumption level of bread. A strong correlation
between urinary tDON and DON daily exposure was reported especially when the average
consumption data from the recent 4 days was used (r2 = 0.83). This study and a similar intervention
study (Turner et al., 2008b) clearly demonstrated a close relationship between tDON biomarker and
DON exposure, and the major contribution of cereal based food to DON exposure. Using samples of
individuals with tDON above 5 ng/mL urine from the intervention study of Turner et al. (2011a), the
mean tDON urine concentration was 17.8 ng/mL (range 5.0–78.2 ng/mL). Unconjugated DON was
detected in 68% of the samples, with a mean urine concentration of 2.4 ng/mL (range 0.5–9.3 ng/mL).
On average, DON-glucuronides constituted 87% of the tDON with the rest being unconjugated DON.
The percentage appeared to be independent from the tDON level. DOM-1 was detected only in one
sample out of 34 samples from 35 persons, at a level approximately 1% of tDON.
Urinary DON and DOM-1 were also measured in 76 male French farmers (23–74 years old) (Turner
et al., 2010b). All but one man had DON detected (range 0.5–28.8 ng/mL). DOM-1 was detected in 26
(34%) out of 76 samples (range 0.2–2.8 ng/mL). The DOM-1 positive group had a higher average
urinary DON level than those of DOM-1 negative (geometric mean 8.1 vs 5.5 ng/mL, p = 0.043).
However, a correlation between DON and DOM-1 concentrations in individuals was not reported.
The single urinary DON biomarker was studied in 85 pregnant women (at last trimester of
pregnancy, age 16–44 years) from a large multiethnic mother/infant birth cohort resident in the UK
(Hepworth et al., 2012). The urinary tDON biomarker was signiﬁcantly higher in the South Asian group
compared to non-South Asian group with the geometric means (95% CI) of 15.2 (10.7–21.5) vs 8.6
(6.6–11.8) ng/mg creatinine. The higher exposure level in the South Asian group was attributed to a
higher consumption of white bread (chapattis) in the South Asian diet. Another study in 98 Egyptian
pregnant women (Piekkola et al., 2012) reported only a moderate urinary tDON level, with a 68%
detectable rate, and a geometric mean (95% CI) at 2.8 (2.1–3.6) ng/mg creatinine for the positive
samples only, possibly reﬂecting the moderate concentrations of tDON and consumption of, e.g. wheat
and maize in the Egyptian diet.
Using the GC–MS method, Cunha and Fernandes (2012) determined tDON in 69% of the 13
samples collected from northern Portuguese, with a mean concentration of 16.3 ng/mL urine (range
1.9–26.2 ng/mL urine).
The multi-biomarker analytical methods have increasingly been used in various studies. Solfrizzo
et al. (2011) reported that seven out of 10 Italian adults had detectable tDON concentrations in urine.
The mean level was 3.7 ng/mL (range < LOD–14.2 ng/mL). In another study by Solfrizzo et al. (2014)
96% of the 52 adults in southern Italy had detectable tDON concentrations (mean  SD) at
11.9  10.1 ng/mL (range < LOQ–67.4 ng/mL).
Warth et al., (2012b) reported that amongst 27 urinary samples from Austria, 22 and 96% of the
samples were positive for DON and DON-glucuronide, respectively. On average, conjugated DON
counted for 86% of the tDON (DON + DON-3-glucuronide + DON-15-glucuronide). DON-15-glucuronide
represented approximately 75% of total DON-glucuronide. The mean concentration of tDON was
20.4  2.4 ng/mL (range < LOD–63 ng/mL). No DOM-1 was detected in any sample.
Ediage et al. (2012b) measured 18 mycotoxins and their metabolites in 40 urine samples from Belgian
volunteers. Five samples had DON levels above the LOD, with range between 5.9 and 68.3 ng/mL.
DON-3-glucuronide was not detected in any sample. Huybrechts et al. (2015) quantiﬁed DON, DON-3-
glucuronide, DON-15-glucuronide in 60, 90 and 100% of the 32 urine samples from Belgian adults. The
mean concentrations were 0.4 ng/mL (maximum 3 ng/mL), 10.7 ng/mL (maximum 55 ng/mL) and 82.6
ng/mL (maximum 420 ng/mL), respectively. Although DOM-1 was not detected, DOM-1-glucuronide was
detected in 25% samples with a mean concentration of 4.6 ng/mL (maximum 16.4 ng/mL). This
indicated that the glucuronide metabolites were the main metabolites of DOM-1.
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Gerding et al. (2015) reported that none of the 50 German adults had urinary free DON above LOQ
although 16% were reported positive and 54% adults were positive with DON-glucuronides with mean
of 11.2 (SD 13.0) ng/mL and median of 7.5 (maximum 60.9) ng/mL.
In Swedish adults (n = 252) urinary DON and DOM-1 were detected in 63 and 8% of the total
group (Wallin et al., 2015). The mean(SD) was 4.40(19.6) ng/mL ((7.0224.4) ng/mg) for DON and
0.12(0.55) ng/mL (1.56(1.26) ng/mg) for DOM-1. DON was the most frequently detected mycotoxins.
DOM-1 was only detected when DON was detected. The adults were subsequently grouped into low,
medium and high multi-toxin group according to the number of multiple mycotoxins being detected.
No signiﬁcant association could be established for the three groups and their speciﬁc food patterns.
Diet information and urinary biomarker data were studied in Belgian children (n = 155 of age 3–12
years; 67 boys and 88 girls) and adults (n = 239 of age 19–65; 106 men and 133 women) by
Heyndrickx et al. (2015) including DON, DON-3-glucuronide, DON-15-glucuronide, 3-Ac-DON,
15-Ac-DON, 3-Ac-DON-15-glucuronide, 15-Ac-DON-3-glucuronide, DOM-1 and DOM-1-glucuronide.
DON was detected in 70% of the children (mean concentration 5.5 ng/mg creatinine) and 37% of the
adults (mean concentration 6.1 ng/mg creatinine). DON-15-glucuronide, being the most prevalent, was
detected in all samples with mean concentration of 65.3 and 50.1 ng/mg creatinine in children and
adults, respectively. DON-3-glucuronide was detected in 91% of the children (mean concentration 12.3
ng/mg creatinine), and in 77% of adults (mean concentration 6.7 ng/mg creatinine). No DOM-1 was
detected. DOM-1-glucuronide was present in 17% of the urine samples from children (mean and
median concentration 100.9 and 28.2 ng/mg creatinine, respectively) and in 22% from adults (mean
concentration 25.0 ng/mg creatinine).
Rodrıguez-Carrasco et al. (2014a) applied a multi-biomarker method to measure DON
concentrations in urine from 54 Spanish volunteers (DON-glucuronides not measured). DON and
DOM-1 were detected in 68.5 and 3.7% of the 54 subjects. 3-Ac-DON was not detected. The urinary
DON was detected in 56, 75 and 73% of the children, young adults and adults, respectively. The mean
(maximum) concentration for urinary DON was 27.8 (84.5), 32.9 (69.1) and 14.8 (56.9) ng/mg
creatinine for children, young adults and adults, respectively. There was no signiﬁcant difference in
urinary DON concentrations between males and females. Statistical signiﬁcance was not reported for
the difference in DON between age groups nor for the difference in creatinine levels between adults
and children.
The highest exposure reported this far, was form the study by Sarkanj et al. (2013) in 40 non-
smoking pregnant women in the last trimester of pregnancy (26–33 years old) from eastern Croatia.
DON-15-glucuronide, DON-3-glucuronide and DON were detected in 98%, 83% and 76% of the
samples, respectively. The mean, median and maximum levels were 120.4, 55.2 and 1,238 ng/mL,
respectively, for DON-15-glucuronide. For DON-3-glucuronide the mean, median and maximum levels
were 28.8, 10.0 and 298.1 ng/mL, respectively, and for DON 18.3, 6.7 and 275.0 ng/mL, respectively.
When daily exposure was estimated based on the sum of DON and DON equivalent concentrations of
DON-glucuronides using an estimated excretion percentage of 72% as reported by Turner et al.
(2010b), 48% of the subjects exceeded 1 000 ng/kg bw per day. The highest estimated exposure of
1,238 ng/mL for the sum (estimated DON exposure 33 ng/kg bw per day) was observed in woman
with 1,238 ng/mL DON-15-glucuronide 298 ng/mL DON-3-glucuronide and 275.0 ng/ml DON This
maximum urinary DON level was nine times higher than the highest level reported in UK also in a
pregnant women (Hepworth et al., 2012).
In the context of a grant agreement between EFSA and the authors, an urinary DON biomarker
project was conducted in 2014 to measure and compare the levels and proportions of urinary DON,
DON-glucuronides and DOM-1 in UK, Italy and Norway, and to investigate the main types of food that
contribute to urinary biomarker levels (Brera et al., 2015). Two consecutive morning urine samples
were collected approximately from 200 subjects per country (~ 40 children (3–9 years), ~ 40
adolescents (10–17 years), ~ 30 adults (18–64 years), ~ 20 elderly (> 65 years), ~ 30 vegetarians and
~ 40 pregnant women). A total of 635 subjects were recruited, and a total of 1,270 urine samples
were collected. The consumption data were obtained through a food frequency questionnaire and
harmonised food diary survey. Urinary DON, DON-glucuronides and DOM-1 were measured in the UK,
Italy and Norway by a single biomarker analytical method following an interlaboratory study (see
details in Brera et al. (2015)). The results are not published in a peer-reviewed journal but as an EFSA
external report.
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tDON was detected in 93%, 76% and 97% of the samples collected from UK, Italy and Norway,
respectively (Brera et al., 2015). The CONTAM Panel noted that the LOQs of the method applied in
the three laboratories varied and did not allow to compare the percentage of samples with detectable
levels between the countries. The median and mean concentrations of urinary DON and glucuronides
are summarised in Table 55 by country, age groups and speciﬁc subpopulations (vegetarians and
pregnant women). For the samples below LOQ, a lower bound approach was taken, and the value of
zero was assigned to these samples when mean concentrations were calculated. Overall the median
tDON in the UK population was about threefold higher than that in the Italian and Norwegian
populations, and in all three populations the median tDON concentration was the highest in children.
There was no signiﬁcant difference on tDON concentrations between samples collected on day 1 and
day 2. DON glucuronide in the 2 days urine samples constituted 82/82, 66/71 and 80/79% of the
tDON in the UK, Italian and Norwegian populations, respectively. DOM-1 was almost completely
absent in the UK and Italian populations, whilst a 12% positive rate was reported in Norwegian
population, which according to the authors probably owed to the lower LOQ of the method used in
Norway.
The CONTAM Panel decided to use the available biomarker data from the Brera et al. (2015) study
to calculate the exposure and to compare this exposure with the exposure to the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside calculated from the diet in Section 6.1.2.2.1 and Appendix F.
Therefore, based on the individual urinary tDON concentrations from the study of Brera et al. (2015)
and assuming that the average excretion rate is 70%, and that 24-h urine volume is 0.5 L for children
(Haga and Sakata, 2010) and 2 L (EFSA FEEDAP Panel, 2012) for adults, the CONTAM Panel estimated
the exposure to DON using the following formula:
DONexposureestimate (lg/kgbwperday)¼Urinary tDONconcentration (ng/mL)24-hurinevolume (mL)
Excretion rate0.7BodyweightðkgÞ
1000
In Table 56, these DON exposure estimates reported together with the exposure estimates for the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside obtained from the diet-based calculations in
this opinion (Section 6.1) using the country speciﬁc food consumption data available for UK and Italy.
For Norway the Danish food consumption data were used to due to the lack of Norwegian food
consumption data in the EFSA Comprehensive Food Consumption Database. Overall, the CONTAM
Panel concluded that the exposure estimates based on the biomarker data were within the same order
of magnitude with the estimates based on diet. However, the CONTAM Panel noted that there were
several aspects which contributed to the uncertainty45 of the exposure estimates of DON by using
biomarker data. These were:
Table 55: Mean and median concentrations of the sum of urinary DON and DON-glucuronides
(ng/mg creatinine) in UK, Italy and Norway reported in Brera et al. (2015)
UK Italy Norway
Population groups n
Mean
(ng/mg)
Median
(ng/mg)
n
Mean
(ng/mg)
Median
(ng/mg)
n
Mean
(ng/mg)
Median
(ng/mg)
Children (3–9 years) 40 41.6 33.3 40 14.0 11.3 40 14.0 10.8
Adolescent (10–17 years) 39 21.0 18.5 40 12.2 9.3 41 7.3 7.0
Adults (18–64 years) 31 19.3 12.9 31 6.4 4.7 58 5.8 4.7
Elderly (> 65 years) 20 25.4 19.9 20 8.3 7.0 20 8.9 5.5
Vegetarians 30 36.6 22.2 30 8.3 4.9 31 7.3 7.2
Pregnant women 42 39.4 14.3 42 4.6 2.0 40 7.7 5.3
Total 202 31.4 19.3 203 9.1 6.5 230 8.3 6.1
n: number of subjects.
45 It should be noted that these uncertainties are not presented in Section 9 on Uncertainty Analysis because the biomarker data
were used as supporting information for this opinion and thus they do not inﬂuence the outcome of the risk assessment on
DON, its acetylated and modiﬁed forms in food and feed.
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1) The DON excretion rate was assumed to be 70%, but individual variation exists and the
extent of this variation is unknown to date. Further, the contribution of 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside to this DON biomarker was unknown.
2) The 24-h urine volume was not recorded and default values for children and adult were
used which contributed to the uncertainty.
3) Different back-calculation methods (e.g. whether or not corrected for molar mass) have
been proposed in literature (Heyndrickx et al., 2015) for more accurate calculation of the
tDON biomarker but they were not all applicable for single biomarker data because the
single biomarker method does not measure each DON-glucuronide individually, hence results
may vary depending on the calculation method used.
7.5.3. Biomarker of effect
A few studies have been published on a biomarker of effect for DON (Hopton et al., 2009; Amuzie
and Pestka, 2010; Flannery et al., 2013) but because this area is still under development no studies on
humans were identiﬁed.
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Table 56: DON exposure estimates back-calculated from the biomarker concentrations reported to EFSA(a),(b) and compared to the dietary based
exposure estimates for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside at the middle bound presented in Section 6.1.2.2.1 and
Appendix F
Age group(age)
MB exposure
estimate
from diet(c)
Urinary
DON and
glucuronides (b)
Exposure
estimate(a)
from
biomarker
MB exposure
estimate
from diet(c)
Urinary
DON and
glucuronides(b)
Exposure
estimate(a)
from
biomarker
MB
exposure
estimate
from diet(c)
Urinary DON and
glucuronides(b)
Exposure
estimate(a)
from
biomarker
lg/kg bw
per day
ng/mL
lg/kg bw
per day
lg/kg bw
per day
ng/mL
lg/kg bw
per day
lg/kg bw
per day
ng/mL
lg/kg bw
per day
UK Italy Norway
Children (3–9 years) 1.15 21.2 0.70 1.33 8.4 0.25 1.10 10.8 0.34
Adolescent (10–17 years) 0.60 20.0 1.14 0.80 7.7 0.40 0.60 8.5 0.50
Adults (18–64 years) 0.45 11.9 0.42 0.54 4.4 0.18 0.47 5.6 0.22
Elderly (65 years or >) 0.42 8.1 0.31 0.50 4.1 0.18 0.42 4.4 0.18
Pregnant women na 12.2 0.42 na 1.4 0.06 na 5.0 0.19
Vegetarian na 10.1 0.42 na 3.9 0.16 na 5.1 0.22
bw: body weight; na: not applicable; MB: middle bound.
(a): Daily exposure is calculated based the DON and glucuronide biomarker and assumption of daily urine volume at 0.5 and 2 L for child and adult, and DON excretion percentage is estimated
at 70%.
(b): The individual urinary DON and glucuronide concentrations as ng/mL were extracted from the EFSA database as submitted to EFSA in the DON biomarker project in 2015 (Brera et al., 2015).
(c): The chronic exposures for UK and Italy are the estimates from the diet as presented in this opinion (see Appendix F.1). The food consumption data reported for Denmark were used to
compare to the exposure estimate from biomarker in Norway due to the lack of Norwegian food consumption data in the EFSA Comprehensive Food Consumption Database.
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7.5.4. Conclusions
Research on DON biomarkers in the past decade has made great progress. The DON urinary
biomarker (DON and DON-glucuronides) has been frequently detected in several European and non-
European populations, largely attributed to the high urinary excretion and frequent contamination in
food. Based on the limited available information the CONTAM Panel estimated that 70% of the
exposed DON is excreted via urine within a day or two after the exposure to DON. Typically DON-
glucuronide constitutes a major proportion (70–90%) of the total DON in urine, with DON-15-
glucuronide being the predominant type of metabolite. DOM-1 appears to be low in human urine and
unsuitable as a biomarker.
The available literature data from DON single and multiple biomarker methods have been shown to
correlate well with dietary DON exposure. There was clear evidence that urinary DON excretion varies
at different time of the day and between individuals. The CONTAM Panel noted that there was limited
knowledge on what determines toxicokinetics of DON in humans, and clear age, gender, regional and
seasonal patterns of the biomarker cannot be established. A recent EFSA study showed the UK
population had higher levels of DON biomarker when compared to the Italian and the Norwegian
populations, although reasons for the different biomarker levels between countries are yet to be
elucidated. However, the CONTAM Panel noted that the exposure estimated based on the EFSA
biomarker study were somewhat lower but still of the same order of magnitude as the national diet
based exposure estimates for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
7.6. Comparative toxicity of DON and 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside
Only few studies compared side by side the toxicity of DON, its acetylated forms 3-Ac-DON and 15-
Ac-DON and DON-3-glucoside (Table 57). The toxicity was assessed both on cell lines, organ tissues
and animals.
DON-3-glucoside was compared to DON on human intestinal epithelium assessing cytotoxic effect,
barrier function and activation of MAP-Kinase (Pierron et al., 2016b). These toxins were also compared
on intestinal tissues for inﬂammatory effect and pan genomic gene expression (Wu et al., 2014a;
Pierron et al., 2016b). Emetic and anorectic effects were also tested on mink and mice, respectively
(Wu et al., 2014). For all these parameters DON-3-glucoside was substantially less toxic than DON.
When DON was compared to 3-Ac-DON and 15-Ac-DON the relative toxicity varied. DON, 3-Ac-DON
and 15-Ac-DON were found to display similar toxicity in terms of anorectic and inﬂammatory effects
(Wu et al., 2012, 2014d). DON and 15-Ac-DON have the same emetic effect and were more emetic
than 3-Ac-DON (Wu et al., 2013a). On intestinal epithelial cells from porcine or human origin, the
cytotoxicity of DON and acetylated form was ranked in increasing order 3-Ac-DON > DON > 15-Ac-
DON (Pinton et al., 2012; Alassane-Kpembi et al., 2013, 2015). Similar ranking was observed for
barrier function, MAP-Kinase activation and expression of tight junction, and for histological alteration
(Pinton et al., 2012). In mice 3T3 ﬁbroblast, DON and 15-Ac-DON were equally cytotoxic and more
cytotoxic than 3-Ac-DON (Sundstøl Eriksen et al., 2004).
In summary, only few studies compared the toxicity of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside head-to-head. DON, 3-Ac-DON and 15-Ac-DON were found to display similar toxicity in terms
of anorectic and inﬂammatory effects, except for emetic capacity which was substantially lower for 3-
Ac-DON compared to DON and 15-Ac-DON. The potency of cytotoxicity in mammalian intestinal cells
ranked in the order of 15-Ac-DON > DON > 3-Ac-DON and that was similar for barrier function, MAP-
Kinase activation and expression of tight junction, and histological alteration. DON-3-glucoside was
considerably less toxic than DON both in vitro and in vivo studies.
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Table 57: Comparative toxicity studies of DON, its acetylated forms of 3-Ac-DON and 15-Ac-DON and the modiﬁed form of DON-3-glucoside
Toxins Model End-point Ranking Reference
DON, 3-Ac-DON, 15-Ac-DON Mink Emetic effect DON = 15-Ac-DON > 3-Ac-DON Wu et al. (2013a)
DON, 3-Ac-DON, 15-Ac-DON Mice Anorectic effect DON = 15-Ac-DON = 3-Ac-DON Wu et al. (2012)
DON, 3-Ac-DON, 15-Ac-DON Human cells
Intestinal epithelial cell
(Caco-2)
Cytotoxicity (MTS and Neutral red assay) 15-Ac-DON > DON ≥ 3-Ac-DON Alassane-Kpembi et al.
(2013)
DON, 3-Ac-DON, 15-Ac-DON Pig cells
Intestinal epithelial cell
(IPEC-1)
Cytotoxicity (MTS assay) 15-Ac-DON > DON > 3-Ac-DON Alassane-Kpembi et al.
(2015)
DON, 3-Ac-DON, 15-Ac-DON Pig cells
Intestinal epithelial cell
(IPEC-1)
- Cell Proliferation (ATP)
- Barrier function (TEER)
- Claudins proteins expression
- MAPK activation
15-Ac-DON > DON > 3-Ac-DON Pinton et al. (2012)
DON, 3-Ac-DON, 15-Ac-DON Pig intestinal tissues - Histological alterations
- MAPK activation
15-Ac-DON > DON > 3-Ac-DON Pinton et al. (2012)
DON, 3-Ac-DON, 15-Ac-DON Mice
3T3 ﬁbroblast
- Cytotoxicity (BrdU bioassay) 15-Ac-DON = DON  3-Ac-DON Sundstøl Eriksen et al.
(2004)
DON, 3-Ac-DON, 15-Ac-DON,
DON-3-glucoside
Mice Inﬂammation (mRNA for IL-1b, IL-6, TNF-a,
CXCL-2); CCL-2; CCL-7 in the liver
DON = 15-Ac-DON = 3-Ac-DON 
DON-3-glucoside
Wu et al. (2014d)
DON, DON-3-glucoside Mice Anorectic effect DON  DON-3-glucoside Wu et al. (2014d)
DON, DON-3-glucoside Mink Emetic effect DON  DON-3-glucoside Wu et al. (2014d)
DON, DON-3-glucoside Pig intestinal tissues Inﬂammation (mRNA for IL-1a, IL-1b, IL8, TNF-a,
IL-17A, IL-22):
Pan-genomic analysis
DON  DON-3-glucoside Pierron et al. (2016b)
DON, DON-3-glucoside Human cell
Intestinal epithelial cell
(Caco-2)
- Cytotoxicity
- Barrier function (TEER)
- MAPK activation
DON  DON-3-glucoside Pierron et al. (2016b)
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7.7. Mode of action
Due to the large database on biochemical mode of action on DON, the CONTAM Panel decided to
report only the main reviews and the studies relevant with regard to the adverse effects observed
in vivo. For 3-Ac-DON, 15-Ac-DON and DON-3-glucoside all the available studies were reviewed.
7.7.1. DON
7.7.1.1. Induction of a ribotoxic stress
DON as other trichothecenes is known to target the ribosome. It binds to the 60S subunit of this
organelle and crystallographic studies indicate that DON more speciﬁcally targets the A site of the
peptidyl transferase centre. This interaction inhibits the chain elongation step of protein synthesis
leading to an inhibition of RNA, DNA and protein synthesis (EFSA 2004; Pestka, 2010a; Garreau de
Loubresse et al., 2014).
This binding of DON to ribosome activates also several ribosome-associated mitogen activated
protein kinases (MAPKs), including p38, c-Jun N-terminal Kinase (JNK), and extracellular signal-regulated
kinase 1 and 2 (ERK1/2), an effect called ribotoxic stress response (Pestka, 2010a,b). Activation of p38
and ERK1/2 triggers two competing signalling pathways, one down-stream of p38 favouring apoptosis
and one downstream of ERK1/2 favouring cell survival and cytokine expression, the net effect on cell
fate depending on the dose and duration of exposure. Leucocytes, notably those of mononuclear
lineage, are particularly sensitive to DON. Upon exposure to DON, MAPK activation drives a
proinﬂammatory cytokines response through rapid and strong transcriptional activation and stabilisation
of mRNAs (Pestka, 2010a,b) (see Section 7.2.5).
7.7.1.2. Induction of oxidative stress
DON-dependent production of reactive oxygen species (ROS) has been reported in several cell
culture studies as well as in vivo in the intestine (review Mishra et al., 2014a). It should be noted that,
DON-induced ROS generation proved to be an early event (Liu et al., 2016) which might lead to
genotoxicity (see Section 7.2.9). Modiﬁcations in antioxidant enzyme activities have been used as a
biosensor for ROS formation during the oxidative assault in the cell system. In this line, DON has also
been reported to alter the antioxidant defence system in various cell lines and in tissues from rodents
or farm animals such as chicken and pigs exposed to DON (reviewed by Mishra et al., 2014a). By
contrast, DON at doses up to 100 lM has been reported to have negligible effects on the production
of nitric oxide (Ji et al., 1998; Graziani et al., 2015).
There was overwhelming evidence for the implication of mitochondria in trichothecene-induced
oxidative stress (Bin-Umer et al., 2011). DON interferes with oxidative stress by inhibiting
mitochondrial translation, however the precise target(s) remain(s) to be characterised.
DON induced oxidative stress leads to enhanced lipid peroxidation, and DNA and protein damage.
Several studies demonstrated an increase in lipid peroxidation levels in mice, rat and chicken exposed
to DON (84 nM to 84 lM), as well as in cells treated in vitro with DON (Mishra et al., 2014a). Very few
studies on DON-induced carbonylation of protein have been reported (Kalaiselvi et al., 2013; Strasser
et al., 2013), however, inhibition of protein synthesis has been reported in a number of studies
(Pestka, 2010a,b).
7.7.1.3. Effect on proliferation, cell-cycle and apoptosis
As already mentioned, DON as other trichothecenes, are known to interfere with DNA synthesis,
cell growth, mitosis and cell-cycle (Brera et al., 2005). When treated with a range of concentrations of
DON (84 nM to 84 lM), human intestinal epithelial Caco-2 cells showed a reduction in proliferation and
survival. Dividing Caco-2 cells were found to be more sensitive compared to differentiated cells. The
greater sensitivity of proliferating cells is probably due to the capacity of DON to inhibit protein
synthesis and subsequently nucleic acid synthesis (Bony et al., 2006). In these cells, DON induced
G2/M phase cell cycle arrest associated with an increase in p21 levels, a cyclin-dependent kinase (CDK)
inhibitor that mainly inhibits cyclin-CDK2 complex and negatively regulates cell cycle progression. This
increase in p21 levels was partly due to up-regulation of p21 mRNA expression and also to p21 mRNA
stabilisation (Yang et al., 2008). DON was also able to promote cell cycle arrest in the G0/G1 phase of
J774A.1 murine macrophages (Marzocco et al., 2009). In addition, DON was found to impair oocyte
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developmental competence by interfering with microtubule dynamics during meiosis and disturbing
oocyte maturation (Schoevers et al., 2010).
DON induces apoptosis through mitochondria-mediated or -independent pathways (Shifrin and
Anderson, 1999; Pestka, 2010a,b). DON stimulated apoptosis in murine macrophages via caspase 3
pathway with an increased expression of Bax and poly-ADP-ribose synthase (PARP) (Marzocco et al.,
2009). HT-29 cells treated with DON underwent a p53 and caspase-dependent apoptosis (Bensassi
et al., 2009). However, other studies demonstrated that DON caused ROS-dependent apoptosis in
HT-29 along with over-expression of NF-kB-P65 (Krishnaswamy et al., 2010; Kalaiselvi et al., 2013).
7.7.1.4. Cell membrane integrity and permeability
DON as other trichothecenes are amphophilic molecules and are capable of exerting cellular toxicity
by affecting cell and organellar membranes including mitochondria (Rocha et al., 2005). A decreased
expression of the several tight junction proteins in the gut barrier, especially caludins, was also
observed in intestinal epithelial cells from human or porcine origin (Pinton et al., 2009; Van De Walle
et al., 2010; Diesing et al., 2011; Akbari et al., 2014). It should be noted that the decrease expression
in protein was accompanied by a compensatory up-regulation of mRNA levels observed both in cell
lines and in animals (Osselaere et al., 2013b; Akbari et al., 2014). This reduction of tight junction was
mediated by MAPK and accompanied with a decreased trans-epithelial electrical resistance (TEER) and
increased permeability to 4 kDa dextran and pathogenic E. coli (Pinton et al., 2009).
The MAPK activation also lead to the inhibition of the expression of resistin-like molecule b, and the
subsequent decreased the level of mRNA encoding for the intestinal membrane-associated (MUC1) and
the secreted MUCs (MUC2, MUC3). This reduced mucin production in the human goblet cell line HT29-
16E cells (Pinton et al., 2015). A reduced number of goblet cells was also observed in the intestine of
pig fed DON contaminated diets (Bracarense et al., 2012).
7.7.1.5. Anorexia and vomiting
Although anorexia and the resultant growth suppression constitute major and relevant adverse
effects of DON and other structurally related trichothecenes, the underlying organismal mechanisms
are not yet fully understood. Two major mediators of DON-induced anorexia, i.e. pro-inﬂammatory
cytokines and satiety hormones, emerged from studies carried out mainly in mice. The suppression of
cytokine signalling and interference with pituitary growth hormone (GH) axis has also been proposed
(EFSA 2014; Lebrun et al., 2015). It is important to point out that, contrary to humans or pigs,
vomiting cannot occur in rodents, but the abnormal food intake behaviour observed in mice (or other
rodents) is considered indicative of nausea-induced anorexia (Yamamoto et al., 2002).
Several studies mentioned in Section 7.2.5 demonstrated that DON induces the synthesis of
cytokines in both the peripheral and in the central nervous system. It has also been shown that upon
injection, the proinﬂammatory cytokines IL-1b, IL-6 and TNF-a induce a set of symptoms characteristic
of sickness behaviour, including anorexia (Kelley et al., 2003). During acute or chronic inﬂammation,
prostaglandins act downstream of proinﬂammatory cytokines and induce some of the symptoms of
sickness behaviour, notably anorexia (Pecchi et al., 2006). It has been observed that DON induces
prostaglandins (Lebrun et al., 2015). It was therefore suggested that DON-induced anorexia could be
triggered by proinﬂammatory cytokines and/or prostaglandins. Genetically deﬁcient mice and
pharmacological inhibitors have been used to test this hypothesis. Mice knockout for either TNF-a
receptor or IL-6 do not exhibit any reduced susceptibility to DON-induced anorexia, as compared to
wild type mice (Pestka and Zhou 2000, 2002). COX-2 knockout mice and wild type littermates
displayed similar decrease in body weight when exposed to DON (Jia and Pestka, 2005). Similarly,
mPGES-1 KO mice were shown to be as sensitive as their wild-type littermates to DON-induced
anorexia upon acute oral exposure (Girardet et al., 2011a). Although these results suggest that DON-
induced anorexia is independent of the production of inﬂammatory mediators, compensatory
mechanisms observed in knockout animal models have to be taken into consideration (Lebrun et al.,
2015). Using TNF-a or IL-1 receptor antagonists, Wu and Zhang (2014) observed a dose-dependent
attenuation of anorexia upon acute oral gavage of mice with DON (5 mg/kg bw). These later data
suggest that TNF and IL-1 could contribute at least in part to the reduced food intake detected after
exposure to DON.
The gut satiety hormones cholecystokinin (CCK), secreted by specialised I cells of the duodenum
and jejunum, and Peptide YY3-36 (PYY), secreted by specialised L cells of the distal ileum and colon,
were identiﬁed as a major mediator of DON-induced anorexia after oral and i.p. administration
respectively (Flannery et al., 2012; Wu et al., 2014b). Plasma levels of CCK and PYY rapidly increased
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upon an acute i.p. exposure to DON (10 mg/kg bw), concomitantly with DON-induced anorexia. By
contrast, DON does not impact plasma levels in glucagon-like peptide-1 (GLP-1), leptin, amylin,
pancreatic polypeptide (PP), gastric inhibitory peptide (GIP) or ghrelin (Flannery et al., 2012). After i.p.
administration of DON, the use of a speciﬁc receptor antagonist demonstrated the implication of PYY
in anorexia in the mouse model (Flannery et al., 2012) and emesis in the mink model (Wu et al
2013b). Oral gavage of mice with DON at the dose of 2.5 mg/kg bw elicited a strong increase in
plasma CCK levels that correlated with food refusal in a mouse anorexia model (Wu et al., 2014b). It is
not yet known how exactly DON activates the secretion of CCK and PYY. However, that the increased
CCK level was responsible for DON-induced anorexia was demonstrated by the observation that CCK
receptor antagonists (SR 27897 or L-365,260) attenuate this adverse anorectic outcome upon
ingestion of DON in a dose-dependent manner (Wu et al., 2014b). Using a cell line, the same group
identiﬁed a speciﬁc G-protein-coupled chemosensor receptor that mediates the CCK response (Zhou
and Pestka, 2015). When CCK is released from the gastrointestinal tract, it can act in a paracrine
manner by activating CCK receptors in the abdominal vagus afferents, which communicate with the
nucleus tractus solitarius (NTS) in the hindbrain (Morton et al., 2006). Neurons of the NTS in turn
possess axons that convey information about the status of the viscera to many areas of the brain
involved in the regulation of feed or food uptake.
In addition to being secreted by cells of the gastrointestinal tract, CCK is also produced directly in
various brain regions (Rehfeld et al., 1985). In this respect, it is important to note that DON penetrates
into the central nervous system after oral exposure (Prelusky et al., 1986, 1990; Pestka et al., 2008),
raising the possibility that it may stimulate CCK secretion directly in speciﬁc brain locations. This view is
further supported by the ﬁnding that DON (12.5 mg/kg bw) induces c-Fos expression (a marker of
neuronal activity) in several brain areas such as the hypothalamus, the dorsal vagal complex, the pons
and the central amygdala (Girardet et al., 2011a,b).
7.7.2. 3-Ac-DON and 15-Ac-DON
3-Ac-DON and 15-Ac-DON are able to bind the ribosome. They only formed 2 hydrogen bonds with
the ribosome, in contrast to DON that forms 3 hydrogen bonds (Payros et al., 2016; Pierron et al.,
2016a).
The ability of 10 and 30 lM 3-Ac-DON and 15-Ac-DON to induce a ribotoxic stress was examined
through the activation of MAPK in differentiated intestinal epithelial cell line, intestinal explant and in
the intestine of exposed animals (Pinton et al., 2012). In these three different models, 15-Ac-DON
activated the MAPKs, ERK1/2, p38, and JNK, at lower dose than DON and 3-Ac-DON. As a
consequence 15-Ac-DON is more toxic than DON. 15-Ac-DON induces greater histological intestinal
lesions and had a higher impact on barrier intestinal function (Pinton et al., 2012).
No data were identiﬁed on induction of oxidative stress.
In relation to the effect on the cell-cycle and apoptosis, 3-Ac-DON and 15-Ac-DON were found to
induce apoptosis of Jurkat T-cell at the same concentration as DON (Pestka et al., 2005). The
underlying mechanism of apoptosis has not been investigated for these two metabolites.
3-Ac-DON and 15-Ac-DON induced anorexia and vomiting (see Section 7.2.1). Both of them also
induced inﬂammatory response, but the inﬂammatory reaction was less pronounced than with DON as
indicated by protein and mRNA levels (Wu et al., 2014a) and the comparable synthesis of satiety CCK
after oral ingestion (Wu et al., 2014b). No studies with inhibitors and/or deﬁcient mice were performed
to determine the underlying mechanism.
7.7.3. DON-3-glucoside
Probably due to the presence of the glucosyl group DON-3-glucoside is unable to bind to the A site
of the ribosome peptidyl transferase centre and to induce a ribotoxic stress. Accordingly, 10 lM DON-
3-glucoside did not activate MAPKs in treated Caco-2 cells and did not alter viability and barrier
function of intestinal cells. Microarray analysis of 30,000 genes also revealed that treatment of
intestinal explants for 4 h with 10 lM DON-3-glucoside does not change the expression of any genes
(Pierron et al., 2016b). No data were identiﬁed on induction of oxidative stress or on effect on the cell-
cycle and apoptosis.
DON-3-glucoside showed reduced anorectic and emetic response compared with DON (see
Section 7.2.1.3) and the underlying mechanism of this response is unknown but does not appear to
involve inﬂammatory response (Wu et al., 2014d).
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7.7.4. Conclusions
The mode of action of DON indicated that DON binds to the ribosome, induces a ribotoxic stress
and activates the MAP-Kinases. Depending on the dose and duration of exposure, activation of
different MAP-Kinases triggered different signalling pathways favouring apoptosis, cell survival or
cytokine expression. DON also triggered an oxidative stress through a mitochondria dependent
mechanism. Anorexia, emesis and the resultant growth suppression constituted major adverse effects
of DON. Two major mediators of DON-induced anorexia/emesis have been described: pro-
inﬂammatory cytokines and secretion of satiety hormones, which activate receptors in the abdominal
vagus afferent.
The data on the mechanism of action of 3-Ac-DON and 15-Ac-DON were scarce but suggested an
activation of MAP-Kinase, as well as an induction of inﬂammatory cytokine and satiety hormones.
Because of steric hindrance, DON-3-glucoside cannot bind to the ribosome, activate MAP-Kinases and
induce inﬂammation.
7.8. Identiﬁcation of critical effects and dose–response/concentration–
response modelling for hazard characterisation
Since the previous evaluations of the SCF (1999, 2002) and EFSA (2004) (see Section 1.1) several
new studies on DON were reported for experimental, farm and companion animals and few on 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside. While a wealth of toxicokinetic and toxicity data was available
for experimental animals to identify and characterise the hazard of DON, the database on adverse
effects and toxicity of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was still scarce for this opinion (see
Sections 7.3 and 7.4), and only a limited number of toxicokinetic studies were identiﬁed for 3-Ac-DON,
15-Ac-DON and DON-3-glucoside (see Section 7.1). Based on that information, the CONTAM
Panel assumed that the acetylated forms were largely deacetylated prior to systemic distribution and
rapidly metabolised to DON, such that they might induce the same acute and chronic effects as DON.
There was evidence that at least 15-Ac-DON elicits similar general chronic toxicity as DON, whereas
the immunotoxicity of 3-Ac-DON and 15-Ac-DON might be less expressed. In contrast, data on the
absorption of DON-3-glucoside were limited and no evidence was found that it is absorbed as such.
The bioavailability of DON-3-glucoside was considered low. On the other hand, it is cleaved in the gut
of animals (mice, pigs and chicken) with large inter- and intraspecies variability. In rats, and similarly in
pigs, DON-3-glucoside was recovered in the gastrointestinal tract at small amounts and only as traces
of metabolites in kidneys. In vitro but not in vivo studies on human gut bacteria demonstrated
cleavage of DON-3-glucoside to DON. While the available data on the mode of action and toxicity of
the acetylated forms indicated a similar toxicity as that of DON, those on the toxicity of DON-3-
glucoside were limited (see Sections 7.2 and 7.6) and in vivo data on the chronic toxicity were missing.
Therefore, no ﬁrm conclusions on the toxicity of DON-3-glucoside could be drawn and by applying a
conservative approach the CONTAM Panel assumed that 1) 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside are all metabolised to DON and absorbed at the same extent as DON, 2) the acetylated
forms of DON induced the same acute and chronic effects as DON and 3) acute and chronic effects of
DON-3-glucoside similar to DON cannot be excluded. Therefore, the CONTAM Panel decided to
characterise the hazard for the group of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside together,
both for chronic and for acute effects in humans and farm and companion animals.
7.8.1 Critical acute effects of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
Gastrointestinal disorders, such as nausea, vomiting, abdominal pain and tensions and diarrhoea,
have been observed in humans in a number of acute intoxications associated with the consumption of
moulded or scabby cereal grains contaminated primarily by Fusarium mycotoxins where DON was
dominant (see Section 7.5.1). Other effects were dizziness and in some cases also headache and fever.
The CONTAM Panel identiﬁed vomiting as critical acute effect to characterise the acute hazard of the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in humans, and decided to use human data
collected in a number of epidemiological studies performed after outbreaks of acute mycotoxicosis in
Asia for acute hazard characterisation. In addition, the CONTAM Panel used the available human
biomarker data as supporting information for the characterisation of acute hazard for humans.
The CONTAM Panel noted that studies on rodents, in particular mice and rats, could not be
considered for the acute risk assessment of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in humans because rodents do not vomit. On the other hand, vomiting was identiﬁed as
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critical endpoint for acute effects of DON for some non-ruminant species of farm and companion
animals, in particular, pigs, farmed mink, and dogs and cats. However, when assessing the suitability of
this information for human risk assessment, the CONTAM Panel noted essential limitations of the
available studies and their data due to a considerable heterogeneity in vomiting (including feed
refusal), both between and within animal species (see Section 7.3.2) and also between different
breeds, see e.g. the heterogeneity in dose–response evaluation for pigs (Section 7.8.4), some studies
on poultry (Section 7.3.3) and also in the one available study on dogs and cats (Section 7.3.7). The
CONTAM Panel noted that vomiting/emesis of mink has been used as animal model to study acute
effects of DON, 3-Ac-DON, 15-Ac-DON or DON-3-glucoside (Section 7.8.5), but decided to base their
acute hazard characterisation on the available human epidemiological data.
7.8.2. Critical chronic effects of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside
In absence of human data on the chronic exposure to DON, 3-Ac-DON, 15-Ac-DON or DON-3-
glucoside, the CONTAM Panel was not able to identify critical chronic effects in humans and considered
reduced body weight gain (also reported as reduced body weight, suppression in weight gain or
growth reduction) in experimental animals as the most relevant and suitable critical effect to
characterise the chronic hazard for humans. In addition, the CONTAM Panel identiﬁed reproductive and
developmental toxicity of DON in experimental animals (see Sections 7.2.2.1 and 7.2.7) as suitable to
characterise the chronic hazard of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in humans.
The CONTAM Panel noted that suppression of growth and anorexia has been identiﬁed as a chronic
effect in experimental and some farm animal species such as pigs. In particular, feed refusal and
reduced feed intake have been associated with hormonal and immunotoxic effects of DON since
changes of satiety hormones (e.g. CCK and PYY) and changes of proinﬂammatory cytokines (e.g.
IL-1b, IL-6, TNF-alpha) have been observed to be related to DON-induced anorexia. However, this
database was too weak to identify any critical endpoint based on immunotoxic or hormonal effects in
experimental animals for chronic hazards of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
humans.
7.8.3. Dose–response modelling for human chronic hazard characterisation of
DON
From the available studies reporting reduced body weight gain, the CONTAM Panel considered the
results of the chronic 2-year study in mice of Iverson et al. (1995) addressing general toxicity of DON
as the most appropriate source of data for dose–response modelling (see Section 7.2.4.1). A clear
dose–response relationship between the exposure to DON and mean body weight was observed in
both female and male mice (see Section 7.2.4.1). In contrast, the dose–response relationship between
DON exposure and feed intake was less clearly expressed in females compared to males (see
Appendix G). The CONTAM Panel considered the dose–response evaluation of the body weight data
available for male and female mice as most appropriate to characterise the hazard of DON and
investigated whether the data of both sexes could be combined to determine a reference point for
chronic exposure to DON. The CONTAM Panel noted that the shape of the dose–response curves of
males and females were not identical but similar enough to be combined in a BMD analysis, and that
the combination with an overall much larger sample size would effectively increase the statistical
power of the analysis (EFSA Scientiﬁc Committee, 2017).
The BMD approach for continuous data was applied using the default benchmark response (BMR)
of 5% in the absence of statistical or toxicological considerations supporting a deviation. Applying the
PROAST software (Version 62.6) dose–response models for continuous data were ﬁtted to the
combination of the data on female and male mice of Iverson et al. (1995) following the EFSA guidance
(EFSA Scientiﬁc Committee, 2017). The benchmark dose (BMD) conﬁdence interval was determined as
0.11–0.32 mg DON/kg bw per day (see Appendix G and Table 57) and the lowest BMDL05 value was
0.11 mg DON/kg bw per day obtained for female mice when using the exponential model was
identiﬁed as reference point for the chronic toxicity of DON.
Although the data on reduced feed intake did not show such a clear dose–response relationship
and differed substantially between males and females (see Section 7.2.2) the BMD approach was also
applicable to the combination of the data on female and male mice of Iverson et al. (1995) and the
BMD analysis resulted in a lowest BMDL05 values of 1.6 mg/kg bw per day for females and 0.22 mg/kg
bw per day for males. Since both were higher than the lowest BMDL05 value of 0.11 mg DON/kg bw
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per day from the combined analysis of the body weight data, the CONTAM Panel concluded that the
reference point 0.11 mg DON/kg bw per day covers also reduced feed intake as endpoint for the
hazard characterisation of DON.
In addition, the CONTAM Panel analysed the dose–response data from the recently published
subchronic study of Bondy et al. (2016) on p53+/+ and p53+/ mice (see Section 7.2.3) using the
doses of 0, 0.09, 0.53 and 1.57 mg/kg bw per day as calculated by the authors from the same
concentrations of DON in the diet (0, 1, 5 and 10 mg DON/kg feed) as used by Iverson et al. (1995).
Since the study of Bondy et al. (2016) with a duration of 26 weeks was subchronic, the CONTAM
Panel decided to use it to support the evaluation of the chronic study of Iverson et al. (1995).
Applying the PROAST software (Version 62.6), dose–response models for continuous data were ﬁtted
to the combination of the data on p53+/+ and p53+/ mice following the EFSA guidance (EFSA
Scientiﬁc Committee, 2017). The calculation resulted in a BMD conﬁdence interval of 0.11–0.90 mg
DON/kg bw per day for decreased body weight, and therefore the results obtained for the subchronic
(26 weeks) study of Bondy et al. (2016) supported well the reference point of 0.11 mg DON/kg bw
per day determined above from the study of Iverson et al. (1995) (see also Section 7.10).
The CONTAM Panel also noted that general toxicity in male and female rats investigated for
developmental toxicity study by Sprando et al. (2005) and Collins et al. (2006), exhibited information
on reduced feed intake, body weight and body weight gain that could be evaluated for dose–response
(see Appendix G). Using the BMD approach, as described above, the lowest BMDL05 values were 0.70,
0.72 and 0.92 mg DON/kg bw per day for reduced feed intake, body weight and body weight gain in
male rats, respectively, as reported by Sprando et al. (2005) and 1.80, 2.34 and 1.14 mg DON/kg bw
per day for reduced feed intake, body weight and body weight gain in dams, respectively, as reported
by Collins et al. (2006). The CONTAM Panel concluded that these BMDL05 values obtained from these
short-term studies also supported the reference point of 0.11 mg/kg bw per day derived from the
study of Iverson et al. (1995). For details see Sections 7.2.2 and 7.2.7, and Appendix G.
7.8.4. Vomiting as a critical acute effect of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside for farm and companion animals
The CONTAM Panel identiﬁed vomiting as the critical effect only for pigs, dogs, cats and farmed
mink when exposed to DON (see Section 7.3) and used this endpoint to characterise the acute hazard
of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in them. The CONTAM Panel noted that several
studies in pigs and farmed mink showed clear concentration–response and dose–response
relationships, respectively, suitable to apply the BMC/D (benchmark concentration/dose) approach (see
Section 7.8.5 below). However, the concentration–response relationships reported in the only available
study for cats and dogs were not so well expressed but still suitable for the application of the BMC
Table 58: Dose–response analysis of critical endpoint of reduced body weight gain based on the
body weight data of Iverson et al. (1995) for female and male mice combined using the
PROAST software for the BMD approach
Best ﬁtting
model
Body weight
BMD05 BMDL05–BMDL05
mg/kg bw per day
Female mice
Exponential model family E3 0.19 0.11–0.28
Hill model family H3 0.19 0.12–0.29
Male mice
Exponential model family E3 0.22 0.15–0.30
Hill model family H3 0.23 0.16–0.32
BMD05: benchmark dose response of 5%; BMDL05/BMDU05: 95% lower/upper conﬁdence limit for the benchmark dose response
of 5%; bw: body weight.
The two sided 90% conﬁdence intervals (BMDL05 – BMDU05) of the BMD05 of the best ﬁtting models deﬁned by the Akaike
Information Criterion (AIC) are reported for the exponential and the Hill family following the EFSA guidance (EFSA Scientiﬁc
Committee, 2017).
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analysis (see Appendix G). Therefore the CONTAM Panel identiﬁed also the NOAELs and/or LOAELs for
the acute exposure of these animal species (see Section 8.2).
7.8.5. Concentration–response modelling for acute toxicity in pigs, dogs and
cats, and dose–response modelling for acute toxicity in farmed mink
The CONTAM Panel noted that vomiting was occasionally reported for pigs, while reduced feed
intake was consistently (occasionally also reduced weight gain) reported after exposure to DON in
feed. From a large database of studies (see Table 48), the CONTAM Panel identiﬁed the two studies of
Young et al. (1983) and Williams et al. (1988) as most suitable to analyse the concentration–response
relationship of vomiting in pigs. Several subtrials reported by Young et al. (1983) contained such
concentration–response information. Using the incidence data for immediate vomiting of piglets of
JECFA (FAO/WHO, 2011; Personal communication, A. Tritscher, WHO, 2015) a lowest BMDL10 of 1.36
mg DON/kg feed was calculated using the data from two of the four subtrials (Trial 2 and 3, each with
20 piglets in 5 dose groups observed for 4 or 11 days, respectively) (see Appendix G). The CONTAM
Panel noted that the co-occurrence of zearalenone in the feed was low in the two subtrials. Therefore,
this co-occurrence could hardly have confounded the outcome of immediate vomiting, because this
effect is not known as relevant effect of zearalenone in pigs. Williams et al. (1988) investigated
vomiting in pigs in two experiments, one with a small (n = 12) and another one with a larger number
of pigs (n = 54) each with a control and ﬁve concentrations. Both experiments showed a clear
concentration–response relationship where vomiting was observed at the higher doses at up to 100%
incidence. Applying the BMD approach to the data of the two experiments resulted in a lowest BMCL10
of 1.84 mg DON/kg feed per day (see Appendix G). The CONTAM Panel decided to use 1.36 mg
DON/kg feed as the overall reference point to characterise the acute risk of pigs when exposed to the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. For a summary of NOAELs and LOAELs for
the acute exposure to DON in pigs, see Section 7.3.
Concentration-response data for dogs were identiﬁed in the only available study of Hughes et al.
(1999) (see Section 7.3.7 and Appendix G) in which a total of 49 dogs were exposed to 6 different
concentrations of DON in feed. The number of animals per group varied between n = 2 and n = 14
and vomiting was observed at the two highest concentrations only. Due to the scarcity of the data not
all models of the set of the models available in the BMDS software could be ﬁtted to the data.
However, when applying the BMD approach following the EFSA guidance (EFSA Scientiﬁc Committee,
2017) three models could be selected to calculate a lowest BMDL10 of 5.1 mg DON/kg feed per day for
dogs.
Concentration-response data for cats were identiﬁed in the same only available study of Hughes
et al. (1998) (see Section 7.3.7 and Appendix G) in which a total of 20 cats were exposed to 5
different concentrations of DON in feed. The number of animals per group varied between n = 2 and
n = 8 and vomiting was observed at a mid (1/2) and at the highest (4/8) concentrations only. Due to
the scarcity of the data not all models of the set of the models available in the BMDS software could
be ﬁtted to the data. However, when applying the BMD approach following the EFSA guidance (EFSA
Scientiﬁc Committee, 2017) two models could be selected to calculate a lowest BMDL10 of 1.0 mg
DON/kg feed per day for cats.
Wu et al. (2013a) reported the incidence of emesis (deﬁned by the authors as vomiting or retching)
from an experiment with 1–2 years old female mink exposed either to DON or to 3-Ac-DON, 15-Ac-
DON or DON-3-glucoside (see Section 7.3.7 and Appendix G). The dose–response data showed a clear
relationship for DON and the two acetylated forms and were evaluated using the BMD approach for
quantal data as described by EFSA Scientiﬁc Committee (2017). The lowest BMDL10 values were 0.004
mg DON/kg bw per day, 0.05 mg 3-Ac-DON/kg bw per day and 0.004 mg 15-Ac-DON/kg bw per day.
A dose–response evaluation of vomiting of farmed mink exposed to DON-3-glucoside was not possible
since vomiting was observed only at highest dose of 2 mg DON-3-glucoside/kg bw in the study of Wu
et al. (2014) (see also Section 7.3.7). The CONTAM Panel noted that the study of Wu et al. (2013)
used intragastric administration with a dosing per kg body weight and decided therefore to use 0.004
mg DON/kg bw per day as reference point to characterise the acute risk of farmed mink when
exposed to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
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7.8.6. Reduced feed intake and reduced body weight or weight gain as critical
chronic adverse effects of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside for farm and companion animals
The CONTAM Panel identiﬁed reduced feed intake and reduced body weight or weight gain as the
critical chronic effects of DON in farm and companion animals (see Section 7.3) to characterise the
chronic hazard of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in animals. Reduced
feed intake was typically the ﬁrst adverse effect observed within the ﬁrst days of the experiments and
its frequency and intensity appeared to decline later in several studies. However, there were also many
studies where reduced feed intake persisted over the whole treatment period with an intensity varying
over time, and differing between individual animals and between species. Therefore, the available data
on the changes in feed intake and body weight, and when available also on feed refusal, were
considered in addition to the data on the reduction of feed intake and reduction of body weight gain.
The CONTAM Panel identiﬁed overall NOAELs or LOAELs (only if NOAELs were not identiﬁed) for all
farm and companion animal species for which exposure data were available (see Section 6.3).
The CONTAM Panel also explored whether the BMD approach can been applied for selected
concentration–response data from the chronic studies on pigs, farmed rabbits, farmed ﬁsh, dogs and
cats. Regarding pigs, considering the vast amount of the available studies, the studies with suitable
concentration–response data were scarce and limited by small numbers of experimental groups and
numbers of animals per concentration group. In addition, the designs (also the overall outcomes) of
the identiﬁed studies varied substantially. Regarding the changes in feed intake and body weight in
rabbits, cats and dogs only one study was identiﬁed that could have been analysed for each of the
three species. The few studies on farmed ﬁsh with concentration–response data were all based on a
speciﬁc (ANOVA-type) statistical design using ﬁsh tanks as the experimental unit rather than the
individual ﬁsh and they reported only limited information on the variability between the tanks and none
between individual ﬁsh. The CONTAM Panel also noted that the calculated BMCL values differed over
an order of magnitude for the same animal species between different models and different data sets.
For a number of data sets they were substantially lower than the identiﬁed NOAELs and often also
orders of magnitude lower than the lowest concentrations tested, probably due to the low number of
animals per concentration group or a design chosen for other aims than concentration/dose response
evaluation. It was also noted that several quantitative response data decreased rapidly between the
control and the low doses and levelled out at the higher doses. This behaviour is analogue to that of
supra-linear curves of incidences with high slopes at low doses where low BMDL values need to be
considered with caution. In view of these complications, the CONTAM Panel did not pursue calculating
the reference points based on concentration–response modelling for the chronic critical effects of the
farm and companion animals.
Overall NOAELs of 5, 10 and 15 mg/kg feed were identiﬁed for reduced feed intake and reduced
weight gain in dairy cows, heifers and steers, respectively (see Section 7.3.1 and Table 59). Lack
of data prevented the identiﬁcation of a NOAEL/LOAEL for goats but the CONTAM Panel decided to use
the NOAEL of dairy cow for goats because the efﬁciency of de-epoxidation of DON in goat is similar to
that in dairy cows. Based on the only one study available for sheep, the CONTAM Panel identiﬁed the
NOAEL of 16 mg/kg feed for reduced feed intake and body weight gain for sheep (see Table 59).
For pigs the CONTAM Panel noted that ranges for the identiﬁed NOAELs and LOAELs for reduced
feed intake and reduced weight gain were wide and overlapped (see Section 7.3.2 and Table 47). The
CONTAM Panel decided to use the overall NOAEL of 0.7 mg/kg feed identiﬁed for reduced feed intake
and/or reduced body weight gain in pigs (see Section 7.3.2 and Table 59).
For broiler chickens, laying hens, ducks and turkeys, the CONTAM Panel identiﬁed the overall
NOAELs of 5, 5, 7 and 7 mg/kg feed, respectively, for reduced feed intake and reduced weight gain
(see Section 7.3.3 and Table 59).
Scarceness or lack of data did not allow identiﬁcation of speciﬁc NOAELs/LOAELs for each farmed
ﬁsh species assessed in Section 7.3.5. However, based on the available data, the CONTAM
Panel decided to use the overall NOAEL of 0.6 mg/kg feed for carp and rainbow trout for all farmed
ﬁsh species (Table 59). The CONTAM Panel noted that salmon is physiologically close to the rainbow
trout and thus the NOAEL derived from rainbow trout data was also used for salmon.
Based on a limited number of studies on horses the overall NOAEL of 36 mg/kg feed for reduced
feed intake and reduced body weight was identiﬁed by the CONTAM Panel (see Section 7.3.4 and
Table 59). Similarly, the identiﬁed overall NOAEL of 4 mg/kg feed for reduced body weight gain,
relative organ weight and haematological parameters in rabbits was based also on a limited number
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of studies (see Section 7.3.5 and Table 59). Only one study was available on dogs, cats and farmed
mink from which the NOAELs of 4, 6 and 1 mg/kg feed, respectively, for the reduced feed intake and
reduced body weight were identiﬁed (see Sections 7.3.6–7.3.8 and Table 59).
7.9. Derivation of a group ARfD for acute risks of the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside in humans
Acute DON toxicosis has been associated with symptoms such as nausea, vomiting, diarrhoea,
abdominal pain, headaches, dizziness, fever, and in severe cases, bloody stool in humans (see
Section 7.5). Despite the limitations in the available human data, the CONTAM Panel decided to use
the data from the DON toxicosis outbreak reported by Luo et al. (1987) (see Sections 7.5.1 and 7.9),
supported by the available biomarker data (see Section 7.5.2), to establish a group acute reference
dose (ARfD) for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
From a large number of outbreaks of mycotoxicoses, most of them in China (Table 51), the
CONTAM Panel identiﬁed the study of Luo et al. (1987), in which primarily gastrointestinal disorders
including vomiting in humans were recorded and could be associated with the measured DON
concentrations in samples of contaminated grains consumed by the affected subjects (Table 52). In
this study none of the 73 persons in the town of Qingzu (one of the three towns studied) became ill
after being exposed to DON concentrations ranging between 1 and 8 mg/kg wheat. The CONTAM
Panel considered this study as the most suitable to derive a NOAEL for vomiting in humans exposed to
DON and identiﬁed the highest concentration of 8 mg/kg wheat from this population as a NOAEL for
vomiting in humans exposed to DON.
The CONTAM Panel noted that wheat processing has been reported to reduce DON concentrations
at a range of 10–80% depending on the method of processing (see Section 4.3), and decided to
account for wheat processing in the calculation of a NOAEL for vomiting in humans exposed to DON.
Considering that a minimal wheat reﬁning process was likely used at the time in China, the CONTAM
Panel assumed a 10% reduction of the concentration of DON when processing wheat to wheat ﬂour
and estimated the DON concentration as of 7.2 mg DON/kg wheat ﬂour. Furthermore, a maximum
wheat ﬂour consumption of 555 g/day for adults was assumed using the data from the Chinese
National Nutrition Survey data in 1982 (CNNS, 1982) that were the closest available data to the
situation during the outbreaks. The CONTAM Panel also noted that, instead of using the daily wheat
ﬂour consumption, a single meal portion of wheat ﬂour was more appropriate because vomiting was
usually reported to occur within 30 min after the eating occasion in the reports from the mycotoxicosis
outbreaks. Because wheat ﬂour is typically consumed in three separate eating occasions per day in
China (YY Gong, personal communication, 2016), the CONTAM Panel subdivided the maximum daily
wheat ﬂour consumption to three eating occasions resulting in an average meal size rounded to 200 g
(0.2 kg) per eating occasion.
By multiplying the 0.2 kg wheat ﬂour per meal with the concentration of 7.2 mg DON/kg wheat
ﬂour and dividing by a 55 kg body weight the average body weight for an Chinese adult at the time
(CNNS, 1982), a NOAEL of 26 lg DON/kg bw per eating occasion for vomiting was calculated. The
CONTAM Panel considered that a default uncertainty factor of 3.16 for toxicokinetic differences in the
human population was needed and established a group ARfD rounded to 8 lg/kg bw per eating
occasion for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
7.9.1. Support of human biomarker data
In addition, the CONTAM Panel decided to investigate to what extent the currently available urinary
DON biomarker data (see Section 7.5.2) could support the established group ARfD of 8 lg/kg bw per
eating occasion. The CONTAM Panel noted that the urinary biomarker only reﬂects previous day(s)
exposure and therefore it would estimate acute but not chronic exposure. From the available studies
on the DON biomarkers, the CONTAM Panel noted that no adverse health effects were reported in any
of these studies and concluded that the reported biomarker data were obtained from healthy adults.46
Therefore, the CONTAM Panel considered that the available urinary DON biomarker data can inform on
a NOAEL for vomiting in humans exposed to DON. Based on this consideration, the CONTAM
46 Participants of the biomarker studies had been studied within a clinical study context under the regulation of the Declaration
of Helsinki and therefore must have been informed on the aim of the biomarker study and given informed consent. The
CONTAM Panel assumed that any illness or acute disease of a participant would have been recognised by the clinical staff and
its presence, in particular vomiting in days before the visit would have excluded the proband.
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Panel searched for the highest tDON biomarker levels observed in the biomarker studies on the
healthy subjects and decided to sum up the urinary DON, DON-3-glucuronide, DON-15-glucuronide
and DOM-1/DOM-1-glucuronide concentrations. The CONTAM Panel noted that different mathematical
formulae have been proposed in the literature (see e.g. Heyndrickx et al., 2015) for the calculation of
tDON urinary biomarker levels accounting for the fact that the DON biomarker in urine comprises both
free and conjugated forms of DON (see also Section 3.4) and concluded that the summation
calculated by the CONTAM Panel is likely an overestimation. To back-calculate the highest human
exposure to DON from the highest tDON biomarker values, the CONTAM Panel used a linear approach
using the equation from Section 7.5.2 assuming an average DON excretion rate of 70%, an average
adult body weight of 70 kg and a default 24-h urine volume of 2 L for adults (EFSA Scientiﬁc
Committee, 2012). The highest urinary tDON biomarker level was reported for a healthy pregnant
woman in Croatia (Sarkanj et al., 2013) (Appendix H) from which the exposure of 74 lg DON/kg bw
per day47 was back-calculated. The next highest urinary biomarker level in healthy adults was
observed in a study from Belgium (Heyndrickx et al., 2015), from which 36 lg DON/kg bw per day
was back-calculated. The CONTAM Panel concluded from these calculations that the range from 36 to
74 lg DON/kg bw per day would represent a range of NOAELs at which vomiting is not expected to
occur in humans.
However, the CONTAM Panel noted several data gaps and uncertainties in the above described
approach which need to be taken into consideration:
a) the presence of an inconsistency between the urinary tDON biomarker levels measured using
single and multiple biomarker methods;
b) calculated the maximum concentration of the tDON biomarker, based on the summing up of
free DON and the glucuronides and DOM-1, is likely to be an overestimation;
c) neglecting the variation of DON excretion and urine volume amongst individuals in the used
back-calculation approach;
d) inconsistent reporting of tDON biomarker results in the literature e.g. when urinary free DON
and DON-3-glucuronide, DON-15-glucuronide and DOM 1 were not always measured or not
reported;
e) being unable to address the contribution of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside to the
tDON biomarker due to the limited or lack of such data.
Considering these multiple sources of uncertainties, the CONTAM Panel noted that it was not
possible to determine an uncertainty factor that would quantify the lack of current knowledge
associated with all these uncertainties and that could be applied to adjust the range of NOAELs of
36–74 lg DON/kg bw per day at which vomiting is not expected to occur in humans. Therefore, no
such uncertainty factor was identiﬁed and the available DON-biomarker data were only used to
support the group ARfD derived from human acute outbreak data in this opinion.
Thus, the CONTAM Panel compared the range of NOAELs of 36–74 lg DON/kg bw per day at which
vomiting is not expected to occur in humans according to the tDON urinary biomarker information with
the dose range of 26–78 lg DON/kg bw per day that was calculated from the NOAEL of 26 lg DON/kg
bw per eating occasion derived from the human outbreak data assuming from one to three eating
occasions per day. The CONTAM Panel concluded that these ranges were in the same order of
magnitude and supported each other.
The CONTAM Panel also noted that the group ARfD of 8 lg/kg bw per eating occasion for the sum
of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is based on human outbreak data while the ARfD
of 8 lg/kg bw per day for DON and its acetylated forms established by JECFA (FAO/WHO, 2011) was
based on the data on vomiting in pigs. Furthermore, the CONTAM Panel noted that FAO/WHO (2011)
used the human epidemiological data from the Henan incidence in China from 1985, and of Luo (1988)
and Guo et al. (1989), to calculate a level of 50 lg DON/kg bw per eating occasion, which could elicit
acute intoxication in humans. The CONTAM Panel noted that its calculated NOAEL of 26 lg DON/kg bw
per eating occasion for vomiting is not in disagreement with these calculations of JECFA (FAO/WHO,
2011).
47 Back-calculated from a tDON value of 1,810.8 ng/mL, which was a sum of free DON (275.0 ng/mL), DON-3-glucuronide
(298.1 g/mL) and DON-15-glucuronide (1,237.7 ng/mL)
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 225 EFSA Journal 2017;15(9):4718
7.10. Derivation of a group TDI for chronic risks of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside in humans
The CONTAM Panel decided to establish a group TDI for the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside. Based on the BMDL05 of 0.11 mg/kg bw per day for reduced body weight gain
in mice, the CONTAM Panel established a group TDI of 1 lg/kg bw per day using the default
uncertainty factor of 100 for inter- and intraspecies variability. Since the BMDL values calculated for
developmental and reproductive toxicity were all larger than the BMDL05 of 0.11 mg DON/kg bw per
day (see Section 7.8.2), the CONTAM Panel concluded that this was also protective for developmental
and reproductive toxicity.
The CONTAM Panel noted that this group TDI of 1 lg/kg bw per day the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside is the same as the previously established health base guidance
values by the SCF (2002) and by JECFA (FAO/WHO, 2011).
8. Risk characterisation
8.1. Human health risk characterisation
For human risk characterisation, the CONTAM Panel took into account the dietary exposure
assessment of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside using the available
analytical results on the occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food
reported to EFSA (Section 4.2) and the consumption patterns described in recent dietary surveys of
European countries available to EFSA (Section 5.1). The estimates of exposure to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside are presented in Section 6.1 and exposure to DON alone
calculated from the data reported to EFSA in Appendix F.
8.1.1. Acute human health risk from the dietary exposure to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside
The CONTAM Panel characterised the human health risk associated with acute dietary exposure to
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside by comparing the mean and 95th
percentile acute dietary LB and UB exposure estimates across European dietary surveys and the age
groups (summarised in Table 33) with the calculated group ARfD of 8 lg/kg bw per eating occasion
for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
The estimated mean acute dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside in food ranged from 0.2 (minimum LB) to 2.9 lg/kg bw per day (maximum UB) across the
dietary surveys and age groups.
For ‘infants’, the estimated 95th percentile acute dietary exposure to the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside in food ranged from 1.7 (minimum LB) to 6.7 lg/kg bw per day
(maximum UB) for ‘toddlers’ and ‘other children’ from 1.5 to 5.4 lg/kg bw, for adolescents from 0.8 to
2.9 lg/kg bw per day and for adult population (‘adults’, ‘elderly’ and ‘very elderly’) from 0.7 to 2.8 lg/kg
bw per day.
All mean and 95th percentile acute dietary exposure were below the group ARfD of 8 lg/kg bw per
eating occasion. The CONTAM Panel also noted that the probabilistic conﬁdence intervals at the UB for
the maximum 95th percentile dietary exposures were all below the group ARfD, including the highest
upper conﬁdence interval bound of 7.1 lg/kg bw per day calculated for ‘infants’. Therefore, the
CONTAM Panel concluded that the current acute exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside in food raises no health concern.
Regarding the vegetarian population, the limited available data on dietary habits of vegetarians
with data available for only ﬁve European countries and with very few subjects in four of them indicate
that mean acute dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is
not notably different from the general population. Although the CONTAM Panel noted that the
population group of infants could not be fully assessed for vegetarians since only one dietary survey
was available, there is no indication that their risk for acute effects would be different from other
vegetarian population groups.
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8.1.2. Chronic human health risk from the dietary exposure to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside
The CONTAM Panel characterised the human health risk associated with chronic dietary exposure to
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside by comparing the mean and 95th
percentile chronic dietary LB and UB exposure estimates across the European dietary surveys and the
age groups (summarised in Table 35) with the group TDI of 1 lg/kg bw per day.
For ‘Infants’, the estimated mean chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside ranged (minimum LB to maximum UB) from 0.2 to 2.0 lg/kg bw per day.
The CONTAM Panel noted that for ‘infants’ the means of LB exposure estimates were below the group
TDI of 1 lg/kg bw per day, whereas the median UB exposure was equal and the maximum UB
exceeded twofold the group TDI. The high (95th percentile) chronic exposures, ranging from 0.7 to
3.7 lg/kg bw per day (minimum LB to maximum UB), exceeded the TDI slightly already at the median
LB, and at all UB exposures.
The estimated mean exposures for ‘toddlers’ ranged from 0.6 (minimum LB) to 1.7 (maximum UB)
lg/kg bw per day, and the group TDI was exceeded at mean LB exposure in some and at mean UB
exposure in all dietary surveys. At the estimated high (95th percentile) exposures, ranging from 1.1 to
2.7 lg/kg bw per day (minimum LB to maximum UB), the TDI was exceeded in all dietary surveys
already at the LB exposure.
For ‘other children’, estimated mean chronic dietary exposures ranged from 0.6 to 1.1 lg/kg bw per
day at the LB and from 0.9 to 1.6 lg/kg bw per day at the UB. The group TDI was exceeded in one
dietary survey at the LB and in the majority at the UB. At the estimates of high (95th percentile)
exposure, ranging from 0.9 to 2.7 lg/kg bw per day (minimum LB to maximum UB), the group TDI
was exceeded in all except one survey.
For ‘adolescents’, the estimated mean chronic exposures ranged from 0.3 to 0.9 lg/kg bw per day
(minimum LB to maximum UB), and were below the group TDI. The estimated high (95th percentile)
exposures, ranged from 0.5 to 1.8 lg/kg bw per day (minimum LB to maximum UB) and the group
TDI was exceeded slightly at the LB exposure in some and at the UB exposure in the majority of the
surveys.
In the adult population groups (‘adults’, ‘elderly’ and ‘very elderly’), the estimated mean exposures
ranged from 0.2 to 0.7 lg/kg bw per day (minimum LB to maximum UB) did not exceeded the group
TDI, whereas the estimates of high (95th percentile) exposures exceeded slightly the group TDI at the
UB in some surveys.
The CONTAM Panel concluded that there is a health concern associated with chronic dietary
exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, particularly for ‘infants’
‘toddlers’ and ‘other children’ at the high (95th percentile) but at least in some European countries also
at the mean LB exposure. In ‘adolescents’ and the adult age groups, the group TDI was exceeded only
at the UB at the high (95th percentile) chronic exposures.
The limited available data on dietary habits of vegetarians with data available for only ﬁve
European countries, with very few subjects in four of them indicate that mean chronic dietary
exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is not notably different from
the general population. Although the CONTAM Panel noted that the population group of infants could
not be fully assessed for vegetarians since only one dietary survey was available, there is no indication
that their risk for chronic effects would be different from other vegetarian population groups.
8.2. Farm and companion animal health risk characterisation for
the exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside
For animal risk characterisation, the CONTAM Panel took into account the dietary exposure
assessment of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside using recent analytical
results on the occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in feed reported to
EFSA (Section 4.2) and the diet composition and feed consumption of farm and companion animals
described in Sections 5.2 and 6.3, and Appendix E. The estimates of exposure to the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside are presented in Section 6.3 and exposure to DON alone
in Appendix F.
The CONTAM Panel characterised the farm and companion animal health risk associated with
chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside by
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comparing the estimated UB mean and UB 95th percentile, calculated as dietary concentrations for the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside (see Section 6.3 and Appendix E), with the
identiﬁed NOAELs (expressed as mg/kg feed) (see Table 58). In addition, for pigs, farmed mink, dogs
and cats, for which vomiting was reported as an acute adverse effect, the acute health risk was
characterised. For pigs, dogs and cats, this was done by comparing the UB 95th percentile dietary
concentrations with the identiﬁed NOAELs and calculated BMCLs (see Sections 7.8.4 and 7.8.5), and
for farmed mink by comparing the estimated UB 95th percentile exposure (lg DON/kg bw per day)
with the calculated BMDL10 (see Section 7.8.5).
8.2.1 Ruminants
For dairy cows, the highest calculated UB mean and UB 95th percentile dietary concentrations
were 4 and 13% of the identiﬁed NOAEL of 5 mg/kg feed for chronic effects, respectively, except for
cows fed on maize silage-based diets were they were 16% and 55% of the NOAEL, respectively (see
Table 59). Therefore, the estimated risk for chronic adverse health effects from feed containing DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside was considered low.
In the absence of any speciﬁc dietary concentrations for heifers, the CONTAM Panel decided to
use the dietary concentrations of fatting cattle fed with fresh grass and/or grass silage-based diets
because their diet rations would be broadly similar. The highest UB mean and UB 95th percentile
dietary concentrations were 1% and 5% of the identiﬁed NOAEL of 10 mg/kg feed for chronic effects,
respectively (see Table 59). Therefore, the estimated risk for chronic adverse health effects from feed
containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was considered low.
For fattening beef cattle (including steers), the highest exposure was for cattle on straw-based
diets. The calculated UB mean and UB 95th percentile dietary concentrations were 6% and 21% of the
NOAEL of 18 mg/kg feed for chronic effects, respectively (see Table 59). For fattening beef cattle with
other feeding systems, the percentages were lower. Therefore, the estimated risk for chronic adverse
health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was considered
low.
For lactating sheep, the UB mean and UB 95th percentile dietary concentrations were 2% and 5%
of the NOAEL of 16 mg/kg feed for chronic effects, respectively (see Table 59), indicating that the
estimated risk for chronic adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside was low.
For goats, the exposure at the UB mean dietary concentrations was higher for lactating than
fattening goats, while it was the opposite at the UB 95th percentile. When comparing the highest
dietary concentrations with the NOAEL of 5 mg/kg feed for chronic effects, the percentages were 8%
for lactating and 15% for fattening goats (see Table 59). Therefore, the estimated risk for chronic
adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was
considered low.
The CONTAM Panel noted further that the risk might be higher for pre-ruminant animals such as
calves (see also Section 7.4.1), which might be more susceptible to the toxic effects of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside. This might also apply for lambs. Overall, the CONTAM
Panel noted that the estimated risk for chronic adverse health effects from feed containing DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside for different ruminant species was clearly lower than for
several other farm animal species considered in this opinion.
8.2.2. Pigs
The CONTAM Panel used the BMCL10 of 1.4 mg DON/kg feed as the reference point for acute risk
characterisation for pigs (fattening pigs and lactating sows) (see Section 7.8.4). The highest UB 95th
percentile dietary concentration (see Table 59) was 93% of the BMCL10 for acute effects (see
Section 7.8.5), indicating that the risk for acute adverse health effects from feed containing DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside was low.
For fattening pigs and lactating sows, the UB mean dietary concentrations were 74% and 89% of
the NOAEL of 0.7 mg/kg feed for chronic effects, respectively (see Table 59) and 186% at the UB 95th
percentile dietary concentrations for these animals. Therefore, the estimated risk for chronic adverse
health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was considered
low for pigs exposed to the mean dietary concentrations. At the UB 95th percentile dietary
concentrations, a possible risk for chronic adverse effects in pigs was identiﬁed.
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8.2.3. Poultry
Amongst the poultry species, the highest exposure was for broiler chickens and laying hens for
which the UB mean and UB 95th percentile dietary concentrations were 16–20% and 66–68% of the
NOAEL of 5 mg/kg feed for chronic effects, respectively (see Table 59). For fattening ducks, the
percentages were 14% and 41%, respectively, and for fattening turkeys 21% and 57%, respectively.
Therefore, the estimated risk for chronic adverse health effects from feed containing DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside was considered low.
8.2.4. Horses
The exposures were similar for horses when fed with diets with and without hay. The highest UB
mean dietary concentration was only 0.6% of the NOAEL of 36 mg/kg feed for chronic effects (see
Table 59), indicating that the estimated risk for chronic adverse health effects from feed containing
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was negligible. An insufﬁcient number of occurrence
data prevented the CONTAM Panel from estimating the risk for adverse health effects at the 95th
percentile dietary concentrations. However, based on the difference between the mean and the 95th
percentile concentrations in feeds in general, it is reasonable to expect that the risk remains negligible
also at the 95th percentile for horses.
The CONTAM Panel noted that the characterisation of the risks for horses should be considered
indicative owing to the uncertainties associated to the identiﬁed NOAEL (see Section 7.8.6).
8.2.5. Farmed rabbits
For rabbits, the calculated UB mean and UB 95th percentile dietary concentrations were 7 and 28%
of the NOAEL of 4 mg/kg feed for chronic effects, respectively (see Table 59), indicating that the
estimated risk for chronic adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside was low.
The CONTAM Panel noted that this characterisation of risks for farmed rabbits should be considered
indicative owing to the uncertainties associated to the identiﬁed NOAEL (see Section 7.8.6).
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Table 59: The identiﬁed overall NOAELs for the chronic adverse effects as detailed in Section 7.8.6 (rounded to the ﬁrst decimal place or to a whole
number) with the calculated upper bound (UB) mean and 95th percentile dietary concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside for the farm and companion animals (see also Section 6.3)
Animal species
for which a NOAEL
was identiﬁed
NOAEL
(mg/kg
feed)
Animal species
for which
exposure was
estimated
Calculated UB
mean dietary
concentration
(mg/kg DM)
Calculated UB
95th percentile
dietary concentration
(mg/kg DM)
% of dietary concentration of the NOAEL
UB
mean(h) (%)
UB 95th
percentile(h) (%)
Ruminants Ruminants
Dairy cows 5 Dairy cows
high yielding(b) 0.11 0.52 2 10
high yielding(c) 0.22 0.66 4 13
maize silage 0.78 2.6 16 55
Heifers 10 Heifers 0.11 0.52 1 5
Beef cattle/Steers 18 Beef cattle
fattening(b) 0.08 0.19 0.4 1
fattening(c) 0.23 0.32 1 2
cereal-based diet 0.39 1.8 2 10
maize silage 0.58 1.7 3 9
straw-based diet 1.0 3.7 6 21
Sheep 16 Lactating sheep 0.29 0.85 2 5
Goats 5(a) Lactating goats 0.41 0.61 8 12
Fattening goats 0.31 0.75 6 15
Pigs 0.7 Pigs
Fattening pigs 0.52 1.3 74 186
Lactating sow 0.62 1.3 89 186
Poultry Poultry
Broiler chickens 5 Broiler chickens 1.0 3.3 20 66
Laying hens 5 Laying hens 0.81 3.4 16 68
Fattening ducks 7 Fattening ducks 1.0 2.9 14 41
Fattening turkeys 7 Fattening turkeys 1.5 4.0 21 57
Farmed rabbits 4 Rabbits 0.28 1.1 7 28
Farmed ﬁsh(d) Farmed ﬁsh
Salmon 0.6 Salmonids 0.12 0.38 20 63
Carp 0.6 Carp 0.39 1.2 65 200
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Animal species
for which a NOAEL
was identiﬁed
NOAEL
(mg/kg
feed)
Animal species
for which
exposure was
estimated
Calculated UB
mean dietary
concentration
(mg/kg DM)
Calculated UB
95th percentile
dietary concentration
(mg/kg DM)
% of dietary concentration of the NOAEL
UB
mean(h) (%)
UB 95th
percentile(h) (%)
Horses 36 Horses(e)
Fresh grass diet(f) 0.17 – 0.5 –
Grass-hay diet(g) 0.25 – 0.6 –
Dogs 4 Dogs 0.21 0.75 5 19
Cats 6 Cats 0.26 1.0 7 25
Farmed mink 1 Farmed mink 0.11 0.41 11 36
NOAEL: no-observed-adverse-effect level; bw: body weight; UB: upper bound; –: insufﬁcient number of samples reported (i.e. < 60) to calculate 95th percentile concentration; DM: dry matter.
(a): NOAEL for the dairy cows used for goats (see Section 7.8.5).
(b): Fresh grass and/or grass silage-based diets (see Section 6.3).
(c): Grass hay-based diets (see Section 6.3).
(d): NOAEL for the carp and rainbow trout was used for salmon (see Section 7.8.5).
(e): Horses with moderate activity and hay based diet.
(f): Fresh grass and/or grass silage-based diets (see Section 6.3).
(g): Grass hay-based diets (see Section 6.3).
(h): Rounded to the ﬁrst decimal place or to the whole number.
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8.2.6. Farmed ﬁsh
For farmed ﬁsh (salmon and carp), the UB mean and UB 95th percentile dietary concentrations
were 20–65% and 63–200% of the NOAEL of 0.6 mg/kg feed for chronic effects, respectively (see
Table 59), indicating that the estimated risk for chronic adverse health effects from feed containing
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was low at the mean dietary concentrations. In
contrast, at the UB 95th percentile dietary concentrations, a possible risk for chronic adverse effects at
least for carp was identiﬁed.
The CONTAM Panel noted that the diet composition of different ﬁsh species may differ to a major
extent between ﬁsh species and that some ﬁsh species might be more tolerant for the adverse effects
than the others.
8.2.7. Farmed mink
For farmed mink, the UB 95th percentile dietary exposure (410 lg/kg bw per day) (see Table 43 in
Section 6.3) was 100-fold the BMDL10 of 4 lg DON/kg bw per day for acute effects (Section 7.8.5),
and therefore, a possible risk for acute adverse health effects from feed containing DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside was identiﬁed.
The calculated UB mean and UB 95th percentile dietary concentrations were 11% and 36% of the
NOAEL of 1 mg DON/kg feed for chronic effects, respectively (see Table 59), indicating that the
estimated risk for chronic adverse health effects from feed containing the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside was low.
The CONTAM Panel noted that the characterisation of chronic risks for farmed mink should be
considered indicative owing to the uncertainties associated to the identiﬁed reference points (see
Section 7.8.6).
8.2.8. Dogs
For dogs, the calculated UB 95th percentile dietary concentration (see Table 59) was 15% of the
BMCL10 of 5 mg/kg feed for acute effects (Section 7.8.5), indicating that the estimated risk for acute
adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was
low.
The UB mean and UB 95th percentile dietary concentrations were 5 and 19% of the NOAEL of 4
mg/kg feed for chronic effects, respectively (see Table 59), indicating that the estimated risk for
chronic adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
was low.
The CONTAM Panel noted that this characterisation of acute and chronic risks for dogs should be
considered indicative owing to the uncertainties associated to the identiﬁed reference points
(see Section 7.8.6).
8.2.9. Cats
For cats, the UB 95th percentile dietary concentration (see Table 59) was 100% of the BMCL10 of
1.0 mg/kg feed for acute effects (Section 7.8.5) and therefore a possible risk for acute adverse health
effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside at the UB 95th
percentile dietary concentrations was identiﬁed.
The calculated UB mean and UB 95th percentile dietary concentrations were 7% and 25% of the
NOAEL of 6 mg/kg feed for chronic effects, respectively (see Table 59), indicating that the estimated
risk for chronic adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside was low.
The CONTAM Panel noted that this characterisation of acute and chronic risks for cats should be
considered indicative owing to the uncertainties associated to the identiﬁed reference points (see
Section 7.8.6).
9. Uncertainty analysis
Evaluation of the inherent uncertainties in the assessment of exposure to the sum of DON, 3-Ac-
DON and 15-Ac-DON and DON-3-glucoside and DON has been performed following the guidance given
in the Opinion of the Scientiﬁc Committee related to Uncertainties in Dietary Exposure Assessment
(EFSA, 2007). In addition, the report on ‘Characterizing and Communicating Uncertainty in Exposure
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Assessment’ has been considered (WHO/IPCS, 2008). According to the guidance provided by the EFSA
opinion (2006) the following sources of uncertainties have been considered: Assessment objectives,
exposure scenario, exposure model and model input (parameters). In addition to the EFSA opinion
(2006), the CONTAM Panel also considered other uncertainties.
9.1. Assessment objectives
The objectives of the assessment were deﬁned in the terms of reference. In communication with
the requestor of the present opinion, the assessment objectives were clariﬁed as described in
Section 1 and thereafter existed no uncertainty in addressing the objectives.
9.2. Exposure scenario and model
The calculation of exposure from food and feed was based on the occurrence data reported to
EFSA for a period from 2007 to 2014 for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside following
the speciﬁcations of EFSA (EFSA, 2010a) and on a substitution of ‘non-analysed’ occurrence data for
3-Ac-DON, 15-Ac-DON and DON-3-glucoside. This substitution was based on the estimated ratios of
10, 15 and 20% of 3-Ac-DON to DON, 15-Ac-DON to DON and DON-3-glucoside to DON, respectively,
in grains for food consumption and grain-based products and cereal grains for feed, and on the
estimated ratio of 80% of DON-3-glucoside to DON for the alcoholic beverages by using the currently
available literature data and the occurrence data submitted to EFSA on the co-occurrence of these four
DON-forms (see Section 4.2.8). The substitution and, particularly the choice of plausible %-ratios
introduced uncertainties in both, the acute and chronic exposure assessments of humans and farm
and companion animals.
The concentrations for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and
feed were not corrected for molar masses which added uncertainties on the overall exposure estimates
for humans and farm and companion animals. This uncertainty is considered small in comparison to
the other uncertainties identiﬁed.
Data on occurrence in food, feed and unprocessed grains of undeﬁned end-use were used as
submitted by the data providers, either corrected for recovery or not. Only data with a predeﬁned
minimum level of the LOQ of the analytical method (LOQ < 100 lg/kg in food and feed, except data
on food for infants where an LOQ < 50 lg/kg was required) were used to estimate exposure. This
might have introduced further uncertainties to the exposure estimates.
Although the occurrence data used covered the relevant food and feed groups known for
contamination by DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, the numbers of samples were
not equally distributed across these groups, and there was a high proportion of left-censored data in
many food and feed categories. These aspects contributed to the overall uncertainty of exposure. The
number of the samples that were analysed for DON alone was almost an order of magnitude larger
then number of samples also analysed for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. Furthermore,
the number of samples analysed simultaneously for DON and at least one of the three other forms was
very small compared to the total number of analytical results available and there was only a minute
number of samples where DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were quantiﬁed
simultaneously.
The lack of analytical methods formally validated through interlaboratory studies hampered a
reliable conclusion on the uncertainty of the currently available results in EFSA’s database or in the
cited literature on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and feed. The lack of
certiﬁed reference materials for DON-3-glucoside, 3-Ac-DON and 15-Ac-DON (as calibrants and in
particular matrix materials) are additional limitations that hamper an uncertainty estimation for
individual laboratories. Both issues, as a result, contribute to the overall uncertainty of the occurrence
data. These limitations are equally valid for the chemical analysis used in toxicokinetic and toxicity
studies and in studies for human urinary biomarkers and their metabolites.
The use of the UB approach for high percentage of occurrence data < LODs/LOQs, even when
100% of the data were left-censored, is conservative and represented an overestimation of both the
acute and the chronic risk, while the use of the LB approach represented an underestimation.
The CONTAM Panel noted that a considerable number of food categories, in particular at EFSA Food
Category levels 2 and where used also at level 3 exhibited 100% left-censored data. Although left-
censored data always adds uncertainty to the exposure assessment, a sensitivity analysis excluding
food groups with 100% left-censored data indicated only a minor impact for the present assessment.
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Based on the information from the available literature data, effects of processing of the food and
the feed contaminated by DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside can lead to increases or
decreases of concentrations of the toxins depending on the type and intensity of the form of
processing. This adds to the overall uncertainty.
Limited data on food consumption for vegetarians adds uncertainty in their exposure assessment.
There was a lack of dietary surveys reporting consumption data for children younger than 1 year,
which led to an uncertainty for this age group. All these aspects added to the overall uncertainty.
For the exposure of farm and companion animals, where species-speciﬁc data on compound feed
were not available the CONTAM Panel formulated example feed rations. This and the considerable
variability that exists between feeds and feeding systems used for farm animals in Europe add to the
uncertainty of animal exposure. Exposure of ruminants may be overestimated when data for grass hay
were used for estimating the contribution from forages for lactating dairy cows and beef cattle. These
aspects contributed further to overall uncertainty for the animal risk assessment.
9.3. Other uncertainties
The approach taken assumed that DON-3-glucoside is metabolised to DON and absorbed at the
same extent as DON and might induce the same acute and chronic effects as DON, and is considered
conservative. The same assumptions made for the 3-Ac-DON and 15-Ac-DON also contribute also to
the overall uncertainty, but to a lesser extent.
The available data from mice indicated that the absorption is higher in weanling mice than in young
adults. This may indicate that young animals are more susceptible than adults and this contributed to
the overall uncertainty.
The CONTAM Panel noted that the available toxicity data indicated that DON is genotoxic in vitro,
however insufﬁcient evidence was identiﬁed to assess whether DON is genotoxic in vivo or not,
although no evidence was found that DON is directly DNA reactive and no evidence for carcinogenicity
was identiﬁed. Currently, available data for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside are too limited
to draw qualiﬁed conclusions on their single or combined genotoxicity and/or carcinogenicity and
therefore the genotoxic potential of the exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside is not fully characterised. The CONTAM Panel also noted a lack of data on
neurotoxicity of DON and on general and gastrointestinal toxicity of 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in experimental animals. All these aspects contributed to the uncertainty of the risk
characterisation for both humans and farm and companion animals.
Most studies in animals on the adverse effects induced by DON used naturally contaminated feed
which contained, in addition to DON and/or 3-Ac-DON, 15-Ac-DON and DON-3-glucoside, other
mycotoxins. The presence and/or concentrations of these were often incompletely reported. This
contributed to the overall uncertainty for the risk assessment of farm and companion animals.
For the risk assessment on dogs and cats, the CONTAM Panel identiﬁed only one study on acute
and chronic adverse effects that reported substantial interindividual variability in behaviour of the
animals. The numbers of animals per dose group was rather small ranging to 10 at its maximum. This
added substantial uncertainty on the identiﬁed reference points, and thus further to the risk
assessment of these animal species. Similarly, only one study on acute and one study on chronic
adverse effects were available on farmed mink introducing uncertainty to the reference points and
their risk assessment. For the adverse health effects in farmed rabbits and horses, a limited number of
studies were available and this introduced uncertainty to their risk assessment.
For the risk assessment on farmed ﬁsh, the CONTAM Panel noted that the design of most studies
used the ﬁsh tank as experimental unit and therefore interindividual variation was not fully accounted
for in the hazard characterisation. This and incomplete reporting of the statistical variability generated
substantial uncertainty. The CONTAM Panel also noted a large uncertainty of the hazard
characterisation for farmed ﬁsh, in general, since only two ﬁsh species could be assessed.
Due to the limited information, combined effects of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside and/or with other mycotoxins could not be characterised and this might lead to over- or
underestimation of the hazard of DON and its acetylated and modiﬁed forms in food and feed. This
contributed to the overall uncertainty.
The assessment for the acute risk from the exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside was based on an ARfD established for vomiting in humans and calculated from a
limited number of occurrence data from only one epidemiological study on previous mycotoxicosis
outbreaks in Asia. Although the ARfD was well supported by well sized human urinary biomarker data
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recruited in Europe, the CONTAM Panel noted several data gaps and uncertainties when assessing
these biomarker data. Therefore, in the absence of an appropriate and well-designed acute
toxicological study on humans and/or experimental animals the overall uncertainty of the acute risk
assessment of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for humans remains high.
The uncertainties related to the application of biomarkers of DON are presented in Section 7.9.
9.4. Summary of uncertainties
In Table 60, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
The CONTAM Panel concluded that although the impact of the uncertainties in the human risk
assessment of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is large, the risk is more
likely to be over than underestimated. The impact of the uncertainties in the risk assessment of farm
and companion animals is large.
Table 60: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of the human and animal dietary exposure to the sum of DON, 3-Ac-DON and
15-Ac-DON and DON-3-glucoside
Sources of uncertainty Direction(a)
Uncertainty of the analytical measurements +/
Considering only occurrence data in food and feed for which the LOQs were reported to be
below the cut-off LOQ values
+/
Effects of food and feed processing +/
Limited data on the co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in the
food and feed samples
+/
Non-analysed concentrations of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside were assigned based on the estimated %-ratios
+/
Across the different food and feed matrices the same estimated %-ratios for the non-analysed
concentrations were used
+/
High variability of the composition of feedstuffs used and feeding systems for farm animals in
Europe
+/
Use of UB occurrence data in the exposure estimations +
Use of LB occurrence data in the exposure estimations 
Limited data on exposure of infants +/
Limited data on exposure of vegetarians +/
Limited or no toxicokinetic data on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for humans,
experimental animals a number of farm animal species and companion animal species
+/
Limited or no toxicological data on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for humans,
experimental animals, a number of farm animal species and companion animal species
+/
Incomplete data on the mode of action underlying the possible genotoxicity of DON 
Similar toxicity and toxicological potency as associated with DON were applied for 3-Ac-DON, 15-
Ac-DON and DON-3-glucoside
+
Lack of information on combined effects with other mycotoxins or other toxic substances in food
and feed
+/
Use of one limited epidemiological study on an outbreak of acute mycotoxicosis in humans in
the absence of an appropriate and well-designed acute toxicological study on humans and/or
experimental animals
+/
Approach and assumptions taken for establishing the ARfD for humans +
DON: deoxynivalenol; LOQ: limit of quantiﬁcation; UB: upper bound; LB: lower bound; ARfD: acute reference dose.
(a): + = uncertainty with potential to cause over-estimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk.
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Conclusions and recommendations
Conclusions
Deoxynivalenol, 3-acetyl-DON (3-Ac-DON), 15-acetyl-DON (15-Ac-DON) and DON-3-glucoside are
currently the most relevant forms of DON in Europe occurring in food and feed, mainly in cereal grains
and cereal-based food. While DON, 3-Ac-DON and 15-Ac-DON are produced by plant pathogenic fungi
of the Fusarium genus as toxic secondary metabolites, DON-3-glucoside is the main plant metabolite
of DON and considered as a modiﬁed mycotoxin.
Methods of analysis
• Analytical methods for detection and quantiﬁcation of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside are well established.
• For DON, performance criteria for methods of analysis and certiﬁed reference materials (both
reference matrices and reference calibrants) are available. Non-certiﬁed calibrants are available
for 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
• Quantiﬁcation of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is mostly carried out by
liquid chromatography (LC) coupled with (multistage) mass spectrometry (MS). This
methodology has not been formally validated through interlaboratory studies, and proﬁciency
studies demonstrated considerable analytical variability in the determination of DON.
• Urinary DON and its metabolites in urine, primarily DON-glucuronides, can be detected using
single or multiple biomarker methods. Commercial sources for the standards of DON-glucuronides
are scarce and no (certiﬁed) reference materials are available for urinary DON biomarkers.
Occurrence
• For food, a total of 41,027 analytical results for DON (n = 21,916), 3-Ac-DON (n = 11,944),
15-Ac-DON (n = 6,370) and DON-3-glucoside (n = 797) fulﬁlled the quality criteria applied and
have been used in the assessment.
• For feed, a total of 6,295 analytical results for DON (n = 4,000), 3-Ac-DON (n = 894), 15-Ac-
DON (n = 470) and DON-3-glucoside (n = 931) fulﬁlled the quality criteria applied and have
been used in the assessment.
• For unprocessed grains of undeﬁned end-use, a total of 3,643 analytical results for DON
(n = 1,621), 3-Ac-DON (n = 1,054), 15-Ac-DON (n = 430) and DON-3-glucoside (n = 538)
fulﬁlled the quality criteria applied and have been used in the assessment.
• The proportion of left-censored data in food (results below the limit of detection (LOD) or limit
of quantiﬁcation (LOQ)) were 63% for DON, 98% for 3-Ac-DON, 97% for 15-Ac-DON, and
57% for DON-3-glucoside. The corresponding values for feed were 43% for DON, 92% for
3-Ac-DON, 65% for 15-AC-DON, and 91% for DON-3-glucoside. The corresponding values for
unprocessed grains were 56, 91, 68 and 66% of the results for DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside, respectively.
• The highest mean concentrations of DON and the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside were recorded for food in the category of ‘Products for special nutritional
use’, followed by ‘Grains and grain-based products’, for feed, in ‘Cereal straw’ and for
unprocessed grains of undeﬁned end-use in ‘Grains as crops’.
• In general, the DON concentrations were either similar to or marginally lower in organically
produced grains compared to conventionally produced grains in the data submitted to EFSA.
This pattern was generally conﬁrmed by the limited data available in the published literature.
Due to lack of data, it was not possible to draw similar conclusions for 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside.
• The co-occurrence ratios of DON with 3-Ac-DON, 15-Ac-DON and/or DON-3-glucoside in food
and feed reported to EFSA varied considerably between different food, feed and grain
categories, both for data submitted to EFSA and data reported in the literature.
• Based on a review of the available information and using expert judgement, the CONTAM
Panel estimated the ratios of concentrations of 3-Ac-DON to DON, 15-Ac-DON to DON and
DON-3-glucoside to DON as 10%, 15% and 20%, respectively. The exception was ‘Alcoholic
beverages’ (‘Beer and beer-like beverage’) for which the ratio of DON-3-glucoside to DON was
estimated as 80%. These %-ratios were used for exposure assessments.
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Effects of processing
• Because DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside are mostly attached to the outer
hull of the grain, cleaning, sorting, sieving and dehulling of grains lead to marked increases in
concentrations of these toxins in cereal by-products, e.g. bran.
• During baking and cooking, DON appears to be relatively stable. Studies on 3-Ac-DON and
15-Ac-DON and DON-3-glucoside were inconclusive
• Malting and brewing do not seem to lead to losses of DON and DON-3-glucoside and no
increased concentrations were observed in by-products of brewing. However, the ratio between
DON and DON-3-glucoside concentrations changed during the process leading to a notable
increase of the concentrations of DON-3-glucoside as compared to DON. Studies on the fate of
3-Ac-DON and 15-Ac-DON during malting and brewing were too limited to draw conclusions.
• Data on feed processing were too limited to draw conclusions. However, since some of the
processes applied to cereal grains for food production are also applied to grains used for
animal feeds, the ﬁndings for food should also apply to feed.
Human exposure
• The estimates of mean acute exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside across 39 different dietary surveys and all age groups using the minimum lower
bound (LB) and the maximum upper bound (UB) concentrations ranged from 0.2 to 2.9 lg/kg
body weight (bw) per day. The estimates of 95th percentile acute exposure ranged from 0.7 to
6.7 lg/kg bw per day. The highest mean and the highest 95th percentile acute dietary
exposures were for infants.
The estimates of mean chronic exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside across 33 different dietary surveys and all age groups using the minimum LB and
the maximum UB concentrations ranged from 0.2 to 2.0 lg/kg bw per day. The estimates of
95th percentile chronic exposure ranged from 0.5 to 3.7 lg/kg bw per day. The highest mean
and the highest 95th percentile chronic dietary exposures were for infants.
• The most important contributors to the chronic dietary exposure to the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside were ‘Grains and grain-based products’, especially
‘Bread and rolls’, ‘Fine bakery wares’ and ‘Pasta (raw)’.
• The limited consumption data on vegetarians do not indicate a major difference in the dietary
exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and 3-DON-glucoside between
vegetarians and the general population.
Farm and companion animal exposure
• The animal exposure was presented as dietary concentrations because the animal risk
assessment was carried out on a concentration–response basis, except for the farmed mink for
which the acute dietary exposure was presented on a dose-response basis expressed per kg
bw.
• Animal exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was
primarily from the consumption of cereal grains and cereal byproducts. With the exception of
forage maize (and maize silage produced from it), levels in forages were generally low.
• For lactating dairy cows and beef cattle, the calculated lowest LB and highest UB mean dietary
concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 64.2 and
996 lg/kg diet, respectively, and the 95th percentile dietary concentrations were 124 and 3,655
lg/kg diet, respectively.
• For small ruminants, the calculated lowest LB and highest UB mean dietary concentrations of
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 151 and 414 lg/kg diet,
respectively, and the 95th percentile dietary concentrations were 561 and 849 lg/kg diet,
respectively.
• For pigs, the calculated lowest LB and highest UB mean dietary concentrations of the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 437 and 618 lg/kg diet, respectively,
and the 95th percentile dietary concentrations were 1,284 and 1,302 lg/kg diet, respectively.
• For poultry, the calculated lowest LB and highest UB mean dietary concentrations of the sum
of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 794 and 1,494 lg/kg diet, and the
95th percentile dietary concentrations were 2,900 and 3,971 lg/kg diet, respectively.
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 237 EFSA Journal 2017;15(9):4718
• For horses, the calculated lowest LB and highest UB mean dietary concentrations of the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 155 and 253 lg/kg diet, respectively.
• For farmed ﬁsh (salmonids and carp), the calculated lowest LB and highest UB mean dietary
concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 83.3 and
388 lg/kg diet, respectively, and the 95th percentile dietary concentrations were 362 and 1,151
lg/kg diet, respectively.
• For farmed rabbits, the calculated LB and UB mean dietary concentrations of the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 196 and 282 lg/kg diet, respectively, and
the 95th percentile dietary concentrations were 1,048 and 1,135 lg/kg diet, respectively.
• For farmed mink, the calculated LB and UB mean dietary concentrations of the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside were 99.5 and 109 lg/kg diet, respectively. The
95th percentile dietary concentrations were 407 lg/kg diet (equivalent to 14.7 lg/kg bw per
day) and 409 lg/kg diet (equivalent to 14.8 lg/kg bw per day), respectively.
• For dogs, the calculated LB and UB mean dietary concentrations of the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside were 174 and 214 lg/kg diet, respectively, and the
95th percentile dietary concentrations were 741 and 753 lg/kg diet, respectively.
• For cats, the calculated LB and UB mean dietary concentrations of the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside were 229 and 264 lg/kg diet, respectively, and the 95th
percentile dietary concentrations were 968 and 975 lg/kg diet, respectively.
Toxicokinetics in rodents
• The oral bioavailability of DON has not been quantiﬁed in mice, but plasma, tissue and urine
concentrations indicated that the absorption is high and maximum plasma concentrations are
reached rapidly.
• Following absorption, DON is rapidly distributed to tissues, e.g. liver, kidney, spleen and heart
in rodents reaching the maximum concentrations at about the same time as in plasma with
exception for the brain, where the total concentrations of DON and metabolites peak later and
at lower concentrations than in other organs.
• In rats, DON is partially transformed to the less toxic de-epoxidised metabolite DOM-1 by gut
bacteria prior to absorption.
• The main biotransformation of DON is conjugation with glucuronic acid leading to the
formation of mainly DON-3-glucuronide and DON-15-glucuronide. DON-sulfonates were the
major metabolites in rat faeces.
• In rats, DON was rapidly excreted in faeces and urine with no apparent accumulation in any
tissue. A mean urinary excretion of at least 70% was noted. In faeces, DON was largely
metabolised to DOM-1.
• In rats and mice, 3-Ac-DON and 15-Ac-DON was mainly transformed to DON by gut microﬂora
prior to absorption and systemic distribution. After transformation, 3-Ac-DON and 15-Ac-DON
followed the kinetics of DON.
• In rats, DON-3-glucoside was also mainly transformed to DON in the gut prior to absorption
and followed the kinetics as DON. However, the total bioavailability was considerably lower
than for DON. The cleavage of DON-3-glucoside in the gastrointestinal tract was species and
strain speciﬁc.
Toxicokinetics in humans
• In humans, an estimated 70% of the ingested DON was excreted to urine, mainly as
glucuronide conjugated DON. DON-15-glucuronide was the predominant conjugate in human
urine, DON-3-glucuronide being about three times less.
• The transformation of DON to DOM-1 in humans was less evident than in rats and mice.
• DON was transported across the human placenta in both in vitro and ex vivo models and can
reach the fetus.
Toxicokinetics in farm animals
• In ruminants, DON was extensively transformed to the less toxic de-epoxidised metabolite
DOM-1. Both are efﬁciently glucuronidated. The main route of excretion is via urine and the
faecal and biliary excretion routes are less important.
• Much less of DOM-1 was generated in ruminants with ruminal acidosis and in young ruminants
such as calves in which the ruminal system is not fully functioning.
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• In dairy cows, DON was almost completely metabolised by the ruminal ﬂora to the de-
epoxidated form DOM-1 and only minor amounts for DON (< 1%) and DOM-1 reached
systemic circulation.
• In sheep, DON was bioavailable at 7.5% and was quickly absorbed.
• In goats, no data were identiﬁed on the toxicokinetics of DON.
• No data were identiﬁed on the toxicokinetics of 3-Ac-DON, 15-Ac-DON and/or DON-3-glucoside
for ruminants except for sheep where one study indicated that 3-Ac-DON was rapidly
hydrolysed to DON.
• In pigs, the absorption of DON was rapid (less than 30 min) and generally high (48–65%),
inﬂuenced by the level of exposure. DON showed an extensive organ distribution and a rapid
renal excretion and it was partly conjugated to glucuronic acid. The plasma elimination half-life
varied from 1 to 4 h. Excretion of DON and its metabolites was via urinary and biliary routes
with urinary excretion being most important. 3-Ac-DON was rapidly deacetylated in the upper
intestinal tract and absorbed exclusively as DON. DON-3-glucoside showed a two times lower
bioavailability compared with DON and was available primarily as aglucone, likely after its
cleavage in the gastrointestinal tract. No data were identiﬁed for 15-Ac-DON.
• In poultry, the oral bioavailability of DON was low (only up to 10%) and it was rapidly
absorbed into plasma with fast metabolism and clearance from plasma. Only low
concentrations of DON and DOM-1 were detected in plasma and bile. The major metabolite of
DON in plasma of broiler chickens and turkeys was DON-3-sulfate. Formation of DON-3-
glucuronide appeared to be a minor pathway. In broiler chickens, a nearly complete hydrolysis
of 3-Ac-DON to DON and a partial hydrolysis of 15-Ac-DON to DON were observed. Limited
results indicated that DON-3-glucoside was not hydrolysed to DON in broiler chickens. The oral
bioavailability of DON-3-glucoside was low and comparable to that of DON.
• In horses, microbial de-epoxidation of DON might take place in gut. A rapid clearance of DON
in plasma was observed in a glucuronide-conjugated form. No data were identiﬁed for 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside in horses.
Transfer
• The transfer of DON to food of animal origin was generally low and residues of DON in
products of animal origin are unlikely substantially to contribute to human exposure. No data
on the transfer of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were identiﬁed.
Toxicity of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in rodents
Acute toxicity
• Acute toxicity of DON was characterised as feed refusal, weight loss and diarrhoea.
• Acute toxicity of 3-Ac-DON was considerably lower than that of DON. In mice, both 3-Ac-DON
and 15-Ac-DON showed shortly after start of exposure feed refusal that appeared to be
compensated later by increased feed intake.
Subacute and subchronic toxicity
• Subacute and subchronic toxicities of DON were characterised as feed refusal, reduced body
weight gain and diarrhoea.
• In the few available subchronic toxicity studies on DON in mice and rats, a no-observed-
adverse-effect level (NOAEL) of 0.1 mg/kg bw per day was identiﬁed based on haematological
disturbances.
• No data on subacute or subchronic toxicity of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
were identiﬁed.
Chronic toxicity
• The only long-term chronic toxicity study on DON was designed in mice as a carcinogenicity
study. This study did not indicate carcinogenic properties of DON. From the general toxicity
reported in this trial, a NOAEL of 0.1 mg/kg bw per day was identiﬁed for reduced feed intake
and body weight gain in mice.
• The available data did not show any haemato- or myelotoxicity of DON.
• Data on neurotoxicological effects of DON were very limited and no dose–response data were
suitable for hazard characterisation or the generation of a link with the data on the mode of
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action of DON. No data on chronic toxicity, haemato- and myelotoxicity, neurotoxicity and
carcinogenicity of 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were identiﬁed.
Immunotoxicity
• DON induced an elevation of IgA in rodents and farm animals. In the available chronic 2-year
study, the increase of IgA was only observed in female mice at the highest dose of 1.6 mg/kg
bw per day.
• In studies with high doses, DON induced inﬂammation in mice. An increase in TNF-a and IL-1-
b was observed at doses as low as 2.5 lg DON/kg bw per day but this was seen in the
absence of an observed adverse effect.
• The DON effects on the immune response (doses 8–10 mg/kg bw) led to an increased
susceptibility to infectious diseases.
• Inﬂammation was observed after exposure to 3-Ac-DON and 15-Ac-DON in mice but not for
DON-3-glucoside. However, data on immune response, were scarce and no effects on IgA
levels were reported.
Reproductive and developmental toxicity
• Oral exposure to DON exhibited both developmental and reproductive toxicity in experimental
animals including reduced fertility, embryotoxicity, skeletal abnormalities, effects on body
weight and relative epididymal weight and postnatal mortality.
• For mice, no new relevant data were identiﬁed since the previous assessment and the
CONTAM Panel conﬁrmed the previous NOAELs of 0.38 mg/kg bw per day for increased
postnatal mortality in pups and 0.5 mg/kg bw per for skeletal abnormalities.
• Studies on rats treated orally with DON, that were carried out since the evaluation of the
Scientiﬁc Committee of Food (SCF), showed a NOAEL of 1.0 mg/kg bw per day for
reproductive endpoints, 1.0 mg/kg bw per day for fetal toxicity and 0.5 mg/kg bw per day for
maternal toxicity.
• No data were identiﬁed for 3-Ac-DON, 15-Ac-DON and DON-3 glucoside.
Genotoxicity
• DON was genotoxic in vitro, and the data available on the genotoxicity of DON in vivo were
inconclusive.
• The available evidence suggested that oxidative stress may be involved in the genotoxicity,
rather than a direct interaction of DON with DNA (e.g. adduct formation).
• 3-Ac-DON was inactive in a bacterial mutation assay and no in vitro genotoxicity data for
15-Ac-DON or DON-3-glucoside were identiﬁed.
• No in vivo genotoxicity studies on 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were identiﬁed.
Human toxicity data
• Human outbreaks from acute exposure to DON have been repeatedly reported in Asia, with
symptoms including nausea, vomiting, diarrhoea, abdominal pain, headaches, dizziness, fever,
and in severe cases, bloody stool; however, no lethality was reported.
• Evidence of adverse health effect in humans due to chronic exposure to DON was lacking.
Human biomarkers of exposure
• A urinary DON biomarker for total DON comprising DON, DON-3-glucuronide and DON-15-
glucuronide correlated well with dietary exposure to DON.
• DON-glucuronides contribute a major portion eventually up to 90% of total DON in urine with
DON-15-glucuronide the predominant metabolite. The limited information on DOM-1 indicated
low levels compared to free DON and DON-glucuronides.
• Exposure estimates derived from the biomarker data from three European countries were of
the same order of magnitude as the exposure estimates for the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside derived from the occurrence data reported to EFSA and the
dietary surveys from those countries.
Mode of action
• DON, 3-Ac-DON and 15-Ac-DON bound to the ribosome peptidyl transferase centre, inhibiting
protein synthesis. This binding also induces a ribotoxic stress and activates different MAPKs.
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Activation of MAPKs explains several effects of DON such as apoptosis/survival, inﬂammatory
effect and oxidative stress.
• Because of steric hindrance DON-3-glucoside could not bind to the ribosome and thus it did
not activate MAPKs and induce inﬂammation.
• Both pro-inﬂammatory cytokines and satiety hormones have been proposed as major
mediators of DON-induced anorexia/emesis.
• The anorectic and emetic potencies of DON-3-glucoside were lower than those of DON and
underlying mechanisms are so far unknown.
Combined effects of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside with other
mycotoxins
• The database describing possible effects of combined exposure to DON and other mycotoxins
was not sufﬁcient for establishing the nature of combined effects. No in vivo studies on the
combined effects of 3-Ac-DON, 15-Ac-DON or DON-3-glucoside with other mycotoxins were
identiﬁed.
Comparative toxicity of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
• Only few studies compared the toxicity of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
the same experiment.
• DON, 3-Ac-DON and 15-Ac-DON were found to display similar toxicity in terms of anorectic and
inﬂammatory effects, except for emetic capacity which was substantially lower for 3-Ac-DON
compared to DON and 15-Ac-DON.
• The potency of cytotoxicity in mammalian intestinal cells ranked in the order of 15-Ac-
DON > DON > 3-Ac-DON and that was similar for barrier function, MAP-Kinase activation and
expression of tight junctions, and histological alterations.
• When compared to DON, DON-3-glucoside was substantially less toxic both in vitro and in vivo.
Consideration for a combined risk assessment for DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside
• The CONTAM Panel noted that 3-Ac-DON and 15-Ac-DON were largely deacetylated prior to
systemic distribution and rapidly metabolised to DON. The available data indicated that DON-3-
glucoside can be cleaved to DON in the gastrointestinal tract and distributed, metabolised and
excreted as DON.
• While the mode of action and the toxicity data for 3-Ac-DON and 15-Ac-DON indicated a
similar toxicity as that of DON, toxicity data for DON-3-glucoside were limited and in vivo data
on the chronic toxicity were missing. Therefore, the CONTAM Panel could not make a ﬁrm
conclusion on the hazard of DON-3-glucoside.
• Applying a conservative approach the CONTAM Panel assumed that (1) 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside are all metabolised to DON and absorbed at the same extent as DON,
(2) 3-Ac-DON and 15-Ac-DON induced the same acute and chronic adverse health effects as
DON and (3) similar acute and chronic adverse health effects of DON-3-glucoside as of DON
cannot be excluded.
• The CONTAM Panel decided to characterise the hazard for the group of DON, 3-Ac-DON, 15-
Ac-DON and DON-3-glucoside together, both for chronic and for acute adverse health effects in
humans, and farm and companion animals.
Adverse effects and derivation of health based guidance values for risk characterisation in
humans
• The CONTAM Panel identiﬁed vomiting as critical acute effect for human risk assessment for
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
• Despite the limitations in the available human data, the CONTAM Panel decided to use these
data, supported by the available human biomarker data, to establish a group acute reference
dose (ARfD) for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
• Based on the human outbreak data in China on gastrointestinal effects after ingestion of
contaminated food and noting that vomiting occurred within 30 min after an eating occasion,
the CONTAM Panel estimated a NOAEL for vomiting in humans of 26 lg DON/kg bw per a
single eating occasion.
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• By applying a default uncertainty factor of 3.16 for toxicodynamic intra-human variability a
group ARfD of 8 lg/kg bw per eating occasion for the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside was established.
• The CONTAM Panel concluded that the dose range back-calculated from the human biomarker
data supported the dose range obtained from the human outbreak data.
• The CONTAM Panel identiﬁed reduced body weight gain in experimental animals as the most
relevant critical chronic effect for human risk assessment.
• A clear dose–response relationship between the exposure to DON and reduced mean body
weight was observed both for female and male mice and the CONTAM Panel noted that the
data from both sexes could be combined to calculate a reference point by using the BMD
approach.
• The CONTAM Panel calculated the BMDL05-BMDU05 interval of 0.11–0.28 mg DON/kg bw per
day and identiﬁed 0.11 mg DON/kg bw per day as a reference point for chronic human risk
characterisation.
• The CONTAM Panel established a group TDI of 1 lg/kg bw per day for the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside by dividing the BMDL05 of 0.11 mg/kg bw per day for
reduced body weight gain in mice by the default uncertainty factor of 100 for inter- and
intraspecies variability.
Adverse effects and identiﬁcation of reference points for risk characterisation in farm and
companion animals
• The CONTAM Panel identiﬁed vomiting as the critical acute adverse effect for pigs, farmed
mink, dogs and cats.
• The CONTAM Panel identiﬁed reduced feed intake, and reduced body weight and body weight
gain as critical chronic adverse effects for farm and companion animals and identiﬁed the
NOAELs/lowest-observed-adverse-effect levels (LOAELs) for these effects as the reference
points of DON in feed.
• The concentration of 5.2 mg DON/kg feed did not generate adverse effects on body weight,
feed intake or any other adverse effect in healthy dairy cows over 13 weeks and 5 mg
DON/kg feed was identiﬁed as NOAEL for dairy cows.
• NOAELs of 10 and 18 mg DON/kg feed were identiﬁed for healthy heifers and steers,
respectively.
• For sheep, a NOAEL of 16 mg DON/kg feed for reduced feed intake and body weight gain
was identiﬁed.
• In the absence of concentration–response data, the NOAEL of 5 mg DON/kg feed of dairy
cows was adopted for goats.
• The CONTAM Panel noted that young animals such as calves, in which the rumen is not fully
developed and adult animals with previous history of ruminal acidosis, could have deﬁciency to
de-epoxidase DON to its less toxic metabolite DOM-1 and consequently, could be more
susceptible to toxic effects of DON.
• In pigs, vomiting was observed as acute adverse effect at a wide range of concentrations of
DON depending on the study design and study duration and the breeds used in the
experiments. While the LOAELs for vomiting in pigs varied from 2.8 to 19.7 mg DON/kg feed
the NOAELs varied from 1.6 to 11.9 mg DON/kg feed. The CONTAM Panel identiﬁed 1.6 DON/
kg feed as an overall NOAEL for acute effects and noted that the lowest BMCL10 of 1.4 mg
DON/kg feed was almost the same concentration.
• Reduced feed intake and body weight gain identiﬁed as chronic effects in pigs ranged also
over a wide concentration range of DON. The identiﬁed overall NOAEL was 0.7 mg DON/kg
feed. The CONTAM Panel noted that for pigs the ranges of reported LOAELs and NOAELs
overlapped substantially.
• The concentration range of 4.6–7.0 mg DON/kg feed did not generate adverse effects such as
reduced feed intake or body weight gain in broiler chickens and NOAELs of 4.6–7.0 mg
DON/kg feed were identiﬁed. At 5.0 mg, DON/kg feed no decrease of feed intake or egg
fertility was observed in laying hens. A NOAEL of 5.0 mg DON/kg feed was identiﬁed for
broiler chickens and laying hens.
• The concentration of 7.0 mg DON/kg feed did not induce changes in body weight, body weight
gain, feed intake or feed conversion ratios in (fattening) ducks and turkeys and was used
the overall NOAEL for these two poultry species.
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• Based on limited data, no reduced feed intake or any other signs of adverse effects were
observed in horses at the concentrations of 36–44 mg DON/kg feed. The concentration of
36 mg DON/kg feed was identiﬁed as the overall NOAEL for horses.
• Based on limited data, a concentration of 30 mg DON/kg feed was associated with maternal
and fetal body weight reduction in farmed rabbits, while a concentration of 15 mg DON/kg
feed did not induce any adverse effects in rabbit fetuses. A concentration of 4.3 mg DON/kg
feed did not induce any effects on feed intake, body weight gain and relative organ weights
and therefore the NOAEL for farmed rabbits was 4 mg DON/kg feed.
• Limited data on farmed ﬁsh did not allow to identify speciﬁc NOAELs/LOAELs for each ﬁsh
species. In carp, the concentration of 0.95 mg DON/kg feed induced lipid peroxidation and
histopathological changes in the liver. In rainbow trout 0.8 mg DON/kg feed induced reduced
feed intake, body weight gain, growth rate and feed efﬁciency. The lowest NOAEL was 0.6 mg
DON/kg feed observed for carps and the CONTAM Panel decided to use this value as overall
NOAEL for farmed ﬁsh.
• Farmed mink were among the most sensitive animals based on a study designed as an
experimental animal study. For vomiting, NOAELs of 10, 5 and 10 lg/kg bw per day were
identiﬁed for DON, 3-Ac-DON and 15-Ac-DON, respectively. The CONTAM Panel calculated
BMDL10 values of 0.004 mg DON/kg bw, 0.03 mg 3-Ac-DON/kg bw and 0.004 mg 15-Ac-DON/
kg bw for vomiting as acute effect. For the reduced feed intake and body weight gain in
farmed mink, the NOAEL of 1 mg DON/kg feed was identiﬁed for chronic effects.
• In dogs, vomiting was not reported in the only one available study on dogs at the
concentration of 6 mg DON/kg feed and it was identiﬁed as the NOAEL for acute effects, while
reduced body weight gain in dogs was observed at this level. Applying the BMD approach, a
lowest BMCL10 of 5 mg DON/kg feed was calculated for vomiting as reference point of acute
effects. For chronic effects, the NOAEL of 4 mg DON/kg feed was identiﬁed for reduced body
weight gain.
• In cats, vomiting was not reported in the only one available study on cats at the concentration
of 8 mg DON/kg feed and it was identiﬁed as the NOAEL for acute effects, while reduced body
weight gain in cats was observed at this level. Applying the BMD approach, a lowest BMCL10 of
5 mg DON/kg feed was calculated for vomiting as reference point of acute effects. For chronic
effects, the NOAEL of 6 mg DON/kg feed was identiﬁed for reduced body weight gain.
Human health risk characterisation
• Based on the available occurrence data, the estimates of acute dietary exposure to the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were below the group ARfD of 8 lg/kg bw
per eating occasion for all age groups of humans, and considered not an acute health concern.
• The estimates of the UB chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON
and DON-3-glucoside based on the available occurrence data were above the group TDI of
1 lg/kg bw per day for the infants, toddlers and other children, and to some extent also for
adolescents and adults. At the LB estimates, only high exposure in toddlers and other children
exceeded the group TDI. Regular exceedance of TDI indicates a potential health concern,
however, the CONTAM Panel noted the uncertainty associated with exposure estimates due to
a high fraction of left-censored data.
• The limited data on dietary habits of vegetarians with data available for only ﬁve European
countries, and with very few subjects in four of them, did not indicate notable differences in
acute and chronic dietary exposure between the vegetarians and the general population.
Therefore, the conclusions on the general population remain valid also for the subpopulation of
vegetarians.
Farm and companion animal health risk characterisation
• Based on the available occurrence data, the calculated UB mean and the 95th percentile
dietary concentrations for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside for
ruminants and horses were clearly below the NOAELs for chronic adverse effects and were
therefore considered unlikely to be a health concern. For poultry and farmed rabbits, the
UB mean and 95th percentile dietary concentrations were higher but below the NOAELs
indicating that the risk of chronic adverse health effects from the feed containing DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside is low.
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• For pigs, the calculated UB 95th percentile dietary concentrations for the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside were lower than the calculated BMCL10 indicating that
the risk of acute adverse health effects is low. The UB mean dietary concentrations were below
the NOAEL for chronic adverse effects, but above the UB 95th percentile dietary concentrations.
Therefore, a possible risk of chronic adverse health effects from feed containing DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside was identiﬁed at the UB 95th percentile.
• For farmed ﬁsh (salmonids and carp), the calculated UB mean dietary concentrations for the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside were below the NOAEL for chronic
adverse effects but above at the UB 95th percentile dietary concentrations for carp. This
indicates that a possible risk of chronic adverse health effects from feed containing DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside was identiﬁed at the UB 95th percentile dietary
concentrations at least for carp. However, the diet composition may majorly differ between the
ﬁsh species and some ﬁsh species might be more tolerant for the adverse effects than others.
• For farmed mink, the calculated UB 95th percentile dietary concentration for the sum of
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was clearly above the BMDL10 for acute
adverse health effects, and therefore a possible risk for acute adverse effects from feed
containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside at the UB 95th percentile dietary
concentration was identiﬁed. The exposure estimates at the UB mean and UB 95th percentile
concentrations in feed were below the NOAEL, and indicate that the risk of chronic adverse
health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is low.
• The calculated UB 95th percentile dietary concentration for the sum of DON, 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside for dogs was below the BMCL10 for acute adverse health effects
and the UB mean and the UB 95th percentile dietary concentrations below the NOAEL for
chronic adverse health effects. Therefore, the risk of acute and chronic adverse health effects
from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside is low.
• For cats, the calculated UB 95th percentile dietary concentration for the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside was above the BMCL10 for acute adverse health
effects, and therefore a possible risk for acute adverse health effects from feed containing
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside at the UB 95th percentile dietary
concentration was identiﬁed. The UB mean and UB 95th percentile dietary concentrations were
lower than the NOAEL for chronic adverse health effects indicating that the risk for chronic
adverse health effects from feed containing DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
is low.
Recommendations
• Interlaboratory validation and standardisation of LC–MS/MS methodology for the simultaneous
quantiﬁcation of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside are needed for more
reliable conclusions on the analytical results and the methods should be sensitive enough to
decrease the uncertainty of the risk assessment.
• Certiﬁed reference materials (both matrix reference materials and calibrants) should be made
available and proﬁciency tests should be facilitated for the determination of 3-Ac-DON, 15-Ac-
DON and DON-3-glucoside.
• Comprehensive studies are needed on co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside in grains intended for human consumption, in food products, in grains intended for
feed and in feed materials, where each sample is analysed for all these four forms.
• Co-occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside need to be monitored in
food and feed, to acquire a knowledge on possible trends due to factors, such as changes in
climate and weather, agronomic factors, breeding practices, storage systems and technological
processing.
• Interlaboratory validation and standardisation of the methods for the analysis of human urinary
DON biomarkers, such as DON glucuronides, are needed before they can be reliably applied
for human risk assessment. Certiﬁed reference materials (both matrix reference materials and
calibrants) should be made available for DON glucuronides.
• Well-designed quantitative studies on DON urinary excretion in different population groups
should be encouraged to enable the use of DON biomarkers for human exposure assessments.
• Well-designed studies that take account of practical feeding conditions are needed for farm
animals, particularly for pigs, poultry, farmed ﬁsh and companion animals to study
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toxicokinetics and toxicity of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside to reduce the
uncertainties in the animal risk assessment.
• Modiﬁed forms of DON, other than those covered in this risk assessment, which could be
potentially relevant concerning their (co-)occurrence and toxicological properties, should be
investigated to further reﬁne the human and animal risk assessment.
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Abbreviations
ACE accelerated solvent extraction
AFRC Agricultural and Food Research Council
AFSSA French Food Safety Authority/Agence Francaise de Securite des Aliments
AIC Akaike Information Criterion
ALP alkaline phosphatase
ALT alanine aminotransferase
ANSES French National Agency for Sanitary Safety of Food, Environment and Labor /Agence
Nationale de Securite Sanitaire de l’Alimentation, de l’Environnement et du Travail
AOAC Association of Ofﬁcial Analytical Chemists
APC antigen-presenting cell
APCI atmospheric pressure chemical ionisation
AST aspartate aminotransferase
ATA alimentary Toxic Aleukia
BAM Federal Institute for Materials Research and Testing
Bax Bcl-2 associated X protein
BE Belgium
BG Bulgaria
BMD benchmark dose
BMDL05 95 % lower conﬁdence limit for the benchmark dose response of 5 %
bw body weight
CAS Chemical Abstracts Service
CD cytotoxicity dose
CK creatine kinase
CONTAM Panel Panel on Contaminants in the Food Chain
CRM certiﬁed reference materials
CY Cyprus
CZ Czech Republic
DAD diode-array detector
DART direct analysis in real time
DCM Unit Dietary and Chemical Monitoring Unit
DDGS Distillers dried grains with solubles
DE Germany
DK Denmark
DM dry matter
DMSO dimethylsulfoxide
DON deoxynivalenol
ECD electron capture detection
ELISA enzyme-linked immunosorbent assay
ERK extracellular signal regulated kinase
ES Spain
ESI electrospray ionization
EVIRA The Finnish Food Safety Authority
EXPOCHI Article 36 project ’Individual food consumption data and exposure assessment
studies for children‘
FAO/WHO Food and Agriculture Organization of the United Nations/World Health Organization
FAPAS Food Analysis Performance Assessment Scheme
FEDIAF European Pet Food Industry Federation
FEFAC European Feed Manufacturers Federation
FI Finland
FID ﬂame ionisation detection
FLD ﬂuorescence detector
fpg Formamidopyrimidine DNA glycosylase
FR France
FSH follicle stimulating hormone
GC gas chromatography
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GEMS/Food Global Environment Monitoring System - Food Contamination Monitoring and
Assessment Programme
GMT gamma glutamyltransferase
GPX glutathione peroxide
GR Greece
GSH glutathione
HAT hours after treatment
HeLa human cervical carcinoma cells
HepG2 human hepatoma cells
HLA-DR human leukocyte antigen-antigen d related
HPLC high-performance liquid chromatography
HPLC-FLD high-performance liquid chromatography coupled with ﬂuorescence detection
HPTLC high-performance thin layer chromatography
HRMS high-resolution mass spectrometry
HT-2 HT-2 toxin
HU Hungary
IA immunoafﬁnity
IARC International Agency for Research on Cancer
IE Ireland
IFN-beta interferon-beta
IFN-c interferon-c
IgA immunoglobulin A
IgE immunoglobulin E
IGF insulin-like growth factor
IgG immunoglobulin G
IgM immunoglobulin M
IL-2 interleukin-2
IL-8 interleukin-8
IL-1b interleukin-1beta
INRA French National Institute for Agricultural Research/Institut national de la
recherche agronomique, France
i.p. intraperitoneal
IPCS International Programme on Chemical Safety
IT Italy
i.v. intravenous
JECFA Joint FAO/WHO Expert Committee on Food Additives
JRC Joint Research Centre
LB lower bound
LC liquid chromatography
LC–MS/MS liquid chromatography coupled to tandem mass spectrometry
LDH lactate dehydrogenase
LOAEL lowest-observed-adverse-effect level
LOD limit of detection
LOQ limit of quantiﬁcation
LPS lipopolysaccharide
LV Latvia
MAPK mitogen-activated protein kinase
MIP molecularly imprinted polymers
ML maximum level
MPS mononuclear phagocyte system
MS mass spectrometry
MS/MS tandem mass spectrometer
MTT Agrifood Research Finland
N Number of samples
ND Not detected
NED no-effect dose
NL Netherlands
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NMR nuclear magnetic resonance
NO nitric oxide
NOAEL no-observed-adverse-effect level
NOEL no-observed- effect level
NRC National Research Council
NS Not speciﬁed
OTA ochratoxin A
P25 25th percentile
P50 50th percentile
P75 75th percentile
P95 95th percentile
PARP poly-adenosine diphosphate (ADP)-ribose polymerase
PCBs polychlorinated biphenyls
PGF2a prosthaglandin F2 alpha
PMTDI provisional maximum tolerable daily intake
RIVM National Institute for Public Health and the Environment
PT prothrombin time
RL Reference Laboratory
QuEChERS Quick, easy, cheap, effective, rugged and safe
RM Reference material
ROS reactive oxygen species
RSD relative standard deviation
RSDr relative standard deviation under repeatability conditions
RSDR relative standard deviation under reproducibility conditions
SCF Scientiﬁc Committee on Food
SCOOP Scientiﬁc co-operation
SE Sweden
SPE solid phase extraction
SRM Selected reaction monitoring
SPE solid phase extraction
T-2 T-2 toxin
TDI tolerable daily intake
tDON total DON
TLC thin-layer chromatography
TOF-MS time-of-ﬂight mass spectrometry
TT thrombin time
t-TDI temporary tolerable daily intake
TNF-alpha tumour necrosis factor-alpha
UB upper bound
UDP uridine 5’-diphospho-glucuronosyltransferase
UGT UDP-Glucuronosyltransferase
UK United Kingdom
USSR Union of Sovietic Socialist Republics
UV ultraviolet
v/v volume/volume
WBC white blood cells
WBG weight body gain
WHO World Health Organization
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Appendix A – Identiﬁcation and selection of evidence relevant for the risk
assessment of deoxynivalenol, its acetylated and modiﬁed forms in food
and feed
For its risk assessment of deoxynivalenol, its acetylated and modiﬁed forms in food and feed, the
CONTAM Panel applied the general principles of the risk assessment procedure as follows:
1) A human dietary exposure assessment for deoxynivalenol, its acetylated and modiﬁed forms
in food was performed in order to compute the current level of exposure to deoxynivalenol
(DON), 3-acetylated-DON (3-Ac-DON), 15-acetylated-DON (15-Ac-DON) and DON-3-
glucoside in the population and to cover speciﬁc consumption habits (see Sections 4, 5 and
6). Dietary exposure assessment for DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was
performed by computation of concentrations in indicative feeds for farm and companion
animals used in Europe in order estimate their exposure (see Sections 4, 5 and 6). An
external scientiﬁc report on ‘Experimental study of deoxynivalenol biomarkers in urine’
(GP/EFSA/CONTAM/2013/04 – Brera et al., 2015) on urinary biomarkers was used to
support the human dietary exposure assessment and the human hazard characterisation
(see Sections 7.5.2 and 7.10).
2) The potential health effects for humans and farm and companion animals caused by DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside were identiﬁed and characterised on the basis
of the available scientiﬁc studies published in the open literature (hazard identiﬁcation and
characterisation (see Section 7). An external scientiﬁc report on ‘The in vivo genotoxicity
studies on nivalenol and deoxynivalenol’ (GP/EFSA/CONTAM/2013/05 – Le Hegarat et al.,
2014) was used to support the available genotoxicity data (see Section 7.2.9).
3) The risk for humans and farm and companion animals was characterised by comparing the
reference point(s) identiﬁed with the exposure estimates to conclude on the likelihood of
adverse effects (see Section 8).
4) The uncertainty analysis was performed by describing the identiﬁed uncertainties
qualitatively and summarised in a summary table. The direction of the over and/or
underestimation was given and the uncertainty for the overall assessment was concluded
(see Section 9).
The principles presented in the following EFSA publications were applied in the different steps of
the process:
• EFSA (European Food Safety Authority), 2005. Opinion of the Scientiﬁc Committee on a
request from EFSA related to A Harmonised Approach for Risk Assessment of Substances
Which are both Genotoxic and Carcinogenic. EFSA Journal 2005;3(10):282, 33 pp. https://doi.
org/10.2903/j.efsa.2005.282
• EFSA (European Food Safety Authority), 2006. Guidance of the Scientiﬁc Committee on a
request from EFSA related to Uncertainties in Dietary Exposure Assessment. EFSA Journal
2006;4(12):438, 54 pp. https://doi.org/10.2903/j.efsa.2007.2438
• EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on
Transparency in the Scientiﬁc Aspects of Risk Assessments carried out by EFSA. Part 2: General
principles. EFSA Journal 2009;7(5):1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051
• EFSA (European Food Safety Authority), 2010a. Standard sample description for food and
feed. EFSA Journal 2010;8(1):1457, 54 pp. https://doi.org/10.2903/j.efsa.2010.1457
• EFSA (European Food Safety Authority), 2010b. Management of left-censored data in dietary
exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. https://doi.
org/10.2903/j.efsa.2010.1557
• EFSA (European Food Safety Authority), 2011. Overview of the procedures currently used at
EFSA for the assessment of dietary exposure to different chemical substances. EFSA Journal
2011;9(12):2490. [33 pp.] https://doi.org/10.2903/j.efsa.2011.2490
• EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal
Feed), 2012. Guidance for the preparation of dossiers for sensory additives. EFSA Journal
2012;10(1):2534, 26 pp. https://doi.org/10.2903/j.efsa.2012.2534
• EFSA Scientiﬁc Committee, 2012a. Guidance on selected default values to be used by the EFSA
Scientiﬁc Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA
Journal 2012;10(3):2579,32 pp. https://doi.org/10.2903/j.efsa.2012.2579
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• EFSA Scientiﬁc Committee, 2012b. Scientiﬁc Opinion on Risk Assessment Terminology. EFSA
Journal 2012;10 (5):2664, 43 pp. https://doi.org/10.2903/j.efsa.2012.2664
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S,
Mortensen A, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck
D, Aerts M, Bodin L, Davis A, Edler L, Gundert-Remy U, Sand S, Slob W, Bottex B, Abrahantes
JC, Marques DC, Kass G and Schlatter JR, 2017. Update: Guidance on the use of the
benchmark dose approach in risk assessment. EFSA Journal 2017;15(1):4658, 41 pp. https://
doi.org/10.2903/j.efsa.2017.4658
In addition, the following guidance was applied in the absence of the EFSA guidance:
• OECD (Organisation for Economic Co-operation and Development) (2010). Guidance for the
derivation of an acute reference dose. OECD Environment, Health and Safety Publications,
Series of Testing and Assessment, No. 124. IOMC Inter-Organisation Programme for the Sound
Management of Chemicals. Environment Directorate, Organisation for Economic Co-operation
and Development. Pars 2010. ENV/JM/MONO(2010)15. Available online: http://www.oecd.org/
officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)15&doclanguage=en
A.1. Hazard identiﬁcation and characterisation
A.1.1. Identiﬁcation of scientiﬁc evidence
For the present human risk assessment, the CONTAM Panel considered the outcome of the
assessment of the SCF in 1999 and 2002 and the new evidence that has become available since then.
For the present animal risk assessment, the CONTAM Panel considered the outcome of its risk
assessment in 2004 and the new evidence that has become available since 2004. The most recent
EFSA opinions and statements (EFSA CONTAM Panel, 2013, 2014), were also consulted, noting that
they were not full risk assessments on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and
feed.
A.1.1.1. The details on the identiﬁcation of the evidence
Search in scientiﬁc databases aimed at identifying studies published in the open scientiﬁc literature
and in scientiﬁc peer-reviewed journals. The collection of scientiﬁc studies available in the public
domain published since 2001 for humans and since 2004 for the farm and companion animals was
done through searching the scientiﬁc literature database Web of Science. The approach taken for
searching was selected in such a way that relevant studies were retrieved for the hazard identiﬁcation
and characterisation of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside. The literature searches
were performed at different time points in May 2013, June 2014, October 2014, April 2015, October
2015, August 2016 and September 2016. The key words reported in Table A.1 were used and Boolean
operators (AND) were used to connect the terms in the searches:
Table A.1: Key words used in the literature search
Key words used Key words used
Deoxynivalenol AND tox* 3-Acetyl-deoxynivalenol
Deoxynivalenol AND acute tox* 15-Acetyl-deoxynivalenol
Deoxynivalenol AND chronic tox* Deoxynivalenol AND masked
Deoxynivalenol AND cytotox* Deoxynivalenol AND deoxynivalenol-3-glucoside
Deoxynivalenol AND development* AND tox* Deoxynivalenol-3-glucoside
Deoxynivalenol AND reprod* Deoxynivalenol AND DOM-1
Deoxynivalenol AND genotox* AND carcino* De-epoxy-deoxynivalenol
Deoxynivalenol AND toxicokinetics DONS-1
Deoxynivalenol AND metabolism AND absorption AND
distribution
DONS-2
Deoxynivalenol AND dose response DONS-3
Deoxynivalenol AND mode of action DOM-1
Deoxynivalenol AND immunotox* De-epoxy-deoxynivalenol
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The search was performed to cover the period since 2001 for humans and since 2004 for the farm
and companion animals till the cut-off date of 31 July 2015 and later extended till 31 July 2016 decided
by the CONTAM Panel. In order to update the database for speciﬁc questions arising during the
discussion, separate searches were conducted when needed. After the cut-off date, the publication of
new papers from the major journals expected to publish articles on mycotoxins was monitored from their
email alerts for content of the issue till the end of 2016 in order to verify if new relevant papers, which
would change the outcome of the risk assessment were published but no new search was conducted.
As background information, the CONTAM Panel considered the earlier scientiﬁc evaluations of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and feed conducted by other national risk
assessment bodies, and other national and international independent expert advisory committees than
SCF and EFSA (see Section 1.1).
A.1.2. Study selection process and its results
The obtained literature database for the this opinion, which was retrieved as outlined above,
included scientiﬁc peer-reviewed papers published in scientiﬁc journals and relevant non-peer reviewed
papers (such as risk assessment reports by national/international bodies and book chapters).
The following criteria were considered for the inclusion of studies in the selection process:
• Experimental toxicity studies in vitro (including biological models) and in vivo.
• Experimental toxicity studies in laboratory animals (oral route), epidemiological studies in
humans addressing associations between exposure to DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside in humans and adverse health outcome(s) in the general population (via the diet).
• Experimental toxicity studies on farm and companion animals (oral route), addressing
associations between exposure to DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in farm
and companion animals and adverse health outcome(s).
The following criteria were considered for the exclusion of studies in the selection process:
• Studies in the ﬁeld of ecotoxicology, i.e. not in the ﬁeld of laboratory animals and human
health, and the health of farm and companion animals.
In addition, the following criteria were used for the inclusion/exclusion of scientiﬁc papers and
reports in the selection process:
• Only studies in English and studies in other languages including an abstract in English were
considered. These papers with other languages than English were submitted for the translation to the
Translation Centre of the Bodies of the European Union in Luxemburg and the received translation
was used in this opinion. The translation of the paper is indicated as footnote in this opinion.
• Conference proceedings were not considered.
• Reviews were considered as source of background information and as an additional source of
scientiﬁc evidence unless otherwise stated in the body of the text. These were not considered
as the pivotal information for the hazard characterisation.
• Book chapters were considered as sources of background information. These were not
considered as the pivotal information for the hazard characterisation.
A.1.3. Result of the study selection process
The search strategy identiﬁed nearly 1,200 studies published in the open literature relevant for the
hazard identiﬁcation and characterisation on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
humans and in the farm and companion animals. The searched literature was grouped as presented in
Table A.2 according to topics of interest. The table includes the numbers of papers of which relevance
was assessed by the CONTAM Panel working group members (some duplicates may have been
included). The selection of the studies for inclusion or non-inclusion in the hazard identiﬁcation and
characterisation of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside was based on consideration of
the extent to which the study was relevant to the assessment and general study quality considerations
(e.g. sufﬁcient details on the methodology, performance or outcome of the studies, route of
administration, clear dose–response relationship, statistical description of the results EFSA, 2009c),
irrespective of whether they yielded positive, negative or null results. The exclusion criteria of the
studies are further detailed in the beginning of the sections (see e.g. Sections 7.3.1 and 7.3.2).
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The application of the selection process described above resulted in the studies cited in this
opinion.
A.2. Exposure assessment for humans and farm and companion
animals
A.2.1. Identiﬁcation of evidence
The following sources of evidence were used:
• The occurrence data on food and feed collected by the Member States/European Countries
submitted in the framework of the EFSA continuous call for data.48
• The EFSA Comprehensive European Food Consumption Database as a source of information on
food consumption across the EU.49
• An external scientiﬁc report on ‘Experimental study of deoxynivalenol biomarkers in urine”
(GP/EFSA/CONTAM/2013/04 –; Brera et al., 2015) (to support the exposure assessment).50
• The catalogue of feed materials speciﬁed in the Commission Regulation (EU) No 575/2011 of
16 June 2011 creating the Catalogue of feed materials.51
• In the absence of EFSA feed consumption database, external databases and the literature on
the public domain were used as outlined in the opinion.
A.2.2. Data selection process and its results
The consideration of the selection criteria for occurrence and consumption data for the dietary
exposure assessment of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside and the results thereafter
are described in Sections 4, 5 and 6.
Table A.2: Number of papers retrieved from the database for hazard identiﬁcation and
characterisation and which relevance was assessed for the opinion within different
classiﬁcation group
Humans - toxicity n
Farm animals – acute and
chronic toxicity and
toxicokinetics
n
Toxicokinetics – experimental animals and animals 57 Pigs 151
Acute toxicity – experimental animals 24 Poultry 117
Chronic toxicity – experimental animals 35 Ruminants 52
Genotoxicity and carcinogenicity 54 Fish 30
Reproductive and developmental toxicity 38 Horses and rabbits 10
Neurotoxicity, hepatotoxicity 16 Dogs and cats 8
Cytotoxicity and immunotoxicity – in vivo studies – Rodents 65 Minks and ferrets 17
Cytotoxicity and immunotoxicity – in vivo studies – Farm
animals
47 Transfer rate 22
Cytotoxicity and immunotoxicity – in vitro studies 176
Mode of action 152 Toxicity assessment – toxicity
reviews in humans, experimental
and farm animals
60
Epidemiology 28
Biomarkers 69
Gastrointestinal toxicity 8 Sum of all papers 1,236
n: number of papers archived at EFSA, and reviewed and assessed for the opinion.
48 http://www.efsa.europa.eu/en/data/call/datex101217.htm
49 http://www.efsa.europa.eu/en/datex/datexfoodcdb.htm
50 http://www.efsa.europa.eu/en/supporting/pub/818e
51 Comission Regulation (EU) No 575/2011 of 16 June 2011 on the Catalogue of feed materials, OJ L 195, 17.6.2011, p. 25-65.
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A.3. Other sections of the draft scientiﬁc opinion
The sections on Introduction (Section 1 and subsections therein), Legislation (Section 2), Sampling
and methods of analysis (Section 3 and subsections therein), Previously reported literature data on
DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food and feed (Section 4.1) and previously
reported human exposure assessment (Section 6.3 and subsections therein) provide generic
background information to support the overall conclusions. The identiﬁcation of evidence for these
chapters was limited to the most relevant information and the following sources of evidence were used:
• Previous scientiﬁc evaluations by national agencies, national and international independent
expert advisory committees.
• Search in scientiﬁc databases (Web of Science) aimed at identifying studies and reviews that
have appeared in the open scientiﬁc literature and published in scientiﬁc peer-reviewed
journals.
• Respective legislation on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
The selection of the studies for inclusion in the aforementioned sections to give a comprehensive
but not exhaustive background information on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in
food and feed was therefore based on consideration of the extent to which the study was informative
and relevant to the assessment, and of general quality of the study. For these other sections,
approximately 1,000 papers were archived at EFSA.
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Appendix B – Occurrence data on food and feed reported in the literature
Table B.1: Published occurrence data on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in grains and food products (excluding food for infants and
young children: for them see Table B.2)
Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Austria,
Germany,
Slovakia(c)
2005 Random Wheat DON 23 8 20 23 1,500 n.r. n.r. n.r. 203 4,130 Berthiller et al.
(2009)DON-3-
glucoside
4 10 23 393 n.r. n.r. n.r. 76 1,070
Austria 2006 Random Maize DON 54 16 40 54 753 n.r. n.r. n.r. 42 3,680 Berthiller et al.
(2009)DON-3-
glucoside
4 10 54 141 n.r. n.r. n.r. 10 763
Austria and
UK(c)
n.r. Random Wheat
bread
DON 4 n.r. 100 0 (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) < LOQ Vendl et al.
(2010)3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOQ
Rye bread DON 4 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Wheat
semolina
DON 3 n.r. 100 0 (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) < LOQ
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Biscuits DON 4 n.r. 100 0 (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) < LOQ
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Beer
(including
wheat
beer)
DON 4 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Breakfast
cereals
(corn
ﬂakes)
DON 3 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Breakfast
cereals
(muesli)
DON 4 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Quinoa
grain or
ﬂour
DON 4 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Polenta DON 3 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Austria 2011 Random Pale beer DON 10 2.2 5.4 4 13 6.8(d) n.r. 2.7 < LOD 30 Malachova
et al. (2012)3-Ac-DON 2.4 6.8 0 < LOD n.r. n.r. < LOD < LOD < LOD
DON-3-
glucoside
0.4 3.5 7 8.3 6.3 n.r. 5.5 < LOQ 19
Wheat
beer
DON 10 1.0 4.5 8 14 12 n.r. 9.2 < LOD 27
3-Ac-DON 2.2 8.2 0 < LOD n.r. n.r. < LOD < LOD < LOD
DON-3-
glucoside
0.9 3.5 7 8.6 6.4 n.r. 5.9 < LOD 15
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Dark beer DON 10 2.9 11 2 11 5 n.r. 5.4 < LOD 11
3-Ac-DON 4.3 11 0 < LOD n.r. n.r. < LOD < LOD < LOD
DON-3-
glucoside
1.4 4.1 7 9.6 7.4 n.r. 6.9 < LOQ 16
Bock beer DON 10 1.2 4.1 10 13 13 n.r. 13 n.r. 22
3-Ac-DON 3.6 9.2 0 < LOD n.r. n.r. < LOD < LOD < LOD
DON-3-
glucoside
0.5 1.5 10 16 16 n.r. 12 n.r. 32
Non-
alcoholic
beer
DON 10 1.2 3.0 1 3.7 0.9 n.r. 0.6 < LOD 3.7
3-Ac-DON 2.6 6.0 0 < LOD n.r. n.r. < LOD
n.r.
< LOD < LOD
DON-3-
glucoside
0.4 1.4 5 2.3 1.3 n.r. 0.9 < LOD 3.1
Shandy
beer
DON 10 1.5 3.9 1 6.4 2.1 n.r. 1.9 < LOQ 6.4
3-Ac-DON 2.7 10 0 < LOD n.r. n.r. < LOD < LOD < LOD
DON-3-
glucoside
0.4 1.3 6 3.5 2.3 n.r. 2.3 < LOQ 5.5
Austria,
Hungary,
Croatia,
Serbia(e)
2011–2012 Random Pale beer DON 217 2.2 5.4 118 12.0 7.5 n.r. 5.6 n.r. 89.3 Varga et al.
(2013)3-Ac-DON 2.4 6.8 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
0.4 3.5 142 9.3 6.7 n.r. 5.2 n.r. 81.3
Wheat
beer
DON 46 1 4.5 36 18.4 14.6 n.r. 9.5 n.r. 49.6
3-Ac-DON 2.2 8.2 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
0.9 3.5 32 11.5 8.4 n.r. 5.4 n.r. 28.4
Dark beer DON 47 2.9 11 14 22.4 9.0 n.r. 5.5 < LOD 45.0
3-Ac-DON 4.3 11 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
1.4 4.1 28 10.7 6.9 n.r. 4.5 n.r. 26.2
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Bock beer DON 20 1.2 4.1 18 13.8 12.4 n.r. 10.8 < LOD 27.1
3-Ac-DON 3.6 9.2 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
0.5 1.5 20 14.8 14.8 n.r. 11.7 2.4 33.3
Non-
alcoholic
beer
DON 19 1.2 3.0 5 8.7 2.7 n.r. < LOD < LOD 26.1
3-Ac-DON 2.6 6.0 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
0.4 1.4 9 3.0 1.5 n.r. < LOD (< LOD) 6.6
Shandy
beer
DON 25 1.5 3.9 13 6.9 4.4 n.r. 4.2 n.r. 12.7
3-Ac-DON 2.7 10 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
0.4 1.3 20 3.8 3.2 n.r. 2.9 n.r. 7.9
Belgium 2010–2011 Random Fibre-
enriched
bread
DON 52 8-13 16-26 44 n.r. n.r. 34 n.r. (< LOQ) 138 De Boevre
et al. (2012)3-Ac-DON 20 n.r. n.r. 14 n.r. (< LOQ) 74
15-Ac-DON 17 n.r. n.r. 9 n.r. (< LOQ) 45
DON-3-
glucoside
25 n.r. n.r. 34 n.r. (< LOQ) 425
Bran-
enriched
bread
DON 36 8-13 16-26 27 n.r. n.r. 25 n.r. (< LOQ) 127
3-Ac-DON 16 n.r. n.r. 16 n.r. (< LOQ) 59
15-Ac-DON 16 n.r. n.r. 7 n.r. (< LOQ) 45
DON-3-
glucoside
19 n.r. n.r. 21 n.r. (< LOQ) 103
Corn-ﬂakes DON 61 7-12 14-24 40 n.r. n.r. 44 n.r. (< LOQ) 718
3-Ac-DON 43 n.r. n.r. 31 n.r. (< LOQ) 431
15-Ac-DON 39 n.r. n.r. 10 n.r. (< LOQ) 194
DON-3-
glucoside
31 n.r. n.r. 13 n.r. (< LOQ) 63
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Popcorn DON 12 n.r. n.r. 6 n.r. n.r. 49 n.r. (< LOQ) 442
3-Ac-DON 10 n.r. n.r. 30 n.r. (< LOQ) 69
15-Ac-DON 10 n.r. n.r. 26 n.r. (< LOQ) 55
DON-3-
glucoside
8 n.r. n.r. 33 n.r. (< LOQ) 96
Oatmeal DON 13 5-12 10-24 5 n.r. n.r. 18 n.r. (< LOQ) 91
3-Ac-DON n.r. n.r. n.r. 45 n.r. (< LOQ) 116
15-Ac-DON n.r. 27 n.r. 7 n.r. (< LOQ) 27
DON-3-
glucoside
n.r. n.r. n.r. 28 n.r. (< LOQ) 97
Belgium 2012 Random Wheat DON 93 31 62 81 1,053 n.r. n.r. n.r. (< LOQ) n.r. Vanheule
et al. (2014)3-Ac-DON 40 81 4 38 n.r. n.r. n.r. (< LOQ) n.r.
15-Ac-DON 25 49 2 87 n.r. n.r. n.r. (< LOQ) n.r.
DON-3-
glucoside
72 143 54 250 n.r. n.r. n.r. (< LOQ) n.r.
Barley DON 65 31 62 64 2,029 n.r. n.r. n.r. (< LOQ) n.r.
3-Ac-DON 40 81 8 120 n.r. n.r. n.r. (< LOQ) n.r.
15-Ac-DON 25 49 10 97 n.r. n.r. n.r. (< LOQ) n.r.
DON-3-
glucoside
72 143 59 390 n.r. n.r. n.r. (< LOQ) n.r.
Triticale DON 10 31 62 8 1,145 n.r. n.r. n.r. (< LOQ) n.r.
3-Ac-DON 40 81 0 (< LOD) n.r. n.r. n.r. (< LOD) (< LOD)
15-Ac-DON 25 49 0 (< LOD) n.r. n.r. n.r. (< LOD) (< LOD)
DON-3-
glucoside
72 143 6 169 n.r. n.r. n.r. (< LOQ) n.r.
Bread DON 25 31 62 24 316 n.r. n.r. n.r. (< LOQ) n.r.
3-Ac-DON 40 81 0 (< LOD) n.r. n.r. n.r. (< LOD) (< LOD)
15-Ac-DON 25 49 0 (< LOD) n.r. n.r. n.r. (< LOD) (< LOD)
DON-3-
glucoside
72 143 15 n.r. n.r. n.r. n.r. (< LOQ) n.r.
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Breakfast
cereals
DON 20 31 62 5 n.r. n.r. n.r. n.r. (< LOQ) n.r.
3-Ac-DON 40 81 0 (< LOD) n.r. n.r. n.r. (< LOD) (< LOD)
15-Ac-DON 25 49 0 (< LOD) n.r. n.r. n.r. (< LOD) (< LOD)
DON-3-
glucoside
72 143 5 n.r. n.r. n.r. n.r. (< LOQ) n.r.
Czech
Republic
2010 Random White ﬂour
products
DON 17 n.r. 12.5 16 n.r. n.r. 125 96 < LOQ 350 Malachova
et al. (2011)DON-3-
glucoside
n.r. 5 14 n.r. n.r. 15 10 < LOQ 30
Mixed ﬂour
products
DON 36 n.r. 12.5 32 n.r. n.r. 139 68 < LOQ 431
DON-3-
glucoside
n.r. 5 28 n.r. n.r. 19 14 < LOQ 41
Breakfast
cereals
DON 7 n.r. 12.5 2 n.r. n.r. 189 LOQ < LOQ 347
DON-3-
glucoside
n.r. 5 6 n.r. n.r. 35 30 < LOQ 66
Snacks DON 34 n.r. 12.5 21 n.r. n.r. 124 36 < LOQ 320
DON-3-
glucoside
n.r. 5 28 n.r. n.r. 32 19 < LOQ 94
Flours DON 22 n.r. 12.5 16 n.r. n.r. 103 41 < LOQ 594
DON-3-
glucoside
n.r. 5 15 n.r. n.r. 15 16 < LOQ 72
Czech
Republic
2012 Random Malt DON 6 n.r. n.r. 6 68 n.r. n.r. n.r. 8.9 139 Zachariasova
et al., (2012)DON-3-
glucoside
n.r. n.r. 6 105 n.r. n.r. n.r. 12.9 186
Beer DON 15 n.r. n.r. 15 21 n.r. n.r. n.r. 5.6 62
DON-3-
glucoside
n.r. n.r. 15 34 n.r. n.r. n.r. 6.0 82
Wheat,
wheat-rye,
multicereal
and
sunﬂower
baguettes
DON 14 n.r. n.r. 14 252 n.r. n.r. n.r. 43 431
DON-3-
glucoside
n.r. n.r. 14 25 n.r. n.r. n.r. 6 33
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
BIO wheat
ﬂakes
DON 1 n.r. n.r. 1 n.r. n.r. n.r. n.r. 347 347
DON-3-
glucoside
n.r. n.r. 1 n.r. n.r. n.r. n.r. 46 46
Denmark 2006–2007 RANDOM Spring
barley
DON 15 18 n.r. n.r. n.r. n.r. n.r. n.r. n.r. < 60 Rasmussen
et al. (2012)3-Ac-DON 40 n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r.
DON-3-
glucoside
35 n.r. 0 n.r. n.r. n.r. (< LOD) (< LOD) < LOD
2007–2008 Rye DON 12 18 n.r. n.r. n.r. n.r. n.r. n.r. n.r. < 50
3-Ac-DON 40 n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r.
DON-3-
glucoside
35 n.r. 0 n.r. n.r. n.r. (< LOD) (< LOD) < LOD
2007–2010 Oat DON 11 18 n.r. 9 (810) n.r. n.r. (683) < LOD 2,216
3-Ac-DON 40 n.r. 4 (102) n.r. n.r. (< LOD) < LOD 136
DON-3-
glucoside
35 n.r. 5 (224) n.r. n.r (< LOD) < LOD 287
2007–2010 Triticale DON 5 18 n.r. 4 (306) n.r. n.r. (192) < LOD 737
3-Ac-DON 40 n.r. 0 (< LOD) n.r. n.r. (< LOD) (< LOD) < LOD
DON-3-
glucoside
35 n.r. 1 (109) n.r. n.r. (< LOD) < LOD 109
2007–2010 Winter
wheat
DON 6 18 n.r. 6 (910) n.r. n.r. (715) 46 2,638
3-Ac-DON 40 n.r. 0 (< LOD) n.r. n.r. (< LOD) (< LOD) < LOD
DON-3-
glucoside
35 n.r. 3 (190) n.r. n.r. (65) (< LOD) 342
Europe (25
countries)
2010–2011 Random Beer DON 106 0.5 1.5 72 n.r. n.r. 2.1 n.r. < LOD 18.6 Bertuzzi et al.
(2011)3-Ac-DON 0.5 1.4 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD)
15-Ac-DON 1.0 2.8 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD)
Finland 2013 Random Barley DON 34 1.2 3.6 28(f) n.r. n.r. 234(g) n.r. (< LOD) 1,180 Nathanail
et al. (2015)3-Ac-DON 3.4 10.2 14(f) n.r. n.r. < LOQ(g) n.r. (< LOD) 23.6
DON-3-
glucoside
2.8 8.4 25(f) n.r. n.r. 148(g) n.r. (< LOD) 1,300
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Oats DON 31 1.8 5.4 31 (f) n.r. n.r. 2,690(g) n.r. n.r. 23,800
3-Ac-DON 5.1 15.3 24(f) n.r. n.r. 341(g) n.r. (< LOD) 2,720
DON-3-
glucoside
3.9 11.7 27(f) n.r. n.r. 806(g) n.r. (< LOD) 6,600
Wheat DON 30 1.3 3.9 29(f) n.r. n.r. 866(g) n.r. (< LOD) 5,510
3-Ac-DON 3.7 11.1 14 (f) n.r. n.r. 24.6 (g) n.r. (< LOD) 71
DON-3-
glucoside
2.2 6.6 25(f) n.r. n.r. 174(g) n.r. (< LOD) 922
France 2009 n.r. Maize
kernels
DON 5 1 2 5 (725) n.r. n.r. (223) 64 2,864 Desmarchelier
and Seefelder
(2011)
DON-3-
glucoside
1 2 5 (73) n.r. n.r. (25) 4 237
Germany 2009 n.r. Wheat
kernels
DON 3 1 2 3 (140) n.r. n.r. (143) 97 181 Desmarchelier
and Seefelder
(2011)
DON-3-
glucoside
1 2 3 (10) n.r. n.r. (11) 8 11
Durum
semolina
DON 1 1 2 1 (177) n.r. n.r. (177) 177 177
DON-3-
glucoside
1 2 1 (12) n.r. n.r. (12) 12 12
Durum
grains
DON 1 1 2 1 (603) n.r. n.r. (603) 603 603
DON-3-
glucoside
1 2 1 (74) n.r. n.r. (74) 74 74
Italy 2009–2010 targeted Durum
wheat
DON 150 8 n.r. 150 n.r. n.r. n.r. n.r. 47 3,715 Dall’Asta et al.
(2013)3-Ac-DON 8 n.r. 86 n.r. n.r. n.r. 134 < LOD 203
15-Ac-DON 8 n.r. 150 n.r. n.r. n.r. 92 n.r. 244
DON-3-
glucoside
8 n.r. 127 n.r. n.r. n.r. n.r. < LOD 842
Italy 2009–2010 Random, 7
regions
Durum
wheat
DON 47 5 15 28 172 102 n.r. n.r. n.r. 1,230 Alkadri et al.
(2014)3-Ac-DON 3 10 4 23 2 n.r. n.r. n.r. 33
15-Ac-DON 3 10 15 45 14 n.r. n.r. n.r. 105
Poland 2009 n.r. Barley ﬂour DON 1 1 2 1 (5.5) n.r. n.r. (5.5) (5.5) 5.5 Desmarchelier
and Seefelder
(2011)
DON-3-
glucoside
1 2 0 (< LOQ) n.r. n.r. < LOQ < LOQ < LOQ
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Oat ﬂour DON 1 1 2 1 (6.3) n.r. n.r. (6.3) (6.3) 6.3
DON-3-
glucoside
1 2 0 (< LOQ) n.r. n.r. (< LOQ) (< LOQ) (< LOQ)
Wheat
ﬂour
DON 2 1 2 2 (10) n.r. n.r. (10) (3) (17)
DON-3-
glucoside
1 2 1 (2.6) n.r. n.r. (2.3) < LOD 2.6
Malt syrup DON 1 1 2 0 (< LOD) n.r. n.r. (< LOD) (< LOD) < LOD
DON-3-
glucoside
1 2 0 (< LOD) n.r. n.r. (< LOD) (< LOD) < LOD
Romania 2009 n.r. Wheat
ﬂour
DON 1 1 2 1 (45) n.r. n.r. (45) (45) 45 Desmarchelier
and Seefelder
(2011)
DON-3-
glucoside
1 2 1 (4.8) n.r. n.r. (4.8) (4.8) 4.8
Spain 2012 random Wheat-
based
cereals
DON 119 n.r. 1.25 95 n.r. n.r. 12.7 n.r. (< LOQ) 83 Rodrıguez-
Carrasco et al.
(2014b)
3-Ac-DON n.r. 1.25 4 n.r. n.r. 4.6 n.r. (< LOQ) 5.3
Rice-based
cereals
DON 23 n.r. 1.25 3 n.r. n.r. 5 n.r. (< LOQ) 5.5
3-Ac-DON n.r. 2.5 0 n.r. n.r. (< LOQ) n.r. (< LOQ) (< LOQ)
Maize-
based
cereals
DON 17 n.r. 1.25 5 n.r. n.r. 10.5 n.r. (< LOQ) 22.1
3-Ac-DON n.r. 1.25 0 n.r. n.r. (< LOQ) n.r. (< LOQ) (< LOQ)
Spelt-
based
cereals
DON 8 n.r. n.r. 5 n.r. n.r. 25.6 n.r. (< LOQ) 56.8
3-Ac-DON n.r. n.r 0 n.r. n.r. (< LOQ) n.r. (< LOQ) (< LOQ)
Oat-based
cereals
DON 8 n.r. n.r. 0 n.r. n.r. (< LOQ) n.r. (< LOQ) (< LOQ)
3-Ac-DON n.r. n.r 0 n.r. n.r. (< LOQ) n.r. (< LOQ) (< LOQ)
Soy-based
cereals
DON 4 n.r. n.r. 1 n.r. n.r. 34.8 n.r. (< LOQ) 34.8
3-Ac-DON n.r. n.r 0 n.r. n.r. (< LOQ) n.r. (< LOQ) (< LOQ)
Tapioca-
based
cereals
DON 3 n.r. n.r. 1 n.r. n.r. 18.3 n.r. (< LOQ) 18.3
3-Ac-DON n.r. n.r 0 n.r. n.r. (< LOQ) n.r. (< LOQ) (< LOQ)
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
UK n.r. Random Wheat four DON 3 n.r. 100 n.r. n.r. n.r. n.r. n.r. n.r. 237 Vendl et al.
(2010)3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Wheat
bread-
whole meal
DON 3 n.r. 100 (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) < LOQ
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) < LOQ
Maize meal
and ﬂour
DON 3 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Extruded
maize
snacks
DON 3 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Pasta DON 4 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Canned
maize
DON 4 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Breakfast
cereals –
wheat
DON 4 n.r. 100 (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) (< LOQ) < LOQ
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON 3 n.r. 100 n.r. n.r. n.r. n.r. n.r. n.r. 254
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Breakfast
cereals –
bran ﬂakes
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Breakfast
cereals –
oats
DON 3 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Crackers DON 3 n.r. 100 n.r. n.r. n.r. n.r. n.r. n.r. 248
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Popcorn DON 3 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Cereal
snack bars
DON 3 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Buck
wheat
grain or
ﬂour
DON 3 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
Extruded
oat snacks
DON 3 n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
3-Ac-DON n.r. n.r. (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
n.r. 100 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
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Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples(a)
lg/kg
Mean (not
speciﬁed)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
UK 2009 n.r. Wheat
ﬂour
DON 3 1 2 3 (981) n.r. n.r. (873) 592 1,478 Desmarchelier
and Seefelder
(2011)
DON-3-
glucoside
1 2 3 (65) n.r. n.r. (60) 37 99
n.r.: not reported; LOD: limit of detection; N: number of samples; DON: deoxynivalenol; Ac: acetyl.
Only those studies, which reported DON-3-glucoside and/or 3-Ac-DON or 15-Ac-DON are reported. Values in brackets were calculated by the CONTAM Panel based on the data provided in the
papers.
(a): Mean values of all samples are calculated by setting samples in which the compounds were not detected to 0 and trace value below LOQ to LOD.
(b): It was not reported in the paper whether the mean was calculated for all samples or for positive samples only.
(c): Exact origin not indicated.
(d): For the calculation of the mean of all samples, 50% of the determined LOD and of the determined LOQ in the speciﬁc beer category were used for values below the LOD and LOQ,
respectively.
(e): Beers produced in 38 countries (88% European), purchased in Austria, Hungary, Croatia and Serbia.
(f): Number of samples greater than LOD.
(g): Concentrations below the respective LOQ were assigned a value of LOQ/2; values below LOD were treated as non-contaminated.
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Table B.2: Published occurrence data on DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in food for infants and young children
Country
Sampling
year
Type of
sampling
Product Toxin
N of
samples
LOD
lg/kg
LOQ
lg/kg
Samples
greater
than LOQ
Mean of
positive
samples
lg/kg
Mean
of all
samples(a)
lg/kg
Mean (not
mentioned)(b)
lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Italy 2008–2009 Random Baby food DON 44 60 n.r. 16 n.r. n.r. n.r. n.r. (< LOD) n.r. Romagnoli
et al. (2010)
Italy n.r. Random Cereal-based
baby foods
DON 25 1 10 19 103 n.r. n.r. n.r. (< LOD) 268 Juan
et al. (2014)3-Ac-DON 25 2 10 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD)
15-Ac-DON 25 2 10 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) (< LOD)
Spain n.r. n.r. Baby food DON 30 n.r. n.r. 12 n.r. n.r. 131 n.r. (< LOQ) 286 Cano-Sancho
et al. (2011)
UK and Austria(c) n.r. Random Wheat-based
baby foods
DON 3 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD Vendl
et al. (2010)3-Ac-DON 3 n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
3 n.r. 10 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
UK n.r. Random Oat-based
baby foods
DON 3 n.r. 100 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD Vendl
et al. (2010)3-Ac-DON 3 n.r. n.r. 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
DON-3-
glucoside
3 n.r. 10 0 (< LOD) (< LOD) (< LOD) (< LOD) (< LOD) < LOD
UK n.r.
(presumably
2011
Random Foods for
infants and
young
children
DON 77 n.r. 10 28 43 n.r. n.r. < LOQ < LOQ 217 FSA (2011)
n.r.: not reported; LOD: limit of detection; N: number of samples; DON: deoxynivalenol; Ac: acetyl.
Values in brackets were calculated values by the CONTAM Panel based on the data provided in the papers.
(a): Mean values of all samples are calculated by setting samples in which the compounds were not detected to 0 and trace value below LOQ to LOD.
(b): It was not reported in the paper whether the mean was calculated for all samples or for positive samples only.
(c): Exact origin not indicated.
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 293 EFSA Journal 2017;15(9):4718
Table B.3: Published data on the occurrence of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in feed materials since 2004
Country Year Product Toxin
No. of
samples
LOD
lg/kg
LOQ
lg/kg
Number of
positive
samples(a)
Median of
positive
samples(a)
(lg/kg)
Mean of
positive
samples(b)
(lg/kg)
Maximum
(lg/kg)
Reference
Netherlands 2002–2004 Maize silage DON 140 n.r. 250 101 n.r. 854 3,142 Driehuis et al.
(2008b)Wheat silage DON 30 n.r. 3 n.r. 621 1,165
2005 Silage(c) DON 47 n.r. 125 25 n.r. 550 1,250 Driehuis et al.
(2008a)Compound feed DON 72 n.r. 125 39 n.r. 433 2,408
Ensiled by-products (d) DON 29 n.r. 125 0 n.r. n.r. n.r.
Feed commodities (e) DON 8 n.r. 125 3 n.r. n.r. n.r.
Forage products(f) DON 13 n.r. 125 2 n.r. n.r. n.r.
Italy n.r. Maize(g) DON 35 n.r. n.r. 13 810 1,000 1,900 Cortinovis
et al. (2012)Barley(g) DON 15 n.r. n.r. 11 650 600 900
Oats(g) DON 12 n.r. n.r. 1 n.r. 400 400
Rice bran(g) DON 10 n.r. n.r. 3 n.r. 800 1,200
Germany 2007–2008 Muesli and mash-type
horse feed(h)
DON 62 10 n.r. 62 n.r. 410 4,900 Liesener et al.
(2010)
Portugal n.r. Compound feeds for
pigs
DON 277 100 n.r. 47 n.r. 223 864 Almeida et al.
(2011)
Austria 2007 Dry dog food DON 76 10 n.r. 63 n.r. n.r. 1,390 B€ohm et al.
(2010)
EU(i) 2008 Wheat DON 8 n.r. n.r. 6 1,898 2,657 8,841 Monbaliu
et al. (2010)Wheat 3-Ac-DON 8 n.r. n.r. 3 18.0 33.3 67
Wheat 15-Ac-DON 8 n.r. n.r. 5 23.0 38.2 100
Maize DON 42 n.r. n.r. 35 520 891 9,528
Maize 3-Ac-DON 42 n.r. n.r. 31 21.0 36.5 339
Maize 15-Ac-DON 42 n.r. n.r. 26 79.5. 134 1,047
Switzerland 2005–2007 Maize grain DON n.r. n.r. n.r. n.r. n.r. n.r. n.r. Dorn et al.
(2011)Maize plant (minus
grain)
DON n.r. n.r. n.r. n.r. n.r. n.r. n.r.
n.r. Maize silage DON 20 n.r. n.r. 19 n.r. 1,356 2,990 Eckard et al.
(2011)Maize silage Sum of 3-Ac-
and 15-Ac-
DON
19 n.r. n.r. 2 n.r. 217 300
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Country Year Product Toxin
No. of
samples
LOD
lg/kg
LOQ
lg/kg
Number of
positive
samples(a)
Median of
positive
samples(a)
(lg/kg)
Mean of
positive
samples(b)
(lg/kg)
Maximum
(lg/kg)
Reference
Lithuania 2007 Winter rapeseed DON 8 n.r. n.r. 8 n.r. 165 176 Mankeviciene
et al. (2011)Spring rapeseed DON 8 n.r. n.r. 8 n.r. 133 181
Linseed DON 6 n.r. n.r. 6 n.r. 155 163
2008 Winter rapeseed DON 25 n.r. n.r. 21 n.r. 209 278
Spring rapeseed DON 11 n.r. n.r. 2 n.r. <LOD 226
Linseed DON 19 n.r. n.r. 19 n.r. 210 226
2009 Linseed DON 10 n.r. n.r. 10 n.r. 116 124
Rapeseed cake DON 7 n.r. n.r. 7 n.r. 387 n.r.
Belgium 2010–2011 Poultry feed DON 14 5–12 10–24 – – 197 894 De Boevre
et al. (2012)3-Ac-DON 14 – – 47 182
15-Ac-DON 14 – – 50 190
DON-3-
glucoside
14 – – 30 90
Piglet feed DON 8 5–12 10–24 – – 318 892
3-Ac-DON 8 – – 25 136
15-Ac-DON 8 – – 42 86
DON-3-
glucoside
8 – – 43 166
Sow feed DON 15 5–11 10–22 – – 135 245
3-Ac-DON 15 – – 11 53
15-Ac-DON 15 – – 20 44
DON-3-
glucoside
15 – – 29 96
Fattening pig feed DON 13 5–11 10–22 – – 291 1,250
3-Ac-DON 13 – – 29 155
15-Ac-DON 13 – – 38 144
DON-3-
glucoside
13 – – 121 1,304
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Country Year Product Toxin
No. of
samples
LOD
lg/kg
LOQ
lg/kg
Number of
positive
samples(a)
Median of
positive
samples(a)
(lg/kg)
Mean of
positive
samples(b)
(lg/kg)
Maximum
(lg/kg)
Reference
Horse feed DON 14 5–11 10–22 – – 200 874
3-Ac-DON 14 – – 13 87
15-Ac-DON 14 – – 44 296
DON-3-
glucoside
14 – – 34 179
Dairy cattle and young
stock
DON 3 5–11 10–22 – – 90 151
3-Ac-DON 3 – – 44 126
15-Ac-DON 3 – – 22 57
DON-3-
glucoside
3 – – n.d n.d.
Croatia 2011 Compound feed
(fattening pigs)
DON 30 150 29 n.r. 817 1,864 Pleadin et al.
(2012)
LOD: limit of detection; LOQ: limit of quantiﬁcation; n.r.: not reported; n: number of samples; –: not reported in the paper; DON: deoxynivalenol; Ac: acetyl.
(a): Number of samples with mycotoxin content greater than the limit of quantiﬁcation or detection.
(c): Mixture of grass and maize silage.
(d): Pressed sugar beet pulp (n = 12), Brewer’s spent grains (n = 15) and potato pulp (n = 2).
(e): Rapeseed/soy meal (n = 4), maize gluten meal (n = 2) and cereal grains (n = 2).
(f): Fresh grass (n = 5), dried grass (n = 2) and grass hay (n = 6).
(g): Feed for horses.
(h): Commercial horse feed preparations (complementary feeds) containing varying proportions of barley, wheat, oats and maize.
(i): Various Member States (the Czech Republic, Hungary, Spain and Portugal). Only data for co-contaminated samples reported.
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Table B.4: Occurrence of DON, DON-3-glucoside and the sum of 3-Ac-DON and 15-Ac-DON in feedingstuffs for livestock as reported by Zachariasova
et al., (2014b) (modiﬁed)
DON DON-3-glucoside Sum of 3-Ac-DON and 15-Ac-DON DON-3-glucoside:
DON ratio(b)n Mean Median Maximum LOQ Mean Median Maximum LOQ Mean Median Maximum LOQ
lg/kg lg/kg lg/kg
Hay 4 46 40 62 50 n.r. n.r. n.r. n.r. n.r. n.r. n.r. 50 0.02
Maize silage(a) 11 867 759 2,950 50 27 25 66 50 211 25 1,150 50 0.09
Feed wheat 21 213 118 1,038 10 16 5 92 10 n.r. n.r. n.r. 10 0.27
Feed barley 16 264 105 1,582 10 56 5 433 10 3 3 41 5 0.06
Feed maize 8 624 599 1,523 10 49 63 86 10 n.r. n.r. n.r. 10
Feed oats 3 102 5 296 10 n.r. n.r. n.r. 10 n.r. n.r. n.r. 10
Soybean meal 10 7 5 25 10 n.r. n.r. n.r. 10 n.r. n.r. n.r. 10
Sugar beet
pulp
6 49 31 128 25 n.r. n.r. n.r. 25 n.r. n.r. n.r. 50 0.05
Extracted oil
seeds
14 134 40 1,285 25 23 20 60 20 n.r. n.r. n.r. 25 1.57
Malt sprouts 28 154 111 494 25 229 168 773 25 153 171 458 25 0.12
Maize dried
distiller’s grains
with solubles
71 1,675 1,393 5,981 50 128 20 710 25 297 266 688 25 0.22
Wheat dried
distillers grains
with solubles
16 262 506 588 25 31 20 130 25 43 13 102 25
Compound feeds
Pigs 26 401 175 1,735 25 48 20 219 25 14 1 169 25 0.13
Poultry 44 328 374 710 25 25 23 13 39 25
Dairy cows(a) 19 524 447 1,262 25 25 20 51 25 4 1 62 25 0.04
n: number of samples; LOQ: limit of quantiﬁcation; n.r., not reported; DON: deoxynivalenol; Ac: acetyl.
For calculating the arithmetic means of mycotoxin concentrations, 1⁄2 of LOQ value (g/kg) was used.
(a): Samples oven dried prior to analysis.
(b): Calculated by the CONTAM Panel using the maximum concentrations.
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Appendix C – Current occurrence of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside in feeds
The concentrations of DON alone and the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside (lg/kg) across feed groups as used in the animal exposure assessment are presented in
Tables C.1 and C.2, respectively. Although data were available for other feeds, they were either poorly
described (e.g. ‘grains as crops’) or the number of samples were insufﬁcient (n < 10) to provide
reliable estimates (EFSA, 2011b). For cereal grains, the data for individual grains speciﬁed for feed
(e.g. wheat, barley etc.) have been combined with those for those unprocessed grains of undeﬁned
end-use to increase the number of samples per cereal type.
Table C.1: Concentrations (lg/kg) of DON across feed groups
Feed group
Concentration (lg/kg)(b)
N(a) %LC(c) Mean 75th percentile 95th percentile Maximum
LB UB LB UB LB UB UB
Feed materials
Barley 525 48.7 346 387 219 250 2,301 2,301 8,978
Maize grain 457 42.0 580 627 455 455 2,300 2,300 15,830
Oats 187 48.1 379 408 240 250 1,907 1,907 6,992
Oat feed 29 20.7 234 237 290 290 599 599 1,313
Wheat 659 37.3 410 436 425 429 1,650 1,650 14,505
Wheat feed 74 55.4 351 376 506 506 1,550 1,550 2,640
Rape seed meal 10 60.0 26 146 50 199 80 199 199
Sunﬂower seed meal 11 100 0 128 0 199 0 199 199
Soya bean meal 111 96.4 5 190 0 200 0 200 220
Pressed sugar beet pulp 10 76.4 108 250 250 250 549 549 549
Forages and roughage, and products derived thereof
Cereals straw 124 44.4 1076 1130 771 771 3,373 3,373 47,218
Grass, ﬁeld dried, hay 93 81.7 9 104 0 138 50 138 138
Maize silage 129 14.7 410 423 469 469 1,340 1,340 4,300
Complete (compound)/complementary feedingstuffs
Dairy cows 96 56.4 131 159 131 135 792 792 1,300
Fattening cattle 42 54.8 261 318 140 250 500 500 7,350
Horses 15 55.2 183 189 236 236 874 874 874
Weaning pigs 193 61.1 149 238 232 250 589 660 2,720
Growing/fattening pigs 229 27.3 266 311 370 370 779 779 2,620
Breeding pigs (sows) 185 27.0 314 369 435 440 790 790 3,970
Laying hens 89 29.2 482 494 696 696 2,050 2,050 2,910
Fattening chickens 496 19.2 617 627 969 969 2,000 2,000 5,200
Fattening ducks 97 23.7 624 633 1,070 1,070 1,760 1,760 2,340
Fattening turkeys 101 20.8 898 907 1,430 1,430 2,410 2,410 3,440
DON: deoxynivalenol; N: number of samples; LC: left-censored data (values below the limit of detection or limit of
quantiﬁcation); LB: lower bound; UB: upper bound.
(a): If N < 60 then the calculated 95th percentile concentration should be considered as an indicative value only due to the
limited number of data (EFSA, 2011b).
(b): Concentration reported as lg/kg 88% dry matter.
(c): Value represent the left-censoring limit.
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Table C.2: Concentrations (lg/kg) of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
across feed groups as used in the animal exposure assessment
Feed group
Concentration (lg/kg)(b)
N(a) Mean 75th percentile 95th percentile Maximum
LB UB LB UB LB UB UB
Feed materials
Barley 525 442 527 311 363 2,761 2,783 10,447
Maize grain 456 844 920 660 663 3,335 3,335 22,954
Oats 187 518 571 348 363 2,452 2,462 9,249
Oat feed 29 304 321 404 404 797 797 1,766
Wheat 659 542 588 542 563 2,173 2,195 16,801
Wheat feed 74 466 528 607 617 2,059 2,059 3,828
Rape seed meal 10 38 211 73 289 116 289 498
Sunﬂower seed meal 11 0 202 0 289 0 289 498
Soya (bean) meal 111 8 289 0 290 0 519 729
Pressed (sugar) beet pulp 10 156 363 363 363 795 795 795
Forages and roughage, and products derived thereof
Cereals straw 124 1,722 1,819 1,090 1,108 5,541 5,541 68,418
Grass, ﬁeld dried, [Hay] 93 13 154 0 200 73 200 359
Maize silage 129 588 624 663 681 1943 1,943 6,235
Complete/complementary feeds
Dairy cows 96 191 248 190 195 1,148 1,148 1,885
Fattening cattle 42 377 474 203 363 725 725 10,658
Horses 15 273 292 378 378 1,432 1,432 1,275
Weaning pigs 193 213 361 336 391 858 957 3,944
Growing/fattening pigs 229 385 453 536 537 1,130 1,130 3,799
Breeding pigs 185 453 544 615 637 1,146 1,146 5,757
Laying hens 89 698 716 1,009 1,009 2,973 2,973 4,220
Fattening chickens 496 894 909 1,404 1,404 2,900 2,900 7,540
Fattening ducks 97 905 918 1,552 1,552 2,552 2,552 3,393
Fattening turkeys 101 1,302 1,315 2,074 2,074 3,495 3,495 4,988
DON: deoxynivalenol; Ac: acetyl; N: number of samples; LC: left-censored data (values below the limit of detection or limit of
quantiﬁcation); LB: lower bound; UB: upper bound.
(a): If N < 60 then the calculated 95th percentile concentration should be considered as an indicative value only due to the
limited number of data (EFSA, 2011b).
(b): Concentration reported as lg/kg 88% dry matter.
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Appendix D – Dietary surveys considered for the acute and chronic human dietary exposure assessment
Table D.1: Dietary surveys used for the estimation of acute and chronic dietary exposure
Country Survey acronym Survey period
N of
days per
subject
N of subjects/N of days
Infants Toddlers Other children
Adolescents
(mean age)
Adults Elderly Very elderly
Austria ASNS – Adults 2010–2012 2 – – – – 308/726 67/181 25/85
ASNS – Children 2010–2012 3 – – 128/384 237/706 – – –
Belgium Regional Flanders 2002–2002 3 36/108 625/1875 – – – –
Belgium Diet National 2004 2004 2 – – 576/1,187 (16a) 1,292/2,648 511/1,045 704/1,408
Bulgaria NSFIN 2004 1 –/162 –/691 –/151 –200
Bulgaria NUTRICHILD 2007 2 861/1,720 428/856 433/867 – – – –
Cyprus Childhealth 2003 3 – – – 303/909 (13a) – – –
CzechRepublic SISP04 2003–2004 2 – – 389/778 298/596 (13a) 1666/3,332 – –
Denmark DANSDA 2005-08 2005–2008 7 – – 298/2,085 377/2,622 (13a) 1739/12,127 274/1,916 12/84
Denmark IAT 2006 07 2006–2007 7 826/5,771 917/6,388 – – – – –
Estonia NDS 1997 1997 1 –/1,866 – –
Finland DIPP 2001 2009 2001–2009 3 500/1,500 500/1,500 750/2,250 – – – –
Finland NWSSP07 08 2007–2008 4 – – 306/1,186 (13a) – – –
Finland FINDIET2012 2012 2 – – – 1,295/2,590 413/826 –
France INCA2 2007 7 – 482/3,315 973/6,728 (14a) 2,276/15,727 264/1,824 84/571
Germany VELS 2001–2002 6 159/927 348/1,947 293/1,610 – – – –
Germany EsKiMo 2006 3 – 835/2,498 393/1,179 (11a) – – –
Germany National Nutrition
Survey II
2007 2 – – 1,011/2,022
(16a)
10,419/20,838 2,006/4,012 490/980
Greece Regional Crete 2004–2005 3 838/2,508 – – – –
Greece DIET LACTATION GR 2005–2007 3 – – – 65/350 – –
Hungary National Repr Surv 2003 3 – – – 1,074/3,222 206/618 80/240
Ireland NANS 2012 2008–2010 4 – – – 1,274/5,096 149/596 77/308
Italy INRAN SCAI 2005 06 2005–2006 3 16/48 36/108 193/579 247/741 (14a) 2,313/6,939 290/870 228/684
Latvia EFSA TEST 2008 2 187/377 453/979 (14a) 1,271/2,655 – –
Latvia FC PREGNANTWOMEN
2011
2011 2 – – – 1,002/2,005 – –
Netherlands VCP kids 2006–2007 3 322/644 957/1,914 – – – –
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Country Survey acronym Survey period
N of
days per
subject
N of subjects/N of days
Infants Toddlers Other children
Adolescents
(mean age)
Adults Elderly Very elderly
Netherlands VCPBasis AVL2007
2010
2007–2010 2 – 447/894 1,142/2,284
(14a)
2,057/4,114 173/346
Netherlands VCP-Elderly 2010–2012 2 – – – – 289/578 450/900
Poland IZZ FAO 2000 2000 1 –/79 –/409 –/666 (14a) –/2,527 –/329 –/124
Romania Dieta Pilot Children 2012 1 – –/205 –/567 (14a) – – –
Romania Dieta Pilot Adults 2012 7 – – – 1,254/8,770 83/581 45/315
Slovakia SK MON 2008 2008 1 – – – 2761 – –
Slovenia CRP 2008 2007–2008 1 – – – 407 – –
Spain enKid 1998–2000 2 17/34 156/312 209/418 (12a) – – –
Spain AESAN 1999–2001 3 – – – 410/828 – –
Spain NUT INK05 2004–2005 2 399/798 651/1,302 (14a) – – –
Spain AESAN FIAB 2009 3 – – 86/226 (17a) 981/2,748 – –
Sweden NFA 2003 4 – 1,473/5875 1018/4047 (12a) – – –
Sweden Riksmaten 2010 2010–2011 4 – – – 1,430/5,680 295/1,167 72/288
UnitedKingdom NDNS-Rolling
Programme Years 1-3
2008–2011 4 185/737 651/2,595 666/2,653 (14a) 1,266/5,040 166/662 139/552
UnitedKingdom DNSIYC 2011 2011 4 1,369/5,446 1,314/5,217 – – – – –
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Appendix E – Intake and composition of diets used in estimating animal
exposure to DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
To estimate the farm and companion animal exposure to DON alone and to the sum of DON, 3-Ac-
DON, 15-Ac-DON and DON-3-glucoside, information is required on both the amount of feed consumed
and the concentration of these compounds in the feed. This Appendix E gives details of the feed
consumption and live weights (Section E.1) and assumed diet compositions (Section E.2) for different
farm and companion animals used to estimate exposures. These are based on published guidelines on
nutrition and feeding (Carabano and Piquer, 1998; NRC, 2007a, 2007b; Leeson and Summers, 2008;
OECD, 2009; McDonald et al., 2011; EFSA FEEDAP Panel, 2012) and information provided by European
feed manufacturers. Given the wide range of livestock and feeding systems in Europe, it has not been
possible to estimate exposures that encompass all production systems. They are therefore estimates of
the Panel on Contaminants in the Food Chain (CONTAM Panel), but agree with common practice.
Based on these estimates of intake, the mean and 95th percentile concentrations of the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside at the lower bound (LB) and upper bound (UB) in the
species-speciﬁc compound feed or in the estimated diets for the farm animal and companion animals,
the dietary concentrations and exposures have been calculated, and are given in this Appendix E and
in Section 6.3. In Appendix F, Section F.4 the estimated dietary concentrations of DON alone and
exposures to DON alone in feed, calculated in the similar manner as for the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside, for farm and companion animals are presented.
E.1. Feed intakes
E.1.1. Cattle, sheep, goats and horses
Dairy cows
Feed intakes by lactating dairy cows vary, and inﬂuenced principally by the quantity and quality of
forages and other feeds available, the milk yield and the size of the cow. Exposures to DON alone and
the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside have been estimated for a 650-kg dairy
cow, with a milk yield of 40 kg/day. Where cows are fed a commercially manufactured complementary
feed it is assumed that this is fed at the rate of 0.3 kg/kg of milk produced (Nix, 2010), and
supplemented as with forage. Assumptions on the amounts of forages and non-forage feed are given
in Appendix E, Table E.1. A second scenario is also considered in which lactating dairy cows are fed a
diet based on maize silage and supplemented with maize grain and soybean meal (Appendix E,
Table E.2).
Beef cattle
There are a wide variety of beef production and husbandry systems in Europe. They may be
categorised broadly as forage-based or cereal-based systems, although combinations of these systems
are commonly found. In this opinion, several feeding systems have been considered for cattle 300 or
400 kg, and feed intakes of between 6.6 and 10 kg dry matter/day, based on guidelines published by
EBLEX (2008, 2012). Details are given in Appendix E, Table E.1.
Sheep and goats
Many breeds and systems of management have been developed for sheep and goats to suit the
land, climate and husbandry conditions in Europe. As for other ruminants, forages may be the only
feeds used after weaning (NRC, 2007a). Common exceptions to this are pregnant and lactating
animals, whose feed is usually supplemented with non-forage feeds or commercially manufactured
compound (complementary) feeds. In this opinion, exposure estimates have been made for lactating
sheep and goats, and for fattening goats. Details of live weights and feed intakes assumed, and the
proportion of the diet from forages, are given in Appendix E, Table E.1.
Horses
Horses are non-ruminant herbivores. They generally consume 2–3.5% of their body weight in feed
(dry matter) each day, of which a minimum of 50% should be as forage (pasture or hay) (NRC,
2007b). The CONTAM Panel has estimated exposure for a 450-kg horse, with a daily intake of 9 kg dry
matter/day (Appendix E, Table E.1).
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E.1.2. Pigs, poultry and farmed ﬁsh
Pigs
Although there is a considerable range of pig production systems in Europe, exposure estimates
have been made for growing pigs (20-kg body weight), fattening pigs (100-kg body weight) and
lactating sows (200-kg body weight) using feed consumption proposed by EFSA FEEDAP Panel (2012)
(Appendix E, Table E.2).
Poultry
The CONTAM Panel applied the live weights and feed intakes reported for fattening chickens
(broilers), laying hens and turkeys proposed by EFSA FEEDAP Panel (2012) and for ducks by Leeson
and Summers (2008) (Appendix E, Table E.2).
Farmed ﬁsh (salmonids and carp)
Commercially reared species include Atlantic salmon, rainbow trout, sea bass, sea bream, cod,
halibut, tuna, eel and turbot. In this opinion, exposures to DON alone and the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside have been made for farmed salmon and carp. Details of the body
weights and feed intakes used are given in Appendix E, Table E.2.
Table E.1: Live weights, growth rate/productivity, dry matter intake for cattle, sheep, goats and
horses, and the proportions of the diet as non-forage
Live
weight
(kg)
Growth rate
or productivity
Dry
matter
intake
(kg/day)
% of diet as
non-forage
feed
Reference
Dairy cows: lactating 650 40 kg milk/day 20.7 40 AFRC (1993)
Fattening cattle: beef(a) 400 1 kg/day 9.6 15 AFRC (1993)
Fattening cattle: maize
silage-based ration
300 1.4 kg/day 6.6 25 Browne et al. (2004)
Fattening cattle: cereal
straw-based diet
300 0.9 kg/day 8.0 68 EBLEX, 2008
Sheep: lactating 80 Feeding twin lambs 2.8 50 OECD (2009)
Goats: milking(b) 60 6 kg milk/day 3.4 65 NRC (2007b, 2007a)
Horses 450 Moderate activity 9.0 50 NRC (2007b)
(a): Housed castrate cattle, medium maturing breed
(b): months 2-3 of lactation.
Table E.2: Live weights and feed intake for pigs, poultry and farmed ﬁsh
Live
weight (kg)
Feed intake
(kg dry matter/day)
Reference
Pigs: piglets 20 1.0 EFSA FEEDAP Panel (2012)
Pigs: fattening pigs 100 3.0 EFSA FEEDAP Panel (2012)
Pigs: lactating sows 200 6.0 EFSA FEEDAP Panel (2012)
Poultry: broilers(a) 2 0.12 EFSA FEEDAP Panel (2012)
Poultry: laying hens 2 0.12 EFSA FEEDAP Panel (2012)
Turkeys: fattening turkeys 12 0.40 EFSA FEEDAP Panel (2012)
Ducks: fattening ducks 3 0.14 Leeson and Summers (2008)
Salmonids 2 0.04 EFSA FEEDAP Panel (2012)
Carp 1 0.02 Schultz et al. (2012)
(a): Chickens for fattening.
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E.1.3. Farmed rabbits
Feed consumptions of 65–80 g/kg bw per day have been reported for farmed rabbits (Carabano
and Piquer, 1998). For the exposure estimates, the CONTAM Panel have assumed a live weight of 2 kg,
and a daily feed consumption of 75 g/kg bw
E.1.4. Companion animals (dogs and cats)
The amount of food consumed is largely a function of the mature weight of the animal, level of
activity, physiological status (e.g. pregnancy or lactation) and the energy content of the diet. In this
opinion, the CONTAM Panel assumed body weights (kg) and feed intakes (g dry matter/day) for dogs
and cats of 25 kg/360 g dry matter per day and 4 kg/60 g dry matter per day, respectively (derived by
the CONTAM Panel from NRC, 2006).
E.1.5. Farmed mink
For estimating exposure, the CONTAM Panel have assumed a live weight of 2.07 kg for a male mink
at pelting, and with a feed intake of 227 g/day (75 g dry matter) (NRC, 1982).
E.2. Diet composition and dietary concentration and exposure
estimates for the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside
Many livestock in the European countries are fed proprietary commercial compound feeds
formulated to meet the nutritional needs of the animals for which they are intended. Where sufﬁcient
data have been provided on the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in species-
speciﬁc compound feeds (see Appendix C, Table C.2), estimates of dietary concentrations and
exposures have been made. Where data on proprietary compound feeds were not available, or were
available but in insufﬁcient numbers, estimates of dietary concentrations and exposure have been
made using dietary inclusion rates of feed materials given in this section. The concentrations for the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside in these feed materials are provided in
Appendix C, Table C.2). The estimated dietary concentrations and exposures for the different farm and
companion animals are presented in Section 6.3.1.
E.2.1. Cattle, sheep, goats and horses
For most ruminants and horses, forages (either fresh or conserved) constitute the largest fraction
of their diet, but they are normally supplemented with non-forage feeds such as cereals, cereal by-
products, oilseed meals and by-products of human food production. These may be fed either as
individual feeds, mixtures of feed materials or as species-speciﬁc complementary feeds in the form of
compound feeds. In some situations, however, forages may represent the total diet.
Fresh (grazed) grass or grass silage are the principal forages for many ruminants and horses in
Europe. As reported elsewhere in this opinion (Section 5.2) DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside have not been widely reported in these feeds, and therefore, it has been assumed that where
they are fed they make no contribution to exposure. Where grass has been conserved as hay, the
presence of DON has been widely reported. Therefore, estimates of dietary concentrations and
exposures have been reported for lactating dairy cows, fattening beef cattle and horses in which
species-speciﬁc compound feeds are supplemented with (a) fresh grass or grass silage or (b) grass hay.
For other forages, particularly maize silage and cereal straw, DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside have been widely reported. Therefore, dietary concentrations and exposures have been
estimated for lactating dairy cows and fattening beef cattle where these represent a signiﬁcant part of the
diet. AFSSA (2009) have provided example consumption of dairy cows fed maize silage supplemented
with maize grain and soybean meal, while example diets of beef cattle on maize silage or cereal straw-
based diets are taken from EBLEX (2008, 2012), and these are given in Appendix E, Table E.3.
While forages represent the main or in some case the only feed for ruminants, some beef cattle are
reared on diets consisting predominantly of cereals to achieve higher growth rates. Therefore, estimates
of dietary concentrations and exposures have also been made for ‘cereal beef’ cattle (intensively reared
beef cattle on cereal-based diet). The assumed ration is given in Appendix E, Table E.3.
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For lactating sheep, milking goats and fattening goats, no information on levels of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside in species-speciﬁc compound feed were available, and therefore,
example diets have been used to estimate dietary concentrations and exposures (Appendix E,
Table E.4).
Table E.3: Assumed diet compositions and feed intake of lactating dairy cows (40 litres/day) and
fattening beef cattle fed diets based on different forages
Quantities of feed consumed(kg dry matter/day)
Reference
Forage
Maize
grain
Soybean
meal
Barley
grain
Rapeseed
meal
Lactating dairy cows:maize
silage-based diet
15.0 9.5 2.8 ni ni AFSSA, 2009
Fattening beef cattle:maize
silage-based diet
4.9 ni ni ni 1.5 EBLEX, 2012
Fattening beef cattle:cereal
straw-based diet
2.5 ni ni 4.1 1.4 EBLEX, 2008
Fattening beef cattle:intensive
cereal-based diet
1.5 ni ni 5.5 1.5 EBLEX, 2008
ni: Not included in the diet formulations.
Table E.4: Assumed diet compositions (%) for lactating sheep and goats, and fattening goats, and
the calculated mean lower bound and upper bound concentrations of the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside in these diets
Non-forage feed materials Lactating sheep Lactating goats Fattening goats
Wheat (%) 14 ni ni
Barley (%) 18 25 20
Oats (%) ni 35 40
Soybean meal (%) 5 10 10
Rapeseed meal (%) 10 10 10
Sunﬂower meal (%) 5 ni ni
Beans (%)(b) 10 ni ni
Maize gluten feed (%) ni ni ni
Wheat feed (%)(a) 15 10 10
Oat feed (%)(a) ni ni ni
Sugar beet pulp (%)(b) 14 1 1
Molasses (%)(b) 4 4 4
Vegetable oils (%)(b) 5 5 5
Minerals, vitamins etc. (%)(b) ni ni ni
% of non-forage feeds in the diet 50 75 40
Estimated mean dietary concentration of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside(c)
Lower bound (lg/kg) 132 262 148
Upper bound (lg/kg) 253 367 270
Estimated 95th percentile dietary concentration of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside(d)
Lower bound (lg/kg) 653 462 559
Upper bound (lg/kg) 749 558 666
ni: Not included in the diet formulations; DON: deoxynivalenol; Ac: acetyl.
(a): By-products of processing these grains See Commission Regulation (EU) No 575/2011 of June 2011 for full description.51
(b): No data for the sum of DON, 3-Ac-DON, 15-Ac-DON or DON-3-glucoside concentration were available, and therefore no
contribution from these feeds has been assumed.
(c): Concentrations calculated by using the mean concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
reported for the individual feeds in Appendix C, Table C.2.
(d): Concentrations calculated by using the 95th percentile concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside reported for the individual feeds in Appendix C, Table C.2.
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E.2.2. Pigs and poultry
Sufﬁcient data for species-speciﬁc compound feeds for pigs, and for most categories of poultry
(fattening chickens, ducks and turkeys, and for laying hens), were provided (see Appendix C,
Table C.2) and these were used to estimate dietary concentrations and exposures of the sum of DON,
3-Ac-DON, 15-Ac-DON and DON-3-glucoside.
E.2.3. Rabbits
Rabbits are usually fed a pelleted diet (in the form of complete feedingstuffs) consisting of dried
forages, cereals and vegetable proteins supplemented with minerals, vitamins and trace elements.
Lebas and Renouf (2009) reviewed diet formulations used in experimental studies: in 58 diets, cereals
and cereal by-products (mostly wheat bran) accounted for up to 40% of all ingredients. In these
studies, maize was a major cereal grain and was included in more than one-third of all diets. In
northern Europe, however, maize may be replaced by barley and wheat. In this opinion, the feed
ingredients used in a typical French commercial rabbit compound, as provided by T. Gidenne, (Personal
communication, 2011) have been used, details of which are given in Appendix E, Table E.5.
E.2.4. Farmed ﬁsh (salmonids and carp)
Traditionally, the principal raw materials used for the manufacture of ﬁsh feeds in Europe have
been ﬁshmeal and ﬁsh oils, and although alternative sources of oil and protein (e.g. soybean meals
and vegetable oils) are increasingly being used ﬁsh-derived feeds still remain the major ingredients.
For many ﬁsh species, digestion of complex carbohydrates and the metabolic utilisation of the
absorbed glucose is low, reﬂecting the scarcity of carbohydrates in the aquatic environment (Guillaume
et al., 2001). Instead, ﬁsh obtain much of their energy from protein in the diet. Where carbohydrates
are used, they generally require some form of pretreatment (e.g. cooking, ﬂaking or toasting).
Berntssen et al. (2010) provided details of the composition of a diet for growing salmonids, and the
CONTAM Panel used this feed formulation to estimate the dietary concentrations and exposures
(Appendix E, Table E.5).
In contrast, studies with the common carp (Cyprinus carpio) have demonstrated greater intestinal
amylase activity than in carnivorous ﬁsh, which accounts for the better utilisation of carbohydrates by
these ﬁsh. The optimum level of carbohydrates appears to be 30–40% (Food and Agriculture
Organization of the United Nations (FAO), Aquaculture Feed and Fertiliser Resources Information
System52), which allows for higher levels of cereals than in diets for salmonids. The CONTAM
Panel used the ingredients of commercial compound feeds for carp reported by Schultz et al. (2012) to
estimate dietary concentrations and exposures of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside.
E.2.5. Farmed mink
Mink are carnivorous animals and are fed high protein diets consisting mainly of meat and meat
by-products. Commercially manufactured mink feed consists largely of ﬁsh and land animal by-
products, with lesser amounts of cereals and cereal by-products, and supplemented with mineral/
vitamin premixtures. Mink are fed diets high in protein, although their nutritional requirements vary
according to the animal’s physiological stage (e.g. gestating, lactating and growing) and climatic
conditions, particularly temperature. The proportions of cereal grains, their products and by-products
used in estimating the dietary concentrations and exposures are given in Appendix E, Table E.5.
E.2.6. Companion animals (dogs and cats)
Most small companion animals derive their nutritional needs from processed food, and in 2010 EU
annual sales of pet food products was approximately 8.3 million tonnes.53 Although a wide range of
ingredients is used in commercial diets, most dog and cat diets contain at least some animal protein.
Other ingredients include cereals (predominantly wheat, rice or maize), cereal by-products, vegetable
proteins and by-products of human food production. The ingredients will vary depending both on the
availability of feed materials and on the nutrient requirements of the animals.
52 http://www.fao.org/fishery/affris/affris-home/en/
53 Available online: www.Fediaf.org
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The European Pet Food Industry Federation (FEDIAF) has provided information on typical inclusion
levels of cereals, cereal by-products and other feed materials in dry cat and dog food.54 In the
absence of sufﬁcient data on species-speciﬁc manufactured complete feedingstuffs, the CONTAM
Panel has used example diets based on information provided by FEDIAF (details given in Appendix E,
Table E.5).
Table E.5: Assumed diet composition (%) for farmed rabbits, farmed mink, farmed ﬁsh (salmonids
and carp) and companion animals (cats and dogs), and the calculated mean lower
bound and upper bound levels of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in these diets
Feed materials Rabbits
Farmed
mink
Farmed ﬁsh Cats/Dogs
Salmonids Carp Cats Dogs
Wheat ni 6 13.2 24 10.0 10.0
Barley ni 1 ni ni ni ni
Maize 17.6 6 ni 10 5.0 6.0
Oats ni ni ni ni ni 0.5
Soybean meal ni ni 12.3 32.4 8.0 4.0
Rapeseed meal ni ni ni 12.5 ni ni
Maize gluten meal ni ni 11.5 ni 17.0 15.0
Sunﬂower meal 20.0 ni ni ni ni ni
Lucerne meal 19.1 ni ni ni ni ni
Beans 10.4 ni ni ni 1.0 2.0
Peas 7.5
Wheat feed(a) 18.3 ni ni ni 12.0 20.0
Sugar beet pulp 11.9 ni ni ni ni ni
Fishmeal(a) ni ni 30.5 6.7 6.0 ni
Meat meal(a) ni 40 ni ni ni ni
Molasses(a) ni ni ni ni ni ni
Fish and vegetable oils(a) ni 8 31.9 2.3 ni ni
Others feeds (unspeciﬁed)(a) ni ni ni 1.0 38.0 40.0
Minerals, vitamins etc.(a) 2.7 3 0.6 3.6 3.0 2.5
Estimated mean dietary concentration of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside(d)
Lower bound (lg/kg) 196 99.5 83.3 254 229 174
Upper bound (lg/kg) 282 109 123 388 264 214
Estimated 95th percentile dietary concentration of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside(d)
Lower bound (lg/kg) 1048 407 362 1084 968 741
Upper bound (lg/kg) 1135 409 380 1152 975 753
ni: These feeds have not been included in the diet formulations; DON: deoxynivalenol; Ac: acetyl.
(a): No data for the sum of DON, 3-Ac-DON, 15-Ac-DON or DON-3-glucoside concentration were available, and therefore no
contribution from these feeds has been assumed.
(b): Diet formulation based on data provided by the Finnish Fur Breeders Association in 2015 and translated from Finnish to
English, www.profur.fi
(c): Concentrations calculated by using the mean concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside
reported for the individual feeds in Appendix C, Table C.2.
(d): Concentrations calculated by using the 95th percentile concentrations of the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-
3-glucoside reported for the individual feeds in Appendix C, Table C.2.
54 The European Pet Food Industry Federation (FEDIAF), Personal communication by email, May 2016.
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Appendix F – Current chronic exposure to the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside across the different surveys, and current
estimates of exposures to DON for humans and animals
F.1. Current chronic human exposure to the sum of DON, 3-Ac-DON,
15-Ac-DON and DON-3-glucoside across the different dietary surveys
Table F.1: Chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-
glucoside in lg/kg bw per day across the different dietary surveys
Age
class Country Survey
Number of
subjects
Mean 95th percentile
Infants LB MB UB LB MB UB
Bulgaria NUTRICHILD 859 0.3 0.6 0.9 1.2 1.7 2.4
Denmark IAT 2006_07 826 0.5 0.8 1.2 1.2 1.7 2.2
Finland DIPP_2001_2009 500 0.3 0.5 0.6 0.7 1.0 1.4
Germany VELS 159 0.5 1.3 2.0 1.5 2.6 3.7
Italy INRAN_SCAI_2005_06 16 0.2 0.5 0.8 – – –
United
Kingdom
DNSIYC_2011 1,369 0.4 0.7 1.1 1.0 1.6 2.2
Toddlers
Belgium Regional_Flanders 36 1.0 1.3 1.6 – – –
Bulgaria NUTRICHILD 428 1.1 1.4 1.7 1.7 2.1 2.6
Denmark IAT 2006_07 917 0.9 1.3 1.6 1.4 1.9 2.4
Finland DIPP_2001_2009 500 0.6 0.9 1.1 1.1 1.4 1.8
Germany VELS 348 0.9 1.2 1.6 1.7 2.1 2.7
Italy INRAN_SCAI_2005_06 36 0.9 1.3 1.7 – – –
Netherlands VCP_kids 322 0.8 1.1 1.4 1.5 1.9 2.4
Spain enKid 17 0.6 0.9 1.1 – – –
United
Kingdom
DNSIYC_2011 1,314 0.8 1.2 1.6 1.5 2.1 2.7
United
Kingdom
NDNS-Rolling Programme
Years 1-3
185 0.8 1.2 1.6 1.5 2.0 2.7
Other children
Austria ASNS_Children 128 0.9 1.1 1.4 1.6 2.0 2.4
Belgium Regional_Flanders 625 0.8 1.1 1.3 1.3 1.7 2.2
Bulgaria NUTRICHILD 433 1.1 1.3 1.6 1.9 2.3 2.7
Czech
Republic
SISP04 389 0.8 1.0 1.2 1.5 1.9 2.3
Denmark DANSDA 2005-08 298 0.8 1.0 1.2 1.2 1.5 1.9
Finland DIPP_2001_2009 750 0.6 0.7 0.9 0.9 1.1 1.4
France INCA2 482 0.7 0.9 1.1 1.2 1.5 1.7
Germany VELS 293 0.9 1.1 1.4 1.5 1.8 2.2
Germany EsKiMo 835 0.8 1.0 1.2 1.4 1.7 2.0
Greece Regional_Crete 838 0.7 0.9 1.2 1.2 1.6 2.0
Italy INRAN_SCAI_2005_06 193 0.9 1.2 1.4 1.7 2.1 2.6
Latvia EFSA_TEST 187 0.6 0.8 1.0 1.4 1.7 2.0
Netherlands VCPBasis_AVL2007_2010 447 0.7 0.8 1.0 1.2 1.4 1.7
Netherlands VCP_kids 957 0.7 0.9 1.2 1.3 1.6 1.9
Spain NUT_INK05 399 0.7 0.9 1.1 1.1 1.5 1.8
Spain enKid 156 0.7 0.8 1.0 1.3 1.5 1.8
Sweden NFA 1,473 0.7 0.9 1.2 1.1 1.5 2.0
United
Kingdom
NDNS-Rolling Programme
Years 1-3
651 0.8 1.0 1.3 1.3 1.7 2.2
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Age
class Country Survey
Number of
subjects
Mean 95th percentile
Infants LB MB UB LB MB UB
Adolescents
Austria ASNS_Children 237 0.5 0.7 0.8 1.0 1.3 1.5
Belgium Diet_National_2004 576 0.4 0.6 0.7 0.8 1.1 1.3
Cyprus Childhealth 303 0.4 0.5 0.6 0.7 0.9 1.1
Czech
Republic
SISP04 298 0.6 0.8 0.9 1.2 1.5 1.8
Denmark DANSDA 2005-08 377 0.4 0.5 0.6 0.7 0.9 1.1
Finland NWSSP07_08 306 0.3 0.4 0.4 0.5 0.6 0.7
France INCA2 973 0.4 0.5 0.6 0.9 1.0 1.2
Germany EsKiMo 393 0.6 0.8 0.9 1.1 1.3 1.6
Germany National_Nutrition_Survey_II 1,011 0.4 0.5 0.6 0.7 1.0 1.2
Italy INRAN_SCAI_2005_06 247 0.6 0.7 0.8 1.1 1.3 1.5
Latvia EFSA_TEST 453 0.5 0.6 0.8 1.0 1.2 1.5
Netherlands VCPBasis_AVL2007_2010 1,142 0.5 0.6 0.7 0.9 1.1 1.2
Spain AESAN_FIAB 86 0.3 0.4 0.5 0.8 0.9 1.1
Spain enKid 209 0.5 0.6 0.7 1.0 1.3 1.5
Spain NUT_INK05 651 0.5 0.6 0.7 0.9 1.0 1.3
Sweden NFA 1,018 0.4 0.6 0.7 0.8 1.0 1.2
United
Kingdom
NDNS-Rolling Programme
Years 1-3
666 0.4 0.5 0.7 0.8 1.0 1.2
Adults
Austria ASNS_Adults 308 0.4 0.5 0.7 0.8 1.0 1.4
Belgium Diet_National_2004 1,292 0.4 0.5 0.6 0.7 0.9 1.1
Czech
Republic
SISP04 1,666 0.4 0.5 0.7 0.7 1.0 1.4
Denmark DANSDA 2005-08 1,739 0.3 0.4 0.5 0.5 0.7 0.9
Finland FINDIET2012 1,295 0.4 0.4 0.5 0.7 0.9 1.1
France INCA2 2,276 0.3 0.4 0.5 0.6 0.7 0.8
Germany National_Nutrition_Survey_II 10,419 0.3 0.4 0.5 0.6 0.8 1.0
Greece DIET LACTATION GR 65 0.3 0.4 0.6 0.6 0.8 1.1
Hungary National_Repr_Surv 1,074 0.3 0.4 0.5 0.6 0.7 0.8
Ireland NANS_2012 1,274 0.3 0.5 0.6 0.6 0.8 1.1
Italy INRAN_SCAI_2005_06 2,313 0.4 0.5 0.6 0.7 0.8 1.0
Latvia EFSA_TEST 1,271 0.3 0.4 0.5 0.7 0.9 1.1
Latvia FC_PREGNANTWOMEN_2011 1,002 0.3 0.5 0.6 0.6 0.8 1.1
Netherlands VCPBasis_AVL2007_2010 2,057 0.3 0.4 0.5 0.6 0.8 1.0
Romania Dieta_Pilot_Adults 1,254 0.3 0.4 0.4 0.5 0.7 0.9
Spain AESAN_FIAB 981 0.3 0.3 0.4 0.5 0.7 0.9
Spain AESAN 410 0.3 0.4 0.5 0.5 0.7 0.9
Sweden Riksmaten 2010 1,430 0.3 0.4 0.5 0.5 0.7 0.9
United
Kingdom
NDNS-Rolling Programme
Years 1-3
1,266 0.3 0.4 0.5 0.5 0.7 1.0
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Age
class Country Survey
Number of
subjects
Mean 95th percentile
Infants LB MB UB LB MB UB
Elderly
Austria ASNS_Adults 67 0.3 0.5 0.6 0.7 0.8 1.0
Belgium Diet_National_2004 511 0.3 0.4 0.5 0.6 0.8 1.0
Denmark DANSDA 2005-08 274 0.3 0.4 0.5 0.5 0.6 0.7
Finland FINDIET2012 413 0.4 0.5 0.6 0.8 1.0 1.1
France INCA2 264 0.3 0.4 0.4 0.6 0.7 0.8
Germany National_Nutrition_Survey_II 2,006 0.3 0.4 0.5 0.6 0.8 1.0
Hungary National_Repr_Surv 206 0.3 0.4 0.4 0.5 0.6 0.7
Ireland NANS_2012 149 0.4 0.5 0.6 0.7 0.8 1.0
Italy INRAN_SCAI_2005_06 290 0.3 0.4 0.5 0.6 0.7 0.9
Netherlands VCP-Elderly 289 0.3 0.4 0.5 0.5 0.6 0.8
Netherlands VCPBasis_AVL2007_2010 173 0.3 0.4 0.5 0.5 0.7 0.9
Romania Dieta_Pilot_Adults 83 0.3 0.4 0.4 0.6 0.7 0.9
Sweden Riksmaten 2010 295 0.2 0.3 0.4 0.5 0.6 0.8
United
Kingdom
NDNS-Rolling Programme
Years 1-3
166 0.3 0.4 0.5 0.5 0.6 0.8
Very elderly
Austria ASNS_Adults 25 0.4 0.5 0.6 – – –
Belgium Diet_National_2004 704 0.3 0.4 0.5 0.5 0.7 1.0
Denmark DANSDA 2005-08 12 0.3 0.4 0.5 – – –
France INCA2 84 0.3 0.3 0.4 0.5 0.6 0.8
Germany National_Nutrition_Survey_II 490 0.3 0.4 0.5 0.6 0.8 1.0
Hungary National_Repr_Surv 80 0.4 0.4 0.5 0.6 0.7 0.8
Ireland NANS_2012 77 0.4 0.5 0.5 0.7 0.8 1.0
Italy INRAN_SCAI_2005_06 228 0.4 0.5 0.6 0.6 0.9 1.0
Netherlands VCP-Elderly 450 0.3 0.4 0.5 0.5 0.7 0.8
Romania Dieta_Pilot_Adults 45 0.4 0.4 0.5 – – –
Sweden Riksmaten 2010 72 0.3 0.4 0.5 0.5 0.7 0.8
United
Kingdom
NDNS-Rolling Programme
Years 1-3
139 0.3 0.4 0.5 0.5 0.6 0.8
DON: deoxynivalenol; Ac: acetyl.
–: The dietary surveys had less than 60 survey participants and therefore could not be included in calculation of the 95th
percentile exposure.
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F.2. Current mean and 95th percentile acute human dietary exposure
to DON alone and the contributions of the different dietary
surveys to chronic DON alone exposure across food groups
For calculating the acute and chronic dietary exposures to DON alone (Tables F.2–F.5, see the
details in the Section 6.1.2). The CONTAM Panel also estimated the levels of exposure separately to
3-Ac-DON, 15-Ac-DON and 3-DON-glucoside, and those estimations are available on the request at
EFSA. The contributions of the different dietary surveys to chronic DON exposure across the food
groups are presented in Table F.5.
F.3. Current mean and 95th percentile human chronic dietary
exposure to DON alone
The mean and the 95th percentile of chronic dietary exposure to DON alone from all food
categories for all age groups across dietary surveys are summarised in Table F.3.
Table F.2: Summary statistics of acute dietary exposure assessment of DON alone by age group
Age group(a)
Mean dietary exposure
(lg/kg bw per day)
95th percentile dietary exposure
(lg/kg bw per day)
Upper bound
n Minimum Maximum Minimum Maximum
Infants(b) 6 0.5 (0.5–0.5) 1.8 (1.8–1.9) 1.5 (1.3–1.6) 4.4 (4.1–4.9)
Toddlers 11 0.7 (0.7–0.8) 1.6 (1.4–1.9) 1.8 (1.7–1.9) 4.3 (2.8–6.2)
Other children 20 0.5 (0.5–0.5) 1.7 (1.6–1.8) 1.1 (1.1–1.2) 4.5 (4.0–4.9)
Adolescents 20 0.2 (0.2–0.2) 1.1 (0.9–1.0) 0.6 (0.5–0.6) 2.5 (2.3–2.7)
Adults 22 0.4 (0.3–0.5) 0.9 (0.8–0.9) 1.1 (1.0–1.2) 2.3 (1.9–2.9)
Elderly 16 0.4 (0.3–0.5) 0.7 (0.6–0.8) 0.9 (0.7–1.2) 2.1 (1.6–3.2)
Very elderly 14 0.4 (0.3–0.5) 0.7 (0.6–0.7) 0.9 (0.8–1.1) 1.8 (1.6–2.0)
DON: deoxynivalenol; bw: body weight; n: number of surveys.
(a): Section 5.1 describes the age range within each age class.
(b): One the dietary surveys had less than 60 survey participants and therefore could not be included in calculation of the 95th
percentile exposure.
Table F.3: Summary statistics of the chronic dietary exposure to DON alone (lg/kg bw per day)
across European countries
Age group
Lower Bound Middle Bound Upper Bound
n Min Median Max Min Median Max Min Median Max
Mean dietary exposure in total population (lg/kg bw per day)
Infants 6 0.2 0.2 0.4 0.3 0.5 0.9 0.4 0.7 1.4
Toddlers 10 0.4 0.6 0.7 0.6 0.8 0.9 0.8 1.1 1.2
Other children 18 0.4 0.5 0.7 0.5 0.7 0.9 0.6 0.8 1.1
Adolescents 17 0.2 0.3 0.4 0.3 0.4 0.5 0.3 0.5 0.7
Adults 17 0.2 0.2 0.3 0.2 0.3 0.4 0.3 0.4 0.5
Elderly 14 0.2 0.2 0.3 0.2 0.3 0.3 0.3 0.3 0.4
Very elderly 12 0.2 0.2 0.3 0.2 0.3 0.4 0.3 0.3 0.4
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Age group
Lower Bound Middle Bound Upper Bound
n Min Median Max Min Median Max Min Median Max
95th percentile dietary exposure in total population (lg/kg bw per day)
Infants(a) 5 0.5 0.8 1.0 0.7 1.1 1.8 1.0 1.6 2.6
Toddlers(a) 7 0.7 1.0 1.2 1.0 1.4 1.5 1.2 1.8 1.9
Other children 18 0.6 0.9 1.3 0.7 1.1 1.6 1.0 1.4 1.9
Adolescents 17 0.4 0.6 0.9 0.4 0.7 1.0 0.5 0.9 1.2
Adults 17 0.3 0.4 0.5 0.5 0.6 0.7 0.6 0.7 1.0
Elderly 14 0.3 0.4 0.6 0.4 0.5 0.7 0.5 0.6 0.8
Very elderly(a) 9 0.3 0.4 0.5 0.4 0.5 0.6 0.5 0.6 0.7
DON: deoxynivalenol; bw: body weight.
(a): One dietary survey for infants, and three dietary surveys for toddlers and very elderly had less than 60 survey participants
and therefore could not be included in calculation of the 95th percentile exposure.
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Table F.4: Number of food dietary surveys split according to their percentage contribution to chronic dietary exposure of DON alone (lower bound)
concentrations across age groups
Food
category
Toddlers(a) Other children(a) Adolescents
≤ 5% 5–10% 10–25% 25–50% ≥ 50% ≤ 5% 5–10% 10–25% 25–50% ≥ 50% ≤ 5% 5–10% 10–25% 25–50% ≥ 50%
Barley grain 4 8 6
Beer and beer-
like beverage
4 12 15
Bread and rolls 1 1 4 4 1 12 5 1 11 5
Breakfast
cereals
4 1 4 1 7 8 3 10 7
Buckwheat
grain
4 5 2
Cereal-based
dishes
4 2 11 1 1 10 2 1
Cereal-based
food for infants
and young
children
7 1 11 6
Cocoa beans
and cocoa
products
10 16 17
Cocoa
beverage
3 7 8
Composite food
(including
frozen
products)
2 7 5
Condiment 9 18 17
Corn grain 2 5 5
Dietary
supplements
6 8 6
Dried fruits 8 16 16
Fine bakery
wares
2 7 1 2 9 7 2 13 2
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Food
category
Toddlers(a) Other children(a) Adolescents
≤ 5% 5–10% 10–25% 25–50% ≥ 50% ≤ 5% 5–10% 10–25% 25–50% ≥ 50% ≤ 5% 5–10% 10–25% 25–50% ≥ 50%
Food for
infants and
small children
1
Grain milling
products
5 1 3 1 9 3 4
Grains and
grain-based
products
1
Grains for
human
consumption
1 3 3
Medical food 2 3 2
Millet grain 3 3 5
Miscellaneous
fruits
10 18 17
Oats, grain 3 3 2
Other grains 2 2 4
Pasta (Raw) 3 2 4 1 4 4 9 1 3 3 10 1
Peanut (Arachis
hypogea)
7 18 17
Pumpkin seeds
(Cucurbita
pepo var.
oleifera)
2 6 6
Ready to eat
soups
8 1 14 1 14 1
Ready-to-eat
meal for
infants and
young children
7 9 2
Rice 10 18 17
Rye grain 1 2
Snack food 7 3 13 5 10 7
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Food
category
Toddlers(a) Other children(a) Adolescents
≤ 5% 5–10% 10–25% 25–50% ≥ 50% ≤ 5% 5–10% 10–25% 25–50% ≥ 50% ≤ 5% 5–10% 10–25% 25–50% ≥ 50%
Soya beans
(Glycine max)
2 5 8
Spelt grain 1 1 1
Stone fruits 9 18 17
Sweet corn
(Zea mays var.
saccharata)
7 16 16
Wheat grain 4 9 8
DON: deoxynivalenol.
(a): FI/1 survey excluded from calculation of the contribution of ‘Grains and grain-based products’.
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Table F.5: Number of surveys split according to their percentage contribution to chronic dietary exposure of the DON alone (lower bound)
concentrations for adults, elderly and very elderly
Food category
Adults Elderly Very elderly

5
%
5
–
1
0
%
1
0
–
2
5
%
2
5
–
5
0
%

5
0
%

5
%
5
–
1
0
%
1
0
–
2
5
%
2
5
–
5
0
%

5
0
%

5
%
5
–
1
0
%
1
0
–
2
5
%
2
5
–
5
0
%

5
0
%
Barley grain 9 4 3
Beer and beer-like beverage 12 5 12 2 11 1
Bread and rolls 11 6 5 9 3 9
Breakfast cereals 12 3 2 8 2 2 2 5 4 2 1
Buckwheat grain 3 3 2
Cereal-based dishes 11 3 9 8
Cereal-based food for infants and young children 5 1 2
Cocoa beans and cocoa products 16 14 11
Cocoa beverage 10 7 5
Composite food (including frozen products) 6 1 1
Condiment 17 14 12
Corn grain 4 3 2 1
Dietary supplements 6 5 1 4
Dried fruits 17 14 11
Fine bakery wares 3 13 1 2 2 8 2 1 3 5 3
Grain milling products 7 5 5 10 4 7 2 2
Grains and grain-based products 2 2 1
Grains for human consumption 6 1 2
Medical food 2 4 4
Millet grain 7 4 2
Miscellaneous fruits 17 14 12
Oats, grain 5 5 2
Other grains 7 3 1
Pasta (Raw) 5 4 7 1 8 4 1 1 6 4 1 1
Peanut (Arachis hypogea) 17 12 9
Pumpkin seeds (Cucurbita pepo var. oleifera) 12 9 6
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Food category
Adults Elderly Very elderly

5
%
5
–
1
0
%
1
0
–
2
5
%
2
5
–
5
0
%

5
0
%

5
%
5
–
1
0
%
1
0
–
2
5
%
2
5
–
5
0
%

5
0
%

5
%
5
–
1
0
%
1
0
–
2
5
%
2
5
–
5
0
%

5
0
%
Ready to eat soups 15 1 12 1 10 1
Ready-to-eat meal for infants and young children 3 1
Rice 17 14 12
Rye grain 3 1 1
Snack food 16 1 14 9
Soya beans (Glycine max) 11 5 3
Spelt grain 1 2 1
Stone fruits 17 14 12
Sweet corn (Zea mays var. saccharata) 16 12 10
Wheat grain 13 6 6
DON: deoxynivalenol.
(a): FI/1 survey excluded from calculation of the contribution of ‘Grains and grain-based products’.
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F.4. Current estimates of the mean and 95th percentile dietary
exposure to DON alone for farm and companion animals
The lower bound and upper bound concentrations for DON alone in compound feeds and individual
feed materials are represented in Appendix C, Table C.1 and the feed intakes and diet composition
applied are presented in Appenidx E. They were used to estimate the dietary concentrations and
exposure to DON alone presented below for the farm and companion animals.
F.4.1. Ruminants and horses
Using available occurrence data on compound feeds (Appendix C, Table C.1) for dairy cows, beef
cattle and horses, estimates of mean and 95th percentile dietary exposure to DON alone have been
estimated and are presented in Table F.6.
For other categories of ruminant livestock and horses, insufﬁcient data for DON in compound feeds
were available, and therefore estimates of dietary concentrations and exposures have been made
using the example rations (Appendix E) and concentrations of DON alone in individual feed materials
(Appendix C, Table C.1). As reported in Section 5.2.1, there is a wide range of feeding systems for
ruminants involving different forages. Since levels of DON in samples of maize silage and cereal straw
were available (Appendix C, Table C.1), estimates of dietary concentration and exposure by lactating
dairy cows and fattening beef cattle on maize-based diets, and beef cattle on cereal and straw-based
diets have also been made. Estimates of dietary concentration and exposure for beef cattle on a
cereal-based diet are also presented (Table F.7).
Table F.6: Estimated mean and 95th percentile dietary concentration and exposure to DON alone
at the LB and UB by dairy cows, fattening beef cattle and horse based on concentrations
in species-speciﬁc compound feeds
Dietary
concentration lg/kg
dry matter
Exposurelg/day
Exposure lg/kg
bw per day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Dairy cow high
yielding(a)
LB 52.4 316 1,084 6558 1.67 10.09
UB 63.4 316 1,313 6558 2.02 10.09
Dairy cow high
yielding(b)
LB 57.8 346 1,197 7179 1.84 11.04
UB 126 400 2,603 8271 4.01 12.72
Fattening beef cattle(a) LB 39.1 316 376 720 0.94 1.80
UB 47.7 75.0 458 720 1.14 1.80
Fattening beef cattle(b) LB 46.9 346 450 1128 1.12 2.82
UB 135 192 1,305 1846 3.26 4.61
Horses(a) LB 91.4 (c) 823 (c) 1.83 (c)
UB 94.5 (c) 851 (c) 1.89 (c)
Horses(b) LB 96.0 (c) 864 (c) 1.92 (c)
UB 146 (c) 1,318 (c) 2.93 (c)
DON: deoxynivalenol; bw: body weight; LB: lower bound; UB: upper bound.
(a): Fresh grass and/or grass silage-based diets.
(b): Grass hay-based diets.
(c): Insufﬁcient sample numbers to reliably calculate 95th percentile exposure.
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F.4.2. Non-ruminant farm animals
Estimates of mean and 95th percentile dietary concentration and exposure to DON alone at the LB
and UB by pigs and poultry, derived from data on species-speciﬁc compound feeds (Appendix C,
Table C.1) are reported in Table F.8.
Table F.7: Estimated mean and 95th percentile dietary concentration and exposure to DON alone
at the LB and UB by ruminants derived from concentrations in individual feed materials
and their relative proportions in diets
Dietary
concentration lg/kg
dry matter
Exposure lg/day
Exposure lg/kg
bw per day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Lactating dairy cows:
maize silage-based diet
LB 428 1,537 11,682 41,950 17.97 64.54
UB 470 1,557 12,829 42,509 19.74 65.40
Fattening beef cattle:
intensive cereal-based
diet
LB 199 1,274 1,987 12,736 4.97 31.84
UB 251 1,300 2,513 13,003 6.28 32.51
Fattening beef cattle:
maize silage-based diet
LB 311 1,013 2050 6,686 6.83 22.29
UB 347 1,040 2,290 6,865 7.63 22.88
Fattening beef cattle:
straw-based diet
LB 519 2,254 4,156 18,033 13.85 60.11
UB 578 2,275 4623 18198 15.41 60.66
Lactating sheep(a) LB 99.7 506 279 1,417 4.65 23.62
UB 178 566 499 1,585 8.32 26.42
Lactating goats(a) LB 196 365 667 1,241 11.12 20.69
UB 261 411 887 1,398 14.78 23.29
Fattening goats(a) LB 110 386 165 579 4.12 14.47
UB 189 451 284 676 7.09 16.90
DON: deoxynivalenol; bw: body weight, LB, lower bound; UB: upped bound.
(a): Note that these exposures assume that the sole forge is grass hay. Where fresh grass is the main or sole forage exposure
will be lower.
Table F.8: Estimated mean and 95th percentile dietary concentration and exposure to DON alone
by pigs and poultry based on concentrations in species-speciﬁc compound feeds
Dietary
concentration lg/kg
dry matter
Exposure lg/day
Exposure lg/kg
bw per day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Pig starter LB 149 589 149 589 7.44 29.5
UB 238 660 238 660 11.88 33.0
Pig ﬁnisher LB 266 779 797 2337 7.97 23.4
UB 311 779 932 2337 9.32 23.4
Lactating sow LB 314 790 1882 4740 9.41 23.7
UB 369 790 2214 4740 11.1 23.7
Fattening chickens LB 617 2,000 74.0 240 37.0 120
UB 627 2,000 75.2 240 37.6 120
Laying hens LB 482 2,050 57.8 246 28.9 123
UB 494 2,050 59.3 246 29.6 123
Fattening turkeys LB 898 2,410 359 964 29.9 80.3
UB 907 2,410 363 964 30.2 80.3
Fattening ducks LB 624 1,760 87.4 246 29.1 82.1
UB 633 1,760 88.6 246 29.5 82.1
DON: deoxynivalenol; bw: body weight; LB, lower bound; UB: upped bound.
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For farmed ﬁsh (salmonids and carp), farmed rabbits and farmed mink insufﬁcient data on levels of
DON alone in compound feeds were available with which to estimate dietary concentration and
exposure, and therefore example rations and concentrations of DON in individual feed materials
(Appendix C, Table C.1) were used (see Appendix E for details of rations used). Dietary concentrations
and exposures to DON alone derived using this approach are given in Table F.9 below.
F.4.3. Companion animals (dogs and cats)
For dogs and cats, insufﬁcient data on concentrations in proprietary feeds were available with
which to estimate dietary concentration and exposure, and therefore example rations (Appendix E)
and concentrations of DON in individual feed materials were used (Appendix C, Table C.1) for details
of rations used). Dietary concentration and exposure to DON derived using this approach are given in
Table F.10 below.
F.5. Contribution of the food groups to the chronic dietary exposure
Estimates of average % contribution (95% conﬁdence intervals) to chronic dietary exposure to the
sum of DON, 3-Ac-DON, 15-Ac-DON and DON-3-glucoside across age class at FoodEx Level 1 in
middle-bound scenario are presented in Table F.11.
Table F.9: Estimated mean and 95th percentile dietary concentration and exposure to DON alone
at the LB and UB by farmed ﬁsh (salmonids and carp), farmed rabbits and farmed mink
derived from concentrations in individual feed materials and their relative proportions in
diets
Dietary
concentration lg/kg
dry matter
Exposure lg/day
Exposure lg/kg
bw per day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Salmonids LB 54.7 218 2.19 8.71 1.09 4.36
UB 81.0 242 3.24 9.69 1.62 4.85
Carp LB 161 636 3.55 14.0 3.55 3.55
UB 247 716 5.44 15.7 5.44 5.44
Farmed rabbits LB 131 728 19.7 109 9.86 54.6
UB 185 768 27.8 115 13.9 57.6
Farmed mink LB 62.9 260 4.71 19.5 2.28 9.42
UB 67.7 260 5.07 19.5 2.45 9.42
DON: deoxynivalenol; bw: body weight; LB, lower bound; UB: upped bound.
Table F.10: Estimated mean and 95th percentile dietary concentration and exposure to DON at the
LB and UB by companion animals (dogs and cats) derived from concentrations in
individual feed materials and their relative proportions in diets
Dietary
concentration lg/kg
dry matter
Exposure lg/day
Exposure lg/kg
bw per day
Mean 95th percentile Mean 95th percentile Mean 95th percentile
Dogs LB 113 466 6.75 28.0 1.69 6.99
UB 135 482 8.12 28.9 2.03 7.23
Cats LB 148 623 53.3 224 2.13 8.96
UB 166 631 59.8 227 2.39 9.08
DON: deoxynivalenol; bw: body weight; LB, lower bound; UB: upped bound.
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Table F.11: Estimates of average % contribution (95% conﬁdence intervals) to chronic dietary exposure to the sum of DON, 3-Ac-DON, 15-Ac-DON and
DON-3-glucoside across age class at FoodEx Level 1 in middle-bound scenario
Food group(a)
Median contribution across dietary surveys (Lowest average contribution–highest average contribution)
Infants Toddlers Other children Adolescents Adults Elderly Very elderly
Median % Median % Median % Median % Median % Median % Median %
Beer and beer-like
beverage
0 (0–0) 0 (0–0) 0 (0–0) 3 (0–5) 8 (2–22) 7 (1–16) 4 (0–13)
Bread and rolls 15 (0–40) 30 (1–55) 37 (1–59) 40 (1–54) 40 (30–56) 46 (32–57) 47 (31–61)
Breakfast cereals 15 (0–22) 8 (0–29) 6 (0–13) 4 (1–10) 3 (1–24) 3 (0–37) 5 (0–32)
Cereal-based dishes 4 (4–4) 2 (0–10) 2 (0–16) 2 (1–18) 1 (0–10) 1 (0–5) 0 (0–0)
Cereal-based food
for infants and
young children
7 (2–20) 2 (0–11) 0 (0–2) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Fine bakery wares 5 (0–14) 14 (1–23) 21 (0–37) 18 (0–31) 16 (3–24) 16 (2–24) 16 (3–27)
Grain milling
products
7 (1–48) 6 (0–47) 3 (0–62) 3 (0–73) 4 (0–19) 2 (0–20) 1 (0–21)
Grains for human
consumption
0 (0–3) 0 (0–4) 0 (0–4) 0 (0–5) 0 (0–4) 0 (0–3) 0 (0–6)
Miscellaneous
fruits(b)
9 (4–14) 8 (5–10) 4 (2–7) 2 (2–5) 3 (1–6) 3 (1–5) 3 (1–6)
Pasta (Raw) 3 (0–27) 8 (3–34) 10 (2–28) 10 (1–22) 7 (1–21) 4 (1–23) 4 (0–23)
Ready to eat
soups(b)
0 (0–12) 1 (0–12) 2 (0–16) 1 (0–13) 2 (0–14) 3 (0–14) 5 (0–16)
Ready-to-eat meal
for infants and
young children(b),(c)
26 (11–35) 1 (0–6) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Snack food 2 (0–2) 3 (0–6) 4 (1–6) 4 (1–7) 2 (0–6) 0 (0–3) 0 (0–1)
Stone fruits(b) 1 (0–10) 1 (0–5) 0 (0–5) 1 (0–3) 1 (0–8) 2 (0–8) 2 (0–6)
Sweet corn (Zea
mays var.
saccharata)
0 (0–8) 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0)
DON: deoxynivalenol; Ac: acetyl.
Median values across dietary surveys and ranges from the lowest to the highest average contribution are presented.
(a): Calculation based on occurrence data with more than 90% of left-censored data for 3-Ac-DON, 15-Ac-DON.
(b): Calculation based on occurrence data with more than 90% of left-censored data for DON.
(c): Calculation based on occurrence data with more than 90% of left-censored data for DON-3-glucoside.
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 321 EFSA Journal 2017;15(9):4718
Appendix G – Dose–response/concentration modelling using the
Benchmark Dose approach
This appendix reports details of use and the outcome of the dose/concentration–response
modelling using the benchmark dose (BMD) approach on the data sets selected to assess the risk of
the acute and chronic toxicity of DON (and when available also of its acetylated forms) for humans,
farm and companion animals. It should be noted that for this opinion both dose–response data
(usually using the dose as mg toxin/kg bw) and concentration–response data (using the concentration
as mg toxin/kg feed) were used. To assess chronic risk in humans dose–response data of experimental
animals were used by the CONTAM Panel, in contrast to assessment in animals where concentration–
response data were analysed. For the acute risk of the four animal species for which data suitable for
the BMD analysis were identiﬁed, the CONTAM Panel used concentration–response data for pigs, dogs
and cats and dose–response data for mink. For convenience, the term dose–response will be used
below when addressing general issues of the application of the BMD approach.
When applying the BMD approach to dose–response data, the methodology used for the selection
of the data and the models, the estimation of the BMDs and their lower one-sided 95% conﬁdence
limits (BMDLs) and the determination of a BMD interval followed the new guidance of EFSA from 2017
(EFSA Scientiﬁc Committee, 2017) with the editorial modiﬁcation to use notions BMC and BMCL when
analysing concentrations. The BMDS software version 2.6.0.1 (BMDS2601_2015 0629) was applied for
quantal data, while the continuous data were analysed using the PROAST software version 62.6. This
appendix reports the results of all endpoints and their dose/concentration–response data sets identiﬁed
as critical and/or relevant for the risk assessment of DON, including the two acetylated forms (see
Sections 7 and 8 in the main text of the opinion). The results are summarised in tables including
conclusions on the ﬁnal BMD/BMC conﬁdence interval and the lowest BMDL/BMCL used to determine a
reference point. Selected graphics illustrate this. Full details of the modelling are given as
Supplementary Information for each data set evaluated in Annex A Supplementary Information (using
identiﬁers, e.g. ‘IVERSONBW’, when reporting the dose/concentration–response modelling of the body
weight of mice of Iverson et al. (1995) – see Section G.2.1 below.
The following sections report BMD modelling for assessing the chronic human risks based on the
data from rodents as experimental animals, and for the acute risks of farm and companion animals. No
chronic or acute human epidemiological dose–response data suitable for the BMD modelling were
identiﬁed by the CONTAM Panel. Regarding the assessment of the chronic risks of farm and companion
animals, the CONTAM Panel examined the dose/concentration–response data available in the literature
for the application of the BMD approach and concluded that no consistent dose–response evaluation
could be performed to determine reference points for the identiﬁed critical endpoints, neither for the
chronic dose–response nor for the chronic concentration–response data available (see Section 7.8.6).
G.1. Speciﬁc considerations when applying the BMD approach to DON
The EFSA guidance (EFSA Scientiﬁc Committee, 2017) recommends to calculate a BMD conﬁdence
interval (BMD-CI), also denoted BMDL–BMDU interval, for each data set and to use the lower limit of
this interval as the reference point. Model averaging is considered the preferred method for calculating
the BMD-CI in EFSA Scientiﬁc Committee et al. (2017). However, since model averaging software was
not available in BMDS and PROAST the alternative approach recommended by EFSA Scientiﬁc
Committee et al. (2017) and explicated in a ﬂow chart in that guidance was used for this opinion.
Similarly to the model averaging, this alternative method is based on the Akaike Information Criterion
(AIC) and since the AIC values are directly related to the log-likelihood values usually used in a BMD
analysis these values were also reported together with the results of the goodness-of-ﬁt likelihood ratio
tests and their p-values.
The BMD-CIs for the quantitative data were analysed using PROAST. In the case of quantal data,
BMD-CIs were not determined because BMDU values were only available for some models in the BMDS
software. As a consequence, only the BMDL/BMCL values are reported for quantal data to determine
the lowest BMDL/BMCL of each data set used to calculate a reference point. Note that the reference
point is speciﬁc for the data set and differs from an overall reference point determined across all the
considered studies similarly as NOAELs of single data set identiﬁed for an assessment differ from an
overall NOAEL.
Therefore, the summary tables for quantal data report type of models, number of model
parameters, negative of the log likelihood value (usually then a positive number), p-value of the
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goodness-of-ﬁt, AIC value, BMD/BMC estimate and BMDL/BMCL values. In the case of quantal data,
the model with the lowest AIC, denoted AICmin and the models with AIC values not larger than
AICmin+2 are highlighted as the models selected to determine the lowest BMDL/BMCL. It should be
noted that the model with the AICmin belongs by deﬁnition to the set of selected models (if no alert is
triggered) The reference point is identiﬁed as the lowest BMDL of that set of selected models. The
AICFull+2 values and the AICNull-2 values can be obtained from the ﬁrst two lines of the summary
table from the results of the BMDS software and are used as thresholds for alerts as recommended in
EFSA Scientiﬁc Committee et al. (2017).
In the case of continuous data, the guidance of EFSA Scientiﬁc Committee et al. (2017) has been
implemented in the PROAST software and therefore the models not selected by the AIC criterion, as
described in EFSA Scientiﬁc Committee et al. (2017), are not reported. Therefore, the summary table
is restricted to the values of the BMD and the BMD-CI of the Exponential and the Hill models selected
by the PROAST software out of the sets of two models E3 and E5 for the Exponential and H3 and H5
for the Hill family, respectively, denoted below as ‘Best ﬁtting model’.
For quantal data, all models available in the BMDS software were selected using the default
benchmark response (BMR) of 10% extra risk. For quantitative data, the BMR was deﬁned as a
percent change of the magnitude of the response when compared to that predicted at background,
i.e. a relative deviation from background. The default value of 5% (BMR = 0.05) has been
recommended by EFSA Scientiﬁc Committee et al. (2017) to be used in the absence of statistical or
toxicological considerations supporting a deviation from that default value.
The BMD analyses of quantitative data were based on means and standard deviations or standard
errors available from the reports of the selected studies. Deviations from the published values and
calculations of standard deviations or standard errors, in cases where incomplete data were reported,
were indicated. For interpreting the graphs and tables obtained by PROAST it should be noted that the
data of each dose group are assumed to be log-normally distributed such that the means are
geometric means and the whiskers are based on geometric standard deviations.55
G.2. Dose–response modelling of chronic toxicity data in mice
Reduced feed intake and reduced body weight gain were identiﬁed as the most sensitive
toxicological endpoints for chronic toxicity in experimental animals.
G.2.1. Reduced body weight gain and reduced feed intake in mice of
Iverson et al. (1995)
The results of Iverson et al. (1995) on feed intake and body weight of male and female B6C3F1
mice were identiﬁed as pivotal for the dose–response modelling of the general toxicity of DON in
rodents. Although this long-term study had been designed to examine DON for possible carcinogenicity
(and being negative for this endpoint), the data reported on general toxicity of the animals, in
particular on feed intake and body weight, over 2 years were suitable for a dose–response analysis
using the BMD approach to assess the critical effect of reduced body weight gain and reduced intake
identiﬁed in Section 7.8. The CONTAM Panel approached the authors of the study through Health
Canada in October 2016 for the availability of the individual animal data but learned that these data
were no more available. Therefore, the CONTAM Panel calculated the doses for the three dose groups
for both male and female mice from the published data of average feed intake and average body
weight (see Table G.1).
55 It should also be noted that all graphics of this Appendix are copied without modiﬁcation from the output of the software
including the terms used by BMDS and PROAST, which are not necessarily the most appropriate terms and may differ from
the text. However, the meaning should be clear from the context. As an example, the new BMDS uses as default now
‘Fraction Affected’ for incidence and it uses always ‘Dose’ even when it is a concentration.
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The CONTAM Panel noted that the body weight data differed between the males and females
although the shape of the curves of average body weight for the two sexes appeared rather similar.
Compared with males, the weights of the females were lower and the dose-dependent decrease was
larger with larger differences between the dose groups. In contrast, feed intake was slightly larger and
dose–response was less expressed in the female mice compared with the male mice where the dose-
dependent decrease of average feed consumption was clear. In a situation like this where the dose–
response data of two groups can be combined in principle and differ only partially, a dose–response
model can be ﬁtted to the combined data set and the BMD approach would result in subgroup speciﬁc
BMD/Ls or BMD conﬁdence intervals; in this case in sex-speciﬁc outcomes, see the subsection on
covariates within the section 2.5.5 of the recent guidance of EFSA (EFSA Scientiﬁc Committee, 2017).
The PROAST software version 62.6 applied to the combined body weight data selected the models
E3 and H3, and due to a statistical difference between males and females BMD-CIs were calculated
separately for females and males (see Table G.2). The overall BMD-CIs were 0.1–0.29 and
0.15–0.32 mg/kg bw per day for females and males, respectively. The overall reference point for body
weight identiﬁed by the CONTAM Panel was 0.11 mg/kg bw per day (see Table G.2). The dose–
response curves for the exponential model E3 and Hill model H3 are presented in Figure G.1. For more
details, see Annex A Supplementary Information IVERSONBW.
Table G.1: Calculations of the doses using available data on average body weight and average daily
feed consumption per dose group reported in Iverson et al. (1995) for female and male
mice
Iverson et al. (1995) data
Concentration as
reported in the
study (mg DON/kg diet)
Average feed
consumption
(g/day)
Number of
animals
per group
Average
body
weight (g)
Number of
animals per
group
Dose
(mg DON/kg
bw per day)
Female mice data
0 4.48 22 41.54 36 0
1 4.44 24 38.71 42 0.115
5 4.46 23 33.76 37 0.661
10 4.34 25 28.55 38 1.520
Male mice data
0 4.30 24 43.85 37 0
1 4.28 24 43.51 35 0.098
5 4.05 25 40.03 43 0.506
10 3.79 25 35.09 42 1.126
bw: body weight.
Table G.2: Dose–response analysis of body weight (see Table G.1) for female and male mice
combined of Iverson et al. (1995)
Best ﬁtting
model
BMD05 BMDL05–BMDU05
mg/kg bw per day
Female mice
Exponential model family E3 0.19 0.11–0.28
Hill model family H3 0.19 0.12–0.29
Male mice
Exponential model family E3 0.22 0.15–0.30
Hill model family H3 0.23 0.16–0.32
BMD05: benchmark dose response of 5%; BMDL05/BMDU05: 95% lower/upper conﬁdence limit for the benchmark dose response
of 5%; bw: body weight.
Deoxynivalenol and its acetylated and modiﬁed forms in food and feed
www.efsa.europa.eu/efsajournal 324 EFSA Journal 2017;15(9):4718
The CONTAM Panel noted that the feed intake data differed substantially between the males and
females, which is also reﬂected by different shapes of the curves of average feed intake for the two
sexes shown in Iverson et al. (1995). The PROAST software version 62.6 applied to the combined feed
intake data selected the models E5 and H5, and due to a statistical difference between males and
females BMD-CIs were calculated separately for the two sexes (see Table G.3). The overall BMD-CIs
were 1.57–17.0 and 0.23–0.66 mg/kg bw per day for females and males, respectively. The overall
reference point for feed intake identiﬁed by the CONTAM Panel was 0.23 mg/kg bw per day (see
Table G.3). The dose–response curves for the exponential model E5 and Hill model H5 are presented
in Figure G.2. For more details of the analysis for the body weight, see Annex A Supplementary
Information IVERSONFDC.
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Mean body weight is expressed as g and dose as mg/kg bw per day. The red (upper) curve is for male and the
black (lower) for female mice data.
Figure G.1: Dose–response curves for the body weight of female and male mice combined (see also
Table G.2)
Table G.3: Dose–response analysis of feed intake (see Table G.1) for female and male mice
combined of Iverson et al. (1995)
Best ﬁtting
model
BMD05 BMDL05–BMDU05
mg/kg bw per day
Female mice
Exponential model family E5 2.95 1.57–17.0
Hill model family H5 2.62 1.58–9.71
Male mice
Exponential model family E5 0.42 0.24–0.66
Hill model family H5 0.42 0.23–0.63
BMD05: benchmark dose response of 5%; BMDL05/BMDU05: 95% lower/upper conﬁdence limit for the benchmark dose response
of 5%; bw: body weight.
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G.2.2. Reduced body weight gain and reduced feed intake in mice of
Iverson et al. (1995) related to the concentration of DON in feed
To allow a comparison with the hazard characterisation of reduced body weight gain and feed
intake for farm and companion animals based on concentration data in feed, the results of Iverson
et al. (1995) on body weight and feed intake of male and female B6C3F1 mice were also analysed as
concentration–response data using the BMD approach using the three concentrations of 1, 5 and
10 mg DON/kg feed (see Table G.1) for which the experiment was designed. The PROAST software
version 62.6 applied to the body weight data of female and male mice combined selected the models
E5 and H5, and, as above, due to a statistical difference between males and females BMC-CIs were
calculated separately for the two sexes (see Table G.4). The overall BMC-CIs were 1.04–2.40 and
1.75–3.39 mg DON/kg feed per day for females and males, respectively. The overall reference point
for feed intake identiﬁed by the CONTAM Panel was therefore 1.0 mg/kg feed per day (see Table G.4).
The dose–response curves of body weight for the exponential model E5 and Hill model H5 are
presented in Figure G.3. For more details of these results, see Annex A Supplementary Information
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Mean feed intake is expressed as g feed per day and dose as mg/kg bw per day. The red curve is for female
mice data and the black for male mice data.
Figure G.2: Dose–response curves for the feed intake of female and male mice combined of Iverson
et al. (1995) (see Table G.3)
Table G.4: Concentration–response analysis of body weight (see Table G.1) for female and male
mice combined of Iverson et al. (1995)
Best ﬁtting
model
BMC05 BMCL05– BMCU05
mg/kg feed per day
Female mice
Exponential model family E5 1.64 1.04–2.37
Hill model family H5 1.68 1.08–2.40
Male mice
Exponential model family E5 2.47 1.75–3.27
Hill model family H5 2.60 1.87–3.39
BMC05: benchmark concentration response of 5%; BMCL05/BMCU05: 95% lower/upper conﬁdence limit for the benchmark dose
response of 5%.
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For feed intake, the overall BMC-CIs were 10.4–100 and 2.39–6.29 mg DON/kg feed per day for
females and males, respectively. The overall reference point for feed intake identiﬁed by the CONTAM
Panel was therefore 2.4 mg DON/kg feed per day (see Table G.5). The dose–response curves of feed
intake for the exponential model E5 and Hill model H5 are presented in Figure G.3. For more details of
these results, see Annex A Supplementary Information IVERSON-concentration–response.
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Mean body weight is expressed as g and concentration as mg/kg feed per day. The red (upper) curve is for
male and the black (lower) for female mice data.
Figure G.3: Concentration–response curves for the body weight of female and male mice combined
(see also Table G.4)
Table G.5: Concentration–response analysis of feed intake (see Table G.1) for female and male
mice combined of Iverson et al. (1995)
Best ﬁtting
model
BMC05 BMCL05–BMCU05
mg/kg feed per day
Female mice
Exponential model family E5 18.6 10.4–100
Hill model family H5 16.5 10.4–61.9
Male mice
Exponential model family E5 4.19 2.46–6.29
Hill model family H5 2.39 4.24–6.13
BMC05: benchmark concentration response of 5%; BMCL05/BMCU05: 95% lower/upper conﬁdence limit for the benchmark dose
response of 5%.
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G.2.3. Reduced body weight gain in mice of Bondy et al. (2016)
Bondy et al. (2016) performed a 26-week study in mice using a diet at concentrations of 0, 1, 5
and 10 mg DON/kg feed (the same as used by Iverson et al. (1995)) to study carcinogenicity and
general chronic effects. The study investigated effects of DON in two strains of male mice (p53+/+ and
p53+/ mice) with initial mean body weight of 27.0 g (SD 2.9 g) and 28.7 g (SD 1.7 g), respectively.
Dietary concentrations of DON were converted into mean doses by the authors (see also Table G.6).
Mean daily feed consumption was shown in a graphic only and could not be evaluated for dose–
response analysis by the CONTAM Panel. The authors noted some uncertainty of the calculation of the
dose (See Table 2 in Bondy et al., 2016). The mean doses over the 26 weeks were reported by the
authors as of ranging from 0.08 to 0.14, 0.42 to 0.69 and 1.22 to 2.24 mg DON/kg diet per day for
the p53+/+ mice, and 0.08 to 0.14, 0.39 to 0.65 and 1.05 to 1.95 mg DON/kg diet per day for the
p53+/ mice, respectively. The mean doses calculated by the authors per dose group were used for
the modelling. Similarly, as done for the two sexes in the study of Iverson et al. (1995), the dose–
response data of two genotypes were combined since they differed only partially and a dose–response
model was ﬁtted to the combined data set such that the BMD approach resulted also in subgroup
speciﬁc BMD/Ls or BMD conﬁdence intervals. Using the PROAST software version 62.6, for the data of
the p53+/+ and p53+/ mice combined the overall BMD-CI was 0.11–0.90 mg/kg bw per day
(Table G.7).56 The lowest BMDL was 0.11 mg/kg bw per day as such identical with the reference point
derived from the body weight data of Iverson et al. (1995). The dose–response curves for the
exponential model E3 and Hill model H3 for the two genotypes are presented in Figure G.5.
Table G.6: Doses of DON, number of animals per dose group and mean body weights reported for
mice by Bondy et al. (2016)
p53+/+ male mice p53+/ male mice
Dose (mg DON/kg
bw per day)
Number of
animals
Mean bw
(SD) g
Dose (mg DON/kg
bw per day)
Number of
animals
Mean bw
(SD) g
0 10 44.8 (2.9) 0 10 43.1 (2.5)
0.09 10 43.8 (3.7) 0.09 10 42.5 (4.9)
0.53 10 39.9 (3.4) 0.49 10 39.7 (2.6)
1.57 9 32.0 (2.8) 1.50 10 32.9 (2.3)
DON: deoxynivalenol; bw: body weight; SD: standard deviation.
0 2 4 6 8 10
3.9
4.0
4.1
4.2
4.3
4.4
4.5
4.6
Dose
M
ea
n
 m5-abv
 v ersion: 62.6 
 loglik    304.92 
 v ar-f      0.00295 
 v ar-m     0.00204 
 a-f      4.47 
 a-m     4.31 
 CED-f      18.6 
 CED-m     4.19 
 c-    0.9 
 d-    1.3 
 CES    -0.05 
 CEDL-f      10.4 
 CEDU-f      99.99 
 CEDL-m     2.459 
 CEDU-m     6.29 
 b:  0.01544 
 b:  0.1073 
 conv  :  1 
 scaling f actor on x :  1 
 dty pe :  10 
  selected :  all 
 remov ed: none 
 cov ariate:  
Exponential model
0 2 4 6 8 10
3.9
4.0
4.1
4.2
4.3
4.4
4.5
4.6
Dose
 m5-abv
 v ersion: 62.6 
 loglik    305.26 
 v ar-f      0.00295 
 v ar-m     0.00203 
 a-f      4.46 
 a-m     4.3 
 CED-f      16.5 
 CED-m     4.24 
 c-    0.9 
 d-    1.99 
 CES    -0.05 
 CEDL-f      10.41 
 CEDU-f      61.87 
 CEDL-m     2.39 
 CEDU-m     6.13 
 b:  16.53 
 b:  4.243 
 conv  :  1 
 scaling f actor on x :  1 
 dty pe :  10 
  selected :  all 
 remov ed: none 
 cov ariate:  
Hill model
Mean feed intake is expressed as g feed per day and concentration as mg/kg feed per day. The red (upper)
curve is for male and the black (lower) for female mice data.
Figure G.4: Concentration–response curves for feed intake of female and male mice combined (see
also Table G.5)
56 Note that the approach used for the BMD and and BMDL calculations reported in the publication of Bondy et al. (2016) is
different from the one recommended by EFSA Scientiﬁc Committee et al. (2017) and used in this opinion.
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The CONTAM Panel noted that this study with a duration of 26 weeks should be considered as
subchronic study. Comparing with the study of Iverson et al. (1995), when a total of 400 male and
female mice were investigated, the study of Bondy et al. (2016) investigated only a total of 100
animals including the two p53 types of male mice. If the outcome of the study of Bondy et al. (2016)
had been the same as reported by the authors but were based on 50 animals per dose group instead
of 10, the BMD-CI would have been 0.20 and 0.59 mg/kg bw per day for the two p53 types of mice at
a higher dose (tentatively calculated by the CONTAM Panel). Therefore, the results of the study by
Bondy et al. (2016) appeared to be in a good agreement with the outcome of the Iverson et al.
(1995) study, even as a subchronic study. The CONTAM Panel concluded that the BMD-interval of
0.11–0.90 mg DON/kg bw per day obtained from the data of Bondy et al., (2016) supported the
results obtained in the dose–response evaluation of the data of Iverson et al. (1995). For more details
of the analysis, see Annex A Supplementary Information BONDY.
G.3. Dose–response modelling of general toxicity in rats observed in
the studies on reproductive and developmental toxicity of
Sprando et al. (2005) and Collins et al. (2006)
General toxicity data of DON were available also from several recent studies in rodents on the
reproductive and developmental toxicity of DON (see Section 7.2.7). Although the duration of these
studies in pregnant dams was usually short and resembled in their duration subacute studies, the
CONTAM Panel considered these data as relevant and supportive to the results of the long term study
on general toxicity of Iverson et al. (1995). Regarding reduced feed intake and body weight gain two
studies were identiﬁed as relevant and suitable for dose–response evaluations, namely the studies of
Sprando et al. (2005) and Collins et al. (2006), both informing reduced feed consumption and reduced
body weight gain.
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Means are expressed as body weight (g) and dose as mg/kg bw per day. The blue (upper) curve is for the
p53+/+ male mice, the green (lower) for the p53+/ male mice and the red (middle) for the combined mice
data.
Figure G.5: Dose–response curves of body weight for p53+/+ and p53+/ mice combined of Bondy
et al. (2016) (see also Table G.7)
Table G.7: Dose–response analysis of body weight (see Table G.6) for male p53 +/+ and p53 +/
mice combined (Bondy et al., 2016)
Best ﬁtting
model
BMD05 BMDL05  BMDU05
mg/kg bw per day
Exponential model family E3 0.38 0.11–0.89
Hill model family H3 0.39 0.12–0.90
BMD05: benchmark dose response of 5%; BMDL05/BMDU05: 95% lower/upper conﬁdence limit for the benchmark dose response
of 5%; bw: body weight.
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G.3.1. Reduced body weight gain and reduced feed intake in male rats
of Sprando et al. (2005)
Mean initial body weight (SD) of male rats was 343.1 (4.2), 341.5 (4.4), 342.1 (4.3), 341.4 (4.9)
and 339.9 (5.8) g for the controls and the four dose groups exposed to 0, 0.5, 1.0, 2.5 and 5 mg/kg
by Sprando et al. (2005). Since the same group reported in Collins et al. (2006) data on male rats
exposed to the same doses of 0, 0.5, 1, 2.5 and 5 in mg DON/kg bw per day, the CONTAM
Panel assumed that the unit in Sprando et al. (2005) was also mg/kg bw per day. The CONTAM
Panel used the PROAST software version 62.6 for the BMDL analysis. The overall BMD-CIs were
0.72–3.91 mg/kg bw per day for body weight, 0.59–2.38 mg/kg bw per day for body weight gain and
0.70–4.08 mg/kg bw per day for feed intake, respectively, in male rats (see Table G.8). The dose–
response curves for the exponential model E3 and Hill model H3 are presented in Figures G.6–G.8).
For more details of the analysis, see Annex A Supplementary Information SPRANDO2005all.
Table G.8: Dose–response analysis of body weight, body weight gain and feed intake (see Annex A
Supplementary Information SPRANDO2005all) for male rats of Sprando et al. (2005)
Best ﬁtting
model
BMD05 BMDL05–BMDU05
mg/kg bw per day
Body weight
Exponential model family E3 2.59 0.72–3.91
Hill model family H3 2.60 0.81–3.90
Body weight gain
Exponential model family E3 1.23 0.59–2.38
Hill model family H3 1.48 0.92–2.38
Feed intake
Exponential model family E3 2.39 0.70–4.08
Hill model family H3 2.41 0.81–4.06
BMD05: benchmark dose response of 5%; BMDL05/BMDU05: 95% lower/upper conﬁdence limit for the benchmark dose response
of 5%; bw: body weight.
1 2 3 4 5
36
0
38
0
40
0
42
0
Dose
M
ea
n
 m3-
 v ersion: 62.6 
 loglik    75.68 
 v ar-    0.00411 
 a-    421 
 CED-    2.59 
 d-    1.63 
 CES    -0.05 
 CEDL    0.7183 
 CEDU    3.908 
 b:  -0.01086 
 conv  :  1 
 scaling f actor on x :  1 
 dty pe :  10 
  selected :  all 
 remov ed: none
Exponential model
1 2 3 4 5
36
0
38
0
40
0
42
0
Dose
 m3-
 v ersion: 62.6 
 loglik    75.69 
 v ar-    0.00411 
 a-    421 
 CED-    2.6 
 d-    1.71 
 CES    -0.05 
 CEDL    0.8143 
 CEDU    3.889 
 b:  14.59 
 conv  :  1 
 scaling f actor on x :  1 
 dty pe :  10 
  selected :  all 
 remov ed: none
Hill model
Mean is expressed as body weight (kg) and dose as mg/kg bw per day.
Figure G.6: Dose–response curve of mean body weight in male rats of Sprando et al. (2005) (see
also Table G.8)
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G.3.2. Body weight, body weight gain and feed intake in female rats of
Collins et al. (2006)
The authors clearly stated in their paper that female rats were treated with doses of 0, 0.5, 1, 2.5
and 5 mg DON/kg bw per day at GD6-19 based on a dose-ranging study at doses of 0.25–7.5 mg
DON/kg bw per day. Initial mean body weights ranged from 326 to 350 g for males and from 201 to
225 g for females, respectively. The overall BMD-CIs 0.72–3.91 mg/kg bw per day were for body
weight, 1.14–3.95 mg/kg bw per day for body weight gain and 1.80–3.62 mg/kg bw per day for feed
intake, respectively (see Table G.9). The dose–response curves for the exponential model E3 and Hill
model H3 are presented in Figures G.9–G.11. For more details of the analysis, see Annex A
Supplementary Information COLLINS.
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Mean is expressed as body weight (kg) and dose as mg/kg bw per day.
Figure G.8: Dose–response curve of feed intake in male rats of Sprando et al. (2005) (see also
Table G.8)
Mean is expressed as body weight (kg) and dose as mg/kg bw per day.
Figure G.7: Dose–response curve of body weight gain in male rats of Sprando et al. (2005) (see also
Table G.8)
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Mean is expressed as body weight (kg) and dose as mg/kg bw per day.
Figure G.9: Dose–response curve of body weight in female rats Collins et al. (2006) (see also
Table G.9)
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Mean is expressed as body weight (kg) and dose as mg/kg bw per day.
Figure G.10: Dose–response curve of body weight gain in female rats Collins et al. (2006) (see also
Table G.9)
Table G.9: Dose–response analysis of body weight, body weight gain and feed intake (see
Supplementary Information COLLINS (Annex A)) for female rats of Collins et al. (2006)
Best ﬁtting
model
BMD05 BMDL05–BMDU05
mg/kg bw per day
Body weight
Exponential model family E3 3.41 2.34–4.43
Hill model family H3 3.39 2.37–4.31
Body weight gain
Exponential model family E3 1.92 1.14–3.95
Hill model family H3 2.01 1.34–3.49
Feed intake
Exponential model family E3 2.58 1.80–3.62
Hill model family H3 2.57 1.82–3.58
BMD05: benchmark dose response of 5%; BMDL05/BMDU05: 95% lower/upper conﬁdence limit for the benchmark dose response
of 5%; bw: body weight.
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G.4. Concentration/dose–response modelling for acute toxicity data on
vomiting in farm and companion animals (pigs, dogs, cats and
farmed mink)
Vomiting was identiﬁed as the critical endpoint to characterise acute toxicity of DON and its
acetylated forms of 3-Ac-DON and 15-Ac-DON (Section 7.10) for those farm animal species, which are
known to be able to vomit. Data on vomiting appearing suitable for applying BMD-approach were
available for pigs from Young et al. (1983) and Williams et al. (1988), for dogs and cats from Hughes
at al. (1999) and for farmed mink from Wu et al. (2013a). The CONTAM Panel decided to use
concentration–response data for pigs, dogs and cats for the reasons outlined in Section 7.3 and dose–
response data for the mink due to the design chosen by Wu et al. (2013a).
G.4.1. Concentration–response data on vomiting in pigs
The data on vomiting in piglets from Young et al. (1983) and Williams et al. (1988) (see
Section 7.3.4.2) were evaluated using the BMD approach as recommended in EFSA Scientiﬁc
Committee et al. (2017). Trials 2 and 3 of the study of Young et al. (1983) were identiﬁed as suitable
for a concentration–response evaluation using the BMD approach with the reported concentrations of
0.79, 44.4, 97.2, 124.9 and 227.5 mg/kg feed for trial 2 and 0.14, 9.0, 19.7, 33.5 and 43.4 mg/kg
feed for trial 3 (see Table G.10). Incidences of vomiting were obtained from the evaluation of JECFA
(FAO/WHO, 2011). Two experiments of Williams et al. (1988) were evaluated with concentrations of
up to 0.05 mg/kg feed in the two control groups and concentrations of 1.6. 4.4. 6.6. 9.1 and 11.0 mg/kg
feed in the main trial with 6–12 animals per group and concentrations of 2.6. 5.0, 8.3, 12.7 and
14.0 mg/kg feed in the pretrial with 2 animals per group.
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Hill model
Mean is expressed as body weight (kg) and dose as mg/kg bw per day.
Figure G.11: Dose–response curve of feed intake in female rats Collins et al. (2006) (see also
Table G.9)
Table G.10: Concentration–response data on vomiting in pigs exposed to DON identiﬁed from the
studies of Young et al. (1983) and Williams et al. (1988)
Young et al. (1983) Williams et al. (1988)
Concentration
(mg DON/kg feed)
N of
animals
Incidence Trial
Concentration (mg
DON/kg feed)
N of
animals
Incidence Trial
0.79 3 0 2 0.05 12 0 2
44.4 4 2 2 1.6 12 0 2
97.2 4 1 2 4.4 12 2 2
124.6 4 4 2 6.6 6 3 2
227.5 4 3 2 9.1 6 2 2
11.0 6 3 2
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G.4.1.1. Concentration–response data on vomiting in pigs of Young et al. (1983)
The CONTAM Panel modelled the data on vomiting in pigs of the two trials of Young et al. (1983)
using the BMDS software following the EFSA guidance (EFSA Scientiﬁc Committee, 2017) and
identiﬁed 1.36 mg/kg feed per day of the Weibull model as the BMDL10 of this data set (see
Table G.11). No alert regarding the criterion AIC-Full+2 = 50.04 and AIC-NULL-2 = 53.68 was obtained.
With AICMIN+2 = 38.92 all models except the probit and the logistic model were selected (see
Table G.11). The ﬁt of the Weibull model with the lowest BMDL10 is shown in Figure G.12. The Gamma
model could not be ﬁtted in reasonable computing time to these data. For more details of the analysis,
see Annex A Supplementary Information YOUNGBMC.
Young et al. (1983) Williams et al. (1988)
Concentration
(mg DON/kg feed)
N of
animals
Incidence Trial
Concentration (mg
DON/kg feed)
N of
animals
Incidence Trial
0.14 4 0 3 0.05 2 0 1
9 4 0 3 2.6 2 0 1
19.7 4 1 3 5.0 2 0 1
33.5 4 1 3 8.3 2 0 1
43.4 4 1 3 12.7 2 1 1
14.1 2 2 1
DON: deoxynivalenol; N: number of animals.
Table G.11: Summary of concentration–response analysis of vomiting in pigs exposed to DON as
reported by Young et al. (1983)
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
BMC10 BMCL10
Comment
(mg/kg feed)
Full model 10 14.02 na 38.04 na na
Null (reduced)
model
1 24.82 0. 01 51.64 na na
Probit 2 19.21 0.24 42.42 32.60 21.80 Not selected
Logistic 2 19.18 0.24 42.36 33.18 21.30 Not selected
LogProbit 2 17.27 0.59 38.54 14.11 2.42 Selected
LogLogistic 2 17.32 0.58 38.63 13.47 2.12 Selected
Multistage 2 17.38 0.57 38.75 10.50 5.54 Selected
Multistage
Cancer
1 17.46 0.65 36.92 12.22 7.78 Selected
Quantal-Linear 1 17.46 0.65 36.92 12.22 7.82 Selected
Weibull 2 17.44 0.55 38.89 10.88 1.36 Selected
Gamma No ﬁt
The models selected to identify the lowest BMDL10 following EFSA guidance (EFSA Scientiﬁc Committee, 2017) are identiﬁed in
the column ‘Comments’ and include the model with the lowest AIC.
BMC10: benchmark concentration response of 10%; BMCL10: 95% lower/upper conﬁdence limit for the benchmark concentration
response (BMR) of 10%; na: not available, including cases where the BMC/Ls were not calculated, the ﬁt was incomplete, or
serious or conﬂicting comments were noted (e.g. parameters reaching boundary).
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G.4.1.2. Concentration–response data on vomiting in pigs of Williams et al.
(1988)
The CONTAM Panel modelled the data on vomiting in pigs of the two trials of Williams et al. (1988)
using the BMDS software following the EFSA guidance (EFSA Scientiﬁc Committee, 2017) and identiﬁed
1.84 mg/kg feed per day of the Multistage cancer model as the BMDL10 of this data set (see Table G.12).
No alert regarding the criterion AIC-Full+2 = 61.86 and AIC-NULL-2 = 67.50 was obtained. With
AICMIN+2 = 48.59 all models except the probit, the logistic model, the Quantal linear and the Weibull
model were selected (see Table G.12). The ﬁt of the Multistage cancer model with the lowest BMDL10 is
shown in Figure G.13. The Gamma model could not be ﬁtted in reasonable computing time to these
data. For more details of the analysis see Annex A Supplementary Information WILLIAMSBMC.
Table G.12: Summary of concentration–response analysis of vomiting in pigs exposed to DON as
reported by Williams et al. (1988)
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
BMC10 BMCL10
Comment
(mg/kg feed)
Full model 12 18.93 na 61.86 na na
Null (reduced)
model
1 32.75 0. 004 67.50 na na
Probit 2 22.84 0.65 49.68 4.64 3.31 Not selected
Logistic 2 23.14 0.59 50.28 4.89 3.53 Not selected
LogProbit 2 22.18 0.77 48.35 3.93 2.07 Selected
LogLogistic 2 22.30 0.75 48.60 3.93 1.95 Selected
Multistage 2 22.26 0.76 48.52 4.28 1.86 Selected
Multistage
Cancer
1 22.29 0.82 46.59 3.97 1.84 AIC minimum
Quantal-Linear 1 23.64 0.58 49.28 2.05 1.33 Not selected
Weibull 2 22.84 0.65 49.68 4.46 3.31 Not selected
Gamma No ﬁt
DON: deoxynivalenol.
The models selected to identify the lowest BMCL10 following EFSA guidance (EFSA Scientiﬁc Committee, 2017) are identiﬁed in
the column ‘Comments’ and include the model with the lowest AIC.
BMC10: benchmark concentration response of 10%; BMCL10: 95% lower/upper conﬁdence limit for the benchmark concentration
response (BMR) of 10%; na: not available, including cases where the BMC/Ls were not calculated, the ﬁt was incomplete, or
serious or conﬂicting comments were noted (e.g. parameters reaching boundary).
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Figure G.12: Concentration–response curve of the incidence of vomiting in pigs reported by Young
et al. (1983) (see also Table G.11)
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G.4.2. Concentration–response data on vomiting in dogs and cats of
Hughes et al. (1999)
The CONTAM Panel used the concentration–response data on vomiting in dogs and cats of Hughes
et al. (1999) (Table 13) for the BMC modelling using the BMDS software following the EFSA Scientiﬁc
Committee et al. (2017) guidance.
G.4.2.1. Vomiting in dogs
The CONTAM Panel modelled the data on vomiting in dogs using the BMDS software following the
EFSA guidance (EFSA Scientiﬁc Committee, 2017) and identiﬁed 5.05 mg DON/kg feed from the
Gamma model as the BMCL10 of this data set. No alert regarding the criterion AIC-Full+2 = 33.94 and
AIC-NULL-2 = 46.74 was obtained. With AIC-MIN+2 = 28.77 only the logprobit and the Gamma model
were selected (see Table G.14). Since the plot of the Gamma model was not available, when applying
BMDS software that of the next nearest concentration–response curve of the LogProbit is shown in
Figure G.14. For more details of the analysis, see Annex A Supplementary Information DOGSVOMIT.
Table G.13: Incidence of vomiting in dogs and cats exposed to DON reported by Hughes et al.
(1999)
Dogs Cats
Concentration
(mg DON/kg feed)
Number of animals
per group
Incidence
Concentration
(mg DON/kg
feed)
Number of
animals per
group
Incidence
0 14 0 0 2 0
1 2 0 – 2 –
2 2 0 2 2 0
4 2 0 4 2 1
6 14 0 6 2 0
8 2 2 8 2 0
10 13 7 10 8 4
DON: deoxynivalenol.
–: not reported in the paper.
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Figure G.13: Concentration–response curve of the incidence of vomiting in pigs reported by Williams
et al. (1988) (see also Table G.12)
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G.4.2.2. Vomiting in cats
The CONTAM Panel modelled the data on vomiting in cats using the BMDS software following the
EFSA guidance (EFSA Scientiﬁc Committee, 2017) and identiﬁed 1.04 mg DON/kg bw from the Quantal
linear model as the BMCL10 of this data set (see Table G.15). No alert regarding the criterion
AIC-Full+2 = 27.86 and AIC-NULL-2 = 22.64 was obtained. With AIC-MIN+2 = 22.47 only the
Multistage cancer and the Quantal linear model were selected. The ﬁt of the Quantal linear model with
the lowest BMDL10 is shown in Figure G.15. For more details of the analysis, see Annex A
Supplementary Information CATSVOMIT.
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Figure G.14: Concentration–response curve of the incidence of vomiting in dogs reported by Hughes
et al. (1999) (see also Table G.14)
Table G.14: Summary of concentration–response analysis of incidence of vomiting in dogs reported
by Hughes et al. (1999)
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
BMC10 BMCL10
Comment
(mg/kg feed)
Full model 7 8.97 na 31.94 na na
Null (reduced)
model
1 23.37 < 0.001 48.74 na na
Probit 2 12.62 0.20 29.23 6.91 4.90 Not selected
Logistic 2 12.86 0.17 29.71 6.87 4.90 Not selected
LogProbit 2 12.28 0.25 28.56 6.85 5.17 Selected
LogLogistic 2 12.51 0.22 29.02 6.79 4.92 Not selected
Multistage Failed
Multistage
Cancer
1 14.73 0.07 31.46 4.22 2.48 Not selected
Quantal-Linear 1 16.61 0.02 35.21 2.32 1.39 Not selected
Weibull 2 12.75 0.18 29.49 6.79 4.65 Selected
Gamma 2 12.39 0.34 26.77 6.83 5.05 AIC minimum
DON: deoxynivalenol.
The models selected to identify the lowest BMCL10 following EFSA guidance (EFSA Scientiﬁc Committee, 2017) are identiﬁed in
the column ‘Comments’ and include the model with the lowest AIC.
BMC10: benchmark concentration response of 10%; BMCL10: 95% lower conﬁdence limit for the benchmark concentration
response (BMR) of 10%; na: not available, including cases where the BMC/Ls were not calculated, the ﬁt was incomplete, or
serious or conﬂicting comments were noted (e.g. parameters reaching boundary).
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G.4.3. Vomiting in farmed mink
The CONTAM Panel used the data on emesis (vomiting and retching) of Wu et al. (2013a) in mink
for the BMD modelling with n = 6 animals in four dose groups and the control group (see Section 7.8.5
for Pestka Personal communication). Tables G.16–G.18 show the data used and the details of the BMD
analyses for DON, 3-Ac-DON and 15-Ac-DON. Doses were applied as mg toxin/kg bw in feed via
gavage after fasting, and therefore, the CONTAM Panel could not transfer the doses into
concentrations of the toxin in the animal feed.
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The (red) curve is the ﬁtted dose–response curve and the dotted line curve indicates the 95% lower
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Figure G.15: Concentration–response curve of the incidence of vomiting in cats reported by Hughes
et al. (1999) (see also Table G.15)
Table G.15: Summary of dose–response analysis of incidence of vomiting in cats reported by
Hughes et al. (1999) using BMDS software
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
BMC10 BMCL10
Comment
(mg/kg feed)
Full model 6 6.93 na 25.86 na na
Null (reduced)
model
1 10.64 < 0.001 22.64 na na
Probit 2 9.25 0.33 22.49 4.21 2.36 Not selected
Logistic 2 9.24 0.33 22.49 4.54 2.50 Not selected
LogProbit Failed
LogLogistic Failed
Multistage Failed
Multistage
Cancer
2 9.19 0.34 22.38 2.80 1.05 Selected
Quantal-Linear 1 9.24 0.47 20.47 2.03 1.04 AIC minimum
Weibull Failed
Gamma Failed
DON: deoxynivalenol.
The models selected to identify the lowest BMCL10 following EFSA guidance (EFSA Scientiﬁc Committee, 2017) are identiﬁed in
the column ‘Comments’ and include the model with the lowest AIC.
BMC10: benchmark concentration response of 10%; BMCL10: 95% lower conﬁdence limit for the benchmark concentration
response (BMR) of 10%; na: not available, including cases where the BMC/Ls were not calculated, the ﬁt was incomplete, or
serious or conﬂicting comments were noted (e.g. parameters reaching boundary).
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G.4.3.1. Vomiting in mink exposed to DON
The CONTAM Panel modelled the data on vomiting/retching in mink using the BMDS software
following the EFSA guidance (EFSA Scientiﬁc Committee, 2017) and identiﬁed 0.0037 mg DON/kg bw
per day from the Multistage cancer model as the BMDL10 of this data set (see Table G.17). No alert
regarding the criterion AIC-Full+2 = 17.40 and AIC-NULL-2 = 41.06 was obtained. With AIC-
MIN+2 = 9.41 all ﬁtted models, except the Quantal linear model, were selected. It was noted that this
model was one of the two models where the ﬁt was not saturated (log-likelihood equal to that of the
full model). The lowest BMDL10 of the data set was three times lower than the lowest dose tested at
which the observed incidence was zero among the six mink tested. The ﬁt of the Multistage cancer
model with the lowest BMDL10 is shown Figure G.16. For more details of the analysis, see Annex A
Supplementary Information WUDON.
Table G.17: Summary of dose–response analysis of incidence of vomiting/retching in mink exposed
to DON reported by Wu et al. (2013a)
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
BMD10 BMDL10
Comment
(mg/kg bw per day)
Full model 5 2.70 na 15.40 na na
Null
(reduced)
model
1 20.53 1 43.06 na na
Probit 2 2.70 1 9.41 0.037 0.010 Selected
Logistic 2 2.70 1 9.41 0.043 0.012 Selected
LogProbit 2 2.70 1 9.41 0.029 0.0067 Selected
LogLogistic 2 2.70 1 9.41 0.037 0.0067 Selected
Multistage 2 no ﬁt
Multistage
Cancer
1 3.11 0.94 8.22 0.013 0.0037 Selected
Quantal-
Linear
1 4.45 0.48 10.89 0.0044 0.0022 Not selected
Weibull 2 2.70 1 9.41 0.032 0.0055 Selected
Gamma(a) 2 2.70 1 7.41 0.029 0.0057 AIC minimum
The models selected to identify the lowest BMDL10 following EFSA guidance (EFSA Scientiﬁc Committee, 2017) are identiﬁed in
the column ‘Comments’ and include the model with the lowest AIC.
AIC: area under the curve; BMD10: benchmark dose response of 10%; BMDL10: 95% lower conﬁdence limit for the benchmark
dose response (BMR) of 10%; bw: body weight; na: not available, including cases where the BMD/Ls were not calculated, the ﬁt
was incomplete, or serious or conﬂicting comments were noted (e.g. parameters reaching boundary).
Table G.16: Incidence data on emesis (vomiting and/or retching) in mink exposed to DON, 3-Ac-
DON and 15-Ac-DON reported by Wu et al. (2013a)
DON 3-Ac-DON 15-Ac-DON
Dose
(mg/kg
bw per
day)
Number of
animals
Incidence
Dose
(mg/kg
bw per
day)
Number
of
animals
Incidence
Dose
(mg/kg
bw per
day)
Number of
animals
Incidence
0 6 0 0 6 0 0 6 0
0.01 6 0 0.05 6 0 0.01 6 0
0.05 6 5 0.25 6 1 0.1 6 5
0.25 6 6 0.5 6 5 0.5 6 6
0.5 6 6 1.0 6 6 1.0 6 6
bw: body weight.
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G.4.3.2. Vomiting in mink exposed to 3-Ac-DON
The CONTAM Panel modelled the data on vomiting/retching in mink using the BMDS software
following the EFSA guidance (EFSA Scientiﬁc Committee, 2017) and identiﬁed 0.054 mg 3-Ac-DON/kg
bw per day from the Multistage cancer model as the BMDL10 of this data set (see Table G.18). This
value was practically identical with the lowest dose tested at which the observed incidence of
vomiting/retching was zero among the six mink tested. No alert for the criterion AIC-Full+2 = 22.08
and AIC-NULL-2 = 40.18 was obtained. With AIC-MIN+2 = 15.52 all models, except the Quantal linear
model, were selected. The ﬁt of the Multistage cancer model with the lowest BMDL10 is shown in
Figure G.17. For details of the analysis, see Annex A Supplementary Information WUDON3Ac.
Table G.18: Summary of dose–response analysis of incidence of vomiting/retching and retching in
mink exposed to 3-Ac-DON reported by Wu et al. (2013a)
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
BMD10 BMDL10
Comment
(mg/kg bw per day)
Full model 5 5.04 na 20.08 na na
Null (reduced)
model
1 20.19 na 42.18 na na
Probit 2 5.44 0.99 14.89 0.22 0.11 Selected
Logistic 2 5.51 0.97 15.03 0.23 0.12 Selected
LogProbit 2 5.41 1.00 14.83 0.22 0.11 Selected
LogLogistic 2 5.45 0.99 14.90 0.22 0.11 Selected
Multistage 2 Failed(a) na
Multistage
Cancer
1 5.89 0.91 13.78 0.14 0.054 AIC minimum
Quantal-
Linear
1 8.08 0.25 18.15 0.045 0.027 Not selected
Weibull 2 5.41 1.00 14.62 0.21 0.081 Selected
Gamma Failed
The models selected to identify the lowest BMDL10 following EFSA guidance (EFSA Scientiﬁc Committee, 2017) are identiﬁed in
the column ‘Comments’ and include the model with the lowest AIC.
AIC: area under the curve; BMD10: benchmark dose response of 10%; BMDL10: 95% lower conﬁdence limit for the benchmark
dose response (BMR) of 10%; bw: body weight; na: not available, including cases where the BMD/Ls were not calculated, the ﬁt
was incomplete, or serious or conﬂicting comments were noted (e.g. parameters reaching boundary)
(a): The multistage model was considered as failed since the output, see Suppl. Information Mink gave for model ﬁt a statistically
impossible p-value of 2 which was taken as an indication for problems of model ﬁtting using BMDS (see also the graphic in
Supplementary Information WUDON3Ac (Annex A).
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Figure G.16: Dose–response curve of the incidence of vomiting/retching in mink exposed to DON
reported by Wu et al. (2013) (see also Table G.17)
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G.4.3.3. Vomiting in mink exposed to 15-Ac-DON
The CONTAM Panel modelled the data on vomiting/retching in mink using the BMDS software
following the EFSA guidance (EFSA Scientiﬁc Committee, 2017) and identiﬁed 0.0035 mg 15-Ac-DON/
kg bw per day from the Quantal linear model as the BMCL10 of this data set (see Table G.19). This
value was three times lower than the lowest dose tested at which the observed incidence of vomiting/
retching was zero among the six mink tested. No alert for the criterion AIC-Full+2 = 17.50 and AIC-
NULL-2 = 41.06 was obtained. With AIC-MIN+2 = 9.62 all models were selected. The ﬁt of the Quantal
linear model with the lowest BMDL10 is shown in Figure G.18. For more details of the analysis, see
Annex A Supplementary Information WUDON15AC.
Table G.19: Summary of dose–response analysis of incidence of vomiting/retching in mink exposed
to 15-Ac-DON reported by Wu et al. (2013a)
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
BMD10 BMDL10
Comment
(mg/kg bw per day)
Full model 5 2.70 na 15.50 na na
Null (reduced)
model
2 20.53 na 43.06 na na
Probit 2 2.70 1 9.41 0.070 0.018 Selected
Logistic 2 2.70 1 9.41 0.084 0.019 Selected
LogProbit 2 2.70 1 9.41 0.047 0.0060 Selected
LogLogistic 2 2.70 1 9.41 0.071 0.0061 Selected
Multistage Failed
Multistage
Cancer
1 2.81 0.99 7.62 0.025 0.0047 AIC minimum
Quantal-Linear 1 3.66 0.75 9.32 0.0074 0.0035 Selected
Weibull 2 2.70 1 9.41 0.057 0.0042 Selected
Gamma 2 2.70 1 9.41 0.0053 0.0041 Selected
The models selected to identify the lowest BMDL10 following EFSA guidance (EFSA Scientiﬁc Committee, 2017) are identiﬁed in
the column ‘Comments’ and include the model with the lowest AIC.
BMD10: benchmark dose response of 10%; BMDL10: 95% lower conﬁdence limit for the benchmark dose response (BMR) of
10%; bw: body weight; na: not available, including cases where the BMD/Ls were not calculated, the ﬁt was incomplete, or
serious or conﬂicting comments were noted (e.g. parameters reaching boundary).
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Figure G.17: Dose–response curve of the incidence of vomiting/retching in mink exposed to 3-Ac-DON
reported by Wu et al. (2013a) (see also Table G.18)
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Figure G.18: Dose–response curve of the incidence of vomiting/retching in mink exposed to 15-Ac-
DON reported by Wu et al. (2013a) (see also Table G.19)
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Appendix H – Total DON (tDON) exposure in adults estimated by applying back-calculation based on the
maximum biomarker levels in the different studies available
Table H.1: Total DON (tDON) exposure in adults estimated by applying back-calculation based on the maximum biomarker levels in the different studies
presented in Tables 53 and 54 in this scientiﬁc opinion and assuming the average excretion rate of 70% and urine volume of 2 L 24-h urine
volume for adults in Europe
Country
Age of study
subjects
(years)
Maximum value of tDON
reported in the study
(ng/mL urine)(a)
Maximum value of
tDON used for the back
calculation (ng/mL
urine)
Maximum value of the
back calculated
exposure to DON
(lg/kg bw per day)
Reference
UK 18–64 436 ng/mL 436 0.4 EFSA (2015)
Italy 18–64 75.9 ng/mL 75.9 0.2
Norway 18–64 86.9 ng/mL 86.9 0.2
UK 22–50 43.1 ng/mL 1.8 Gratz et al. (2014)
Sweden 18–80 65.8 ng/mL 65.8 2.7 Wallin et al. (2013)
Germany Adults Free DON < 0.4 (LOQ) ng/mL
DON-glucuronide: 60.9 ng/mL
61.0 2.5 Gerding et al (2015)
UK n.r. 10.05 ng/mL 10.1 0.4 Gratz et al. (2013)
UK 16–44 116.7 ng/mg(b) 116.7 4.8 Hepworth et al. (2012)
UK 21–59 78.2 ng/mL 78.2 3.2 Turner et al. (2011a)
UK 21–59 78.2 ng/mL 78.2 3.2 Turner et al. (2010a)
France 23–74 28.8 ng/mL 28.8 1.2 Turner et al. (2010b)
UK 19–64 48.2 ng/mg(b) 48.2 2.0 Turner et al. (2008a)
UK 21–59 67.8 ng/mL 67.8 2.8 Turner et al. (2008b)
Spain 26 18.8 ng/mL 18.8 0.8 Rodriguez-Carrasco et al. (2015)
Belgium 18–65 Free DON: 129.8 ng/mL
DON-15-glucuronide: 460.8 ng/mL
DON-3-glucuronide: 126.2 ng/mL
DOM-glucuronide: 172.0 ng/mL
888.8 36.3 Heyndrickx et al. (2015)
Italy (Southern) 3–85(c) 67.36 ng/mL 67.4 2.8 Solfrizzo et al. (2014)
Belgium > 18 Free DON: 3.0 ng/mL DON-15-
glucuronide: 420.0 ng/mL DON-3-
glucuronide: 35.0 ng/mL
DOM-glucuronide: 11.0 ng/mL
469.0 19.1 Huybrechts et al. (2015)
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Country
Age of study
subjects
(years)
Maximum value of tDON
reported in the study
(ng/mL urine)(a)
Maximum value of
tDON used for the back
calculation (ng/mL
urine)
Maximum value of the
back calculated
exposure to DON
(lg/kg bw per day)
Reference
Croatia 26–33 Free DON: 275.0 ng/mL
DON-15-glucuronide: 1,237.7 ng/mL
DON-3-glucuronide: 298.1 ng/mL
1810.8 73.9 Sarkanj et al. (2013)
Belgium n.r. DON: 68.3 ng/mL 68.3 2.8 Ediage et al. (2012b)
Austria 20–63 DON-15-glucuronide: 43.0 ng/mL
DON-3-glucuronide: 13.0 ng/mL
56 2.3 Warth et al. (2012b)
Portugal 20–50 26.2 ng/mL 26.2 1.1 Cunha and Fernandes (2012)
Italy 26–87 14.2 ng/mL 14.2 0.6 Solfrizzo et al. (2011)
Italy 30–45 8.0 ng/mL 8 0.3 Lattanzio et al. (2011)
Spain 21–77 35 ng/mL 35 1.4 Rubert et al. (2011)
bw: body weight; n.r.: not reported, na: not applicable.
(a): Total DON (tDON) unless speciﬁed.
(b): Creatinine adjusted DON biomarker.
(c): Age speciﬁc biomarker data were not reported.
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Annex A – Supplementary information for the BMD calculations
Annex A can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4718/abstract
Annex A contains supplementary information for the BMD calculations mentioned in Appendix G.
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